# 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. _Endorsed by the European Stroke Organisation (ESO)_

Isabelle C Van Gelder,

Isabelle C Van Gelder[](javascript:;)

(Chairperson)

(

Netherlands

)

Corresponding author: Isabelle C. Van Gelder, Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. Tel: +31 50 361 1327. Email: [i.c.van.gelder@umcg.nl](mailto:i.c.van.gelder@umcg.nl)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-7579-1201](https://orcid.org/0000-0002-7579-1201)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Isabelle+C+Van+Gelder)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Van Gelder I)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Van Gelder Isabelle C%22)

Michiel Rienstra,

Michiel Rienstra

(Task Force Co-ordinator)

(

Netherlands

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-2581-070X](https://orcid.org/0000-0002-2581-070X)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Michiel+Rienstra)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Rienstra M)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Rienstra Michiel%22)

Karina V Bunting,

Karina V Bunting

(Task Force Co-ordinator)

(

United Kingdom

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-4602-4377](https://orcid.org/0000-0003-4602-4377)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Karina+V+Bunting)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Bunting K)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Bunting Karina V%22)

Ruben Casado-Arroyo,

Ruben Casado-Arroyo

(

Belgium

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-3876-6074](https://orcid.org/0000-0002-3876-6074)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Ruben+Casado-Arroyo)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Casado-Arroyo R)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Casado-Arroyo Ruben%22)

Valeria Caso,

Valeria Caso

(

Italy

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-2020-8891](https://orcid.org/0000-0002-2020-8891)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Valeria+Caso)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Caso V)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Caso Valeria%22)

Harry J G M Crijns,

Harry J G M Crijns

(

Netherlands

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-1073-5337](https://orcid.org/0000-0003-1073-5337)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Harry+J+G+M+Crijns)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Crijns H)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Crijns Harry J G M%22)

Tom J R De Potter,

Tom J R De Potter

(

Belgium

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-1424-114X](https://orcid.org/0000-0003-1424-114X)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Tom+J+R+De+Potter)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=De Potter T)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22De Potter Tom J R%22)

Jeremy Dwight,

Jeremy Dwight

(

United Kingdom

)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Jeremy+Dwight)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Dwight J)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Dwight Jeremy%22)

Luigina Guasti,

Luigina Guasti

(

Italy

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-4524-4864](https://orcid.org/0000-0002-4524-4864)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Luigina+Guasti)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Guasti L)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Guasti Luigina%22)

Thorsten Hanke,

Thorsten Hanke

(

Germany

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-8481-4700](https://orcid.org/0000-0002-8481-4700)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Thorsten+Hanke)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Hanke T)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Hanke Thorsten%22)

[... Show more](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#)

Tiny Jaarsma,

Tiny Jaarsma

(

Sweden

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-4197-4026](https://orcid.org/0000-0002-4197-4026)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Tiny+Jaarsma)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Jaarsma T)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Jaarsma Tiny%22)

Maddalena Lettino,

Maddalena Lettino

(

Italy

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-0146-9196](https://orcid.org/0000-0003-0146-9196)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Maddalena+Lettino)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Lettino M)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Lettino Maddalena%22)

Maja-Lisa Løchen,

Maja-Lisa Løchen

(

Norway

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-8532-6573](https://orcid.org/0000-0002-8532-6573)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Maja-Lisa+L%c3%b8chen)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Løchen M)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Løchen Maja-Lisa%22)

R Thomas Lumbers,

R Thomas Lumbers

(

United Kingdom

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-9077-4741](https://orcid.org/0000-0002-9077-4741)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=R+Thomas+Lumbers)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Lumbers R)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Lumbers R Thomas%22)

Bart Maesen,

Bart Maesen

(

Netherlands

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0001-8622-1450](https://orcid.org/0000-0001-8622-1450)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Bart+Maesen)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Maesen B)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Maesen Bart%22)

Inge Mølgaard,

Inge Mølgaard

(

Denmark

)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Inge+M%c3%b8lgaard)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Mølgaard I)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Mølgaard Inge%22)

Giuseppe M C Rosano,

Giuseppe M C Rosano

(

United Kingdom

)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Giuseppe+M+C+Rosano)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Rosano G)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Rosano Giuseppe M C%22)

Prashanthan Sanders,

Prashanthan Sanders

(

Australia

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-3803-8429](https://orcid.org/0000-0003-3803-8429)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Prashanthan+Sanders)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Sanders P)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Sanders Prashanthan%22)

Renate B Schnabel,

Renate B Schnabel

(

Germany

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0001-7170-9509](https://orcid.org/0000-0001-7170-9509)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Renate+B+Schnabel)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Schnabel R)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Schnabel Renate B%22)

Piotr Suwalski,

Piotr Suwalski

(

Poland

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-2670-4164](https://orcid.org/0000-0003-2670-4164)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Piotr+Suwalski)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Suwalski P)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Suwalski Piotr%22)

Emma Svennberg,

Emma Svennberg

(

Sweden

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-6413-0870](https://orcid.org/0000-0002-6413-0870)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Emma+Svennberg)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Svennberg E)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Svennberg Emma%22)

Juan Tamargo,

Juan Tamargo

(

Spain

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-7979-7758](https://orcid.org/0000-0002-7979-7758)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Juan+Tamargo)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Tamargo J)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Tamargo Juan%22)

Otilia Tica,

Otilia Tica

(

Romania

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-6019-122X](https://orcid.org/0000-0002-6019-122X)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Otilia+Tica)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Tica O)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Tica Otilia%22)

Vassil Traykov,

Vassil Traykov

(

Bulgaria

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-9523-6416](https://orcid.org/0000-0002-9523-6416)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Vassil+Traykov)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Traykov V)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Traykov Vassil%22)

Stylianos Tzeis,

Stylianos Tzeis

(

Greece

)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Stylianos+Tzeis)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Tzeis S)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Tzeis Stylianos%22)

Dipak Kotecha,

Dipak Kotecha[](javascript:;)

(Chairperson)

(

United Kingdom

)

Corresponding author: Dipak Kotecha, Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom & NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. Tel: +44 121 371 8124. Email: [d.kotecha@bham.ac.uk](mailto:d.kotecha@bham.ac.uk)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-2570-9812](https://orcid.org/0000-0002-2570-9812)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Dipak+Kotecha)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Kotecha D)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Kotecha Dipak%22)

ESC Scientific Document Group

ESC Scientific Document Group

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=ESC+Scientific+Document+Group+)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=ESC Scientific Document Group )

[Google Scholar](http://scholar.google.com/scholar?q=author:%22ESC Scientific Document Group %22)

Isabelle C Van Gelder and Dipak Kotecha Chairpersons contributed equally to the document and are joint corresponding authors.

Michiel Rienstra and Karina V Bunting Task Force Co-ordinators contributed equally to the document.

**Author/Task Force Member affiliations are listed in author information.**

Representing European Stroke Organisation (ESO).

Representing European Association for Cardio-Thoracic Surgery (EACTS).

**ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.**

**ESC subspecialty communities having participated in the development of this document:**

**Associations:** Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).

**Councils:** Council for Cardiology Practice, Council of Cardio-Oncology, Council on Cardiovascular Genomics, Council on Stroke.

**Working Groups:** Cardiac Cellular Electrophysiology, Cardiovascular Pharmacotherapy, E-Cardiology, Thrombosis.

**Patient Forum**

  ![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176il3.jpeg?Expires=1728478928&Signature=SCxXno2RCVJu9VT~QIHm21GGcsbgpf7A~ElUn6~pr8zCjIU-QidKZHdjrvQDai0RYadQPJjrI0oMTT42q-s-OQQsniNpJQ4k8KcXpAgH3p9U9tnzJROx0pxjH-0D3TqPOP5bk2HpFgUP7rp-QEI8Uu40259fNWqs~jZHO596ISdu2CO7dZjouSDQ1OBujUArZRsZWyXBuCUld0iPWoGziVHbr2c0H3sXEBPahLI~sJdaYxBtKQoMrUKERe0SLg7L5EZsY1ows-nVI0DWLQRjJ5e9m17mwu1KfvURMeUQDv-2oTpTVSnoE6HPBwC-z5AqWTfluCCTXhcG6wUjWx6Jpw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  **All experts involved in the development of these guidelines have submitted declarations of interest which are reported in a supplementary document to the guidelines. See the _European Heart Journal_ online or [www.escardio.org/guidelines](https://www.escardio.org/Guidelines) for supplementary documents as well as evidence tables.**

**Disclaimer.** The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.

**Permissions.** The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the _European Heart Journal_ and the party authorized to handle such permissions on behalf of the ESC ([journals.permissions@oup.com](mailto:journals.permissions@oup.com)).

[Author Notes](javascript:;)

_European Heart Journal_, ehae176, [https://doi.org/10.1093/eurheartj/ehae176](https://doi.org/10.1093/eurheartj/ehae176)

Published:

30 August 2024

$(document).ready(function () { $('.article-top-widget').on('click', '.ati-toggle-trigger', function () { $(this).find('.icon-general-add, .icon-minus').toggleClass('icon-minus icon-general-add'); $(this).siblings('.ati-toggle-content').toggleClass('hide'); }); // In Chrome, an anchor tag with target="\_blank" and a "mailto:" href opens a new tab/window as well as the email client // I suspect this behavior will be corrected in the future // Remove the target="\_blank" $('ul.wi-affiliationList').find('a\[href^="mailto:"\]').each(function () { $(this).removeAttr('target'); }); });

- [![pdf](https://academic.oup.com//oup.silverchair-cdn.com/UI/app/svg/pdf.svg)PDF](https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehae176/58970727/ehae176.pdf)
- [Split View](javascript:;)
- [

Views



](javascript:;)

- [Article contents](javascript:;)
- [Figures & tables](javascript:;)
- [Supplementary Data](javascript:;)
- [Cite](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#)

### Cite

Isabelle C Van Gelder, Michiel Rienstra, Karina V Bunting, Ruben Casado-Arroyo, Valeria Caso, Harry J G M Crijns, Tom J R De Potter, Jeremy Dwight, Luigina Guasti, Thorsten Hanke, Tiny Jaarsma, Maddalena Lettino, Maja-Lisa Løchen, R Thomas Lumbers, Bart Maesen, Inge Mølgaard, Giuseppe M C Rosano, Prashanthan Sanders, Renate B Schnabel, Piotr Suwalski, Emma Svennberg, Juan Tamargo, Otilia Tica, Vassil Traykov, Stylianos Tzeis, Dipak Kotecha, ESC Scientific Document Group , 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. _Endorsed by the European Stroke Organisation (ESO)_, _European Heart Journal_, 2024;, ehae176, [https://doi.org/10.1093/eurheartj/ehae176](https://doi.org/10.1093/eurheartj/ehae176)

Select Format Select format .ris (Mendeley, Papers, Zotero) .enw (EndNote) .bibtex (BibTex) .txt (Medlars, RefWorks) Download citation

[Close](javascript:;)

- [_Permissions Icon_ Permissions](https://s100.copyright.com/AppDispatchServlet?publisherName=OUP&publication=1522-9645&title=2024%20ESC%20Guidelines%20for%20the%20management%20of%20atrial%20fibrillation%20developed%20in%20collaboration%20with%20the%20European%20Association%20for%20Cardio-Thoracic%20Surgery%20%28EACTS%29%20Developed%20by%20the%20task%20force%20for%20the%20management%20of%20atrial%20fibrillation%20of%20the%20European%20Society%20of%20Cardiology%20%28ESC%29%2C%20with%20the%20special%20contribution%20of%20the%20European%20Heart%20Rhythm%20Association%20%28EHRA%29%20of%20the%20ESC.%20Endorsed%20by%20the%20European%20Stroke%20Organisation%20%28ESO%29&publicationDate=2024-08-30&volumeNum=&issueNum=&author=Van%20Gelder%2C%20Isabelle%20C%3B%20Rienstra%2C%20Michiel&startPage=1&endPage=101&contentId=10.1093%2Feurheartj%2Fehae176&oa=&copyright=%C2%A9%20The%20European%20Society%20of%20Cardiology%202024.%20All%20rights%20reserved.%20For%20permissions%2C%20please%20email%3A%20journals.permissions%40oup.com.&orderBeanReset=True)

- [_Share Icon_ Share](javascript:;)
- [Facebook](javascript:;)
- [Twitter](javascript:;)
- [LinkedIn](javascript:;)
- [Email](javascript:;)

Navbar Search Filter European Heart JournalESC Publications Cardiovascular MedicineBooksJournalsOxford Academic Mobile Enter search term[Search](javascript:;)

[Close](javascript:;)

Navbar Search Filter European Heart JournalESC Publications Cardiovascular MedicineBooksJournalsOxford Academic Enter search term[Search](javascript:;)

[Advanced Search](https://academic.oup.com/eurheartj/advanced-search?page=1&fl_SiteID=5375&SearchSourceType=1)

[Search Menu](javascript:;)

[Guidelines](javascript:;), [Atrial fibrillation](javascript:;), [AF-CARE](javascript:;), [Comorbidity](javascript:;), [Risk factors](javascript:;), [Anticoagulation](javascript:;), [Rate control](javascript:;), [Rhythm control](javascript:;), [Cardioversion](javascript:;), [Antiarrhythmic drugs](javascript:;), [Catheter ablation](javascript:;), [AF surgery](javascript:;), [Evaluation](javascript:;), [Stroke](javascript:;), [Thromboembolism](javascript:;)

Topic:

- [anticoagulation](javascript:;)
- [atrial fibrillation](javascript:;)
- [electric countershock](javascript:;)
- [thromboembolism](javascript:;)
- [cardiac ablation](javascript:;)
- [hemorrhage](javascript:;)
- [cerebrovascular accident](javascript:;)
- [ischemic stroke](javascript:;)
- [heart failure](javascript:;)
- [advisory committees](javascript:;)
- [comorbidity](javascript:;)
- [surgical procedures, operative](javascript:;)
- [diagnosis](javascript:;)
- [guidelines](javascript:;)
- [vitamin k antagonists](javascript:;)
- [ablation](javascript:;)
- [risk of excessive or recurrent bleeding](javascript:;)
- [european society of cardiology](javascript:;)
- [rhythm](javascript:;)
- [direct oral anticoagulants](javascript:;)

## Table of contents

- 1\. Preamble 6

- 2\. Introduction 8

-  2.1. What is new 9

- 3\. Definitions and clinical impact 13

-  3.1. Definition and classification of AF 13

-  3.2. Diagnostic criteria for AF 14

-  3.3. Symptoms attributable to AF 15

-  3.4. Diagnostic evaluation of new AF 15

-  3.5. Adverse events associated with AF 16

-  3.6. Atrial flutter 17

- 4\. Patient pathways and management of AF 17

-  4.1. Patient-centred, multidisciplinary AF management 17

-   4.1.1. The patient at the heart of care 17

-   4.1.2. Education and shared decision-making 18

-   4.1.3. Education of healthcare professionals 19

-   4.1.4. Inclusive management of AF 19

-  4.2. Principles of AF-CARE 19

- 5\. \[C\] Comorbidity and risk factor management 25

-  5.1. Hypertension 26

-  5.2. Heart failure 26

-  5.3. Type 2 diabetes mellitus 27

-  5.4. Obesity 27

-  5.5. Obstructive sleep apnoea 27

-  5.6. Physical inactivity 27

-  5.7. Alcohol excess 28

- 6\. \[A\] Avoid stroke and thromboembolism 28

-  6.1. Initiating oral anticoagulation 28

-   6.1.1. Decision support for anticoagulation in AF 28

-  6.2. Oral anticoagulants 30

-   6.2.1. Direct oral anticoagulants 31

-   6.2.2. Vitamin K antagonists 32

-   6.2.3. Clinical vs. device-detected subclinical AF 32

-  6.3. Antiplatelet drugs and combinations with anticoagulants 33

-  6.4. Residual ischaemic stroke risk despite anticoagulation 33

-  6.5. Percutaneous left atrial appendage occlusion 33

-  6.6. Surgical left atrial appendage occlusion 34

-  6.7. Bleeding risk 35

-   6.7.1. Assessment of bleeding risk 35

-   6.7.2. Management of bleeding on anticoagulant therapy 35

- 7\. \[R\] Reduce symptoms by rate and rhythm control 38

-  7.1. Management of heart rate in patients with AF 38

-   7.1.1. Indications and target heart rate 39

-   7.1.2. Heart rate control in the acute setting 39

-   7.1.3. Long-term heart rate control 39

-   7.1.4. Atrioventricular node ablation and pacemaker implantation 40

-  7.2. Rhythm control strategies in patients with AF 40

-   7.2.1. General principles and anticoagulation 40

-   7.2.2. Electrical cardioversion 43

-   7.2.3. Pharmacological cardioversion 43

-   7.2.4. Antiarrhythmic drugs 44

-   7.2.5. Catheter ablation 45

-   7.2.6. Anticoagulation in patients undergoing catheter ablation 46

-   7.2.7. Endoscopic and hybrid AF ablation 47

-   7.2.8. AF ablation during cardiac surgery 48

-   7.2.9. Atrial tachycardia after pulmonary vein isolation 48

- 8\. \[E\] Evaluation and dynamic reassessment 48

-  8.1. Implementation of dynamic care 49

-  8.2. Improving treatment adherence 49

-  8.3. Cardiac imaging 49

-  8.4. Patient-reported outcome measures 50

- 9\. The AF-CARE pathway in specific clinical settings 51

-  9.1. AF-CARE in unstable patients 51

-  9.2. AF-CARE in acute and chronic coronary syndromes 51

-  9.3. AF-CARE in vascular disease 53

-  9.4. AF-CARE in acute stroke or intracranial haemorrhage 53

-   9.4.1. Management of acute ischaemic stroke 53

-   9.4.2. Introduction or re-introduction of anticoagulation after ischaemic stroke 54

-   9.4.3. Introduction or re-introduction of anticoagulation after haemorrhagic stroke 54

-  9.5. AF-CARE for trigger-induced AF 54

-  9.6. AF-CARE in post-operative patients 55

-  9.7. AF-CARE in embolic stroke of unknown source 55

-  9.8. AF-CARE during pregnancy 56

-  9.9. AF-CARE in congenital heart disease 57

-  9.10. AF-CARE in endocrine disorders 57

-  9.11. AF-CARE in inherited cardiomyopathies and primary arrhythmia syndromes 57

-  9.12. AF-CARE in cancer 58

-  9.13. AF-CARE in older, multimorbid, or frail patients 58

-  9.14. AF-CARE in atrial flutter 58

- 10\. Screening and prevention of AF 58

-  10.1. Epidemiology of AF 58

-  10.2. Screening tools for AF 59

-  10.3. Screening strategies for AF 60

-   10.3.1. Single timepoint screening ‘snapshot’ 61

-   10.3.2. Prolonged screening 61

-  10.4. Factors associated with incident AF 62

-  10.5. Primary prevention of AF 62

-   10.5.1. Hypertension 63

-   10.5.2. Heart failure 63

-   10.5.3. Type 2 diabetes mellitus 63

-   10.5.4. Obesity 63

-   10.5.5. Sleep apnoea syndrome 63

-   10.5.6. Physical activity 63

-   10.5.7. Alcohol intake 64

- 11\. Key messages 64

- 12\. Gaps in evidence 64

- 13\. ‘What to do’ and ‘What not to do’ messages from the guidelines 66

- 14\. Evidence tables 69

- 15\. Data availability statement 69

- 16\. Author information 69

- 17\. Appendix 70

- 18\. References 71


## Tables of Recommendations

- Recommendation Table 1 — Recommendations for the diagnosis of AF (see also Evidence Table 1) 15

- Recommendation Table 2 — Recommendations for symptom evaluation in patients with AF (see also Evidence Table 2) 15

- Recommendation Table 3 — Recommendations for diagnostic evaluation in patients with new AF (see also Evidence Table 3) 15

- Recommendation Table 4 — Recommendations for patient-centred care and education (see also Evidence Table 4) 19

- Recommendation Table 5 — Recommendations for comorbidity and risk factor management in AF (see also Evidence Table 5) 26

- Recommendation Table 6 — Recommendations to assess and manage thromboembolic risk in AF (see also Evidence Table 6) 29

- Recommendation Table 7 — Recommendations for oral anticoagulation in AF (see also Evidence Table 7) 31

- Recommendation Table 8 — Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8) 33

- Recommendation Table 9 — Recommendations for thromboembolism despite anticoagulation (see also Evidence Table 9) 33

- Recommendation Table 10 — Recommendations for percutaneous left atrial appendage occlusion (see also Evidence Table 10) 34

- Recommendation Table 11 — Recommendations for surgical left atrial appendage occlusion (see also Evidence Table 11) 35

- Recommendation Table 12 — Recommendations for assessment of bleeding risk (see also Evidence Table 12) 35

- Recommendation Table 13 — Recommendations for management of bleeding in anticoagulated patients (see also Evidence Table 13) 38

- Recommendation Table 14 — Recommendations for heart rate control in patients with AF (see also Evidence Table 14) 38

- Recommendation Table 15 — Recommendations for general concepts in rhythm control (see also Evidence Table 15) 42

- Recommendation Table 16 — Recommendations for electrical cardioversion of AF (see also Evidence Table 16) 43

- Recommendation Table 17 — Recommendations for pharmacological cardioversion of AF (see also Evidence Table 17) 43

- Recommendation Table 18 — Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm (see also Evidence Table 18) 45

- Recommendation Table 19 — Recommendations for catheter ablation of AF (see also Evidence Table 19) 46

- Recommendation Table 20 — Recommendations for anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20) 47

- Recommendation Table 21 — Recommendations for endoscopic and hybrid AF ablation (see also Evidence Table 21) 47

- Recommendation Table 22 — Recommendations for AF ablation during cardiac surgery (see also Evidence Table 22) 48

- Recommendation Table 23 — Recommendations to improve patient experience (see also Evidence Table 23) 51

- Recommendation Table 24 — Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24) 53

- Recommendation Table 25 — Recommendations for trigger-induced AF (see also Evidence Table 25) 55

- Recommendation Table 26 — Recommendations for management of post-operative AF (see also Evidence Table 26) 55

- Recommendation Table 27 — Recommendations for patients with embolic stroke of unknown source (see also Evidence Table 27) 56

- Recommendation Table 28 — Recommendations for patients with AF during pregnancy (see also Evidence Table 28) 56

- Recommendation Table 29 — Recommendations for patients with AF and congenital heart disease (see also Evidence Table 29) 57

- Recommendation Table 30 — Recommendations for prevention of thromboembolism in atrial flutter (see also Evidence Table 30) 58

- Recommendation Table 31 — Recommendations for screening for AF (see also Evidence Table 31) 61

- Recommendation Table 32 — Recommendations for primary prevention of AF (see also Evidence Table 32) 63


## List of tables

- Table 1 Classes of recommendations 7

- Table 2 Levels of evidence 7

- Table 3 New recommendations 9

- Table 4 Revised recommendations 12

- Table 5 Definitions and classifications for the temporal pattern of AF 14

- Table 6 Other clinical concepts relevant to AF 14

- Table 7 The modified European Heart Rhythm Association (mEHRA) symptom classification 16

- Table 8 Diagnostic work-up for patients with AF 17

- Table 9 Achieving patient-centred AF management 18

- Table 10 Updated definitions for the CHA2DS2-VA score 29

- Table 11 Recommended doses for direct oral anticoagulant therapy 32

- Table 12 Drugs for rate control in AF 39

- Table 13 Antiarrhythmic drugs for sinus rhythm restoration 44

- Table 14 Non-cardiac conditions associated with trigger-induced AF 54

- Table 15 Tools for AF screening 60

- Table 16 Factors associated with incident AF 62

- Table 17 ‘What to do’ and ‘what not to do’ 66


## List of figures

- Figure 1 Impacts and outcomes associated with clinical AF. AF, atrial fibrillation 16

- Figure 2 Multidisciplinary approach to AF management 18

- Figure 3 Central illustration. Patient pathway for AF-CARE (see Figures 4, 5, 6, and 7 for the \[R\] pathways for first-diagnosed, paroxysmal, persistent and permanent AF) 20

- Figure 4 \[R\] Pathway for patients with first-diagnosed AF 21

- Figure 5 \[R\] Pathway for patients with paroxysmal AF 22

- Figure 6 \[R\] Pathway for patients with persistent AF 23

- Figure 7 \[R\] Pathway for patients with permanent AF 24

- Figure 8 Management of key comorbidities to reduce AF recurrence 25

- Figure 9 Common drug interactions with oral anticoagulants 30

- Figure 10 Modifying the risk of bleeding associated with OAC 36

- Figure 11 Management of oral anticoagulant-related bleeding in patients with AF 37

- Figure 12 Approaches for cardioversion in patients with AF 41

- Figure 13 Relevance of echocardiography in the AF-CARE pathway 50

- Figure 14 Antithrombotic therapy in patients with AF and acute or chronic coronary syndromes 52

- Figure 15 Non-invasive diagnostic methods for AF screening 59

- Figure 16 Approaches to screening for AF 61


## Abbreviations and acronyms

 - AAD

Antiarrhythmic drugs

 - ACE

Angiotensin-converting enzyme

 - ACEi

Angiotensin-converting enzyme inhibitor

 - ACS

Acute coronary syndromes

 - ACTIVE W

Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (trial)

 - AF

Atrial fibrillation

 - AF-CARE

Atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment

 - AFEQT

Atrial Fibrillation Effect on QualiTy-of-Life (questionnaire)

 - AFFIRM

Atrial Fibrillation Follow-up Investigation of Rhythm Management (trial)

 - AFL

Atrial flutter

 - AFQLQ

Atrial Fibrillation Quality of Life Questionnaire

 - AF-QoL

Atrial Fibrillation Quality of Life (questionnaire)

 - AFSS

Atrial Fibrillation Severity Scale

 - AI

Artificial intelligence

 - APACHE-AF

Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation (trial)

 - APAF-CRT

Ablate and Pace for Atrial Fibrillation—cardiac resynchronization therapy

 - ARB

Angiotensin receptor blocker

 - ARTESiA

Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (trial)

 - AT

Atrial tachycardia

 - ATHENA

A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg twice daily for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter (trial)

 - AUGUSTUS

An open-label, 2 × 2 factorial, randomized controlled, clinical trial to evaluate the safety of apixaban vs. vitamin k antagonist and aspirin vs. aspirin placebo in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention

 - AVERROES

Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (trial)

 - AVN

Atrioventricular node

 - b.p.m.

Beats per minute

 - BMI

Body mass index

 - BNP

B-type natriuretic peptide

 - BP

Blood pressure

 - C<sub>2</sub>HEST

Coronary artery disease or chronic obstructive pulmonary disease (1 point each); hypertension (1 point); elderly (age ≥75 years, 2 points); systolic heart failure (2 points); thyroid disease (hyperthyroidism, 1 point)

 - CABANA

Catheter Ablation versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (trial)

 - CAD

Coronary artery disease

 - CASTLE-AF

Catheter Ablation versus Standard Conventional Treatment in Patients With Left Ventricle (LV) Dysfunction and AF (trial)

 - CASTLE-HTx

Catheter Ablation for Atrial Fibrillation in Patients With End-Stage Heart Failure and Eligibility for Heart Transplantation (trial)

 - CCS

Chronic coronary syndrome

 - CHADS<sub>2</sub>

Congestive heart failure, hypertension, age >75 years, diabetes; previous stroke (2 points)

 - CHA<sub>2</sub>DS<sub>2</sub>\-VA

Congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years (score)

 - CHA<sub>2</sub>DS<sub>2</sub>\-VASc

Congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke or TIA or thromboembolism (2 points), vascular disease, age 65–74 years, sex category

 - CKD

Chronic kidney disease

 - CMR

Cardiac magnetic resonance

 - COMPASS

Cardiovascular Outcomes for People Using Anticoagulation Strategies (trial)

 - CPAP

Continuous positive airway pressure

 - CrCl

Creatinine clearance

 - CRT

Cardiac resynchronization therapy

 - CT

Computed tomography

 - CTA

Computed tomography angiography

 - CTI

Cavo-tricuspid isthmus

 - DAPT

Dual antiplatelet therapy

 - DOAC

Direct oral anticoagulant

 - EAST-AFNET 4

Early treatment of Atrial fibrillation for Stroke prevention Trial

 - ECG

Electrocardiogram

 - ECV

Electrical cardioversion

 - EHRA

European Heart Rhythm Association

 - ELAN

Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (trial)

 - ESUS

Embolic stroke of undetermined source

 - FFP

Fresh frozen plasma

 - GI

Gastrointestinal

 - GWAS

Genome-wide association studies

 - HAS-BLED

Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly (score)

 - HAVOC

Hypertension, age, valvular heart disease, peripheral vascular disease, obesity, congestive heart failure, and coronary artery disease

 - HbA1c

Haemoglobin A1c (glycated or glycosylated haemoglobin)

 - HCM

Hypertrophic cardiomyopathy

 - HF

Heart failure

 - HFmrEF

Heart failure with mildly reduced ejection fraction

 - HFpEF

Heart failure with preserved ejection fraction

 - HFrEF

Heart failure with reduced ejection fraction

 - HR

Hazard ratio

 - i.v.

Intravenous

 - ICH

Intracranial haemorrhage

 - ICHOM

International Consortium for Health Outcomes Measurement

 - IMT

Intima-media thickness

 - INR

International normalized ratio (of prothrombin time)

 - LA

Left atrium

 - LAA

Left atrial appendage

 - LAAO

Left atrial appendage occlusion

 - LAAOS III

Left Atrial Appendage Occlusion Study

 - LEGACY

Long-Term Effect of Goal directed weight management on Atrial Fibrillation Cohort: a 5 Year follow-up study

 - LMWH

Low molecular weight heparin

 - LOOP

Atrial Fibrillation Detected by Continuous ECG Monitoring (trial)

 - LV

Left ventricle

 - LVEF

Left ventricular ejection fraction

 - LVH

Left ventricular hypertrophy

 - mEHRA

Modified European Heart Rhythm Association score

 - MI

Myocardial infarction

 - MRI

Magnetic resonance imaging

 - NOAH

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (trial)

 - NSAID

Non-steroidal anti-inflammatory drug

 - NT-proBNP

N-terminal pro-B-type natriuretic peptide

 - NYHA

New York Heart Association

 - OAC

Oral anticoagulant(s)

 - OR

Odds ratio

 - OSA

Obstructive sleep apnoea

 - PAD

Peripheral arterial disease

 - PCC

Prothrombin complex concentrate

 - PCI

Percutaneous intervention

 - PFO

Patent foramen ovale

 - POAF

Post-operative atrial fibrillation

 - PPG

Photoplethysmography

 - PROM

Patient-reported outcome measure

 - PVD

Peripheral vascular disease

 - PVI

Pulmonary vein isolation

 - QLAF

Quality of Life in Atrial Fibrillation (questionnaire)

 - QRS

Q wave, R wave, and S wave, the ‘QRS complex’ represents ventricular depolarization

 - RACE 7 ACWAS

Rate Control versus Electrical Cardioversion Trial 7—Acute Cardioversion versus Wait and See (trial)

 - RACE I

RAte Control versus Electrical cardioversion study

 - RACE II

Rate Control Efficacy in Permanent Atrial Fibrillation (trial)

 - RACE 3

Routine versus Aggressive upstream rhythm Control for prevention of Early AF in heart failure (trial)

 - RACE 4

IntegRAted Chronic Care Program at Specialized AF Clinic Versus Usual CarE in Patients with Atrial Fibrillation (trial)

 - RATE-AF

RAte control Therapy Evaluation in permanent Atrial Fibrillation (trial)

 - RCT

Randomized controlled trial

 - RR

Relative risk

 - SAVE

Sleep Apnea cardioVascular Endpoints (trial)

 - SBP

Systolic blood pressure

 - SGLT2

Sodium-glucose cotransporter-2

 - SIC-AF

Successful Intravenous Cardioversion for Atrial Fibrillation

 - SORT-AF

Supervised Obesity Reduction Trial for AF Ablation Patients (trial)

 - SoSTART

Start or STop Anticoagulants Randomised Trial

 - SR

Sinus rhythm

 - STEEER-AF

Stroke prevention and rhythm control Therapy: Evaluation of an Educational programme of the European Society of Cardiology in a cluster-Randomised trial in patients with Atrial Fibrillation (trial)

 - STEMI

ST-segment elevation myocardial infarction

 - STROKESTOP

Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden (trial)

 - TE

Thromboembolism

 - TIA

Transient ischaemic attack

 - TIMING

Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation (trial)

 - TOE

Transoesophageal echocardiography

 - TSH

Thyroid-stimulating hormone

 - TTE

Transthoracic echocardiogram

 - TTR

Time in therapeutic range

 - UFH

Unfractionated heparin

 - VKA

Vitamin K antagonist


## 1\. Preamble

Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use by health professionals and the European Society of Cardiology (ESC) makes its Guidelines freely available.

ESC Guidelines do not override the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient or the patient's caregiver where appropriate and/or necessary. It is also the health professional's responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession.

ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated when warranted by new evidence. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website ([https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines](https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines)). This guideline updates and replaces the previous version from 2020.

The Members of this task force were selected by the ESC to include professionals involved with the medical care of patients with this pathology as well as patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include members from across the whole of the ESC region and from relevant ESC Subspecialty Communities. Consideration was given to diversity and inclusion, notably with respect to gender and country of origin. The task force performed a critical review and evaluation of the published literature on diagnostic and therapeutic approaches including assessment of the risk–benefit ratio. The strength of every recommendation and the level of evidence supporting them were weighed and scored according to predefined scales as outlined in _[Tables 1](javascript:;) and [2](javascript:;)_ below. Patient-reported outcome measures (PROMs) and patient-reported experience measures were also evaluated as the basis for recommendations and/or discussion in these guidelines. The task force followed ESC voting procedures and all approved recommendations were subject to a vote and achieved at least 75% agreement among voting members. Members of the task force with declared interests on specific topics were asked to abstain from voting on related recommendations.

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules which can be found on the ESC website ([http://www.escardio.org/guidelines](http://www.escardio.org/guidelines)) and have been compiled in a report published in a supplementary document with the guidelines. Funding for the development of ESC Guidelines is derived entirely from the ESC with no involvement of the healthcare industry.

Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884123)

Classes of recommendations

![Classes of recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176il1.jpeg?Expires=1728478928&Signature=TXNDe10I9wudNHyUYMQO4DJUEdaCdZ5NeMOccA-iyPe~qP17F7V7ycDl5A16ItRuSNSVljoQqmjPcXfC4B~-at1C9hOyFP8Gne3s~uq9RFiGRJ89f6FPUEqYGIVeT0xO9aGW9fccY3KcPCK9rSqEFzydmF0nSQcylLKp0umLrwr773jsrV6acRT1m9EtRVTHkIT5jL5bPsrTWujxH1TKiuOTZI6hYFnu3wPiNKcNDCT~GEjrICVMUDY9Z1AL-R8eMWyx2h2Gw6e9RPvdhQTDBPrxhRF7iq~jNeeHlg3Pd7RfU6p22gbjxQYEFz9U~KjASINBb1AtJgBqcBYrGJcK6Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884123)

Classes of recommendations

![Classes of recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176il1.jpeg?Expires=1728478928&Signature=TXNDe10I9wudNHyUYMQO4DJUEdaCdZ5NeMOccA-iyPe~qP17F7V7ycDl5A16ItRuSNSVljoQqmjPcXfC4B~-at1C9hOyFP8Gne3s~uq9RFiGRJ89f6FPUEqYGIVeT0xO9aGW9fccY3KcPCK9rSqEFzydmF0nSQcylLKp0umLrwr773jsrV6acRT1m9EtRVTHkIT5jL5bPsrTWujxH1TKiuOTZI6hYFnu3wPiNKcNDCT~GEjrICVMUDY9Z1AL-R8eMWyx2h2Gw6e9RPvdhQTDBPrxhRF7iq~jNeeHlg3Pd7RfU6p22gbjxQYEFz9U~KjASINBb1AtJgBqcBYrGJcK6Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884124)

Levels of evidence

![Levels of evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176il2.jpeg?Expires=1728478928&Signature=TSQj3ZVy2fApwN1OxMNSKOGpnoHY7tVJ8~RYU845GvT6itutpvO87QXuF8~CxGduA~eui1t1ODfyksWH8xEcPxetEaMUNgiRjEdcrqmukTHLlZx4pmQTq-NDKbKHfTdr50PSLCJyOHhrCc-RpSiyVtiycITDIObzneLp2lFCM4ZmrSKM0NpM72UpqvSvDfKNBwMZcethwAIYJfpOUoC~JVp4ff-nUmadO0fVcgUPw2ziNa62XUIta5Hib2U3moBzTNfDQe9uAzx3608nRSG-~9I4tL9pfiBKkUcYVzxgWC0vwVWton~DJdnhBwE45Z~GeaclJdYgE1ZsTLR2A4MVbg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884124)

Levels of evidence

![Levels of evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176il2.jpeg?Expires=1728478928&Signature=TSQj3ZVy2fApwN1OxMNSKOGpnoHY7tVJ8~RYU845GvT6itutpvO87QXuF8~CxGduA~eui1t1ODfyksWH8xEcPxetEaMUNgiRjEdcrqmukTHLlZx4pmQTq-NDKbKHfTdr50PSLCJyOHhrCc-RpSiyVtiycITDIObzneLp2lFCM4ZmrSKM0NpM72UpqvSvDfKNBwMZcethwAIYJfpOUoC~JVp4ff-nUmadO0fVcgUPw2ziNa62XUIta5Hib2U3moBzTNfDQe9uAzx3608nRSG-~9I4tL9pfiBKkUcYVzxgWC0vwVWton~DJdnhBwE45Z~GeaclJdYgE1ZsTLR2A4MVbg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

The ESC Clinical Practice Guidelines (CPG) Committee supervises and co-ordinates the preparation of new guidelines and is responsible for the approval process. In addition to review by the CPG Committee, ESC Guidelines undergo multiple rounds of double-blind peer review by external experts, including members from across the whole of the ESC region, all National Cardiac Societies of the ESC and from relevant ESC Subspecialty Communities. After appropriate revisions, the guidelines are signed off by all the experts in the task force. The finalized document is signed off by the CPG Committee for publication in the _European Heart Journal_.

ESC Guidelines are based on analyses of published evidence, chiefly on clinical trials and meta-analyses of trials, but potentially including other types of studies. Evidence tables summarizing key information from relevant studies are generated early in the guideline development process to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and reinforce transparency in the guidelines development process. The tables are published in their own section of ESC Guidelines and reference specific recommendation tables.

Off-label use of medication may be presented in this guideline if a sufficient level of evidence shows that it can be considered medically appropriate for a given condition. However, the final decisions concerning an individual patient must be made by the responsible health professional giving special consideration to:

- The specific situation of the patient. Unless otherwise provided for by national regulations, off-label use of medication should be limited to situations where it is in the patient's interest with regard to the quality, safety, and efficacy of care, and only after the patient has been informed and has provided consent.

- Country-specific health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.


## 2\. Introduction

Atrial fibrillation (AF) is one of the most commonly encountered heart conditions, with a broad impact on all health services across primary and secondary care. The prevalence of AF is expected to double in the next few decades as a consequence of the ageing population, an increasing burden of comorbidities, improved awareness, and new technologies for detection.

The effects of AF are variable across individual patients; however, morbidity from AF remains highly concerning. Patients with AF can suffer from a variety of symptoms and poor quality of life. Stroke and heart failure as consequences of AF are now well appreciated by healthcare professionals, but AF is also linked to a range of other thromboembolic outcomes. These include subclinical cerebral damage (potentially leading to vascular dementia), and thromboembolism to every other organ, all of which contribute to the higher risk of mortality associated with AF.

The typical drivers of AF onset and progression are a range of comorbidities and associated risk factors. To achieve optimal care for patients with AF, it is now widely accepted that these comorbidities and risk factors must be managed early and in a dynamic way. Failure to do so contributes to recurrent cycles of AF, treatment failure, poor patient outcomes, and a waste of healthcare resources. In this iteration of the European Society of Cardiology (ESC) practice guidelines on AF, the task force has consolidated and evolved past approaches to develop the AF-CARE framework (Atrial Fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment). Comorbidities and risk factors is placed as the initial and central component of patient management. This should be considered first as it applies to all patients with AF, regardless of their thromboembolic risk factors or any symptoms that might warrant intervention. This is followed by considering how best to \[A\] avoid stroke and thromboembolism, and then the options available to reduce symptoms, and in some cases improve prognosis, through \[R\] rate and rhythm control. \[E\] Evaluation and reassessment should be individualized for every patient, with a dynamic approach that accounts for how AF and its associated conditions change over time.

Patient empowerment is critical in any long-term medical problem to achieve better outcomes, encourage adherence, and to seek timely guidance on changes in clinical status. A patient-centred, shared decision-making approach will facilitate the choice of management that suits each individual patient, particularly in AF where some therapies and interventions improve clinical outcomes, and others are focused on addressing symptoms and quality of life. Education and awareness are essential, not only for patients but also healthcare professionals in order to constrain the impact of AF on patients and healthcare services.

With this in mind, the task force have created a range of patient pathways that cover the major aspects of AF-CARE. At present, these remain based on the time-orientated classification of AF (first-diagnosed, paroxysmal, persistent, and permanent), but ongoing research may allow for pathology-based classifications and a future of personalized medicine. Clinical practice guidelines can only cover common scenarios with an evidence base, and so there remains a need for healthcare professionals to care for patients within a local multidisciplinary team. While guideline-adherent care has repeatedly been shown to improve patient outcomes, the actual implementation of guidelines is often poor in many healthcare settings. This has been demonstrated in the ESC's first randomized controlled trial (RCT), STEEER-AF (Stroke prevention and rhythm control Therapy: Evaluation of an Educational programme of the European Society of Cardiology in a cluster-Randomised trial in patients with Atrial Fibrillation), which has sought to improve guideline adherence in parallel to guideline production. The task force developing the 2024 AF Guidelines have made implementation a key goal by focusing on the underpinning evidence and using a consistent writing style for each recommendation (the intervention proposed, the population it should be applied to, and the potential value to the patient, followed by any exceptions). _[Tables 3](javascript:;)_ and _[4](javascript:;)_ below outline new recommendations and those with important revisions. These initiatives have been designed to make the _2024 ESC Guidelines for the management of AF_ easier to read, follow, and implement, with the aim of improving the lives of patients with AF. A patient version of these guidelines is also available at [http://www.escardio.org/Guidelines/guidelines-for-patients](http://www.escardio.org/Guidelines/guidelines-for-patients).

### 2.1. What is new

Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884136)

New recommendations

![New recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t3.jpeg?Expires=1728478928&Signature=U8JMswTWpQMT-~TwXGLCksmjBcz8l~YeCZka1lmirzyN5GHK-6zqNQbAp4eThHHnz9zr1XrT5y2Q2X6Yx751PQfzdIaFC4XiP4a4CSI0bNGESMSNwHstsQC6wirZnj5Tf8XgitsHyj-esqAWoITehcobEcHftkAwFCcPqlclhuOgMo4~oXG3vEP7MGAnoc-Op5pQ854d0AzZl3~s3740LkeuL0yzRwYGpshA6vtFRq5rUn1rs4KUJIeP-vc84pt-5FhQUTmd0k4am2BV7i9WvpMFf62-jVg-33qJerdVZlzui8L~2ffkAhDFTt9AuD6oL1wYEkyeDE7zOhwnAq1j4A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884136)

New recommendations

![New recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t3.jpeg?Expires=1728478928&Signature=U8JMswTWpQMT-~TwXGLCksmjBcz8l~YeCZka1lmirzyN5GHK-6zqNQbAp4eThHHnz9zr1XrT5y2Q2X6Yx751PQfzdIaFC4XiP4a4CSI0bNGESMSNwHstsQC6wirZnj5Tf8XgitsHyj-esqAWoITehcobEcHftkAwFCcPqlclhuOgMo4~oXG3vEP7MGAnoc-Op5pQ854d0AzZl3~s3740LkeuL0yzRwYGpshA6vtFRq5rUn1rs4KUJIeP-vc84pt-5FhQUTmd0k4am2BV7i9WvpMFf62-jVg-33qJerdVZlzui8L~2ffkAhDFTt9AuD6oL1wYEkyeDE7zOhwnAq1j4A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884137)

Revised recommendations

![Revised recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t4.jpeg?Expires=1728478928&Signature=hnhYtEceR6fr~eWR9wCtN-ZrxpUo0wn1l4emYTSK8tgasPlB963uBCTiV9sRPSFHOPVkeIMjaK6SPhVnZy5p6sxHPkjyFOnuS6oLXRqoj1~Oypj~cwO7M0zHBN6Zw1AJopqTrzk1RNRbUJHxORCmCmNCs3x0v1heW50GwQLRMcyFXY1-0LCdWbdclJsBcgAgTUOFIC2T6cUJLeaEc4GIbura6uCufXFfOyJy7dxa36CCtYVanX9qcFqr8a0LC2OjM3lEWgjJwZTFZtbObeDYw2tstFEjlX11rgaH5SBOkHoyJ7bhZmQsWVy5P4VvyawpkuTUj1TNmXaeSZp~vZCM1A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884137)

Revised recommendations

![Revised recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t4.jpeg?Expires=1728478928&Signature=hnhYtEceR6fr~eWR9wCtN-ZrxpUo0wn1l4emYTSK8tgasPlB963uBCTiV9sRPSFHOPVkeIMjaK6SPhVnZy5p6sxHPkjyFOnuS6oLXRqoj1~Oypj~cwO7M0zHBN6Zw1AJopqTrzk1RNRbUJHxORCmCmNCs3x0v1heW50GwQLRMcyFXY1-0LCdWbdclJsBcgAgTUOFIC2T6cUJLeaEc4GIbura6uCufXFfOyJy7dxa36CCtYVanX9qcFqr8a0LC2OjM3lEWgjJwZTFZtbObeDYw2tstFEjlX11rgaH5SBOkHoyJ7bhZmQsWVy5P4VvyawpkuTUj1TNmXaeSZp~vZCM1A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 3\. Definitions and clinical impact

### 3.1. Definition and classification of AF

Atrial fibrillation is one of the most common heart rhythm disorders. A supraventricular arrhythmia with uncoordinated atrial activation, AF results in a loss of effective atrial contraction (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478928&Signature=LeTi7xCg0DZMpxCixcN6zSZvbi-PIvNWtpQuMSNg3jTFo8H4ms8EdOwIz-bBU3hicL-g0WFc2z-3hGi7f5RQTiQxNAc0o~B24kGKyUCRc5yGbgWOUG1zxo3NtCpkehEK9uF3PBD9iuFkoXlXU1E~wfDrGbUjBWjPxPP8CZ-lR2Fydkj4P3oWN6sTT4DCuy~TytQjp9~PKREiFqdHHPiStM-4Fy3MWzbgC5~9Xln9cYxRbp7UtP6suHz92PgRwSMrGD~15IVutLq-xYXjbh9pAdsHfgnn8avOhC5PjDkZ7lI1Kb~rjZuGEbuXIKnmQuoGlyNG6axlhUJpIXHUBaWHJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) for pathophysiology). AF is reflected on the surface electrocardiogram (ECG) by the absence of discernible and regular P waves, and irregular activation of the ventricles. This results in no specific pattern to RR intervals, in the absence of an atrioventricular block. The definition of AF by temporal pattern is presented in _[Table 5](javascript:;)_. It should be noted that these categories reflect observed episodes of AF and do not suggest the underlying pathophysiological process. Some patients may progress consecutively through these categories, while others may need periodic reclassification due to their individual clinical status. Over time, some patients with AF develop atrial and ventricular damage, which can make attempts at rhythm control futile. For this reason, or when patients and physicians make a joint decision for rate control, AF is classified as permanent (the most common ‘type’ of AF in historical registries).<sup><span class="xrefLink" id="jumplink-ehae176-B1"></span><a href="javascript:;" reveal-id="ehae176-B1" data-open="ehae176-B1" class="link link-ref link-reveal xref-bibr">1</a></sup> Despite many limitations, this task force have retained this temporal approach because most trials in patients with AF have used these definitions. Classifying AF by underlying drivers could inform management, but the evidence in support of the clinical use of such classification is currently lacking.

Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884141)

Definitions and classifications for the temporal pattern of AF

| Temporal classification .  | Definition .  |
| --- | --- |
| **First-diagnosed AF** | AF that has not been diagnosed before, regardless of symptom status, temporal pattern, or duration. |
| **Paroxysmal AF** | AF which terminates spontaneously within 7 days or with the assistance of an intervention. Evidence suggests that most self-terminating paroxysms last <48 h.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> |
| **Persistent AF** | AF episodes which are not self-terminating. Many intervention trials have used 7 days as a cut-off for defining persistent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a>,<span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> Long-standing persistent AF is arbitrarily defined as continuous AF of at least 12 months' duration but where rhythm control is still a treatment option in selected patients, distinguishing it from permanent AF. |
| **Permanent AF** | AF for which no further attempts at restoration of sinus rhythm are planned, after a shared decision between the patient and physician. |

| Temporal classification .  | Definition .  |
| --- | --- |
| **First-diagnosed AF** | AF that has not been diagnosed before, regardless of symptom status, temporal pattern, or duration. |
| **Paroxysmal AF** | AF which terminates spontaneously within 7 days or with the assistance of an intervention. Evidence suggests that most self-terminating paroxysms last <48 h.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> |
| **Persistent AF** | AF episodes which are not self-terminating. Many intervention trials have used 7 days as a cut-off for defining persistent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a>,<span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> Long-standing persistent AF is arbitrarily defined as continuous AF of at least 12 months' duration but where rhythm control is still a treatment option in selected patients, distinguishing it from permanent AF. |
| **Permanent AF** | AF for which no further attempts at restoration of sinus rhythm are planned, after a shared decision between the patient and physician. |

AF, atrial fibrillation.

© ESC 2024

Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884141)

Definitions and classifications for the temporal pattern of AF

| Temporal classification .  | Definition .  |
| --- | --- |
| **First-diagnosed AF** | AF that has not been diagnosed before, regardless of symptom status, temporal pattern, or duration. |
| **Paroxysmal AF** | AF which terminates spontaneously within 7 days or with the assistance of an intervention. Evidence suggests that most self-terminating paroxysms last <48 h.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> |
| **Persistent AF** | AF episodes which are not self-terminating. Many intervention trials have used 7 days as a cut-off for defining persistent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a>,<span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> Long-standing persistent AF is arbitrarily defined as continuous AF of at least 12 months' duration but where rhythm control is still a treatment option in selected patients, distinguishing it from permanent AF. |
| **Permanent AF** | AF for which no further attempts at restoration of sinus rhythm are planned, after a shared decision between the patient and physician. |

| Temporal classification .  | Definition .  |
| --- | --- |
| **First-diagnosed AF** | AF that has not been diagnosed before, regardless of symptom status, temporal pattern, or duration. |
| **Paroxysmal AF** | AF which terminates spontaneously within 7 days or with the assistance of an intervention. Evidence suggests that most self-terminating paroxysms last <48 h.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> |
| **Persistent AF** | AF episodes which are not self-terminating. Many intervention trials have used 7 days as a cut-off for defining persistent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a>,<span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> Long-standing persistent AF is arbitrarily defined as continuous AF of at least 12 months' duration but where rhythm control is still a treatment option in selected patients, distinguishing it from permanent AF. |
| **Permanent AF** | AF for which no further attempts at restoration of sinus rhythm are planned, after a shared decision between the patient and physician. |

AF, atrial fibrillation.

© ESC 2024

Several other classifications have been applied to patients with AF, many of which have limited evidence to support them. The definition of AF is a developing field and ongoing research may allow for pathology-based strategies that could facilitate personalized management in the future. _[Table 6](javascript:;)_ presents some commonly used concepts in current clinical practice. Due to the lack of supporting evidence (particularly for the time periods stated), this task force have edited and updated these definitions by consensus.

Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884143)

Other clinical concepts relevant to AF

| Clinical concept .  | Definition .  |
| --- | --- |
| **Clinical AF** | Symptomatic or asymptomatic AF that is clearly documented by an ECG (12-lead ECG or other ECG devices). The minimum duration to establish the diagnosis of clinical AF for ambulatory ECG is not clear and depends on the clinical context. Periods of 30 s or more may indicate clinical concern, and trigger further monitoring or risk stratification for thromboembolism. |
| **Device-detected subclinical AF** | Device-detected subclinical AF refers to asymptomatic episodes of AF detected on continuous monitoring devices. These devices include implanted cardiac electronic devices, for which most atrial high-rate episodes<sup><span class="xrefLink" id="jumplink-tblfn108"></span><a href="javascript:;" reveal-id="tblfn108" data-open="tblfn108" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> may be AF, as well as consumer-based wearable monitors. Confirmation is needed by a competent professional reviewing intracardiac electrograms or an ECG-recorded rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> Device-detected subclinical AF is a predictor of future clinical AF.<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a></sup> |
| **AF burden** | The overall time spent in AF during a clearly specified and reported period of monitoring, expressed as a percentage of time. |
| **Recent-onset AF** | There is accumulating data on the value of the term recent-onset AF in decision-making for acute pharmacological or electrical cardioversion of AF. The cut-off time interval to define this entity has not yet been established.<sup><span class="xrefLink" id="jumplink-ehae176-B8 ehae176-B9 ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B8 ehae176-B9 ehae176-B10" data-open="ehae176-B8 ehae176-B9 ehae176-B10" class="link link-ref link-reveal xref-bibr">8–10</a></sup> |
| **Trigger-induced AF** | New AF episode in close proximity to a precipitating and potentially reversible factor.<sup><span class="xrefLink" id="jumplink-ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14"></span><a href="javascript:;" reveal-id="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" data-open="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" class="link link-ref link-reveal xref-bibr">11–14</a></sup> |
| **Early AF** | The time since diagnosis that qualifies for early AF is dissociated from any underlying atrial cardiomyopathy and is not well defined, broadly ranging from 3 to 24 months.<sup><span class="xrefLink" id="jumplink-ehae176-B15 ehae176-B16 ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B15 ehae176-B16 ehae176-B17" data-open="ehae176-B15 ehae176-B16 ehae176-B17" class="link link-ref link-reveal xref-bibr">15–17</a></sup> The definition of early AF also does not necessarily determine early timing of intervention. |
| **Self-terminating AF** | Paroxysmal AF which terminates spontaneously.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> This definition may be of value for decisions on acute rhythm control taken jointly by the patient and healthcare provider. |
| **Non-self-terminating AF** | Atrial fibrillation which does not terminate spontaneously and, if needed, termination can be achieved only with an intervention. |
| **Atrial cardiomyopathy** | A combination of structural, electrical, or functional changes in the atria that leads to clinical impact (e.g. progression/recurrence of AF, limited effectiveness of AF therapy, and/or development of heart failure).<sup><span class="xrefLink" id="jumplink-ehae176-B18"></span><a href="javascript:;" reveal-id="ehae176-B18" data-open="ehae176-B18" class="link link-ref link-reveal xref-bibr">18</a>,<span class="xrefLink" id="jumplink-ehae176-B19"></span><a href="javascript:;" reveal-id="ehae176-B19" data-open="ehae176-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> Atrial cardiomyopathy includes inflammatory and prothrombotic remodelling of the atria, neurohormonal activation (thereby affecting the ventricles), and fibrosis of myocardial tissue.<sup><span class="xrefLink" id="jumplink-ehae176-B20"></span><a href="javascript:;" reveal-id="ehae176-B20" data-open="ehae176-B20" class="link link-ref link-reveal xref-bibr">20</a></sup> |

| Clinical concept .  | Definition .  |
| --- | --- |
| **Clinical AF** | Symptomatic or asymptomatic AF that is clearly documented by an ECG (12-lead ECG or other ECG devices). The minimum duration to establish the diagnosis of clinical AF for ambulatory ECG is not clear and depends on the clinical context. Periods of 30 s or more may indicate clinical concern, and trigger further monitoring or risk stratification for thromboembolism. |
| **Device-detected subclinical AF** | Device-detected subclinical AF refers to asymptomatic episodes of AF detected on continuous monitoring devices. These devices include implanted cardiac electronic devices, for which most atrial high-rate episodes<sup><span class="xrefLink" id="jumplink-tblfn108"></span><a href="javascript:;" reveal-id="tblfn108" data-open="tblfn108" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> may be AF, as well as consumer-based wearable monitors. Confirmation is needed by a competent professional reviewing intracardiac electrograms or an ECG-recorded rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> Device-detected subclinical AF is a predictor of future clinical AF.<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a></sup> |
| **AF burden** | The overall time spent in AF during a clearly specified and reported period of monitoring, expressed as a percentage of time. |
| **Recent-onset AF** | There is accumulating data on the value of the term recent-onset AF in decision-making for acute pharmacological or electrical cardioversion of AF. The cut-off time interval to define this entity has not yet been established.<sup><span class="xrefLink" id="jumplink-ehae176-B8 ehae176-B9 ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B8 ehae176-B9 ehae176-B10" data-open="ehae176-B8 ehae176-B9 ehae176-B10" class="link link-ref link-reveal xref-bibr">8–10</a></sup> |
| **Trigger-induced AF** | New AF episode in close proximity to a precipitating and potentially reversible factor.<sup><span class="xrefLink" id="jumplink-ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14"></span><a href="javascript:;" reveal-id="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" data-open="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" class="link link-ref link-reveal xref-bibr">11–14</a></sup> |
| **Early AF** | The time since diagnosis that qualifies for early AF is dissociated from any underlying atrial cardiomyopathy and is not well defined, broadly ranging from 3 to 24 months.<sup><span class="xrefLink" id="jumplink-ehae176-B15 ehae176-B16 ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B15 ehae176-B16 ehae176-B17" data-open="ehae176-B15 ehae176-B16 ehae176-B17" class="link link-ref link-reveal xref-bibr">15–17</a></sup> The definition of early AF also does not necessarily determine early timing of intervention. |
| **Self-terminating AF** | Paroxysmal AF which terminates spontaneously.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> This definition may be of value for decisions on acute rhythm control taken jointly by the patient and healthcare provider. |
| **Non-self-terminating AF** | Atrial fibrillation which does not terminate spontaneously and, if needed, termination can be achieved only with an intervention. |
| **Atrial cardiomyopathy** | A combination of structural, electrical, or functional changes in the atria that leads to clinical impact (e.g. progression/recurrence of AF, limited effectiveness of AF therapy, and/or development of heart failure).<sup><span class="xrefLink" id="jumplink-ehae176-B18"></span><a href="javascript:;" reveal-id="ehae176-B18" data-open="ehae176-B18" class="link link-ref link-reveal xref-bibr">18</a>,<span class="xrefLink" id="jumplink-ehae176-B19"></span><a href="javascript:;" reveal-id="ehae176-B19" data-open="ehae176-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> Atrial cardiomyopathy includes inflammatory and prothrombotic remodelling of the atria, neurohormonal activation (thereby affecting the ventricles), and fibrosis of myocardial tissue.<sup><span class="xrefLink" id="jumplink-ehae176-B20"></span><a href="javascript:;" reveal-id="ehae176-B20" data-open="ehae176-B20" class="link link-ref link-reveal xref-bibr">20</a></sup> |

AF, atrial fibrillation; b.p.m., beats per minute; ECG, electrocardiogram.

<sup>a</sup>Atrial high-rate episodes are defined as episodes generally lasting more than 5 min with an atrial lead rate ≥170 b.p.m.,<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a>,<span class="xrefLink" id="jumplink-ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24"></span><a href="javascript:;" reveal-id="ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24" data-open="ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24" class="link link-ref link-reveal xref-bibr">21–24</a></sup> detected by implanted cardiac devices that allow for automated continuous monitoring and storage of atrial rhythm. Atrial high-rate episodes need to be visually inspected because some may be electrical artefacts or false positives.

© ESC 2024

Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884143)

Other clinical concepts relevant to AF

| Clinical concept .  | Definition .  |
| --- | --- |
| **Clinical AF** | Symptomatic or asymptomatic AF that is clearly documented by an ECG (12-lead ECG or other ECG devices). The minimum duration to establish the diagnosis of clinical AF for ambulatory ECG is not clear and depends on the clinical context. Periods of 30 s or more may indicate clinical concern, and trigger further monitoring or risk stratification for thromboembolism. |
| **Device-detected subclinical AF** | Device-detected subclinical AF refers to asymptomatic episodes of AF detected on continuous monitoring devices. These devices include implanted cardiac electronic devices, for which most atrial high-rate episodes<sup><span class="xrefLink" id="jumplink-tblfn108"></span><a href="javascript:;" reveal-id="tblfn108" data-open="tblfn108" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> may be AF, as well as consumer-based wearable monitors. Confirmation is needed by a competent professional reviewing intracardiac electrograms or an ECG-recorded rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> Device-detected subclinical AF is a predictor of future clinical AF.<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a></sup> |
| **AF burden** | The overall time spent in AF during a clearly specified and reported period of monitoring, expressed as a percentage of time. |
| **Recent-onset AF** | There is accumulating data on the value of the term recent-onset AF in decision-making for acute pharmacological or electrical cardioversion of AF. The cut-off time interval to define this entity has not yet been established.<sup><span class="xrefLink" id="jumplink-ehae176-B8 ehae176-B9 ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B8 ehae176-B9 ehae176-B10" data-open="ehae176-B8 ehae176-B9 ehae176-B10" class="link link-ref link-reveal xref-bibr">8–10</a></sup> |
| **Trigger-induced AF** | New AF episode in close proximity to a precipitating and potentially reversible factor.<sup><span class="xrefLink" id="jumplink-ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14"></span><a href="javascript:;" reveal-id="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" data-open="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" class="link link-ref link-reveal xref-bibr">11–14</a></sup> |
| **Early AF** | The time since diagnosis that qualifies for early AF is dissociated from any underlying atrial cardiomyopathy and is not well defined, broadly ranging from 3 to 24 months.<sup><span class="xrefLink" id="jumplink-ehae176-B15 ehae176-B16 ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B15 ehae176-B16 ehae176-B17" data-open="ehae176-B15 ehae176-B16 ehae176-B17" class="link link-ref link-reveal xref-bibr">15–17</a></sup> The definition of early AF also does not necessarily determine early timing of intervention. |
| **Self-terminating AF** | Paroxysmal AF which terminates spontaneously.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> This definition may be of value for decisions on acute rhythm control taken jointly by the patient and healthcare provider. |
| **Non-self-terminating AF** | Atrial fibrillation which does not terminate spontaneously and, if needed, termination can be achieved only with an intervention. |
| **Atrial cardiomyopathy** | A combination of structural, electrical, or functional changes in the atria that leads to clinical impact (e.g. progression/recurrence of AF, limited effectiveness of AF therapy, and/or development of heart failure).<sup><span class="xrefLink" id="jumplink-ehae176-B18"></span><a href="javascript:;" reveal-id="ehae176-B18" data-open="ehae176-B18" class="link link-ref link-reveal xref-bibr">18</a>,<span class="xrefLink" id="jumplink-ehae176-B19"></span><a href="javascript:;" reveal-id="ehae176-B19" data-open="ehae176-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> Atrial cardiomyopathy includes inflammatory and prothrombotic remodelling of the atria, neurohormonal activation (thereby affecting the ventricles), and fibrosis of myocardial tissue.<sup><span class="xrefLink" id="jumplink-ehae176-B20"></span><a href="javascript:;" reveal-id="ehae176-B20" data-open="ehae176-B20" class="link link-ref link-reveal xref-bibr">20</a></sup> |

| Clinical concept .  | Definition .  |
| --- | --- |
| **Clinical AF** | Symptomatic or asymptomatic AF that is clearly documented by an ECG (12-lead ECG or other ECG devices). The minimum duration to establish the diagnosis of clinical AF for ambulatory ECG is not clear and depends on the clinical context. Periods of 30 s or more may indicate clinical concern, and trigger further monitoring or risk stratification for thromboembolism. |
| **Device-detected subclinical AF** | Device-detected subclinical AF refers to asymptomatic episodes of AF detected on continuous monitoring devices. These devices include implanted cardiac electronic devices, for which most atrial high-rate episodes<sup><span class="xrefLink" id="jumplink-tblfn108"></span><a href="javascript:;" reveal-id="tblfn108" data-open="tblfn108" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> may be AF, as well as consumer-based wearable monitors. Confirmation is needed by a competent professional reviewing intracardiac electrograms or an ECG-recorded rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> Device-detected subclinical AF is a predictor of future clinical AF.<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a></sup> |
| **AF burden** | The overall time spent in AF during a clearly specified and reported period of monitoring, expressed as a percentage of time. |
| **Recent-onset AF** | There is accumulating data on the value of the term recent-onset AF in decision-making for acute pharmacological or electrical cardioversion of AF. The cut-off time interval to define this entity has not yet been established.<sup><span class="xrefLink" id="jumplink-ehae176-B8 ehae176-B9 ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B8 ehae176-B9 ehae176-B10" data-open="ehae176-B8 ehae176-B9 ehae176-B10" class="link link-ref link-reveal xref-bibr">8–10</a></sup> |
| **Trigger-induced AF** | New AF episode in close proximity to a precipitating and potentially reversible factor.<sup><span class="xrefLink" id="jumplink-ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14"></span><a href="javascript:;" reveal-id="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" data-open="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" class="link link-ref link-reveal xref-bibr">11–14</a></sup> |
| **Early AF** | The time since diagnosis that qualifies for early AF is dissociated from any underlying atrial cardiomyopathy and is not well defined, broadly ranging from 3 to 24 months.<sup><span class="xrefLink" id="jumplink-ehae176-B15 ehae176-B16 ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B15 ehae176-B16 ehae176-B17" data-open="ehae176-B15 ehae176-B16 ehae176-B17" class="link link-ref link-reveal xref-bibr">15–17</a></sup> The definition of early AF also does not necessarily determine early timing of intervention. |
| **Self-terminating AF** | Paroxysmal AF which terminates spontaneously.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> This definition may be of value for decisions on acute rhythm control taken jointly by the patient and healthcare provider. |
| **Non-self-terminating AF** | Atrial fibrillation which does not terminate spontaneously and, if needed, termination can be achieved only with an intervention. |
| **Atrial cardiomyopathy** | A combination of structural, electrical, or functional changes in the atria that leads to clinical impact (e.g. progression/recurrence of AF, limited effectiveness of AF therapy, and/or development of heart failure).<sup><span class="xrefLink" id="jumplink-ehae176-B18"></span><a href="javascript:;" reveal-id="ehae176-B18" data-open="ehae176-B18" class="link link-ref link-reveal xref-bibr">18</a>,<span class="xrefLink" id="jumplink-ehae176-B19"></span><a href="javascript:;" reveal-id="ehae176-B19" data-open="ehae176-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> Atrial cardiomyopathy includes inflammatory and prothrombotic remodelling of the atria, neurohormonal activation (thereby affecting the ventricles), and fibrosis of myocardial tissue.<sup><span class="xrefLink" id="jumplink-ehae176-B20"></span><a href="javascript:;" reveal-id="ehae176-B20" data-open="ehae176-B20" class="link link-ref link-reveal xref-bibr">20</a></sup> |

AF, atrial fibrillation; b.p.m., beats per minute; ECG, electrocardiogram.

<sup>a</sup>Atrial high-rate episodes are defined as episodes generally lasting more than 5 min with an atrial lead rate ≥170 b.p.m.,<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a>,<span class="xrefLink" id="jumplink-ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24"></span><a href="javascript:;" reveal-id="ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24" data-open="ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24" class="link link-ref link-reveal xref-bibr">21–24</a></sup> detected by implanted cardiac devices that allow for automated continuous monitoring and storage of atrial rhythm. Atrial high-rate episodes need to be visually inspected because some may be electrical artefacts or false positives.

© ESC 2024

### 3.2. Diagnostic criteria for AF

In many patients, the diagnosis of AF is straightforward, e.g. typical symptoms associated with characteristic features on a standard 12-lead ECG that indicate the need for AF management. Diagnosis becomes more challenging in the context of asymptomatic episodes or AF detected on longer-term monitoring devices, particularly those that do not provide an ECG (see _Section [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s9)_). To guard against inappropriate diagnosis of AF, this task force continues to recommend that ECG documentation is required to initiate risk stratification and AF management. In current practice, ECG confirmation can include multiple options: not only where AF persists across a standard 12-lead ECG, but also single- and multiple-lead devices that provide an ECG (see [Supplementary data online, Additional Evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478928&Signature=sYPSkc059rzSsSo6~r0xwLGmW-M0Rv7xwul7KcNwszjWMC8gVHVAwqMgkRxMRKYpzAKJLAhzP~U7wa5MVlCzK~iOm9uxrzZKH13uwuC58sd05TSq5sbB~z6MBP6fy-oOgfv8gGq6D-ZIjwcugiuOUUCtl5pzaYUqbngt-M9BeQtwmHgyFPgiyBzYXocwwtv7P8k-BvoWZx3OnbHs5m4LJ6ZaY3RiAMKV0Y13OH5Q~1IcGmBJVu9UzD6dQISR2PTy-AcQ0~zoK-k8Oy9SaHeT8NiHRuo7y5UTRFOGupYBPqABrtWs-Gjjqd2ykJdFQsvptIUiPfLT80TOsS5d5PcSFg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  _[Table S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478928&Signature=sYPSkc059rzSsSo6~r0xwLGmW-M0Rv7xwul7KcNwszjWMC8gVHVAwqMgkRxMRKYpzAKJLAhzP~U7wa5MVlCzK~iOm9uxrzZKH13uwuC58sd05TSq5sbB~z6MBP6fy-oOgfv8gGq6D-ZIjwcugiuOUUCtl5pzaYUqbngt-M9BeQtwmHgyFPgiyBzYXocwwtv7P8k-BvoWZx3OnbHs5m4LJ6ZaY3RiAMKV0Y13OH5Q~1IcGmBJVu9UzD6dQISR2PTy-AcQ0~zoK-k8Oy9SaHeT8NiHRuo7y5UTRFOGupYBPqABrtWs-Gjjqd2ykJdFQsvptIUiPfLT80TOsS5d5PcSFg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). This does not include non-ECG wearables and other devices that typically use photoplethysmography. Note that many pivotal AF trials required two or more ECGs documenting AF, or an established AF diagnosis before randomization.<sup><span class="xrefLink" id="jumplink-ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28 ehae176-B29"></span><a href="javascript:;" reveal-id="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28 ehae176-B29" data-open="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28 ehae176-B29" class="link link-ref link-reveal xref-bibr">25–29</a></sup> The time period of AF required for diagnosis on monitoring devices is not clear cut. A standard 12-lead ECG measures 10 s, while 30 s or more on single-lead or multiple-lead ECG devices has generally been the consensus opinion, albeit with limited evidence.

Recommendation Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884146)

Recommendations for the diagnosis of AF (see also Evidence Table 1)

![Recommendations for the diagnosis of AF (see also Evidence Table 1)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt1.jpeg?Expires=1728478928&Signature=qIvzt8ZBjGo7OgMOoW3GYixmRdLGPolrdxCKv3DXaGo5TscrcY72byyuUGEMYQgS~r343uNWP8ctEiWq9ExA2XkKnirX46Zc-y6ogVz9YRC0cgGEOvhg7bGBtlqrK-hqyhCOamsCcONucCkKsZeMdufKbeRENIcpGkHI8U0ePtYjBKRushruAznkv8QPT3BZDPCLx~NQWrvfZRnViwN7tm1i-UfYQULxSRe--Hh~HbKwn37jiWba-SAjviFmAWu2mDpesj3b1VXdbml-F6q8rsGRa52WvmpdbiI5pUVglBbn1Kobntwh~QwV1Gfg7foRNP8RvkwouGBzQtFk4mdlhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884146)

Recommendations for the diagnosis of AF (see also Evidence Table 1)

![Recommendations for the diagnosis of AF (see also Evidence Table 1)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt1.jpeg?Expires=1728478928&Signature=qIvzt8ZBjGo7OgMOoW3GYixmRdLGPolrdxCKv3DXaGo5TscrcY72byyuUGEMYQgS~r343uNWP8ctEiWq9ExA2XkKnirX46Zc-y6ogVz9YRC0cgGEOvhg7bGBtlqrK-hqyhCOamsCcONucCkKsZeMdufKbeRENIcpGkHI8U0ePtYjBKRushruAznkv8QPT3BZDPCLx~NQWrvfZRnViwN7tm1i-UfYQULxSRe--Hh~HbKwn37jiWba-SAjviFmAWu2mDpesj3b1VXdbml-F6q8rsGRa52WvmpdbiI5pUVglBbn1Kobntwh~QwV1Gfg7foRNP8RvkwouGBzQtFk4mdlhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 3.3. Symptoms attributable to AF

Symptoms related to episodes of AF are variable and broad, and not just typical palpitations (_[Figure 1](javascript:;)_). Asymptomatic episodes of AF can occur,<sup><span class="xrefLink" id="jumplink-ehae176-B30"></span><a href="javascript:;" reveal-id="ehae176-B30" data-open="ehae176-B30" class="link link-ref link-reveal xref-bibr">30</a></sup> although 90% of patients with AF describe symptoms with variable severity.<sup><span class="xrefLink" id="jumplink-ehae176-B31"></span><a href="javascript:;" reveal-id="ehae176-B31" data-open="ehae176-B31" class="link link-ref link-reveal xref-bibr">31</a></sup> Even in symptomatic patients, some episodes of AF may remain asymptomatic.<sup><span class="xrefLink" id="jumplink-ehae176-B32"></span><a href="javascript:;" reveal-id="ehae176-B32" data-open="ehae176-B32" class="link link-ref link-reveal xref-bibr">32</a>,<span class="xrefLink" id="jumplink-ehae176-B33"></span><a href="javascript:;" reveal-id="ehae176-B33" data-open="ehae176-B33" class="link link-ref link-reveal xref-bibr">33</a></sup> The presence or absence of symptoms is not related to incident stroke, systemic embolism, or mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B34"></span><a href="javascript:;" reveal-id="ehae176-B34" data-open="ehae176-B34" class="link link-ref link-reveal xref-bibr">34</a></sup> However, symptoms do impact on patient quality of life.<sup><span class="xrefLink" id="jumplink-ehae176-B35"></span><a href="javascript:;" reveal-id="ehae176-B35" data-open="ehae176-B35" class="link link-ref link-reveal xref-bibr">35</a>,<span class="xrefLink" id="jumplink-ehae176-B36"></span><a href="javascript:;" reveal-id="ehae176-B36" data-open="ehae176-B36" class="link link-ref link-reveal xref-bibr">36</a></sup> Cardiac-specific AF symptoms such as palpitations are less common than non-specific symptoms such as fatigue, but they significantly impair quality of life.<sup><span class="xrefLink" id="jumplink-ehae176-B36"></span><a href="javascript:;" reveal-id="ehae176-B36" data-open="ehae176-B36" class="link link-ref link-reveal xref-bibr">36</a>,<span class="xrefLink" id="jumplink-ehae176-B37"></span><a href="javascript:;" reveal-id="ehae176-B37" data-open="ehae176-B37" class="link link-ref link-reveal xref-bibr">37</a></sup> Although women are often underrepresented in clinical trials of AF,<sup><span class="xrefLink" id="jumplink-ehae176-B38 ehae176-B39 ehae176-B40"></span><a href="javascript:;" reveal-id="ehae176-B38 ehae176-B39 ehae176-B40" data-open="ehae176-B38 ehae176-B39 ehae176-B40" class="link link-ref link-reveal xref-bibr">38–40</a></sup> the available literature suggests that women with AF appear to be more symptomatic and have poorer quality of life.<sup><span class="xrefLink" id="jumplink-ehae176-B41"></span><a href="javascript:;" reveal-id="ehae176-B41" data-open="ehae176-B41" class="link link-ref link-reveal xref-bibr">41</a>,<span class="xrefLink" id="jumplink-ehae176-B42"></span><a href="javascript:;" reveal-id="ehae176-B42" data-open="ehae176-B42" class="link link-ref link-reveal xref-bibr">42</a></sup> Patients with AF report a higher burden of anxiety and severity of depression (odds ratio \[OR\], 1.08; 95% confidence interval \[CI\], 1.02–1.15; _P_ = .009) as compared with the general population,<sup><span class="xrefLink" id="jumplink-ehae176-B43"></span><a href="javascript:;" reveal-id="ehae176-B43" data-open="ehae176-B43" class="link link-ref link-reveal xref-bibr">43</a>,<span class="xrefLink" id="jumplink-ehae176-B44"></span><a href="javascript:;" reveal-id="ehae176-B44" data-open="ehae176-B44" class="link link-ref link-reveal xref-bibr">44</a></sup> with higher prevalence of these symptoms in women with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B45"></span><a href="javascript:;" reveal-id="ehae176-B45" data-open="ehae176-B45" class="link link-ref link-reveal xref-bibr">45</a></sup>

![Impacts and outcomes associated with clinical AF. AF, atrial fibrillation.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f1.jpeg?Expires=1728478928&Signature=YWjr8zklr79On2DKd-gb0WuudFUGHH4X5jVncMS7ibxtHn2jcbqXdbvPDhD0SJdNJg4OSMsXGzUm0gNwX0q8IJBdHUwPkjVVBgduWfoySf5EClkVsjFCNMWwEWpdArRInrqVe~wuM22n0hHcVa57BYMZXXuiijYzoPA9URSoHaZ1N9ScPBya3fwLYOyvLT1HTGElC5-~rMVfXYd4l554MRZiPeZS18InJxUpslHD0s-twh0Rp7nEhXnEwQY5WiornUMP3uenckOj9Fc5IZFXiQHy3yB2cPt78vbDtaGRL3Ikz8SZgfaI3afieAwtTp0IRxMRX~6-xp5R4~vuU~HQpQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 1

Impacts and outcomes associated with clinical AF. AF, atrial fibrillation.

[Open in new tab](https://academic.oup.com/view-large/figure/479884149/ehae176f1.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f1.jpeg?Expires=1728478928&Signature=kukWaFslF7PHgOSNyhxuS76BnKdynvTlV3~tmUO-~ERjqHA7VqcUGhEi0pv7OCdwZ5tA0E0U8y5NJEPS4lLW7Q53fnKYfXkkXkh6qUzd0cFN1~aYtRldhhLn2LMq8V58xfLj0dkaHkHNhLJ8MXvbQEPJ-bcQ~kvwHNTZNqzkrcbJl6bMmWneZE~Fv5RwgZeK8XUL6uwqm9-Y3Lu~U6ggkT1xpszzcg4SkaEWjmk7MzZWxBiTkOYmV2DYDEaJdu8cYLJB2DTkA1skjg-mG8wnzr6F-lwM3ZL6yh-7lHUZkhnSzlrkB7SuG7gk9ZNOw0xJeqyIYExcyCHBS3o7siOseQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884149&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Assessment of AF-related symptoms should be recorded initially, after a change in treatment, or before and after intervention. The modified European Heart Rhythm Association score (mEHRA) symptom classification (_[Table 7](javascript:;)_) is similar to the New York Heart Association (NYHA) functional class for heart failure. It correlates with quality of life scores in clinical trials, is associated with clinical progress and events, and may be a valuable starting point in routine practice to assess the burden and impact of symptoms together with the patient.<sup><span class="xrefLink" id="jumplink-ehae176-B46 ehae176-B47 ehae176-B48"></span><a href="javascript:;" reveal-id="ehae176-B46 ehae176-B47 ehae176-B48" data-open="ehae176-B46 ehae176-B47 ehae176-B48" class="link link-ref link-reveal xref-bibr">46–48</a></sup> Note that symptoms may also relate to associated comorbidities and not just the AF component. The patient-related effects of symptoms from AF over time can alternatively be evaluated using patient-reported outcome measures (see _Section [8.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s7.4)_).

Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884151)

The modified European Heart Rhythm Association (mEHRA) symptom classification

| Score .  | Symptoms .  | Description .  |
| --- | --- | --- |
| 1 | None | AF does not cause any symptoms |
| 2a | Mild | Normal daily activity not affected by symptoms related to AF |
| 2b | Moderate | Normal daily activity not affected by symptoms related to AF, but patient troubled by symptoms |
| 3 | Severe | Normal daily activity affected by symptoms related to AF |
| 4 | Disabling | Normal daily activity discontinued |

| Score .  | Symptoms .  | Description .  |
| --- | --- | --- |
| 1 | None | AF does not cause any symptoms |
| 2a | Mild | Normal daily activity not affected by symptoms related to AF |
| 2b | Moderate | Normal daily activity not affected by symptoms related to AF, but patient troubled by symptoms |
| 3 | Severe | Normal daily activity affected by symptoms related to AF |
| 4 | Disabling | Normal daily activity discontinued |

AF, atrial fibrillation.

© ESC 2024

Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884151)

The modified European Heart Rhythm Association (mEHRA) symptom classification

| Score .  | Symptoms .  | Description .  |
| --- | --- | --- |
| 1 | None | AF does not cause any symptoms |
| 2a | Mild | Normal daily activity not affected by symptoms related to AF |
| 2b | Moderate | Normal daily activity not affected by symptoms related to AF, but patient troubled by symptoms |
| 3 | Severe | Normal daily activity affected by symptoms related to AF |
| 4 | Disabling | Normal daily activity discontinued |

| Score .  | Symptoms .  | Description .  |
| --- | --- | --- |
| 1 | None | AF does not cause any symptoms |
| 2a | Mild | Normal daily activity not affected by symptoms related to AF |
| 2b | Moderate | Normal daily activity not affected by symptoms related to AF, but patient troubled by symptoms |
| 3 | Severe | Normal daily activity affected by symptoms related to AF |
| 4 | Disabling | Normal daily activity discontinued |

AF, atrial fibrillation.

© ESC 2024

Recommendation Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884152)

Recommendations for symptom evaluation in patients with AF (see also Evidence Table 2)

![Recommendations for symptom evaluation in patients with AF (see also Evidence Table 2)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt2.jpeg?Expires=1728478928&Signature=LXtIApkOVtTPeieHwCjLGrwzJ6XP-r5ZpTyT1Mh6F2UZpfYLnuImwsJ0lj~9xb7md-JRWDYQZY-C8k~UTUNpZyLWsgmgFqknD2sea3oqszVxmTVOFT3p~DS0ps8CERTo7shIVBO2xxdHDvydnvvOwOZGCqyKI6TVK0z60~2et8jJqrQH4mZtS2XcOqUlYRCC2iIUyHWYYy3bsivLQP45Jez68Y95eC~TQV3ebxPTNLIaKse8Vlva1NGvgQd9-lEz3~Jm~Y7zjW6ctz-EZwS2zgKlKeLTzYT2RxLbIsR-djgp30y4IRmV2~Iicf98jxO5dPpMH~uMWUrrtTQ-5NXRtg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884152)

Recommendations for symptom evaluation in patients with AF (see also Evidence Table 2)

![Recommendations for symptom evaluation in patients with AF (see also Evidence Table 2)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt2.jpeg?Expires=1728478928&Signature=LXtIApkOVtTPeieHwCjLGrwzJ6XP-r5ZpTyT1Mh6F2UZpfYLnuImwsJ0lj~9xb7md-JRWDYQZY-C8k~UTUNpZyLWsgmgFqknD2sea3oqszVxmTVOFT3p~DS0ps8CERTo7shIVBO2xxdHDvydnvvOwOZGCqyKI6TVK0z60~2et8jJqrQH4mZtS2XcOqUlYRCC2iIUyHWYYy3bsivLQP45Jez68Y95eC~TQV3ebxPTNLIaKse8Vlva1NGvgQd9-lEz3~Jm~Y7zjW6ctz-EZwS2zgKlKeLTzYT2RxLbIsR-djgp30y4IRmV2~Iicf98jxO5dPpMH~uMWUrrtTQ-5NXRtg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 3.4. Diagnostic evaluation of new AF

All patients with AF should be offered a comprehensive diagnostic assessment and review of medical history to identify risk factors and/or comorbidities needing active treatment. _[Table 8](javascript:;)_ displays the essential diagnostic work-up for a patient with AF.

Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884155)

Diagnostic work-up for patients with AF

| All patients .  | Selected patients .  |
| --- | --- |
| 
- Medical history to determine AF pattern, relevant family history, and comorbidities, and to assess risk factors for thromboembolism and bleeding


 | 

- Ambulatory ECG monitoring for assessing AF burden and ventricular rate control

- Exercise ECG to evaluate rate control or effects of class IC antiarrhythmic drugs


 |
| 

- 12-lead ECG


 | 

- Further blood tests for investigation of cardiovascular disease and refinement of stroke/bleeding risk (e.g. NT-proBNP, troponin)


 |
| 

- Assess symptoms and functional impairment


 | 

- Transoesophageal echocardiography for left atrial thrombus and valvular disease assessment


 |
| 

- Collect generic or AF-specific patient-reported outcome measures


 | 

- Coronary CT, angiography, or ischaemia imaging for suspected CAD


 |
| 

- Blood tests (full blood count, kidney function, serum electrolytes, liver function, glucose/HbA1c, and thyroid function)


 | 

- CMR for evaluation of atrial and ventricular cardiomyopathies, and to plan interventional procedures


 |
| 

- Transthoracic echocardiography where this will guide AF-CARE management decisions


 | 

- Brain imaging and cognitive function assessment for cerebrovascular disease and dementia risk


 |

| All patients .  | Selected patients .  |
| --- | --- |
| 
- Medical history to determine AF pattern, relevant family history, and comorbidities, and to assess risk factors for thromboembolism and bleeding


 | 

- Ambulatory ECG monitoring for assessing AF burden and ventricular rate control

- Exercise ECG to evaluate rate control or effects of class IC antiarrhythmic drugs


 |
| 

- 12-lead ECG


 | 

- Further blood tests for investigation of cardiovascular disease and refinement of stroke/bleeding risk (e.g. NT-proBNP, troponin)


 |
| 

- Assess symptoms and functional impairment


 | 

- Transoesophageal echocardiography for left atrial thrombus and valvular disease assessment


 |
| 

- Collect generic or AF-specific patient-reported outcome measures


 | 

- Coronary CT, angiography, or ischaemia imaging for suspected CAD


 |
| 

- Blood tests (full blood count, kidney function, serum electrolytes, liver function, glucose/HbA1c, and thyroid function)


 | 

- CMR for evaluation of atrial and ventricular cardiomyopathies, and to plan interventional procedures


 |
| 

- Transthoracic echocardiography where this will guide AF-CARE management decisions


 | 

- Brain imaging and cognitive function assessment for cerebrovascular disease and dementia risk


 |

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; CAD, coronary artery disease; CMR, cardiac magnetic resonance; CT, computed tomography; CTA, computed tomography angiography; ECG, electrocardiogram; HbA1c, glycated haemoglobin; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

© ESC 2024

Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884155)

Diagnostic work-up for patients with AF

| All patients .  | Selected patients .  |
| --- | --- |
| 
- Medical history to determine AF pattern, relevant family history, and comorbidities, and to assess risk factors for thromboembolism and bleeding


 | 

- Ambulatory ECG monitoring for assessing AF burden and ventricular rate control

- Exercise ECG to evaluate rate control or effects of class IC antiarrhythmic drugs


 |
| 

- 12-lead ECG


 | 

- Further blood tests for investigation of cardiovascular disease and refinement of stroke/bleeding risk (e.g. NT-proBNP, troponin)


 |
| 

- Assess symptoms and functional impairment


 | 

- Transoesophageal echocardiography for left atrial thrombus and valvular disease assessment


 |
| 

- Collect generic or AF-specific patient-reported outcome measures


 | 

- Coronary CT, angiography, or ischaemia imaging for suspected CAD


 |
| 

- Blood tests (full blood count, kidney function, serum electrolytes, liver function, glucose/HbA1c, and thyroid function)


 | 

- CMR for evaluation of atrial and ventricular cardiomyopathies, and to plan interventional procedures


 |
| 

- Transthoracic echocardiography where this will guide AF-CARE management decisions


 | 

- Brain imaging and cognitive function assessment for cerebrovascular disease and dementia risk


 |

| All patients .  | Selected patients .  |
| --- | --- |
| 
- Medical history to determine AF pattern, relevant family history, and comorbidities, and to assess risk factors for thromboembolism and bleeding


 | 

- Ambulatory ECG monitoring for assessing AF burden and ventricular rate control

- Exercise ECG to evaluate rate control or effects of class IC antiarrhythmic drugs


 |
| 

- 12-lead ECG


 | 

- Further blood tests for investigation of cardiovascular disease and refinement of stroke/bleeding risk (e.g. NT-proBNP, troponin)


 |
| 

- Assess symptoms and functional impairment


 | 

- Transoesophageal echocardiography for left atrial thrombus and valvular disease assessment


 |
| 

- Collect generic or AF-specific patient-reported outcome measures


 | 

- Coronary CT, angiography, or ischaemia imaging for suspected CAD


 |
| 

- Blood tests (full blood count, kidney function, serum electrolytes, liver function, glucose/HbA1c, and thyroid function)


 | 

- CMR for evaluation of atrial and ventricular cardiomyopathies, and to plan interventional procedures


 |
| 

- Transthoracic echocardiography where this will guide AF-CARE management decisions


 | 

- Brain imaging and cognitive function assessment for cerebrovascular disease and dementia risk


 |

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; CAD, coronary artery disease; CMR, cardiac magnetic resonance; CT, computed tomography; CTA, computed tomography angiography; ECG, electrocardiogram; HbA1c, glycated haemoglobin; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

© ESC 2024

A 12-lead ECG is warranted in all AF patients to confirm rhythm, determine ventricular rate, and look for signs of structural heart disease, conduction defects, or ischaemia.<sup><span class="xrefLink" id="jumplink-ehae176-B56"></span><a href="javascript:;" reveal-id="ehae176-B56" data-open="ehae176-B56" class="link link-ref link-reveal xref-bibr">56</a></sup> Blood tests should be carried out (kidney function, serum electrolytes, liver function, full blood count, glucose/glycated haemoglobin \[HbA1c\], and thyroid tests) to detect any concomitant conditions that may exacerbate AF or increase the risk of bleeding and/or thromboembolism.<sup><span class="xrefLink" id="jumplink-ehae176-B57"></span><a href="javascript:;" reveal-id="ehae176-B57" data-open="ehae176-B57" class="link link-ref link-reveal xref-bibr">57</a>,<span class="xrefLink" id="jumplink-ehae176-B58"></span><a href="javascript:;" reveal-id="ehae176-B58" data-open="ehae176-B58" class="link link-ref link-reveal xref-bibr">58</a></sup>

Other investigations will depend on individualized assessment and the planned treatment strategy.<sup><span class="xrefLink" id="jumplink-ehae176-B59 ehae176-B60 ehae176-B61 ehae176-B62 ehae176-B63 ehae176-B64 ehae176-B65"></span><a href="javascript:;" reveal-id="ehae176-B59 ehae176-B60 ehae176-B61 ehae176-B62 ehae176-B63 ehae176-B64 ehae176-B65" data-open="ehae176-B59 ehae176-B60 ehae176-B61 ehae176-B62 ehae176-B63 ehae176-B64 ehae176-B65" class="link link-ref link-reveal xref-bibr">59–65</a></sup> A transthoracic echocardiogram (TTE) should be carried out in the initial work-up, where this will guide management decisions, or in patients where there is a change in cardiovascular signs or symptoms. The task force recognizes that accessibility to TTE might be limited or delayed in the primary care setting, but this should not delay initiation of oral anticoagulation (OAC) or other components of AF-CARE where indicated.<sup><span class="xrefLink" id="jumplink-ehae176-B66"></span><a href="javascript:;" reveal-id="ehae176-B66" data-open="ehae176-B66" class="link link-ref link-reveal xref-bibr">66</a></sup> Further details on TTE and reassessment (e.g. if elevated heart rate limits diagnostic imaging, or where there is a change in clinical status) are presented in _Section [8.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s7.3)_. Additional imaging using different modalities may be required to assist with comorbidity and AF-related management (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478928&Signature=LeTi7xCg0DZMpxCixcN6zSZvbi-PIvNWtpQuMSNg3jTFo8H4ms8EdOwIz-bBU3hicL-g0WFc2z-3hGi7f5RQTiQxNAc0o~B24kGKyUCRc5yGbgWOUG1zxo3NtCpkehEK9uF3PBD9iuFkoXlXU1E~wfDrGbUjBWjPxPP8CZ-lR2Fydkj4P3oWN6sTT4DCuy~TytQjp9~PKREiFqdHHPiStM-4Fy3MWzbgC5~9Xln9cYxRbp7UtP6suHz92PgRwSMrGD~15IVutLq-xYXjbh9pAdsHfgnn8avOhC5PjDkZ7lI1Kb~rjZuGEbuXIKnmQuoGlyNG6axlhUJpIXHUBaWHJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Figure S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478928&Signature=LeTi7xCg0DZMpxCixcN6zSZvbi-PIvNWtpQuMSNg3jTFo8H4ms8EdOwIz-bBU3hicL-g0WFc2z-3hGi7f5RQTiQxNAc0o~B24kGKyUCRc5yGbgWOUG1zxo3NtCpkehEK9uF3PBD9iuFkoXlXU1E~wfDrGbUjBWjPxPP8CZ-lR2Fydkj4P3oWN6sTT4DCuy~TytQjp9~PKREiFqdHHPiStM-4Fy3MWzbgC5~9Xln9cYxRbp7UtP6suHz92PgRwSMrGD~15IVutLq-xYXjbh9pAdsHfgnn8avOhC5PjDkZ7lI1Kb~rjZuGEbuXIKnmQuoGlyNG6axlhUJpIXHUBaWHJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

Recommendation Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884158)

Recommendations for diagnostic evaluation in patients with new AF (see also Evidence Table 3)

![Recommendations for diagnostic evaluation in patients with new AF (see also Evidence Table 3)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt3.jpeg?Expires=1728478929&Signature=EfdShtJaDlxcCuPE0Zi-FW39qmdZNeURqbuPUJ-A58kS22S4suXk98KhhdXu9x~dAFRsGC7guqA~CrltkZVcplBo4ygthqZ-v5A5Rag38d4G0~GxWaIeeQOC~RITMZqhU641RYNk6nIFeXYfrgSTWxC3InW9lxTdSxB4S-RxWPg1ogiCL9ZodPmrTGIgKmKgICiLnA7Xdo7QyCorEkbX~C2~x-n-Rf72MiY-UyOM2gAH0wMHK8xjW5wAIu4MwH~3xdMY8jjAvFAXhBZ28Rphnm5c4uJsVPdmZoQBiNAgbSS0WQ02pn3bvAxZj9AGfLxFdvIkWaZ6hWnRCMGCBzcZ9Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884158)

Recommendations for diagnostic evaluation in patients with new AF (see also Evidence Table 3)

![Recommendations for diagnostic evaluation in patients with new AF (see also Evidence Table 3)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt3.jpeg?Expires=1728478929&Signature=EfdShtJaDlxcCuPE0Zi-FW39qmdZNeURqbuPUJ-A58kS22S4suXk98KhhdXu9x~dAFRsGC7guqA~CrltkZVcplBo4ygthqZ-v5A5Rag38d4G0~GxWaIeeQOC~RITMZqhU641RYNk6nIFeXYfrgSTWxC3InW9lxTdSxB4S-RxWPg1ogiCL9ZodPmrTGIgKmKgICiLnA7Xdo7QyCorEkbX~C2~x-n-Rf72MiY-UyOM2gAH0wMHK8xjW5wAIu4MwH~3xdMY8jjAvFAXhBZ28Rphnm5c4uJsVPdmZoQBiNAgbSS0WQ02pn3bvAxZj9AGfLxFdvIkWaZ6hWnRCMGCBzcZ9Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 3.5. Adverse events associated with AF

Atrial fibrillation is associated with a range of serious adverse events (_[Figure 1](javascript:;)_) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Patients with AF also have high rates of hospitalization and complications from coexisting medical conditions. The most common non-fatal outcome in those with AF is heart failure, occurring in around half of patients over time. Patients with AF have a four- to five-fold increase in the relative risk (RR) of heart failure compared with those without AF, as demonstrated in two meta-analyses (RR, 4.62; 95% CI, 3.13–6.83 and RR, 4.99; 95% CI, 3.0–8.22).<sup><span class="xrefLink" id="jumplink-ehae176-B68"></span><a href="javascript:;" reveal-id="ehae176-B68" data-open="ehae176-B68" class="link link-ref link-reveal xref-bibr">68</a>,<span class="xrefLink" id="jumplink-ehae176-B69"></span><a href="javascript:;" reveal-id="ehae176-B69" data-open="ehae176-B69" class="link link-ref link-reveal xref-bibr">69</a></sup> The next most common adverse impacts from AF are ischaemic stroke (RR, 2.3; 95% CI, 1.84–2.94), ischaemic heart disease (RR, 1.61; 95% CI, 1.38–1.87), and other thromboembolic events.<sup><span class="xrefLink" id="jumplink-ehae176-B69 ehae176-B70 ehae176-B71"></span><a href="javascript:;" reveal-id="ehae176-B69 ehae176-B70 ehae176-B71" data-open="ehae176-B69 ehae176-B70 ehae176-B71" class="link link-ref link-reveal xref-bibr">69–71</a></sup> The latter typically include arterial thromboembolic events (preferred to the term systemic), although venous thromboembolism is also associated with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B72"></span><a href="javascript:;" reveal-id="ehae176-B72" data-open="ehae176-B72" class="link link-ref link-reveal xref-bibr">72</a>,<span class="xrefLink" id="jumplink-ehae176-B73"></span><a href="javascript:;" reveal-id="ehae176-B73" data-open="ehae176-B73" class="link link-ref link-reveal xref-bibr">73</a></sup> Patients with AF also have an increased risk of cognitive impairment (adjusted hazard ratio \[HR\], 1.39; 95% CI, 1.25–1.53)<sup><span class="xrefLink" id="jumplink-ehae176-B74"></span><a href="javascript:;" reveal-id="ehae176-B74" data-open="ehae176-B74" class="link link-ref link-reveal xref-bibr">74</a></sup> and dementia (OR, 1.6; 95% CI, 1.3–2.0).<sup><span class="xrefLink" id="jumplink-ehae176-B75 ehae176-B76 ehae176-B77"></span><a href="javascript:;" reveal-id="ehae176-B75 ehae176-B76 ehae176-B77" data-open="ehae176-B75 ehae176-B76 ehae176-B77" class="link link-ref link-reveal xref-bibr">75–77</a></sup> It should be noted that most of the observational studies on adverse events have a mix of patients taking and not taking OAC. When carefully controlling for the confounding effects of stroke, comorbidities, and OAC, AF exposure was still significantly associated with vascular dementia (HR, 1.68; 95% CI, 1.33–2.12; _P_ < .001), but not Alzheimer's disease (HR, 0.85; 95% CI, 0.70–1.03; _P_ = .09).<sup><span class="xrefLink" id="jumplink-ehae176-B78"></span><a href="javascript:;" reveal-id="ehae176-B78" data-open="ehae176-B78" class="link link-ref link-reveal xref-bibr">78</a></sup>

Hospital admission rates due to AF vary widely depending on the population studied, and may be skewed by selection bias. In a Dutch RCT including first-diagnosed AF patients (mean age 64 years), cardiovascular hospitalization rates were 7.0% to 9.4% per year.<sup><span class="xrefLink" id="jumplink-ehae176-B79"></span><a href="javascript:;" reveal-id="ehae176-B79" data-open="ehae176-B79" class="link link-ref link-reveal xref-bibr">79</a></sup> An Australian study identified 473 501 hospitalizations for AF during 15 years of follow-up (300 million person-years), with a relative increase in AF hospitalizations of 203% over the study period, in contrast to an increase for all hospitalizations of 71%. The age-specific incidence of hospital admission increased particularly in the older age groups.<sup><span class="xrefLink" id="jumplink-ehae176-B80"></span><a href="javascript:;" reveal-id="ehae176-B80" data-open="ehae176-B80" class="link link-ref link-reveal xref-bibr">80</a></sup>

Atrial fibrillation is also associated with increased mortality. In 2017, AF contributed to over 250 000 deaths globally, with an age-standardized mortality rate of 4.0 per 100 000 people (95% uncertainty interval 3.9–4.2).<sup><span class="xrefLink" id="jumplink-ehae176-B81"></span><a href="javascript:;" reveal-id="ehae176-B81" data-open="ehae176-B81" class="link link-ref link-reveal xref-bibr">81</a></sup> The most frequent cause of death in patients with AF is heart failure related,<sup><span class="xrefLink" id="jumplink-ehae176-B70"></span><a href="javascript:;" reveal-id="ehae176-B70" data-open="ehae176-B70" class="link link-ref link-reveal xref-bibr">70</a></sup> with complex relationships to cardiovascular and non-cardiovascular disease.<sup><span class="xrefLink" id="jumplink-ehae176-B82"></span><a href="javascript:;" reveal-id="ehae176-B82" data-open="ehae176-B82" class="link link-ref link-reveal xref-bibr">82</a></sup> There is up to a two-fold increased risk of all-cause mortality (RR, 1.95; 95% CI, 1.50–2.54),<sup><span class="xrefLink" id="jumplink-ehae176-B68"></span><a href="javascript:;" reveal-id="ehae176-B68" data-open="ehae176-B68" class="link link-ref link-reveal xref-bibr">68</a></sup> and cardiovascular mortality (RR, 2.03; 95% CI, 1.79–2.30)<sup><span class="xrefLink" id="jumplink-ehae176-B69"></span><a href="javascript:;" reveal-id="ehae176-B69" data-open="ehae176-B69" class="link link-ref link-reveal xref-bibr">69</a></sup> in AF compared with sinus rhythm. Even in the absence of major thromboembolic risk factors, the incidence of death is 15.5 per 1000 person-years in those with AF exposure, compared with 9.4 per 1000 person-years without (adjusted HR, 1.44; 95% CI, 1.38–1.50; _P_ < .001).<sup><span class="xrefLink" id="jumplink-ehae176-B78"></span><a href="javascript:;" reveal-id="ehae176-B78" data-open="ehae176-B78" class="link link-ref link-reveal xref-bibr">78</a></sup> Patients with OAC-related bleeding have higher mortality, including both minor and major bleeding (as defined by the International Society on Thrombosis and Haemostasis scale).<sup><span class="xrefLink" id="jumplink-ehae176-B83"></span><a href="javascript:;" reveal-id="ehae176-B83" data-open="ehae176-B83" class="link link-ref link-reveal xref-bibr">83</a></sup> Despite OAC, patients with AF remain at high residual risk of death, highlighting the importance of attention to concomitant disease.<sup><span class="xrefLink" id="jumplink-ehae176-B84"></span><a href="javascript:;" reveal-id="ehae176-B84" data-open="ehae176-B84" class="link link-ref link-reveal xref-bibr">84</a></sup>

### 3.6. Atrial flutter

Atrial flutter (AFL) is the among the most common atrial tachyarrhythmias, with an overall incidence rate of 88 per 100 000 person-years, rising to 317 per 100 000 person-years in people over 50 years of age.<sup><span class="xrefLink" id="jumplink-ehae176-B85"></span><a href="javascript:;" reveal-id="ehae176-B85" data-open="ehae176-B85" class="link link-ref link-reveal xref-bibr">85</a></sup> Risk factors for AFL and AF are similar, and more than half of all patients with AFL will develop AF.<sup><span class="xrefLink" id="jumplink-ehae176-B85"></span><a href="javascript:;" reveal-id="ehae176-B85" data-open="ehae176-B85" class="link link-ref link-reveal xref-bibr">85</a></sup> Observational studies suggest that thromboembolic risk is elevated in AFL.<sup><span class="xrefLink" id="jumplink-ehae176-B86"></span><a href="javascript:;" reveal-id="ehae176-B86" data-open="ehae176-B86" class="link link-ref link-reveal xref-bibr">86</a></sup> In direct comparison of AFL with AF, some studies suggest a similar risk of stroke and others a lower risk in AFL,<sup><span class="xrefLink" id="jumplink-ehae176-B87 ehae176-B88 ehae176-B89 ehae176-B90"></span><a href="javascript:;" reveal-id="ehae176-B87 ehae176-B88 ehae176-B89 ehae176-B90" data-open="ehae176-B87 ehae176-B88 ehae176-B89 ehae176-B90" class="link link-ref link-reveal xref-bibr">87–90</a></sup> possibly due to different comorbidity burdens and the impact of confounders such as AFL/AF ablation and anticoagulation (more frequently stopped in AFL).<sup><span class="xrefLink" id="jumplink-ehae176-B91"></span><a href="javascript:;" reveal-id="ehae176-B91" data-open="ehae176-B91" class="link link-ref link-reveal xref-bibr">91</a></sup>

## 4\. Patient pathways and management of AF

### 4.1. Patient-centred, multidisciplinary AF management

#### 4.1.1. The patient at the heart of care

A patient-centred and integrated approach to AF management means working with a model of care that respects the patient's experience, values, needs, and preferences for planning, co-ordination, and delivery of care. A central component of this model is the therapeutic relationship between the patient and the multidisciplinary team of healthcare professionals (_[Figure 2](javascript:;)_). In patient-centred AF management, patients are seen not as passive recipients of health services, but as active participants who work as partners alongside healthcare professionals. Patient-centred AF management requires integration of all aspects of AF management. This includes symptom control, lifestyle recommendations, psychosocial support, and management of comorbidities, alongside optimal medical treatment consisting of pharmacotherapy, cardioversion, and interventional or surgical ablation (_[Table 9](javascript:;)_). Services should be designed to ensure that all patients have access to an organized model of AF management, including tertiary care specialist services when indicated (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_, _[Evidence Table 4 and Additional Evidence Table S3](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). It is equally important to maintain pathways for patients to promptly re-engage with specialist services when their condition alters.

![Multidisciplinary approach to AF management.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f2.jpeg?Expires=1728478929&Signature=iU~wifyyfffuDkYi5XpTS93o5bcRLQve~r~jPobGiQpJEbc1-2pb-8SieWnasO9WRuXeej-nK5L-i3HzzkGyDPXEd~dyy15A0NWG~6MuzNtuz1xIy602QQSmaZf4ao5OiTFDe5Shq6sUZKnlbyyV0XW0ohLuTskm8sEqY3z0zKIxlD0GhoIt0VDUPG5BpcxYBuK06fNHPnyU5r3mh-hVPYgiVqqNniwx1pjaID7RIXvYxxvuZzC3AncXwGB~tvPHm3QSp1gniIh3NadbTEoITJjA-UH4zk6AkCMjzk43Jo447jxeTZMQRbBl8GDPVoaqvCfUa8u9JRZlM~495RloiA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 2

Multidisciplinary approach to AF management.

Principal caregivers are involved in the community and hospital settings to provide optimal, patient-centred care for patients living with AF. AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment.

[Open in new tab](https://academic.oup.com/view-large/figure/479884169/ehae176f2.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f2.jpeg?Expires=1728478929&Signature=ZrRmmgCz0QFElKi0UptaeQKnU1Oa5~My0BOyg6-q~9YbizJY7qjv2l0fETKyDQSriFn3fI2GCQ~iduS6Q5h54NRfjrcP5pP5oJ8m~ZWTwRNgX~D8ELXlo9OK4ss9M~FPZjgtuBoBRTle-VOpcyeTbbYbxPAaoIJGxL86CC8chyNu08gDMOFqqaHqHMRjU-XjhpYhayJnb5omBptvoDRo0S9Uam7K4yrLEzAEi4xqQLuv6ADUZAxLuhWj2igs1T320YIXaqhPZaPI5MV0t6TDfOjixnOGtnVd9Ot9RDq1Y-dL5ORXfP-W9h6PCfhetN9quYu-H0MH7oNE7euu6Vb9lQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884169&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884170)

Achieving patient-centred AF management

| Components of patient-centred AF management: .  |
| --- |
| 
- Optimal treatment according to the AF-CARE pathway, which includes:


 |
|   ∘ \[C\] Comorbidity and risk factor management |
|   ∘ \[A\] Avoid stroke and thromboembolism |
|   ∘ \[R\] Reduce symptoms by rate and rhythm control |
|   ∘ \[E\] Evaluation and dynamic reassessment |
| 

- Lifestyle recommendations


 |
| 

- Psychosocial support


 |
| 

- Education and awareness for patients, family members, and caregivers


 |
| 

- Seamless co-ordination between primary care and specialized AF care


 |
| **How to implement patient-centred AF management:** |
| 

- Shared decision-making


 |
| 

- Multidisciplinary team approach


 |
| 

- Patient education and empowerment, with emphasis on self-care


 |
| 

- Structured educational programmes for healthcare professionals


 |
| 

- Technology support (e-Health, m-Health, telemedicine)<sup><span class="xrefLink" id="jumplink-tblfn112"></span><a href="javascript:;" reveal-id="tblfn112" data-open="tblfn112" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup>


 |

| Components of patient-centred AF management: .  |
| --- |
| 
- Optimal treatment according to the AF-CARE pathway, which includes:


 |
|   ∘ \[C\] Comorbidity and risk factor management |
|   ∘ \[A\] Avoid stroke and thromboembolism |
|   ∘ \[R\] Reduce symptoms by rate and rhythm control |
|   ∘ \[E\] Evaluation and dynamic reassessment |
| 

- Lifestyle recommendations


 |
| 

- Psychosocial support


 |
| 

- Education and awareness for patients, family members, and caregivers


 |
| 

- Seamless co-ordination between primary care and specialized AF care


 |
| **How to implement patient-centred AF management:** |
| 

- Shared decision-making


 |
| 

- Multidisciplinary team approach


 |
| 

- Patient education and empowerment, with emphasis on self-care


 |
| 

- Structured educational programmes for healthcare professionals


 |
| 

- Technology support (e-Health, m-Health, telemedicine)<sup><span class="xrefLink" id="jumplink-tblfn112"></span><a href="javascript:;" reveal-id="tblfn112" data-open="tblfn112" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup>


 |

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment.

<sup>a</sup>e-Health refers to healthcare services provided using electronic methods; m-Health, refers to healthcare services supported by mobile devices; and telemedicine refers to remote diagnosis or treatment supported by telecommunications technology.

© ESC 2024

Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884170)

Achieving patient-centred AF management

| Components of patient-centred AF management: .  |
| --- |
| 
- Optimal treatment according to the AF-CARE pathway, which includes:


 |
|   ∘ \[C\] Comorbidity and risk factor management |
|   ∘ \[A\] Avoid stroke and thromboembolism |
|   ∘ \[R\] Reduce symptoms by rate and rhythm control |
|   ∘ \[E\] Evaluation and dynamic reassessment |
| 

- Lifestyle recommendations


 |
| 

- Psychosocial support


 |
| 

- Education and awareness for patients, family members, and caregivers


 |
| 

- Seamless co-ordination between primary care and specialized AF care


 |
| **How to implement patient-centred AF management:** |
| 

- Shared decision-making


 |
| 

- Multidisciplinary team approach


 |
| 

- Patient education and empowerment, with emphasis on self-care


 |
| 

- Structured educational programmes for healthcare professionals


 |
| 

- Technology support (e-Health, m-Health, telemedicine)<sup><span class="xrefLink" id="jumplink-tblfn112"></span><a href="javascript:;" reveal-id="tblfn112" data-open="tblfn112" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup>


 |

| Components of patient-centred AF management: .  |
| --- |
| 
- Optimal treatment according to the AF-CARE pathway, which includes:


 |
|   ∘ \[C\] Comorbidity and risk factor management |
|   ∘ \[A\] Avoid stroke and thromboembolism |
|   ∘ \[R\] Reduce symptoms by rate and rhythm control |
|   ∘ \[E\] Evaluation and dynamic reassessment |
| 

- Lifestyle recommendations


 |
| 

- Psychosocial support


 |
| 

- Education and awareness for patients, family members, and caregivers


 |
| 

- Seamless co-ordination between primary care and specialized AF care


 |
| **How to implement patient-centred AF management:** |
| 

- Shared decision-making


 |
| 

- Multidisciplinary team approach


 |
| 

- Patient education and empowerment, with emphasis on self-care


 |
| 

- Structured educational programmes for healthcare professionals


 |
| 

- Technology support (e-Health, m-Health, telemedicine)<sup><span class="xrefLink" id="jumplink-tblfn112"></span><a href="javascript:;" reveal-id="tblfn112" data-open="tblfn112" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup>


 |

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment.

<sup>a</sup>e-Health refers to healthcare services provided using electronic methods; m-Health, refers to healthcare services supported by mobile devices; and telemedicine refers to remote diagnosis or treatment supported by telecommunications technology.

© ESC 2024

#### 4.1.2. Education and shared decision-making

Clear advice about the rationale for treatments, the possibility of treatment modification, and shared decision-making can help patients live with AF (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B92"></span><a href="javascript:;" reveal-id="ehae176-B92" data-open="ehae176-B92" class="link link-ref link-reveal xref-bibr">92</a></sup> An open and effective relationship between the patient and the healthcare professional is critical, with shared decision-making found to improve outcomes for OAC and arrhythmia management.<sup><span class="xrefLink" id="jumplink-ehae176-B93"></span><a href="javascript:;" reveal-id="ehae176-B93" data-open="ehae176-B93" class="link link-ref link-reveal xref-bibr">93</a>,<span class="xrefLink" id="jumplink-ehae176-B94"></span><a href="javascript:;" reveal-id="ehae176-B94" data-open="ehae176-B94" class="link link-ref link-reveal xref-bibr">94</a></sup> In using a shared approach, both the clinician and patient are involved in the decision-making process (to the extent that the patient prefers). Information is shared in both directions. Furthermore, both the clinician and the patient express their preferences and discuss the options. Of the potential treatment decisions, no treatment is also a possibility.<sup><span class="xrefLink" id="jumplink-ehae176-B95"></span><a href="javascript:;" reveal-id="ehae176-B95" data-open="ehae176-B95" class="link link-ref link-reveal xref-bibr">95</a></sup> There are several toolkits available to facilitate this, although most are focused on anticoagulation decisions. For example, the Shared Decision-Making Toolkit ([http://afibguide.com](http://afibguide.com), [http://afibguide.com/clinician](http://afibguide.com/clinician)) and the Successful Intravenous Cardioversion for Atrial Fibrillation (SIC-AF) score have been shown to reduce decisional conflict compared with usual care in patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B93"></span><a href="javascript:;" reveal-id="ehae176-B93" data-open="ehae176-B93" class="link link-ref link-reveal xref-bibr">93</a>,<span class="xrefLink" id="jumplink-ehae176-B94"></span><a href="javascript:;" reveal-id="ehae176-B94" data-open="ehae176-B94" class="link link-ref link-reveal xref-bibr">94</a></sup> Patient-support organizations can also make an important contribution to providing understandable and actionable knowledge about AF and its treatments (e.g. local support groups and international charities, such as [http://afa-international.org](http://afa-international.org)). As AF is a chronic or recurrent disease in most patients, education is central to empower patients, their families, and caregivers.

#### 4.1.3. Education of healthcare professionals

Gaps in knowledge and skills across all domains of AF care are consistently described among cardiologists, neurologists, internal medicine specialists, emergency physicians, general practitioners, nurses, and allied health practitioners.<sup><span class="xrefLink" id="jumplink-ehae176-B96 ehae176-B97 ehae176-B98"></span><a href="javascript:;" reveal-id="ehae176-B96 ehae176-B97 ehae176-B98" data-open="ehae176-B96 ehae176-B97 ehae176-B98" class="link link-ref link-reveal xref-bibr">96–98</a></sup> Healthcare professionals involved in multidisciplinary AF management should have a knowledge of all available options for diagnosis and treatment.<sup><span class="xrefLink" id="jumplink-ehae176-B99 ehae176-B100 ehae176-B101"></span><a href="javascript:;" reveal-id="ehae176-B99 ehae176-B100 ehae176-B101" data-open="ehae176-B99 ehae176-B100 ehae176-B101" class="link link-ref link-reveal xref-bibr">99–101</a></sup> In the STEEER-AF trial,<sup><span class="xrefLink" id="jumplink-ehae176-B99"></span><a href="javascript:;" reveal-id="ehae176-B99" data-open="ehae176-B99" class="link link-ref link-reveal xref-bibr">99</a></sup> real-world adherence to clinical practice guidelines for AF across six ESC countries was poor. These findings highlight the critical need for appropriate training and education of healthcare professionals.<sup><span class="xrefLink" id="jumplink-ehae176-B102"></span><a href="javascript:;" reveal-id="ehae176-B102" data-open="ehae176-B102" class="link link-ref link-reveal xref-bibr">102</a></sup>

Specifically targeted education for healthcare professionals can increase knowledge and lead to more appropriate use of OAC for prevention of thromboembolism.<sup><span class="xrefLink" id="jumplink-ehae176-B103"></span><a href="javascript:;" reveal-id="ehae176-B103" data-open="ehae176-B103" class="link link-ref link-reveal xref-bibr">103</a></sup> However, educational interventions for healthcare providers are often not enough to sustainably impact behaviour.<sup><span class="xrefLink" id="jumplink-ehae176-B104"></span><a href="javascript:;" reveal-id="ehae176-B104" data-open="ehae176-B104" class="link link-ref link-reveal xref-bibr">104</a></sup> Other tools may be needed, such as active feedback,<sup><span class="xrefLink" id="jumplink-ehae176-B103"></span><a href="javascript:;" reveal-id="ehae176-B103" data-open="ehae176-B103" class="link link-ref link-reveal xref-bibr">103</a></sup> clinical decision support tools,<sup><span class="xrefLink" id="jumplink-ehae176-B105"></span><a href="javascript:;" reveal-id="ehae176-B105" data-open="ehae176-B105" class="link link-ref link-reveal xref-bibr">105</a></sup> expert consultation,<sup><span class="xrefLink" id="jumplink-ehae176-B106"></span><a href="javascript:;" reveal-id="ehae176-B106" data-open="ehae176-B106" class="link link-ref link-reveal xref-bibr">106</a></sup> or e-Health learning.<sup><span class="xrefLink" id="jumplink-ehae176-B107"></span><a href="javascript:;" reveal-id="ehae176-B107" data-open="ehae176-B107" class="link link-ref link-reveal xref-bibr">107</a></sup>

#### 4.1.4. Inclusive management of AF

Evidence is growing on differences in AF incidence, prevalence, risk factors, comorbidities, and outcomes according to gender.<sup><span class="xrefLink" id="jumplink-ehae176-B108"></span><a href="javascript:;" reveal-id="ehae176-B108" data-open="ehae176-B108" class="link link-ref link-reveal xref-bibr">108</a></sup> Women diagnosed with AF are generally older, have more hypertension and heart failure with preserved ejection fraction (HFpEF), and have less diagnosed coronary artery disease (CAD).<sup><span class="xrefLink" id="jumplink-ehae176-B109"></span><a href="javascript:;" reveal-id="ehae176-B109" data-open="ehae176-B109" class="link link-ref link-reveal xref-bibr">109</a></sup> Registry studies have reported differences in outcomes, with higher morbidity and mortality in women, although these may be confounded by age and comorbidity burden.<sup><span class="xrefLink" id="jumplink-ehae176-B110 ehae176-B111 ehae176-B112"></span><a href="javascript:;" reveal-id="ehae176-B110 ehae176-B111 ehae176-B112" data-open="ehae176-B110 ehae176-B111 ehae176-B112" class="link link-ref link-reveal xref-bibr">110–112</a></sup> Women with AF may be more symptomatic, and report a lower quality of life.<sup><span class="xrefLink" id="jumplink-ehae176-B41"></span><a href="javascript:;" reveal-id="ehae176-B41" data-open="ehae176-B41" class="link link-ref link-reveal xref-bibr">41</a>,<span class="xrefLink" id="jumplink-ehae176-B113"></span><a href="javascript:;" reveal-id="ehae176-B113" data-open="ehae176-B113" class="link link-ref link-reveal xref-bibr">113</a></sup> It is unclear whether this is related to delayed medical assessment in women, or whether there are genuine sex differences. Despite a higher symptom load, women are less likely to undergo AF ablation than men, even though antiarrhythmic drug therapy seems to be associated with more proarrhythmic events in women.<sup><span class="xrefLink" id="jumplink-ehae176-B109"></span><a href="javascript:;" reveal-id="ehae176-B109" data-open="ehae176-B109" class="link link-ref link-reveal xref-bibr">109</a></sup> These observations call for more research on gender differences in order to prevent disparities and inequality in care. Other diversity aspects such as age, race, ethnicity, and transgender issues, as well as social determinants (including socioeconomic status, disability, education level, health literacy, and rural/urban location) are important contributors to inequality that should be actively considered to improve patient outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B114"></span><a href="javascript:;" reveal-id="ehae176-B114" data-open="ehae176-B114" class="link link-ref link-reveal xref-bibr">114</a></sup>

### 4.2. Principles of AF-CARE

The _2024 ESC Guidelines for the management of AF_ have compiled and evolved past approaches to create principles of management to aid implementation of these guidelines, and hence improve patient care and outcomes. There is growing evidence that clinical support tools<sup><span class="xrefLink" id="jumplink-ehae176-B115 ehae176-B116 ehae176-B117 ehae176-B118"></span><a href="javascript:;" reveal-id="ehae176-B115 ehae176-B116 ehae176-B117 ehae176-B118" data-open="ehae176-B115 ehae176-B116 ehae176-B117 ehae176-B118" class="link link-ref link-reveal xref-bibr">115–118</a></sup> can aid best-practice management, with the caveat that any tool is a guide only, and that all patients require personalized attention. The AF-CARE approach covers many established principles in the management of AF, but does so in a systematic, time-orientated format with four essential treatment pillars (_[Figure 3](javascript:;)_; central illustration). Joint management with each patient forms the starting point of the AF-CARE approach. Notably, it takes account of the growing evidence base that therapies for AF are most effective when associated health conditions are addressed. A careful search for these comorbidities and risk factors \[C\] is critical and should be applied in all patients with a diagnosis of AF. Avoidance of stroke and thromboembolism \[A\] in patients with risk factors is considered next, focused on appropriate use of anticoagulant therapy. Reducing AF-related symptoms and morbidity by effective use of heart rate and rhythm control \[R\] is then applied, which in selected patients may also reduce hospitalization or improve prognosis. The potential benefit of rhythm control, accompanied by consideration of all risks involved, should be considered in all patients at each contact point with healthcare professionals. As AF, and its related comorbidities, changes over time, different levels of evaluation \[E\] and re-evaluation are required in each patient, and these approaches should be dynamic. Due to the wide variability in response to therapy, and the changing pathophysiology of AF as age and comorbidities advance, reassessment should be built into the standard care pathway to prevent adverse outcomes for patients and improve population health.

![Central illustration. Patient pathway for AF-CARE (see Figures 4, 5, 6, and 7 for the [R] pathways for first-diagnosed, paroxysmal, persistent and permanent AF).](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f3.jpeg?Expires=1728478929&Signature=zJZqFezmkxa0RyS97axu20ABh1114xZryDgGMF2GAuOER-yNjZk2l8-6FdxDt0LK3uaCTsFeqsuvRH-XdEXwigRVCEp~aUPIlHaqMZ4S7Ls59VbbOjiRkytVfdKe7r0jUDd6RUlIiJi15QF8AEngdQxvwAqtD7rgrVMLIuOD1SciWeSFxEwKEOrzyLyJRr2hlNAFl-XhEFEWqGiI0uEc1icXz9OePpkB2z-T9teNdyjYqPm9YsHKAi4n37-pSwjUyC3q-waoaBj01BS5AG1myesSY3CHZdj~KqzS5ZKjlXLzaQ~0sRirENGWy3146~6Qy-gTetrcSwxeBdNplGgeMg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 3

Central illustration. Patient pathway for AF-CARE (see _[Figures 4](javascript:;), [5](javascript:;), [6](javascript:;)_, and _[7](javascript:;)_ for the \[R\] pathways for first-diagnosed, paroxysmal, persistent and permanent AF).

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; CCS, chronic coronary syndrome; CHA<sub>2</sub>DS<sub>2</sub>\-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; DOAC, direct oral anticoagulant; ECG, electrocardiogram; HFrEF, heart failure with reduced ejection fraction; INR, international normalized ratio of prothrombin time; OAC, oral anticoagulant; OSA, obstructive sleep apnoea; PVD, peripheral vascular disease; SGLT2, sodium-glucose cotransporter-2; VKA, vitamin K antagonist. <sup>a</sup>As part of a comprehensive management of cardiometabolic risk factors.

[Open in new tab](https://academic.oup.com/view-large/figure/479884180/ehae176f3.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f3.jpeg?Expires=1728478929&Signature=uyIKPAXDcVOqPOiwbdI2~WFOziMtH~Y~aY0HqafD2jcjebI4t8jbO4ylXsjulYV6uIhSJCjWSR-SmK36qSx5bnugUB8Xj9R10slFw24PJkup5EYOxApqmp8y2H99XBh~nnjOesN2f6bb3izP52W4hKC-y4RnY5eOCyOEr2friPC5COKtxqWooUVJu2r50vVM6yfzT9uonbiB7J753RivchCoCuQCvpOqP-uLBhVUig13vf8Fe9Hf~B5wDb4E9oPU-ZR73bCoNGRtXtG-yeoKd~zrXsyfP8Zf1-1xJ-qMRRdY27QKuEj6gfvQJTuqCE6iqb98Sy0ihL4KRVq5ZoGNQA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884180&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

AF-CARE builds upon prior ESC Guidelines, e.g. the five-step outcome-focused integrated approach in the _2016 ESC Guidelines for the management of AF_,<sup><span class="xrefLink" id="jumplink-ehae176-B119"></span><a href="javascript:;" reveal-id="ehae176-B119" data-open="ehae176-B119" class="link link-ref link-reveal xref-bibr">119</a></sup> and the AF Better Care (ABC) pathway in the _2020 ESC Guidelines for the diagnosis and management of AF_.<sup><span class="xrefLink" id="jumplink-ehae176-B120"></span><a href="javascript:;" reveal-id="ehae176-B120" data-open="ehae176-B120" class="link link-ref link-reveal xref-bibr">120</a></sup> The reorganization into AF-CARE was based on the parallel developments in new approaches and technologies (in particular for rhythm control), with new evidence consistently suggesting that all aspects of AF management are more effective when comorbidities and risk factors have been considered. This includes management relating to symptom benefit, improving prognosis, prevention of thromboembolism, and the response to rate and rhythm control strategies. AF-CARE makes explicit the need for individualized evaluation and follow-up in every patient, with an active approach that accounts for how patients, their AF, and associated comorbidities change over time. The AF-CARE principles have been applied to different patient pathways for ease of implementation into routine clinical care. This includes the management of first-diagnosed AF (_[Figure 4](javascript:;)_), paroxysmal AF (_[Figure 5](javascript:;)_), persistent AF (_[Figure 6](javascript:;)_), and permanent AF (_[Figure 7](javascript:;)_).

![[R] Pathway for patients with first-diagnosed AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f4.jpeg?Expires=1728478929&Signature=3eeYtI4x~bRORLoZGpH1y11e4W-7sEp3M6mkuScw2YS-LzFW2XD8Er6umJv1NgxSikibsPL1EOuSGWcjz7pGeuxDhQIK5Wt9wO4v9MZic0R8yDeF4s6tLBqI62cvI29D7LAA0In~KbqxbNmI3cDPJfc5~8A-I-ug3XpRqsxon--rVXrzK199nEEaBPcBOuawxtJ6XrK~yfExqlhpvheiR6hnFPhGrpE94mOvEYJjrNHughTJqwKS08AqlgMPSE2rV~b1-ykXVld81xMTCjgp6h-TTJancS8wCOBgBS7tbELcAu5qKErVX50233nhOBJsniZyw-rZ4RA5bPyRM5UoEg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 4

\[R\] Pathway for patients with first-diagnosed AF.

AF, atrial fibrillation; AF-CARE, Atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; LVEF, left ventricular ejection fraction. After following the pathway for first-diagnosed AF, patients with recurrent AF should enter the AF-CARE \[R\] pathway for paroxysmal, persistent, or permanent AF, depending on the type of their AF.

[Open in new tab](https://academic.oup.com/view-large/figure/479884182/ehae176f4.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f4.jpeg?Expires=1728478929&Signature=tnES761iKAdaFLrLmMuLV04X03H3yjapOrjqv2Smt2l3KQy1Df8kKlPRck1zQLCCrga~84WCRedF4gdsPnZgYi2T8BKMNSR5G4XAxd-wwpVQOcOL7T94F0W8n890Oww-H8NOm5dVXQoVvPt7iMBsYtgvRRGvasjpASostyNY0znAuPUYWFJpthb~YaCOeVKNcmef0piIITibVMQOKvg5MdxH6PZzBEeZC-zMbdh~R2rkahvw5Wi0PKf9uy~w9G8uc793u-ID8RbIIsigcz6mwANkKBbilf8vbXqq175rcH59WZrWR5BE2XSfWyAersvjIdABEO5L5zutrMILt6bbCg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884182&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![[R] Pathway for patients with paroxysmal AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f5.jpeg?Expires=1728478929&Signature=gleLWqjFGA3c7PhbngMUuwRWimUtZX1zpF8RMIVndC2M8xBx18gnK9W8n7Kj-RrjaTBi5ZK4H50cGVOxGkQHZ48ntCFlz5zrn2TGshQ2LK2DDEl1Q0pSQO4hcHDbZtchKP1qMq9I9mzqkSMwXhuxolEsMA~0uORNdXx~jtk5zfs0VvFca~aIlhIBYo4WD-2GIQNVaTkNHgh5zKzPTUp5cYtWmBcEeWl4BIj86v8NJ9PAU7pXgk3ioTFQhdof0k5bNh2vsKWP2pkrpGZk7Ih0t7wcHUqDTJoU-WwhJ0nP6LlKjn5AzyxZtN~gXuQP0PxBaY4VgrLWHRIjE1LyHZroWA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 5

\[R\] Pathway for patients with paroxysmal AF.

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; b.p.m., beats per minute; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, Heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. <sup>a</sup>In patients with HFrEF: Class I if high probability of tachycardia-induced cardiomyopathy; and Class IIa in selected patients to improve prognosis.

[Open in new tab](https://academic.oup.com/view-large/figure/479884183/ehae176f5.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f5.jpeg?Expires=1728478929&Signature=RP3cfAVmClvel6VQ-dJnFyNmQ7nyibSBpi1m5oXSm7thcrv-RiaRx-ambvfev6h0bGOAqsPTR~s4defX3vsMtkCXQK~jQSobCm8YaCPSQOQX0USZDXlKgaybKL3qrs6nIhGKAaS52o69HyuZJ2TE8-TZMAfCvvmd0Wd0komJqtbuSTGBle-iGLfPzTy5SySdd7kciu8OCKbtGkUwbpODffi3kT7VjUKQdFIKzWnHdXBYGVbu1~nyQ1xHzYDzdTXajDncWQZT1eFBNBo4K85AjjaH0PoGo3nEnB2dC6glDSGFK969DnyzY4CQo0XTiCzdGZt2wpE0qr3080tMD~z8hw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884183&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![[R] Pathway for patients with persistent AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f6.jpeg?Expires=1728478929&Signature=YIyg~Ot8A9KbqGmdWVWPkw7EXqdC6Pdcqj7cwdmmOHMMytU5zLdOZGel54IR7diH2Exe3PvnRC5MQWwNpf-NRvat3zlDNaSuYNeONohJyZ~-svgmleTvw~vO5~esEh42v-cCfILGktZxwO~FLpyaYtUkXUQHqHwYCKwMxt92exkBr6BL6RlupjcUuWrxP0xXcKYrkglyRvwCi~GVSOGD92pOO-yKFRzBxHap4ttjFoVI7B4ec7nJ4bZXACdeeKACO4XKaDTYCIu6vj1C5sZ3k90kAFb1MbaMqvaS6Dgt7rowgrjDzFpRuREWNLD1Hio3V36zRZ56TR8r3vdGzBSi9Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 6

\[R\] Pathway for patients with persistent AF.

AF, atrial fibrillation; AF-CARE, Atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; b.p.m., beats per minute; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. <sup>a</sup>In patients with HFrEF: Class I if high probability of tachycardia-induced cardiomyopathy; and Class IIa in selected patients to improve prognosis.

[Open in new tab](https://academic.oup.com/view-large/figure/479884184/ehae176f6.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f6.jpeg?Expires=1728478929&Signature=Q9tPdW~RQvfAE8sBEFwxIdrf4Aw-64pUhodor3C6p3i7T41kMbv0SUBlOS4MJxqu-~8CfBmTsBFnuWT4qDgYCsez4TM1AyYGpZg8D7o-JOcvWTuaQnA6ZgmMQSJbUIJnIVG3co~8Mw1nwF-RrSE8ymJNVCOeIS-6gmaFn24YOcObzao8ORbPdIywrJRsRwNmyRcXqD2AOEM5Gca3zZMaI94mu5OlrY2C-UpkSr83wkZ~sZCngishsno43uhj3Okpk7eJ2YprhiI7OHr--MLbNXLIDKqMFv7RuzsSW-~qThtQGQzwj3uBwQzgy3nZX7CjO~eGVh9iiYBx207jwk8vVA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884184&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![[R] Pathway for patients with permanent AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f7.jpeg?Expires=1728478929&Signature=1vjTRkfX4u4sbtou~hl8dK6C0074clM2-fLVGDDSnp~gKa3gTNaon~SMncvaxhS8M6p9iUBMEd1junPwsEnYMBo8k7nMKcZUbQ2zojwSjZm5zLJt1BhYdyEoN65sEwh6mX~mqtf8y1KtaZ4KVlfyyhp8I3PsrAxqcCc05s7RZ57lU-A6UlIfQxA8QsS7zk0POnwIYg9lZXAZFpKC2Bg~nYgo8x0RWd8bYaM0ybGZI3plFcjJEK88vgkOn9lYKRwvZnAZBrBy2Iyeu8XYszrC-bow3Lhzg4rXwoZ3HGHgBIwVq4RoP5KewyMwaGngRlr0i-PAbOqFTknE4J3rP0Y1lA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 7

\[R\] Pathway for patients with permanent AF.

AF, atrial fibrillation; AF-CARE, Atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; b.p.m., beats per minute; CRT, cardiac resynchronization therapy; HF, heart failure; LVEF, left ventricular ejection fraction. Permanent AF is a shared decision made between the patient and physician that no further attempts at restoration of sinus rhythm are planned. <sup>a</sup>Note that the combination of beta-blockers with diltiazem or verapamil should only be used under specialist advice, and monitored with an ambulatory ECG to check for bradycardia.

[Open in new tab](https://academic.oup.com/view-large/figure/479884185/ehae176f7.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f7.jpeg?Expires=1728478929&Signature=pGgZylpuPfcRtjqoYirlF01Cdap6wIRSt2lOaWH7Q~4U9uhD-1RHuoNJ5g5dNSd9~SR1UthWWmkjWvSLypeeresfnPqRwHxoNp9Tz8z2YtfPq089tqeXkS6vthFNAxso~r0eLYO3iMRHTb~ORgWtb2xxuTgifaiOCVXQZHyaomUpA0CPLCdl2n9iINvZzbhItX9Lt4ZQ-lVF9WbyxvZTX6a~eAdjFRSf8kjFNVCxRurT~y~ZVGcYCCJvNGGpPaIpUutSzk3oXtKMxz6bgTHZERP-VtfuCUuK93r57JD-EDJsjU2kQHVGy6uuKdClwtnngVzdGF36GWbxjjZuTqcFjQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884185&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884186)

Recommendations for patient-centred care and education (see also Evidence Table 4)

![Recommendations for patient-centred care and education (see also Evidence Table 4)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt4.jpeg?Expires=1728478929&Signature=dSGKHnbd109Sez--XkdmCGDvnfsgwDNmEE-cOBfrFFC2iM-pA20rHiOlzSCVmGgUX3WJEEvJQxPNKcFnl0TpP~PcbPUPWfDpw6Y7Yeorh2wxRmUZNgKw5I70dMODTA-FZA-JceRHTQTzAMMF6Q90mWpp3pJiAtqZwD0kI7CkwN7PH971Q2fCpARE1VXALo4TSaFBMKb8B2~LWHzILMOQgpvzWq9hNgI2zcv~8QfVDrUn3WA69R8Z~YDkEbiHJnUIpsSeGno~40L~-y6rF6SBe3l3Elzk6jJ0V0sAl-EjV6mdY-vTnnb1r8fzxQ0EvRgJi1-aOyvNmxl4SMHjAxboxg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884186)

Recommendations for patient-centred care and education (see also Evidence Table 4)

![Recommendations for patient-centred care and education (see also Evidence Table 4)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt4.jpeg?Expires=1728478929&Signature=dSGKHnbd109Sez--XkdmCGDvnfsgwDNmEE-cOBfrFFC2iM-pA20rHiOlzSCVmGgUX3WJEEvJQxPNKcFnl0TpP~PcbPUPWfDpw6Y7Yeorh2wxRmUZNgKw5I70dMODTA-FZA-JceRHTQTzAMMF6Q90mWpp3pJiAtqZwD0kI7CkwN7PH971Q2fCpARE1VXALo4TSaFBMKb8B2~LWHzILMOQgpvzWq9hNgI2zcv~8QfVDrUn3WA69R8Z~YDkEbiHJnUIpsSeGno~40L~-y6rF6SBe3l3Elzk6jJ0V0sAl-EjV6mdY-vTnnb1r8fzxQ0EvRgJi1-aOyvNmxl4SMHjAxboxg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 5\. \[C\] Comorbidity and risk factor management

A broad array of comorbidities are associated with the recurrence and progression of AF. Managing comorbidities is also central to the success of other aspects of care for patients with AF, with evidence available for hypertension, heart failure, diabetes mellitus, obesity, and sleep apnoea, along with lifestyle changes that improve physical activity and reduce alcohol intake (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Identification and treatment of these comorbidities and clusters of risk factors form an important part of effective AF-CARE (_[Figure 8](javascript:;)_), with the evidence outlined in the rest of this section highlighting where management can improve patient outcomes or prevent AF recurrence. Many of these factors (and more) are also associated with incident AF (see _Section [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s9)_).

![Management of key comorbidities to reduce AF recurrence.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f8.jpeg?Expires=1728478929&Signature=zJzeMf7YU-Q~iIEpwnzjjXJtqScDDj9Ib7xXSM5jphv4PAcx5RVcA8Km~dOfjNuWjLTmTfXLeSTe6TGXyjzKwWP1wXJobui9GVcxzVXWF~Whzgq7tw-Q2hagtqA5zbCO79u-Mf0ZyqCnGLjWnCWRA911MxG7zt0hPtMkVrllGY53Y4TL89ts~~~m7efl~pEhhAZ2IjsyB3dXn1y8rDt-OkqbKclej3hYQ4TBW~TyZguZnCZWzCWuoJ-qmsY7g~mbrr4BeZmasVM0PG-ufZQmJq17afZzjgoBs6NNJGOkkyIXWaoWg-jgLrMT-AYkc7pwMrOizeRE7idCoBN6WMsNpQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 8

Management of key comorbidities to reduce AF recurrence.

LVEF, left ventricular ejection fraction; SGLT2, sodium-glucose cotransporter-2.

[Open in new tab](https://academic.oup.com/view-large/figure/479884189/ehae176f8.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f8.jpeg?Expires=1728478929&Signature=OfmvrmKFbZDjuqTS5k2TX8HzOyxEVMo9QlDBp9ZmzfazcBCaLZKCVyPvZ~yVP4kyLD9jYHxaNeV8i3xkiOqeH8w0tcFLCzvyJWbq7aDhJ5CPn2MArZqRqj76HEApzTq-EfbZJDBHVe59sQZh064fzhUVGuGIHLYZfFX6RFEUOLubT~0oI9beY74UiKYpODML4gdwt~ERn7JZtYkA~QN34bIpkAgLpvjl-dRS49Qp7nlp3fgzhhr7kHUnWgkE5trfcEq1lcJ-oUzaI579AQu8LNnPFldlu~jh~850T8IXRJ0CobciwqDJ8LsWRpdMzRrcjAJIahAPhDGbrS68GV3hmw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884189&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884190)

Recommendations for comorbidity and risk factor management in AF (see also Evidence Table 5)

![Recommendations for comorbidity and risk factor management in AF (see also Evidence Table 5)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt5.jpeg?Expires=1728478929&Signature=kd~DZdmPmV2hb6dBThEfHxr41Pia3Fw0abQlzzPL2Yo4oWcCFqs-AKK1sQimGomdDQatS6t6IdKST3-FBQK1f0jMiROW87ZLbWz1uVZKPjCA2T8URX8~YFAEGUs4DvrSCZbj8guwM52EgcW4pQ3iAIHwLr5y73C6kWFSlAfFuraEqBgmWAERnYc-TUpPCbAq4PgqICs8LFSkFVMiNvt9WqnVmFfdwCewxTwdpwnKlcnGqyiHUxQDeqIlpq4ydly7pwTe4pjVZNgBkxkZqY6OLE7-R~Zj5qRJcW1caxypC9FLSrWN5v9SsvpMcqQrg7giiZjzHshLEmOAiQe9i4cnBg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884190)

Recommendations for comorbidity and risk factor management in AF (see also Evidence Table 5)

![Recommendations for comorbidity and risk factor management in AF (see also Evidence Table 5)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt5.jpeg?Expires=1728478929&Signature=kd~DZdmPmV2hb6dBThEfHxr41Pia3Fw0abQlzzPL2Yo4oWcCFqs-AKK1sQimGomdDQatS6t6IdKST3-FBQK1f0jMiROW87ZLbWz1uVZKPjCA2T8URX8~YFAEGUs4DvrSCZbj8guwM52EgcW4pQ3iAIHwLr5y73C6kWFSlAfFuraEqBgmWAERnYc-TUpPCbAq4PgqICs8LFSkFVMiNvt9WqnVmFfdwCewxTwdpwnKlcnGqyiHUxQDeqIlpq4ydly7pwTe4pjVZNgBkxkZqY6OLE7-R~Zj5qRJcW1caxypC9FLSrWN5v9SsvpMcqQrg7giiZjzHshLEmOAiQe9i4cnBg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 5.1. Hypertension

Hypertension in patients with AF is associated with an increased risk of stroke, heart failure, major bleeding, and cardiovascular mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B158 ehae176-B159 ehae176-B160 ehae176-B161"></span><a href="javascript:;" reveal-id="ehae176-B158 ehae176-B159 ehae176-B160 ehae176-B161" data-open="ehae176-B158 ehae176-B159 ehae176-B160 ehae176-B161" class="link link-ref link-reveal xref-bibr">158–161</a></sup> The target for treated systolic blood pressure (BP) in most adults is 120–129 mmHg. Where BP-lowering treatment is poorly tolerated, clinically significant frailty exists or the patient's age is 85 years or older, a more lenient target of <140 mmHg is acceptable or ‘as low as reasonably achievable’. On-treatment diastolic BP should ideally be 70–79 mmHg.<sup><span class="xrefLink" id="jumplink-ehae176-B162"></span><a href="javascript:;" reveal-id="ehae176-B162" data-open="ehae176-B162" class="link link-ref link-reveal xref-bibr">162</a></sup> In an individual participant data meta-analysis of 22 randomized trials reporting baseline AF, a 5 mmHg reduction in systolic BP reduced the risk of major cardiovascular events by 9% (HR, 0.91; 95% CI, 0.83–1.00), with identical effect in patients with AF or sinus rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B129"></span><a href="javascript:;" reveal-id="ehae176-B129" data-open="ehae176-B129" class="link link-ref link-reveal xref-bibr">129</a></sup>

In individuals with AF, hypertension often coexists with other modifiable and non-modifiable risk factors that all contribute to recurrence of AF, readmission to hospital, and ongoing symptoms after rhythm control.<sup><span class="xrefLink" id="jumplink-ehae176-B163 ehae176-B164 ehae176-B165 ehae176-B166 ehae176-B167 ehae176-B168 ehae176-B169 ehae176-B170 ehae176-B171"></span><a href="javascript:;" reveal-id="ehae176-B163 ehae176-B164 ehae176-B165 ehae176-B166 ehae176-B167 ehae176-B168 ehae176-B169 ehae176-B170 ehae176-B171" data-open="ehae176-B163 ehae176-B164 ehae176-B165 ehae176-B166 ehae176-B167 ehae176-B168 ehae176-B169 ehae176-B170 ehae176-B171" class="link link-ref link-reveal xref-bibr">163–171</a></sup> Optimal control of blood pressure should be considered an essential component of treating AF and undertaken within a strategy of comprehensive risk factor management.<sup><span class="xrefLink" id="jumplink-ehae176-B126 ehae176-B127 ehae176-B128"></span><a href="javascript:;" reveal-id="ehae176-B126 ehae176-B127 ehae176-B128" data-open="ehae176-B126 ehae176-B127 ehae176-B128" class="link link-ref link-reveal xref-bibr">126–128</a></sup> Although the majority of research has focused on clinical outcomes, limited comparative data on hypertension medication suggests that use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) may be superior for prevention of recurrent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B172 ehae176-B173 ehae176-B174 ehae176-B175"></span><a href="javascript:;" reveal-id="ehae176-B172 ehae176-B173 ehae176-B174 ehae176-B175" data-open="ehae176-B172 ehae176-B173 ehae176-B174 ehae176-B175" class="link link-ref link-reveal xref-bibr">172–175</a></sup>

### 5.2. Heart failure

Heart failure is a key determinant of prognosis in patients with AF, as well as an important factor associated with recurrence and progression of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B176"></span><a href="javascript:;" reveal-id="ehae176-B176" data-open="ehae176-B176" class="link link-ref link-reveal xref-bibr">176</a>,<span class="xrefLink" id="jumplink-ehae176-B177"></span><a href="javascript:;" reveal-id="ehae176-B177" data-open="ehae176-B177" class="link link-ref link-reveal xref-bibr">177</a></sup> During 30 years of follow-up in the Framingham cohort, 57% of those with new heart failure had concomitant AF, and 37% of those with new AF had heart failure.<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a></sup> Numerous cardiovascular and non-cardiovascular conditions impact the development of both AF and heart failure, leading to the common pathway of atrial cardiomyopathy.<sup><span class="xrefLink" id="jumplink-ehae176-B18"></span><a href="javascript:;" reveal-id="ehae176-B18" data-open="ehae176-B18" class="link link-ref link-reveal xref-bibr">18</a></sup> In patients with acute heart failure attending the emergency department, AF is one of the most prevalent triggering factors of the episode.<sup><span class="xrefLink" id="jumplink-ehae176-B179"></span><a href="javascript:;" reveal-id="ehae176-B179" data-open="ehae176-B179" class="link link-ref link-reveal xref-bibr">179</a></sup> The development of heart failure in patients with AF is associated with a two-fold increase in stroke and thromboembolism,<sup><span class="xrefLink" id="jumplink-ehae176-B180"></span><a href="javascript:;" reveal-id="ehae176-B180" data-open="ehae176-B180" class="link link-ref link-reveal xref-bibr">180</a></sup> even after anticoagulation,<sup><span class="xrefLink" id="jumplink-ehae176-B181"></span><a href="javascript:;" reveal-id="ehae176-B181" data-open="ehae176-B181" class="link link-ref link-reveal xref-bibr">181</a></sup> and 25% higher all-cause mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a></sup> Prognosis may be affected by left ventricular ejection fraction (LVEF), with the rate of death highest with the combination of AF and heart failure with reduced ejection fraction (HFrEF) (LVEF ≤ 40%), as compared with AF and HFpEF (LVEF ≥ 50%). However, rates of stroke and incident heart failure hospitalization are similar regardless of LVEF.<sup><span class="xrefLink" id="jumplink-ehae176-B182"></span><a href="javascript:;" reveal-id="ehae176-B182" data-open="ehae176-B182" class="link link-ref link-reveal xref-bibr">182</a></sup> Due to how common concomitant AF and heart failure are in clinical practice, strategies to improve outcomes in these patients are detailed within each component of the AF-CARE pathway. However, it is also critical that heart failure itself is managed appropriately in patients with AF to prevent avoidable adverse events.

Optimization of heart failure management should follow current ESC Guidelines: 2023 Focused Update<sup><span class="xrefLink" id="jumplink-ehae176-B183"></span><a href="javascript:;" reveal-id="ehae176-B183" data-open="ehae176-B183" class="link link-ref link-reveal xref-bibr">183</a></sup> of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.<sup><span class="xrefLink" id="jumplink-ehae176-B137"></span><a href="javascript:;" reveal-id="ehae176-B137" data-open="ehae176-B137" class="link link-ref link-reveal xref-bibr">137</a></sup> Achieving euvolaemia with diuretics is an important first step that not only manages the heart failure component, but can also facilitate better control of heart rate in AF. For HFrEF, it should be highlighted that many older guideline-recommended therapies lack specific evidence for benefit in patients with coexisting AF. No trial data are available in this context for ACE inhibitors, there are conflicting data on ARBs,<sup><span class="xrefLink" id="jumplink-ehae176-B132"></span><a href="javascript:;" reveal-id="ehae176-B132" data-open="ehae176-B132" class="link link-ref link-reveal xref-bibr">132</a>,<span class="xrefLink" id="jumplink-ehae176-B184"></span><a href="javascript:;" reveal-id="ehae176-B184" data-open="ehae176-B184" class="link link-ref link-reveal xref-bibr">184</a></sup> and an individual patient-level analysis of RCTs found no difference between beta-blockers and placebo for all-cause mortality in HFrEF with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B133"></span><a href="javascript:;" reveal-id="ehae176-B133" data-open="ehae176-B133" class="link link-ref link-reveal xref-bibr">133</a></sup> However, these drugs have clear proof of safety and there may be other indications for these therapies beyond prognosis, including comorbidity management and symptom improvement. These and other therapies may also have dual functions, for example, beta-blockers or digoxin for rate control of AF, in addition to improving heart failure metrics and reducing hospitalization.<sup><span class="xrefLink" id="jumplink-ehae176-B48"></span><a href="javascript:;" reveal-id="ehae176-B48" data-open="ehae176-B48" class="link link-ref link-reveal xref-bibr">48</a>,<span class="xrefLink" id="jumplink-ehae176-B185"></span><a href="javascript:;" reveal-id="ehae176-B185" data-open="ehae176-B185" class="link link-ref link-reveal xref-bibr">185</a>,<span class="xrefLink" id="jumplink-ehae176-B186"></span><a href="javascript:;" reveal-id="ehae176-B186" data-open="ehae176-B186" class="link link-ref link-reveal xref-bibr">186</a></sup> More recent additions to HFrEF management, such as eplerenone, sacubitril-valsartan, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, had substantial numbers of patients with AF enrolled in RCTs, with no evidence that AF status affected their ability to reduce cardiovascular mortality/heart failure hospitalization.<sup><span class="xrefLink" id="jumplink-ehae176-B134 ehae176-B135 ehae176-B136"></span><a href="javascript:;" reveal-id="ehae176-B134 ehae176-B135 ehae176-B136" data-open="ehae176-B134 ehae176-B135 ehae176-B136" class="link link-ref link-reveal xref-bibr">134–136</a></sup> Cardiac resynchronization therapy (CRT) in the context of HFrEF and AF is discussed in detail in the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy, with an important focus on ensuring effective biventricular pacing (with a low threshold for considering atrioventricular node ablation).<sup><span class="xrefLink" id="jumplink-ehae176-B187"></span><a href="javascript:;" reveal-id="ehae176-B187" data-open="ehae176-B187" class="link link-ref link-reveal xref-bibr">187</a></sup> Patients who have heart failure with mildly reduced ejection fraction (HFmrEF) (LVEF 41%–49%) and AF should generally be treated according to guidance for HFrEF,<sup><span class="xrefLink" id="jumplink-ehae176-B137"></span><a href="javascript:;" reveal-id="ehae176-B137" data-open="ehae176-B137" class="link link-ref link-reveal xref-bibr">137</a></sup> albeit with limited evidence to date in AF.<sup><span class="xrefLink" id="jumplink-ehae176-B188 ehae176-B189 ehae176-B190"></span><a href="javascript:;" reveal-id="ehae176-B188 ehae176-B189 ehae176-B190" data-open="ehae176-B188 ehae176-B189 ehae176-B190" class="link link-ref link-reveal xref-bibr">188–190</a></sup> For treatment of HFpEF and AF,<sup><span class="xrefLink" id="jumplink-ehae176-B191"></span><a href="javascript:;" reveal-id="ehae176-B191" data-open="ehae176-B191" class="link link-ref link-reveal xref-bibr">191</a></sup> pre-specified subgroup data on AF from multiple large trials show that the SGLT2 inhibitors dapagliflozin, empaglifozin, and sotagliflozin are effective in improving prognosis.<sup><span class="xrefLink" id="jumplink-ehae176-B138 ehae176-B139 ehae176-B140"></span><a href="javascript:;" reveal-id="ehae176-B138 ehae176-B139 ehae176-B140" data-open="ehae176-B138 ehae176-B139 ehae176-B140" class="link link-ref link-reveal xref-bibr">138–140</a></sup>

Appropriate management of heart failure has the potential to reduce recurrence of AF, e.g. by reducing adverse atrial and ventricular myocardial remodelling, but there are limited data for specific therapies. In the Routine versus Aggressive upstream rhythm Control for prevention of Early AF in heart failure (RACE 3) trial, combined management of mild-to-moderate heart failure with ACE inhibitors/ARBs, mineralocorticoid receptor antagonists, statins, and cardiac rehabilitation increased the maintenance of sinus rhythm on ambulatory monitoring at 12 months.<sup><span class="xrefLink" id="jumplink-ehae176-B39"></span><a href="javascript:;" reveal-id="ehae176-B39" data-open="ehae176-B39" class="link link-ref link-reveal xref-bibr">39</a></sup> This benefit was not preserved at the 5 year follow-up, although this may have been confounded by the lack of ongoing intervention beyond the initial 12 months.<sup><span class="xrefLink" id="jumplink-ehae176-B192"></span><a href="javascript:;" reveal-id="ehae176-B192" data-open="ehae176-B192" class="link link-ref link-reveal xref-bibr">192</a></sup>

### 5.3. Type 2 diabetes mellitus

Diabetes mellitus is present in around 25% of patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B193 ehae176-B194 ehae176-B195"></span><a href="javascript:;" reveal-id="ehae176-B193 ehae176-B194 ehae176-B195" data-open="ehae176-B193 ehae176-B194 ehae176-B195" class="link link-ref link-reveal xref-bibr">193–195</a></sup> Patients with both diabetes and AF have a worse prognosis,<sup><span class="xrefLink" id="jumplink-ehae176-B196"></span><a href="javascript:;" reveal-id="ehae176-B196" data-open="ehae176-B196" class="link link-ref link-reveal xref-bibr">196</a></sup> with increased healthcare utilization and excess mortality and cardiovascular events. The prevalence and incidence of AF and type 2 diabetes are widely increasing, thus making the association of these two conditions a public health challenge.<sup><span class="xrefLink" id="jumplink-ehae176-B195"></span><a href="javascript:;" reveal-id="ehae176-B195" data-open="ehae176-B195" class="link link-ref link-reveal xref-bibr">195</a>,<span class="xrefLink" id="jumplink-ehae176-B197"></span><a href="javascript:;" reveal-id="ehae176-B197" data-open="ehae176-B197" class="link link-ref link-reveal xref-bibr">197</a></sup> Moreover, diabetes is a major factor influencing thromboembolic risk.<sup><span class="xrefLink" id="jumplink-ehae176-B198"></span><a href="javascript:;" reveal-id="ehae176-B198" data-open="ehae176-B198" class="link link-ref link-reveal xref-bibr">198</a>,<span class="xrefLink" id="jumplink-ehae176-B199"></span><a href="javascript:;" reveal-id="ehae176-B199" data-open="ehae176-B199" class="link link-ref link-reveal xref-bibr">199</a></sup> Following catheter ablation of AF, diabetes and higher HbA1c are associated with increased length of stay and a greater recurrence of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B200 ehae176-B201 ehae176-B202 ehae176-B203"></span><a href="javascript:;" reveal-id="ehae176-B200 ehae176-B201 ehae176-B202 ehae176-B203" data-open="ehae176-B200 ehae176-B201 ehae176-B202 ehae176-B203" class="link link-ref link-reveal xref-bibr">200–203</a></sup>

In cohort studies, the management of diabetes mellitus as part of comprehensive risk factor management has been associated with reduced AF symptoms, burden, reversal of the type of AF (from persistent to paroxysmal or no AF), and improved maintenance of sinus rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B126 ehae176-B127 ehae176-B128"></span><a href="javascript:;" reveal-id="ehae176-B126 ehae176-B127 ehae176-B128" data-open="ehae176-B126 ehae176-B127 ehae176-B128" class="link link-ref link-reveal xref-bibr">126–128</a></sup> However, robust evidence is limited, and individual glucose-lowering medications have had variable effects on AF.<sup><span class="xrefLink" id="jumplink-ehae176-B204 ehae176-B205 ehae176-B206"></span><a href="javascript:;" reveal-id="ehae176-B204 ehae176-B205 ehae176-B206" data-open="ehae176-B204 ehae176-B205 ehae176-B206" class="link link-ref link-reveal xref-bibr">204–206</a></sup> There are emerging data of the use of SGLT2 and glucagon-like peptide-1 antagonists in patients with diabetes and AF that may impact on treatment choice in the near future. Importantly, diabetes frequently coexists with multiple risk factors in patients with AF, and a comprehensive approach to management is required. Further details are provided in the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.<sup><span class="xrefLink" id="jumplink-ehae176-B207"></span><a href="javascript:;" reveal-id="ehae176-B207" data-open="ehae176-B207" class="link link-ref link-reveal xref-bibr">207</a></sup>

### 5.4. Obesity

Obesity frequently coexists with other risk factors that have been independently associated with the development of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B208"></span><a href="javascript:;" reveal-id="ehae176-B208" data-open="ehae176-B208" class="link link-ref link-reveal xref-bibr">208</a>,<span class="xrefLink" id="jumplink-ehae176-B209"></span><a href="javascript:;" reveal-id="ehae176-B209" data-open="ehae176-B209" class="link link-ref link-reveal xref-bibr">209</a></sup> Obesity (body mass index \[BMI\] ≥30 kg/m<sup>2</sup>) and being overweight (BMI >25 kg/m<sup>2</sup>) are associated with a greater risk of recurrent atrial arrhythmias after AF ablation (13% increase for every 5 kg/m<sup>2</sup> higher BMI).<sup><span class="xrefLink" id="jumplink-ehae176-B210 ehae176-B211 ehae176-B212"></span><a href="javascript:;" reveal-id="ehae176-B210 ehae176-B211 ehae176-B212" data-open="ehae176-B210 ehae176-B211 ehae176-B212" class="link link-ref link-reveal xref-bibr">210–212</a></sup> In the setting of comprehensive risk factor management, weight loss of ≥10% in overweight and obese individuals with AF has been associated with reduced AF symptoms and AF burden in an RCT (aiming for BMI <27 kg/m<sup>2</sup>).<sup><span class="xrefLink" id="jumplink-ehae176-B125"></span><a href="javascript:;" reveal-id="ehae176-B125" data-open="ehae176-B125" class="link link-ref link-reveal xref-bibr">125</a></sup> Cohort studies have also shown a graded response to maintenance of sinus rhythm,<sup><span class="xrefLink" id="jumplink-ehae176-B126"></span><a href="javascript:;" reveal-id="ehae176-B126" data-open="ehae176-B126" class="link link-ref link-reveal xref-bibr">126</a></sup> improved ablation outcomes,<sup><span class="xrefLink" id="jumplink-ehae176-B128"></span><a href="javascript:;" reveal-id="ehae176-B128" data-open="ehae176-B128" class="link link-ref link-reveal xref-bibr">128</a></sup> and reversal of the type of AF<sup><span class="xrefLink" id="jumplink-ehae176-B127"></span><a href="javascript:;" reveal-id="ehae176-B127" data-open="ehae176-B127" class="link link-ref link-reveal xref-bibr">127</a></sup> commensurate with the degree of weight loss and risk factor management. However, in the Supervised Obesity Reduction Trial for AF Ablation Patients (SORT-AF) randomized trial in AF ablation patients, a sole weight loss intervention that achieved 4% loss in weight over 12 months did not impact ablation outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B213"></span><a href="javascript:;" reveal-id="ehae176-B213" data-open="ehae176-B213" class="link link-ref link-reveal xref-bibr">213</a></sup> This is consistent with the findings in LEGACY (Long-Term Effect of Goal directed weight management on Atrial Fibrillation Cohort: a 5 Year follow-up study) that showed that weight loss of ≤3% had no impact on AF recurrence.<sup><span class="xrefLink" id="jumplink-ehae176-B126"></span><a href="javascript:;" reveal-id="ehae176-B126" data-open="ehae176-B126" class="link link-ref link-reveal xref-bibr">126</a></sup> Observational studies have raised the possibility of a point of no return in terms of the benefit of weight loss,<sup><span class="xrefLink" id="jumplink-ehae176-B214"></span><a href="javascript:;" reveal-id="ehae176-B214" data-open="ehae176-B214" class="link link-ref link-reveal xref-bibr">214</a></sup> but also the possibility that bariatric surgery can improve symptoms and reduce AF recurrence.<sup><span class="xrefLink" id="jumplink-ehae176-B215 ehae176-B216 ehae176-B217"></span><a href="javascript:;" reveal-id="ehae176-B215 ehae176-B216 ehae176-B217" data-open="ehae176-B215 ehae176-B216 ehae176-B217" class="link link-ref link-reveal xref-bibr">215–217</a></sup>

### 5.5. Obstructive sleep apnoea

Obstructive sleep apnoea (OSA) is a highly prevalent condition, particularly in patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B157"></span><a href="javascript:;" reveal-id="ehae176-B157" data-open="ehae176-B157" class="link link-ref link-reveal xref-bibr">157</a>,<span class="xrefLink" id="jumplink-ehae176-B218"></span><a href="javascript:;" reveal-id="ehae176-B218" data-open="ehae176-B218" class="link link-ref link-reveal xref-bibr">218</a></sup> Optimal screening tools in the AF population are still under evaluation, although it may be reasonable to screen for OSA in patients where a rhythm control strategy is being pursued. Polysomnography or home sleep apnoea testing are suggested in preference to screening questionnaires.<sup><span class="xrefLink" id="jumplink-ehae176-B155 ehae176-B156 ehae176-B157"></span><a href="javascript:;" reveal-id="ehae176-B155 ehae176-B156 ehae176-B157" data-open="ehae176-B155 ehae176-B156 ehae176-B157" class="link link-ref link-reveal xref-bibr">155–157</a>,<span class="xrefLink" id="jumplink-ehae176-B219"></span><a href="javascript:;" reveal-id="ehae176-B219" data-open="ehae176-B219" class="link link-ref link-reveal xref-bibr">219</a></sup> Questionnaires assessing daytime sleepiness are poor predictors of moderate-to-severe OSA.<sup><span class="xrefLink" id="jumplink-ehae176-B155"></span><a href="javascript:;" reveal-id="ehae176-B155" data-open="ehae176-B155" class="link link-ref link-reveal xref-bibr">155</a></sup> Which parameter should be used to focus on risk of AF in patients with OSA, and to guide OSA treatment in patients with AF, is still unclear.<sup><span class="xrefLink" id="jumplink-ehae176-B220"></span><a href="javascript:;" reveal-id="ehae176-B220" data-open="ehae176-B220" class="link link-ref link-reveal xref-bibr">220</a>,<span class="xrefLink" id="jumplink-ehae176-B221"></span><a href="javascript:;" reveal-id="ehae176-B221" data-open="ehae176-B221" class="link link-ref link-reveal xref-bibr">221</a></sup>

Observational studies have suggested that individuals with OSA not treated with continuous positive airway pressure (CPAP) respond poorly to treatments for AF, with an increased risk of recurrence after cardioversion or ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B222"></span><a href="javascript:;" reveal-id="ehae176-B222" data-open="ehae176-B222" class="link link-ref link-reveal xref-bibr">222</a></sup> Conversely, OSA patients treated with CPAP seem to mitigate their propensity toward developing AF.<sup><span class="xrefLink" id="jumplink-ehae176-B148 ehae176-B149 ehae176-B150 ehae176-B151 ehae176-B152 ehae176-B153"></span><a href="javascript:;" reveal-id="ehae176-B148 ehae176-B149 ehae176-B150 ehae176-B151 ehae176-B152 ehae176-B153" data-open="ehae176-B148 ehae176-B149 ehae176-B150 ehae176-B151 ehae176-B152 ehae176-B153" class="link link-ref link-reveal xref-bibr">148–153</a>,<span class="xrefLink" id="jumplink-ehae176-B222 ehae176-B223 ehae176-B224"></span><a href="javascript:;" reveal-id="ehae176-B222 ehae176-B223 ehae176-B224" data-open="ehae176-B222 ehae176-B223 ehae176-B224" class="link link-ref link-reveal xref-bibr">222–224</a></sup> A small randomized trial of CPAP vs. no therapy demonstrated reversal of atrial remodelling in individuals with moderate OSA.<sup><span class="xrefLink" id="jumplink-ehae176-B154"></span><a href="javascript:;" reveal-id="ehae176-B154" data-open="ehae176-B154" class="link link-ref link-reveal xref-bibr">154</a></sup> However, other small RCTs have failed to show a benefit of CPAP therapy on ablation outcomes<sup><span class="xrefLink" id="jumplink-ehae176-B225"></span><a href="javascript:;" reveal-id="ehae176-B225" data-open="ehae176-B225" class="link link-ref link-reveal xref-bibr">225</a></sup> or post-cardioversion.<sup><span class="xrefLink" id="jumplink-ehae176-B226"></span><a href="javascript:;" reveal-id="ehae176-B226" data-open="ehae176-B226" class="link link-ref link-reveal xref-bibr">226</a></sup> Data on the cardiovascular mortality benefit of CPAP therapy in OSA are inconclusive.<sup><span class="xrefLink" id="jumplink-ehae176-B227 ehae176-B228 ehae176-B229 ehae176-B230"></span><a href="javascript:;" reveal-id="ehae176-B227 ehae176-B228 ehae176-B229 ehae176-B230" data-open="ehae176-B227 ehae176-B228 ehae176-B229 ehae176-B230" class="link link-ref link-reveal xref-bibr">227–230</a></sup>

### 5.6. Physical inactivity

Reduced cardiorespiratory fitness frequently coexists with other modifiable risk factors and has been associated with a greater recurrence of AF after catheter ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B141"></span><a href="javascript:;" reveal-id="ehae176-B141" data-open="ehae176-B141" class="link link-ref link-reveal xref-bibr">141</a></sup> Better cardiorespiratory fitness has a demonstrated inverse relationship to AF burden in both middle-aged and elderly people.<sup><span class="xrefLink" id="jumplink-ehae176-B141"></span><a href="javascript:;" reveal-id="ehae176-B141" data-open="ehae176-B141" class="link link-ref link-reveal xref-bibr">141</a></sup> Small RCTs, meta-analyses, and observational cohorts have shown that regular aerobic exercise may also improve AF-related symptoms, quality of life, and exercise capacity.<sup><span class="xrefLink" id="jumplink-ehae176-B142"></span><a href="javascript:;" reveal-id="ehae176-B142" data-open="ehae176-B142" class="link link-ref link-reveal xref-bibr">142</a>,<span class="xrefLink" id="jumplink-ehae176-B143"></span><a href="javascript:;" reveal-id="ehae176-B143" data-open="ehae176-B143" class="link link-ref link-reveal xref-bibr">143</a></sup> Better cardiorespiratory fitness and a gain in cardiorespiratory fitness over time are associated with a greater reduction in AF burden and improved maintenance of sinus rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B141 ehae176-B142 ehae176-B143 ehae176-B144 ehae176-B145"></span><a href="javascript:;" reveal-id="ehae176-B141 ehae176-B142 ehae176-B143 ehae176-B144 ehae176-B145" data-open="ehae176-B141 ehae176-B142 ehae176-B143 ehae176-B144 ehae176-B145" class="link link-ref link-reveal xref-bibr">141–145</a></sup>

### 5.7. Alcohol excess

Alcohol consumption can increase the risk of adverse events in patients with AF, such as thromboembolism, death, or AF-related hospitalization.<sup><span class="xrefLink" id="jumplink-ehae176-B231"></span><a href="javascript:;" reveal-id="ehae176-B231" data-open="ehae176-B231" class="link link-ref link-reveal xref-bibr">231</a>,<span class="xrefLink" id="jumplink-ehae176-B232"></span><a href="javascript:;" reveal-id="ehae176-B232" data-open="ehae176-B232" class="link link-ref link-reveal xref-bibr">232</a></sup> Alcohol is associated with an increased risk of ischaemic stroke in patients with newly diagnosed AF, and alcohol abstinence after AF diagnosis can reduce the risk of ischaemic stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B233"></span><a href="javascript:;" reveal-id="ehae176-B233" data-open="ehae176-B233" class="link link-ref link-reveal xref-bibr">233</a></sup> In patients receiving OAC, alcohol excess is associated with a greater risk of bleeding,<sup><span class="xrefLink" id="jumplink-ehae176-B234"></span><a href="javascript:;" reveal-id="ehae176-B234" data-open="ehae176-B234" class="link link-ref link-reveal xref-bibr">234</a></sup> mediated by poor adherence, alcohol–drug interactions, liver disease, and variceal bleeding.

Alcohol consumption is associated with a dose-dependent increase in the recurrence of AF after catheter ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B147"></span><a href="javascript:;" reveal-id="ehae176-B147" data-open="ehae176-B147" class="link link-ref link-reveal xref-bibr">147</a>,<span class="xrefLink" id="jumplink-ehae176-B235"></span><a href="javascript:;" reveal-id="ehae176-B235" data-open="ehae176-B235" class="link link-ref link-reveal xref-bibr">235</a></sup> In an RCT among regular non-binge drinkers with AF, the goal of abstinence led to a significant reduction in AF recurrence and burden; alcohol intake was reduced from 16.8 to 2.1 standard drinks per week (≤30 grams or 3 standard drinks of alcohol) in the intervention arm, with 61% attaining abstinence.<sup><span class="xrefLink" id="jumplink-ehae176-B147"></span><a href="javascript:;" reveal-id="ehae176-B147" data-open="ehae176-B147" class="link link-ref link-reveal xref-bibr">147</a></sup> In observational data of patients undergoing catheter ablation, reduction of consumption to ≤7 standard drinks (≤70 grams of alcohol) per week was associated with improved maintenance of sinus rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B128"></span><a href="javascript:;" reveal-id="ehae176-B128" data-open="ehae176-B128" class="link link-ref link-reveal xref-bibr">128</a>,<span class="xrefLink" id="jumplink-ehae176-B235"></span><a href="javascript:;" reveal-id="ehae176-B235" data-open="ehae176-B235" class="link link-ref link-reveal xref-bibr">235</a></sup>

## 6\. \[A\] Avoid stroke and thromboembolism

### 6.1. Initiating oral anticoagulation

Atrial fibrillation is a major risk factor for thromboembolism, irrespective of whether it is paroxysmal, persistent, or permanent.<sup><span class="xrefLink" id="jumplink-ehae176-B236"></span><a href="javascript:;" reveal-id="ehae176-B236" data-open="ehae176-B236" class="link link-ref link-reveal xref-bibr">236</a>,<span class="xrefLink" id="jumplink-ehae176-B237"></span><a href="javascript:;" reveal-id="ehae176-B237" data-open="ehae176-B237" class="link link-ref link-reveal xref-bibr">237</a></sup> Left untreated, and dependent on other patient-specific factors, the risk of ischaemic stroke in AF is increased five-fold, and one in every five strokes is associated with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B238"></span><a href="javascript:;" reveal-id="ehae176-B238" data-open="ehae176-B238" class="link link-ref link-reveal xref-bibr">238</a></sup> The default approach should therefore be to provide OAC to all eligible patients, except those at low risk of incident stroke or thromboembolism. The effectiveness of OAC to prevent ischaemic stroke in patients with AF is well established.<sup><span class="xrefLink" id="jumplink-ehae176-B239"></span><a href="javascript:;" reveal-id="ehae176-B239" data-open="ehae176-B239" class="link link-ref link-reveal xref-bibr">239</a>,<span class="xrefLink" id="jumplink-ehae176-B240"></span><a href="javascript:;" reveal-id="ehae176-B240" data-open="ehae176-B240" class="link link-ref link-reveal xref-bibr">240</a></sup> Antiplatelet drugs alone (aspirin, or aspirin in combination with clopidogrel) are not recommended for stroke prevention in AF.<sup><span class="xrefLink" id="jumplink-ehae176-B241"></span><a href="javascript:;" reveal-id="ehae176-B241" data-open="ehae176-B241" class="link link-ref link-reveal xref-bibr">241</a>,<span class="xrefLink" id="jumplink-ehae176-B242"></span><a href="javascript:;" reveal-id="ehae176-B242" data-open="ehae176-B242" class="link link-ref link-reveal xref-bibr">242</a></sup>

#### 6.1.1. Decision support for anticoagulation in AF

Tools have been developed to enable easier implementation of OAC in patients with clinical AF. The majority of OAC clinical trials have used variations of the CHADS<sub>2</sub> score to indicate those at risk (with points for chronic heart failure, hypertension, age, diabetes, and 2 points for prior stroke/transient ischaemic attack \[TIA\]). Although most available stroke risk scores are simple and practical, the predictive value of scores is generally modest (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S3](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B243 ehae176-B244 ehae176-B245"></span><a href="javascript:;" reveal-id="ehae176-B243 ehae176-B244 ehae176-B245" data-open="ehae176-B243 ehae176-B244 ehae176-B245" class="link link-ref link-reveal xref-bibr">243–245</a></sup> Classification and discrimination of adverse events is relatively poor for all scores and hence the benefit of using them to select patients for OAC is unclear. There is also considerable variation in the definition of risk factors across countries,<sup><span class="xrefLink" id="jumplink-ehae176-B246"></span><a href="javascript:;" reveal-id="ehae176-B246" data-open="ehae176-B246" class="link link-ref link-reveal xref-bibr">246</a></sup> and a lack of evidence from clinical trials on the ability of stroke risk scoring to enhance clinical practice.<sup><span class="xrefLink" id="jumplink-ehae176-B243"></span><a href="javascript:;" reveal-id="ehae176-B243" data-open="ehae176-B243" class="link link-ref link-reveal xref-bibr">243</a></sup> This guideline continues to provide a Class IA recommendation for the use of OAC in patients at risk of thromboembolism. However, in the absence of strong evidence for how to apply risk scores in real-world patients, this has been separated from the use of any particular risk score. This is also in line with regulatory approvals for direct oral anticoagulants (DOACs), which do not stipulate risk scores or numerical thresholds.<sup><span class="xrefLink" id="jumplink-ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28"></span><a href="javascript:;" reveal-id="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" data-open="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" class="link link-ref link-reveal xref-bibr">25–28</a>,<span class="xrefLink" id="jumplink-ehae176-B245"></span><a href="javascript:;" reveal-id="ehae176-B245" data-open="ehae176-B245" class="link link-ref link-reveal xref-bibr">245</a></sup>

Substantive changes have occurred in the decades since these risk scores were developed in regards to population-level risk factor profiles, therapies, and targets.<sup><span class="xrefLink" id="jumplink-ehae176-B198"></span><a href="javascript:;" reveal-id="ehae176-B198" data-open="ehae176-B198" class="link link-ref link-reveal xref-bibr">198</a></sup> Historical scores do not take into account parameters that have been associated with thromboembolism in contemporary cohorts, such as cancer, chronic kidney disease (CKD), ethnicity, and a range of circulating biomarkers (including troponin and B-type natriuretic peptide \[BNP\]). As an example, for CKD there is a correlation between decreasing glomerular filtration rate and proteinuria with stroke risk,<sup><span class="xrefLink" id="jumplink-ehae176-B247 ehae176-B248 ehae176-B249 ehae176-B250"></span><a href="javascript:;" reveal-id="ehae176-B247 ehae176-B248 ehae176-B249 ehae176-B250" data-open="ehae176-B247 ehae176-B248 ehae176-B249 ehae176-B250" class="link link-ref link-reveal xref-bibr">247–250</a></sup> and cohort data suggest a two-fold increased risk of ischaemic stroke and mortality in AF patients with CKD vs. without.<sup><span class="xrefLink" id="jumplink-ehae176-B251"></span><a href="javascript:;" reveal-id="ehae176-B251" data-open="ehae176-B251" class="link link-ref link-reveal xref-bibr">251</a></sup> Other factors, such as atrial enlargement, hyperlipidaemia, smoking, and obesity, have been identified in specific cohort studies as additional risk factors for ischaemic stroke in AF.<sup><span class="xrefLink" id="jumplink-ehae176-B70"></span><a href="javascript:;" reveal-id="ehae176-B70" data-open="ehae176-B70" class="link link-ref link-reveal xref-bibr">70</a>,<span class="xrefLink" id="jumplink-ehae176-B252"></span><a href="javascript:;" reveal-id="ehae176-B252" data-open="ehae176-B252" class="link link-ref link-reveal xref-bibr">252</a>,<span class="xrefLink" id="jumplink-ehae176-B253"></span><a href="javascript:;" reveal-id="ehae176-B253" data-open="ehae176-B253" class="link link-ref link-reveal xref-bibr">253</a></sup> Biomarkers, such as troponin, natriuretic peptides, growth differentiation factor-15, cystatin C, and interleukin-6, can also indicate residual stroke risk among anticoagulated AF patients.<sup><span class="xrefLink" id="jumplink-ehae176-B254"></span><a href="javascript:;" reveal-id="ehae176-B254" data-open="ehae176-B254" class="link link-ref link-reveal xref-bibr">254</a>,<span class="xrefLink" id="jumplink-ehae176-B255"></span><a href="javascript:;" reveal-id="ehae176-B255" data-open="ehae176-B255" class="link link-ref link-reveal xref-bibr">255</a></sup> Biomarker-guided stroke prevention is currently being evaluated in an ongoing RCT (NCT03753490). Until further validation within RCTs is available, this task force continues to support using simple clinical classification for implementation of OAC. Clinicians should use tools that have been validated in their local population and take an individualized approach to thromboembolic risk stratification that considers the full range of each patient's specific risk factors. The absolute risk level at which to start OAC in individual patients cannot be estimated from population-level studies. It will vary depending on how those factors interact with other medical issues, and the degree of risk acceptable or tolerated by that person. In general, most of the available risk scores have a threshold of 0.6%–1.0% per annum of thromboembolic events for clinical AF to warrant OAC prescription.

Across Europe, the most popular risk score is CHA<sub>2</sub>DS<sub>2</sub>–VASc, giving points for congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/TIA/thromboembolism (2 points), vascular disease, age 65–74 years and female sex. However, implementation has varied in terms of gender. Female sex is an age-dependent stroke risk modifier rather than a risk factor per se.<sup><span class="xrefLink" id="jumplink-ehae176-B112"></span><a href="javascript:;" reveal-id="ehae176-B112" data-open="ehae176-B112" class="link link-ref link-reveal xref-bibr">112</a>,<span class="xrefLink" id="jumplink-ehae176-B256"></span><a href="javascript:;" reveal-id="ehae176-B256" data-open="ehae176-B256" class="link link-ref link-reveal xref-bibr">256</a>,<span class="xrefLink" id="jumplink-ehae176-B257"></span><a href="javascript:;" reveal-id="ehae176-B257" data-open="ehae176-B257" class="link link-ref link-reveal xref-bibr">257</a></sup> The inclusion of gender complicates clinical practice both for healthcare professionals and patients.<sup><span class="xrefLink" id="jumplink-ehae176-B258"></span><a href="javascript:;" reveal-id="ehae176-B258" data-open="ehae176-B258" class="link link-ref link-reveal xref-bibr">258</a></sup> It also omits individuals who identify as non-binary, transgender, or are undergoing sex hormone therapy. Previous guidelines from the ESC (and globally) have not actually used CHA<sub>2</sub>DS<sub>2</sub>\-VASc; instead providing different score levels for women and men with AF to qualify for OAC. Hence, CHA<sub>2</sub>DS<sub>2</sub>\-VA (excluding gender) has effectively been in place (_[Table 10](javascript:;)_).<sup><span class="xrefLink" id="jumplink-ehae176-B78"></span><a href="javascript:;" reveal-id="ehae176-B78" data-open="ehae176-B78" class="link link-ref link-reveal xref-bibr">78</a></sup> This task force proposes, in the absence of other locally validated alternatives, that clinicians and patients should use the CHA<sub>2</sub>DS<sub>2</sub>\-VA score to assist in decisions on OAC therapy (i.e. without a criterion for birth sex or gender). Pending further trials in lower risk patients (NCT04700826,<sup><span class="xrefLink" id="jumplink-ehae176-B259"></span><a href="javascript:;" reveal-id="ehae176-B259" data-open="ehae176-B259" class="link link-ref link-reveal xref-bibr">259</a></sup> NCT02387229<sup><span class="xrefLink" id="jumplink-ehae176-B260"></span><a href="javascript:;" reveal-id="ehae176-B260" data-open="ehae176-B260" class="link link-ref link-reveal xref-bibr">260</a></sup>), OAC are recommended in those with a CHA<sub>2</sub>DS<sub>2</sub>\-VA score of 2 or more and should be considered in those with a CHA<sub>2</sub>DS<sub>2</sub>\-VA score of 1, following a patient-centred and shared care approach. Healthcare professionals should take care to assess for other thromboembolic risk factors that may also indicate the need for OAC prescription.

Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884218)

Updated definitions for the CHA<sub>2</sub>DS<sub>2</sub>\-VA score

| CHA<sub>2</sub>DS<sub>2</sub>\-VA component .  | Definition and comments .  | Points awarded<sup><span class="xrefLink" id="jumplink-tblfn114"></span><a href="javascript:;" reveal-id="tblfn114" data-open="tblfn114" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  |
| --- | --- | --- |
| C | Chronic heart failure | Symptoms and signs of heart failure (irrespective of LVEF, thus including HFpEF, HFmrEF, and HFrEF), or the presence of asymptomatic LVEF ≤40%.<sup><span class="xrefLink" id="jumplink-ehae176-B261 ehae176-B262 ehae176-B263"></span><a href="javascript:;" reveal-id="ehae176-B261 ehae176-B262 ehae176-B263" data-open="ehae176-B261 ehae176-B262 ehae176-B263" class="link link-ref link-reveal xref-bibr">261–263</a></sup> | 1 |
| H | Hypertension | Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive treatment. The optimal BP target associated with lowest risk of major cardiovascular events is 120–129/70–79 mmHg (or keep as low as reasonably achievable).<sup><span class="xrefLink" id="jumplink-ehae176-B162"></span><a href="javascript:;" reveal-id="ehae176-B162" data-open="ehae176-B162" class="link link-ref link-reveal xref-bibr">162</a>,<span class="xrefLink" id="jumplink-ehae176-B264"></span><a href="javascript:;" reveal-id="ehae176-B264" data-open="ehae176-B264" class="link link-ref link-reveal xref-bibr">264</a></sup> | 1 |
| A | Age 75 years or above | Age is an independent determinant of ischaemic stroke risk.<sup><span class="xrefLink" id="jumplink-ehae176-B265"></span><a href="javascript:;" reveal-id="ehae176-B265" data-open="ehae176-B265" class="link link-ref link-reveal xref-bibr">265</a></sup> Age-related risk is a continuum, but for reasons of practicality, two points are given for age ≥75 years. | 2 |
| D | Diabetes mellitus | Diabetes mellitus (type 1 or type 2), as defined by currently accepted criteria,<sup><span class="xrefLink" id="jumplink-ehae176-B266"></span><a href="javascript:;" reveal-id="ehae176-B266" data-open="ehae176-B266" class="link link-ref link-reveal xref-bibr">266</a></sup> or treatment with glucose lowering therapy. | 1 |
| S | Prior stroke, TIA, or arterial thromboembolism | Previous thromboembolism is associated with highly elevated risk of recurrence and therefore weighted 2 points. | 2 |
| V | Vascular disease | Coronary artery disease, including prior myocardial infarction, angina, history of coronary revascularization (surgical or percutaneous), and significant CAD on angiography or cardiac imaging.<sup><span class="xrefLink" id="jumplink-ehae176-B267"></span><a href="javascript:;" reveal-id="ehae176-B267" data-open="ehae176-B267" class="link link-ref link-reveal xref-bibr">267</a></sup>
OR
Peripheral vascular disease, including: intermittent claudication, previous revascularization for PVD, percutaneous or surgical intervention on the abdominal aorta, and complex aortic plaque on imaging (defined as features of mobility, ulceration, pedunculation, or thickness ≥4 mm).<sup><span class="xrefLink" id="jumplink-ehae176-B268"></span><a href="javascript:;" reveal-id="ehae176-B268" data-open="ehae176-B268" class="link link-ref link-reveal xref-bibr">268</a>,<span class="xrefLink" id="jumplink-ehae176-B269"></span><a href="javascript:;" reveal-id="ehae176-B269" data-open="ehae176-B269" class="link link-ref link-reveal xref-bibr">269</a></sup> | 1 |
| A | Age 65–74 years | 1 point is given for age between 65 and 74 years. | 1 |

| CHA<sub>2</sub>DS<sub>2</sub>\-VA component .  | Definition and comments .  | Points awarded<sup><span class="xrefLink" id="jumplink-tblfn114"></span><a href="javascript:;" reveal-id="tblfn114" data-open="tblfn114" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  |
| --- | --- | --- |
| C | Chronic heart failure | Symptoms and signs of heart failure (irrespective of LVEF, thus including HFpEF, HFmrEF, and HFrEF), or the presence of asymptomatic LVEF ≤40%.<sup><span class="xrefLink" id="jumplink-ehae176-B261 ehae176-B262 ehae176-B263"></span><a href="javascript:;" reveal-id="ehae176-B261 ehae176-B262 ehae176-B263" data-open="ehae176-B261 ehae176-B262 ehae176-B263" class="link link-ref link-reveal xref-bibr">261–263</a></sup> | 1 |
| H | Hypertension | Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive treatment. The optimal BP target associated with lowest risk of major cardiovascular events is 120–129/70–79 mmHg (or keep as low as reasonably achievable).<sup><span class="xrefLink" id="jumplink-ehae176-B162"></span><a href="javascript:;" reveal-id="ehae176-B162" data-open="ehae176-B162" class="link link-ref link-reveal xref-bibr">162</a>,<span class="xrefLink" id="jumplink-ehae176-B264"></span><a href="javascript:;" reveal-id="ehae176-B264" data-open="ehae176-B264" class="link link-ref link-reveal xref-bibr">264</a></sup> | 1 |
| A | Age 75 years or above | Age is an independent determinant of ischaemic stroke risk.<sup><span class="xrefLink" id="jumplink-ehae176-B265"></span><a href="javascript:;" reveal-id="ehae176-B265" data-open="ehae176-B265" class="link link-ref link-reveal xref-bibr">265</a></sup> Age-related risk is a continuum, but for reasons of practicality, two points are given for age ≥75 years. | 2 |
| D | Diabetes mellitus | Diabetes mellitus (type 1 or type 2), as defined by currently accepted criteria,<sup><span class="xrefLink" id="jumplink-ehae176-B266"></span><a href="javascript:;" reveal-id="ehae176-B266" data-open="ehae176-B266" class="link link-ref link-reveal xref-bibr">266</a></sup> or treatment with glucose lowering therapy. | 1 |
| S | Prior stroke, TIA, or arterial thromboembolism | Previous thromboembolism is associated with highly elevated risk of recurrence and therefore weighted 2 points. | 2 |
| V | Vascular disease | Coronary artery disease, including prior myocardial infarction, angina, history of coronary revascularization (surgical or percutaneous), and significant CAD on angiography or cardiac imaging.<sup><span class="xrefLink" id="jumplink-ehae176-B267"></span><a href="javascript:;" reveal-id="ehae176-B267" data-open="ehae176-B267" class="link link-ref link-reveal xref-bibr">267</a></sup>
OR
Peripheral vascular disease, including: intermittent claudication, previous revascularization for PVD, percutaneous or surgical intervention on the abdominal aorta, and complex aortic plaque on imaging (defined as features of mobility, ulceration, pedunculation, or thickness ≥4 mm).<sup><span class="xrefLink" id="jumplink-ehae176-B268"></span><a href="javascript:;" reveal-id="ehae176-B268" data-open="ehae176-B268" class="link link-ref link-reveal xref-bibr">268</a>,<span class="xrefLink" id="jumplink-ehae176-B269"></span><a href="javascript:;" reveal-id="ehae176-B269" data-open="ehae176-B269" class="link link-ref link-reveal xref-bibr">269</a></sup> | 1 |
| A | Age 65–74 years | 1 point is given for age between 65 and 74 years. | 1 |

BP, blood pressure; CAD, coronary artery disease; CHA<sub>2</sub>DS<sub>2</sub>\-VA, chronic heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PVD, peripheral vascular disease.

<sup>a</sup>In addition to these factors, other markers that modify an individual's risk for stroke and thromboembolism should be considered, including cancer, chronic kidney disease, ethnicity (black, Hispanic, Asian), biomarkers (troponin and BNP), and in specific groups, atrial enlargement, hyperlipidaemia, smoking, and obesity.

© ESC 2024

Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884218)

Updated definitions for the CHA<sub>2</sub>DS<sub>2</sub>\-VA score

| CHA<sub>2</sub>DS<sub>2</sub>\-VA component .  | Definition and comments .  | Points awarded<sup><span class="xrefLink" id="jumplink-tblfn114"></span><a href="javascript:;" reveal-id="tblfn114" data-open="tblfn114" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  |
| --- | --- | --- |
| C | Chronic heart failure | Symptoms and signs of heart failure (irrespective of LVEF, thus including HFpEF, HFmrEF, and HFrEF), or the presence of asymptomatic LVEF ≤40%.<sup><span class="xrefLink" id="jumplink-ehae176-B261 ehae176-B262 ehae176-B263"></span><a href="javascript:;" reveal-id="ehae176-B261 ehae176-B262 ehae176-B263" data-open="ehae176-B261 ehae176-B262 ehae176-B263" class="link link-ref link-reveal xref-bibr">261–263</a></sup> | 1 |
| H | Hypertension | Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive treatment. The optimal BP target associated with lowest risk of major cardiovascular events is 120–129/70–79 mmHg (or keep as low as reasonably achievable).<sup><span class="xrefLink" id="jumplink-ehae176-B162"></span><a href="javascript:;" reveal-id="ehae176-B162" data-open="ehae176-B162" class="link link-ref link-reveal xref-bibr">162</a>,<span class="xrefLink" id="jumplink-ehae176-B264"></span><a href="javascript:;" reveal-id="ehae176-B264" data-open="ehae176-B264" class="link link-ref link-reveal xref-bibr">264</a></sup> | 1 |
| A | Age 75 years or above | Age is an independent determinant of ischaemic stroke risk.<sup><span class="xrefLink" id="jumplink-ehae176-B265"></span><a href="javascript:;" reveal-id="ehae176-B265" data-open="ehae176-B265" class="link link-ref link-reveal xref-bibr">265</a></sup> Age-related risk is a continuum, but for reasons of practicality, two points are given for age ≥75 years. | 2 |
| D | Diabetes mellitus | Diabetes mellitus (type 1 or type 2), as defined by currently accepted criteria,<sup><span class="xrefLink" id="jumplink-ehae176-B266"></span><a href="javascript:;" reveal-id="ehae176-B266" data-open="ehae176-B266" class="link link-ref link-reveal xref-bibr">266</a></sup> or treatment with glucose lowering therapy. | 1 |
| S | Prior stroke, TIA, or arterial thromboembolism | Previous thromboembolism is associated with highly elevated risk of recurrence and therefore weighted 2 points. | 2 |
| V | Vascular disease | Coronary artery disease, including prior myocardial infarction, angina, history of coronary revascularization (surgical or percutaneous), and significant CAD on angiography or cardiac imaging.<sup><span class="xrefLink" id="jumplink-ehae176-B267"></span><a href="javascript:;" reveal-id="ehae176-B267" data-open="ehae176-B267" class="link link-ref link-reveal xref-bibr">267</a></sup>
OR
Peripheral vascular disease, including: intermittent claudication, previous revascularization for PVD, percutaneous or surgical intervention on the abdominal aorta, and complex aortic plaque on imaging (defined as features of mobility, ulceration, pedunculation, or thickness ≥4 mm).<sup><span class="xrefLink" id="jumplink-ehae176-B268"></span><a href="javascript:;" reveal-id="ehae176-B268" data-open="ehae176-B268" class="link link-ref link-reveal xref-bibr">268</a>,<span class="xrefLink" id="jumplink-ehae176-B269"></span><a href="javascript:;" reveal-id="ehae176-B269" data-open="ehae176-B269" class="link link-ref link-reveal xref-bibr">269</a></sup> | 1 |
| A | Age 65–74 years | 1 point is given for age between 65 and 74 years. | 1 |

| CHA<sub>2</sub>DS<sub>2</sub>\-VA component .  | Definition and comments .  | Points awarded<sup><span class="xrefLink" id="jumplink-tblfn114"></span><a href="javascript:;" reveal-id="tblfn114" data-open="tblfn114" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  |
| --- | --- | --- |
| C | Chronic heart failure | Symptoms and signs of heart failure (irrespective of LVEF, thus including HFpEF, HFmrEF, and HFrEF), or the presence of asymptomatic LVEF ≤40%.<sup><span class="xrefLink" id="jumplink-ehae176-B261 ehae176-B262 ehae176-B263"></span><a href="javascript:;" reveal-id="ehae176-B261 ehae176-B262 ehae176-B263" data-open="ehae176-B261 ehae176-B262 ehae176-B263" class="link link-ref link-reveal xref-bibr">261–263</a></sup> | 1 |
| H | Hypertension | Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive treatment. The optimal BP target associated with lowest risk of major cardiovascular events is 120–129/70–79 mmHg (or keep as low as reasonably achievable).<sup><span class="xrefLink" id="jumplink-ehae176-B162"></span><a href="javascript:;" reveal-id="ehae176-B162" data-open="ehae176-B162" class="link link-ref link-reveal xref-bibr">162</a>,<span class="xrefLink" id="jumplink-ehae176-B264"></span><a href="javascript:;" reveal-id="ehae176-B264" data-open="ehae176-B264" class="link link-ref link-reveal xref-bibr">264</a></sup> | 1 |
| A | Age 75 years or above | Age is an independent determinant of ischaemic stroke risk.<sup><span class="xrefLink" id="jumplink-ehae176-B265"></span><a href="javascript:;" reveal-id="ehae176-B265" data-open="ehae176-B265" class="link link-ref link-reveal xref-bibr">265</a></sup> Age-related risk is a continuum, but for reasons of practicality, two points are given for age ≥75 years. | 2 |
| D | Diabetes mellitus | Diabetes mellitus (type 1 or type 2), as defined by currently accepted criteria,<sup><span class="xrefLink" id="jumplink-ehae176-B266"></span><a href="javascript:;" reveal-id="ehae176-B266" data-open="ehae176-B266" class="link link-ref link-reveal xref-bibr">266</a></sup> or treatment with glucose lowering therapy. | 1 |
| S | Prior stroke, TIA, or arterial thromboembolism | Previous thromboembolism is associated with highly elevated risk of recurrence and therefore weighted 2 points. | 2 |
| V | Vascular disease | Coronary artery disease, including prior myocardial infarction, angina, history of coronary revascularization (surgical or percutaneous), and significant CAD on angiography or cardiac imaging.<sup><span class="xrefLink" id="jumplink-ehae176-B267"></span><a href="javascript:;" reveal-id="ehae176-B267" data-open="ehae176-B267" class="link link-ref link-reveal xref-bibr">267</a></sup>
OR
Peripheral vascular disease, including: intermittent claudication, previous revascularization for PVD, percutaneous or surgical intervention on the abdominal aorta, and complex aortic plaque on imaging (defined as features of mobility, ulceration, pedunculation, or thickness ≥4 mm).<sup><span class="xrefLink" id="jumplink-ehae176-B268"></span><a href="javascript:;" reveal-id="ehae176-B268" data-open="ehae176-B268" class="link link-ref link-reveal xref-bibr">268</a>,<span class="xrefLink" id="jumplink-ehae176-B269"></span><a href="javascript:;" reveal-id="ehae176-B269" data-open="ehae176-B269" class="link link-ref link-reveal xref-bibr">269</a></sup> | 1 |
| A | Age 65–74 years | 1 point is given for age between 65 and 74 years. | 1 |

BP, blood pressure; CAD, coronary artery disease; CHA<sub>2</sub>DS<sub>2</sub>\-VA, chronic heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PVD, peripheral vascular disease.

<sup>a</sup>In addition to these factors, other markers that modify an individual's risk for stroke and thromboembolism should be considered, including cancer, chronic kidney disease, ethnicity (black, Hispanic, Asian), biomarkers (troponin and BNP), and in specific groups, atrial enlargement, hyperlipidaemia, smoking, and obesity.

© ESC 2024

Recommendation Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884219)

Recommendations to assess and manage thromboembolic risk in AF (see also Evidence Table 6)

![Recommendations to assess and manage thromboembolic risk in AF (see also Evidence Table 6)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt6.jpeg?Expires=1728478929&Signature=FUNXJbhkRpHPHd5xIlQEC7KwxhcRIrgSX68r0co-8mPBuyTsKE8ZSoA7lYqYPSOCXzYg2zIv4WiGUcS-yqX0wc4g2yPN3f803Vl2q1VwLRW1SwsVvjL98SnCRNAY8TyYnr4-kEdlmMuqq-PHmp8qudu4WoRs2Fcpy7w2DS3cYLjE-oTlYk4MJIax4SsgUoyS-LXffEObyTHHEiE1P~GNjz-nliqVKnNvS0OgP0VxMXGEtnMTqyat0209hJVmRVwghui9YgE85VT1DCg23LPnX~3nDlsjw~FNxHcOyrY-OS9uDow3NWo2cZMbtUV5uFcnBY6aVOY-Hr5A8006bud8-g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884219)

Recommendations to assess and manage thromboembolic risk in AF (see also Evidence Table 6)

![Recommendations to assess and manage thromboembolic risk in AF (see also Evidence Table 6)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt6.jpeg?Expires=1728478929&Signature=FUNXJbhkRpHPHd5xIlQEC7KwxhcRIrgSX68r0co-8mPBuyTsKE8ZSoA7lYqYPSOCXzYg2zIv4WiGUcS-yqX0wc4g2yPN3f803Vl2q1VwLRW1SwsVvjL98SnCRNAY8TyYnr4-kEdlmMuqq-PHmp8qudu4WoRs2Fcpy7w2DS3cYLjE-oTlYk4MJIax4SsgUoyS-LXffEObyTHHEiE1P~GNjz-nliqVKnNvS0OgP0VxMXGEtnMTqyat0209hJVmRVwghui9YgE85VT1DCg23LPnX~3nDlsjw~FNxHcOyrY-OS9uDow3NWo2cZMbtUV5uFcnBY6aVOY-Hr5A8006bud8-g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.2. Oral anticoagulants

Vitamin K antagonists (VKA), predominantly warfarin but also other coumarin and indandione derivatives, have been the principal drugs to prevent thromboembolic events in the context of AF. As with any anticoagulant, a balance must be reached between preventing thromboembolism and preserving physiological haemostasis, with VKA-associated intracranial and other major haemorrhage the most critical limitation for acceptance of OAC. The global switch to DOACs as first-line therapy has changed this risk–benefit balance, allowing more widespread prescription with no need for routine monitoring (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Tables S5–S7](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). This component of AF management may see substantive changes in the coming years, with a number of factor XI inhibitors in various stages of clinical evaluation. A phase 2 trial of abelacimab in patients with AF has shown lower rates of bleeding compared with rivaroxaban<sup><span class="xrefLink" id="jumplink-ehae176-B286"></span><a href="javascript:;" reveal-id="ehae176-B286" data-open="ehae176-B286" class="link link-ref link-reveal xref-bibr">286</a></sup>; however, a phase 3 trial of asundexian was terminated early due to lack of efficacy against apixaban (NCT05643573), despite favourable phase 2 results.<sup><span class="xrefLink" id="jumplink-ehae176-B287"></span><a href="javascript:;" reveal-id="ehae176-B287" data-open="ehae176-B287" class="link link-ref link-reveal xref-bibr">287</a></sup> Regardless of the type of OAC prescribed, healthcare teams should be aware of the potential for interactions with other drugs, foods, and supplements, and incorporate this information into the education provided to patients and their carers. The list of potential interactions with VKA is broad,<sup><span class="xrefLink" id="jumplink-ehae176-B288"></span><a href="javascript:;" reveal-id="ehae176-B288" data-open="ehae176-B288" class="link link-ref link-reveal xref-bibr">288</a>,<span class="xrefLink" id="jumplink-ehae176-B289"></span><a href="javascript:;" reveal-id="ehae176-B289" data-open="ehae176-B289" class="link link-ref link-reveal xref-bibr">289</a></sup> but there are also some common cardiovascular and non-cardiovascular drugs that interact with DOACs.<sup><span class="xrefLink" id="jumplink-ehae176-B290"></span><a href="javascript:;" reveal-id="ehae176-B290" data-open="ehae176-B290" class="link link-ref link-reveal xref-bibr">290</a>,<span class="xrefLink" id="jumplink-ehae176-B291"></span><a href="javascript:;" reveal-id="ehae176-B291" data-open="ehae176-B291" class="link link-ref link-reveal xref-bibr">291</a></sup>  _[Figure 9](javascript:;)_ highlights common and major interactions to consider for VKAs and DOACs.

![Common drug interactions with oral anticoagulants.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f9.jpeg?Expires=1728478929&Signature=cTGxy9uzRdKS8fxABvRKotvBjap32Qm3ROZ8PwMDzxqh~K1f~58yWxYbfATWQtE3c4id~WpFIA~0FigUVTTh~eH8jqxjjOLnfvSE1MQWWSHOx6BGKInCd47Uy~dypVtPjCQcqyznDPIVi9fJE4KemZxWxz~lWP9uEMf4CkTcUNQlaAZbQO5AMTlHPD-8AHhEQeSeVa461CwyyfKw-0~6LcXOcluaQD7tgXs-AUY14GQcfCFJDLEFHuOPyyNpi~FKkME7YysVjmTjlvmGoM8qfaNYGUcn3XzhMdQ-EPBveQWN3UdT5rR~WogGFjl62CcCm~RP0op8cQLoApooTPXmeg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 9

Common drug interactions with oral anticoagulants.

INR, international normalized ratio of prothrombin time; NSAID, non-steroidal anti-inflammatory drug. This figure depicts only common or major interactions and is not an exhaustive list of all potential interactions. Please see the European Medicines Agency website or your local formulary for more information.

[Open in new tab](https://academic.oup.com/view-large/figure/479884222/ehae176f9.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f9.jpeg?Expires=1728478929&Signature=e9gILpxeCTc6ULYQ~KMTLzlZfDGrTEXd7T2n6yTc1IBqwLGlrAVEC3TNl1pGk0JwU9K44ZTOnsgDdofK-vT8gDpqtXUZqY91f5EiPD-xodh~UQiNQ7SJNcjgYdY1ZdEPpGimpKZAczf4SNgS6KF9ArtF9ht0m4fQv7L~yOtotdhe7E2GScLERK4malrVthL9ykk0NW8GrlzHc~Krf8NckaN~4TxQKuXb0D0bUDaty3ZzRXe8pyeCbIxt4imMOR25vMhUJgIQ~bwI9ZTQZuWXR4bcHMJwy8jo1ObKr~ZFxJZEiJvxvdN7ZJWhVhjxe1NxuRzeeM9KDVzdD~0VWKgWpQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884222&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884223)

Recommendations for oral anticoagulation in AF (see also Evidence Table 7)

![Recommendations for oral anticoagulation in AF (see also Evidence Table 7)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt7.jpeg?Expires=1728478929&Signature=PTxhz4qtsPD07jddtPh2yuR9mqo~mAXYM1IxIwCVCBWXI-Gb9dKIgqiStIjhhCdY4bz4u7NtmOfEvHJvBcusmKvRkZf74sYXM2fWc6P34dX-ozoXexUil7VRxP-M83tSO9HirA8beQ4oKwO-5pDfM6V4iQXH3loq07xnkC~6xGMmZjfiPmDcFJnVi3aZllJh6p6lL9s6WOtOQujHNc9lsfoyFGfsH-DfOON4BYUEXAvqst1DL~GQ1~yOUDo672CeQNJ2VJ9QfIO~FKIpQLq8-a98iMu1CH~mVkLwbrhFXqz6WqovD6czeXZXr0DOziKDXlkr11O~849llI7X755ejw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884223)

Recommendations for oral anticoagulation in AF (see also Evidence Table 7)

![Recommendations for oral anticoagulation in AF (see also Evidence Table 7)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt7.jpeg?Expires=1728478929&Signature=PTxhz4qtsPD07jddtPh2yuR9mqo~mAXYM1IxIwCVCBWXI-Gb9dKIgqiStIjhhCdY4bz4u7NtmOfEvHJvBcusmKvRkZf74sYXM2fWc6P34dX-ozoXexUil7VRxP-M83tSO9HirA8beQ4oKwO-5pDfM6V4iQXH3loq07xnkC~6xGMmZjfiPmDcFJnVi3aZllJh6p6lL9s6WOtOQujHNc9lsfoyFGfsH-DfOON4BYUEXAvqst1DL~GQ1~yOUDo672CeQNJ2VJ9QfIO~FKIpQLq8-a98iMu1CH~mVkLwbrhFXqz6WqovD6czeXZXr0DOziKDXlkr11O~849llI7X755ejw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 6.2.1. Direct oral anticoagulants

The DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) have all demonstrated at least non-inferior efficacy compared with warfarin for the prevention of thromboembolism, but with the added benefit of a 50% reduction in intracranial haemorrhage (ICH).<sup><span class="xrefLink" id="jumplink-ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28"></span><a href="javascript:;" reveal-id="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" data-open="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" class="link link-ref link-reveal xref-bibr">25–28</a></sup> Meta-analyses of individual data from 71 683 RCT patients showed that standard, full-dose DOAC treatment compared with warfarin reduces the risk of stroke or systemic embolism (HR, 0.81; 95% CI, 0.73–0.91), all-cause mortality (HR, 0.90; 95% CI, 0.85–0.95), and intracranial bleeding (HR, 0.48; 95% CI, 0.39–0.59), with no significant difference in other major bleeding (HR, 0.86; 95% CI, 0.73–1.00) and little or no between-trial heterogeneity.<sup><span class="xrefLink" id="jumplink-ehae176-B292"></span><a href="javascript:;" reveal-id="ehae176-B292" data-open="ehae176-B292" class="link link-ref link-reveal xref-bibr">292</a></sup> Post-marketing observational data on the effectiveness and safety of dabigatran,<sup><span class="xrefLink" id="jumplink-ehae176-B313"></span><a href="javascript:;" reveal-id="ehae176-B313" data-open="ehae176-B313" class="link link-ref link-reveal xref-bibr">313</a>,<span class="xrefLink" id="jumplink-ehae176-B314"></span><a href="javascript:;" reveal-id="ehae176-B314" data-open="ehae176-B314" class="link link-ref link-reveal xref-bibr">314</a></sup> rivaroxaban,<sup><span class="xrefLink" id="jumplink-ehae176-B315"></span><a href="javascript:;" reveal-id="ehae176-B315" data-open="ehae176-B315" class="link link-ref link-reveal xref-bibr">315</a>,<span class="xrefLink" id="jumplink-ehae176-B316"></span><a href="javascript:;" reveal-id="ehae176-B316" data-open="ehae176-B316" class="link link-ref link-reveal xref-bibr">316</a></sup> apixaban,<sup><span class="xrefLink" id="jumplink-ehae176-B317"></span><a href="javascript:;" reveal-id="ehae176-B317" data-open="ehae176-B317" class="link link-ref link-reveal xref-bibr">317</a></sup> and edoxaban<sup><span class="xrefLink" id="jumplink-ehae176-B318"></span><a href="javascript:;" reveal-id="ehae176-B318" data-open="ehae176-B318" class="link link-ref link-reveal xref-bibr">318</a></sup> vs. warfarin show general consistency with the respective phase 3 RCTs.

For patients undergoing cardioversion, three underpowered trials showed non-significantly lower rates of cardiovascular events with DOACs compared with warfarin.<sup><span class="xrefLink" id="jumplink-ehae176-B319 ehae176-B320 ehae176-B321"></span><a href="javascript:;" reveal-id="ehae176-B319 ehae176-B320 ehae176-B321" data-open="ehae176-B319 ehae176-B320 ehae176-B321" class="link link-ref link-reveal xref-bibr">319–321</a></sup> In meta-analysis of these 5203 patients predominantly undergoing electrical cardioversion, the composite of stroke, systemic embolism, myocardial infarction (MI), and cardiovascular death was significantly lower at 0.42% in patients randomized to a DOAC vs. 0.98% in those allocated VKA (risk ratio, 0.42; 95% CI, 0.21–0.86; _P_ = .017), with no heterogeneity between trials and no significant difference in major bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B293"></span><a href="javascript:;" reveal-id="ehae176-B293" data-open="ehae176-B293" class="link link-ref link-reveal xref-bibr">293</a></sup>

Specific patient subgroups show consistent benefit with DOACs vs. VKAs. For heart failure, major thromboembolic events were lower in DOAC-treated patients vs. warfarin in subgroup analysis of landmark RCTs,<sup><span class="xrefLink" id="jumplink-ehae176-B322"></span><a href="javascript:;" reveal-id="ehae176-B322" data-open="ehae176-B322" class="link link-ref link-reveal xref-bibr">322</a></sup> confirmed in large-scale real-world data.<sup><span class="xrefLink" id="jumplink-ehae176-B323"></span><a href="javascript:;" reveal-id="ehae176-B323" data-open="ehae176-B323" class="link link-ref link-reveal xref-bibr">323</a></sup> In a retrospective cohort of patients aged over 80 years, DOAC use was associated with a lower risk of ischaemic stroke, dementia, mortality, and major bleeding than warfarin,<sup><span class="xrefLink" id="jumplink-ehae176-B324"></span><a href="javascript:;" reveal-id="ehae176-B324" data-open="ehae176-B324" class="link link-ref link-reveal xref-bibr">324</a></sup> but this may be confounded by prescription bias.

Direct oral anticoagulants retain their efficacy and safety over VKAs in patients with mild-to-moderate CKD (creatinine clearance \[CrCl\] >30 mL/min),<sup><span class="xrefLink" id="jumplink-ehae176-B325"></span><a href="javascript:;" reveal-id="ehae176-B325" data-open="ehae176-B325" class="link link-ref link-reveal xref-bibr">325</a></sup> although specific dosing adjustments apply.<sup><span class="xrefLink" id="jumplink-ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28"></span><a href="javascript:;" reveal-id="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" data-open="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" class="link link-ref link-reveal xref-bibr">25–28</a>,<span class="xrefLink" id="jumplink-ehae176-B326"></span><a href="javascript:;" reveal-id="ehae176-B326" data-open="ehae176-B326" class="link link-ref link-reveal xref-bibr">326</a></sup> In Europe, reduced doses of rivaroxaban, apixaban, and edoxaban are approved in patients with severe CKD (CrCl 15–29 mL/min), although limited numbers of patients were included in the major RCTs against VKA.<sup><span class="xrefLink" id="jumplink-ehae176-B327"></span><a href="javascript:;" reveal-id="ehae176-B327" data-open="ehae176-B327" class="link link-ref link-reveal xref-bibr">327</a></sup> Dabigatran is more dependent on renal elimination and so is contraindicated with an estimated glomerular filtration rate <30 mL/min/1.73 m<sup>2</sup>. Small trials have been performed in patients on haemodialysis, with two finding no difference between apixaban 2.5 mg twice daily and VKA for efficacy or safety outcomes,<sup><span class="xrefLink" id="jumplink-ehae176-B328"></span><a href="javascript:;" reveal-id="ehae176-B328" data-open="ehae176-B328" class="link link-ref link-reveal xref-bibr">328</a>,<span class="xrefLink" id="jumplink-ehae176-B329"></span><a href="javascript:;" reveal-id="ehae176-B329" data-open="ehae176-B329" class="link link-ref link-reveal xref-bibr">329</a></sup> and one trial showing that rivaroxaban 10 mg led to significantly lower rates of cardiovascular events and major bleeding compared with VKA.<sup><span class="xrefLink" id="jumplink-ehae176-B330"></span><a href="javascript:;" reveal-id="ehae176-B330" data-open="ehae176-B330" class="link link-ref link-reveal xref-bibr">330</a></sup> Careful institution and regular follow-up are advised when instituting anticoagulants in any patient with impaired renal function (See [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table 8](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B326"></span><a href="javascript:;" reveal-id="ehae176-B326" data-open="ehae176-B326" class="link link-ref link-reveal xref-bibr">326</a></sup>

Direct oral anticoagulants as a class should be avoided in specific patient groups, such as those with mechanical heart valves or moderate-to-severe mitral stenosis. In patients with mechanical heart valves, an excess of thromboembolic and major bleeding events among patients on dabigatran therapy vs. VKA was observed, with an RCT terminated prematurely.<sup><span class="xrefLink" id="jumplink-ehae176-B331"></span><a href="javascript:;" reveal-id="ehae176-B331" data-open="ehae176-B331" class="link link-ref link-reveal xref-bibr">331</a></sup> A trial of apixaban vs. VKA after implantation of a mechanical aortic valve was also stopped due to excess thromboembolic events in the apixaban group.<sup><span class="xrefLink" id="jumplink-ehae176-B332"></span><a href="javascript:;" reveal-id="ehae176-B332" data-open="ehae176-B332" class="link link-ref link-reveal xref-bibr">332</a></sup> The restriction on DOAC use does not apply to bioprosthetic heart valves (including mitral) or after transcatheter aortic valve implantation, where DOACs can be used and trial data show non-inferiority for clinical events compared with VKAs.<sup><span class="xrefLink" id="jumplink-ehae176-B304"></span><a href="javascript:;" reveal-id="ehae176-B304" data-open="ehae176-B304" class="link link-ref link-reveal xref-bibr">304</a>,<span class="xrefLink" id="jumplink-ehae176-B333"></span><a href="javascript:;" reveal-id="ehae176-B333" data-open="ehae176-B333" class="link link-ref link-reveal xref-bibr">333</a>,<span class="xrefLink" id="jumplink-ehae176-B334"></span><a href="javascript:;" reveal-id="ehae176-B334" data-open="ehae176-B334" class="link link-ref link-reveal xref-bibr">334</a></sup> With regards to mitral stenosis, the DOAC vs. VKA trials excluded patients with moderate-to-severe disease. In 4531 randomized patients with rheumatic heart disease and AF, VKAs led to a lower rate of composite cardiovascular events and death than rivaroxaban, without a higher rate of bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B294"></span><a href="javascript:;" reveal-id="ehae176-B294" data-open="ehae176-B294" class="link link-ref link-reveal xref-bibr">294</a></sup> Eighty-two per cent of the patients included had a mitral valve area ≤2 cm, supporting the restriction of DOAC use in patients with moderate-to-severe mitral stenosis. Note that patients with other types of valve disease (mitral regurgitation and others) should preferentially be prescribed a DOAC, and the term ‘valvular’ AF is obsolete and should be avoided.

Inappropriate dose reductions for DOACs are frequent in clinical practice,<sup><span class="xrefLink" id="jumplink-ehae176-B311"></span><a href="javascript:;" reveal-id="ehae176-B311" data-open="ehae176-B311" class="link link-ref link-reveal xref-bibr">311</a></sup> but need to be avoided as they increase the risk of stroke without decreasing bleeding risk.<sup><span class="xrefLink" id="jumplink-ehae176-B310"></span><a href="javascript:;" reveal-id="ehae176-B310" data-open="ehae176-B310" class="link link-ref link-reveal xref-bibr">310</a></sup> Hence, DOAC therapy should be instituted according to the standard full dose as tested in phase 3 RCTs and approved by regulators (_[Table 11](javascript:;)_). The prescribed dosage should consider the individual patient's profile.<sup><span class="xrefLink" id="jumplink-ehae176-B335"></span><a href="javascript:;" reveal-id="ehae176-B335" data-open="ehae176-B335" class="link link-ref link-reveal xref-bibr">335</a></sup> Drug interactions need to be considered in all patients taking or planned for DOACs (see _[Figure 9](javascript:;)_ for common drug interactions).<sup><span class="xrefLink" id="jumplink-ehae176-B336"></span><a href="javascript:;" reveal-id="ehae176-B336" data-open="ehae176-B336" class="link link-ref link-reveal xref-bibr">336</a></sup> There is insufficient evidence currently to advise on routine laboratory testing for DOAC levels. However, in certain situations, measurement of DOAC levels (where available) may be helpful, such as severe bleeding, the need for urgent surgery, or thromboembolic events despite apparent DOAC compliance.<sup><span class="xrefLink" id="jumplink-ehae176-B337"></span><a href="javascript:;" reveal-id="ehae176-B337" data-open="ehae176-B337" class="link link-ref link-reveal xref-bibr">337</a>,<span class="xrefLink" id="jumplink-ehae176-B338"></span><a href="javascript:;" reveal-id="ehae176-B338" data-open="ehae176-B338" class="link link-ref link-reveal xref-bibr">338</a></sup> Patients should always be involved in decision-making on anticoagulation,<sup><span class="xrefLink" id="jumplink-ehae176-B339"></span><a href="javascript:;" reveal-id="ehae176-B339" data-open="ehae176-B339" class="link link-ref link-reveal xref-bibr">339</a></sup> leading to better alignment with personal preferences that can help to increase understanding and adherence.

Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884231)

Recommended doses for direct oral anticoagulant therapy

| DOAC .  | Standard full dose .  | Criteria for dose reduction .  | Reduced dose only if criteria met .  |
| --- | --- | --- | --- |
| Apixaban | 5 mg twice daily | Two out of three needed for dose reduction:
(i) age ≥80 years
(ii) body weight ≤60 kg
(iii) serum creatinine ≥133 mmol/L. | 2.5 mg twice daily |
| Dabigatran | 150 mg twice daily | Dose reduction recommended if any apply:
(i) age ≥80 years
(ii) receiving concomitant verapamil.
Dose reduction considered on an individual basis if any apply:
(i) age 75–80
(ii) moderate renal impairment (creatinine clearance 30–50 mL/min)
(iii) patients with gastritis, oesophagitis, or gastro-oesophageal reflux
(iv) others at increased risk of bleeding. | 110 mg twice daily |
| Edoxaban | 60 mg once daily | Dose reduction if any apply:
(i) moderate or severe renal impairment (creatinine clearance 15–50 mL/min)
(ii) body weight ≤60 kg
(iii) concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole. | 30 mg once daily |
| Rivaroxaban | 20 mg once daily | Creatinine clearance 15–49 mL/min. | 15 mg once daily |

| DOAC .  | Standard full dose .  | Criteria for dose reduction .  | Reduced dose only if criteria met .  |
| --- | --- | --- | --- |
| Apixaban | 5 mg twice daily | Two out of three needed for dose reduction:
(i) age ≥80 years
(ii) body weight ≤60 kg
(iii) serum creatinine ≥133 mmol/L. | 2.5 mg twice daily |
| Dabigatran | 150 mg twice daily | Dose reduction recommended if any apply:
(i) age ≥80 years
(ii) receiving concomitant verapamil.
Dose reduction considered on an individual basis if any apply:
(i) age 75–80
(ii) moderate renal impairment (creatinine clearance 30–50 mL/min)
(iii) patients with gastritis, oesophagitis, or gastro-oesophageal reflux
(iv) others at increased risk of bleeding. | 110 mg twice daily |
| Edoxaban | 60 mg once daily | Dose reduction if any apply:
(i) moderate or severe renal impairment (creatinine clearance 15–50 mL/min)
(ii) body weight ≤60 kg
(iii) concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole. | 30 mg once daily |
| Rivaroxaban | 20 mg once daily | Creatinine clearance 15–49 mL/min. | 15 mg once daily |

DOAC, direct oral anticoagulant.

Dose and dose adjustments are taken from the European Medicines Association Summary of Product Characteristics for each DOAC. There may be other patient-specific reasons for providing a reduced dose, but, in general, the standard full dose should be used to provide optimal prevention of thromboembolism related to AF. Note that antiplatelet agents should be stopped in most patients when commencing a DOAC (see _Section [6.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5.3)_). A number of drug interactions exist with each DOAC and should be taken into consideration (see _[Figure 9](javascript:;)_).

© ESC 2024

Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884231)

Recommended doses for direct oral anticoagulant therapy

| DOAC .  | Standard full dose .  | Criteria for dose reduction .  | Reduced dose only if criteria met .  |
| --- | --- | --- | --- |
| Apixaban | 5 mg twice daily | Two out of three needed for dose reduction:
(i) age ≥80 years
(ii) body weight ≤60 kg
(iii) serum creatinine ≥133 mmol/L. | 2.5 mg twice daily |
| Dabigatran | 150 mg twice daily | Dose reduction recommended if any apply:
(i) age ≥80 years
(ii) receiving concomitant verapamil.
Dose reduction considered on an individual basis if any apply:
(i) age 75–80
(ii) moderate renal impairment (creatinine clearance 30–50 mL/min)
(iii) patients with gastritis, oesophagitis, or gastro-oesophageal reflux
(iv) others at increased risk of bleeding. | 110 mg twice daily |
| Edoxaban | 60 mg once daily | Dose reduction if any apply:
(i) moderate or severe renal impairment (creatinine clearance 15–50 mL/min)
(ii) body weight ≤60 kg
(iii) concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole. | 30 mg once daily |
| Rivaroxaban | 20 mg once daily | Creatinine clearance 15–49 mL/min. | 15 mg once daily |

| DOAC .  | Standard full dose .  | Criteria for dose reduction .  | Reduced dose only if criteria met .  |
| --- | --- | --- | --- |
| Apixaban | 5 mg twice daily | Two out of three needed for dose reduction:
(i) age ≥80 years
(ii) body weight ≤60 kg
(iii) serum creatinine ≥133 mmol/L. | 2.5 mg twice daily |
| Dabigatran | 150 mg twice daily | Dose reduction recommended if any apply:
(i) age ≥80 years
(ii) receiving concomitant verapamil.
Dose reduction considered on an individual basis if any apply:
(i) age 75–80
(ii) moderate renal impairment (creatinine clearance 30–50 mL/min)
(iii) patients with gastritis, oesophagitis, or gastro-oesophageal reflux
(iv) others at increased risk of bleeding. | 110 mg twice daily |
| Edoxaban | 60 mg once daily | Dose reduction if any apply:
(i) moderate or severe renal impairment (creatinine clearance 15–50 mL/min)
(ii) body weight ≤60 kg
(iii) concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole. | 30 mg once daily |
| Rivaroxaban | 20 mg once daily | Creatinine clearance 15–49 mL/min. | 15 mg once daily |

DOAC, direct oral anticoagulant.

Dose and dose adjustments are taken from the European Medicines Association Summary of Product Characteristics for each DOAC. There may be other patient-specific reasons for providing a reduced dose, but, in general, the standard full dose should be used to provide optimal prevention of thromboembolism related to AF. Note that antiplatelet agents should be stopped in most patients when commencing a DOAC (see _Section [6.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5.3)_). A number of drug interactions exist with each DOAC and should be taken into consideration (see _[Figure 9](javascript:;)_).

© ESC 2024

#### 6.2.2. Vitamin K antagonists

Vitamin K antagonist therapy reduces stroke risk by 64% and mortality by 26% in patients with AF at elevated thromboembolic risk (mostly warfarin in trials, compared with placebo or no treatment).<sup><span class="xrefLink" id="jumplink-ehae176-B239"></span><a href="javascript:;" reveal-id="ehae176-B239" data-open="ehae176-B239" class="link link-ref link-reveal xref-bibr">239</a></sup> Vitamin K antagonists are still used in many patients worldwide, but prescriptions have declined sharply since the introduction of DOACs.<sup><span class="xrefLink" id="jumplink-ehae176-B340"></span><a href="javascript:;" reveal-id="ehae176-B340" data-open="ehae176-B340" class="link link-ref link-reveal xref-bibr">340</a>,<span class="xrefLink" id="jumplink-ehae176-B341"></span><a href="javascript:;" reveal-id="ehae176-B341" data-open="ehae176-B341" class="link link-ref link-reveal xref-bibr">341</a></sup> Vitamin K antagonists are currently the only treatment option in AF patients with mechanical heart valves or moderate-to-severe mitral valve stenosis.<sup><span class="xrefLink" id="jumplink-ehae176-B294"></span><a href="javascript:;" reveal-id="ehae176-B294" data-open="ehae176-B294" class="link link-ref link-reveal xref-bibr">294</a>,<span class="xrefLink" id="jumplink-ehae176-B331"></span><a href="javascript:;" reveal-id="ehae176-B331" data-open="ehae176-B331" class="link link-ref link-reveal xref-bibr">331</a></sup> The use of VKAs is not only limited by numerous drug and food interactions (_[Figure 9](javascript:;)_), but also a narrow therapeutic range. This requires frequent monitoring and dose adjustment according to the prothrombin time expressed as the international normalized ratio (INR).<sup><span class="xrefLink" id="jumplink-ehae176-B342"></span><a href="javascript:;" reveal-id="ehae176-B342" data-open="ehae176-B342" class="link link-ref link-reveal xref-bibr">342</a></sup> If the time in therapeutic range (TTR) is maintained for long periods (e.g. >70% with INR 2.0–3.0), then VKA can be effective for thromboembolic protection with an acceptable safety profile.<sup><span class="xrefLink" id="jumplink-ehae176-B295 ehae176-B296 ehae176-B297"></span><a href="javascript:;" reveal-id="ehae176-B295 ehae176-B296 ehae176-B297" data-open="ehae176-B295 ehae176-B296 ehae176-B297" class="link link-ref link-reveal xref-bibr">295–297</a>,<span class="xrefLink" id="jumplink-ehae176-B343"></span><a href="javascript:;" reveal-id="ehae176-B343" data-open="ehae176-B343" class="link link-ref link-reveal xref-bibr">343</a></sup> However, VKAs are associated with higher rates of intracranial bleeding,<sup><span class="xrefLink" id="jumplink-ehae176-B299"></span><a href="javascript:;" reveal-id="ehae176-B299" data-open="ehae176-B299" class="link link-ref link-reveal xref-bibr">299</a>,<span class="xrefLink" id="jumplink-ehae176-B300"></span><a href="javascript:;" reveal-id="ehae176-B300" data-open="ehae176-B300" class="link link-ref link-reveal xref-bibr">300</a></sup> and also higher rates of other types of bleeding compared with DOACs.<sup><span class="xrefLink" id="jumplink-ehae176-B83"></span><a href="javascript:;" reveal-id="ehae176-B83" data-open="ehae176-B83" class="link link-ref link-reveal xref-bibr">83</a></sup>

In view of the potential safety benefits, switching from VKAs to a DOAC is justified where there are concerns about intracranial bleeding or for patient-choice reasons, and a switch is recommended where patients have failed to maintain an adequate TTR (<70%). This depends on patients fulfilling eligibility criteria for DOACs and should take into account other correctable reasons for poor INR control. There is limited data on switching OAC in older patients (≥75 years) with polypharmacy or other markers of frailty. A recent trial in this patient group prematurely stopped for futility showed that switching from VKAs to DOACs led to a higher primary outcome rate of major or clinically relevant non-major bleeding events compared with continuing with INR-guided VKA (17.8 vs. 10.5 per 100 patient-years, driven by non-major bleeds).<sup><span class="xrefLink" id="jumplink-ehae176-B309"></span><a href="javascript:;" reveal-id="ehae176-B309" data-open="ehae176-B309" class="link link-ref link-reveal xref-bibr">309</a></sup> Hence, in such patients who are clinically stable with good TTR, VKAs may be continued rather than switching to a DOAC after an open discussion with the patient and shared decision-making.

#### 6.2.3. Clinical vs. device-detected subclinical AF

The known benefit of anticoagulation applies to clinical AF. Two RCTs have been published assessing the value of DOAC therapy in device-detected subclinical AF. The ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) was completed with 4012 patients with device-detected subclinical AF and a mean follow-up of 3.5 years.<sup><span class="xrefLink" id="jumplink-ehae176-B282"></span><a href="javascript:;" reveal-id="ehae176-B282" data-open="ehae176-B282" class="link link-ref link-reveal xref-bibr">282</a></sup> The primary efficacy outcome of stroke or systemic embolism was significantly less in those randomized to apixaban compared with aspirin (HR, 0.63; 95% CI, 0.45–0.88; _P_ = .007). In the intention-to-treat analysis, the primary safety outcome of major bleeding was higher with apixaban (HR, 1.36; 95% CI, 1.01–1.82; _P_ = .04). The NOAH trial (Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes) was stopped prematurely due to safety concerns and futility for the efficacy of edoxaban, and hence provides limited information.<sup><span class="xrefLink" id="jumplink-ehae176-B281"></span><a href="javascript:;" reveal-id="ehae176-B281" data-open="ehae176-B281" class="link link-ref link-reveal xref-bibr">281</a></sup> The analysis of 2536 patients with device-detected atrial high-rate episodes and a median follow-up of 21 months identified no difference in a composite of cardiovascular death, stroke, or embolism comparing edoxaban and placebo (HR, 0.81; 95% CI, 0.60–1.08; _P_ = .15). Those randomized to edoxaban had a higher rate of the composite of death or major bleeding than placebo (HR, 1.31; 95% CI, 1.02–1.67; _P_ = .03). Patients had a low burden of device-detected subclinical AF in both trials (median duration 1.5 h and 2.8 h, respectively), with lower rates of thromboembolism (around 1% per patient-year) than would be expected for an equivalent cohort of patients with clinical AF and a CHA<sub>2</sub>DS<sub>2</sub>\-VASc score of 4.

Considering the trade-off between potential benefit and the risk of major bleeding, this task force concludes that DOAC therapy may be considered in subgroups of patients with asymptomatic device-detected subclinical AF who have high estimated stroke risk and an absence of major bleeding risk factors (see _Section [6.7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5.7)_). The duration and burden of subclinical AF that could indicate potential benefit from OAC remains uncertain.<sup><span class="xrefLink" id="jumplink-ehae176-B344"></span><a href="javascript:;" reveal-id="ehae176-B344" data-open="ehae176-B344" class="link link-ref link-reveal xref-bibr">344</a></sup> Regardless of the initial decision on OAC, patients with subclinical AF should receive management and follow-up for all aspects of AF-CARE as the risk of developing clinical AF is high (6%–9% per year).

### 6.3. Antiplatelet drugs and combinations with anticoagulants

Antiplatelet drugs, such as aspirin and clopidogrel, are not an alternative to OAC. They should not be used for stroke prevention, and can lead to potential harm (especially among elderly patients with AF).<sup><span class="xrefLink" id="jumplink-ehae176-B345 ehae176-B346 ehae176-B347"></span><a href="javascript:;" reveal-id="ehae176-B345 ehae176-B346 ehae176-B347" data-open="ehae176-B345 ehae176-B346 ehae176-B347" class="link link-ref link-reveal xref-bibr">345–347</a></sup> In ACTIVE W (Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events), dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was less effective than warfarin for the prevention of stroke, systemic embolism, MI, or vascular death (annual risk of events 5.6% vs. 3.9%, respectively; _P_ = .0003), with similar rates of major bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B348"></span><a href="javascript:;" reveal-id="ehae176-B348" data-open="ehae176-B348" class="link link-ref link-reveal xref-bibr">348</a></sup> The AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment) trial demonstrated a lower rate of stroke or systemic embolism with apixaban compared with aspirin (HR, 0.45; 95% CI, 0.32–0.62; _P_ < .001), with no significant difference in major bleeding (there were 11 cases of intracranial bleeding with apixaban and 13 with aspirin).<sup><span class="xrefLink" id="jumplink-ehae176-B242"></span><a href="javascript:;" reveal-id="ehae176-B242" data-open="ehae176-B242" class="link link-ref link-reveal xref-bibr">242</a></sup>

The combination of OAC with antiplatelet agents (especially aspirin) without an adequate indication occurs frequently in clinical practice (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S9](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B349"></span><a href="javascript:;" reveal-id="ehae176-B349" data-open="ehae176-B349" class="link link-ref link-reveal xref-bibr">349</a>,<span class="xrefLink" id="jumplink-ehae176-B350"></span><a href="javascript:;" reveal-id="ehae176-B350" data-open="ehae176-B350" class="link link-ref link-reveal xref-bibr">350</a></sup> Bleeding events are more common when antithrombotic agents are combined, and no clear benefit has been observed in terms of prevention of stroke or death.<sup><span class="xrefLink" id="jumplink-ehae176-B349"></span><a href="javascript:;" reveal-id="ehae176-B349" data-open="ehae176-B349" class="link link-ref link-reveal xref-bibr">349</a></sup> In general, combining antiplatelet drugs with anticoagulants (DOACs or VKAs) should only occur in selected patients with acute vascular disease (e.g. acute coronary syndromes; see _Section [9.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.2)_). The combination of low-dose rivaroxaban (2.5 mg) with aspirin reduced the risk of stroke in patients with chronic vascular disease in a subanalysis of the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial,<sup><span class="xrefLink" id="jumplink-ehae176-B351"></span><a href="javascript:;" reveal-id="ehae176-B351" data-open="ehae176-B351" class="link link-ref link-reveal xref-bibr">351</a>,<span class="xrefLink" id="jumplink-ehae176-B352"></span><a href="javascript:;" reveal-id="ehae176-B352" data-open="ehae176-B352" class="link link-ref link-reveal xref-bibr">352</a></sup> but this cannot be generalized to AF patients because those with an indication for full-dose anticoagulants were excluded.

Recommendation Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884241)

Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8)

![Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt8.jpeg?Expires=1728478929&Signature=abLagSKlqN7nmBc7ZC2t5UeAk8at30lFtWZTgdxEf8RQP6E4kx-3~Rqj~J5cNujtI1ybI4-0cOJ-du1UfvkeQlTXW8DbdKofCu2QeytxWS1Iilr9HrDZOHgt3Fu5cb0UdX3kRItypnKUwb0iUGeo6bsS5KCc~~7Ad95wV13QThfXzkPhXdnAo6yweEU8~2qcF03dJRCM~Q5GtHiS8OBA9D86G2qygaHtr9qfVXOrk6fs8xBvES3oPw6dF47dx2DQbhKDqph53P0PfAVXFQIG7PPTgOnWGF9SPYsx7inTr32J9ZXUGZW-y7waQ0XHjDYng6Q034kn5ujCHR6s5gTo6A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884241)

Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8)

![Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt8.jpeg?Expires=1728478929&Signature=abLagSKlqN7nmBc7ZC2t5UeAk8at30lFtWZTgdxEf8RQP6E4kx-3~Rqj~J5cNujtI1ybI4-0cOJ-du1UfvkeQlTXW8DbdKofCu2QeytxWS1Iilr9HrDZOHgt3Fu5cb0UdX3kRItypnKUwb0iUGeo6bsS5KCc~~7Ad95wV13QThfXzkPhXdnAo6yweEU8~2qcF03dJRCM~Q5GtHiS8OBA9D86G2qygaHtr9qfVXOrk6fs8xBvES3oPw6dF47dx2DQbhKDqph53P0PfAVXFQIG7PPTgOnWGF9SPYsx7inTr32J9ZXUGZW-y7waQ0XHjDYng6Q034kn5ujCHR6s5gTo6A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.4. Residual ischaemic stroke risk despite anticoagulation

Although OAC significantly reduces the risk of ischaemic stroke in patients with AF, there remains a residual risk.<sup><span class="xrefLink" id="jumplink-ehae176-B252"></span><a href="javascript:;" reveal-id="ehae176-B252" data-open="ehae176-B252" class="link link-ref link-reveal xref-bibr">252</a>,<span class="xrefLink" id="jumplink-ehae176-B354"></span><a href="javascript:;" reveal-id="ehae176-B354" data-open="ehae176-B354" class="link link-ref link-reveal xref-bibr">354</a></sup> One-third of patients with AF presenting with an ischaemic stroke are already on anticoagulation,<sup><span class="xrefLink" id="jumplink-ehae176-B355"></span><a href="javascript:;" reveal-id="ehae176-B355" data-open="ehae176-B355" class="link link-ref link-reveal xref-bibr">355</a></sup> with heterogeneous aetiology.<sup><span class="xrefLink" id="jumplink-ehae176-B356"></span><a href="javascript:;" reveal-id="ehae176-B356" data-open="ehae176-B356" class="link link-ref link-reveal xref-bibr">356</a></sup> This may include non-AF-related competing stroke mechanisms (such as large artery and small vessel diseases), non-adherence to therapy, an inappropriately low dose of anticoagulant, or thromboembolism despite sufficient anticoagulation.<sup><span class="xrefLink" id="jumplink-ehae176-B357"></span><a href="javascript:;" reveal-id="ehae176-B357" data-open="ehae176-B357" class="link link-ref link-reveal xref-bibr">357</a></sup> Laboratory measurement of INR or DOAC levels may contribute to revealing an amenable cause of the stroke. Regardless of anticoagulation status, patients with ischaemic stroke are more likely to have cardiovascular risk factors.<sup><span class="xrefLink" id="jumplink-ehae176-B358"></span><a href="javascript:;" reveal-id="ehae176-B358" data-open="ehae176-B358" class="link link-ref link-reveal xref-bibr">358</a></sup> Many clinicians managing patients with an incident stroke despite taking anticoagulation will be tempted to switch their anticoagulant regimen. While there may be some advantage in switching from VKAs to DOACs for protection against future recurrent ischaemic or haemorrhagic stroke, this task force does not recommend routinely switching from one DOAC to another, or from a DOAC to a VKA, since this has no proven efficacy.<sup><span class="xrefLink" id="jumplink-ehae176-B252"></span><a href="javascript:;" reveal-id="ehae176-B252" data-open="ehae176-B252" class="link link-ref link-reveal xref-bibr">252</a>,<span class="xrefLink" id="jumplink-ehae176-B356"></span><a href="javascript:;" reveal-id="ehae176-B356" data-open="ehae176-B356" class="link link-ref link-reveal xref-bibr">356</a>,<span class="xrefLink" id="jumplink-ehae176-B359"></span><a href="javascript:;" reveal-id="ehae176-B359" data-open="ehae176-B359" class="link link-ref link-reveal xref-bibr">359</a></sup> There may be individual reasons for switching, including potential interactions with new drugs; however, there is no consistent data across countries that adherence or efficacy differs between once- and twice-daily approaches.<sup><span class="xrefLink" id="jumplink-ehae176-B360"></span><a href="javascript:;" reveal-id="ehae176-B360" data-open="ehae176-B360" class="link link-ref link-reveal xref-bibr">360</a>,<span class="xrefLink" id="jumplink-ehae176-B361"></span><a href="javascript:;" reveal-id="ehae176-B361" data-open="ehae176-B361" class="link link-ref link-reveal xref-bibr">361</a></sup> Emerging, but observational evidence suggests that switching provides limited reduction in the risk of recurrent ischaemic stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B252"></span><a href="javascript:;" reveal-id="ehae176-B252" data-open="ehae176-B252" class="link link-ref link-reveal xref-bibr">252</a>,<span class="xrefLink" id="jumplink-ehae176-B356"></span><a href="javascript:;" reveal-id="ehae176-B356" data-open="ehae176-B356" class="link link-ref link-reveal xref-bibr">356</a>,<span class="xrefLink" id="jumplink-ehae176-B359"></span><a href="javascript:;" reveal-id="ehae176-B359" data-open="ehae176-B359" class="link link-ref link-reveal xref-bibr">359</a></sup> The alternative strategy of adding antiplatelet therapy to OAC may lead to an increased risk of bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B356"></span><a href="javascript:;" reveal-id="ehae176-B356" data-open="ehae176-B356" class="link link-ref link-reveal xref-bibr">356</a>,<span class="xrefLink" id="jumplink-ehae176-B359"></span><a href="javascript:;" reveal-id="ehae176-B359" data-open="ehae176-B359" class="link link-ref link-reveal xref-bibr">359</a></sup> Aside from thorough attention to underlying risk factors and comorbidities, the approach to management of patients with a stroke despite OAC remains a distinct challenge.

Recommendation Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884244)

Recommendations for thromboembolism despite anticoagulation (see also Evidence Table 9)

![Recommendations for thromboembolism despite anticoagulation (see also Evidence Table 9)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt9.jpeg?Expires=1728478929&Signature=mNNS1jJFgB5riIX0I2HUPoYiP8TI2MFL7irdW-wEQtjl3DSqM-~0GiLFAcwLYqzQJEeCAv~efd6fxQyam2PoMaobaIEyY~kg4rVXpiSHl0k~6N2dzveaxX-UmMeUxvjOEpwilX0x5nvLw88BVUQWVznmRql4aFizjs~2etBVLa-T21IEv2PL2wz6upXPPqNVORO0qiZw3W8uZPEkXOrP1EkPLtN~UfR2NmylRN2YSkoWUdwgxLAoLAb~ZT7Ip3gfY4BS8kfJyMyE2AUNwxI-TPoOSl013fveVSsFEfQAGyHS9dMbrUp3OOnvgIFDt3iMWqyGKv1-KaT~GfTccJ3yww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884244)

Recommendations for thromboembolism despite anticoagulation (see also Evidence Table 9)

![Recommendations for thromboembolism despite anticoagulation (see also Evidence Table 9)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt9.jpeg?Expires=1728478929&Signature=mNNS1jJFgB5riIX0I2HUPoYiP8TI2MFL7irdW-wEQtjl3DSqM-~0GiLFAcwLYqzQJEeCAv~efd6fxQyam2PoMaobaIEyY~kg4rVXpiSHl0k~6N2dzveaxX-UmMeUxvjOEpwilX0x5nvLw88BVUQWVznmRql4aFizjs~2etBVLa-T21IEv2PL2wz6upXPPqNVORO0qiZw3W8uZPEkXOrP1EkPLtN~UfR2NmylRN2YSkoWUdwgxLAoLAb~ZT7Ip3gfY4BS8kfJyMyE2AUNwxI-TPoOSl013fveVSsFEfQAGyHS9dMbrUp3OOnvgIFDt3iMWqyGKv1-KaT~GfTccJ3yww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.5. Percutaneous left atrial appendage occlusion

Percutaneous left atrial appendage occlusion (LAAO) is a device-based therapy that aims to prevent ischaemic stroke in patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B362"></span><a href="javascript:;" reveal-id="ehae176-B362" data-open="ehae176-B362" class="link link-ref link-reveal xref-bibr">362</a>,<span class="xrefLink" id="jumplink-ehae176-B363"></span><a href="javascript:;" reveal-id="ehae176-B363" data-open="ehae176-B363" class="link link-ref link-reveal xref-bibr">363</a></sup> In the VKA era, two RCTs compared warfarin with LAAO using the Watchman device. The 5-year pooled outcomes demonstrated a similar rate of the composite endpoint (cardiovascular or unexplained death, systemic embolism, and stroke) between the LAAO and warfarin arms. Those randomized to LAAO had significantly lower rates of haemorrhagic stroke and all-cause death, but also a 71% non-significant increase in ischaemic stroke and systemic embolism.<sup><span class="xrefLink" id="jumplink-ehae176-B364"></span><a href="javascript:;" reveal-id="ehae176-B364" data-open="ehae176-B364" class="link link-ref link-reveal xref-bibr">364</a></sup> With DOACs demonstrating similar rates of major bleeding to aspirin,<sup><span class="xrefLink" id="jumplink-ehae176-B242"></span><a href="javascript:;" reveal-id="ehae176-B242" data-open="ehae176-B242" class="link link-ref link-reveal xref-bibr">242</a></sup> warfarin in the control arms in these trials is no longer standard of care and hence the place of LAAO in current practice is unclear. The Amulet occluder is an alternative LAAO device which was non-inferior in an RCT to the Watchman device for safety events (procedure-related complications, death, or major bleeding) and thromboembolism.<sup><span class="xrefLink" id="jumplink-ehae176-B365"></span><a href="javascript:;" reveal-id="ehae176-B365" data-open="ehae176-B365" class="link link-ref link-reveal xref-bibr">365</a></sup> In the PRAGUE-17 trial, 402 AF patients were randomized to DOAC or LAAO (Watchman or Amulet), with non-inferiority reported for a broad composite primary endpoint of stroke, TIA, systemic embolism, cardiovascular death, major or non-major clinically relevant bleeding, and procedure/device-related complications.<sup><span class="xrefLink" id="jumplink-ehae176-B366"></span><a href="javascript:;" reveal-id="ehae176-B366" data-open="ehae176-B366" class="link link-ref link-reveal xref-bibr">366</a>,<span class="xrefLink" id="jumplink-ehae176-B367"></span><a href="javascript:;" reveal-id="ehae176-B367" data-open="ehae176-B367" class="link link-ref link-reveal xref-bibr">367</a></sup> Larger trials<sup><span class="xrefLink" id="jumplink-ehae176-B368"></span><a href="javascript:;" reveal-id="ehae176-B368" data-open="ehae176-B368" class="link link-ref link-reveal xref-bibr">368</a>,<span class="xrefLink" id="jumplink-ehae176-B369"></span><a href="javascript:;" reveal-id="ehae176-B369" data-open="ehae176-B369" class="link link-ref link-reveal xref-bibr">369</a></sup> are expected to provide more comprehensive data that can add to the current evidence base (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S10](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

Pending further RCTs (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_), patients with a contraindication to all of the OAC options (the four DOACs and VKAs) have the most appropriate rationale for LAAO implantation, despite the paradox that the need for post-procedure antithrombotic treatment exposes the patient to a bleeding risk that may be equivalent to that of DOACs. Regulatory approvals based on RCT protocols suggest the need for 45 days of VKA plus aspirin after implantation, followed by 6 months of DAPT in patients with no major peri-device leaks, and then ongoing aspirin (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Figure S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B370 ehae176-B371 ehae176-B372"></span><a href="javascript:;" reveal-id="ehae176-B370 ehae176-B371 ehae176-B372" data-open="ehae176-B370 ehae176-B371 ehae176-B372" class="link link-ref link-reveal xref-bibr">370–372</a></sup> However, real-world practice is markedly different and also varied. Direct oral anticoagulant administration at full or reduced dose has been proposed as a treatment alternative to warfarin.<sup><span class="xrefLink" id="jumplink-ehae176-B373"></span><a href="javascript:;" reveal-id="ehae176-B373" data-open="ehae176-B373" class="link link-ref link-reveal xref-bibr">373</a></sup> Observational studies have also supported the use of antiplatelet therapy without associated increases in device-related thrombosis or stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B374 ehae176-B375 ehae176-B376"></span><a href="javascript:;" reveal-id="ehae176-B374 ehae176-B375 ehae176-B376" data-open="ehae176-B374 ehae176-B375 ehae176-B376" class="link link-ref link-reveal xref-bibr">374–376</a></sup> In a propensity-matched comparison of patients receiving limited early OAC vs. antiplatelet treatment post-Watchman implantation, thromboembolic event rates and bleeding complications were similar.<sup><span class="xrefLink" id="jumplink-ehae176-B377"></span><a href="javascript:;" reveal-id="ehae176-B377" data-open="ehae176-B377" class="link link-ref link-reveal xref-bibr">377</a></sup> While waiting for solid RCT data (NCT03445949, NCT03568890),<sup><span class="xrefLink" id="jumplink-ehae176-B378"></span><a href="javascript:;" reveal-id="ehae176-B378" data-open="ehae176-B378" class="link link-ref link-reveal xref-bibr">378</a></sup> pertinent decisions on antithrombotic treatment are usually made on an individualized basis.<sup><span class="xrefLink" id="jumplink-ehae176-B379 ehae176-B380 ehae176-B381"></span><a href="javascript:;" reveal-id="ehae176-B379 ehae176-B380 ehae176-B381" data-open="ehae176-B379 ehae176-B380 ehae176-B381" class="link link-ref link-reveal xref-bibr">379–381</a></sup> Prevention of recurrent stroke, in addition to OAC, is another potential indication for LAAO. Only limited data are so far available from registries,<sup><span class="xrefLink" id="jumplink-ehae176-B382"></span><a href="javascript:;" reveal-id="ehae176-B382" data-open="ehae176-B382" class="link link-ref link-reveal xref-bibr">382</a></sup> with ongoing trials expected to provide more insight (NCT03642509, NCT05963698).

Left atrial appendage occlusion device implantation is associated with procedural risk including stroke, major bleeding, device-related thrombus, pericardial effusion, vascular complications, and death.<sup><span class="xrefLink" id="jumplink-ehae176-B362"></span><a href="javascript:;" reveal-id="ehae176-B362" data-open="ehae176-B362" class="link link-ref link-reveal xref-bibr">362</a>,<span class="xrefLink" id="jumplink-ehae176-B383 ehae176-B384 ehae176-B385"></span><a href="javascript:;" reveal-id="ehae176-B383 ehae176-B384 ehae176-B385" data-open="ehae176-B383 ehae176-B384 ehae176-B385" class="link link-ref link-reveal xref-bibr">383–385</a></sup> Voluntary registries enrolling patients considered ineligible for OAC have reported low peri-procedural risk,<sup><span class="xrefLink" id="jumplink-ehae176-B372"></span><a href="javascript:;" reveal-id="ehae176-B372" data-open="ehae176-B372" class="link link-ref link-reveal xref-bibr">372</a>,<span class="xrefLink" id="jumplink-ehae176-B376"></span><a href="javascript:;" reveal-id="ehae176-B376" data-open="ehae176-B376" class="link link-ref link-reveal xref-bibr">376</a>,<span class="xrefLink" id="jumplink-ehae176-B386"></span><a href="javascript:;" reveal-id="ehae176-B386" data-open="ehae176-B386" class="link link-ref link-reveal xref-bibr">386</a>,<span class="xrefLink" id="jumplink-ehae176-B387"></span><a href="javascript:;" reveal-id="ehae176-B387" data-open="ehae176-B387" class="link link-ref link-reveal xref-bibr">387</a></sup> although national registries report in-hospital major adverse event rates of 9.5% in centres performing 5–15 LAAO cases per year, and 5.6% performing 32–211 cases per year (_P_ < .001).<sup><span class="xrefLink" id="jumplink-ehae176-B388"></span><a href="javascript:;" reveal-id="ehae176-B388" data-open="ehae176-B388" class="link link-ref link-reveal xref-bibr">388</a></sup> Registries with new-generation devices report a lower complication rate compared with RCT data.<sup><span class="xrefLink" id="jumplink-ehae176-B389"></span><a href="javascript:;" reveal-id="ehae176-B389" data-open="ehae176-B389" class="link link-ref link-reveal xref-bibr">389</a>,<span class="xrefLink" id="jumplink-ehae176-B390"></span><a href="javascript:;" reveal-id="ehae176-B390" data-open="ehae176-B390" class="link link-ref link-reveal xref-bibr">390</a></sup> Device-related thrombi occur with an incidence of 1.7%–7.2% and are associated with a higher risk of ischaemic stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B386"></span><a href="javascript:;" reveal-id="ehae176-B386" data-open="ehae176-B386" class="link link-ref link-reveal xref-bibr">386</a>,<span class="xrefLink" id="jumplink-ehae176-B391 ehae176-B392 ehae176-B393 ehae176-B394 ehae176-B395 ehae176-B396 ehae176-B397"></span><a href="javascript:;" reveal-id="ehae176-B391 ehae176-B392 ehae176-B393 ehae176-B394 ehae176-B395 ehae176-B396 ehae176-B397" data-open="ehae176-B391 ehae176-B392 ehae176-B393 ehae176-B394 ehae176-B395 ehae176-B396 ehae176-B397" class="link link-ref link-reveal xref-bibr">391–397</a></sup> Their detection can be documented as late as 1 year post-implantation in one-fifth of patients, thus mandating a late ‘rule-out’ imaging approach.<sup><span class="xrefLink" id="jumplink-ehae176-B391"></span><a href="javascript:;" reveal-id="ehae176-B391" data-open="ehae176-B391" class="link link-ref link-reveal xref-bibr">391</a></sup> Likewise, follow-up screening for peri-device leaks is relevant, as small leaks (0–5 mm) are present in ∼25% and have been associated with higher thromboembolic and bleeding events during 1 year follow-up in a large observational registry of one particular device.<sup><span class="xrefLink" id="jumplink-ehae176-B398"></span><a href="javascript:;" reveal-id="ehae176-B398" data-open="ehae176-B398" class="link link-ref link-reveal xref-bibr">398</a></sup>

Recommendation Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884249)

Recommendations for percutaneous left atrial appendage occlusion (see also Evidence Table 10)

![Recommendations for percutaneous left atrial appendage occlusion (see also Evidence Table 10)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt10.jpeg?Expires=1728478929&Signature=JJCaruoxDFNyB8WhI6JMxPDNNlzw0Dt6YMhlnz9Pj94aAkiXPOsvRzJISaHD4Tk6EKo2BDBE611DBPZ6zjls3h6ik9sur9lavhI3rwOQNqi9rECGZNyqHpmR5vjgfRlIWzmPIG3ahPRlIo0lmWPF7-0i5Gl4qdKkqvOZVWRVz0VNdtnCOI9Z6UGalHyM3e3B8xApNrKUzVT7YVQnbbWAnk2JcLfOtm9waqkGoyjtEECI2mYK6WpUDTdHtjNBAwpLGCaB6kSi8Q7ZNRDFpGnP2j6c3edHY8ryt1Fi09u78bhEdd4e8LegnPgDrTFkY8b3udehcDEWaGqFhbXzz9rSmA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884249)

Recommendations for percutaneous left atrial appendage occlusion (see also Evidence Table 10)

![Recommendations for percutaneous left atrial appendage occlusion (see also Evidence Table 10)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt10.jpeg?Expires=1728478929&Signature=JJCaruoxDFNyB8WhI6JMxPDNNlzw0Dt6YMhlnz9Pj94aAkiXPOsvRzJISaHD4Tk6EKo2BDBE611DBPZ6zjls3h6ik9sur9lavhI3rwOQNqi9rECGZNyqHpmR5vjgfRlIWzmPIG3ahPRlIo0lmWPF7-0i5Gl4qdKkqvOZVWRVz0VNdtnCOI9Z6UGalHyM3e3B8xApNrKUzVT7YVQnbbWAnk2JcLfOtm9waqkGoyjtEECI2mYK6WpUDTdHtjNBAwpLGCaB6kSi8Q7ZNRDFpGnP2j6c3edHY8ryt1Fi09u78bhEdd4e8LegnPgDrTFkY8b3udehcDEWaGqFhbXzz9rSmA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.6. Surgical left atrial appendage occlusion

Surgical occlusion or exclusion of the left atrial appendage (LAA) can contribute to stroke prevention in patients with AF undergoing cardiac surgery.<sup><span class="xrefLink" id="jumplink-ehae176-B399"></span><a href="javascript:;" reveal-id="ehae176-B399" data-open="ehae176-B399" class="link link-ref link-reveal xref-bibr">399</a>,<span class="xrefLink" id="jumplink-ehae176-B400"></span><a href="javascript:;" reveal-id="ehae176-B400" data-open="ehae176-B400" class="link link-ref link-reveal xref-bibr">400</a></sup> The Left Atrial Appendage Occlusion Study (LAAOS III) randomized 4811 patients with AF to undergo or not undergo LAAO at the time of cardiac surgery for another indication. During a mean of 3.8 years follow-up, ischaemic stroke or systemic embolism occurred in 114 patients (4.8%) in the occlusion group and 168 (7.0%) in the control arm (HR, 0.67; 95% CI, 0.53–0.85; _P_ = .001).<sup><span class="xrefLink" id="jumplink-ehae176-B401"></span><a href="javascript:;" reveal-id="ehae176-B401" data-open="ehae176-B401" class="link link-ref link-reveal xref-bibr">401</a></sup> The LAAOS III trial did not compare appendage occlusion with anticoagulation (77% of participants continued to receive OAC), and therefore, surgical LAA closure should be considered as an adjunct therapy to prevent thromboembolism in addition to anticoagulation in patients with AF.

There are no RCT data showing a beneficial effect on ischaemic stroke or systemic embolism in patients with AF undergoing LAAO during endoscopic or hybrid AF ablation. A meta-analysis of RCT and observational data showed no differences in stroke prevention or all-cause mortality when comparing LAA clipping during thoracoscopic AF ablation with percutaneous LAAO and catheter ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B402"></span><a href="javascript:;" reveal-id="ehae176-B402" data-open="ehae176-B402" class="link link-ref link-reveal xref-bibr">402</a></sup> While the percutaneous LAAO/catheter ablation group showed a higher acute success rate, it was also associated with a higher risk of haemorrhage during the peri-operative period. In an observational study evaluating 222 AF patients undergoing LAA closure using a clipping device as a part of endoscopic or hybrid AF ablation, complete closure was achieved in 95% of patients.<sup><span class="xrefLink" id="jumplink-ehae176-B403"></span><a href="javascript:;" reveal-id="ehae176-B403" data-open="ehae176-B403" class="link link-ref link-reveal xref-bibr">403</a></sup> There were no intra-operative complications, and freedom from a combined endpoint of ischaemic stroke, haemorrhagic stroke, or TIA was 99.1% over 369 patient-years of follow-up. Trials evaluating the beneficial effect of surgical LAA closure in patients undergoing cardiac surgery but without a known history of AF are ongoing (NCT03724318, NCT02701062).<sup><span class="xrefLink" id="jumplink-ehae176-B404"></span><a href="javascript:;" reveal-id="ehae176-B404" data-open="ehae176-B404" class="link link-ref link-reveal xref-bibr">404</a></sup>

There is a potential advantage for stand-alone epicardial over percutaneous LAA closure in patients with a contraindication for OAC, as there is no need for post-procedure anticoagulation after epicardial closure. Observational data show that stand-alone LAA closure using an epicardial clip is feasible and safe.<sup><span class="xrefLink" id="jumplink-ehae176-B405"></span><a href="javascript:;" reveal-id="ehae176-B405" data-open="ehae176-B405" class="link link-ref link-reveal xref-bibr">405</a></sup> A multidisciplinary team approach can facilitate the choice between epicardial or percutaneous LAA closure in such patients.<sup><span class="xrefLink" id="jumplink-ehae176-B406"></span><a href="javascript:;" reveal-id="ehae176-B406" data-open="ehae176-B406" class="link link-ref link-reveal xref-bibr">406</a></sup> The majority of safety data and experience in epicardial LAA closure originate from a single clipping device (AtriClip)<sup><span class="xrefLink" id="jumplink-ehae176-B403"></span><a href="javascript:;" reveal-id="ehae176-B403" data-open="ehae176-B403" class="link link-ref link-reveal xref-bibr">403</a>,<span class="xrefLink" id="jumplink-ehae176-B407"></span><a href="javascript:;" reveal-id="ehae176-B407" data-open="ehae176-B407" class="link link-ref link-reveal xref-bibr">407</a>,<span class="xrefLink" id="jumplink-ehae176-B408"></span><a href="javascript:;" reveal-id="ehae176-B408" data-open="ehae176-B408" class="link link-ref link-reveal xref-bibr">408</a></sup> (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S11](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

Recommendation Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884254)

Recommendations for surgical left atrial appendage occlusion (see also Evidence Table 11)

![Recommendations for surgical left atrial appendage occlusion (see also Evidence Table 11)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt11.jpeg?Expires=1728478929&Signature=xvXaidwzlXbQAuf7DkXpIa69pVeEy68QHLYdVZfa-3y2wOeY4QJGCidDXMkUcKr7yYKyl1-52X70ct6j-9t1ojvJZ3oRUNtiNzOGUjVbOiee6Qbizm2CN5baJcJUufV4rmQZQH8aOwaSfsNvuvpX8SAlzgqsq29wfzuzM2YSTATJ6tQUdnUqO3HScapbk32KRMbAMDdc3j0DutZfl6wo4KTVFJ4G162VL61rSc7iohuWBypfFXyxbggQd1FkPyphw5~Vu9HjaXwwmOtKdFoSACRB6b72EfFAIgON1Ipc9zarJyz2B2SdMZFhiFN1KvbUsOxLz7aR9SCDwuQ-4wHkoA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884254)

Recommendations for surgical left atrial appendage occlusion (see also Evidence Table 11)

![Recommendations for surgical left atrial appendage occlusion (see also Evidence Table 11)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt11.jpeg?Expires=1728478929&Signature=xvXaidwzlXbQAuf7DkXpIa69pVeEy68QHLYdVZfa-3y2wOeY4QJGCidDXMkUcKr7yYKyl1-52X70ct6j-9t1ojvJZ3oRUNtiNzOGUjVbOiee6Qbizm2CN5baJcJUufV4rmQZQH8aOwaSfsNvuvpX8SAlzgqsq29wfzuzM2YSTATJ6tQUdnUqO3HScapbk32KRMbAMDdc3j0DutZfl6wo4KTVFJ4G162VL61rSc7iohuWBypfFXyxbggQd1FkPyphw5~Vu9HjaXwwmOtKdFoSACRB6b72EfFAIgON1Ipc9zarJyz2B2SdMZFhiFN1KvbUsOxLz7aR9SCDwuQ-4wHkoA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.7. Bleeding risk

#### 6.7.1. Assessment of bleeding risk

When initiating antithrombotic therapy, modifiable bleeding risk factors should be managed to improve safety (_[Figure 10](javascript:;)_).<sup><span class="xrefLink" id="jumplink-ehae176-B414 ehae176-B415 ehae176-B416 ehae176-B417 ehae176-B418"></span><a href="javascript:;" reveal-id="ehae176-B414 ehae176-B415 ehae176-B416 ehae176-B417 ehae176-B418" data-open="ehae176-B414 ehae176-B415 ehae176-B416 ehae176-B417 ehae176-B418" class="link link-ref link-reveal xref-bibr">414–418</a></sup> This includes strict control of hypertension, advice to reduce excess alcohol intake, avoidance of unnecessary antiplatelet or anti-inflammatory agents, and attention to OAC therapy (adherence, control of TTR if on VKAs, and review of interacting medications). Clinicians should consider the balance between stroke and bleeding risk—as factors for both are dynamic and overlapping, they should be re-assessed at each review depending on the individual patient.<sup><span class="xrefLink" id="jumplink-ehae176-B419 ehae176-B420 ehae176-B421"></span><a href="javascript:;" reveal-id="ehae176-B419 ehae176-B420 ehae176-B421" data-open="ehae176-B419 ehae176-B420 ehae176-B421" class="link link-ref link-reveal xref-bibr">419–421</a></sup> Bleeding risk factors are rarely a reason to withdraw or withhold OAC in eligible patients, as the risk of stroke without anticoagulation often outweighs the risk of major bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B422"></span><a href="javascript:;" reveal-id="ehae176-B422" data-open="ehae176-B422" class="link link-ref link-reveal xref-bibr">422</a>,<span class="xrefLink" id="jumplink-ehae176-B423"></span><a href="javascript:;" reveal-id="ehae176-B423" data-open="ehae176-B423" class="link link-ref link-reveal xref-bibr">423</a></sup> Patients with non-modifiable risk factors should be reviewed more often, and where appropriate, a multidisciplinary team approach should be instituted to guide management.

![Modifying the risk of bleeding associated with OAC.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f10.jpeg?Expires=1728478929&Signature=P1kWyoigG8SwZbmpfWg7k0VvuZKYMkp1Xt7yNPtiEp9ecJmrspImsCPk3W0aJioRSM3bBt7wZI5EJuzI4uKqntwz3qbjqAzkFyRFwzW8I09V1A23wdPCFk-LzNRvX4Y6pzhUTt83DEm3GZKyXNi48gjaVqtRdw9TuibJacLWU8ZG4sPivyerBXP5Blwekt98~WHJgU1aq7P8C0ROA7~fTUGmXQ9D7228xFAiuRxwSlxUUnxqA83GDxHba28W2rX77IbnRzVc2-5ukuwoUZGEFXjM1g2aT0r3f3t9tPZAT42C5SakYrYZfwsFMqWM405L1lJDcTghIGC1e4idGpaLtA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 10

Modifying the risk of bleeding associated with OAC.

DOAC, direct oral anticoagulant; GI, gastrointestinal; INR, international normalized ratio of prothrombin time; NSAID, non-steroidal anti-inflammatory drug; OAC, oral anticoagulant; TTR, time in therapeutic range; VKA, vitamin K antagonist. <sup>a</sup>Absolute contraindications for OAC therapy are rare, and include primary intracranial tumours and intracerebral bleeds related to amyloid angiopathy. In most cases, contraindications may be relative or temporary. Left atrial appendage occlusion can be performed through a percutaneous or endoscopic approach.

[Open in new tab](https://academic.oup.com/view-large/figure/479884258/ehae176f10.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f10.jpeg?Expires=1728478929&Signature=bWB9MVXrv-~7Vn7o5rDvc0sbiCztCELC4OOd4Js8xE78aiTd5DO-a7phXtbsIllsOgjhriFuucIQq2UaKBnHwC4rinXngbr~2d4aktfduMAvxX9pdKzoExDQhR5d2H4a6vhj965md2hqqwozVefQWRdP5V-HeLycpcIqbci0Yw-FEJUPOJ8B3GQbfk1F56kvNFbBv0rDbI1hYHJSKN-W-zOOXmH~N4rXz2alcnNWnwNE5OOLuZpQvTkDsvvRd3xOg5VjrMrCEfHjZa4aPbW0RQ4lnLP0-Z6XxNXOiMv-9wVicjlpFoUrkcDAklKDtKjpBPI0eqBVSQ5v3Z6lwI9X7Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884258&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Several bleeding risk scores have been developed to account for a wide range of clinical factors (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[Additional Evidence Tables S12](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S13](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B424"></span><a href="javascript:;" reveal-id="ehae176-B424" data-open="ehae176-B424" class="link link-ref link-reveal xref-bibr">424</a></sup> Systematic reviews and validation studies in external cohorts have shown contrasting results and only modest predictive ability.<sup><span class="xrefLink" id="jumplink-ehae176-B244"></span><a href="javascript:;" reveal-id="ehae176-B244" data-open="ehae176-B244" class="link link-ref link-reveal xref-bibr">244</a>,<span class="xrefLink" id="jumplink-ehae176-B425 ehae176-B426 ehae176-B427 ehae176-B428 ehae176-B429 ehae176-B430 ehae176-B431 ehae176-B432 ehae176-B433 ehae176-B434"></span><a href="javascript:;" reveal-id="ehae176-B425 ehae176-B426 ehae176-B427 ehae176-B428 ehae176-B429 ehae176-B430 ehae176-B431 ehae176-B432 ehae176-B433 ehae176-B434" data-open="ehae176-B425 ehae176-B426 ehae176-B427 ehae176-B428 ehae176-B429 ehae176-B430 ehae176-B431 ehae176-B432 ehae176-B433 ehae176-B434" class="link link-ref link-reveal xref-bibr">425–434</a></sup> This task force does not recommend a specific bleeding risk score given the uncertainty in accuracy and potential adverse implications of not providing appropriate OAC to those at thromboembolic risk. There are very few absolute contraindications to OAC (especially DOAC therapy). Whereas primary intracranial tumours<sup><span class="xrefLink" id="jumplink-ehae176-B435"></span><a href="javascript:;" reveal-id="ehae176-B435" data-open="ehae176-B435" class="link link-ref link-reveal xref-bibr">435</a></sup> or an intracerebral bleed related to cerebral amyloid angiopathy<sup><span class="xrefLink" id="jumplink-ehae176-B436"></span><a href="javascript:;" reveal-id="ehae176-B436" data-open="ehae176-B436" class="link link-ref link-reveal xref-bibr">436</a></sup> are examples where OAC should be avoided, many other contraindications are relative or temporary. For example, a DOAC can often be safely initiated or re-initiated after acute bleeding has stopped, as long as the source has been fully investigated and managed. Co-prescription of proton pump inhibitors is common in clinical practice for patients receiving OAC that are at high risk of gastrointestinal bleeding. However, the evidence base is limited and not specifically in patients with AF. Whereas observational studies have shown potential benefit from proton pump inhibitors,<sup><span class="xrefLink" id="jumplink-ehae176-B437"></span><a href="javascript:;" reveal-id="ehae176-B437" data-open="ehae176-B437" class="link link-ref link-reveal xref-bibr">437</a></sup> a large RCT in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease found that pantoprazole had no significant impact on upper gastrointestinal bleeding events compared with placebo (HR, 0.88; 95% CI, 0.67–1.15).<sup><span class="xrefLink" id="jumplink-ehae176-B438"></span><a href="javascript:;" reveal-id="ehae176-B438" data-open="ehae176-B438" class="link link-ref link-reveal xref-bibr">438</a></sup> Hence, the use of gastric protection should be individualized for each patient according to the totality of their perceived bleeding risk.

Recommendation Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884260)

Recommendations for assessment of bleeding risk (see also Evidence Table 12)

![Recommendations for assessment of bleeding risk (see also Evidence Table 12)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt12.jpeg?Expires=1728478929&Signature=TRtVXNbK5vRv-YGY8UufXbtMMoNREhABrRVXUu65ekppPLOow~eWKPQ0cZ5XErJyh-O1I4-GOQbc7Dc87EHN1Cs-KZqo-7oDdNcpNasXoTW4rC5F~m12xAit3mvhISeVmElmJjxDg26EwEl~6NNYuzH2qdoDUDzNOZ~MZaA9Q11fF2TLhlbVhhYAQ3Fs4WM-z6Q2J6SgCIISCFvqX3OJZr7T0iKdHshT1SkzxRxShFwUOmN0fb2MacDTMtDZusaMzHMOp2buUtt0yM8unHKAiTY1g~QDNqglDQBpzSYpIgFiTcsj~XB9Dcn07uRXUTpKKXH7YgcSyB1dKcC~3UhSRA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884260)

Recommendations for assessment of bleeding risk (see also Evidence Table 12)

![Recommendations for assessment of bleeding risk (see also Evidence Table 12)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt12.jpeg?Expires=1728478929&Signature=TRtVXNbK5vRv-YGY8UufXbtMMoNREhABrRVXUu65ekppPLOow~eWKPQ0cZ5XErJyh-O1I4-GOQbc7Dc87EHN1Cs-KZqo-7oDdNcpNasXoTW4rC5F~m12xAit3mvhISeVmElmJjxDg26EwEl~6NNYuzH2qdoDUDzNOZ~MZaA9Q11fF2TLhlbVhhYAQ3Fs4WM-z6Q2J6SgCIISCFvqX3OJZr7T0iKdHshT1SkzxRxShFwUOmN0fb2MacDTMtDZusaMzHMOp2buUtt0yM8unHKAiTY1g~QDNqglDQBpzSYpIgFiTcsj~XB9Dcn07uRXUTpKKXH7YgcSyB1dKcC~3UhSRA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 6.7.2. Management of bleeding on anticoagulant therapy

General management of bleeding in patients receiving OAC is outlined in _[Figure 11](javascript:;)_. Cause-specific management is beyond the scope of these guidelines, and will depend on the individual circumstances of the patient and the healthcare environment.<sup><span class="xrefLink" id="jumplink-ehae176-B447"></span><a href="javascript:;" reveal-id="ehae176-B447" data-open="ehae176-B447" class="link link-ref link-reveal xref-bibr">447</a></sup> Assessment of patients with active bleeding should include confirmation of the bleeding site, bleeding severity, type/dose/timepoint of last anticoagulant intake, concomitant use of other antithrombotic agents, and other factors influencing bleeding risk (renal function, platelet count, and medications such as non-steroidal anti-inflammatories). INR testing and information on recent results are invaluable for patients taking VKAs. Specific coagulation tests for DOACs include diluted thrombin time, ecarin clotting time, ecarin chromogenic assay for dabigatran, and chromogenic anti-factor Xa assay for rivaroxaban, apixaban, and edoxaban.<sup><span class="xrefLink" id="jumplink-ehae176-B447 ehae176-B448 ehae176-B449"></span><a href="javascript:;" reveal-id="ehae176-B447 ehae176-B448 ehae176-B449" data-open="ehae176-B447 ehae176-B448 ehae176-B449" class="link link-ref link-reveal xref-bibr">447–449</a></sup> Diagnostic and treatment interventions to identify and manage the cause of bleeding (e.g. gastroscopy) should be performed promptly.

![Management of oral anticoagulant-related bleeding in patients with AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f11.jpeg?Expires=1728478929&Signature=oc~YHaIU0JYcL5HNOvSVwuQCoH0PMsMo84Cy24PPhFQ8s-fuGrlypKt6IHnwJTeZnGJFdWHUcIr3mNFjLhppP6UPgnDnrq3YFgyO-YiFNO~DoYw~wdb-6DkobM889mUnPgaPvtlRwVJSU1optLgg0NIJGU3l~IqRkD0QT2GsFQeNfyVm0bpTdkoLZCwQ057lGjCHWfldQZAe9HSK4KkBWuLih9ACNoxEFQVs0QV2EwSLvQiFLzee~sHM360sjX3JLFbZyw8ki7w-RS~t1dd2Azgt4RB98crFgDMo0crUWbzor-3qkfnwV7CGuYVZDnpWZSJ~R0Ykh2Umoju4v8V6qw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 11

Management of oral anticoagulant-related bleeding in patients with AF.

DOAC, direct oral anticoagulant; FFP, fresh frozen plasma; INR, international normalized ratio of prothrombin time; OAC, oral anticoagulant; PCC, prothrombin complex concentrate; VKA, vitamin K antagonist.

[Open in new tab](https://academic.oup.com/view-large/figure/479884263/ehae176f11.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f11.jpeg?Expires=1728478929&Signature=jIPU1r1hkOmBTVVfxlWXZc9vgWb91jyQh3fzSXwiKv5ralvtOr9M4vC~YZshN94t8db1-PlTjyqNpkhhy9GGXLZRxOmFlvHG0P8KDSYm8UpmNAOzytj0g4Fghy5BrKqj095r5Kwhm~22mdDOulauS8QUOC~PKghszdX3oENQ9uqW2F4d-zLytqX1xj8~ZdxgznsvN15qziIV25bKDlhppux3VFIxKd6jBc7jek23HH7YeY8mMK-4V70aar2ilLNWzcEpk8ow1XMfGlq5~RWG4dwXzZYNxL-aWK4nMXIiTf3yXi~D~Dr1jpwS67lVLxWRYuFbjsDc1aI2Vdtrk0Tbjg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884263&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

In cases of minor bleeding, temporary withdrawal of OAC while the cause is managed is usually sufficient, noting that the reduction in anticoagulant effect is dependent on the INR level for VKAs or the half-life of the particular DOAC.

For major bleeding events in patients taking VKAs, administration of fresh frozen plasma restores coagulation more rapidly than vitamin K, but prothrombin complex concentrates achieve even faster blood coagulation with fewer complications, and so are preferrable to achieve haemostasis.<sup><span class="xrefLink" id="jumplink-ehae176-B450"></span><a href="javascript:;" reveal-id="ehae176-B450" data-open="ehae176-B450" class="link link-ref link-reveal xref-bibr">450</a></sup> In DOAC-treated patients where the last DOAC dose was taken within 2–4 h, charcoal administration and/or gastric lavage may reduce further exposure. If the patient is taking dabigatran, idarucizumab can fully reverse its anticoagulant effect and help to achieve haemostasis within 2–4 h in uncontrolled bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B451"></span><a href="javascript:;" reveal-id="ehae176-B451" data-open="ehae176-B451" class="link link-ref link-reveal xref-bibr">451</a></sup> Dialysis can also be effective in reducing dabigatran concentration. Andexanet alfa rapidly reverses the activity of factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional evidence Table S14](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). An open-label RCT comparing andexanet alfa to usual care in patients presenting with acute ICH within 6 h of symptom onset was stopped early due to improved control of bleeding after 450 patients had been randomized.<sup><span class="xrefLink" id="jumplink-ehae176-B452"></span><a href="javascript:;" reveal-id="ehae176-B452" data-open="ehae176-B452" class="link link-ref link-reveal xref-bibr">452</a></sup> As DOAC-specific antidotes are not yet available in all institutions, prothrombin complex concentrates are often used in cases of serious bleeding on factor Xa inhibitors, with evidence limited to observational studies.<sup><span class="xrefLink" id="jumplink-ehae176-B453"></span><a href="javascript:;" reveal-id="ehae176-B453" data-open="ehae176-B453" class="link link-ref link-reveal xref-bibr">453</a></sup>

Due to the complexities of managing bleeding in patients taking OAC, it is advisable that each institution develop specific policies involving a multidisciplinary team that includes cardiologists, haematologists, emergency physicians/intensive care specialists, surgeons, and others. It is also important to educate patients taking anticoagulants on the signs and symptoms of bleeding events and to alert their healthcare provider when such events occur.<sup><span class="xrefLink" id="jumplink-ehae176-B335"></span><a href="javascript:;" reveal-id="ehae176-B335" data-open="ehae176-B335" class="link link-ref link-reveal xref-bibr">335</a></sup>

The decision to reinstate OAC will be determined by the severity, cause, and subsequent management of bleeding, preferably by a multidisciplinary team and with close monitoring. Failure to reinstitute OAC after a bleed significantly increases the risk of MI, stroke, and death.<sup><span class="xrefLink" id="jumplink-ehae176-B454"></span><a href="javascript:;" reveal-id="ehae176-B454" data-open="ehae176-B454" class="link link-ref link-reveal xref-bibr">454</a></sup> However, if the cause of severe or life-threatening bleeds cannot be treated or reversed, the risk of ongoing bleeding may outweigh the benefit of thromboembolic protection.<sup><span class="xrefLink" id="jumplink-ehae176-B335"></span><a href="javascript:;" reveal-id="ehae176-B335" data-open="ehae176-B335" class="link link-ref link-reveal xref-bibr">335</a></sup>

Recommendation Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884268)

Recommendations for management of bleeding in anticoagulated patients (see also Evidence Table 13)

![Recommendations for management of bleeding in anticoagulated patients (see also Evidence Table 13)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt13.jpeg?Expires=1728478929&Signature=GOuxrlh5yTzWTdZc-QdYnEBIu7~bsrcswCZ9I8eLdwWmqHgThwFaVtfwCsVp1Zkn5yafetqM6YmSeHIiKZLAPbv9UZoZMGzvJKHCLUsB6vwoReyGvQWu0waUM3E9Ivp4mrZ-otR6DFjHhsMLl5t4U-psy7jgCp4ndzgyS2e5NSKt6JEJcblTqRJlLWFOB8lpIzDya8uMO-dnO3xu6md2b8RQgnjdvchQzL-~FLHykX10F~xMqCt070fZv82pwAnz1UiYQwzPU5kw457vadW5hjnlWTmRwt2DqwALxr46ttf2p7VMapqMtstMIthM~GanQVDH6n0hhhmFzCdO5cbXCA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884268)

Recommendations for management of bleeding in anticoagulated patients (see also Evidence Table 13)

![Recommendations for management of bleeding in anticoagulated patients (see also Evidence Table 13)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt13.jpeg?Expires=1728478929&Signature=GOuxrlh5yTzWTdZc-QdYnEBIu7~bsrcswCZ9I8eLdwWmqHgThwFaVtfwCsVp1Zkn5yafetqM6YmSeHIiKZLAPbv9UZoZMGzvJKHCLUsB6vwoReyGvQWu0waUM3E9Ivp4mrZ-otR6DFjHhsMLl5t4U-psy7jgCp4ndzgyS2e5NSKt6JEJcblTqRJlLWFOB8lpIzDya8uMO-dnO3xu6md2b8RQgnjdvchQzL-~FLHykX10F~xMqCt070fZv82pwAnz1UiYQwzPU5kw457vadW5hjnlWTmRwt2DqwALxr46ttf2p7VMapqMtstMIthM~GanQVDH6n0hhhmFzCdO5cbXCA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 7\. \[R\] Reduce symptoms by rate and rhythm control

Most patients diagnosed with AF will need therapies and/or interventions to control heart rate, revert to sinus rhythm, or maintain sinus rhythm to limit symptoms or improve outcomes. While the concept of choosing between rate and rhythm control is often discussed, in reality most patients require a combination approach which should be consciously re-evaluated during follow-up. Within a patient-centred and shared-management approach, rhythm control should be a consideration in all suitable AF patients, with explicit discussion of benefits and risks.

### 7.1. Management of heart rate in patients with AF

Limiting tachycardia is an integral part of AF management and is often sufficient to improve AF-related symptoms. Rate control is indicated as initial therapy in the acute setting, in combination with rhythm control therapies, or as the sole treatment strategy to control heart rate and reduce symptoms. Limited evidence exists to inform the best type and intensity of rate control treatment.<sup><span class="xrefLink" id="jumplink-ehae176-B457"></span><a href="javascript:;" reveal-id="ehae176-B457" data-open="ehae176-B457" class="link link-ref link-reveal xref-bibr">457</a></sup> The approach to heart rate control presented in _[Figure 7](javascript:;)_ can be used for all types of AF, including paroxysmal, persistent, and permanent AF.

Recommendation Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884273)

Recommendations for heart rate control in patients with AF (see also Evidence Table 14)

![Recommendations for heart rate control in patients with AF (see also Evidence Table 14)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt14.jpeg?Expires=1728478929&Signature=U6RIZNLOzuE6hNozMykRpeN0aTe-rzAE9CvadCBdAbBFF553skmWt5BXh8LhevFslMFbGF8YfL~uwRSN4u19sMYkZD5cFmVXNmPwG5XxArh0xHVdQg1zfxYpEZHjnI7r6NMzMX5HNkZRQ11hS26-AW3-UFjKLCWnVHyuu9SvJQeKkGl-EBbuiMxP733LUONh675mJp2w6XBdzWDNKB~NR5I3g7nr6xkMXkCZC6AnB~rdOoZgrvFvoFawSL9At~ZFWnUvaVPQvHf~ULmE1wMD~BJqWYrVC5ZrYxu4aOrmDrs-EuXXcSvttsFJ9JC2tDKJRskmVlrhZLlNnXPm7Jodbw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884273)

Recommendations for heart rate control in patients with AF (see also Evidence Table 14)

![Recommendations for heart rate control in patients with AF (see also Evidence Table 14)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt14.jpeg?Expires=1728478929&Signature=U6RIZNLOzuE6hNozMykRpeN0aTe-rzAE9CvadCBdAbBFF553skmWt5BXh8LhevFslMFbGF8YfL~uwRSN4u19sMYkZD5cFmVXNmPwG5XxArh0xHVdQg1zfxYpEZHjnI7r6NMzMX5HNkZRQ11hS26-AW3-UFjKLCWnVHyuu9SvJQeKkGl-EBbuiMxP733LUONh675mJp2w6XBdzWDNKB~NR5I3g7nr6xkMXkCZC6AnB~rdOoZgrvFvoFawSL9At~ZFWnUvaVPQvHf~ULmE1wMD~BJqWYrVC5ZrYxu4aOrmDrs-EuXXcSvttsFJ9JC2tDKJRskmVlrhZLlNnXPm7Jodbw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.1.1. Indications and target heart rate

The optimal heart rate target in AF patients depends on the setting, symptom burden, presence of heart failure, and whether rate control is combined with a rhythm control strategy. In the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation) RCT of patients with permanent AF, lenient rate control (target heart rate <110  \[beats per minute\] b.p.m.) was non-inferior to a strict approach (<80 b.p.m. at rest; <110 b.p.m. during exercise; Holter for safety) for a composite of clinical events, NYHA class, or hospitalization.<sup><span class="xrefLink" id="jumplink-ehae176-B186"></span><a href="javascript:;" reveal-id="ehae176-B186" data-open="ehae176-B186" class="link link-ref link-reveal xref-bibr">186</a>,<span class="xrefLink" id="jumplink-ehae176-B459"></span><a href="javascript:;" reveal-id="ehae176-B459" data-open="ehae176-B459" class="link link-ref link-reveal xref-bibr">459</a></sup> Similar results were found in a post-hoc combined analysis from the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) and the RACE (Rate Control versus Electrical cardioversion) studies.<sup><span class="xrefLink" id="jumplink-ehae176-B474"></span><a href="javascript:;" reveal-id="ehae176-B474" data-open="ehae176-B474" class="link link-ref link-reveal xref-bibr">474</a></sup> Therefore, lenient rate control is an acceptable initial approach, unless there are ongoing symptoms or suspicion of tachycardia-induced cardiomyopathy, where stricter targets may be indicated.

#### 7.1.2. Heart rate control in the acute setting

In acute settings, physicians should always evaluate and manage underlying causes for the initiation of AF prior to, or in parallel to, instituting acute rate and/or rhythm control. These include treating sepsis, addressing fluid overload, or managing cardiogenic shock. The choice of drug (_[Table 12](javascript:;)_) will depend on the patient's characteristics, presence of heart failure and LVEF, and haemodynamic profile (_[Figure 7](javascript:;)_). In general for acute rate control, beta-blockers (for all LVEF) and diltiazem/verapamil (for LVEF >40%) are preferred over digoxin because of their more rapid onset of action and dose-dependent effects.<sup><span class="xrefLink" id="jumplink-ehae176-B462"></span><a href="javascript:;" reveal-id="ehae176-B462" data-open="ehae176-B462" class="link link-ref link-reveal xref-bibr">462</a>,<span class="xrefLink" id="jumplink-ehae176-B475"></span><a href="javascript:;" reveal-id="ehae176-B475" data-open="ehae176-B475" class="link link-ref link-reveal xref-bibr">475</a>,<span class="xrefLink" id="jumplink-ehae176-B476"></span><a href="javascript:;" reveal-id="ehae176-B476" data-open="ehae176-B476" class="link link-ref link-reveal xref-bibr">476</a></sup> More selective beta-1 receptor blockers have a better efficacy and safety profile than unselective beta-blockers.<sup><span class="xrefLink" id="jumplink-ehae176-B477"></span><a href="javascript:;" reveal-id="ehae176-B477" data-open="ehae176-B477" class="link link-ref link-reveal xref-bibr">477</a></sup> Combination therapy with digoxin may be required in acute settings (combination of beta-blockers with diltiazem/verapamil should be avoided except in closely monitored situations).<sup><span class="xrefLink" id="jumplink-ehae176-B177"></span><a href="javascript:;" reveal-id="ehae176-B177" data-open="ehae176-B177" class="link link-ref link-reveal xref-bibr">177</a>,<span class="xrefLink" id="jumplink-ehae176-B478"></span><a href="javascript:;" reveal-id="ehae176-B478" data-open="ehae176-B478" class="link link-ref link-reveal xref-bibr">478</a></sup> In selected patients who are haemodynamically unstable or with severely impaired LVEF, intravenous amiodarone, landiolol, or digoxin can be used.<sup><span class="xrefLink" id="jumplink-ehae176-B472"></span><a href="javascript:;" reveal-id="ehae176-B472" data-open="ehae176-B472" class="link link-ref link-reveal xref-bibr">472</a>,<span class="xrefLink" id="jumplink-ehae176-B473"></span><a href="javascript:;" reveal-id="ehae176-B473" data-open="ehae176-B473" class="link link-ref link-reveal xref-bibr">473</a>,<span class="xrefLink" id="jumplink-ehae176-B479"></span><a href="javascript:;" reveal-id="ehae176-B479" data-open="ehae176-B479" class="link link-ref link-reveal xref-bibr">479</a></sup>

#### 7.1.3. Long-term heart rate control

Pharmacological rate control can be achieved with beta-blockers, diltiazem, verapamil, digoxin, or combination therapy (_[Table 12](javascript:;)_) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S15](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B480"></span><a href="javascript:;" reveal-id="ehae176-B480" data-open="ehae176-B480" class="link link-ref link-reveal xref-bibr">480</a></sup>

Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884280)

Drugs for rate control in AF

| Agent<sup><span class="xrefLink" id="jumplink-tblfn118"></span><a href="javascript:;" reveal-id="tblfn118" data-open="tblfn118" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  | Intravenous administration .  | Usual range for oral maintenance dose .  | Contraindicated .  |
| --- | --- | --- | --- |
| **Beta-blockers**<sup><span class="xrefLink" id="jumplink-tblfn119"></span><a href="javascript:;" reveal-id="tblfn119" data-open="tblfn119" class="link link-ref link-reveal xref-fn js-xref-fn">b</a></sup> |
| Metoprolol tartrate | 2.5–5 mg bolus over 2 mins; up to 15 mg maximal cumulative dose | 25–100 mg twice daily | In case of asthma, non-selective beta-blockers should be avoided. Contraindicated in acute HF and history of severe bronchospasm. |
| Metoprolol XL (succinate) | N/A | 50–200 mg once daily |
| Bisoprolol | N/A | 1.25–20 mg once daily |
| Atenolol<sup><span class="xrefLink" id="jumplink-tblfn120"></span><a href="javascript:;" reveal-id="tblfn120" data-open="tblfn120" class="link link-ref link-reveal xref-fn js-xref-fn">c</a></sup> | N/A | 25–100 mg once daily |
| Esmolol | 500 µg/kg i.v. bolus over 1 min; followed by 50–300 µg/kg/min | N/A |
| Landiolol | 100 µg/kg i.v. bolus over 1 min; followed by 10–40 µg/kg/min | N/A |
| Nebivolol | N/A | 2.5–10 mg once daily |
| Carvedilol | N/A | 3.125–50 mg twice daily |
| **Non-dihydropyridine calcium channel antagonists** |
| Verapamil | 2.5–10 mg i.v. bolus over 5 min | 40 mg twice daily to 480 mg (extended release) once daily | Contraindicated if LVEF ≤40%. Adapt doses in hepatic and renal impairment. |
| Diltiazem | 0.25 mg/kg i.v. bolus over 5 min, then 5–15 mg/h | 60 mg three times daily to 360 mg (extended release) once daily |
| **Digitalis glycosides** |
| Digoxin | 0.5 mg i.v. bolus (0.75–1.5 mg over 24 h in divided doses) | 0.0625–0.25 mg once daily | High plasma levels associated with adverse events.
Check renal function before starting digoxin and adapt dose in CKD patients. |
| Digitoxin | 0.4–0.6 mg | 0.05–0.1 mg once daily |
| **Other** |
| Amiodarone<sup><span class="xrefLink" id="jumplink-tblfn121"></span><a href="javascript:;" reveal-id="tblfn121" data-open="tblfn121" class="link link-ref link-reveal xref-fn js-xref-fn">d</a></sup> | 300 mg i.v. diluted in 250 mL 5% dextrose over 30–60 min (preferably via central venous cannula), followed by 900–1200 mg i.v. over 24 h diluted in 500–1000 mL via a central venous cannula | 200 mg once daily after loading
Loading: 200 mg three times daily for 4 weeks, then 200 mg daily or less as appropriate (reduce other rate control drugs according to heart rate) | Contraindicated in iodine sensitivity.
Serious potential adverse effects (including pulmonary, ophthalmic, hepatic, and thyroid). Consider numerous drug interactions. |

| Agent<sup><span class="xrefLink" id="jumplink-tblfn118"></span><a href="javascript:;" reveal-id="tblfn118" data-open="tblfn118" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  | Intravenous administration .  | Usual range for oral maintenance dose .  | Contraindicated .  |
| --- | --- | --- | --- |
| **Beta-blockers**<sup><span class="xrefLink" id="jumplink-tblfn119"></span><a href="javascript:;" reveal-id="tblfn119" data-open="tblfn119" class="link link-ref link-reveal xref-fn js-xref-fn">b</a></sup> |
| Metoprolol tartrate | 2.5–5 mg bolus over 2 mins; up to 15 mg maximal cumulative dose | 25–100 mg twice daily | In case of asthma, non-selective beta-blockers should be avoided. Contraindicated in acute HF and history of severe bronchospasm. |
| Metoprolol XL (succinate) | N/A | 50–200 mg once daily |
| Bisoprolol | N/A | 1.25–20 mg once daily |
| Atenolol<sup><span class="xrefLink" id="jumplink-tblfn120"></span><a href="javascript:;" reveal-id="tblfn120" data-open="tblfn120" class="link link-ref link-reveal xref-fn js-xref-fn">c</a></sup> | N/A | 25–100 mg once daily |
| Esmolol | 500 µg/kg i.v. bolus over 1 min; followed by 50–300 µg/kg/min | N/A |
| Landiolol | 100 µg/kg i.v. bolus over 1 min; followed by 10–40 µg/kg/min | N/A |
| Nebivolol | N/A | 2.5–10 mg once daily |
| Carvedilol | N/A | 3.125–50 mg twice daily |
| **Non-dihydropyridine calcium channel antagonists** |
| Verapamil | 2.5–10 mg i.v. bolus over 5 min | 40 mg twice daily to 480 mg (extended release) once daily | Contraindicated if LVEF ≤40%. Adapt doses in hepatic and renal impairment. |
| Diltiazem | 0.25 mg/kg i.v. bolus over 5 min, then 5–15 mg/h | 60 mg three times daily to 360 mg (extended release) once daily |
| **Digitalis glycosides** |
| Digoxin | 0.5 mg i.v. bolus (0.75–1.5 mg over 24 h in divided doses) | 0.0625–0.25 mg once daily | High plasma levels associated with adverse events.
Check renal function before starting digoxin and adapt dose in CKD patients. |
| Digitoxin | 0.4–0.6 mg | 0.05–0.1 mg once daily |
| **Other** |
| Amiodarone<sup><span class="xrefLink" id="jumplink-tblfn121"></span><a href="javascript:;" reveal-id="tblfn121" data-open="tblfn121" class="link link-ref link-reveal xref-fn js-xref-fn">d</a></sup> | 300 mg i.v. diluted in 250 mL 5% dextrose over 30–60 min (preferably via central venous cannula), followed by 900–1200 mg i.v. over 24 h diluted in 500–1000 mL via a central venous cannula | 200 mg once daily after loading
Loading: 200 mg three times daily for 4 weeks, then 200 mg daily or less as appropriate (reduce other rate control drugs according to heart rate) | Contraindicated in iodine sensitivity.
Serious potential adverse effects (including pulmonary, ophthalmic, hepatic, and thyroid). Consider numerous drug interactions. |

AF, atrial fibrillation; CKD, chronic kidney disease; HF, heart failure; i.v., intravenous; min, minutes; N/A, not available or not widely available. Maximum doses have been defined based on the summary of product characteristic of each drug.

<sup>a</sup>All rate control drugs are contraindicated in Wolff–Parkinson–White syndrome; also intravenous amiodarone.

<sup>b</sup>Other beta-blockers are available but not recommended as specific rate control therapy in AF and therefore not mentioned here (e.g. propranolol and labetalol).

<sup>c</sup>No data on atenolol; should not be used in heart failure with reduced ejection fraction or in pregnancy.

<sup>d</sup>Loading regimen may vary; i.v. dosage should be considered when calculating total load.

© ESC 2024

Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884280)

Drugs for rate control in AF

| Agent<sup><span class="xrefLink" id="jumplink-tblfn118"></span><a href="javascript:;" reveal-id="tblfn118" data-open="tblfn118" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  | Intravenous administration .  | Usual range for oral maintenance dose .  | Contraindicated .  |
| --- | --- | --- | --- |
| **Beta-blockers**<sup><span class="xrefLink" id="jumplink-tblfn119"></span><a href="javascript:;" reveal-id="tblfn119" data-open="tblfn119" class="link link-ref link-reveal xref-fn js-xref-fn">b</a></sup> |
| Metoprolol tartrate | 2.5–5 mg bolus over 2 mins; up to 15 mg maximal cumulative dose | 25–100 mg twice daily | In case of asthma, non-selective beta-blockers should be avoided. Contraindicated in acute HF and history of severe bronchospasm. |
| Metoprolol XL (succinate) | N/A | 50–200 mg once daily |
| Bisoprolol | N/A | 1.25–20 mg once daily |
| Atenolol<sup><span class="xrefLink" id="jumplink-tblfn120"></span><a href="javascript:;" reveal-id="tblfn120" data-open="tblfn120" class="link link-ref link-reveal xref-fn js-xref-fn">c</a></sup> | N/A | 25–100 mg once daily |
| Esmolol | 500 µg/kg i.v. bolus over 1 min; followed by 50–300 µg/kg/min | N/A |
| Landiolol | 100 µg/kg i.v. bolus over 1 min; followed by 10–40 µg/kg/min | N/A |
| Nebivolol | N/A | 2.5–10 mg once daily |
| Carvedilol | N/A | 3.125–50 mg twice daily |
| **Non-dihydropyridine calcium channel antagonists** |
| Verapamil | 2.5–10 mg i.v. bolus over 5 min | 40 mg twice daily to 480 mg (extended release) once daily | Contraindicated if LVEF ≤40%. Adapt doses in hepatic and renal impairment. |
| Diltiazem | 0.25 mg/kg i.v. bolus over 5 min, then 5–15 mg/h | 60 mg three times daily to 360 mg (extended release) once daily |
| **Digitalis glycosides** |
| Digoxin | 0.5 mg i.v. bolus (0.75–1.5 mg over 24 h in divided doses) | 0.0625–0.25 mg once daily | High plasma levels associated with adverse events.
Check renal function before starting digoxin and adapt dose in CKD patients. |
| Digitoxin | 0.4–0.6 mg | 0.05–0.1 mg once daily |
| **Other** |
| Amiodarone<sup><span class="xrefLink" id="jumplink-tblfn121"></span><a href="javascript:;" reveal-id="tblfn121" data-open="tblfn121" class="link link-ref link-reveal xref-fn js-xref-fn">d</a></sup> | 300 mg i.v. diluted in 250 mL 5% dextrose over 30–60 min (preferably via central venous cannula), followed by 900–1200 mg i.v. over 24 h diluted in 500–1000 mL via a central venous cannula | 200 mg once daily after loading
Loading: 200 mg three times daily for 4 weeks, then 200 mg daily or less as appropriate (reduce other rate control drugs according to heart rate) | Contraindicated in iodine sensitivity.
Serious potential adverse effects (including pulmonary, ophthalmic, hepatic, and thyroid). Consider numerous drug interactions. |

| Agent<sup><span class="xrefLink" id="jumplink-tblfn118"></span><a href="javascript:;" reveal-id="tblfn118" data-open="tblfn118" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  | Intravenous administration .  | Usual range for oral maintenance dose .  | Contraindicated .  |
| --- | --- | --- | --- |
| **Beta-blockers**<sup><span class="xrefLink" id="jumplink-tblfn119"></span><a href="javascript:;" reveal-id="tblfn119" data-open="tblfn119" class="link link-ref link-reveal xref-fn js-xref-fn">b</a></sup> |
| Metoprolol tartrate | 2.5–5 mg bolus over 2 mins; up to 15 mg maximal cumulative dose | 25–100 mg twice daily | In case of asthma, non-selective beta-blockers should be avoided. Contraindicated in acute HF and history of severe bronchospasm. |
| Metoprolol XL (succinate) | N/A | 50–200 mg once daily |
| Bisoprolol | N/A | 1.25–20 mg once daily |
| Atenolol<sup><span class="xrefLink" id="jumplink-tblfn120"></span><a href="javascript:;" reveal-id="tblfn120" data-open="tblfn120" class="link link-ref link-reveal xref-fn js-xref-fn">c</a></sup> | N/A | 25–100 mg once daily |
| Esmolol | 500 µg/kg i.v. bolus over 1 min; followed by 50–300 µg/kg/min | N/A |
| Landiolol | 100 µg/kg i.v. bolus over 1 min; followed by 10–40 µg/kg/min | N/A |
| Nebivolol | N/A | 2.5–10 mg once daily |
| Carvedilol | N/A | 3.125–50 mg twice daily |
| **Non-dihydropyridine calcium channel antagonists** |
| Verapamil | 2.5–10 mg i.v. bolus over 5 min | 40 mg twice daily to 480 mg (extended release) once daily | Contraindicated if LVEF ≤40%. Adapt doses in hepatic and renal impairment. |
| Diltiazem | 0.25 mg/kg i.v. bolus over 5 min, then 5–15 mg/h | 60 mg three times daily to 360 mg (extended release) once daily |
| **Digitalis glycosides** |
| Digoxin | 0.5 mg i.v. bolus (0.75–1.5 mg over 24 h in divided doses) | 0.0625–0.25 mg once daily | High plasma levels associated with adverse events.
Check renal function before starting digoxin and adapt dose in CKD patients. |
| Digitoxin | 0.4–0.6 mg | 0.05–0.1 mg once daily |
| **Other** |
| Amiodarone<sup><span class="xrefLink" id="jumplink-tblfn121"></span><a href="javascript:;" reveal-id="tblfn121" data-open="tblfn121" class="link link-ref link-reveal xref-fn js-xref-fn">d</a></sup> | 300 mg i.v. diluted in 250 mL 5% dextrose over 30–60 min (preferably via central venous cannula), followed by 900–1200 mg i.v. over 24 h diluted in 500–1000 mL via a central venous cannula | 200 mg once daily after loading
Loading: 200 mg three times daily for 4 weeks, then 200 mg daily or less as appropriate (reduce other rate control drugs according to heart rate) | Contraindicated in iodine sensitivity.
Serious potential adverse effects (including pulmonary, ophthalmic, hepatic, and thyroid). Consider numerous drug interactions. |

AF, atrial fibrillation; CKD, chronic kidney disease; HF, heart failure; i.v., intravenous; min, minutes; N/A, not available or not widely available. Maximum doses have been defined based on the summary of product characteristic of each drug.

<sup>a</sup>All rate control drugs are contraindicated in Wolff–Parkinson–White syndrome; also intravenous amiodarone.

<sup>b</sup>Other beta-blockers are available but not recommended as specific rate control therapy in AF and therefore not mentioned here (e.g. propranolol and labetalol).

<sup>c</sup>No data on atenolol; should not be used in heart failure with reduced ejection fraction or in pregnancy.

<sup>d</sup>Loading regimen may vary; i.v. dosage should be considered when calculating total load.

© ESC 2024

The choice of rate control drugs depends on symptoms, comorbidities, and the potential for side effects and interactions. Combination therapy of different rate-controlling drugs should be considered only when needed to achieve the target heart rate, and careful follow-up to avoid bradycardia is advised. Combining beta-blockers with verapamil or diltiazem should only be performed in secondary care with regular monitoring of heart rate by 24 h ECG to check for bradycardia.<sup><span class="xrefLink" id="jumplink-ehae176-B459"></span><a href="javascript:;" reveal-id="ehae176-B459" data-open="ehae176-B459" class="link link-ref link-reveal xref-bibr">459</a></sup> Some antiarrhythmic drugs (AADs) also have rate-limiting properties (e.g. amiodarone, sotalol), but they should generally be used only for rhythm control. Dronedarone should not be instituted for rate control since it increases rates of heart failure, stroke, and cardiovascular death in permanent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B481"></span><a href="javascript:;" reveal-id="ehae176-B481" data-open="ehae176-B481" class="link link-ref link-reveal xref-bibr">481</a></sup>

**Beta-blockers**, specifically beta-1 selective adrenoreceptor antagonists, are often first-line rate-controlling agents largely based on their acute effect on heart rate and the beneficial effects demonstrated in patients with chronic HFrEF. However, the prognostic benefit of beta-blockers seen in HFrEF patients with sinus rhythm may not be present in patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B133"></span><a href="javascript:;" reveal-id="ehae176-B133" data-open="ehae176-B133" class="link link-ref link-reveal xref-bibr">133</a>,<span class="xrefLink" id="jumplink-ehae176-B482"></span><a href="javascript:;" reveal-id="ehae176-B482" data-open="ehae176-B482" class="link link-ref link-reveal xref-bibr">482</a></sup>

**Verapamil** and **diltiazem** are non-dihydropyridine calcium channel blockers. They provide rate control<sup><span class="xrefLink" id="jumplink-ehae176-B461"></span><a href="javascript:;" reveal-id="ehae176-B461" data-open="ehae176-B461" class="link link-ref link-reveal xref-bibr">461</a></sup> and have a different adverse effect profile, making verapamil or diltiazem useful for those experiencing side effects from beta-blockers.<sup><span class="xrefLink" id="jumplink-ehae176-B483"></span><a href="javascript:;" reveal-id="ehae176-B483" data-open="ehae176-B483" class="link link-ref link-reveal xref-bibr">483</a></sup> In a 60 patient crossover RCT, verapamil and diltiazem did not lead to the same reduction in exercise capacity as seen with beta-blockers, and had a beneficial impact on BNP.<sup><span class="xrefLink" id="jumplink-ehae176-B480"></span><a href="javascript:;" reveal-id="ehae176-B480" data-open="ehae176-B480" class="link link-ref link-reveal xref-bibr">480</a></sup>

**Digoxin** and **digitoxin** are cardiac glycosides that inhibit the sodium–potassium adenosine triphosphatase and augment parasympathetic tone. In RCTs, there is no association between the use of digoxin and any increase in all-cause mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B185"></span><a href="javascript:;" reveal-id="ehae176-B185" data-open="ehae176-B185" class="link link-ref link-reveal xref-bibr">185</a>,<span class="xrefLink" id="jumplink-ehae176-B484"></span><a href="javascript:;" reveal-id="ehae176-B484" data-open="ehae176-B484" class="link link-ref link-reveal xref-bibr">484</a></sup> Lower doses of digoxin may be associated with better prognosis.<sup><span class="xrefLink" id="jumplink-ehae176-B185"></span><a href="javascript:;" reveal-id="ehae176-B185" data-open="ehae176-B185" class="link link-ref link-reveal xref-bibr">185</a></sup> Serum digoxin concentrations can be monitored to avoid toxicity,<sup><span class="xrefLink" id="jumplink-ehae176-B485"></span><a href="javascript:;" reveal-id="ehae176-B485" data-open="ehae176-B485" class="link link-ref link-reveal xref-bibr">485</a></sup> especially in patients at higher risk due to older age, renal dysfunction, or use of interacting medications. In RATE-AF (RAte control Therapy Evaluation in permanent Atrial Fibrillation), a trial in patients with symptomatic permanent AF, there was no difference between low-dose digoxin and bisoprolol for patient-reported quality of life outcomes at 6 months. However, those randomized to digoxin demonstrated fewer adverse effects, a greater improvement in mEHRA and NYHA scores, and a reduction in BNP.<sup><span class="xrefLink" id="jumplink-ehae176-B48"></span><a href="javascript:;" reveal-id="ehae176-B48" data-open="ehae176-B48" class="link link-ref link-reveal xref-bibr">48</a></sup> Two ongoing RCTs are addressing digoxin and digitoxin use in patients with HFrEF with and without AF (EudraCT-2013-005326-38, NCT03783429).<sup><span class="xrefLink" id="jumplink-ehae176-B486"></span><a href="javascript:;" reveal-id="ehae176-B486" data-open="ehae176-B486" class="link link-ref link-reveal xref-bibr">486</a></sup>

Due to its broad extracardiac adverse effect profile, **amiodarone** is reserved as a last option when heart rate cannot be controlled even with maximal tolerated combination therapy, or in patients who do not qualify for atrioventricular node ablation and pacing. Many of the adverse effects from amiodarone have a direct relationship with cumulative dose, restricting the long-term value of amiodarone for rate control.<sup><span class="xrefLink" id="jumplink-ehae176-B487"></span><a href="javascript:;" reveal-id="ehae176-B487" data-open="ehae176-B487" class="link link-ref link-reveal xref-bibr">487</a></sup>

#### 7.1.4. Atrioventricular node ablation and pacemaker implantation

Ablation of the atrioventricular node and pacemaker implantation (‘ablate and pace’) can lower and regularize heart rate in patients with AF (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S16](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). The procedure has a low complication rate and a low long-term mortality risk.<sup><span class="xrefLink" id="jumplink-ehae176-B468"></span><a href="javascript:;" reveal-id="ehae176-B468" data-open="ehae176-B468" class="link link-ref link-reveal xref-bibr">468</a>,<span class="xrefLink" id="jumplink-ehae176-B488"></span><a href="javascript:;" reveal-id="ehae176-B488" data-open="ehae176-B488" class="link link-ref link-reveal xref-bibr">488</a></sup> The pacemaker should be implanted a few weeks before the atrioventricular node ablation, with the initial pacing rate after ablation set at 70–90 b.p.m.<sup><span class="xrefLink" id="jumplink-ehae176-B489"></span><a href="javascript:;" reveal-id="ehae176-B489" data-open="ehae176-B489" class="link link-ref link-reveal xref-bibr">489</a>,<span class="xrefLink" id="jumplink-ehae176-B490"></span><a href="javascript:;" reveal-id="ehae176-B490" data-open="ehae176-B490" class="link link-ref link-reveal xref-bibr">490</a></sup> This strategy does not worsen LV function,<sup><span class="xrefLink" id="jumplink-ehae176-B491"></span><a href="javascript:;" reveal-id="ehae176-B491" data-open="ehae176-B491" class="link link-ref link-reveal xref-bibr">491</a></sup> and may even improve LVEF in selected patients.<sup><span class="xrefLink" id="jumplink-ehae176-B492"></span><a href="javascript:;" reveal-id="ehae176-B492" data-open="ehae176-B492" class="link link-ref link-reveal xref-bibr">492</a>,<span class="xrefLink" id="jumplink-ehae176-B493"></span><a href="javascript:;" reveal-id="ehae176-B493" data-open="ehae176-B493" class="link link-ref link-reveal xref-bibr">493</a></sup> The evidence base has typically included older patients. For younger patients, ablate and pace should only be considered if heart rate remains uncontrolled despite consideration of other pharmacological and non-pharmacological treatment options. The choice of pacing therapy (right ventricular or biventricular pacing) depends on patient characteristics, presence of heart failure, and LVEF.<sup><span class="xrefLink" id="jumplink-ehae176-B187"></span><a href="javascript:;" reveal-id="ehae176-B187" data-open="ehae176-B187" class="link link-ref link-reveal xref-bibr">187</a>,<span class="xrefLink" id="jumplink-ehae176-B494"></span><a href="javascript:;" reveal-id="ehae176-B494" data-open="ehae176-B494" class="link link-ref link-reveal xref-bibr">494</a></sup>

In severely symptomatic patients with permanent AF and at least one hospitalization for heart failure, atrioventricular node ablation combined with CRT should be considered. In the APAF-CRT (Ablate and Pace for Atrial Fibrillation-cardiac resynchronization therapy) trial in a population with narrow QRS complexes, atrioventricular node ablation combined with CRT was superior to rate control drugs for the primary outcomes (all-cause mortality, and death or hospitalization for heart failure), and secondary outcomes (symptom burden and physical limitation).<sup><span class="xrefLink" id="jumplink-ehae176-B470"></span><a href="javascript:;" reveal-id="ehae176-B470" data-open="ehae176-B470" class="link link-ref link-reveal xref-bibr">470</a>,<span class="xrefLink" id="jumplink-ehae176-B471"></span><a href="javascript:;" reveal-id="ehae176-B471" data-open="ehae176-B471" class="link link-ref link-reveal xref-bibr">471</a></sup> Conduction system pacing may become a potentially useful alternate pacing mode when implementing a pace and ablate strategy, once safety and efficacy have been confirmed in larger RCTs.<sup><span class="xrefLink" id="jumplink-ehae176-B495"></span><a href="javascript:;" reveal-id="ehae176-B495" data-open="ehae176-B495" class="link link-ref link-reveal xref-bibr">495</a>,<span class="xrefLink" id="jumplink-ehae176-B496"></span><a href="javascript:;" reveal-id="ehae176-B496" data-open="ehae176-B496" class="link link-ref link-reveal xref-bibr">496</a></sup> In CRT recipients, the presence (or occurrence) of AF is one of the main reasons for suboptimal biventricular pacing.<sup><span class="xrefLink" id="jumplink-ehae176-B187"></span><a href="javascript:;" reveal-id="ehae176-B187" data-open="ehae176-B187" class="link link-ref link-reveal xref-bibr">187</a></sup> Improvement of biventricular pacing is indicated and can be reached by intensification of rate control drug regimens, atrioventricular node ablation, or rhythm control, depending on patient and AF characteristics.<sup><span class="xrefLink" id="jumplink-ehae176-B187"></span><a href="javascript:;" reveal-id="ehae176-B187" data-open="ehae176-B187" class="link link-ref link-reveal xref-bibr">187</a></sup>

### 7.2. Rhythm control strategies in patients with AF

#### 7.2.1. General principles and anticoagulation

Rhythm control refers to therapies dedicated to restoring and maintaining sinus rhythm. These treatments include cardioversion, AADs, percutaneous catheter ablation, endoscopic and hybrid ablation, and open surgical approaches (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S17](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Rhythm control is never a strategy on its own; instead, it should always be part of the AF-CARE approach.

In patients with acute or worsening haemodynamic instability thought to be caused by AF, rapid electrical cardioversion is recommended. For other patients, a wait-and-see approach should be considered as an alternative to immediate cardioversion (_[Figure 12](javascript:;)_). The Rate Control versus Electrical Cardioversion Trial 7–Acute Cardioversion versus Wait and See (RACE 7 ACWAS) trial in patients with recent-onset symptomatic AF without haemodynamic compromise showed a wait-and-see approach for spontaneous conversion until 48 h after the onset of AF symptoms was non-inferior as compared with immediate cardioversion at 4 weeks follow-up.<sup><span class="xrefLink" id="jumplink-ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B10" data-open="ehae176-B10" class="link link-ref link-reveal xref-bibr">10</a></sup>

![Approaches for cardioversion in patients with AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f12.jpeg?Expires=1728478929&Signature=4DaAjFe1~rapm2tK31uVgPhifiAHtjxg8qStK8aVSpyWue~ckl0AlAjcg86uc3-ShjIIdR1nNxypyzFD0Lg27AEGuO2kexgmqT-9r3lEXPJXIAiFJ5YdxDkY6Fj9H6~m7V4aP0PkGVI6be1pa5~Czb7kRYWBOoP~P6J~aSuQqe8GhYOrXs4hDglHvR0FwszmRfRulYLYePU41bDP5xi4iSVqXjzc03mKWcecJvEky4F2P0wHG-xWel~FwMm~v3ZjKGcwy~XTzKFVbbhbyINegOv~4VTwBVdMnqKrbAF215li7D40iVssvV0gmczhVxLX1ZJPzz1HKY0lOV6GFp4sYA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 12

Approaches for cardioversion in patients with AF.

AF, atrial fibrillation; CHA<sub>2</sub>DS<sub>2</sub>\-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; h, hour; LMWH, low molecular weight heparin; DOAC, direct oral anticoagulant; OAC, oral anticoagulant; TOE, transoesophageal echocardiography; UFH, unfractionated heparin; VKA, vitamin K antagonist. Flowchart for decision-making on cardioversion of AF depending on clinical presentation, AF onset, oral anticoagulation intake, and risk factors for stroke. <sup>a</sup>See _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5)_.

[Open in new tab](https://academic.oup.com/view-large/figure/479884293/ehae176f12.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f12.jpeg?Expires=1728478929&Signature=hKJWdIPRA8QdylcbSQzVQAePcSzD0Fe4tXhJJDpSa8vX~~5QCoXY7uavUbN2~x--WRH0RrA2d3le6EuK5G01ThxCl6pop4JFjKO2xjuzRAGVB~XYgfWtaCoCIsPVRVUS0MkwfEq4CRfBKH~vgT~uivAYg3KEqWZ59AYnpxmSu6YGukjQukZfUNOrH5JTAdmcpdeGSSkPjxa6mdmMg8W7-mfSyQts25vUEIjBytAnOsa~8WOk1cRwmAkS7J7Owt3fXChL-ZtYcf93yuqqlMBPU4hlu5Ctmnn0017Qi7BE-CwxclBKfIJnw4z5blMF-PYIpdJCUKqtOCvSf8-44vFzKQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884293&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Since the publication of landmark trials more than 20 years ago, the main reason to consider longer-term rhythm control therapy has been the reduction in symptoms from AF.<sup><span class="xrefLink" id="jumplink-ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500"></span><a href="javascript:;" reveal-id="ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500" data-open="ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500" class="link link-ref link-reveal xref-bibr">497–500</a></sup> Older studies have shown that the institution of a rhythm control strategy using AADs does not reduce mortality and morbidity when compared with a rate control-only strategy,<sup><span class="xrefLink" id="jumplink-ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500"></span><a href="javascript:;" reveal-id="ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500" data-open="ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500" class="link link-ref link-reveal xref-bibr">497–500</a></sup> and may increase hospitalization.<sup><span class="xrefLink" id="jumplink-ehae176-B457"></span><a href="javascript:;" reveal-id="ehae176-B457" data-open="ehae176-B457" class="link link-ref link-reveal xref-bibr">457</a></sup> In contrast, multiple studies have shown that rhythm control strategies have a positive effect on quality of life once sinus rhythm is maintained.<sup><span class="xrefLink" id="jumplink-ehae176-B501"></span><a href="javascript:;" reveal-id="ehae176-B501" data-open="ehae176-B501" class="link link-ref link-reveal xref-bibr">501</a>,<span class="xrefLink" id="jumplink-ehae176-B502"></span><a href="javascript:;" reveal-id="ehae176-B502" data-open="ehae176-B502" class="link link-ref link-reveal xref-bibr">502</a></sup> Therefore, in the case of uncertainty of the presence of symptoms associated with AF, an attempt to restore sinus rhythm is a rational first step. In patients with symptoms, patient factors that favour an attempt at rhythm control should be considered, including suspected tachycardiomyopathy, a brief AF history, non-dilated left atrium, or patient preference.

Rhythm control strategies have significantly evolved due to an increasing experience in the safe use of antiarrhythmic drugs,<sup><span class="xrefLink" id="jumplink-ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B17" data-open="ehae176-B17" class="link link-ref link-reveal xref-bibr">17</a></sup> consistent use of OAC, improvements in ablation technology,<sup><span class="xrefLink" id="jumplink-ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509"></span><a href="javascript:;" reveal-id="ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509" data-open="ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509" class="link link-ref link-reveal xref-bibr">503–509</a></sup> and identification and management of risk factors and comorbidities.<sup><span class="xrefLink" id="jumplink-ehae176-B39"></span><a href="javascript:;" reveal-id="ehae176-B39" data-open="ehae176-B39" class="link link-ref link-reveal xref-bibr">39</a>,<span class="xrefLink" id="jumplink-ehae176-B510"></span><a href="javascript:;" reveal-id="ehae176-B510" data-open="ehae176-B510" class="link link-ref link-reveal xref-bibr">510</a>,<span class="xrefLink" id="jumplink-ehae176-B511"></span><a href="javascript:;" reveal-id="ehae176-B511" data-open="ehae176-B511" class="link link-ref link-reveal xref-bibr">511</a></sup> In the ATHENA trial (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg twice daily for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter), dronedarone significantly reduced the risk of hospitalization due to cardiovascular events or death as compared with placebo in patients with paroxysmal or persistent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B512"></span><a href="javascript:;" reveal-id="ehae176-B512" data-open="ehae176-B512" class="link link-ref link-reveal xref-bibr">512</a></sup> The CASTLE-AF trial (Catheter Ablation versus Standard Conventional Treatment in Patients With Left Ventricle Dysfunction and AF) demonstrated that a rhythm control strategy with catheter ablation can improve mortality and morbidity in selected patients with HFrEF and an implanted cardiac device.<sup><span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> In end-stage HFrEF, the CASTLE-HTx trial (Catheter Ablation for Atrial Fibrillation in Patients With End-Stage Heart Failure and Eligibility for Heart Transplantation) found, in a single centre, that catheter ablation combined with guideline-directed medical therapy significantly reduced the composite of death from any cause, implantation of left ventricular assist device, or urgent heart transplantation compared with medical treatment.<sup><span class="xrefLink" id="jumplink-ehae176-B513"></span><a href="javascript:;" reveal-id="ehae176-B513" data-open="ehae176-B513" class="link link-ref link-reveal xref-bibr">513</a></sup> At the same time, however, the CABANA trial (Catheter Ablation versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation) could not demonstrate a significant difference in mortality and morbidity between catheter ablation and standard rhythm and/or rate control drugs in symptomatic AF patients older than 64 years, or younger than 65 years with risk factors for stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a></sup> EAST-AFNET 4 (Early treatment of Atrial fibrillation for Stroke prevention Trial) reported that implementation of a rhythm control strategy within 1 year compared with usual care significantly reduced the risk of cardiovascular death, stroke, or hospitalization for heart failure or acute coronary syndrome in patients older than 75 years or with cardiovascular conditions.<sup><span class="xrefLink" id="jumplink-ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B17" data-open="ehae176-B17" class="link link-ref link-reveal xref-bibr">17</a></sup> Of note, rhythm control was predominantly pursued with antiarrhythmic drugs (80% of patients in the intervention arm). Usual care consisted of rate control therapy; only when uncontrolled AF-related symptoms occurred was rhythm control considered. Patients in the EAST-AFNET 4 trial all had cardiovascular risk factors but were at an early stage of AF, with more than 50% being in sinus rhythm and 30% being asymptomatic at the start of the study.

Based on all of these studies, this task force concludes that implementation of a rhythm control strategy can be safely instituted and confers amelioration of AF-related symptoms. Beyond control of symptoms, sinus rhythm maintenance should also be pursued to reduce morbidity and mortality in selected groups of patients.<sup><span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a>,<span class="xrefLink" id="jumplink-ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B17" data-open="ehae176-B17" class="link link-ref link-reveal xref-bibr">17</a>,<span class="xrefLink" id="jumplink-ehae176-B502"></span><a href="javascript:;" reveal-id="ehae176-B502" data-open="ehae176-B502" class="link link-ref link-reveal xref-bibr">502</a>,<span class="xrefLink" id="jumplink-ehae176-B513"></span><a href="javascript:;" reveal-id="ehae176-B513" data-open="ehae176-B513" class="link link-ref link-reveal xref-bibr">513</a>,<span class="xrefLink" id="jumplink-ehae176-B514"></span><a href="javascript:;" reveal-id="ehae176-B514" data-open="ehae176-B514" class="link link-ref link-reveal xref-bibr">514</a></sup>

Any rhythm control procedure has an inherent risk of thromboembolism. Patients undergoing cardioversion require at least 3 weeks of therapeutic anticoagulation (adherence to DOACs or INR >2 if VKA) prior to the electrical or pharmacological procedure. In acute settings or when early cardioversion is needed, transoesophageal echocardiography (TOE) can be performed to exclude cardiac thrombus prior to cardioversion. These approaches have been tested in multiple RCTs.<sup><span class="xrefLink" id="jumplink-ehae176-B319 ehae176-B320 ehae176-B321"></span><a href="javascript:;" reveal-id="ehae176-B319 ehae176-B320 ehae176-B321" data-open="ehae176-B319 ehae176-B320 ehae176-B321" class="link link-ref link-reveal xref-bibr">319–321</a></sup> In the case of thrombus detection, therapeutic anticoagulation should be instituted for a minimum of 4 weeks followed by repeat TOE to ensure thrombus resolution. When the definite duration of AF is less than 48 hours, cardioversion has typically been considered without the need for pre-procedure OAC or TOE for thrombus exclusion. However, the ‘definite’ onset of AF is often not known, and observational data suggest that stroke/thromboembolism risk is lowest within a much shorter time period.<sup><span class="xrefLink" id="jumplink-ehae176-B515 ehae176-B516 ehae176-B517 ehae176-B518 ehae176-B519"></span><a href="javascript:;" reveal-id="ehae176-B515 ehae176-B516 ehae176-B517 ehae176-B518 ehae176-B519" data-open="ehae176-B515 ehae176-B516 ehae176-B517 ehae176-B518 ehae176-B519" class="link link-ref link-reveal xref-bibr">515–519</a></sup> This task force reached consensus that safety should come first. Cardioversion is not recommended if AF duration is longer than 24 hours, unless the patient has already received at least 3 weeks of therapeutic anticoagulation or a TOE is performed to exclude intracardiac thrombus. Most patients should continue OAC for at least 4 weeks post-cardioversion. Only for those without thromboembolic risk factors and sinus rhythm restoration within 24 h of AF onset is post-cardioversion OAC optional. In the presence of any thromboembolic risk factors, long-term OAC should be instituted irrespective of the rhythm outcome.

Recommendation Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884298)

Recommendations for general concepts in rhythm control (see also Evidence Table 15)

![Recommendations for general concepts in rhythm control (see also Evidence Table 15)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt15.jpeg?Expires=1728478929&Signature=XwWRNIH1SwXJEPoI98WSrhux7KhesauETjuyKoAH0A806qPiqNbVgMX23VBFItFXaBb9RyMomhFNeDtPMFRFrUOoQ6O14mHSmvihEZ3yVAOM73PWeKXVbqOGpIjNiPSfPEENdRH4uEsl500By08eTq0UclyFF1rmUxykbTWbr5RBun0SaPYWiuhravTz0ar62-579NouJi6PdG5~PvQdk9IrF-HqTs0vbfrzTHnJHfW3YOJKRor8-LUZB6Yej2KrSl9nuBmEu3ywwk4ju7xOOXsBeJ~gm2oW5Lx0~NWWaWy6YhsHIRkZVooB4H6uxYLhHiwzLTk7F1oqrk6T3ShyzA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884298)

Recommendations for general concepts in rhythm control (see also Evidence Table 15)

![Recommendations for general concepts in rhythm control (see also Evidence Table 15)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt15.jpeg?Expires=1728478929&Signature=XwWRNIH1SwXJEPoI98WSrhux7KhesauETjuyKoAH0A806qPiqNbVgMX23VBFItFXaBb9RyMomhFNeDtPMFRFrUOoQ6O14mHSmvihEZ3yVAOM73PWeKXVbqOGpIjNiPSfPEENdRH4uEsl500By08eTq0UclyFF1rmUxykbTWbr5RBun0SaPYWiuhravTz0ar62-579NouJi6PdG5~PvQdk9IrF-HqTs0vbfrzTHnJHfW3YOJKRor8-LUZB6Yej2KrSl9nuBmEu3ywwk4ju7xOOXsBeJ~gm2oW5Lx0~NWWaWy6YhsHIRkZVooB4H6uxYLhHiwzLTk7F1oqrk6T3ShyzA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.2. Electrical cardioversion

Electrical cardioversion (ECV) can be safely applied in the elective and acute setting (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S18](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_) with sedation by intravenous midazolam, propofol, or etomidate.<sup><span class="xrefLink" id="jumplink-ehae176-B530"></span><a href="javascript:;" reveal-id="ehae176-B530" data-open="ehae176-B530" class="link link-ref link-reveal xref-bibr">530</a></sup> Structured and integrated care for patients with acute-onset AF at the emergency department is associated with better outcomes without compromising safety.<sup><span class="xrefLink" id="jumplink-ehae176-B531"></span><a href="javascript:;" reveal-id="ehae176-B531" data-open="ehae176-B531" class="link link-ref link-reveal xref-bibr">531</a></sup> Rates of major adverse clinical events after cardioversion are significantly lower with DOACs compared with warfarin.<sup><span class="xrefLink" id="jumplink-ehae176-B293"></span><a href="javascript:;" reveal-id="ehae176-B293" data-open="ehae176-B293" class="link link-ref link-reveal xref-bibr">293</a></sup>

Blood pressure monitoring and oximetry should be used routinely. Intravenous atropine or isoproterenol, or temporary transcutaneous pacing, should be available in case of post-cardioversion bradycardia. Biphasic defibrillators are standard because of their superior efficacy compared with monophasic defibrillators.<sup><span class="xrefLink" id="jumplink-ehae176-B532 ehae176-B533 ehae176-B534"></span><a href="javascript:;" reveal-id="ehae176-B532 ehae176-B533 ehae176-B534" data-open="ehae176-B532 ehae176-B533 ehae176-B534" class="link link-ref link-reveal xref-bibr">532–534</a></sup> There is no single optimal position for electrodes, with a meta-analysis of 10 RCTs showing no difference in sinus rhythm restoration comparing anterior-posterior with antero-lateral electrode positioning.<sup><span class="xrefLink" id="jumplink-ehae176-B535"></span><a href="javascript:;" reveal-id="ehae176-B535" data-open="ehae176-B535" class="link link-ref link-reveal xref-bibr">535</a></sup> Applying active compression to the defibrillation pads is associated with lower defibrillation thresholds, lower total energy delivery, fewer shocks for successful ECV, and higher success rates.<sup><span class="xrefLink" id="jumplink-ehae176-B536"></span><a href="javascript:;" reveal-id="ehae176-B536" data-open="ehae176-B536" class="link link-ref link-reveal xref-bibr">536</a></sup> A randomized trial showed that maximum fixed-energy shocks were more effective than low-escalating energy for ECV.<sup><span class="xrefLink" id="jumplink-ehae176-B537"></span><a href="javascript:;" reveal-id="ehae176-B537" data-open="ehae176-B537" class="link link-ref link-reveal xref-bibr">537</a></sup>

Immediate administration of vernakalant,<sup><span class="xrefLink" id="jumplink-ehae176-B538"></span><a href="javascript:;" reveal-id="ehae176-B538" data-open="ehae176-B538" class="link link-ref link-reveal xref-bibr">538</a></sup> or pre-treatment for 3–4 days with flecainide,<sup><span class="xrefLink" id="jumplink-ehae176-B539"></span><a href="javascript:;" reveal-id="ehae176-B539" data-open="ehae176-B539" class="link link-ref link-reveal xref-bibr">539</a>,<span class="xrefLink" id="jumplink-ehae176-B540"></span><a href="javascript:;" reveal-id="ehae176-B540" data-open="ehae176-B540" class="link link-ref link-reveal xref-bibr">540</a></sup> ibutilide,<sup><span class="xrefLink" id="jumplink-ehae176-B541"></span><a href="javascript:;" reveal-id="ehae176-B541" data-open="ehae176-B541" class="link link-ref link-reveal xref-bibr">541</a>,<span class="xrefLink" id="jumplink-ehae176-B542"></span><a href="javascript:;" reveal-id="ehae176-B542" data-open="ehae176-B542" class="link link-ref link-reveal xref-bibr">542</a></sup> propafenone,<sup><span class="xrefLink" id="jumplink-ehae176-B543"></span><a href="javascript:;" reveal-id="ehae176-B543" data-open="ehae176-B543" class="link link-ref link-reveal xref-bibr">543</a></sup> or amiodarone<sup><span class="xrefLink" id="jumplink-ehae176-B544 ehae176-B545 ehae176-B546"></span><a href="javascript:;" reveal-id="ehae176-B544 ehae176-B545 ehae176-B546" data-open="ehae176-B544 ehae176-B545 ehae176-B546" class="link link-ref link-reveal xref-bibr">544–546</a></sup> improves the rate of successful ECV and can facilitate long-term maintenance of sinus rhythm by preventing early recurrent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B547"></span><a href="javascript:;" reveal-id="ehae176-B547" data-open="ehae176-B547" class="link link-ref link-reveal xref-bibr">547</a></sup> A meta-analysis demonstrated that pre-treatment with amiodarone (200–800 mg/day for 1–6 weeks pre-cardioversion) and post-treatment (200 mg/day) significantly improved the restoration and maintenance of sinus rhythm after ECV of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B546"></span><a href="javascript:;" reveal-id="ehae176-B546" data-open="ehae176-B546" class="link link-ref link-reveal xref-bibr">546</a></sup>

In some cases of persistent AF there is no clear relationship between the arrhythmia and symptoms. In these cases, restoring sinus rhythm by ECV might serve to confirm the impact of arrhythmia on symptoms and/or on heart failure symptoms and signs. Such an approach might be useful to identify truly asymptomatic individuals, to assess the impact of AF on LV function in patients with HFrEF, and to distinguish AF-related symptoms from heart failure symptoms.

Recommendation Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884304)

Recommendations for electrical cardioversion of AF (see also Evidence Table 16)

![Recommendations for electrical cardioversion of AF (see also Evidence Table 16)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt16.jpeg?Expires=1728478929&Signature=DSaaO4Mdu67CEMNfNxKOKKNq9my3haJ3GQE5AC5V77XlLaeBC6EnojJF7vpmfHZwNeXJi8j4O1UbkhENp8qy2FJTbvE9R41BEQ3pnFGKmFFIrrJonkgqWxCFiMXjTQ0hj5D82uO9KzTDOHQGzzXNh4EMxerOm4yxc26zj6W4pDuxZzJNRG~LDCdNsXrt7SBAG0T0Weo775aMOW7LTBOf0Fny-QFP1iNpwoBDyTHIqEKZnu5N~3393hE7zwVRK9qDtHUVtDeaFxmvgIT9bYc52e8-uYG53DZWryi1OYvLo9uRRU0-Mmxud4NLttjQ3ohJvorTXSc~VXxul0CAMOgNpg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884304)

Recommendations for electrical cardioversion of AF (see also Evidence Table 16)

![Recommendations for electrical cardioversion of AF (see also Evidence Table 16)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt16.jpeg?Expires=1728478929&Signature=DSaaO4Mdu67CEMNfNxKOKKNq9my3haJ3GQE5AC5V77XlLaeBC6EnojJF7vpmfHZwNeXJi8j4O1UbkhENp8qy2FJTbvE9R41BEQ3pnFGKmFFIrrJonkgqWxCFiMXjTQ0hj5D82uO9KzTDOHQGzzXNh4EMxerOm4yxc26zj6W4pDuxZzJNRG~LDCdNsXrt7SBAG0T0Weo775aMOW7LTBOf0Fny-QFP1iNpwoBDyTHIqEKZnu5N~3393hE7zwVRK9qDtHUVtDeaFxmvgIT9bYc52e8-uYG53DZWryi1OYvLo9uRRU0-Mmxud4NLttjQ3ohJvorTXSc~VXxul0CAMOgNpg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.3. Pharmacological cardioversion

Pharmacological cardioversion to sinus rhythm is an elective procedure in haemodynamically stable patients. It is less effective than electrical cardioversion for restoration of sinus rhythm,<sup><span class="xrefLink" id="jumplink-ehae176-B549"></span><a href="javascript:;" reveal-id="ehae176-B549" data-open="ehae176-B549" class="link link-ref link-reveal xref-bibr">549</a></sup> with timing of cardioversion being a significant determinant of success.<sup><span class="xrefLink" id="jumplink-ehae176-B550"></span><a href="javascript:;" reveal-id="ehae176-B550" data-open="ehae176-B550" class="link link-ref link-reveal xref-bibr">550</a></sup> There are limited contemporary data on the true efficacy of pharmacological cardioversion, which are likely biased by the spontaneous restoration of sinus rhythm in 76%–83% of patients with recent-onset AF (10%–18% within the first 3 h, 55%–66% within 24 h, and 69% within 48 h).<sup><span class="xrefLink" id="jumplink-ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B10" data-open="ehae176-B10" class="link link-ref link-reveal xref-bibr">10</a>,<span class="xrefLink" id="jumplink-ehae176-B119"></span><a href="javascript:;" reveal-id="ehae176-B119" data-open="ehae176-B119" class="link link-ref link-reveal xref-bibr">119</a>,<span class="xrefLink" id="jumplink-ehae176-B445"></span><a href="javascript:;" reveal-id="ehae176-B445" data-open="ehae176-B445" class="link link-ref link-reveal xref-bibr">445</a>,<span class="xrefLink" id="jumplink-ehae176-B551 ehae176-B552 ehae176-B553 ehae176-B554 ehae176-B555"></span><a href="javascript:;" reveal-id="ehae176-B551 ehae176-B552 ehae176-B553 ehae176-B554 ehae176-B555" data-open="ehae176-B551 ehae176-B552 ehae176-B553 ehae176-B554 ehae176-B555" class="link link-ref link-reveal xref-bibr">551–555</a></sup>

The choice of a specific drug is based on the type and severity of concomitant heart disease (_[Table 13](javascript:;)_). A meta-analysis demonstrated that intravenous vernakalant and flecainide have the highest conversion rate within 4 h, possibly allowing discharge from the emergency department and reducing hospital admissions. Intravenous and oral formulations of Class IC antiarrhythmics (flecainide more so than propafenone) are superior regarding conversion rates within 12 h, while amiodarone efficacy is exhibited in a delayed fashion (within 24 h).<sup><span class="xrefLink" id="jumplink-ehae176-B556"></span><a href="javascript:;" reveal-id="ehae176-B556" data-open="ehae176-B556" class="link link-ref link-reveal xref-bibr">556</a></sup> Pharmacological cardioversion does not require fasting, sedation, or anaesthesia. Anticoagulation should be started or continued according to a formal (re-)assessment of thromboembolic risk.<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a>,<span class="xrefLink" id="jumplink-ehae176-B557 ehae176-B558 ehae176-B559"></span><a href="javascript:;" reveal-id="ehae176-B557 ehae176-B558 ehae176-B559" data-open="ehae176-B557 ehae176-B558 ehae176-B559" class="link link-ref link-reveal xref-bibr">557–559</a></sup>

Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884308)

Antiarrhythmic drugs for sinus rhythm restoration

| Drug .  | Administration route .  | Initial dosing .  | Subsequent dosing \[long-term approach\] .  | Acute success rate and time to sinus rhythm .  | Contraindications and precautions .  |
| --- | --- | --- | --- | --- | --- |
| Flecainide | Oral | 200–300 mg | \[long-term 50−150 mg twice daily\] | 50%–60% at 3 h and 75%–85% at 6–8 h (3–8 h) | 
- Should not be used in patients with severe structural or coronary artery disease, Brugada syndrome, or severe renal failure (CrCl <35 mL/min/1.73 m<sup>2</sup>).

- Prior documentation of safety and efficacy in an inpatient setting is recommended prior to pill-in-the-pocket use.

- An AVN-blocking agent should be administered to avoid 1:1 conduction if transformation to AFL.

- Drug infusion should be discontinued in case of QRS widening >25% or bundle branch block occurrence.

- Caution is needed in patients with sinus node disease and AVN dysfunction.

- Do NOT use for conversion of atrial flutter.


 |
| Intravenous | 1–2 mg/kg over 10 min || 52%–95% (Up to 6 h) |
| Propafenone | Oral | 450–600 mg | \[long-term 150-300 mg three times daily\] | 45%–55% at 3 h, 69%–78% at 8 h (3–8 h) |
| Intravenous | 1.5–2 mg/kg over 10 min || 43%–89% (Up to 6 h) |
| Amiodarone | Intravenous (/oral) | 300 mg intravenous over 30–60 min | 900-1200 mg intravenous over 24 hours (or 200 mg oral three times daily for 4 weeks).\[long-term 200 mg oral daily\] | 44% (8–12 h to several days) | 

- May cause phlebitis (use a large peripheral vein, avoid i.v. administration >24 h and use preferably volumetric pump).

- May cause hypotension, bradycardia/atrioventricular block, QT prolongation.

- Only if no other option in patients with hyperthyroidism (risk of thyrotoxicosis).

- Consider the broad range of drug interactions.


 |
| Ibutilide | Intravenous | 1 mg over 10 min (0.01 mg/kg if body weight <60 kg) | 1 mg over 10 min
(10–20 min after the initial dose) | 31%–51% (30–90 min) in AF
60–75% in AFL (60 min) | 

- Should be used in the setting of a cardiac care unit as it may cause QT prolongation and torsades de pointes.

- ECG monitoring for at least 4 h after administration to detect any proarrhythmic effects.

- Should not be used in patients with prolonged QT, severe LVH, or low LVEF.


 |
| Vernakalant | Intravenous | 3 mg/kg over 10 min (maximum 339 mg) | 2 mg/kg over 10 min
(10–15 min after the initial dose) (maximum 226 mg) | 50% within 10 min | 

- Should not be used in patients with arterial hypotension (SBP <100 mmHg), recent ACS (within 1 month), NYHA III or IV HF, QT prolongation or severe aortic stenosis.

- May cause arterial hypotension, QT prolongation, QRS widening, or non-sustained ventricular tachycardia.


 |

| Drug .  | Administration route .  | Initial dosing .  | Subsequent dosing \[long-term approach\] .  | Acute success rate and time to sinus rhythm .  | Contraindications and precautions .  |
| --- | --- | --- | --- | --- | --- |
| Flecainide | Oral | 200–300 mg | \[long-term 50−150 mg twice daily\] | 50%–60% at 3 h and 75%–85% at 6–8 h (3–8 h) | 
- Should not be used in patients with severe structural or coronary artery disease, Brugada syndrome, or severe renal failure (CrCl <35 mL/min/1.73 m<sup>2</sup>).

- Prior documentation of safety and efficacy in an inpatient setting is recommended prior to pill-in-the-pocket use.

- An AVN-blocking agent should be administered to avoid 1:1 conduction if transformation to AFL.

- Drug infusion should be discontinued in case of QRS widening >25% or bundle branch block occurrence.

- Caution is needed in patients with sinus node disease and AVN dysfunction.

- Do NOT use for conversion of atrial flutter.


 |
| Intravenous | 1–2 mg/kg over 10 min || 52%–95% (Up to 6 h) |
| Propafenone | Oral | 450–600 mg | \[long-term 150-300 mg three times daily\] | 45%–55% at 3 h, 69%–78% at 8 h (3–8 h) |
| Intravenous | 1.5–2 mg/kg over 10 min || 43%–89% (Up to 6 h) |
| Amiodarone | Intravenous (/oral) | 300 mg intravenous over 30–60 min | 900-1200 mg intravenous over 24 hours (or 200 mg oral three times daily for 4 weeks).\[long-term 200 mg oral daily\] | 44% (8–12 h to several days) | 

- May cause phlebitis (use a large peripheral vein, avoid i.v. administration >24 h and use preferably volumetric pump).

- May cause hypotension, bradycardia/atrioventricular block, QT prolongation.

- Only if no other option in patients with hyperthyroidism (risk of thyrotoxicosis).

- Consider the broad range of drug interactions.


 |
| Ibutilide | Intravenous | 1 mg over 10 min (0.01 mg/kg if body weight <60 kg) | 1 mg over 10 min
(10–20 min after the initial dose) | 31%–51% (30–90 min) in AF
60–75% in AFL (60 min) | 

- Should be used in the setting of a cardiac care unit as it may cause QT prolongation and torsades de pointes.

- ECG monitoring for at least 4 h after administration to detect any proarrhythmic effects.

- Should not be used in patients with prolonged QT, severe LVH, or low LVEF.


 |
| Vernakalant | Intravenous | 3 mg/kg over 10 min (maximum 339 mg) | 2 mg/kg over 10 min
(10–15 min after the initial dose) (maximum 226 mg) | 50% within 10 min | 

- Should not be used in patients with arterial hypotension (SBP <100 mmHg), recent ACS (within 1 month), NYHA III or IV HF, QT prolongation or severe aortic stenosis.

- May cause arterial hypotension, QT prolongation, QRS widening, or non-sustained ventricular tachycardia.


 |

ACS, acute coronary syndromes; AF, atrial fibrillation; AFL, atrial flutter; AVN, atrioventricular node; CrCl, creatinine clearance; ECG, electrocardiogram; HF, heart failure; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; QT, QT interval; SBP, systolic blood pressure. Long-term dosage for maintenance of sinus rhythm is indicated in \[square brackets\]. Long-term oral dosing for dronedarone is 400 mg twice daily, and for sotalol 80-160 mg twice daily.

© ESC 2024

Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884308)

Antiarrhythmic drugs for sinus rhythm restoration

| Drug .  | Administration route .  | Initial dosing .  | Subsequent dosing \[long-term approach\] .  | Acute success rate and time to sinus rhythm .  | Contraindications and precautions .  |
| --- | --- | --- | --- | --- | --- |
| Flecainide | Oral | 200–300 mg | \[long-term 50−150 mg twice daily\] | 50%–60% at 3 h and 75%–85% at 6–8 h (3–8 h) | 
- Should not be used in patients with severe structural or coronary artery disease, Brugada syndrome, or severe renal failure (CrCl <35 mL/min/1.73 m<sup>2</sup>).

- Prior documentation of safety and efficacy in an inpatient setting is recommended prior to pill-in-the-pocket use.

- An AVN-blocking agent should be administered to avoid 1:1 conduction if transformation to AFL.

- Drug infusion should be discontinued in case of QRS widening >25% or bundle branch block occurrence.

- Caution is needed in patients with sinus node disease and AVN dysfunction.

- Do NOT use for conversion of atrial flutter.


 |
| Intravenous | 1–2 mg/kg over 10 min || 52%–95% (Up to 6 h) |
| Propafenone | Oral | 450–600 mg | \[long-term 150-300 mg three times daily\] | 45%–55% at 3 h, 69%–78% at 8 h (3–8 h) |
| Intravenous | 1.5–2 mg/kg over 10 min || 43%–89% (Up to 6 h) |
| Amiodarone | Intravenous (/oral) | 300 mg intravenous over 30–60 min | 900-1200 mg intravenous over 24 hours (or 200 mg oral three times daily for 4 weeks).\[long-term 200 mg oral daily\] | 44% (8–12 h to several days) | 

- May cause phlebitis (use a large peripheral vein, avoid i.v. administration >24 h and use preferably volumetric pump).

- May cause hypotension, bradycardia/atrioventricular block, QT prolongation.

- Only if no other option in patients with hyperthyroidism (risk of thyrotoxicosis).

- Consider the broad range of drug interactions.


 |
| Ibutilide | Intravenous | 1 mg over 10 min (0.01 mg/kg if body weight <60 kg) | 1 mg over 10 min
(10–20 min after the initial dose) | 31%–51% (30–90 min) in AF
60–75% in AFL (60 min) | 

- Should be used in the setting of a cardiac care unit as it may cause QT prolongation and torsades de pointes.

- ECG monitoring for at least 4 h after administration to detect any proarrhythmic effects.

- Should not be used in patients with prolonged QT, severe LVH, or low LVEF.


 |
| Vernakalant | Intravenous | 3 mg/kg over 10 min (maximum 339 mg) | 2 mg/kg over 10 min
(10–15 min after the initial dose) (maximum 226 mg) | 50% within 10 min | 

- Should not be used in patients with arterial hypotension (SBP <100 mmHg), recent ACS (within 1 month), NYHA III or IV HF, QT prolongation or severe aortic stenosis.

- May cause arterial hypotension, QT prolongation, QRS widening, or non-sustained ventricular tachycardia.


 |

| Drug .  | Administration route .  | Initial dosing .  | Subsequent dosing \[long-term approach\] .  | Acute success rate and time to sinus rhythm .  | Contraindications and precautions .  |
| --- | --- | --- | --- | --- | --- |
| Flecainide | Oral | 200–300 mg | \[long-term 50−150 mg twice daily\] | 50%–60% at 3 h and 75%–85% at 6–8 h (3–8 h) | 
- Should not be used in patients with severe structural or coronary artery disease, Brugada syndrome, or severe renal failure (CrCl <35 mL/min/1.73 m<sup>2</sup>).

- Prior documentation of safety and efficacy in an inpatient setting is recommended prior to pill-in-the-pocket use.

- An AVN-blocking agent should be administered to avoid 1:1 conduction if transformation to AFL.

- Drug infusion should be discontinued in case of QRS widening >25% or bundle branch block occurrence.

- Caution is needed in patients with sinus node disease and AVN dysfunction.

- Do NOT use for conversion of atrial flutter.


 |
| Intravenous | 1–2 mg/kg over 10 min || 52%–95% (Up to 6 h) |
| Propafenone | Oral | 450–600 mg | \[long-term 150-300 mg three times daily\] | 45%–55% at 3 h, 69%–78% at 8 h (3–8 h) |
| Intravenous | 1.5–2 mg/kg over 10 min || 43%–89% (Up to 6 h) |
| Amiodarone | Intravenous (/oral) | 300 mg intravenous over 30–60 min | 900-1200 mg intravenous over 24 hours (or 200 mg oral three times daily for 4 weeks).\[long-term 200 mg oral daily\] | 44% (8–12 h to several days) | 

- May cause phlebitis (use a large peripheral vein, avoid i.v. administration >24 h and use preferably volumetric pump).

- May cause hypotension, bradycardia/atrioventricular block, QT prolongation.

- Only if no other option in patients with hyperthyroidism (risk of thyrotoxicosis).

- Consider the broad range of drug interactions.


 |
| Ibutilide | Intravenous | 1 mg over 10 min (0.01 mg/kg if body weight <60 kg) | 1 mg over 10 min
(10–20 min after the initial dose) | 31%–51% (30–90 min) in AF
60–75% in AFL (60 min) | 

- Should be used in the setting of a cardiac care unit as it may cause QT prolongation and torsades de pointes.

- ECG monitoring for at least 4 h after administration to detect any proarrhythmic effects.

- Should not be used in patients with prolonged QT, severe LVH, or low LVEF.


 |
| Vernakalant | Intravenous | 3 mg/kg over 10 min (maximum 339 mg) | 2 mg/kg over 10 min
(10–15 min after the initial dose) (maximum 226 mg) | 50% within 10 min | 

- Should not be used in patients with arterial hypotension (SBP <100 mmHg), recent ACS (within 1 month), NYHA III or IV HF, QT prolongation or severe aortic stenosis.

- May cause arterial hypotension, QT prolongation, QRS widening, or non-sustained ventricular tachycardia.


 |

ACS, acute coronary syndromes; AF, atrial fibrillation; AFL, atrial flutter; AVN, atrioventricular node; CrCl, creatinine clearance; ECG, electrocardiogram; HF, heart failure; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; QT, QT interval; SBP, systolic blood pressure. Long-term dosage for maintenance of sinus rhythm is indicated in \[square brackets\]. Long-term oral dosing for dronedarone is 400 mg twice daily, and for sotalol 80-160 mg twice daily.

© ESC 2024

A single self-administered oral dose of flecainide or propafenone (pill-in-the-pocket) is effective in symptomatic patients with infrequent and recent-onset paroxysmal AF. Safe implementation of this strategy requires patient screening to exclude sinus node dysfunction, atrioventricular conduction defects, or Brugada syndrome, as well as prior in-hospital validation of its efficacy and safety.<sup><span class="xrefLink" id="jumplink-ehae176-B560"></span><a href="javascript:;" reveal-id="ehae176-B560" data-open="ehae176-B560" class="link link-ref link-reveal xref-bibr">560</a></sup> An atrioventricular node-blocking drug should be instituted in patients treated with Class IC AADs to avoid 1:1 conduction if the rhythm transforms to AFL.<sup><span class="xrefLink" id="jumplink-ehae176-B561"></span><a href="javascript:;" reveal-id="ehae176-B561" data-open="ehae176-B561" class="link link-ref link-reveal xref-bibr">561</a></sup>

Recommendation Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884310)

Recommendations for pharmacological cardioversion of AF (see also Evidence Table 17)

![Recommendations for pharmacological cardioversion of AF (see also Evidence Table 17)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt17.jpeg?Expires=1728478929&Signature=dxyUlR7R1pMqSjh17L6J1KGLikcdkURLLL~FpzfMeL4k5CRpVeagskQ7e7XtRSV0LfXreBFDT3n5ly0gMGK9R-UDtjTfr9uztU62ZzvvWwoKc646a~WSIkaBweSOfXGBaUyJtnuGgGFCNnOdgyD7MiotTC5JuthHQh6HMGEcer76mLtAjbQRtxIEFbGf0PnRRoANqsB9mXzeWBhUD1zQSgyndCLCv9bG3xY3XUAZpO9tan~RMVkn7bRfrhGDz5I0p955vpv5cWJrnftqu7q1ng8WYdbx9-gD-GHQ9XfUbrWnLO~npc4~-oDcw2J~hi4QcpSDdgc92UTxl91m5Tp6hw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884310)

Recommendations for pharmacological cardioversion of AF (see also Evidence Table 17)

![Recommendations for pharmacological cardioversion of AF (see also Evidence Table 17)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt17.jpeg?Expires=1728478929&Signature=dxyUlR7R1pMqSjh17L6J1KGLikcdkURLLL~FpzfMeL4k5CRpVeagskQ7e7XtRSV0LfXreBFDT3n5ly0gMGK9R-UDtjTfr9uztU62ZzvvWwoKc646a~WSIkaBweSOfXGBaUyJtnuGgGFCNnOdgyD7MiotTC5JuthHQh6HMGEcer76mLtAjbQRtxIEFbGf0PnRRoANqsB9mXzeWBhUD1zQSgyndCLCv9bG3xY3XUAZpO9tan~RMVkn7bRfrhGDz5I0p955vpv5cWJrnftqu7q1ng8WYdbx9-gD-GHQ9XfUbrWnLO~npc4~-oDcw2J~hi4QcpSDdgc92UTxl91m5Tp6hw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.4. Antiarrhythmic drugs

The aims of long-term rhythm control are to maintain sinus rhythm, improve quality of life, slow the progression of AF, and potentially reduce morbidity related to AF episodes (see [Supplementary data online, Additional Evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  _[Table S19](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B17" data-open="ehae176-B17" class="link link-ref link-reveal xref-bibr">17</a>,<span class="xrefLink" id="jumplink-ehae176-B445"></span><a href="javascript:;" reveal-id="ehae176-B445" data-open="ehae176-B445" class="link link-ref link-reveal xref-bibr">445</a>,<span class="xrefLink" id="jumplink-ehae176-B574"></span><a href="javascript:;" reveal-id="ehae176-B574" data-open="ehae176-B574" class="link link-ref link-reveal xref-bibr">574</a>,<span class="xrefLink" id="jumplink-ehae176-B575"></span><a href="javascript:;" reveal-id="ehae176-B575" data-open="ehae176-B575" class="link link-ref link-reveal xref-bibr">575</a></sup> Antiarrhythmic drugs do not eliminate recurrences of AF, but in patients with paroxysmal or persistent AF, a recurrence is not equivalent to treatment failure if episodes are less frequent, briefer, or less symptomatic. Antiarrhythmic drugs also have a role for long-term rhythm control in AF patients that are considered ineligible or unwilling to undergo catheter or surgical ablation.

Before starting AAD treatment, reversible triggers should be identified and underlying comorbidities treated to reduce the arrhythmogenic substrate, prevent progression of AF, and facilitate maintenance of sinus rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B39"></span><a href="javascript:;" reveal-id="ehae176-B39" data-open="ehae176-B39" class="link link-ref link-reveal xref-bibr">39</a>,<span class="xrefLink" id="jumplink-ehae176-B128"></span><a href="javascript:;" reveal-id="ehae176-B128" data-open="ehae176-B128" class="link link-ref link-reveal xref-bibr">128</a></sup> The RACE 3 trial, including patients with early persistent AF and mild-to-moderate heart failure (predominantly HFpEF and HFmrEF), showed that targeted therapy of underlying conditions improved sinus rhythm maintenance at 1 year (75% vs. 63% as compared with standard care).<sup><span class="xrefLink" id="jumplink-ehae176-B39"></span><a href="javascript:;" reveal-id="ehae176-B39" data-open="ehae176-B39" class="link link-ref link-reveal xref-bibr">39</a></sup> The selection of an AAD for long-term rhythm control requires careful evaluation that takes into account AF type, patient parameters, and safety profile.<sup><span class="xrefLink" id="jumplink-ehae176-B445"></span><a href="javascript:;" reveal-id="ehae176-B445" data-open="ehae176-B445" class="link link-ref link-reveal xref-bibr">445</a></sup> It also includes shared decision-making, balancing the benefit/risk ratio of AADs in comparison with other strategies. Notably, recent evidence has shown that careful institution of AADs can be performed safely.<sup><span class="xrefLink" id="jumplink-ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B17" data-open="ehae176-B17" class="link link-ref link-reveal xref-bibr">17</a></sup>

The long-term effectiveness of AADs is limited. In a meta-analysis of 59 RCTs, AADs reduced AF recurrences by 20%–50% compared with no treatment, placebo, or drugs for rate control.<sup><span class="xrefLink" id="jumplink-ehae176-B576"></span><a href="javascript:;" reveal-id="ehae176-B576" data-open="ehae176-B576" class="link link-ref link-reveal xref-bibr">576</a>,<span class="xrefLink" id="jumplink-ehae176-B577"></span><a href="javascript:;" reveal-id="ehae176-B577" data-open="ehae176-B577" class="link link-ref link-reveal xref-bibr">577</a></sup> When one AAD fails to reduce AF recurrences, a clinically acceptable response may be achieved with another drug, particularly if from a different class.<sup><span class="xrefLink" id="jumplink-ehae176-B578"></span><a href="javascript:;" reveal-id="ehae176-B578" data-open="ehae176-B578" class="link link-ref link-reveal xref-bibr">578</a></sup> Combinations of AADs are not recommended. The data available suggest that AADs do not produce an appreciable effect on mortality or other cardiovascular complications with the exception of increased mortality signals for sotalol<sup><span class="xrefLink" id="jumplink-ehae176-B574"></span><a href="javascript:;" reveal-id="ehae176-B574" data-open="ehae176-B574" class="link link-ref link-reveal xref-bibr">574</a>,<span class="xrefLink" id="jumplink-ehae176-B579"></span><a href="javascript:;" reveal-id="ehae176-B579" data-open="ehae176-B579" class="link link-ref link-reveal xref-bibr">579</a>,<span class="xrefLink" id="jumplink-ehae176-B580"></span><a href="javascript:;" reveal-id="ehae176-B580" data-open="ehae176-B580" class="link link-ref link-reveal xref-bibr">580</a></sup> and amiodarone.<sup><span class="xrefLink" id="jumplink-ehae176-B581"></span><a href="javascript:;" reveal-id="ehae176-B581" data-open="ehae176-B581" class="link link-ref link-reveal xref-bibr">581</a></sup> In contrast, use of AADs within a rhythm control strategy can be associated with reduction of morbidity and mortality in selected patients.<sup><span class="xrefLink" id="jumplink-ehae176-B582"></span><a href="javascript:;" reveal-id="ehae176-B582" data-open="ehae176-B582" class="link link-ref link-reveal xref-bibr">582</a></sup>

All AADs may produce serious cardiac (proarrhythmia, negative inotropism, hypotension) and extracardiac adverse effects (organ toxicity, predominantly amiodarone). Drug safety, rather than efficacy, should determine the choice of drug. The risk of proarrhythmia increases in patients with structural heart disease. Suggested doses for long-term oral AAD are presented in _[Table 13](javascript:;)_.<sup><span class="xrefLink" id="jumplink-ehae176-B577"></span><a href="javascript:;" reveal-id="ehae176-B577" data-open="ehae176-B577" class="link link-ref link-reveal xref-bibr">577</a>,<span class="xrefLink" id="jumplink-ehae176-B583"></span><a href="javascript:;" reveal-id="ehae176-B583" data-open="ehae176-B583" class="link link-ref link-reveal xref-bibr">583</a>,<span class="xrefLink" id="jumplink-ehae176-B584"></span><a href="javascript:;" reveal-id="ehae176-B584" data-open="ehae176-B584" class="link link-ref link-reveal xref-bibr">584</a></sup>

Recommendation Table 18

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884316)

Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm (see also Evidence Table 18)

![Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm (see also Evidence Table 18)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt18.jpeg?Expires=1728478929&Signature=o-dNSa11BQdncRdoxDHBqh2DadckAxgfvNW~7mhxEC07eeYopPjT9MxqeSKc1teTBaro95ulhF5qVu6cFRTKvfYRIhwSkzPpE6j0Qe5nmlTR2FyE5-Q20kTFTD1Ku4MDBqWjhdUN-Zr9M0Ku5NrqZFw-xKQXM3VOGv9mQtCr88xV4RutU9z0kwYZk8Yxk4yEn8XUMo5vwUD1pzod5rzuvjzC61sRdYw38cv1zoX7-BHCg2uAd5wPcGSaPooAJwqrq8UV7~-Dh~KdpMnMuhnctGRbm7S4nXF2LMdLJKHj820WvpWQrzSRJvHuhC4h8kq7j5HnF-BKRRafecLQ9FCcwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 18

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884316)

Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm (see also Evidence Table 18)

![Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm (see also Evidence Table 18)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt18.jpeg?Expires=1728478929&Signature=o-dNSa11BQdncRdoxDHBqh2DadckAxgfvNW~7mhxEC07eeYopPjT9MxqeSKc1teTBaro95ulhF5qVu6cFRTKvfYRIhwSkzPpE6j0Qe5nmlTR2FyE5-Q20kTFTD1Ku4MDBqWjhdUN-Zr9M0Ku5NrqZFw-xKQXM3VOGv9mQtCr88xV4RutU9z0kwYZk8Yxk4yEn8XUMo5vwUD1pzod5rzuvjzC61sRdYw38cv1zoX7-BHCg2uAd5wPcGSaPooAJwqrq8UV7~-Dh~KdpMnMuhnctGRbm7S4nXF2LMdLJKHj820WvpWQrzSRJvHuhC4h8kq7j5HnF-BKRRafecLQ9FCcwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.5. Catheter ablation

Catheter ablation prevents AF recurrences, reduces AF burden, and improves quality of life in symptomatic paroxysmal or persistent AF where the patient is intolerant or does not respond to AAD.<sup><span class="xrefLink" id="jumplink-ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509"></span><a href="javascript:;" reveal-id="ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509" data-open="ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509" class="link link-ref link-reveal xref-bibr">503–509</a></sup> Multiple RCTs have provided evidence in favour of catheter ablation as a first-line approach for rhythm control in patients with paroxysmal AF, with a similar risk of adverse events as compared with initial AAD treatment (see [Supplementary data online, Additional Evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  _[Table S20](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B15"></span><a href="javascript:;" reveal-id="ehae176-B15" data-open="ehae176-B15" class="link link-ref link-reveal xref-bibr">15</a>,<span class="xrefLink" id="jumplink-ehae176-B16"></span><a href="javascript:;" reveal-id="ehae176-B16" data-open="ehae176-B16" class="link link-ref link-reveal xref-bibr">16</a>,<span class="xrefLink" id="jumplink-ehae176-B591 ehae176-B592 ehae176-B593 ehae176-B594"></span><a href="javascript:;" reveal-id="ehae176-B591 ehae176-B592 ehae176-B593 ehae176-B594" data-open="ehae176-B591 ehae176-B592 ehae176-B593 ehae176-B594" class="link link-ref link-reveal xref-bibr">591–594</a></sup> In contrast, it is not clear whether first-line ablation is superior to drug therapy in persistent AF. Catheter ablation may also have a role in patients with symptoms due to prolonged pauses upon AF termination, where non-randomized data have shown improved symptoms, and avoidance of pacemaker implantation.<sup><span class="xrefLink" id="jumplink-ehae176-B595 ehae176-B596 ehae176-B597 ehae176-B598"></span><a href="javascript:;" reveal-id="ehae176-B595 ehae176-B596 ehae176-B597 ehae176-B598" data-open="ehae176-B595 ehae176-B596 ehae176-B597 ehae176-B598" class="link link-ref link-reveal xref-bibr">595–598</a></sup>

Pulmonary vein isolation (PVI) remains the cornerstone of AF catheter ablation,<sup><span class="xrefLink" id="jumplink-ehae176-B503"></span><a href="javascript:;" reveal-id="ehae176-B503" data-open="ehae176-B503" class="link link-ref link-reveal xref-bibr">503</a>,<span class="xrefLink" id="jumplink-ehae176-B508"></span><a href="javascript:;" reveal-id="ehae176-B508" data-open="ehae176-B508" class="link link-ref link-reveal xref-bibr">508</a>,<span class="xrefLink" id="jumplink-ehae176-B593"></span><a href="javascript:;" reveal-id="ehae176-B593" data-open="ehae176-B593" class="link link-ref link-reveal xref-bibr">593</a>,<span class="xrefLink" id="jumplink-ehae176-B599"></span><a href="javascript:;" reveal-id="ehae176-B599" data-open="ehae176-B599" class="link link-ref link-reveal xref-bibr">599</a></sup> but the optimal ablation strategy has not been clarified in the non-paroxysmal AF population.<sup><span class="xrefLink" id="jumplink-ehae176-B600"></span><a href="javascript:;" reveal-id="ehae176-B600" data-open="ehae176-B600" class="link link-ref link-reveal xref-bibr">600</a></sup> New technologies are emerging, such as pulsed field ablation, in which high-amplitude electrical pulses are used to ablate the myocardium by electroporation with high tissue specificity. In a single-blind RCT of 607 patients, pulsed field ablation was non-inferior for efficacy and safety endpoints compared with conventional radiofrequency or cryoballoon ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B601"></span><a href="javascript:;" reveal-id="ehae176-B601" data-open="ehae176-B601" class="link link-ref link-reveal xref-bibr">601</a></sup> Regarding timing of ablation, a small RCT found that delaying catheter ablation in patients with paroxysmal or persistent AF by 12 months (while on optimized medical therapy) did not impact on arrhythmia-free survival compared with ablation within 1 month.<sup><span class="xrefLink" id="jumplink-ehae176-B602"></span><a href="javascript:;" reveal-id="ehae176-B602" data-open="ehae176-B602" class="link link-ref link-reveal xref-bibr">602</a></sup>

As with any type of rhythm control, many patients in clinical practice will not be suitable for catheter ablation due to factors that reduce the likelihood of a positive response, such as left atrial dilatation. Definitive evidence that supports the prognostic benefit of catheter ablation is needed before this invasive treatment can be considered for truly asymptomatic patients. As previously noted, the CABANA trial did not confirm a benefit of catheter ablation compared with medical therapy, although high crossover rates and low event rates may have diluted the treatment effect.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a></sup> Therefore, only highly selected asymptomatic patients could be candidates for catheter ablation, and only after detailed discussion of associated risks and potential benefit of delaying AF progression.<sup><span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a>,<span class="xrefLink" id="jumplink-ehae176-B603"></span><a href="javascript:;" reveal-id="ehae176-B603" data-open="ehae176-B603" class="link link-ref link-reveal xref-bibr">603</a></sup> Randomized trials have shown that AF catheter ablation in patients with HFrEF significantly reduces arrhythmia recurrence and increases ejection fraction, with improvement in clinical outcomes and mortality also observed in selected patients.<sup><span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a>,<span class="xrefLink" id="jumplink-ehae176-B513"></span><a href="javascript:;" reveal-id="ehae176-B513" data-open="ehae176-B513" class="link link-ref link-reveal xref-bibr">513</a>,<span class="xrefLink" id="jumplink-ehae176-B514"></span><a href="javascript:;" reveal-id="ehae176-B514" data-open="ehae176-B514" class="link link-ref link-reveal xref-bibr">514</a>,<span class="xrefLink" id="jumplink-ehae176-B604 ehae176-B605 ehae176-B606 ehae176-B607 ehae176-B608 ehae176-B609 ehae176-B610 ehae176-B611 ehae176-B612"></span><a href="javascript:;" reveal-id="ehae176-B604 ehae176-B605 ehae176-B606 ehae176-B607 ehae176-B608 ehae176-B609 ehae176-B610 ehae176-B611 ehae176-B612" data-open="ehae176-B604 ehae176-B605 ehae176-B606 ehae176-B607 ehae176-B608 ehae176-B609 ehae176-B610 ehae176-B611 ehae176-B612" class="link link-ref link-reveal xref-bibr">604–612</a></sup> Several characteristics, including but not limited to AF type, left atrial dilatation, and the presence of atrial and/or ventricular fibrosis, could refine patient selection to maximize outcome benefit from AF catheter ablation in patients with HFrEF.<sup><span class="xrefLink" id="jumplink-ehae176-B604"></span><a href="javascript:;" reveal-id="ehae176-B604" data-open="ehae176-B604" class="link link-ref link-reveal xref-bibr">604</a>,<span class="xrefLink" id="jumplink-ehae176-B608"></span><a href="javascript:;" reveal-id="ehae176-B608" data-open="ehae176-B608" class="link link-ref link-reveal xref-bibr">608</a>,<span class="xrefLink" id="jumplink-ehae176-B613 ehae176-B614 ehae176-B615 ehae176-B616 ehae176-B617"></span><a href="javascript:;" reveal-id="ehae176-B613 ehae176-B614 ehae176-B615 ehae176-B616 ehae176-B617" data-open="ehae176-B613 ehae176-B614 ehae176-B615 ehae176-B616 ehae176-B617" class="link link-ref link-reveal xref-bibr">613–617</a></sup> The prognostic value of catheter ablation in patients with HFpEF is less well established than for HFrEF.<sup><span class="xrefLink" id="jumplink-ehae176-B617 ehae176-B618 ehae176-B619 ehae176-B620 ehae176-B621 ehae176-B622 ehae176-B623 ehae176-B624 ehae176-B625 ehae176-B626"></span><a href="javascript:;" reveal-id="ehae176-B617 ehae176-B618 ehae176-B619 ehae176-B620 ehae176-B621 ehae176-B622 ehae176-B623 ehae176-B624 ehae176-B625 ehae176-B626" data-open="ehae176-B617 ehae176-B618 ehae176-B619 ehae176-B620 ehae176-B621 ehae176-B622 ehae176-B623 ehae176-B624 ehae176-B625 ehae176-B626" class="link link-ref link-reveal xref-bibr">617–626</a></sup>

Recent registries and trials report varying rates of peri-procedural serious adverse events associated with catheter ablation (2.9%–7.2%) with a very low 30 day mortality rate (<0.1%). Operator experience and procedural volume at the ablation centre are critical, since they are associated with complication rates and 30 day mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B627 ehae176-B628 ehae176-B629 ehae176-B630 ehae176-B631"></span><a href="javascript:;" reveal-id="ehae176-B627 ehae176-B628 ehae176-B629 ehae176-B630 ehae176-B631" data-open="ehae176-B627 ehae176-B628 ehae176-B629 ehae176-B630 ehae176-B631" class="link link-ref link-reveal xref-bibr">627–631</a></sup>

Intermittent rhythm monitoring has typically been used to detect AF relapses following catheter ablation. Recent technology developments such as smartwatch or smartphone photoplethysmography and wearable patches may have an emerging role in post-ablation monitoring.<sup><span class="xrefLink" id="jumplink-ehae176-B632"></span><a href="javascript:;" reveal-id="ehae176-B632" data-open="ehae176-B632" class="link link-ref link-reveal xref-bibr">632</a>,<span class="xrefLink" id="jumplink-ehae176-B633"></span><a href="javascript:;" reveal-id="ehae176-B633" data-open="ehae176-B633" class="link link-ref link-reveal xref-bibr">633</a></sup> In addition, implantable loop recorders have been used to quantify AF burden before and after ablation as an additional endpoint beyond binary AF elimination.<sup><span class="xrefLink" id="jumplink-ehae176-B634"></span><a href="javascript:;" reveal-id="ehae176-B634" data-open="ehae176-B634" class="link link-ref link-reveal xref-bibr">634</a></sup> Management of arrhythmia recurrence post-ablation is an informed, shared decision-making process driven by available options for symptom control. In the post-AF ablation context, there is data supporting a role for AAD continuation or re-initiation, even for previously ineffective drugs.<sup><span class="xrefLink" id="jumplink-ehae176-B635"></span><a href="javascript:;" reveal-id="ehae176-B635" data-open="ehae176-B635" class="link link-ref link-reveal xref-bibr">635</a></sup> A short-term AAD treatment (2–3 months) following ablation reduces early recurrences of AF,<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a>,<span class="xrefLink" id="jumplink-ehae176-B635 ehae176-B636 ehae176-B637 ehae176-B638 ehae176-B639"></span><a href="javascript:;" reveal-id="ehae176-B635 ehae176-B636 ehae176-B637 ehae176-B638 ehae176-B639" data-open="ehae176-B635 ehae176-B636 ehae176-B637 ehae176-B638 ehae176-B639" class="link link-ref link-reveal xref-bibr">635–639</a></sup> but does not affect late recurrences<sup><span class="xrefLink" id="jumplink-ehae176-B636"></span><a href="javascript:;" reveal-id="ehae176-B636" data-open="ehae176-B636" class="link link-ref link-reveal xref-bibr">636</a>,<span class="xrefLink" id="jumplink-ehae176-B637"></span><a href="javascript:;" reveal-id="ehae176-B637" data-open="ehae176-B637" class="link link-ref link-reveal xref-bibr">637</a>,<span class="xrefLink" id="jumplink-ehae176-B640 ehae176-B641 ehae176-B642"></span><a href="javascript:;" reveal-id="ehae176-B640 ehae176-B641 ehae176-B642" data-open="ehae176-B640 ehae176-B641 ehae176-B642" class="link link-ref link-reveal xref-bibr">640–642</a></sup> or 1 year clinical outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B642"></span><a href="javascript:;" reveal-id="ehae176-B642" data-open="ehae176-B642" class="link link-ref link-reveal xref-bibr">642</a></sup> Repeat PVI should be offered in patients with AF recurrence if symptom improvement was demonstrated after the first ablation, with shared decision-making and clear goals of treatment.<sup><span class="xrefLink" id="jumplink-ehae176-B643 ehae176-B644 ehae176-B645"></span><a href="javascript:;" reveal-id="ehae176-B643 ehae176-B644 ehae176-B645" data-open="ehae176-B643 ehae176-B644 ehae176-B645" class="link link-ref link-reveal xref-bibr">643–645</a></sup>

Recommendation Table 19

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884323)

Recommendations for catheter ablation of AF (see also Evidence Table 19)

![Recommendations for catheter ablation of AF (see also Evidence Table 19)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt19.jpeg?Expires=1728478929&Signature=l5a4SPCgi9wF7s1DGLVqfYewBV22PEaBjLM6XxZAlwHcYzpHgnc-1L1wzwVR8IINQM-7E5b-Cw4HRNGXZuiE7mSlnATJbEO--SZdyMZzp3Y-MAtmYPJ9X8HL0cYfEOs4BXkV4hQiLcA6OkcDhRF0uRSq~hZjLj7Qne43qhcaWVLGAojY5KIQR2pve2vebmTLYUXK-UFu7cxiJmUy2JnbQN~doHIADCUNQR0pdfQsfvMKgcBppzpyDXBLi4uhrv1fEXyzw9q81wI97UsYhh4nj1c3VcdVXN6mEO3kFXP6Kexu5aUmBtIC8vCUqeVj4Vf7YEAX9HFAU0oi6vWwS1NjSQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 19

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884323)

Recommendations for catheter ablation of AF (see also Evidence Table 19)

![Recommendations for catheter ablation of AF (see also Evidence Table 19)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt19.jpeg?Expires=1728478929&Signature=l5a4SPCgi9wF7s1DGLVqfYewBV22PEaBjLM6XxZAlwHcYzpHgnc-1L1wzwVR8IINQM-7E5b-Cw4HRNGXZuiE7mSlnATJbEO--SZdyMZzp3Y-MAtmYPJ9X8HL0cYfEOs4BXkV4hQiLcA6OkcDhRF0uRSq~hZjLj7Qne43qhcaWVLGAojY5KIQR2pve2vebmTLYUXK-UFu7cxiJmUy2JnbQN~doHIADCUNQR0pdfQsfvMKgcBppzpyDXBLi4uhrv1fEXyzw9q81wI97UsYhh4nj1c3VcdVXN6mEO3kFXP6Kexu5aUmBtIC8vCUqeVj4Vf7YEAX9HFAU0oi6vWwS1NjSQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.6. Anticoagulation in patients undergoing catheter ablation

The presence of left atrial thrombus is a contraindication to catheter-based AF ablation due to the risk of thrombus dislodgement leading to ischaemic stroke. Patients planned for catheter ablation of AF with an increased risk of thromboembolism should be on OAC for at least 3 full weeks prior to the procedure.<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a>,<span class="xrefLink" id="jumplink-ehae176-B647"></span><a href="javascript:;" reveal-id="ehae176-B647" data-open="ehae176-B647" class="link link-ref link-reveal xref-bibr">647</a></sup>

There is a wide range in practice for visualization of intra-atrial thrombi prior to catheter ablation, including TOE, intracardiac echocardiography, or delayed phase cardiac computed tomography (CT).<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a>,<span class="xrefLink" id="jumplink-ehae176-B648"></span><a href="javascript:;" reveal-id="ehae176-B648" data-open="ehae176-B648" class="link link-ref link-reveal xref-bibr">648</a></sup> The prevalence of left atrial thrombus was 1.3% and 2.7% in two meta-analyses of observational studies in patients planned for catheter ablation of AF on adequate OAC.<sup><span class="xrefLink" id="jumplink-ehae176-B649"></span><a href="javascript:;" reveal-id="ehae176-B649" data-open="ehae176-B649" class="link link-ref link-reveal xref-bibr">649</a>,<span class="xrefLink" id="jumplink-ehae176-B650"></span><a href="javascript:;" reveal-id="ehae176-B650" data-open="ehae176-B650" class="link link-ref link-reveal xref-bibr">650</a></sup> The prevalence of left atrial thrombus was higher in patients with elevated stroke risk scores, and in patients with non-paroxysmal compared with paroxysmal AF.<sup><span class="xrefLink" id="jumplink-ehae176-B650"></span><a href="javascript:;" reveal-id="ehae176-B650" data-open="ehae176-B650" class="link link-ref link-reveal xref-bibr">650</a></sup> In addition, several patient subgroups with AF have increased risk of ischaemic stroke and intracardiac thrombus even if treated with adequate anticoagulation, including those with cardiac amyloidosis, rheumatic heart disease, and hypertrophic cardiomyopathy (HCM). Cardiac imaging before catheter ablation should be considered in these high-risk patient groups regardless of preceding effective OAC. Observational studies suggest that patients with a low thromboembolic risk profile may be managed without visualization of the LAA,<sup><span class="xrefLink" id="jumplink-ehae176-B651 ehae176-B652 ehae176-B653"></span><a href="javascript:;" reveal-id="ehae176-B651 ehae176-B652 ehae176-B653" data-open="ehae176-B651 ehae176-B652 ehae176-B653" class="link link-ref link-reveal xref-bibr">651–653</a></sup> but no RCTs have been performed (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S21](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

For patients who have been anticoagulated prior to the ablation procedure it is recommended to avoid interruption of OAC (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S22](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B654 ehae176-B655 ehae176-B656"></span><a href="javascript:;" reveal-id="ehae176-B654 ehae176-B655 ehae176-B656" data-open="ehae176-B654 ehae176-B655 ehae176-B656" class="link link-ref link-reveal xref-bibr">654–656</a></sup> Patients with interrupted OAC showed an increase in silent stroke detected by brain magnetic resonance imaging (MRI) as compared with those with uninterrupted OAC.<sup><span class="xrefLink" id="jumplink-ehae176-B657 ehae176-B658 ehae176-B659"></span><a href="javascript:;" reveal-id="ehae176-B657 ehae176-B658 ehae176-B659" data-open="ehae176-B657 ehae176-B658 ehae176-B659" class="link link-ref link-reveal xref-bibr">657–659</a></sup> In a true uninterrupted DOAC strategy for once-daily dosing, a pre-procedural shift to evening intake might be considered to mitigate bleeding risk. Randomized trials show comparable safety and efficacy with minimally interrupted OAC (withholding the morning DOAC dose on the day of the procedure) and a totally uninterrupted peri-ablation OAC strategy.<sup><span class="xrefLink" id="jumplink-ehae176-B655"></span><a href="javascript:;" reveal-id="ehae176-B655" data-open="ehae176-B655" class="link link-ref link-reveal xref-bibr">655</a></sup>

Anticoagulation with heparin during AF ablation is common practice.<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a></sup> Post-ablation DOACs should be continued as per the dosing regimen when haemostasis has been achieved.<sup><span class="xrefLink" id="jumplink-ehae176-B335"></span><a href="javascript:;" reveal-id="ehae176-B335" data-open="ehae176-B335" class="link link-ref link-reveal xref-bibr">335</a>,<span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a>,<span class="xrefLink" id="jumplink-ehae176-B647"></span><a href="javascript:;" reveal-id="ehae176-B647" data-open="ehae176-B647" class="link link-ref link-reveal xref-bibr">647</a></sup> All patients should be kept on an OAC for at least 2 months after an AF ablation procedure irrespective of estimated thromboembolic risk (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S23](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B647"></span><a href="javascript:;" reveal-id="ehae176-B647" data-open="ehae176-B647" class="link link-ref link-reveal xref-bibr">647</a></sup> Meta-analyses of observational studies have tried to assess the safety of stopping OAC treatment after catheter ablation for AF, but the results have been heterogenous.<sup><span class="xrefLink" id="jumplink-ehae176-B660 ehae176-B661 ehae176-B662 ehae176-B663"></span><a href="javascript:;" reveal-id="ehae176-B660 ehae176-B661 ehae176-B662 ehae176-B663" data-open="ehae176-B660 ehae176-B661 ehae176-B662 ehae176-B663" class="link link-ref link-reveal xref-bibr">660–663</a></sup> Until the completion of relevant RCTs (e.g. NCT02168829), it is recommended to continue OAC therapy post-AF ablation according to the patient's CHA<sub>2</sub>DS<sub>2</sub>\-VA score and not the perceived success of the ablation procedure.<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a></sup>

Recommendation Table 20

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884329)

Recommendations for anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20)

![Recommendations for anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt20.jpeg?Expires=1728478929&Signature=IxAwZumdINE4wvbOHuDdXWx-qc~4IzEW9M~MSG375NyEUgQTcyPPFcW7fOLw0b7Hq2b3cIrO50WaitRpFJEk1Cl-hoka6y2BG7OVVuK3kclsy-RE16XxBSudo~ylWABoTDQ7msXQIkWBg6jpNQM40cFe9qTO24shs~7cIvmRAi218ec8~1b9h9vTrid73xSGovkxVtSPTsMUkvxf1qGIvgMaF7k5Tkk2RXBGjJVGH7oPWiOct~LqI6L6GpTa3wJ8WcZraHPV8N8F9UaWG0sOFn6LAZWo~RMzHU3FUxhw2tzH5EhDb6nWgbcReiRQdVK0XqzmTjRKOLK1iSTPf07QUg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 20

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884329)

Recommendations for anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20)

![Recommendations for anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt20.jpeg?Expires=1728478929&Signature=IxAwZumdINE4wvbOHuDdXWx-qc~4IzEW9M~MSG375NyEUgQTcyPPFcW7fOLw0b7Hq2b3cIrO50WaitRpFJEk1Cl-hoka6y2BG7OVVuK3kclsy-RE16XxBSudo~ylWABoTDQ7msXQIkWBg6jpNQM40cFe9qTO24shs~7cIvmRAi218ec8~1b9h9vTrid73xSGovkxVtSPTsMUkvxf1qGIvgMaF7k5Tkk2RXBGjJVGH7oPWiOct~LqI6L6GpTa3wJ8WcZraHPV8N8F9UaWG0sOFn6LAZWo~RMzHU3FUxhw2tzH5EhDb6nWgbcReiRQdVK0XqzmTjRKOLK1iSTPf07QUg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.7. Endoscopic and hybrid AF ablation

Minimally invasive surgical AF ablation can be performed via a thoracoscopic approach or a subxiphoid approach. The term endoscopic covers both strategies. Hybrid ablation approaches have been developed where endoscopic epicardial ablation on the beating heart is performed in combination with endocardial catheter ablation, either in a simultaneous or sequential procedure. The rationale for combining an endocardial with an epicardial approach is that a more effective transmural ablation strategy can be pursued.<sup><span class="xrefLink" id="jumplink-ehae176-B666"></span><a href="javascript:;" reveal-id="ehae176-B666" data-open="ehae176-B666" class="link link-ref link-reveal xref-bibr">666</a>,<span class="xrefLink" id="jumplink-ehae176-B667"></span><a href="javascript:;" reveal-id="ehae176-B667" data-open="ehae176-B667" class="link link-ref link-reveal xref-bibr">667</a></sup>

For paroxysmal AF, an endoscopic or hybrid ablation approach may be considered after a failed percutaneous catheter ablation strategy.<sup><span class="xrefLink" id="jumplink-ehae176-B668 ehae176-B669 ehae176-B670"></span><a href="javascript:;" reveal-id="ehae176-B668 ehae176-B669 ehae176-B670" data-open="ehae176-B668 ehae176-B669 ehae176-B670" class="link link-ref link-reveal xref-bibr">668–670</a></sup> Long-term follow-up of the FAST RCT (mean of 7.0 years), which included patients with paroxysmal and persistent AF, found arrhythmia recurrence was common but substantially lower with thoracoscopic ablation than catheter ablation: 34/61 patients (56%) compared with 55/63 patients (87%), with _P_ < .001 for the comparison.<sup><span class="xrefLink" id="jumplink-ehae176-B669"></span><a href="javascript:;" reveal-id="ehae176-B669" data-open="ehae176-B669" class="link link-ref link-reveal xref-bibr">669</a></sup> For persistent AF, endoscopic or hybrid ablation approaches are suitable as a first procedure to maintain long-term sinus rhythm in selected patients.<sup><span class="xrefLink" id="jumplink-ehae176-B667 ehae176-B668 ehae176-B669 ehae176-B670 ehae176-B671 ehae176-B672"></span><a href="javascript:;" reveal-id="ehae176-B667 ehae176-B668 ehae176-B669 ehae176-B670 ehae176-B671 ehae176-B672" data-open="ehae176-B667 ehae176-B668 ehae176-B669 ehae176-B670 ehae176-B671 ehae176-B672" class="link link-ref link-reveal xref-bibr">667–672</a></sup> A meta-analysis of three RCTs confirmed a lower rate of atrial arrhythmia recurrence after thoracoscopic vs. catheter ablation (incidence rate ratio, 0.55; 95% CI, 0.38–0.78; with no heterogeneity between trials).<sup><span class="xrefLink" id="jumplink-ehae176-B669"></span><a href="javascript:;" reveal-id="ehae176-B669" data-open="ehae176-B669" class="link link-ref link-reveal xref-bibr">669</a></sup> An RCT with 12 month follow-up published after the meta-analysis in patients with long-standing persistent AF found no difference in arrhythmia freedom comparing thoracoscopic with catheter ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B673"></span><a href="javascript:;" reveal-id="ehae176-B673" data-open="ehae176-B673" class="link link-ref link-reveal xref-bibr">673</a></sup> Although overall morbidity and mortality of both techniques is low, endoscopic and hybrid ablation have higher complication rates than catheter ablation, but similar long-term rates of the composite of mortality, MI, or stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B667"></span><a href="javascript:;" reveal-id="ehae176-B667" data-open="ehae176-B667" class="link link-ref link-reveal xref-bibr">667</a>,<span class="xrefLink" id="jumplink-ehae176-B669"></span><a href="javascript:;" reveal-id="ehae176-B669" data-open="ehae176-B669" class="link link-ref link-reveal xref-bibr">669</a></sup>

More recent trials have assessed the efficacy and safety of the hybrid epicardial-plus-endocardial approach in persistent AF refractory to AAD therapy, including a single-centre RCT<sup><span class="xrefLink" id="jumplink-ehae176-B670"></span><a href="javascript:;" reveal-id="ehae176-B670" data-open="ehae176-B670" class="link link-ref link-reveal xref-bibr">670</a></sup> and two multicentre RCTs.<sup><span class="xrefLink" id="jumplink-ehae176-B671"></span><a href="javascript:;" reveal-id="ehae176-B671" data-open="ehae176-B671" class="link link-ref link-reveal xref-bibr">671</a>,<span class="xrefLink" id="jumplink-ehae176-B674"></span><a href="javascript:;" reveal-id="ehae176-B674" data-open="ehae176-B674" class="link link-ref link-reveal xref-bibr">674</a></sup> Across these trials, hybrid ablation was consistently superior to catheter ablation alone for maintaining long-term sinus rhythm, without significant differences in major adverse events. Notably, these studies were typically performed in highly experienced centres (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S24](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

Similar to other rhythm control approaches, this task force recommends that OAC are continued in all patients who have a risk of thromboembolism, irrespective of rhythm outcome, and regardless of LAA exclusion performed as part of the surgical procedure.

Recommendation Table 21

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884335)

Recommendations for endoscopic and hybrid AF ablation (see also Evidence Table 21)

![Recommendations for endoscopic and hybrid AF ablation (see also Evidence Table 21)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt21.jpeg?Expires=1728478929&Signature=LI6nN6fiZWTYP~Iws9nRpiw6kmYRZDHIw2jm1QglWBdeaRSuYxEkOr~t-e5xMN45uQB92aKYU6c~6cfoB7Tm-4Igp3JiZ~5B85uD~v9zhnOJNUejqzOJm1Rg13zyoZn9Recv~GAbYOScCnrPXRQH-ncMbT7F13e3bfMByA~CBDvtPuVZ5bt8pHdkmjZOX7FBFLz1sOXttngoRVumRmmgtpBR2tA5MYyVgkktpe7Pl9Tm~An84jra1ggslplKDo1R6IVp6TD4hVs6Yt0LW~0LBhFXBsMAYpdV2gfThjgGGafz5BED5A275QEnpWCCSQnoDZLHaCUOpCK8JJs0tjIn~g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 21

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884335)

Recommendations for endoscopic and hybrid AF ablation (see also Evidence Table 21)

![Recommendations for endoscopic and hybrid AF ablation (see also Evidence Table 21)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt21.jpeg?Expires=1728478929&Signature=LI6nN6fiZWTYP~Iws9nRpiw6kmYRZDHIw2jm1QglWBdeaRSuYxEkOr~t-e5xMN45uQB92aKYU6c~6cfoB7Tm-4Igp3JiZ~5B85uD~v9zhnOJNUejqzOJm1Rg13zyoZn9Recv~GAbYOScCnrPXRQH-ncMbT7F13e3bfMByA~CBDvtPuVZ5bt8pHdkmjZOX7FBFLz1sOXttngoRVumRmmgtpBR2tA5MYyVgkktpe7Pl9Tm~An84jra1ggslplKDo1R6IVp6TD4hVs6Yt0LW~0LBhFXBsMAYpdV2gfThjgGGafz5BED5A275QEnpWCCSQnoDZLHaCUOpCK8JJs0tjIn~g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.8. AF ablation during cardiac surgery

Atrial fibrillation is a significant risk factor for early mortality, late mortality, and stroke in patients referred for cardiac surgery.<sup><span class="xrefLink" id="jumplink-ehae176-B675 ehae176-B676 ehae176-B677"></span><a href="javascript:;" reveal-id="ehae176-B675 ehae176-B676 ehae176-B677" data-open="ehae176-B675 ehae176-B676 ehae176-B677" class="link link-ref link-reveal xref-bibr">675–677</a></sup> The best validated method of surgical ablation is the Maze procedure, consisting of a pattern of transmural lesions including PVI, with subsequent modifications using bipolar radiofrequency and/or cryothermy ablation with LAA amputation (see [Supplementary data online, Additional Evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  _[Table S25](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B678 ehae176-B679 ehae176-B680 ehae176-B681"></span><a href="javascript:;" reveal-id="ehae176-B678 ehae176-B679 ehae176-B680 ehae176-B681" data-open="ehae176-B678 ehae176-B679 ehae176-B680 ehae176-B681" class="link link-ref link-reveal xref-bibr">678–681</a></sup> Education and training, close co-operation within a multidisciplinary team, and shared decision-making can improve the quality and outcomes of surgical ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B682"></span><a href="javascript:;" reveal-id="ehae176-B682" data-open="ehae176-B682" class="link link-ref link-reveal xref-bibr">682</a></sup>

A number of RCTs have shown that surgical AF ablation during cardiac surgery increases freedom from arrhythmia recurrence.<sup><span class="xrefLink" id="jumplink-ehae176-B683 ehae176-B684 ehae176-B685 ehae176-B686 ehae176-B687 ehae176-B688"></span><a href="javascript:;" reveal-id="ehae176-B683 ehae176-B684 ehae176-B685 ehae176-B686 ehae176-B687 ehae176-B688" data-open="ehae176-B683 ehae176-B684 ehae176-B685 ehae176-B686 ehae176-B687 ehae176-B688" class="link link-ref link-reveal xref-bibr">683–688</a></sup> Performing surgical AF ablation, mainly targeting those patients needing mitral valve surgery, is not associated with increased morbidity or mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B678"></span><a href="javascript:;" reveal-id="ehae176-B678" data-open="ehae176-B678" class="link link-ref link-reveal xref-bibr">678</a>,<span class="xrefLink" id="jumplink-ehae176-B683 ehae176-B684 ehae176-B685"></span><a href="javascript:;" reveal-id="ehae176-B683 ehae176-B684 ehae176-B685" data-open="ehae176-B683 ehae176-B684 ehae176-B685" class="link link-ref link-reveal xref-bibr">683–685</a></sup> Observational data, including large registries, have supported the potential value of surgical AF ablation,<sup><span class="xrefLink" id="jumplink-ehae176-B689 ehae176-B690 ehae176-B691 ehae176-B692 ehae176-B693 ehae176-B694 ehae176-B695 ehae176-B696 ehae176-B697 ehae176-B698 ehae176-B699 ehae176-B700"></span><a href="javascript:;" reveal-id="ehae176-B689 ehae176-B690 ehae176-B691 ehae176-B692 ehae176-B693 ehae176-B694 ehae176-B695 ehae176-B696 ehae176-B697 ehae176-B698 ehae176-B699 ehae176-B700" data-open="ehae176-B689 ehae176-B690 ehae176-B691 ehae176-B692 ehae176-B693 ehae176-B694 ehae176-B695 ehae176-B696 ehae176-B697 ehae176-B698 ehae176-B699 ehae176-B700" class="link link-ref link-reveal xref-bibr">689–700</a></sup> but further RCTs are needed to evaluate which patients should be selected, and whether this approach contributes to the prevention of stroke, thromboembolism, and death.

Data on pacemaker implantation rates after surgical AF ablation are variable and are likely influenced by centre experience and the patients treated (e.g. underlying sinus node disease). In a systematic review of 22 RCTs (1726 patients), permanent pacemaker implantation rates were higher with surgical AF ablation than without concomitant AF surgery (6.0% vs. 4.1%; RR, 1.69; 95% CI, 1.12–2.54).<sup><span class="xrefLink" id="jumplink-ehae176-B701"></span><a href="javascript:;" reveal-id="ehae176-B701" data-open="ehae176-B701" class="link link-ref link-reveal xref-bibr">701</a></sup> Observational registry data from contemporary cohorts (2011–2020) suggest an overall pacemaker rate post-operatively of 2.1% in patients selected for surgical AF ablation, with no discernible impact of surgical ablation on the need for a pacemaker, but higher rates in those needing multivalve surgery.<sup><span class="xrefLink" id="jumplink-ehae176-B702"></span><a href="javascript:;" reveal-id="ehae176-B702" data-open="ehae176-B702" class="link link-ref link-reveal xref-bibr">702</a></sup> With a safety-first approach in mind, imaging is advised during surgical AF ablation to exclude thrombus and help to plan the surgical approach (e.g. with TOE), regardless of effective pre-procedural anticoagulant use.

Recommendation Table 22

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884340)

Recommendations for AF ablation during cardiac surgery (see also Evidence Table 22)

![Recommendations for AF ablation during cardiac surgery (see also Evidence Table 22)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt22.jpeg?Expires=1728478929&Signature=PKiJQhFz6wATUb9ELYU3WPE4YqPur~DAXKbEHtTdeXk2P9ZXd2~UT2JSYUyFLcvWN1i83uKq6lM~w5q0h9NhJl6wDHf42N96E3KpfR0zd72YeAOBPF6E0Hxi6WaD1HHDjs7H3yi-eBusgUR93GhxA2HtpVErSZEt4M1NSG2bN5BaNaFEnGpgnQAd~wyD4m5YHoJQTXvbYtugrmF3xTX7p9UdtcJviF4BCV6Bt4~oEMam49OHFJT52pmc2eGCLeR4LbYTr4o2rala9rIfNkL4ighaJjyKTmvN-LmXbAg1FSvpeUh5LMms7sQOaiMKzEIxSqvggr78cG5FUEjPhLfvMw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 22

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884340)

Recommendations for AF ablation during cardiac surgery (see also Evidence Table 22)

![Recommendations for AF ablation during cardiac surgery (see also Evidence Table 22)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt22.jpeg?Expires=1728478929&Signature=PKiJQhFz6wATUb9ELYU3WPE4YqPur~DAXKbEHtTdeXk2P9ZXd2~UT2JSYUyFLcvWN1i83uKq6lM~w5q0h9NhJl6wDHf42N96E3KpfR0zd72YeAOBPF6E0Hxi6WaD1HHDjs7H3yi-eBusgUR93GhxA2HtpVErSZEt4M1NSG2bN5BaNaFEnGpgnQAd~wyD4m5YHoJQTXvbYtugrmF3xTX7p9UdtcJviF4BCV6Bt4~oEMam49OHFJT52pmc2eGCLeR4LbYTr4o2rala9rIfNkL4ighaJjyKTmvN-LmXbAg1FSvpeUh5LMms7sQOaiMKzEIxSqvggr78cG5FUEjPhLfvMw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.9. Atrial tachycardia after pulmonary vein isolation

After any ablation for AF, recurrent arrhythmias may manifest as AF, but also as atrial tachycardia (AT). Although AT may be perceived as a step in the right direction by the treating physician, this view is often not shared by the patient because AT can be equally or more symptomatic than the original AF. Conventionally, an early arrhythmia recurrence post-PVI (whether AT, AF, or flutter) is considered potentially transitory.<sup><span class="xrefLink" id="jumplink-ehae176-B708"></span><a href="javascript:;" reveal-id="ehae176-B708" data-open="ehae176-B708" class="link link-ref link-reveal xref-bibr">708</a></sup> Recent trials using continuous implantable loop recorders for peri-procedural monitoring have provided insight into the incidence and significance of early arrhythmia recurrences, and have confirmed a link between early and later recurrence.<sup><span class="xrefLink" id="jumplink-ehae176-B709"></span><a href="javascript:;" reveal-id="ehae176-B709" data-open="ehae176-B709" class="link link-ref link-reveal xref-bibr">709</a></sup> Discussion of management options for AT post-ablation should ideally involve a multidisciplinary team with experience in interventional management of complex arrhythmias, considering technical challenges, procedural efficacy, and safety, in the context of patient preferences.

## 8\. \[E\] Evaluation and dynamic reassessment

The development and progression of AF results from continuous interactions between underlying mechanisms (electrical, cellular, neurohormonal, and haemodynamic), coupled with a broad range of clinical factors and associated comorbidities. Each individual factor has considerable variability over time, affecting its contribution to the AF-promoting substrate. The risk profile of each patient is also far from static, and requires a dynamic mode of care to ensure optimal AF management.<sup><span class="xrefLink" id="jumplink-ehae176-B710"></span><a href="javascript:;" reveal-id="ehae176-B710" data-open="ehae176-B710" class="link link-ref link-reveal xref-bibr">710</a>,<span class="xrefLink" id="jumplink-ehae176-B711"></span><a href="javascript:;" reveal-id="ehae176-B711" data-open="ehae176-B711" class="link link-ref link-reveal xref-bibr">711</a></sup> Patients with AF require periodic reassessment of therapy based on this changing risk status if we are to improve the overall quality of care. Timely attention to modifiable factors and underpinning comorbidities has the potential to slow or reverse the progression of AF, increase quality of life, and prevent adverse outcomes such as heart failure, thromboembolism, and major bleeding.

The \[E\] in AF-CARE encompasses the range of activity needed by healthcare professionals and patients to: (i) thoroughly evaluate associated comorbidities and risk factors that can guide treatment; and (ii) provide the dynamic assessment needed to ensure that treatment plans remain suited to that particular patient. This task force recommends an adaptive strategy that not only reacts to changes notified by a patient, but also proactively seeks out issues where altering management could impact on patient wellbeing. Avoidance of unnecessary and costly follow-up is also inherent in this framework, with educated and empowered patients contributing to identifying the need for access to specialist care or an escalation of management. The patient-centred, shared decision philosophy is embedded to improve efficiency in models of care and to address the needs of patients with AF.

Medical history and the results of any tests should be regularly re-evaluated to address the dynamic nature of comorbidities and risk factors.<sup><span class="xrefLink" id="jumplink-ehae176-B712"></span><a href="javascript:;" reveal-id="ehae176-B712" data-open="ehae176-B712" class="link link-ref link-reveal xref-bibr">712</a></sup> This may have impact on therapeutic decisions; e.g. resumption of full-dose DOAC therapy after improvement in the patient's renal function. The timing of review of the AF-CARE pathway is patient specific and should respond to changes in clinical status. In most cases, this task force advises re-evaluation 6 months after initial presentation, and then at least annually by a healthcare professional in primary or secondary care (see _[Figure 3](javascript:;)_).

### 8.1. Implementation of dynamic care

A multidisciplinary-based approach is advocated to improve implementation of dynamic AF-CARE (see _[Figure 2](javascript:;)_); although potentially resource intensive, this is preferred to more simplistic or opportunistic methods. For example, in a pragmatic trial of 47 333 AF patients identified through health insurance claims, there was no difference in OAC initiation at 1 year in those randomized to a single mailout of patient and clinician education, compared with those in the usual care group.<sup><span class="xrefLink" id="jumplink-ehae176-B713"></span><a href="javascript:;" reveal-id="ehae176-B713" data-open="ehae176-B713" class="link link-ref link-reveal xref-bibr">713</a></sup> For co-ordination of care there is a core role for cardiologists, general practitioners, specialized nurses, and pharmacists.<sup><span class="xrefLink" id="jumplink-ehae176-B714"></span><a href="javascript:;" reveal-id="ehae176-B714" data-open="ehae176-B714" class="link link-ref link-reveal xref-bibr">714</a></sup> If needed, and depending on local resources, others may also be involved (cardiac surgeons, physiotherapists, neurologists, psychologists, and other allied health professionals). It is strongly advocated that one core team member co-ordinates care, and that additional team members become involved according to the needs of the individual patient throughout their AF trajectory.

Several organizational models of integrated care for AF have been evaluated, but which components are most useful remains unclear. Some models include a multidisciplinary team,<sup><span class="xrefLink" id="jumplink-ehae176-B715"></span><a href="javascript:;" reveal-id="ehae176-B715" data-open="ehae176-B715" class="link link-ref link-reveal xref-bibr">715</a>,<span class="xrefLink" id="jumplink-ehae176-B716"></span><a href="javascript:;" reveal-id="ehae176-B716" data-open="ehae176-B716" class="link link-ref link-reveal xref-bibr">716</a></sup> while others are nurse-led<sup><span class="xrefLink" id="jumplink-ehae176-B79"></span><a href="javascript:;" reveal-id="ehae176-B79" data-open="ehae176-B79" class="link link-ref link-reveal xref-bibr">79</a>,<span class="xrefLink" id="jumplink-ehae176-B122"></span><a href="javascript:;" reveal-id="ehae176-B122" data-open="ehae176-B122" class="link link-ref link-reveal xref-bibr">122</a>,<span class="xrefLink" id="jumplink-ehae176-B124"></span><a href="javascript:;" reveal-id="ehae176-B124" data-open="ehae176-B124" class="link link-ref link-reveal xref-bibr">124</a>,<span class="xrefLink" id="jumplink-ehae176-B717"></span><a href="javascript:;" reveal-id="ehae176-B717" data-open="ehae176-B717" class="link link-ref link-reveal xref-bibr">717</a></sup> or cardiologist-led.<sup><span class="xrefLink" id="jumplink-ehae176-B79"></span><a href="javascript:;" reveal-id="ehae176-B79" data-open="ehae176-B79" class="link link-ref link-reveal xref-bibr">79</a>,<span class="xrefLink" id="jumplink-ehae176-B122"></span><a href="javascript:;" reveal-id="ehae176-B122" data-open="ehae176-B122" class="link link-ref link-reveal xref-bibr">122</a>,<span class="xrefLink" id="jumplink-ehae176-B124"></span><a href="javascript:;" reveal-id="ehae176-B124" data-open="ehae176-B124" class="link link-ref link-reveal xref-bibr">124</a>,<span class="xrefLink" id="jumplink-ehae176-B717"></span><a href="javascript:;" reveal-id="ehae176-B717" data-open="ehae176-B717" class="link link-ref link-reveal xref-bibr">717</a></sup> Several published models used computerized decision support systems or electronic health applications.<sup><span class="xrefLink" id="jumplink-ehae176-B79"></span><a href="javascript:;" reveal-id="ehae176-B79" data-open="ehae176-B79" class="link link-ref link-reveal xref-bibr">79</a>,<span class="xrefLink" id="jumplink-ehae176-B122"></span><a href="javascript:;" reveal-id="ehae176-B122" data-open="ehae176-B122" class="link link-ref link-reveal xref-bibr">122</a>,<span class="xrefLink" id="jumplink-ehae176-B715"></span><a href="javascript:;" reveal-id="ehae176-B715" data-open="ehae176-B715" class="link link-ref link-reveal xref-bibr">715</a>,<span class="xrefLink" id="jumplink-ehae176-B718"></span><a href="javascript:;" reveal-id="ehae176-B718" data-open="ehae176-B718" class="link link-ref link-reveal xref-bibr">718</a></sup> Evaluation within RCTs has demonstrated mixed results due to the variety of methods tested and differences in regional care. Several studies report significant improvements with respect to adherence to anticoagulation, cardiovascular mortality, and hospitalization relative to standard of care.<sup><span class="xrefLink" id="jumplink-ehae176-B121 ehae176-B122 ehae176-B123"></span><a href="javascript:;" reveal-id="ehae176-B121 ehae176-B122 ehae176-B123" data-open="ehae176-B121 ehae176-B122 ehae176-B123" class="link link-ref link-reveal xref-bibr">121–123</a></sup> However, the RACE 4 (IntegRAted Chronic Care Program at Specialized AF Clinic Versus Usual CarE in Patients with Atrial Fibrillation) trial, which included 1375 patients, failed to demonstrate superiority of nurse-led over usual care.<sup><span class="xrefLink" id="jumplink-ehae176-B79"></span><a href="javascript:;" reveal-id="ehae176-B79" data-open="ehae176-B79" class="link link-ref link-reveal xref-bibr">79</a></sup> New studies of the components and optimal models for delivery for integrated care approaches in routine practice are ongoing (ACTRN12616001109493, NCT03924739).

### 8.2. Improving treatment adherence

Advances in the care of patients with AF can only be effective if appropriate tools are available to support the implementation of the treatment regimen.<sup><span class="xrefLink" id="jumplink-ehae176-B719"></span><a href="javascript:;" reveal-id="ehae176-B719" data-open="ehae176-B719" class="link link-ref link-reveal xref-bibr">719</a></sup> A number of factors are related to the optimal implementation of care at the level of: (i) the individual patient (culture, cognitive impairment, and psychological status); (ii) the treatment (complexity, side effects, polypharmacy, impact on daily life, and cost); (iii) the healthcare system (access to treatment and multidisciplinary approach); and (iv) the healthcare professional (knowledge, awareness of guidelines, expertise, and communication skills). A collaborative approach to patient care, based upon shared decision-making and goals tailored to individual patient needs, is crucial in promoting ongoing patient adherence to the agreed treatment regimen.<sup><span class="xrefLink" id="jumplink-ehae176-B720"></span><a href="javascript:;" reveal-id="ehae176-B720" data-open="ehae176-B720" class="link link-ref link-reveal xref-bibr">720</a></sup> Even when treatment seems feasible for the individual, patients often lack access to reliable and up-to-date information about risks and benefits of various treatment options, and consequently are not empowered to engage in their own management. A sense of ownership that promotes the achievement of joint goals can be encouraged through the use of educational programmes, websites (such as [https://afibmatters.org](https://afibmatters.org)), app-based tools, and individually tailored treatment protocols which take into account gender, ethnic, socioeconomic, environmental, and work factors. In addition, practical tools (e.g. schedules, apps, brochures, reminders, pillboxes) can help to implement treatment in daily life.<sup><span class="xrefLink" id="jumplink-ehae176-B721"></span><a href="javascript:;" reveal-id="ehae176-B721" data-open="ehae176-B721" class="link link-ref link-reveal xref-bibr">721</a>,<span class="xrefLink" id="jumplink-ehae176-B722"></span><a href="javascript:;" reveal-id="ehae176-B722" data-open="ehae176-B722" class="link link-ref link-reveal xref-bibr">722</a></sup> Regular review by members of the multidisciplinary team enables the evolution of a flexible and responsive management regimen that the patient will find easier to follow.

### 8.3. Cardiac imaging

A TTE is a valuable asset across all four AF-CARE domains when there are changes in the clinical status of an individual patient (_[Figure 13](javascript:;)_).<sup><span class="xrefLink" id="jumplink-ehae176-B723 ehae176-B724 ehae176-B725"></span><a href="javascript:;" reveal-id="ehae176-B723 ehae176-B724 ehae176-B725" data-open="ehae176-B723 ehae176-B724 ehae176-B725" class="link link-ref link-reveal xref-bibr">723–725</a></sup> The key findings to consider from an echocardiogram are any structural heart disease (e.g. valvular disease or left ventricular hypertrophy), impairment of left ventricular function (systolic and/or diastolic to classify heart failure subtype), left atrial dilatation, and right heart dysfunction.<sup><span class="xrefLink" id="jumplink-ehae176-B59"></span><a href="javascript:;" reveal-id="ehae176-B59" data-open="ehae176-B59" class="link link-ref link-reveal xref-bibr">59</a>,<span class="xrefLink" id="jumplink-ehae176-B67"></span><a href="javascript:;" reveal-id="ehae176-B67" data-open="ehae176-B67" class="link link-ref link-reveal xref-bibr">67</a>,<span class="xrefLink" id="jumplink-ehae176-B726"></span><a href="javascript:;" reveal-id="ehae176-B726" data-open="ehae176-B726" class="link link-ref link-reveal xref-bibr">726</a></sup> To counter irregularity when in AF, obtaining measurements in cardiac cycles that follow two similar RR intervals can improve the value of parameters compared with sequential averaging of cardiac cycles.<sup><span class="xrefLink" id="jumplink-ehae176-B723"></span><a href="javascript:;" reveal-id="ehae176-B723" data-open="ehae176-B723" class="link link-ref link-reveal xref-bibr">723</a>,<span class="xrefLink" id="jumplink-ehae176-B727"></span><a href="javascript:;" reveal-id="ehae176-B727" data-open="ehae176-B727" class="link link-ref link-reveal xref-bibr">727</a></sup> Contrast TTE or alternative imaging modalities may be required where image quality is poor, and quantification of left ventricular systolic function is needed for decisions on rate or rhythm control. Other cardiac imaging techniques, such as cardiac magnetic resonance (CMR), CT, TOE, and nuclear imaging can be valuable when: (i) TTE quality is suboptimal for diagnostic purposes; (ii) additional information is needed on structure, substrate, or function; and (iii) to support decisions on interventional procedures (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Figure S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B59"></span><a href="javascript:;" reveal-id="ehae176-B59" data-open="ehae176-B59" class="link link-ref link-reveal xref-bibr">59</a>,<span class="xrefLink" id="jumplink-ehae176-B724"></span><a href="javascript:;" reveal-id="ehae176-B724" data-open="ehae176-B724" class="link link-ref link-reveal xref-bibr">724</a>,<span class="xrefLink" id="jumplink-ehae176-B725"></span><a href="javascript:;" reveal-id="ehae176-B725" data-open="ehae176-B725" class="link link-ref link-reveal xref-bibr">725</a>,<span class="xrefLink" id="jumplink-ehae176-B728"></span><a href="javascript:;" reveal-id="ehae176-B728" data-open="ehae176-B728" class="link link-ref link-reveal xref-bibr">728</a></sup> As with TTE, other types of cardiac imaging can be challenging in the context of AF irregularity or with rapid heart rate, requiring technique-specific modifications when acquiring ECG-gated sequences.<sup><span class="xrefLink" id="jumplink-ehae176-B729 ehae176-B730 ehae176-B731"></span><a href="javascript:;" reveal-id="ehae176-B729 ehae176-B730 ehae176-B731" data-open="ehae176-B729 ehae176-B730 ehae176-B731" class="link link-ref link-reveal xref-bibr">729–731</a></sup>

![Relevance of echocardiography in the AF-CARE pathway.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f13.jpeg?Expires=1728478929&Signature=K3Bs-JM-j7uQmY1GDAwZKDCJxHDHj5piZOL5nZ4nQes~LRiM1XmAZbYeyiVMLrGRf6pH2FruV9Rq85pXs7lAh61IY-tbPMFHrlqlINO8FcIA5qxKNdQUdT4IX4RdkGFouRk2C0ZHf9wYYRwkIUYlGUPEvGfkbrAj8DqZdvPAgEhJ6rhUwYUmYj90Om-WUXRcCUcLxL-6o-d8fk3Xh-u8moMujKRXjwnIq3Ll2yKiLUdv2sKR0bxY3yJYfwRpdNOMqZwqizLzeXKYFIChhsjg6BQHXtF3LxYJx5CSkwz7UmPDUx7T53qccIrQdeqfJYsiIgU5YSTuPrjHvNx24eDMvg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 13

Relevance of echocardiography in the AF-CARE pathway.

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; CHA<sub>2</sub>DS<sub>2</sub>\-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; LAA, left atrial appendage; LV, left ventricle.

[Open in new tab](https://academic.oup.com/view-large/figure/479884354/ehae176f13.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f13.jpeg?Expires=1728478929&Signature=ew1Fin9XtTJSV-XUhJivNuCYRSp3NMCdPnssgQLpgzh0Ti-poCbA7GW5DtWAURMxMC18XpdfBED~YdUY8k2FJxSTcA51xzsMJUum6-VgoLR-U2dCkQWbu8swE-6pqT7IuycC3CNrW3iqRWIS3owKvIaNWMy~hImiKBjmH6bbmSN8klqrNFy6oe4L7nlpZHSBOeWXk5Xrhl2pGRZCsFAu2OawcizO82iX7-DOo9kZlZpLYtbilIW-jbRfMoBiZJiPb6keCrVM429B6cyDjCowt7Cc0E~zV6QC1WQEP51dFfkUZQuRKRfagDjph9b93vFYt7Gq4FYLYnmLvbMiIRBxcQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884354&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

### 8.4. Patient-reported outcome measures

Patients with AF have a lower quality of life compared with the general population.<sup><span class="xrefLink" id="jumplink-ehae176-B732"></span><a href="javascript:;" reveal-id="ehae176-B732" data-open="ehae176-B732" class="link link-ref link-reveal xref-bibr">732</a></sup> Improvement in quality of life and functional status should play a key role in assessing and reassessing treatment decisions (see [Supplementary data online, Additional Evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  _[Table S26](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B36"></span><a href="javascript:;" reveal-id="ehae176-B36" data-open="ehae176-B36" class="link link-ref link-reveal xref-bibr">36</a></sup> Patient-reported outcome measures are valuable to measure quality of life, functional status, symptoms, and treatment burden for patients with AF over time.<sup><span class="xrefLink" id="jumplink-ehae176-B55"></span><a href="javascript:;" reveal-id="ehae176-B55" data-open="ehae176-B55" class="link link-ref link-reveal xref-bibr">55</a>,<span class="xrefLink" id="jumplink-ehae176-B733 ehae176-B734 ehae176-B735"></span><a href="javascript:;" reveal-id="ehae176-B733 ehae176-B734 ehae176-B735" data-open="ehae176-B733 ehae176-B734 ehae176-B735" class="link link-ref link-reveal xref-bibr">733–735</a></sup> Patient-reported outcome measures are playing an increasing role in clinical trials to assess the success of treatment; however, they remain under-utilized.<sup><span class="xrefLink" id="jumplink-ehae176-B736"></span><a href="javascript:;" reveal-id="ehae176-B736" data-open="ehae176-B736" class="link link-ref link-reveal xref-bibr">736</a>,<span class="xrefLink" id="jumplink-ehae176-B737"></span><a href="javascript:;" reveal-id="ehae176-B737" data-open="ehae176-B737" class="link link-ref link-reveal xref-bibr">737</a></sup> They can be divided into generic or disease-specific tools, with the latter helping to provide insight into AF-related impacts.<sup><span class="xrefLink" id="jumplink-ehae176-B738"></span><a href="javascript:;" reveal-id="ehae176-B738" data-open="ehae176-B738" class="link link-ref link-reveal xref-bibr">738</a></sup> However, multimorbidity can still confound the sensitivity of all PROMs, impacting on association with other established metrics of treatment performance such as mEHRA symptom class and natriuretic peptides.<sup><span class="xrefLink" id="jumplink-ehae176-B48"></span><a href="javascript:;" reveal-id="ehae176-B48" data-open="ehae176-B48" class="link link-ref link-reveal xref-bibr">48</a></sup> Intervention studies have demonstrated an association between improvement in PROM scores and reduction in AF burden and symptoms.<sup><span class="xrefLink" id="jumplink-ehae176-B48"></span><a href="javascript:;" reveal-id="ehae176-B48" data-open="ehae176-B48" class="link link-ref link-reveal xref-bibr">48</a>,<span class="xrefLink" id="jumplink-ehae176-B738"></span><a href="javascript:;" reveal-id="ehae176-B738" data-open="ehae176-B738" class="link link-ref link-reveal xref-bibr">738</a></sup>

Atrial fibrillation-specific questionnaires include the AF 6 (AF6),<sup><span class="xrefLink" id="jumplink-ehae176-B739"></span><a href="javascript:;" reveal-id="ehae176-B739" data-open="ehae176-B739" class="link link-ref link-reveal xref-bibr">739</a></sup> Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT),<sup><span class="xrefLink" id="jumplink-ehae176-B740"></span><a href="javascript:;" reveal-id="ehae176-B740" data-open="ehae176-B740" class="link link-ref link-reveal xref-bibr">740</a></sup> the Atrial Fibrillation Quality of Life Questionnaire (AFQLQ),<sup><span class="xrefLink" id="jumplink-ehae176-B741"></span><a href="javascript:;" reveal-id="ehae176-B741" data-open="ehae176-B741" class="link link-ref link-reveal xref-bibr">741</a></sup> the Atrial Fibrillation Quality of Life (AF-QoL),<sup><span class="xrefLink" id="jumplink-ehae176-B742"></span><a href="javascript:;" reveal-id="ehae176-B742" data-open="ehae176-B742" class="link link-ref link-reveal xref-bibr">742</a></sup> and the Quality of Life in Atrial Fibrillation (QLAF).<sup><span class="xrefLink" id="jumplink-ehae176-B743"></span><a href="javascript:;" reveal-id="ehae176-B743" data-open="ehae176-B743" class="link link-ref link-reveal xref-bibr">743</a></sup> The measurement properties of most of these tools lack sufficient validation.<sup><span class="xrefLink" id="jumplink-ehae176-B49"></span><a href="javascript:;" reveal-id="ehae176-B49" data-open="ehae176-B49" class="link link-ref link-reveal xref-bibr">49</a></sup> The International Consortium for Health Outcomes Measurement (ICHOM) working group recommends the use of the AFEQT PROM or a symptom questionnaire called the Atrial Fibrillation Severity Scale (AFSS) for measuring exercise tolerance and the impact of symptoms in AF.<sup><span class="xrefLink" id="jumplink-ehae176-B744"></span><a href="javascript:;" reveal-id="ehae176-B744" data-open="ehae176-B744" class="link link-ref link-reveal xref-bibr">744</a></sup> Through wider use of patient experience measures, there is an opportunity at the institutional level to improve the quality of care delivered to patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B49 ehae176-B50 ehae176-B51 ehae176-B52 ehae176-B53 ehae176-B54 ehae176-B55"></span><a href="javascript:;" reveal-id="ehae176-B49 ehae176-B50 ehae176-B51 ehae176-B52 ehae176-B53 ehae176-B54 ehae176-B55" data-open="ehae176-B49 ehae176-B50 ehae176-B51 ehae176-B52 ehae176-B53 ehae176-B54 ehae176-B55" class="link link-ref link-reveal xref-bibr">49–55</a></sup>

Recommendation Table 23

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884358)

Recommendations to improve patient experience (see also Evidence Table 23)

![Recommendations to improve patient experience (see also Evidence Table 23)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt23.jpeg?Expires=1728478929&Signature=3RBXaWsps45dcMNtehck62CTBKam9~RoChyQqZoxmWija-sc1KdJMGNyekDn-tMFsbaTDkumTdkoHNGBzeQVcfvgcTA--DeYexOYNOF7JwGRLvd3kZKnrsZeR0Zfq2iYyzvBPIj0ZWLJ7R66L4-6mMX67r-Yvbkzo9Pgtwp8~M~S3fHsDTfDzO6JtAoq4VLS1kaEawlr8IMvpDbrr9-QsPpK8DKQh~-M8qRapEhbMKcoP9RJUAd8OR4PMlAZjCQodQMSpgTI42yuKo3DBhXs9ezEVaWKwbqZMCYIqii7Ceky07psFnDbot9jbnZyNs5wwqAnXvSKNjcua7GAT2TZJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 23

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884358)

Recommendations to improve patient experience (see also Evidence Table 23)

![Recommendations to improve patient experience (see also Evidence Table 23)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt23.jpeg?Expires=1728478929&Signature=3RBXaWsps45dcMNtehck62CTBKam9~RoChyQqZoxmWija-sc1KdJMGNyekDn-tMFsbaTDkumTdkoHNGBzeQVcfvgcTA--DeYexOYNOF7JwGRLvd3kZKnrsZeR0Zfq2iYyzvBPIj0ZWLJ7R66L4-6mMX67r-Yvbkzo9Pgtwp8~M~S3fHsDTfDzO6JtAoq4VLS1kaEawlr8IMvpDbrr9-QsPpK8DKQh~-M8qRapEhbMKcoP9RJUAd8OR4PMlAZjCQodQMSpgTI42yuKo3DBhXs9ezEVaWKwbqZMCYIqii7Ceky07psFnDbot9jbnZyNs5wwqAnXvSKNjcua7GAT2TZJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 9\. The AF-CARE pathway in specific clinical settings

The following sections detail specific clinical settings where approaches to AF-CARE may vary. Unless specially discussed, measures for \[C\] comorbidity and risk factor management, \[A\] avoidance of stroke and thromboembolism, \[R\] rate and rhythm control, and \[E\] evaluation and dynamic reassessment should follow the standard pathways introduced in _Section [4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s3)_.

### 9.1. AF-CARE in unstable patients

Unstable patients with AF include those with haemodynamic instability caused by the arrhythmia or acute cardiac conditions, and severely ill patients who develop AF (sepsis, trauma, surgery, and particularly cancer-related surgery). Conditions such as sepsis, adrenergic overstimulation, and electrolyte disturbances contribute to onset and recurrence of AF in these patients. Spontaneous restoration of sinus rhythm has been reported in up to 83% during the first 48 h after appropriate treatment of the underlying cause.<sup><span class="xrefLink" id="jumplink-ehae176-B551"></span><a href="javascript:;" reveal-id="ehae176-B551" data-open="ehae176-B551" class="link link-ref link-reveal xref-bibr">551</a>,<span class="xrefLink" id="jumplink-ehae176-B745"></span><a href="javascript:;" reveal-id="ehae176-B745" data-open="ehae176-B745" class="link link-ref link-reveal xref-bibr">745</a></sup>

Emergency electrical cardioversion is still considered the first-choice treatment if sinus rhythm is thought to be beneficial, despite the limitation of having a high rate of immediate relapse.<sup><span class="xrefLink" id="jumplink-ehae176-B746"></span><a href="javascript:;" reveal-id="ehae176-B746" data-open="ehae176-B746" class="link link-ref link-reveal xref-bibr">746</a></sup> Amiodarone is a second-line option because of its delayed activity; however, it may be an appropriate alternative in the acute setting.<sup><span class="xrefLink" id="jumplink-ehae176-B747"></span><a href="javascript:;" reveal-id="ehae176-B747" data-open="ehae176-B747" class="link link-ref link-reveal xref-bibr">747</a>,<span class="xrefLink" id="jumplink-ehae176-B748"></span><a href="javascript:;" reveal-id="ehae176-B748" data-open="ehae176-B748" class="link link-ref link-reveal xref-bibr">748</a></sup> In a multicentre cohort study carried out in the United Kingdom and the United States of America, amiodarone and beta-blockers were similarly effective for rate control in intensive care patients, and superior to digoxin and calcium channel blockers.<sup><span class="xrefLink" id="jumplink-ehae176-B749"></span><a href="javascript:;" reveal-id="ehae176-B749" data-open="ehae176-B749" class="link link-ref link-reveal xref-bibr">749</a></sup> The ultra-short acting and highly selective beta-blocker landiolol can safely control rapid AF in patients with low ejection fraction and acutely decompensated heart failure, with a limited impact on myocardial contractility or blood pressure.<sup><span class="xrefLink" id="jumplink-ehae176-B477"></span><a href="javascript:;" reveal-id="ehae176-B477" data-open="ehae176-B477" class="link link-ref link-reveal xref-bibr">477</a>,<span class="xrefLink" id="jumplink-ehae176-B750"></span><a href="javascript:;" reveal-id="ehae176-B750" data-open="ehae176-B750" class="link link-ref link-reveal xref-bibr">750</a>,<span class="xrefLink" id="jumplink-ehae176-B751"></span><a href="javascript:;" reveal-id="ehae176-B751" data-open="ehae176-B751" class="link link-ref link-reveal xref-bibr">751</a></sup>

### 9.2. AF-CARE in acute and chronic coronary syndromes

The incidence of AF in acute coronary syndromes (ACS) ranges from 2% to 23%.<sup><span class="xrefLink" id="jumplink-ehae176-B752"></span><a href="javascript:;" reveal-id="ehae176-B752" data-open="ehae176-B752" class="link link-ref link-reveal xref-bibr">752</a></sup> The risk of new-onset AF is increased by 60%–77% in patients suffering an MI,<sup><span class="xrefLink" id="jumplink-ehae176-B753"></span><a href="javascript:;" reveal-id="ehae176-B753" data-open="ehae176-B753" class="link link-ref link-reveal xref-bibr">753</a></sup> and AF may be associated with an increased risk of ST-segment elevation myocardial infarction (STEMI) or non-STEMI ACS.<sup><span class="xrefLink" id="jumplink-ehae176-B754"></span><a href="javascript:;" reveal-id="ehae176-B754" data-open="ehae176-B754" class="link link-ref link-reveal xref-bibr">754</a></sup> Overall, 10%–15% of AF patients undergo percutaneous intervention (PCI) for CAD.<sup><span class="xrefLink" id="jumplink-ehae176-B755"></span><a href="javascript:;" reveal-id="ehae176-B755" data-open="ehae176-B755" class="link link-ref link-reveal xref-bibr">755</a></sup> In addition, AF is a common precipitant for type 2 MI.<sup><span class="xrefLink" id="jumplink-ehae176-B756"></span><a href="javascript:;" reveal-id="ehae176-B756" data-open="ehae176-B756" class="link link-ref link-reveal xref-bibr">756</a></sup> Observational studies show that patients with both ACS and AF are less likely to receive appropriate antithrombotic therapy<sup><span class="xrefLink" id="jumplink-ehae176-B757"></span><a href="javascript:;" reveal-id="ehae176-B757" data-open="ehae176-B757" class="link link-ref link-reveal xref-bibr">757</a></sup> and more likely to experience adverse outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B758"></span><a href="javascript:;" reveal-id="ehae176-B758" data-open="ehae176-B758" class="link link-ref link-reveal xref-bibr">758</a></sup> Peri-procedural management of patients with ACS or chronic coronary syndromes (CCS) are detailed in the _2023 ESC Guidelines for the management of acute coronary syndromes_ and _2024 ESC Guidelines for the management of chronic coronary syndromes_.<sup><span class="xrefLink" id="jumplink-ehae176-B759"></span><a href="javascript:;" reveal-id="ehae176-B759" data-open="ehae176-B759" class="link link-ref link-reveal xref-bibr">759</a>,<span class="xrefLink" id="jumplink-ehae176-B760"></span><a href="javascript:;" reveal-id="ehae176-B760" data-open="ehae176-B760" class="link link-ref link-reveal xref-bibr">760</a></sup>

The combination of AF with ACS is the area where use of multiple antithrombotic drugs is most frequently indicated, consisting of antiplatelet agents plus OAC (_[Figure 14](javascript:;)_) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S27](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). There is a general trend to decrease the duration of DAPT to reduce bleeding; however, this may increase ischaemic events and stent thrombosis.<sup><span class="xrefLink" id="jumplink-ehae176-B761"></span><a href="javascript:;" reveal-id="ehae176-B761" data-open="ehae176-B761" class="link link-ref link-reveal xref-bibr">761</a>,<span class="xrefLink" id="jumplink-ehae176-B762"></span><a href="javascript:;" reveal-id="ehae176-B762" data-open="ehae176-B762" class="link link-ref link-reveal xref-bibr">762</a></sup> In ACS there is a high risk of predominantly platelet-driven atherothrombosis and thus of coronary ischaemic events. Acute coronary syndromes treated by PCI require DAPT for improved short- and long-term prognosis. Therefore, a peri-procedural triple antithrombotic regimen including an OAC, aspirin, and a P2Y<sub>12</sub> inhibitor should be the default strategy for most patients. Major thrombotic events vs. major bleeding risk need to be balanced when prescribing antiplatelet therapy and OAC after the acute phase and/or after PCI. The combination of OAC (preferably a DOAC) and a P2Y<sub>12</sub> inhibitor results in less major bleeding than triple therapy that includes aspirin. Clopidogrel is the preferred P2Y<sub>12</sub> inhibitor, as the evidence for ticagrelor and prasugrel is less clear with higher bleeding risk.<sup><span class="xrefLink" id="jumplink-ehae176-B763 ehae176-B764 ehae176-B765 ehae176-B766 ehae176-B767 ehae176-B768 ehae176-B769"></span><a href="javascript:;" reveal-id="ehae176-B763 ehae176-B764 ehae176-B765 ehae176-B766 ehae176-B767 ehae176-B768 ehae176-B769" data-open="ehae176-B763 ehae176-B764 ehae176-B765 ehae176-B766 ehae176-B767 ehae176-B768 ehae176-B769" class="link link-ref link-reveal xref-bibr">763–769</a></sup> Ongoing trials will add to our knowledge about safely combining DOACs with antiplatelet agents (NCT04981041, NCT04436978). When using VKAs with antiplatelet agents, there is consensus opinion to use an INR range of 2.0–2.5 to mitigate excess bleeding risk.

![Antithrombotic therapy in patients with AF and acute or chronic coronary syndromes.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f14.jpeg?Expires=1728478929&Signature=Yzw2~hkelfsBJmq9jcJyDWci73lZ5nv0-T8PVSvhlStgygpOtdOPHg98QbPVnEe24-rGtTgQHMEHLxrvaHSUSzcLHdmNniHJTSHo-PII62GP90zjK-hpyKm4mmei3QhDZcQjWIIV7ibAYwWgIJCYzmsZ4WYEMfljmh6xdwAPP2PkNI1XECMkQ9-dT4hGtNWIY4aGje4Botv7cF76BsKjQtPMuzvMa6TbJwl9fU4VX5mmSrpb86EWbELGAS5mmvK5nccWGv3ghYm4eL3RAXhT0JuWwIa8nOo-ibOXLKPuCiXcwdAwoO3~1R3Kxyx6Skv8y-JBsMr~TTr4rfqCFS6mvA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 14

Antithrombotic therapy in patients with AF and acute or chronic coronary syndromes.

ACS, acute coronary syndromes; CCS, chronic coronary syndrome; DOAC, direct oral anticoagulant; INR, international normalized ratio of prothrombin time; OAC, oral anticoagulant; P2Y<sub>12</sub>i, P2Y<sub>12</sub>\-receptor inhibitor antiplatelet agents (clopidogrel, prasugrel, ticagrelor); PCI, percutaneous intervention; TTR, time in therapeutic range; VKA, vitamin K antagonist. The flowchart applies to those patients with an indication for oral anticoagulant therapy. <sup>a</sup>The full standard dose of DOACs should be used unless the patient fulfils dose-reduction criteria (_[Table 11](javascript:;)_). When rivaroxaban or dabigatran are used as the DOAC and concerns about bleeding risk prevail over stent thrombosis or ischaemic stroke, the reduced dose should be considered (15 mg and 110 mg respectively; Class IIa). <sup>b</sup>In patients with diabetes mellitus undergoing coronary stent implantation, prolonging triple antithrombotic therapy for up to 3 months may be of value if thrombotic risk outweighs the bleeding risk.

[Open in new tab](https://academic.oup.com/view-large/figure/479884367/ehae176f14.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f14.jpeg?Expires=1728478929&Signature=nb34nQSLhXdOKX0rjtD3WbHmiDO9FE-ZkpoloJqQvbmKHU3Z04ILDWdqZf5iw-6HEfL1in9lbAlqp~p8KU2yu8U~Pvw0CtR5~AqNBe7IiNF~LTRLN6zwbPB-LRFiHPiy9OxOwFgKPiysWuMg-jCMsMRqDm34Z2jSAtgDw5lMvjdp7TBK0~GOUawCGBbDaxOf3SWL63IbiJZpHPHrzSingcOFyv98uDifaUG9rHk~X3mMSGRajaEnGPnT-40WnKtpBFldSrg40PAzfcYMDhrlmHFmhOUcz7-JgvXQsGeIjv6EmhZGyJKYoypJ6AwJYz3m9Ip9CwmI3bt1eeI4QYlzLw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884367&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Short–term triple therapy (≤1 week) is recommended for all patients without diabetes after ACS or PCI. In pooled analyses of RCTs, omitting aspirin in patients with ACS undergoing PCI has the potential for higher rates of ischaemic/stent thrombosis, without impact on incident stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B761"></span><a href="javascript:;" reveal-id="ehae176-B761" data-open="ehae176-B761" class="link link-ref link-reveal xref-bibr">761</a>,<span class="xrefLink" id="jumplink-ehae176-B762"></span><a href="javascript:;" reveal-id="ehae176-B762" data-open="ehae176-B762" class="link link-ref link-reveal xref-bibr">762</a>,<span class="xrefLink" id="jumplink-ehae176-B770 ehae176-B771 ehae176-B772"></span><a href="javascript:;" reveal-id="ehae176-B770 ehae176-B771 ehae176-B772" data-open="ehae176-B770 ehae176-B771 ehae176-B772" class="link link-ref link-reveal xref-bibr">770–772</a></sup> None of the trials were powered for ischaemic events. All patients in AUGUSTUS (an open–label, 2 × 2 factorial, randomized controlled clinical trial to evaluate the safety of apixaban vs. vitamin k antagonist and aspirin vs. aspirin placebo in patients with AF and ACS or PCI) received aspirin plus a P2Y<sub>12</sub> inhibitor for a median time of 6 days.<sup><span class="xrefLink" id="jumplink-ehae176-B773"></span><a href="javascript:;" reveal-id="ehae176-B773" data-open="ehae176-B773" class="link link-ref link-reveal xref-bibr">773</a></sup> At the end of the trial, apixaban and a P2Y<sub>12</sub> inhibitor without aspirin was the optimal treatment regimen for most patients with AF and ACS and/or PCI, irrespective of the patient's baseline bleeding and stroke risk.<sup><span class="xrefLink" id="jumplink-ehae176-B774"></span><a href="javascript:;" reveal-id="ehae176-B774" data-open="ehae176-B774" class="link link-ref link-reveal xref-bibr">774</a>,<span class="xrefLink" id="jumplink-ehae176-B775"></span><a href="javascript:;" reveal-id="ehae176-B775" data-open="ehae176-B775" class="link link-ref link-reveal xref-bibr">775</a></sup>

Prolonged triple therapy up to 1 month after ACS/PCI should be considered in patients at high ischaemic risk, e.g. STEMI, prior stent thrombosis, complex coronary procedures, and prolonged cardiac instability, even though these patients were not adequately represented in the RCTs so far available.<sup><span class="xrefLink" id="jumplink-ehae176-B776"></span><a href="javascript:;" reveal-id="ehae176-B776" data-open="ehae176-B776" class="link link-ref link-reveal xref-bibr">776</a></sup> In AF patients with ACS or CCS and diabetes mellitus undergoing coronary stent implantation, prolonging triple therapy with low-dose aspirin, clopidogrel, and an OAC up to 3 months may be of benefit if thrombotic risk outweighs bleeding risk in the individual patient.<sup><span class="xrefLink" id="jumplink-ehae176-B207"></span><a href="javascript:;" reveal-id="ehae176-B207" data-open="ehae176-B207" class="link link-ref link-reveal xref-bibr">207</a></sup>

The evidence for ACS treated without revascularization is limited. Six to 12 months of a single antiplatelet agent in addition to a long-term DOAC is usually sufficient and can minimize bleeding risk.<sup><span class="xrefLink" id="jumplink-ehae176-B760"></span><a href="javascript:;" reveal-id="ehae176-B760" data-open="ehae176-B760" class="link link-ref link-reveal xref-bibr">760</a>,<span class="xrefLink" id="jumplink-ehae176-B764"></span><a href="javascript:;" reveal-id="ehae176-B764" data-open="ehae176-B764" class="link link-ref link-reveal xref-bibr">764</a>,<span class="xrefLink" id="jumplink-ehae176-B774"></span><a href="javascript:;" reveal-id="ehae176-B774" data-open="ehae176-B774" class="link link-ref link-reveal xref-bibr">774</a></sup> Although there are no head-to-head comparisons between aspirin and clopidogrel, studies have typically used clopidogrel. In patients with stable CCS for more than 12 months, sole therapy with a DOAC is sufficient and no additional antiplatelet therapy is required.<sup><span class="xrefLink" id="jumplink-ehae176-B353"></span><a href="javascript:;" reveal-id="ehae176-B353" data-open="ehae176-B353" class="link link-ref link-reveal xref-bibr">353</a></sup> In patients at potential risk of gastrointestinal bleeding, use of proton pump inhibitors is reasonable during combined antithrombotic therapy, although evidence in AF patients is limited.<sup><span class="xrefLink" id="jumplink-ehae176-B437"></span><a href="javascript:;" reveal-id="ehae176-B437" data-open="ehae176-B437" class="link link-ref link-reveal xref-bibr">437</a>,<span class="xrefLink" id="jumplink-ehae176-B777 ehae176-B778 ehae176-B779"></span><a href="javascript:;" reveal-id="ehae176-B777 ehae176-B778 ehae176-B779" data-open="ehae176-B777 ehae176-B778 ehae176-B779" class="link link-ref link-reveal xref-bibr">777–779</a></sup> Multimorbid patients with ACS or CCS need careful assessment of ischaemic risk and management of modifiable bleeding risk factors, with a comprehensive work-up to individually adapt antithrombotic therapy.

Recommendation Table 24

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884371)

Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24)

![Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt24.jpeg?Expires=1728478929&Signature=1KqML8y4Mpfbey6F5nbv87qyqKf3m8j~lctuTurpN-KpfdEkRArHC8xPXwJJscKItyhK7nOj-1ozv-VDqTjAflCVffi0bJHJzmyUdxqnW8veNT7gMXUtmPoSkB633xcUeIj~GUz9opm7IiLWuhLiRJdDqkeOiE6Sk9~MDsrUYanbjUOcGLoisWdUYB-Lu7GkMeOCLN7XdFv1ykicoFAmfHyZBPZAVgE8PuZpAfGURpLW0dlVGOR0Q4r9Ij1iWmr2WC5dzLU2nX54acLDcJOcl3H5yZitCsH06U8tpobo0O0LG3SAy7-F2pcBAsc8HVvfu2o5EEZ9Yyacg2H3-ZYI5Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 24

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884371)

Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24)

![Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt24.jpeg?Expires=1728478929&Signature=1KqML8y4Mpfbey6F5nbv87qyqKf3m8j~lctuTurpN-KpfdEkRArHC8xPXwJJscKItyhK7nOj-1ozv-VDqTjAflCVffi0bJHJzmyUdxqnW8veNT7gMXUtmPoSkB633xcUeIj~GUz9opm7IiLWuhLiRJdDqkeOiE6Sk9~MDsrUYanbjUOcGLoisWdUYB-Lu7GkMeOCLN7XdFv1ykicoFAmfHyZBPZAVgE8PuZpAfGURpLW0dlVGOR0Q4r9Ij1iWmr2WC5dzLU2nX54acLDcJOcl3H5yZitCsH06U8tpobo0O0LG3SAy7-F2pcBAsc8HVvfu2o5EEZ9Yyacg2H3-ZYI5Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.3. AF-CARE in vascular disease

Peripheral arterial disease (PAD) is common in patients with AF, ranging from 6.7% to 14% of patients.<sup><span class="xrefLink" id="jumplink-ehae176-B783"></span><a href="javascript:;" reveal-id="ehae176-B783" data-open="ehae176-B783" class="link link-ref link-reveal xref-bibr">783</a>,<span class="xrefLink" id="jumplink-ehae176-B784"></span><a href="javascript:;" reveal-id="ehae176-B784" data-open="ehae176-B784" class="link link-ref link-reveal xref-bibr">784</a></sup> Manifest PAD is associated with incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B785"></span><a href="javascript:;" reveal-id="ehae176-B785" data-open="ehae176-B785" class="link link-ref link-reveal xref-bibr">785</a></sup> PAD predicts a higher mortality in patients with AF and is an independent predictor of stroke in those not on OAC.<sup><span class="xrefLink" id="jumplink-ehae176-B783"></span><a href="javascript:;" reveal-id="ehae176-B783" data-open="ehae176-B783" class="link link-ref link-reveal xref-bibr">783</a>,<span class="xrefLink" id="jumplink-ehae176-B786"></span><a href="javascript:;" reveal-id="ehae176-B786" data-open="ehae176-B786" class="link link-ref link-reveal xref-bibr">786</a></sup> Patients with lower extremity artery disease and AF also have a higher overall mortality and risk of major cardiac events.<sup><span class="xrefLink" id="jumplink-ehae176-B784"></span><a href="javascript:;" reveal-id="ehae176-B784" data-open="ehae176-B784" class="link link-ref link-reveal xref-bibr">784</a>,<span class="xrefLink" id="jumplink-ehae176-B787"></span><a href="javascript:;" reveal-id="ehae176-B787" data-open="ehae176-B787" class="link link-ref link-reveal xref-bibr">787</a>,<span class="xrefLink" id="jumplink-ehae176-B788"></span><a href="javascript:;" reveal-id="ehae176-B788" data-open="ehae176-B788" class="link link-ref link-reveal xref-bibr">788</a></sup> A public health database of >40 000 patients hospitalized for PAD or critical limb ischaemia showed AF to be an independent predictor for mortality (HR, 1.46; 95% CI, 1.39–1.52) and ischaemic stroke (HR, 1.63; 95% CI, 1.44–1.85) as compared with propensity-matched controls.<sup><span class="xrefLink" id="jumplink-ehae176-B784"></span><a href="javascript:;" reveal-id="ehae176-B784" data-open="ehae176-B784" class="link link-ref link-reveal xref-bibr">784</a></sup> Similarly, in patients undergoing carotid endarterectomy or stenting, the presence of AF is associated with higher mortality (OR, 1.59; 95% CI, 1.11–2.26).<sup><span class="xrefLink" id="jumplink-ehae176-B789"></span><a href="javascript:;" reveal-id="ehae176-B789" data-open="ehae176-B789" class="link link-ref link-reveal xref-bibr">789</a></sup>

Anticoagulation alone is usually sufficient in the chronic disease phase, with DOACs being the preferred agents despite one RCT subanalysis showing a higher risk of bleeding as compared with warfarin.<sup><span class="xrefLink" id="jumplink-ehae176-B790"></span><a href="javascript:;" reveal-id="ehae176-B790" data-open="ehae176-B790" class="link link-ref link-reveal xref-bibr">790</a></sup> In the case of recent endovascular revascularization, a period of combination with single antiplatelet therapy should be considered, weighing bleeding and thrombotic risks and keeping the period of combination antithrombotic therapy as brief as possible (ranging between 1 month for peripheral<sup><span class="xrefLink" id="jumplink-ehae176-B791"></span><a href="javascript:;" reveal-id="ehae176-B791" data-open="ehae176-B791" class="link link-ref link-reveal xref-bibr">791</a></sup> and 90 days for neuro-interventional procedures).<sup><span class="xrefLink" id="jumplink-ehae176-B792"></span><a href="javascript:;" reveal-id="ehae176-B792" data-open="ehae176-B792" class="link link-ref link-reveal xref-bibr">792</a></sup>

### 9.4. AF-CARE in acute stroke or intracranial haemorrhage

#### 9.4.1. Management of acute ischaemic stroke

Management of acute stroke in patients with AF is beyond the scope of these guidelines. In AF patients presenting with acute ischaemic stroke while taking OAC, acute therapy depends on the treatment regimen and intensity of OAC. Management should be co-ordinated by a specialist neurologist team according to relevant guidelines.<sup><span class="xrefLink" id="jumplink-ehae176-B793"></span><a href="javascript:;" reveal-id="ehae176-B793" data-open="ehae176-B793" class="link link-ref link-reveal xref-bibr">793</a></sup>

#### 9.4.2. Introduction or re-introduction of anticoagulation after ischaemic stroke

The optimal time for administering OAC in patients with acute cardioembolic stroke and AF remains unclear. Randomized control trials have been unable to provide any evidence to support the administration of anticoagulants or heparin in patients with acute ischaemic stroke within 48 h from stroke onset. This suggests that low-dose aspirin should be administered to all patients during this timeframe.<sup><span class="xrefLink" id="jumplink-ehae176-B794"></span><a href="javascript:;" reveal-id="ehae176-B794" data-open="ehae176-B794" class="link link-ref link-reveal xref-bibr">794</a></sup>

Two trials have examined the use of DOAC therapy early after stroke, with no difference in clinical outcomes compared with delayed DOAC prescription. The ELAN (Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN) trial randomized 2013 patients with acute ischaemic stroke and AF to open-label early use of DOACs (<48 h after minor/moderate stroke; day 6–7 after major stroke) vs. later DOAC prescription (day 3–4 after minor stroke; day 6–7 after moderate stroke; day 12–14 after major stroke). There was no significant difference in the composite thromboembolic, bleeding, and vascular death outcome at 30 days (risk difference early vs. late, −1.18%; 95% CI, −2.84 to 0.47).<sup><span class="xrefLink" id="jumplink-ehae176-B795"></span><a href="javascript:;" reveal-id="ehae176-B795" data-open="ehae176-B795" class="link link-ref link-reveal xref-bibr">795</a></sup> The TIMING (Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation) trial, a registry-based, non-inferiority, open-label, blinded endpoint trial randomized 888 patients within 72 h of ischaemic stroke onset to early (≤4 days) or delayed (5–10 days) DOAC initiation. Early DOAC use was non-inferior to the delayed strategy for the composite of thromboembolism, bleeding and all-cause mortality at 90 days (risk difference, −1.79%; 95% CI, −5.31% to 1.74%).<sup><span class="xrefLink" id="jumplink-ehae176-B796"></span><a href="javascript:;" reveal-id="ehae176-B796" data-open="ehae176-B796" class="link link-ref link-reveal xref-bibr">796</a></sup> Two ongoing trials will provide further guidance on the most appropriate timing of DOAC therapy after ischaemic stroke (NCT03759938, NCT03021928).

#### 9.4.3. Introduction or re-introduction of anticoagulation after haemorrhagic stroke

There is insufficient evidence currently to recommend whether OAC should be started or re-started after ICH to protect against the high risk of ischaemic stroke in these patients (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S28](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Data from two pilot trials are available. The APACHE-AF (Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation) trial was a prospective, randomized, open-label trial with masked endpoint assessment; 101 patients who survived 7–90 days after anticoagulation-associated ICH were randomized to apixaban or no OAC. During a median of 1.9 years follow-up (222 person-years), there was no difference in non-fatal stroke or vascular death, with an annual event rate of 12.6% with apixaban and 11.9% with no OAC (adjusted HR, 1.05; 95% CI, 0.48–2.31; _P_ = .90).<sup><span class="xrefLink" id="jumplink-ehae176-B797"></span><a href="javascript:;" reveal-id="ehae176-B797" data-open="ehae176-B797" class="link link-ref link-reveal xref-bibr">797</a></sup> SoSTART (Start or STop Anticoagulants Randomised Trial) was an open-label RCT in 203 patients with AF after symptomatic spontaneous ICH. Starting OAC was not non-inferior to avoiding long-term (≥1 year) OAC, with ICH recurrence in 8/101 (8%) vs. 4/102 (4%) patients (adjusted HR, 2.42; 95% CI, 0.72–8.09). Mortality occurred in 22/101 (22%) patients in the OAC group vs. 11/102 (11%) patients where OAC were avoided.<sup><span class="xrefLink" id="jumplink-ehae176-B798"></span><a href="javascript:;" reveal-id="ehae176-B798" data-open="ehae176-B798" class="link link-ref link-reveal xref-bibr">798</a></sup>

Until additional trials report on the clinical challenge of post-ICH anticoagulation (NCT03950076, NCT03996772), an individualized multidisciplinary approach is advised led by an expert neurology team.

### 9.5. AF-CARE for trigger-induced AF

Trigger-induced AF is defined as new AF in the immediate association of a precipitating and potentially reversible factor. Also known as ‘secondary’ AF, this task force prefer the term trigger-induced as there are almost always underlying factors in individual patients that can benefit from full consideration of the AF-CARE pathway. The most common precipitant unmasking a tendency to AF is acute sepsis, where AF prevalence is between 9% and 20% and has been associated with a worse prognosis.<sup><span class="xrefLink" id="jumplink-ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14"></span><a href="javascript:;" reveal-id="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" data-open="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" class="link link-ref link-reveal xref-bibr">11–14</a></sup> The degree of inflammation correlates with the incidence of AF,<sup><span class="xrefLink" id="jumplink-ehae176-B799"></span><a href="javascript:;" reveal-id="ehae176-B799" data-open="ehae176-B799" class="link link-ref link-reveal xref-bibr">799</a></sup> which may partly explain the wide variability across studies in prevalence, as well as recurrence of AF. Longer-term data suggest that AF triggered by sepsis recurs after discharge in between a third to a half of patients.<sup><span class="xrefLink" id="jumplink-ehae176-B12"></span><a href="javascript:;" reveal-id="ehae176-B12" data-open="ehae176-B12" class="link link-ref link-reveal xref-bibr">12</a>,<span class="xrefLink" id="jumplink-ehae176-B800 ehae176-B801 ehae176-B802 ehae176-B803 ehae176-B804 ehae176-B805 ehae176-B806 ehae176-B807"></span><a href="javascript:;" reveal-id="ehae176-B800 ehae176-B801 ehae176-B802 ehae176-B803 ehae176-B804 ehae176-B805 ehae176-B806 ehae176-B807" data-open="ehae176-B800 ehae176-B801 ehae176-B802 ehae176-B803 ehae176-B804 ehae176-B805 ehae176-B806 ehae176-B807" class="link link-ref link-reveal xref-bibr">800–807</a></sup> In addition to other acute triggers which may be causal (such as alcohol<sup><span class="xrefLink" id="jumplink-ehae176-B808"></span><a href="javascript:;" reveal-id="ehae176-B808" data-open="ehae176-B808" class="link link-ref link-reveal xref-bibr">808</a>,<span class="xrefLink" id="jumplink-ehae176-B809"></span><a href="javascript:;" reveal-id="ehae176-B809" data-open="ehae176-B809" class="link link-ref link-reveal xref-bibr">809</a></sup> and illicit drug use<sup><span class="xrefLink" id="jumplink-ehae176-B810"></span><a href="javascript:;" reveal-id="ehae176-B810" data-open="ehae176-B810" class="link link-ref link-reveal xref-bibr">810</a></sup>), numerous conditions are also associated with chronic inflammation leading to subacute stimuli for AF (_[Table 14](javascript:;)_). The specific trigger of an operative procedure is discussed in _Section [9.6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.6)_.

Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884386)

Non-cardiac conditions associated with trigger-induced AF

| Acute conditions .  |
| --- |
| Infections (bacterial and viral) |
| Pericarditis, myocarditis |
| Emergency conditions (burn injury, severe trauma, shock) |
| Binge alcohol consumption |
| Drug use, including methamphetamines, cocaine, opiates, and cannabis |
| Acute interventions, procedures, and surgery |
| Endocrine disorders (thyroid, adrenal, pituitary, others) |

| Acute conditions .  |
| --- |
| Infections (bacterial and viral) |
| Pericarditis, myocarditis |
| Emergency conditions (burn injury, severe trauma, shock) |
| Binge alcohol consumption |
| Drug use, including methamphetamines, cocaine, opiates, and cannabis |
| Acute interventions, procedures, and surgery |
| Endocrine disorders (thyroid, adrenal, pituitary, others) |

| Chronic conditions with inflammation and enhanced AF substrate .  |
| --- |
| Immune-mediated diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, coeliac disease, psoriasis, others) |
| Obesity |
| Chronic obstructive airways disease |
| Obstructive sleep apnoea |
| Cancer |
| Fatty liver disease |
| Stress |
| Endocrine disorders (see _Section [9.10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.10)_) |

| Chronic conditions with inflammation and enhanced AF substrate .  |
| --- |
| Immune-mediated diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, coeliac disease, psoriasis, others) |
| Obesity |
| Chronic obstructive airways disease |
| Obstructive sleep apnoea |
| Cancer |
| Fatty liver disease |
| Stress |
| Endocrine disorders (see _Section [9.10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.10)_) |

Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884386)

Non-cardiac conditions associated with trigger-induced AF

| Acute conditions .  |
| --- |
| Infections (bacterial and viral) |
| Pericarditis, myocarditis |
| Emergency conditions (burn injury, severe trauma, shock) |
| Binge alcohol consumption |
| Drug use, including methamphetamines, cocaine, opiates, and cannabis |
| Acute interventions, procedures, and surgery |
| Endocrine disorders (thyroid, adrenal, pituitary, others) |

| Acute conditions .  |
| --- |
| Infections (bacterial and viral) |
| Pericarditis, myocarditis |
| Emergency conditions (burn injury, severe trauma, shock) |
| Binge alcohol consumption |
| Drug use, including methamphetamines, cocaine, opiates, and cannabis |
| Acute interventions, procedures, and surgery |
| Endocrine disorders (thyroid, adrenal, pituitary, others) |

| Chronic conditions with inflammation and enhanced AF substrate .  |
| --- |
| Immune-mediated diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, coeliac disease, psoriasis, others) |
| Obesity |
| Chronic obstructive airways disease |
| Obstructive sleep apnoea |
| Cancer |
| Fatty liver disease |
| Stress |
| Endocrine disorders (see _Section [9.10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.10)_) |

| Chronic conditions with inflammation and enhanced AF substrate .  |
| --- |
| Immune-mediated diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, coeliac disease, psoriasis, others) |
| Obesity |
| Chronic obstructive airways disease |
| Obstructive sleep apnoea |
| Cancer |
| Fatty liver disease |
| Stress |
| Endocrine disorders (see _Section [9.10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.10)_) |

After meeting the diagnostic criteria for AF (see _Section [3.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s2.2)_), the management of trigger-induced AF is recommended to follow the AF-CARE principles, with critical consideration of underlying risk factors and comorbidities. Based on retrospective and observational data, patients with AF and trigger-induced AF seem to carry the same thromboembolic risk as patients with primary AF.<sup><span class="xrefLink" id="jumplink-ehae176-B811"></span><a href="javascript:;" reveal-id="ehae176-B811" data-open="ehae176-B811" class="link link-ref link-reveal xref-bibr">811</a>,<span class="xrefLink" id="jumplink-ehae176-B812"></span><a href="javascript:;" reveal-id="ehae176-B812" data-open="ehae176-B812" class="link link-ref link-reveal xref-bibr">812</a></sup> In the acute phase of sepsis, patients show an unclear risk–benefit profile with anticoagulation therapy.<sup><span class="xrefLink" id="jumplink-ehae176-B813"></span><a href="javascript:;" reveal-id="ehae176-B813" data-open="ehae176-B813" class="link link-ref link-reveal xref-bibr">813</a>,<span class="xrefLink" id="jumplink-ehae176-B814"></span><a href="javascript:;" reveal-id="ehae176-B814" data-open="ehae176-B814" class="link link-ref link-reveal xref-bibr">814</a></sup> Prospective studies on anticoagulation in patients with triggered AF episodes are lacking.<sup><span class="xrefLink" id="jumplink-ehae176-B802"></span><a href="javascript:;" reveal-id="ehae176-B802" data-open="ehae176-B802" class="link link-ref link-reveal xref-bibr">802</a>,<span class="xrefLink" id="jumplink-ehae176-B812"></span><a href="javascript:;" reveal-id="ehae176-B812" data-open="ehae176-B812" class="link link-ref link-reveal xref-bibr">812</a>,<span class="xrefLink" id="jumplink-ehae176-B815"></span><a href="javascript:;" reveal-id="ehae176-B815" data-open="ehae176-B815" class="link link-ref link-reveal xref-bibr">815</a></sup> Acknowledging that there are no RCTs specifically available in this population to assess trigger-induced AF, long-term OAC therapy should be considered in suitable patients with trigger-induced AF who are at elevated risk of thromboembolism, starting OAC after the acute trigger has been corrected and considering the anticipated net clinical benefit and informed patient preferences. As with any decision on OAC, not all patients will be suitable for OAC, depending on relative and absolute contraindications and the risk of major bleeding. The approach to rate and rhythm control will depend on subsequent recurrence of AF or any associated symptoms, and re-evaluation should be individualized to take account of the often high AF recurrence rate.

Recommendation Table 25

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884388)

Recommendations for trigger-induced AF (see also Evidence Table 25)

![Recommendations for trigger-induced AF (see also Evidence Table 25)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt25.jpeg?Expires=1728478929&Signature=onbEC~BN009T4GOHmJp6gpk3-VslP7~qJPRW18Lb4RmEQ7AUXbWDgd2a8It8QZGjAil6-DOUy64o~N1NWmel~wutOdYWUhC5yogII2DXUiZ3ANRBPq3yUFY9ZgiJo3RbO-ngZh04wE-dalXMe98xzMOhiaeFuVC64UurfVczAacqMwAQykCnvwcveXeayIuq4oXrqMQuMMsTbU2Mt1XNV2YtlXDCV8i8pDJKgEvK5YrTEIpjpNwF7kZt7kOpBMNZPEMkIdzG0AbWydyYNR7AbEUNbHVsTG1hT65PP82kqAKabrGYDrNrIKDWtPimx8jb3cKpbgMJugFjDIV3DcMWEA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 25

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884388)

Recommendations for trigger-induced AF (see also Evidence Table 25)

![Recommendations for trigger-induced AF (see also Evidence Table 25)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt25.jpeg?Expires=1728478929&Signature=onbEC~BN009T4GOHmJp6gpk3-VslP7~qJPRW18Lb4RmEQ7AUXbWDgd2a8It8QZGjAil6-DOUy64o~N1NWmel~wutOdYWUhC5yogII2DXUiZ3ANRBPq3yUFY9ZgiJo3RbO-ngZh04wE-dalXMe98xzMOhiaeFuVC64UurfVczAacqMwAQykCnvwcveXeayIuq4oXrqMQuMMsTbU2Mt1XNV2YtlXDCV8i8pDJKgEvK5YrTEIpjpNwF7kZt7kOpBMNZPEMkIdzG0AbWydyYNR7AbEUNbHVsTG1hT65PP82kqAKabrGYDrNrIKDWtPimx8jb3cKpbgMJugFjDIV3DcMWEA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.6. AF-CARE in post-operative patients

Peri-operative AF describes the onset of the arrhythmia during an ongoing intervention. Post-operative AF (POAF), defined as new-onset AF in the immediate post-operative period, is a common complication with clinical impact that occurs in 30%–50% of patients undergoing cardiac surgery,<sup><span class="xrefLink" id="jumplink-ehae176-B816 ehae176-B817 ehae176-B818"></span><a href="javascript:;" reveal-id="ehae176-B816 ehae176-B817 ehae176-B818" data-open="ehae176-B816 ehae176-B817 ehae176-B818" class="link link-ref link-reveal xref-bibr">816–818</a></sup> and in 5%–30% of patients undergoing non-cardiac surgery. Intra- and post-operative changes and specific AF triggers (including peri-operative complications) and pre-existing AF-related risk factors and comorbidities increase the susceptibility to POAF.<sup><span class="xrefLink" id="jumplink-ehae176-B819"></span><a href="javascript:;" reveal-id="ehae176-B819" data-open="ehae176-B819" class="link link-ref link-reveal xref-bibr">819</a></sup> Although POAF episodes may be self-terminating, POAF is associated with 4–5 times increase in recurrent AF during the next 5 years,<sup><span class="xrefLink" id="jumplink-ehae176-B820"></span><a href="javascript:;" reveal-id="ehae176-B820" data-open="ehae176-B820" class="link link-ref link-reveal xref-bibr">820</a>,<span class="xrefLink" id="jumplink-ehae176-B821"></span><a href="javascript:;" reveal-id="ehae176-B821" data-open="ehae176-B821" class="link link-ref link-reveal xref-bibr">821</a></sup> and is a risk factor for stroke, MI, heart failure, and death.<sup><span class="xrefLink" id="jumplink-ehae176-B822 ehae176-B823 ehae176-B824 ehae176-B825 ehae176-B826 ehae176-B827"></span><a href="javascript:;" reveal-id="ehae176-B822 ehae176-B823 ehae176-B824 ehae176-B825 ehae176-B826 ehae176-B827" data-open="ehae176-B822 ehae176-B823 ehae176-B824 ehae176-B825 ehae176-B826 ehae176-B827" class="link link-ref link-reveal xref-bibr">822–827</a></sup> Other adverse events associated with POAF include haemodynamic instability, prolonged hospital stay, infections, renal complications, bleeding, increased in-hospital death, and greater healthcare cost.<sup><span class="xrefLink" id="jumplink-ehae176-B828 ehae176-B829 ehae176-B830"></span><a href="javascript:;" reveal-id="ehae176-B828 ehae176-B829 ehae176-B830" data-open="ehae176-B828 ehae176-B829 ehae176-B830" class="link link-ref link-reveal xref-bibr">828–830</a></sup>

While multiple strategies to prevent POAF with pre-treatment or acute drug treatment have been described, there is a lack of evidence from large RCTs. Pre-operative use of propranolol or carvedilol plus _N_\-acetyl cysteine in cardiac and non-cardiac surgery is associated with a reduced incidence of POAF,<sup><span class="xrefLink" id="jumplink-ehae176-B831 ehae176-B832 ehae176-B833 ehae176-B834"></span><a href="javascript:;" reveal-id="ehae176-B831 ehae176-B832 ehae176-B833 ehae176-B834" data-open="ehae176-B831 ehae176-B832 ehae176-B833 ehae176-B834" class="link link-ref link-reveal xref-bibr">831–834</a></sup> but not major adverse events.<sup><span class="xrefLink" id="jumplink-ehae176-B835"></span><a href="javascript:;" reveal-id="ehae176-B835" data-open="ehae176-B835" class="link link-ref link-reveal xref-bibr">835</a></sup> An umbrella review of 89 RCTs from 23 meta-analyses (19 211 patients, but not necessarily in AF) showed no benefit from beta-blockers in cardiac surgery for mortality, MI, or stroke. In non-cardiac surgery, beta-blockers were associated with reduced rates of MI after surgery (RR range, 0.08–0.92), but higher mortality (RR range, 1.03–1.31), and increased risk of stroke (RR range, 1.33–7.72).<sup><span class="xrefLink" id="jumplink-ehae176-B836"></span><a href="javascript:;" reveal-id="ehae176-B836" data-open="ehae176-B836" class="link link-ref link-reveal xref-bibr">836</a></sup> Prevention of peri-operative AF can also be achieved with amiodarone. In a meta-analyses, amiodarone (oral or intravenous \[i.v.\]) and beta-blockers were equally effective in reducing post-operative AF,<sup><span class="xrefLink" id="jumplink-ehae176-B837"></span><a href="javascript:;" reveal-id="ehae176-B837" data-open="ehae176-B837" class="link link-ref link-reveal xref-bibr">837</a></sup> but their combination was better than beta-blockers alone.<sup><span class="xrefLink" id="jumplink-ehae176-B838"></span><a href="javascript:;" reveal-id="ehae176-B838" data-open="ehae176-B838" class="link link-ref link-reveal xref-bibr">838</a></sup> Lower cumulative doses of amiodarone (<3000 mg during the loading phase) could be effective, with fewer adverse events.<sup><span class="xrefLink" id="jumplink-ehae176-B837"></span><a href="javascript:;" reveal-id="ehae176-B837" data-open="ehae176-B837" class="link link-ref link-reveal xref-bibr">837</a>,<span class="xrefLink" id="jumplink-ehae176-B839"></span><a href="javascript:;" reveal-id="ehae176-B839" data-open="ehae176-B839" class="link link-ref link-reveal xref-bibr">839</a>,<span class="xrefLink" id="jumplink-ehae176-B840"></span><a href="javascript:;" reveal-id="ehae176-B840" data-open="ehae176-B840" class="link link-ref link-reveal xref-bibr">840</a></sup> Withdrawal of beta-blockers should be avoided due to increased risk of POAF.<sup><span class="xrefLink" id="jumplink-ehae176-B841"></span><a href="javascript:;" reveal-id="ehae176-B841" data-open="ehae176-B841" class="link link-ref link-reveal xref-bibr">841</a></sup> Other treatment strategies (steroids, magnesium, sotalol, (bi)atrial pacing, and botulium injection into the epicardial fat pad) lack scientific evidence for the prevention of peri-operative AF.<sup><span class="xrefLink" id="jumplink-ehae176-B842"></span><a href="javascript:;" reveal-id="ehae176-B842" data-open="ehae176-B842" class="link link-ref link-reveal xref-bibr">842</a>,<span class="xrefLink" id="jumplink-ehae176-B843"></span><a href="javascript:;" reveal-id="ehae176-B843" data-open="ehae176-B843" class="link link-ref link-reveal xref-bibr">843</a></sup> Peri-operative posterior pericardiotomy, due to the reduction of post-operative pericardial effusion, showed a significant decrease in POAF in patients undergoing cardiac surgery (OR, 0.44; 95% CI, 0.27–0.70; _P_ = .0005).<sup><span class="xrefLink" id="jumplink-ehae176-B844 ehae176-B845 ehae176-B846"></span><a href="javascript:;" reveal-id="ehae176-B844 ehae176-B845 ehae176-B846" data-open="ehae176-B844 ehae176-B845 ehae176-B846" class="link link-ref link-reveal xref-bibr">844–846</a></sup> In 3209 patients undergoing non-cardiac thoracic surgery, colchicine did not lead to any significant reduction in AF compared with placebo (HR, 0.85; 95% CI, 0.65–1.10; _P_ = .22).<sup><span class="xrefLink" id="jumplink-ehae176-B847"></span><a href="javascript:;" reveal-id="ehae176-B847" data-open="ehae176-B847" class="link link-ref link-reveal xref-bibr">847</a></sup>

The evidence for prevention of ischaemic stroke in POAF by OAC is limited.<sup><span class="xrefLink" id="jumplink-ehae176-B822"></span><a href="javascript:;" reveal-id="ehae176-B822" data-open="ehae176-B822" class="link link-ref link-reveal xref-bibr">822</a>,<span class="xrefLink" id="jumplink-ehae176-B827"></span><a href="javascript:;" reveal-id="ehae176-B827" data-open="ehae176-B827" class="link link-ref link-reveal xref-bibr">827</a></sup> Oral anticoagulant therapy is associated with a high bleeding risk soon after cardiac surgery or major non-cardiac interventions.<sup><span class="xrefLink" id="jumplink-ehae176-B827"></span><a href="javascript:;" reveal-id="ehae176-B827" data-open="ehae176-B827" class="link link-ref link-reveal xref-bibr">827</a></sup> Conversely, meta-analyses of observational cohort studies suggest a possible protective impact of OAC in POAF for all-cause mortality<sup><span class="xrefLink" id="jumplink-ehae176-B848"></span><a href="javascript:;" reveal-id="ehae176-B848" data-open="ehae176-B848" class="link link-ref link-reveal xref-bibr">848</a></sup> and a lower risk of thromboembolic events following cardiac surgery, accompanied by higher rates of bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B849"></span><a href="javascript:;" reveal-id="ehae176-B849" data-open="ehae176-B849" class="link link-ref link-reveal xref-bibr">849</a></sup> This task force recommends to treat post-operative AF according to the AF-CARE pathway as discussed for trigger-induced AF (with the \[R\] pathway the same as for first-diagnosed AF). Ongoing RCTs in cardiac surgery (NCT04045665) and non-cardiac surgery (NCT03968393) will inform optimal long-term OAC use among patients with POAF. While awaiting the results of these trials, this task force recommends that after acute bleeding risk has settled, long-term OAC should be considered in patients with POAF according to their thromboembolic risk factors.

Recommendation Table 26

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884393)

Recommendations for management of post-operative AF (see also Evidence Table 26)

![Recommendations for management of post-operative AF (see also Evidence Table 26)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt26.jpeg?Expires=1728478929&Signature=Kbv2oXbQL0MWDTdDaS00RFTSr30WqRx3D3Gph6PBD~zDgTrNvLTP6cGbm-05yEJJmceSjo4PQavjGHLbUl3aYIvuJMRiafCNbxUpE1ZcIMZ8aZcSTzgCb2Q~0UdKRu7QSUK-mbyaNoZRAnb~vM2nI08Sh1kajtABwUx7vLdwcuzmo~scj116h9rd-R4-OiYXm7jA3tcS4-Sjz2W8LLb0ysw41fMFd4aMOkgO9ycYNTy~RHbm5j65l-to-CVWyrhQDL~GmXycAsABOMshP3e1wqKZCZts4Io9yxC2l3yQXNkUNpfeVdom60o5-AgLjJA9gMcW9PyZ1EV9u~5yNcG4Lg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 26

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884393)

Recommendations for management of post-operative AF (see also Evidence Table 26)

![Recommendations for management of post-operative AF (see also Evidence Table 26)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt26.jpeg?Expires=1728478929&Signature=Kbv2oXbQL0MWDTdDaS00RFTSr30WqRx3D3Gph6PBD~zDgTrNvLTP6cGbm-05yEJJmceSjo4PQavjGHLbUl3aYIvuJMRiafCNbxUpE1ZcIMZ8aZcSTzgCb2Q~0UdKRu7QSUK-mbyaNoZRAnb~vM2nI08Sh1kajtABwUx7vLdwcuzmo~scj116h9rd-R4-OiYXm7jA3tcS4-Sjz2W8LLb0ysw41fMFd4aMOkgO9ycYNTy~RHbm5j65l-to-CVWyrhQDL~GmXycAsABOMshP3e1wqKZCZts4Io9yxC2l3yQXNkUNpfeVdom60o5-AgLjJA9gMcW9PyZ1EV9u~5yNcG4Lg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.7. AF-CARE in embolic stroke of unknown source

The term ‘embolic stroke of undetermined source’ (ESUS) was introduced to identify non-lacunar strokes whose mechanism is likely to be embolic, but the source remains unidentified.<sup><span class="xrefLink" id="jumplink-ehae176-B856"></span><a href="javascript:;" reveal-id="ehae176-B856" data-open="ehae176-B856" class="link link-ref link-reveal xref-bibr">856</a></sup> Of note, these patients have a recurrent risk of stroke of 4%–5% per year.<sup><span class="xrefLink" id="jumplink-ehae176-B856"></span><a href="javascript:;" reveal-id="ehae176-B856" data-open="ehae176-B856" class="link link-ref link-reveal xref-bibr">856</a></sup> The main embolic sources associated with ESUS are concealed AF, atrial cardiomyopathy, left ventricular disease, atherosclerotic plaques, patent foramen ovale (PFO), valvular diseases, and cancer. Atrial cardiomyopathy and left ventricular disease are the most prevalent causes.<sup><span class="xrefLink" id="jumplink-ehae176-B856"></span><a href="javascript:;" reveal-id="ehae176-B856" data-open="ehae176-B856" class="link link-ref link-reveal xref-bibr">856</a></sup> AF is reported to be the underlying mechanism in 30% of ESUS patients.<sup><span class="xrefLink" id="jumplink-ehae176-B857 ehae176-B858 ehae176-B859"></span><a href="javascript:;" reveal-id="ehae176-B857 ehae176-B858 ehae176-B859" data-open="ehae176-B857 ehae176-B858 ehae176-B859" class="link link-ref link-reveal xref-bibr">857–859</a></sup> The detection of AF among ESUS patients increases the longer cardiac monitoring is provided (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S29](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B857"></span><a href="javascript:;" reveal-id="ehae176-B857" data-open="ehae176-B857" class="link link-ref link-reveal xref-bibr">857</a>,<span class="xrefLink" id="jumplink-ehae176-B860 ehae176-B861 ehae176-B862 ehae176-B863 ehae176-B864"></span><a href="javascript:;" reveal-id="ehae176-B860 ehae176-B861 ehae176-B862 ehae176-B863 ehae176-B864" data-open="ehae176-B860 ehae176-B861 ehae176-B862 ehae176-B863 ehae176-B864" class="link link-ref link-reveal xref-bibr">860–864</a></sup> This also holds for the duration of implantable cardiac monitoring, with probability of AF detection ranging from 2% with 1 week to over 20% by 3 years.<sup><span class="xrefLink" id="jumplink-ehae176-B865"></span><a href="javascript:;" reveal-id="ehae176-B865" data-open="ehae176-B865" class="link link-ref link-reveal xref-bibr">865</a></sup> In patients with ESUS, factors associated with an increased detection of AF are increasing age,<sup><span class="xrefLink" id="jumplink-ehae176-B866"></span><a href="javascript:;" reveal-id="ehae176-B866" data-open="ehae176-B866" class="link link-ref link-reveal xref-bibr">866</a>,<span class="xrefLink" id="jumplink-ehae176-B867"></span><a href="javascript:;" reveal-id="ehae176-B867" data-open="ehae176-B867" class="link link-ref link-reveal xref-bibr">867</a></sup> left atrial enlargement,<sup><span class="xrefLink" id="jumplink-ehae176-B866"></span><a href="javascript:;" reveal-id="ehae176-B866" data-open="ehae176-B866" class="link link-ref link-reveal xref-bibr">866</a></sup> cortical location of stroke,<sup><span class="xrefLink" id="jumplink-ehae176-B868"></span><a href="javascript:;" reveal-id="ehae176-B868" data-open="ehae176-B868" class="link link-ref link-reveal xref-bibr">868</a></sup> large or small vessel disease,<sup><span class="xrefLink" id="jumplink-ehae176-B863"></span><a href="javascript:;" reveal-id="ehae176-B863" data-open="ehae176-B863" class="link link-ref link-reveal xref-bibr">863</a></sup> an increased number of atrial premature beats per 24 h,<sup><span class="xrefLink" id="jumplink-ehae176-B868"></span><a href="javascript:;" reveal-id="ehae176-B868" data-open="ehae176-B868" class="link link-ref link-reveal xref-bibr">868</a></sup> rhythm irregularity,<sup><span class="xrefLink" id="jumplink-ehae176-B859"></span><a href="javascript:;" reveal-id="ehae176-B859" data-open="ehae176-B859" class="link link-ref link-reveal xref-bibr">859</a></sup> and risk stratification scores (such as CHA<sub>2</sub>DS<sub>2-</sub>VASc,<sup><span class="xrefLink" id="jumplink-ehae176-B869"></span><a href="javascript:;" reveal-id="ehae176-B869" data-open="ehae176-B869" class="link link-ref link-reveal xref-bibr">869</a></sup> Brown ESUS-AF,<sup><span class="xrefLink" id="jumplink-ehae176-B870"></span><a href="javascript:;" reveal-id="ehae176-B870" data-open="ehae176-B870" class="link link-ref link-reveal xref-bibr">870</a></sup> HAVOC,<sup><span class="xrefLink" id="jumplink-ehae176-B871"></span><a href="javascript:;" reveal-id="ehae176-B871" data-open="ehae176-B871" class="link link-ref link-reveal xref-bibr">871</a></sup> and C<sub>2</sub>HEST<sup><span class="xrefLink" id="jumplink-ehae176-B872"></span><a href="javascript:;" reveal-id="ehae176-B872" data-open="ehae176-B872" class="link link-ref link-reveal xref-bibr">872</a></sup>). This task force recommends prolonged monitoring depending on the presence of the above-mentioned risk markers.<sup><span class="xrefLink" id="jumplink-ehae176-B865"></span><a href="javascript:;" reveal-id="ehae176-B865" data-open="ehae176-B865" class="link link-ref link-reveal xref-bibr">865</a>,<span class="xrefLink" id="jumplink-ehae176-B873"></span><a href="javascript:;" reveal-id="ehae176-B873" data-open="ehae176-B873" class="link link-ref link-reveal xref-bibr">873</a>,<span class="xrefLink" id="jumplink-ehae176-B874"></span><a href="javascript:;" reveal-id="ehae176-B874" data-open="ehae176-B874" class="link link-ref link-reveal xref-bibr">874</a></sup>

Currently available evidence, including two completed RCTs and one stopped for futility, do not support the use of DOACs compared with aspirin in patients with acute ESUS without documented AF.<sup><span class="xrefLink" id="jumplink-ehae176-B875 ehae176-B876 ehae176-B877"></span><a href="javascript:;" reveal-id="ehae176-B875 ehae176-B876 ehae176-B877" data-open="ehae176-B875 ehae176-B876 ehae176-B877" class="link link-ref link-reveal xref-bibr">875–877</a></sup> Ongoing trials will provide further guidance (NCT05134454, NCT05293080, NCT04371055).

Recommendation Table 27

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884397)

Recommendations for patients with embolic stroke of unknown source (see also Evidence Table 27)

![Recommendations for patients with embolic stroke of unknown source (see also Evidence Table 27)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt27.jpeg?Expires=1728478929&Signature=jvl2RulOn-nPv0e0rbFPdDY21Ri~sc~J4UULYhaY-vmXo~iVuJJ0uB66a0RnbF2UQqRhobhnvR-cLzoBxC4tGoX8Akw7gvMxJV0A1YhbTbbr5RnOAZA-5E8DXog6fJYtbhVASXaHLAK6dGKoO~6hDu4QF73QutZ~JbxXeov-bF0xzJgflv9LdGBWze3PDPy8exeHnHus8h1Q66iF0duqoEjKcztVLAqEshQERsTrwKuFMlmUsqCKC3vU5ch4pgvPHav6sV4m0k1IvepypejYdVq8TAZuBPNnqa9S0ixiUmyBcrAfVfSTVKmm26Fh4SJYnF2TVm7~JO2Irwz1rO797g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 27

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884397)

Recommendations for patients with embolic stroke of unknown source (see also Evidence Table 27)

![Recommendations for patients with embolic stroke of unknown source (see also Evidence Table 27)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt27.jpeg?Expires=1728478929&Signature=jvl2RulOn-nPv0e0rbFPdDY21Ri~sc~J4UULYhaY-vmXo~iVuJJ0uB66a0RnbF2UQqRhobhnvR-cLzoBxC4tGoX8Akw7gvMxJV0A1YhbTbbr5RnOAZA-5E8DXog6fJYtbhVASXaHLAK6dGKoO~6hDu4QF73QutZ~JbxXeov-bF0xzJgflv9LdGBWze3PDPy8exeHnHus8h1Q66iF0duqoEjKcztVLAqEshQERsTrwKuFMlmUsqCKC3vU5ch4pgvPHav6sV4m0k1IvepypejYdVq8TAZuBPNnqa9S0ixiUmyBcrAfVfSTVKmm26Fh4SJYnF2TVm7~JO2Irwz1rO797g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.8. AF-CARE during pregnancy

Atrial fibrillation is one of the most common arrhythmias during pregnancy, with prevalence increasing due to higher maternal age and changes in lifestyle, and because more women with congenital heart disease survive to childbearing age.<sup><span class="xrefLink" id="jumplink-ehae176-B878 ehae176-B879 ehae176-B880 ehae176-B881"></span><a href="javascript:;" reveal-id="ehae176-B878 ehae176-B879 ehae176-B880 ehae176-B881" data-open="ehae176-B878 ehae176-B879 ehae176-B880 ehae176-B881" class="link link-ref link-reveal xref-bibr">878–881</a></sup> Rapid atrioventricular conduction of AF may have serious haemodynamic consequences for mother and foetus. AF during pregnancy is associated with an increased risk of death.<sup><span class="xrefLink" id="jumplink-ehae176-B882"></span><a href="javascript:;" reveal-id="ehae176-B882" data-open="ehae176-B882" class="link link-ref link-reveal xref-bibr">882</a></sup> A multidisciplinary approach is essential to prevent maternal and foetal complications, bringing together gynaecologists, neonatologists, anaesthesiologists, and cardiologists experienced in maternal medicine.<sup><span class="xrefLink" id="jumplink-ehae176-B883"></span><a href="javascript:;" reveal-id="ehae176-B883" data-open="ehae176-B883" class="link link-ref link-reveal xref-bibr">883</a></sup>

Pregnancy is associated with a hypercoagulable state and increased thromboembolic risk.<sup><span class="xrefLink" id="jumplink-ehae176-B884"></span><a href="javascript:;" reveal-id="ehae176-B884" data-open="ehae176-B884" class="link link-ref link-reveal xref-bibr">884</a></sup> The same rules for risk assessment of thromboembolism should be used as in non-pregnant women, as detailed in the _2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy_.<sup><span class="xrefLink" id="jumplink-ehae176-B885"></span><a href="javascript:;" reveal-id="ehae176-B885" data-open="ehae176-B885" class="link link-ref link-reveal xref-bibr">885</a></sup> The preferred agents for anticoagulation of AF during pregnancy are unfractionated or low molecular weight heparins (LMWHs), which do not cross the placenta. Vitamin K antagonists should be avoided in the first trimester (risk of miscarriage, teratogenicity) and from week 36 onwards (risk of foetal intracranial bleeding if early unexpected delivery). Direct oral anticoagulants are not recommended during pregnancy due to concerns about safety.<sup><span class="xrefLink" id="jumplink-ehae176-B886"></span><a href="javascript:;" reveal-id="ehae176-B886" data-open="ehae176-B886" class="link link-ref link-reveal xref-bibr">886</a></sup> However, an accidental exposure during pregnancy should not lead to a recommendation for termination of the pregnancy.<sup><span class="xrefLink" id="jumplink-ehae176-B887"></span><a href="javascript:;" reveal-id="ehae176-B887" data-open="ehae176-B887" class="link link-ref link-reveal xref-bibr">887</a></sup> Vaginal delivery should be advised for most women, but is contraindicated during VKA treatment because of the risk of foetal intracranial bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B885"></span><a href="javascript:;" reveal-id="ehae176-B885" data-open="ehae176-B885" class="link link-ref link-reveal xref-bibr">885</a></sup>

Intravenous selective beta-1 receptor blockers are recommended as first choice for acute heart rate control of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B888"></span><a href="javascript:;" reveal-id="ehae176-B888" data-open="ehae176-B888" class="link link-ref link-reveal xref-bibr">888</a></sup> This does not include atenolol, which can lead to intrauterine growth retardation.<sup><span class="xrefLink" id="jumplink-ehae176-B889"></span><a href="javascript:;" reveal-id="ehae176-B889" data-open="ehae176-B889" class="link link-ref link-reveal xref-bibr">889</a></sup> If beta-blockers fail, digoxin and verapamil can be considered for rate control (verapamil should be avoided in the first trimester). Rhythm control is the preferred strategy during pregnancy. Electrical cardioversion is recommended if there is haemodynamic instability, considerable risk to mother or foetus, or with concomitant HCM. Electrical cardioversion can be performed safely without compromising foetal blood flow, and the consequent risk for foetal arrhythmias or pre-term labour is low. The foetal heart rate should be closely monitored throughout and after cardioversion, which should generally be preceded by anticoagulation.<sup><span class="xrefLink" id="jumplink-ehae176-B885"></span><a href="javascript:;" reveal-id="ehae176-B885" data-open="ehae176-B885" class="link link-ref link-reveal xref-bibr">885</a></sup> In haemodynamically stable women without structural heart disease, intravenous ibutilide or flecainide may be considered for termination of AF, but experience is limited.<sup><span class="xrefLink" id="jumplink-ehae176-B890"></span><a href="javascript:;" reveal-id="ehae176-B890" data-open="ehae176-B890" class="link link-ref link-reveal xref-bibr">890</a></sup> Catheter ablation is normally avoided during pregnancy,<sup><span class="xrefLink" id="jumplink-ehae176-B883"></span><a href="javascript:;" reveal-id="ehae176-B883" data-open="ehae176-B883" class="link link-ref link-reveal xref-bibr">883</a></sup> but is technically feasible without radiation in refractory symptomatic cases with a minimal/zero fluoroscopy approach.<sup><span class="xrefLink" id="jumplink-ehae176-B883"></span><a href="javascript:;" reveal-id="ehae176-B883" data-open="ehae176-B883" class="link link-ref link-reveal xref-bibr">883</a></sup>

Counselling is important in women of childbearing potential prior to pregnancy, highlighting the potential risks of anticoagulation and rate or rhythm control drugs (including teratogenic risk, where relevant). Contraception and timely switch to safe drugs should be proactively discussed.

Recommendation Table 28

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884403)

Recommendations for patients with AF during pregnancy (see also Evidence Table 28)

![Recommendations for patients with AF during pregnancy (see also Evidence Table 28)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt28.jpeg?Expires=1728478929&Signature=d-e9bkaTk8NW45OcwVlkvqDJhKkwj-QgYx1ulj8mA6JvBrJk6CByVsDPmo1jUnUEkx7kbm2MvLiB8nVd1zQM48LsiaJsjw4dUsXp~DcWgBC9vJmJec75e0ZzShnhy~fijMZzVpPFvh17YlSKgxUpvnLJA6y25uZsWa2N0WZitJwn7mHH-fubJJe0J9sz~TqhM9812czkViXgzw5JQ-ck~xSqVOluLVxEoUt1RvWai1qhgaRbmzOTigDMEwIB1JcXZafpWzxPmg4Zj28gk4fjKfZSBpc6sy8muR7WiLmc6Wrag5LeSTWGE0WM9WzSf32AWdoJhd28PkCjuKVbo7srsw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 28

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884403)

Recommendations for patients with AF during pregnancy (see also Evidence Table 28)

![Recommendations for patients with AF during pregnancy (see also Evidence Table 28)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt28.jpeg?Expires=1728478929&Signature=d-e9bkaTk8NW45OcwVlkvqDJhKkwj-QgYx1ulj8mA6JvBrJk6CByVsDPmo1jUnUEkx7kbm2MvLiB8nVd1zQM48LsiaJsjw4dUsXp~DcWgBC9vJmJec75e0ZzShnhy~fijMZzVpPFvh17YlSKgxUpvnLJA6y25uZsWa2N0WZitJwn7mHH-fubJJe0J9sz~TqhM9812czkViXgzw5JQ-ck~xSqVOluLVxEoUt1RvWai1qhgaRbmzOTigDMEwIB1JcXZafpWzxPmg4Zj28gk4fjKfZSBpc6sy8muR7WiLmc6Wrag5LeSTWGE0WM9WzSf32AWdoJhd28PkCjuKVbo7srsw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.9. AF-CARE in congenital heart disease

Survival of patients with congenital heart disease has increased over time, but robust data on the management of AF are missing and available evidence is derived mainly from observational studies. Oral anticoagulants are recommended for all patients with AF and intracardiac repair, cyanotic congenital heart disease, Fontan palliation, or systemic right ventricle irrespective of the individuals' thromboembolic risk factors.<sup><span class="xrefLink" id="jumplink-ehae176-B897"></span><a href="javascript:;" reveal-id="ehae176-B897" data-open="ehae176-B897" class="link link-ref link-reveal xref-bibr">897</a></sup> Patients with AF and other congenital heart diseases should follow the general risk stratification for OAC use in AF (i.e. depending on the thromboembolic risk or CHA<sub>2</sub>DS<sub>2</sub>\-VA score). Direct oral anticoagulants are contraindicated in patients with mechanical heart valves,<sup><span class="xrefLink" id="jumplink-ehae176-B331"></span><a href="javascript:;" reveal-id="ehae176-B331" data-open="ehae176-B331" class="link link-ref link-reveal xref-bibr">331</a></sup> but appear safe in patients with congenital heart disease,<sup><span class="xrefLink" id="jumplink-ehae176-B898"></span><a href="javascript:;" reveal-id="ehae176-B898" data-open="ehae176-B898" class="link link-ref link-reveal xref-bibr">898</a>,<span class="xrefLink" id="jumplink-ehae176-B899"></span><a href="javascript:;" reveal-id="ehae176-B899" data-open="ehae176-B899" class="link link-ref link-reveal xref-bibr">899</a></sup> or those with a valvular bioprosthesis.<sup><span class="xrefLink" id="jumplink-ehae176-B900"></span><a href="javascript:;" reveal-id="ehae176-B900" data-open="ehae176-B900" class="link link-ref link-reveal xref-bibr">900</a>,<span class="xrefLink" id="jumplink-ehae176-B901"></span><a href="javascript:;" reveal-id="ehae176-B901" data-open="ehae176-B901" class="link link-ref link-reveal xref-bibr">901</a></sup>

Rate control drugs such as selective beta-1 receptor blockers, verapamil, diltiazem, and digoxin can be used with caution, with monitoring for bradycardia and hypotension. Rhythm control strategies such as amiodarone may be effective, but warrant monitoring for bradycardia. When cardioversion is planned, both 3 weeks of OAC and TOE should be considered because thrombi are common in patients with congenital heart disease and atrial arrhythmias.<sup><span class="xrefLink" id="jumplink-ehae176-B902"></span><a href="javascript:;" reveal-id="ehae176-B902" data-open="ehae176-B902" class="link link-ref link-reveal xref-bibr">902</a>,<span class="xrefLink" id="jumplink-ehae176-B903"></span><a href="javascript:;" reveal-id="ehae176-B903" data-open="ehae176-B903" class="link link-ref link-reveal xref-bibr">903</a></sup> Ablation approaches can be successful in patients with congenital heart disease, but AF recurrence rates may be high (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S30](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

In patients with atrial septal defect, closure may be performed before the fourth decade of life to decrease the risk of AF or AFL.<sup><span class="xrefLink" id="jumplink-ehae176-B904"></span><a href="javascript:;" reveal-id="ehae176-B904" data-open="ehae176-B904" class="link link-ref link-reveal xref-bibr">904</a></sup> Patients with stroke who underwent closure of their PFO may have an increased risk of AF,<sup><span class="xrefLink" id="jumplink-ehae176-B905"></span><a href="javascript:;" reveal-id="ehae176-B905" data-open="ehae176-B905" class="link link-ref link-reveal xref-bibr">905</a></sup> but in patients with PFO and AF, PFO closure is not recommended for stroke prevention. AF surgery or catheter ablation can be considered at the time of closure of the atrial septal defect within a multidisciplinary team.<sup><span class="xrefLink" id="jumplink-ehae176-B906 ehae176-B907 ehae176-B908"></span><a href="javascript:;" reveal-id="ehae176-B906 ehae176-B907 ehae176-B908" data-open="ehae176-B906 ehae176-B907 ehae176-B908" class="link link-ref link-reveal xref-bibr">906–908</a></sup> AF catheter ablation of late atrial arrhythmias is likely to be effective after surgical atrial septal closure.<sup><span class="xrefLink" id="jumplink-ehae176-B909"></span><a href="javascript:;" reveal-id="ehae176-B909" data-open="ehae176-B909" class="link link-ref link-reveal xref-bibr">909</a></sup>

Recommendation Table 29

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884408)

Recommendations for patients with AF and congenital heart disease (see also Evidence Table 29)

![Recommendations for patients with AF and congenital heart disease (see also Evidence Table 29)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt29.jpeg?Expires=1728478929&Signature=hNCpWZg8C033PHHzeSK2Y-tWpfbA62RsFLc5cgWvoqcjIqy~ErwDlz8Ta9FLQMfSP3KmmmSrsqSVDdfeYXsq37iNo9~1f7y844jkDHmjT8UvLNGN7sSPNs4b2TVzTnJzKZk9XmtxWduZGWxp9-vYQbw7EHC4fXeUJFrPZcU2bwznO7XaZ47X7AOvtu9NV1pYr2APenbtcdNalmBvzP1k59YbClsS1b5gVJdRudtqIIg1ZAeaSHtRH~N4yAvwDBgFQMk8LsIh3haBRIbkcIRxiWutDnSSGIMYh~n-~cSrepwrGxDJcLdP65~gwJuRJYzSGARuITZnm4Yu9rIo5OHYpA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 29

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884408)

Recommendations for patients with AF and congenital heart disease (see also Evidence Table 29)

![Recommendations for patients with AF and congenital heart disease (see also Evidence Table 29)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt29.jpeg?Expires=1728478929&Signature=hNCpWZg8C033PHHzeSK2Y-tWpfbA62RsFLc5cgWvoqcjIqy~ErwDlz8Ta9FLQMfSP3KmmmSrsqSVDdfeYXsq37iNo9~1f7y844jkDHmjT8UvLNGN7sSPNs4b2TVzTnJzKZk9XmtxWduZGWxp9-vYQbw7EHC4fXeUJFrPZcU2bwznO7XaZ47X7AOvtu9NV1pYr2APenbtcdNalmBvzP1k59YbClsS1b5gVJdRudtqIIg1ZAeaSHtRH~N4yAvwDBgFQMk8LsIh3haBRIbkcIRxiWutDnSSGIMYh~n-~cSrepwrGxDJcLdP65~gwJuRJYzSGARuITZnm4Yu9rIo5OHYpA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.10. AF-CARE in endocrine disorders

Endocrine dysfunction is closely related to AF, both as the direct action of endocrine hormones and as a consequence of treatments for endocrine disease. Optimal management of endocrine disorders is therefore part of the AF-CARE pathway.<sup><span class="xrefLink" id="jumplink-ehae176-B910"></span><a href="javascript:;" reveal-id="ehae176-B910" data-open="ehae176-B910" class="link link-ref link-reveal xref-bibr">910</a>,<span class="xrefLink" id="jumplink-ehae176-B911"></span><a href="javascript:;" reveal-id="ehae176-B911" data-open="ehae176-B911" class="link link-ref link-reveal xref-bibr">911</a></sup>

Clinical and subclinical hyperthyroidism, as well as subclinical hypothyroidism, are associated with an increased risk of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B912"></span><a href="javascript:;" reveal-id="ehae176-B912" data-open="ehae176-B912" class="link link-ref link-reveal xref-bibr">912</a>,<span class="xrefLink" id="jumplink-ehae176-B913"></span><a href="javascript:;" reveal-id="ehae176-B913" data-open="ehae176-B913" class="link link-ref link-reveal xref-bibr">913</a></sup> Patients presenting with new-onset or recurrent AF should be tested for thyroid-stimulating hormone (TSH) levels. The risk of AF is enhanced in vulnerable patients, including the elderly and those with structural atrial diseases,<sup><span class="xrefLink" id="jumplink-ehae176-B914"></span><a href="javascript:;" reveal-id="ehae176-B914" data-open="ehae176-B914" class="link link-ref link-reveal xref-bibr">914</a>,<span class="xrefLink" id="jumplink-ehae176-B915"></span><a href="javascript:;" reveal-id="ehae176-B915" data-open="ehae176-B915" class="link link-ref link-reveal xref-bibr">915</a></sup> as well as cancer patients on immune checkpoint inhibitors.<sup><span class="xrefLink" id="jumplink-ehae176-B916"></span><a href="javascript:;" reveal-id="ehae176-B916" data-open="ehae176-B916" class="link link-ref link-reveal xref-bibr">916</a>,<span class="xrefLink" id="jumplink-ehae176-B917"></span><a href="javascript:;" reveal-id="ehae176-B917" data-open="ehae176-B917" class="link link-ref link-reveal xref-bibr">917</a></sup> In hyperthyroidism, and even in the euthyroid range, the risk of AF increases according to the reduction in TSH and elevated levels of thyroxine.<sup><span class="xrefLink" id="jumplink-ehae176-B918"></span><a href="javascript:;" reveal-id="ehae176-B918" data-open="ehae176-B918" class="link link-ref link-reveal xref-bibr">918</a>,<span class="xrefLink" id="jumplink-ehae176-B919"></span><a href="javascript:;" reveal-id="ehae176-B919" data-open="ehae176-B919" class="link link-ref link-reveal xref-bibr">919</a></sup> Moreover, the risk of stroke is higher in patients with hyperthyroidism, which can be mitigated by treating the thyroid disorder.<sup><span class="xrefLink" id="jumplink-ehae176-B920"></span><a href="javascript:;" reveal-id="ehae176-B920" data-open="ehae176-B920" class="link link-ref link-reveal xref-bibr">920</a>,<span class="xrefLink" id="jumplink-ehae176-B921"></span><a href="javascript:;" reveal-id="ehae176-B921" data-open="ehae176-B921" class="link link-ref link-reveal xref-bibr">921</a></sup> Amiodarone induces thyroid dysfunction in 15%–20% of treated patients, leading to both hypo- and hyperthyroidism,<sup><span class="xrefLink" id="jumplink-ehae176-B922"></span><a href="javascript:;" reveal-id="ehae176-B922" data-open="ehae176-B922" class="link link-ref link-reveal xref-bibr">922</a>,<span class="xrefLink" id="jumplink-ehae176-B923"></span><a href="javascript:;" reveal-id="ehae176-B923" data-open="ehae176-B923" class="link link-ref link-reveal xref-bibr">923</a></sup> which warrants referral to an endocrinologist (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) for further details).

Hypercalcaemia may also induce arrhythmias, but the role of primary hyperparathyroidism in incident AF is poorly studied. Surgical parathyroidectomy has been found to reduce both supraventricular and ventricular premature beats.<sup><span class="xrefLink" id="jumplink-ehae176-B924 ehae176-B925 ehae176-B926"></span><a href="javascript:;" reveal-id="ehae176-B924 ehae176-B925 ehae176-B926" data-open="ehae176-B924 ehae176-B925 ehae176-B926" class="link link-ref link-reveal xref-bibr">924–926</a></sup> Primary aldosteronism is related to an increased risk of AF through direct actions and vascular effects,<sup><span class="xrefLink" id="jumplink-ehae176-B927"></span><a href="javascript:;" reveal-id="ehae176-B927" data-open="ehae176-B927" class="link link-ref link-reveal xref-bibr">927</a>,<span class="xrefLink" id="jumplink-ehae176-B928"></span><a href="javascript:;" reveal-id="ehae176-B928" data-open="ehae176-B928" class="link link-ref link-reveal xref-bibr">928</a></sup> with a three-fold higher rate of incident AF compared with patients with essential hypertension.<sup><span class="xrefLink" id="jumplink-ehae176-B929"></span><a href="javascript:;" reveal-id="ehae176-B929" data-open="ehae176-B929" class="link link-ref link-reveal xref-bibr">929</a></sup> Increases in genetically predicted plasma cortisol are associated with greater risk of AF, and patients with adrenal incidentalomas with subclinical cortisol secretion have a higher prevalence of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B930"></span><a href="javascript:;" reveal-id="ehae176-B930" data-open="ehae176-B930" class="link link-ref link-reveal xref-bibr">930</a>,<span class="xrefLink" id="jumplink-ehae176-B931"></span><a href="javascript:;" reveal-id="ehae176-B931" data-open="ehae176-B931" class="link link-ref link-reveal xref-bibr">931</a></sup> Acromegaly may predispose to an increased substrate for AF, with incident AF rates significantly higher than controls in long-term follow-up, even after adjusting for AF risk factors.<sup><span class="xrefLink" id="jumplink-ehae176-B932"></span><a href="javascript:;" reveal-id="ehae176-B932" data-open="ehae176-B932" class="link link-ref link-reveal xref-bibr">932</a></sup>

The association between type 2 diabetes and AF is discussed in _Sections [5.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s4.3)_ (AF recurrence) and _Section [10.5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s9.5)_ (incident AF). In addition to insulin-resistance mechanisms typical of type 2 diabetes, the loss of insulin signalling has recently been associated with electrical changes that can lead to AF. Type 1 diabetes is associated with an increased risk of several cardiovascular diseases including AF.<sup><span class="xrefLink" id="jumplink-ehae176-B933 ehae176-B934 ehae176-B935 ehae176-B936 ehae176-B937"></span><a href="javascript:;" reveal-id="ehae176-B933 ehae176-B934 ehae176-B935 ehae176-B936 ehae176-B937" data-open="ehae176-B933 ehae176-B934 ehae176-B935 ehae176-B936 ehae176-B937" class="link link-ref link-reveal xref-bibr">933–937</a></sup>

### 9.11. AF-CARE in inherited cardiomyopathies and primary arrhythmia syndromes

A higher incidence and prevalence of AF have been described in patients with inherited cardiomyopathies and primary arrhythmia syndromes.<sup><span class="xrefLink" id="jumplink-ehae176-B271"></span><a href="javascript:;" reveal-id="ehae176-B271" data-open="ehae176-B271" class="link link-ref link-reveal xref-bibr">271</a>,<span class="xrefLink" id="jumplink-ehae176-B938 ehae176-B939 ehae176-B940 ehae176-B941 ehae176-B942 ehae176-B943 ehae176-B944 ehae176-B945 ehae176-B946 ehae176-B947 ehae176-B948 ehae176-B949 ehae176-B950 ehae176-B951 ehae176-B952 ehae176-B953 ehae176-B954 ehae176-B955 ehae176-B956 ehae176-B957 ehae176-B958 ehae176-B959 ehae176-B960 ehae176-B961 ehae176-B962 ehae176-B963 ehae176-B964 ehae176-B965 ehae176-B966 ehae176-B967 ehae176-B968 ehae176-B969 ehae176-B970"></span><a href="javascript:;" reveal-id="ehae176-B938 ehae176-B939 ehae176-B940 ehae176-B941 ehae176-B942 ehae176-B943 ehae176-B944 ehae176-B945 ehae176-B946 ehae176-B947 ehae176-B948 ehae176-B949 ehae176-B950 ehae176-B951 ehae176-B952 ehae176-B953 ehae176-B954 ehae176-B955 ehae176-B956 ehae176-B957 ehae176-B958 ehae176-B959 ehae176-B960 ehae176-B961 ehae176-B962 ehae176-B963 ehae176-B964 ehae176-B965 ehae176-B966 ehae176-B967 ehae176-B968 ehae176-B969 ehae176-B970" data-open="ehae176-B938 ehae176-B939 ehae176-B940 ehae176-B941 ehae176-B942 ehae176-B943 ehae176-B944 ehae176-B945 ehae176-B946 ehae176-B947 ehae176-B948 ehae176-B949 ehae176-B950 ehae176-B951 ehae176-B952 ehae176-B953 ehae176-B954 ehae176-B955 ehae176-B956 ehae176-B957 ehae176-B958 ehae176-B959 ehae176-B960 ehae176-B961 ehae176-B962 ehae176-B963 ehae176-B964 ehae176-B965 ehae176-B966 ehae176-B967 ehae176-B968 ehae176-B969 ehae176-B970" class="link link-ref link-reveal xref-bibr">938–970</a></sup> AF can be the presenting or only clinically overt feature.<sup><span class="xrefLink" id="jumplink-ehae176-B969"></span><a href="javascript:;" reveal-id="ehae176-B969" data-open="ehae176-B969" class="link link-ref link-reveal xref-bibr">969</a>,<span class="xrefLink" id="jumplink-ehae176-B971 ehae176-B972 ehae176-B973 ehae176-B974 ehae176-B975"></span><a href="javascript:;" reveal-id="ehae176-B971 ehae176-B972 ehae176-B973 ehae176-B974 ehae176-B975" data-open="ehae176-B971 ehae176-B972 ehae176-B973 ehae176-B974 ehae176-B975" class="link link-ref link-reveal xref-bibr">971–975</a></sup> AF in these patients is associated with adverse clinical outcomes,<sup><span class="xrefLink" id="jumplink-ehae176-B947"></span><a href="javascript:;" reveal-id="ehae176-B947" data-open="ehae176-B947" class="link link-ref link-reveal xref-bibr">947</a>,<span class="xrefLink" id="jumplink-ehae176-B954"></span><a href="javascript:;" reveal-id="ehae176-B954" data-open="ehae176-B954" class="link link-ref link-reveal xref-bibr">954</a>,<span class="xrefLink" id="jumplink-ehae176-B959"></span><a href="javascript:;" reveal-id="ehae176-B959" data-open="ehae176-B959" class="link link-ref link-reveal xref-bibr">959</a>,<span class="xrefLink" id="jumplink-ehae176-B963"></span><a href="javascript:;" reveal-id="ehae176-B963" data-open="ehae176-B963" class="link link-ref link-reveal xref-bibr">963</a>,<span class="xrefLink" id="jumplink-ehae176-B965"></span><a href="javascript:;" reveal-id="ehae176-B965" data-open="ehae176-B965" class="link link-ref link-reveal xref-bibr">965</a>,<span class="xrefLink" id="jumplink-ehae176-B976 ehae176-B977 ehae176-B978"></span><a href="javascript:;" reveal-id="ehae176-B976 ehae176-B977 ehae176-B978" data-open="ehae176-B976 ehae176-B977 ehae176-B978" class="link link-ref link-reveal xref-bibr">976–978</a></sup> and has important implications on management (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S31](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). When AF presents at a young age, there should be a careful interrogation about family history and a search for underlying disease.<sup><span class="xrefLink" id="jumplink-ehae176-B979"></span><a href="javascript:;" reveal-id="ehae176-B979" data-open="ehae176-B979" class="link link-ref link-reveal xref-bibr">979</a></sup>

Rhythm control approaches may be challenging in patients with inherited cardiomyopathies and primary arrhythmia syndromes. For example, many drugs have a higher risk of adverse events or may be contraindicated (e.g. amiodarone and sotalol in congenital long QT syndrome, and Class IC AADs in Brugada syndrome) (see [Supplementary Data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S6](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Owing to long-term adverse effects, chronic use of amiodarone is problematic in these typically young individuals. In patients with an implantable cardioverter defibrillator, AF is a common cause of inappropriate shocks.<sup><span class="xrefLink" id="jumplink-ehae176-B959"></span><a href="javascript:;" reveal-id="ehae176-B959" data-open="ehae176-B959" class="link link-ref link-reveal xref-bibr">959</a>,<span class="xrefLink" id="jumplink-ehae176-B966"></span><a href="javascript:;" reveal-id="ehae176-B966" data-open="ehae176-B966" class="link link-ref link-reveal xref-bibr">966</a>,<span class="xrefLink" id="jumplink-ehae176-B980"></span><a href="javascript:;" reveal-id="ehae176-B980" data-open="ehae176-B980" class="link link-ref link-reveal xref-bibr">980</a>,<span class="xrefLink" id="jumplink-ehae176-B981"></span><a href="javascript:;" reveal-id="ehae176-B981" data-open="ehae176-B981" class="link link-ref link-reveal xref-bibr">981</a></sup> Programming a single high-rate ventricular fibrillation zone ≥210–220 b.p.m. with long detection time is safe,<sup><span class="xrefLink" id="jumplink-ehae176-B950"></span><a href="javascript:;" reveal-id="ehae176-B950" data-open="ehae176-B950" class="link link-ref link-reveal xref-bibr">950</a>,<span class="xrefLink" id="jumplink-ehae176-B953"></span><a href="javascript:;" reveal-id="ehae176-B953" data-open="ehae176-B953" class="link link-ref link-reveal xref-bibr">953</a>,<span class="xrefLink" id="jumplink-ehae176-B982"></span><a href="javascript:;" reveal-id="ehae176-B982" data-open="ehae176-B982" class="link link-ref link-reveal xref-bibr">982</a></sup> and is suggested in patients without documented slow monomorphic ventricular tachycardia. Implantation of an atrial lead may be considered in the case of significant bradycardia with beta-blocker treatment.

Patients with Wolff–Parkinson–White syndrome and AF are at risk of fast ventricular rates from rapid conduction of atrial electrical activity to the ventricles via the accessory pathway, potentially leading to ventricular fibrillation and sudden death.<sup><span class="xrefLink" id="jumplink-ehae176-B983"></span><a href="javascript:;" reveal-id="ehae176-B983" data-open="ehae176-B983" class="link link-ref link-reveal xref-bibr">983</a>,<span class="xrefLink" id="jumplink-ehae176-B984"></span><a href="javascript:;" reveal-id="ehae176-B984" data-open="ehae176-B984" class="link link-ref link-reveal xref-bibr">984</a></sup> Immediate electrical cardioversion is needed for haemodynamically compromised patients with pre-excited AF, and atrioventricular node-modulating drugs should be avoided.<sup><span class="xrefLink" id="jumplink-ehae176-B985"></span><a href="javascript:;" reveal-id="ehae176-B985" data-open="ehae176-B985" class="link link-ref link-reveal xref-bibr">985</a>,<span class="xrefLink" id="jumplink-ehae176-B986"></span><a href="javascript:;" reveal-id="ehae176-B986" data-open="ehae176-B986" class="link link-ref link-reveal xref-bibr">986</a></sup> Pharmacological cardioversion can be attempted using ibutilide<sup><span class="xrefLink" id="jumplink-ehae176-B987"></span><a href="javascript:;" reveal-id="ehae176-B987" data-open="ehae176-B987" class="link link-ref link-reveal xref-bibr">987</a></sup> or flecainide, while propafenone should be used with caution due to effects on the atrioventricular node.<sup><span class="xrefLink" id="jumplink-ehae176-B988"></span><a href="javascript:;" reveal-id="ehae176-B988" data-open="ehae176-B988" class="link link-ref link-reveal xref-bibr">988</a>,<span class="xrefLink" id="jumplink-ehae176-B989"></span><a href="javascript:;" reveal-id="ehae176-B989" data-open="ehae176-B989" class="link link-ref link-reveal xref-bibr">989</a></sup> Amiodarone should be avoided in pre-excited AF due to its delayed action. Further details on inherited cardiomyopathies can be found in the _2023 ESC Guidelines for the management of cardiomyopathies_.<sup><span class="xrefLink" id="jumplink-ehae176-B990"></span><a href="javascript:;" reveal-id="ehae176-B990" data-open="ehae176-B990" class="link link-ref link-reveal xref-bibr">990</a></sup>

### 9.12. AF-CARE in cancer

All types of cancer show an increased risk of AF, with prevalence varying from 2% to 28%.<sup><span class="xrefLink" id="jumplink-ehae176-B991 ehae176-B992 ehae176-B993 ehae176-B994 ehae176-B995"></span><a href="javascript:;" reveal-id="ehae176-B991 ehae176-B992 ehae176-B993 ehae176-B994 ehae176-B995" data-open="ehae176-B991 ehae176-B992 ehae176-B993 ehae176-B994 ehae176-B995" class="link link-ref link-reveal xref-bibr">991–995</a></sup> The occurrence of AF may often be related to a pre-existing atrial substrate with vulnerability to AF. AF may be an indicator of an occult cancer, but also can appear in the context of concomitant surgery, chemotherapy, or radiotherapy.<sup><span class="xrefLink" id="jumplink-ehae176-B916"></span><a href="javascript:;" reveal-id="ehae176-B916" data-open="ehae176-B916" class="link link-ref link-reveal xref-bibr">916</a>,<span class="xrefLink" id="jumplink-ehae176-B994"></span><a href="javascript:;" reveal-id="ehae176-B994" data-open="ehae176-B994" class="link link-ref link-reveal xref-bibr">994</a>,<span class="xrefLink" id="jumplink-ehae176-B996"></span><a href="javascript:;" reveal-id="ehae176-B996" data-open="ehae176-B996" class="link link-ref link-reveal xref-bibr">996</a></sup> Risk of AF is dependent on, among other factors, the cancer type and stage,<sup><span class="xrefLink" id="jumplink-ehae176-B997"></span><a href="javascript:;" reveal-id="ehae176-B997" data-open="ehae176-B997" class="link link-ref link-reveal xref-bibr">997</a></sup> and is greater in older patients with pre-existing cardiovascular disease.<sup><span class="xrefLink" id="jumplink-ehae176-B991"></span><a href="javascript:;" reveal-id="ehae176-B991" data-open="ehae176-B991" class="link link-ref link-reveal xref-bibr">991</a>,<span class="xrefLink" id="jumplink-ehae176-B993"></span><a href="javascript:;" reveal-id="ehae176-B993" data-open="ehae176-B993" class="link link-ref link-reveal xref-bibr">993</a>,<span class="xrefLink" id="jumplink-ehae176-B994"></span><a href="javascript:;" reveal-id="ehae176-B994" data-open="ehae176-B994" class="link link-ref link-reveal xref-bibr">994</a></sup> Some procedures are associated with higher incidence of AF, including lung surgery (from 6% to 32%) and non-thoracic surgery such as a colectomy (4%–5%).<sup><span class="xrefLink" id="jumplink-ehae176-B994"></span><a href="javascript:;" reveal-id="ehae176-B994" data-open="ehae176-B994" class="link link-ref link-reveal xref-bibr">994</a></sup>

Atrial fibrillation in the context of cancer is associated with a two-fold higher risk of systemic thromboembolism and stroke, and six-fold increased risk of heart failure.<sup><span class="xrefLink" id="jumplink-ehae176-B991"></span><a href="javascript:;" reveal-id="ehae176-B991" data-open="ehae176-B991" class="link link-ref link-reveal xref-bibr">991</a>,<span class="xrefLink" id="jumplink-ehae176-B994"></span><a href="javascript:;" reveal-id="ehae176-B994" data-open="ehae176-B994" class="link link-ref link-reveal xref-bibr">994</a></sup> On the other hand, the coexistence of cancer increases the risk of all-cause mortality and major bleeding in patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B998"></span><a href="javascript:;" reveal-id="ehae176-B998" data-open="ehae176-B998" class="link link-ref link-reveal xref-bibr">998</a></sup> Bleeding in those receiving OAC can also unmask the presence of cancer.<sup><span class="xrefLink" id="jumplink-ehae176-B999"></span><a href="javascript:;" reveal-id="ehae176-B999" data-open="ehae176-B999" class="link link-ref link-reveal xref-bibr">999</a></sup>

Stroke risk scores may underestimate thromboembolic risk in cancer patients.<sup><span class="xrefLink" id="jumplink-ehae176-B1000"></span><a href="javascript:;" reveal-id="ehae176-B1000" data-open="ehae176-B1000" class="link link-ref link-reveal xref-bibr">1000</a></sup> The association between cancer, AF, and ischaemic stroke also differs between cancer types. In some types of cancer, the risk of bleeding seems to exceed the risk of thromboembolism.<sup><span class="xrefLink" id="jumplink-ehae176-B998"></span><a href="javascript:;" reveal-id="ehae176-B998" data-open="ehae176-B998" class="link link-ref link-reveal xref-bibr">998</a></sup> Risk stratification is therefore complex in this population, and should be performed on an individual basis considering cancer type, stage, prognosis, bleeding risk, and other risk factors. These aspects can change within a short period of time, requiring dynamic assessment and management.

As with non-cancer patients, DOACs in those with cancer have similar efficacy and better safety compared with VKAs.<sup><span class="xrefLink" id="jumplink-ehae176-B1001 ehae176-B1002 ehae176-B1003 ehae176-B1004 ehae176-B1005 ehae176-B1006 ehae176-B1007 ehae176-B1008 ehae176-B1009 ehae176-B1010"></span><a href="javascript:;" reveal-id="ehae176-B1001 ehae176-B1002 ehae176-B1003 ehae176-B1004 ehae176-B1005 ehae176-B1006 ehae176-B1007 ehae176-B1008 ehae176-B1009 ehae176-B1010" data-open="ehae176-B1001 ehae176-B1002 ehae176-B1003 ehae176-B1004 ehae176-B1005 ehae176-B1006 ehae176-B1007 ehae176-B1008 ehae176-B1009 ehae176-B1010" class="link link-ref link-reveal xref-bibr">1001–1010</a></sup> Low molecular weight heparin is a short-term anticoagulation option, mostly during some cancer treatments, recent active bleeding, or thrombocytopaenia.<sup><span class="xrefLink" id="jumplink-ehae176-B1011"></span><a href="javascript:;" reveal-id="ehae176-B1011" data-open="ehae176-B1011" class="link link-ref link-reveal xref-bibr">1011</a></sup> Decision-making on AF management, including on rhythm control, is best performed within a cardio-oncology multidisciplinary team.<sup><span class="xrefLink" id="jumplink-ehae176-B916"></span><a href="javascript:;" reveal-id="ehae176-B916" data-open="ehae176-B916" class="link link-ref link-reveal xref-bibr">916</a>,<span class="xrefLink" id="jumplink-ehae176-B1012"></span><a href="javascript:;" reveal-id="ehae176-B1012" data-open="ehae176-B1012" class="link link-ref link-reveal xref-bibr">1012</a></sup> Attention is required on interactions with cancer treatments, in particular QT-interval prolongation with AADs.

### 9.13. AF-CARE in older, multimorbid, or frail patients

Atrial fibrillation increases with age, and older patients more frequently have multimorbidity and frailty which are associated with worse clinical outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B1013 ehae176-B1014 ehae176-B1015 ehae176-B1016"></span><a href="javascript:;" reveal-id="ehae176-B1013 ehae176-B1014 ehae176-B1015 ehae176-B1016" data-open="ehae176-B1013 ehae176-B1014 ehae176-B1015 ehae176-B1016" class="link link-ref link-reveal xref-bibr">1013–1016</a></sup> Multimorbidity is the coexistence of two or more medically diagnosed diseases in the same individual. Frailty is defined as a person more vulnerable and less able to respond to a stressor or acute event, increasing the risk of adverse outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B1016"></span><a href="javascript:;" reveal-id="ehae176-B1016" data-open="ehae176-B1016" class="link link-ref link-reveal xref-bibr">1016</a>,<span class="xrefLink" id="jumplink-ehae176-B1017"></span><a href="javascript:;" reveal-id="ehae176-B1017" data-open="ehae176-B1017" class="link link-ref link-reveal xref-bibr">1017</a></sup> The prevalence of frailty in AF varies due to different methods of assessment from 4.4% to 75.4%, and AF prevalence in the frail population ranges from 48.2% to 75.4%.<sup><span class="xrefLink" id="jumplink-ehae176-B1018"></span><a href="javascript:;" reveal-id="ehae176-B1018" data-open="ehae176-B1018" class="link link-ref link-reveal xref-bibr">1018</a></sup> Frailty status is a strong independent risk factor for new-onset AF among older adults with hypertension.<sup><span class="xrefLink" id="jumplink-ehae176-B1019"></span><a href="javascript:;" reveal-id="ehae176-B1019" data-open="ehae176-B1019" class="link link-ref link-reveal xref-bibr">1019</a></sup>

Atrial fibrillation in frail patients is associated with less use of OAC and lower rates of management with a rhythm control strategy.<sup><span class="xrefLink" id="jumplink-ehae176-B1015"></span><a href="javascript:;" reveal-id="ehae176-B1015" data-open="ehae176-B1015" class="link link-ref link-reveal xref-bibr">1015</a>,<span class="xrefLink" id="jumplink-ehae176-B1018"></span><a href="javascript:;" reveal-id="ehae176-B1018" data-open="ehae176-B1018" class="link link-ref link-reveal xref-bibr">1018</a>,<span class="xrefLink" id="jumplink-ehae176-B1020"></span><a href="javascript:;" reveal-id="ehae176-B1020" data-open="ehae176-B1020" class="link link-ref link-reveal xref-bibr">1020</a></sup> Oral anticoagulation initiation in older, frail multimorbid AF patients has improved since the introduction of DOACs, but is still lower in AF patients at older age (OR, 0.98 per year; 95% CI, 0.98–0.98), with dementia (OR, 0.57; 95% CI, 0.55–0.58), or frailty (OR, 0.74; 95% CI, 0.72–0.76).<sup><span class="xrefLink" id="jumplink-ehae176-B1021"></span><a href="javascript:;" reveal-id="ehae176-B1021" data-open="ehae176-B1021" class="link link-ref link-reveal xref-bibr">1021</a></sup> The value of observational data which show potential benefit from OAC (in particular, DOACs) is limited due to prescription biases.<sup><span class="xrefLink" id="jumplink-ehae176-B1022 ehae176-B1023 ehae176-B1024 ehae176-B1025 ehae176-B1026 ehae176-B1027"></span><a href="javascript:;" reveal-id="ehae176-B1022 ehae176-B1023 ehae176-B1024 ehae176-B1025 ehae176-B1026 ehae176-B1027" data-open="ehae176-B1022 ehae176-B1023 ehae176-B1024 ehae176-B1025 ehae176-B1026 ehae176-B1027" class="link link-ref link-reveal xref-bibr">1022–1027</a></sup> Frail patients aged ≥75 years with polypharmacy and stable on a VKA may remain on the VKA rather than switching to a DOAC (_Section [6.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5.2)_).<sup><span class="xrefLink" id="jumplink-ehae176-B309"></span><a href="javascript:;" reveal-id="ehae176-B309" data-open="ehae176-B309" class="link link-ref link-reveal xref-bibr">309</a></sup>

### 9.14. AF-CARE in atrial flutter

Due to the association between AFL and thromboembolic outcomes, and the frequent development of AF in patients with AFL, the management of comorbidities and risk factors in AFL should mirror that for AF (see _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s4)_). Similarly, the approach to prevent thromboembolism in AFL includes peri-procedural and long-term OAC (see _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5)_). Rate control can be difficult to achieve in AFL, despite combination therapy. Rhythm control is often the first-line approach,<sup><span class="xrefLink" id="jumplink-ehae176-B983"></span><a href="javascript:;" reveal-id="ehae176-B983" data-open="ehae176-B983" class="link link-ref link-reveal xref-bibr">983</a></sup> with small randomized trials showing that cavo-tricuspid isthmus (CTI) ablation is superior to AADs.<sup><span class="xrefLink" id="jumplink-ehae176-B1028"></span><a href="javascript:;" reveal-id="ehae176-B1028" data-open="ehae176-B1028" class="link link-ref link-reveal xref-bibr">1028</a>,<span class="xrefLink" id="jumplink-ehae176-B1029"></span><a href="javascript:;" reveal-id="ehae176-B1029" data-open="ehae176-B1029" class="link link-ref link-reveal xref-bibr">1029</a></sup> Recurrence of AFL is uncommon after achieving and confirming bidirectional block in typical CTI-dependent AFL. However, the majority of patients (50%–70%) have manifested AF during long-term follow-up in observational studies after AFL ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B1030"></span><a href="javascript:;" reveal-id="ehae176-B1030" data-open="ehae176-B1030" class="link link-ref link-reveal xref-bibr">1030</a>,<span class="xrefLink" id="jumplink-ehae176-B1031"></span><a href="javascript:;" reveal-id="ehae176-B1031" data-open="ehae176-B1031" class="link link-ref link-reveal xref-bibr">1031</a></sup> Hence the necessity for long-term dynamic re-evaluation in all patients with AFL in keeping with the AF-CARE approach. More detail on the management of AFL and other atrial arrhythmias is described in the _2019 ESC Guidelines for the management of patients with supraventricular tachycardia_.<sup><span class="xrefLink" id="jumplink-ehae176-B983"></span><a href="javascript:;" reveal-id="ehae176-B983" data-open="ehae176-B983" class="link link-ref link-reveal xref-bibr">983</a></sup>

Recommendation Table 30

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884428)

Recommendations for prevention of thromboembolism in atrial flutter (see also Evidence Table 30)

![Recommendations for prevention of thromboembolism in atrial flutter (see also Evidence Table 30)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt30.jpeg?Expires=1728478929&Signature=jVBeb-LOPeKiXfC6kizs1qyXo05jZ8TxEOzDDFrsUFiaBk-6WCfnDJt1GlFVNTz6rLyzJGRtsYFxF9w1YqIvw2DD7zu-lrAAY5Q177OVgM8GXnfz5aZCtitooyUdyRniJbWLuwSzfDZJDxMDp-fstu-442BX5nc8ePwp2~NruI97Oy3q6C3wJqDPf8WPihasA20qgY~FtfnpeuC11o1ZOTSWbHFUkLBDkLHVV7Im0nI~nCoNspNnMzrkFkYDpA7r-GVlsOMYxMzNU6pe3yYTD5EAxD9PVZc8PrGrfxObFR0XmSq8PT83odIByxjkU7HJ4nlz7sm~BgjkIykf4GYOxQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 30

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884428)

Recommendations for prevention of thromboembolism in atrial flutter (see also Evidence Table 30)

![Recommendations for prevention of thromboembolism in atrial flutter (see also Evidence Table 30)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt30.jpeg?Expires=1728478929&Signature=jVBeb-LOPeKiXfC6kizs1qyXo05jZ8TxEOzDDFrsUFiaBk-6WCfnDJt1GlFVNTz6rLyzJGRtsYFxF9w1YqIvw2DD7zu-lrAAY5Q177OVgM8GXnfz5aZCtitooyUdyRniJbWLuwSzfDZJDxMDp-fstu-442BX5nc8ePwp2~NruI97Oy3q6C3wJqDPf8WPihasA20qgY~FtfnpeuC11o1ZOTSWbHFUkLBDkLHVV7Im0nI~nCoNspNnMzrkFkYDpA7r-GVlsOMYxMzNU6pe3yYTD5EAxD9PVZc8PrGrfxObFR0XmSq8PT83odIByxjkU7HJ4nlz7sm~BgjkIykf4GYOxQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 10\. Screening and prevention of AF

### 10.1. Epidemiology of AF

Atrial fibrillation is the most common sustained arrhythmia worldwide, with an estimated global prevalence in 2019 of 59.7 million persons with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1033"></span><a href="javascript:;" reveal-id="ehae176-B1033" data-open="ehae176-B1033" class="link link-ref link-reveal xref-bibr">1033</a></sup> Incident cases of AF are doubling every few decades.<sup><span class="xrefLink" id="jumplink-ehae176-B1034"></span><a href="javascript:;" reveal-id="ehae176-B1034" data-open="ehae176-B1034" class="link link-ref link-reveal xref-bibr">1034</a></sup> Future increases are anticipated, in particular in middle-income countries.<sup><span class="xrefLink" id="jumplink-ehae176-B1034"></span><a href="javascript:;" reveal-id="ehae176-B1034" data-open="ehae176-B1034" class="link link-ref link-reveal xref-bibr">1034</a></sup> In community-based individuals, the prevalence of AF in a United States of America cohort was up to 5.9%.<sup><span class="xrefLink" id="jumplink-ehae176-B1035"></span><a href="javascript:;" reveal-id="ehae176-B1035" data-open="ehae176-B1035" class="link link-ref link-reveal xref-bibr">1035</a></sup> The age-standardized prevalence and incidence rates have remained constant over time.<sup><span class="xrefLink" id="jumplink-ehae176-B1033"></span><a href="javascript:;" reveal-id="ehae176-B1033" data-open="ehae176-B1033" class="link link-ref link-reveal xref-bibr">1033</a>,<span class="xrefLink" id="jumplink-ehae176-B1036"></span><a href="javascript:;" reveal-id="ehae176-B1036" data-open="ehae176-B1036" class="link link-ref link-reveal xref-bibr">1036</a></sup> The increase in overall prevalence is largely attributable to population growth, ageing, and survival from other cardiac conditions. In parallel, increases in risk factor burden, better awareness, and improved detection of AF have been observed.<sup><span class="xrefLink" id="jumplink-ehae176-B1037"></span><a href="javascript:;" reveal-id="ehae176-B1037" data-open="ehae176-B1037" class="link link-ref link-reveal xref-bibr">1037</a></sup> The lifetime risk of AF has been estimated to be as high as 1 in 3 for older individuals,<sup><span class="xrefLink" id="jumplink-ehae176-B1038"></span><a href="javascript:;" reveal-id="ehae176-B1038" data-open="ehae176-B1038" class="link link-ref link-reveal xref-bibr">1038</a></sup> with age-standardized incidence rates higher for men than women. Populations of European ancestry are typically found to have higher AF prevalence, individuals of African ancestry have worse outcomes, and other groups may have less access to interventions.<sup><span class="xrefLink" id="jumplink-ehae176-B1039 ehae176-B1040 ehae176-B1041"></span><a href="javascript:;" reveal-id="ehae176-B1039 ehae176-B1040 ehae176-B1041" data-open="ehae176-B1039 ehae176-B1040 ehae176-B1041" class="link link-ref link-reveal xref-bibr">1039–1041</a></sup> Socioeconomic and other factors likely play a role in racial and ethnic differences in AF, but studies are also limited due to differences in how groups access healthcare. Greater deprivation in socioeconomic and living status is associated with higher AF incidence.<sup><span class="xrefLink" id="jumplink-ehae176-B1042"></span><a href="javascript:;" reveal-id="ehae176-B1042" data-open="ehae176-B1042" class="link link-ref link-reveal xref-bibr">1042</a></sup>

### 10.2. Screening tools for AF

In recent years, an abundance of novel devices that can monitor heart rhythm have come to the market, including fitness bands and smartwatches. Although the evidence for clinical effectiveness of digital devices is limited, they may be useful in detecting AF, and their clinical, economic, legal, and policy implications merit further investigation.<sup><span class="xrefLink" id="jumplink-ehae176-B1043"></span><a href="javascript:;" reveal-id="ehae176-B1043" data-open="ehae176-B1043" class="link link-ref link-reveal xref-bibr">1043</a>,<span class="xrefLink" id="jumplink-ehae176-B1044"></span><a href="javascript:;" reveal-id="ehae176-B1044" data-open="ehae176-B1044" class="link link-ref link-reveal xref-bibr">1044</a></sup> Devices for AF detection can broadly be divided into those that provide an ECG, and those with non-ECG approaches such as photoplethysmography (_[Figure 15](javascript:;)_ and _[Table 15](javascript:;)_).

![Non-invasive diagnostic methods for AF screening.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f15.jpeg?Expires=1728478929&Signature=H4UiMQDvUAPgxEzgpikJQygpuUJFjVeRcSvbPjBcLEy6o27o5vRF3shQIAyI2Ixh7GBXj8fr6xsCjMO7A5SixLiATRprMARfGEHXGy6MDBhnqNrs7Af-yo2jkKJa9CH6-LUTEVKi6Lq3HFvhFLEJr7G2Xz4UqE-dToNNxyiJbTPEcxQWmj79kcjPh-ZsKDRdXptF4auFh2G4PM8c9Wuj9dn~Nj7fn142HEqQ2hoyNKTtYCMRVYz0X2PIh-KYdZxOAZcZL~CP0e7Fve19kTiv8MniJ3sXgOBu3SdI37Qt5sdKiguev9nk5yT2JC-cJQicXiyTi6XALMh66XUtoRIPHg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 15

Non-invasive diagnostic methods for AF screening.

AF, atrial fibrillation; BP, blood pressure; ECG, electrocardiogram; PPG, photoplethysmography.

[Open in new tab](https://academic.oup.com/view-large/figure/479884434/ehae176f15.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f15.jpeg?Expires=1728478929&Signature=BLyBQRhJNs06nNBJRsbrlmbnGHbUeeopAdHAYZBkWb~rDl7DQFMXY~Udvav2NE6GCd9iLxv7wgBtrt8S7PEHkiEsAUhDdtoVOkRt3kcHtId5jTenJyDmmfVf6YwiJVT79AYQ9g~s7-BcQjGLl3CA77StCA2Zoor2lH3ioyYLTLxeVIn3sFmfkKhPPWCc8J3vO69~7PPY-9KEsW5SL44r2MxzibP3noERE33Ww~utNjA3ilE3HEVfJa8a-Ln6H4Zwo-lo5Ds7zvypuXAE43-ywhyR343V~laj~k22qLiiTuyZXrQBr2PW-FT5~8~G3EEJG8i3k0G5omcVdaqh84ZOyw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884434&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884435)

Tools for AF screening

| Tools for AF screening .  |
| --- |
| 
- (i) Pulse palpation<sup><span class="xrefLink" id="jumplink-ehae176-B1045"></span><a href="javascript:;" reveal-id="ehae176-B1045" data-open="ehae176-B1045" class="link link-ref link-reveal xref-bibr">1045</a></sup>

- (ii) Use of artificial intelligence algorithms to identify patients at risk<sup><span class="xrefLink" id="jumplink-ehae176-B1046"></span><a href="javascript:;" reveal-id="ehae176-B1046" data-open="ehae176-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup>

- (iii) ECG-based devices

- (a) Conventional ECG devices

- (1) Classic 12-lead ECG <sup><span class="xrefLink" id="jumplink-ehae176-B1047"></span><a href="javascript:;" reveal-id="ehae176-B1047" data-open="ehae176-B1047" class="link link-ref link-reveal xref-bibr">1047</a></sup>

- (2) Holter monitoring (from 24 h to a week or more)<sup><span class="xrefLink" id="jumplink-ehae176-B1048"></span><a href="javascript:;" reveal-id="ehae176-B1048" data-open="ehae176-B1048" class="link link-ref link-reveal xref-bibr">1048</a></sup>

- (3) Mobile cardiac telemetry (during hospitalization)<sup><span class="xrefLink" id="jumplink-ehae176-B1049"></span><a href="javascript:;" reveal-id="ehae176-B1049" data-open="ehae176-B1049" class="link link-ref link-reveal xref-bibr">1049</a></sup>

- (4) Handheld devices<sup><span class="xrefLink" id="jumplink-ehae176-B1050 ehae176-B1051 ehae176-B1052"></span><a href="javascript:;" reveal-id="ehae176-B1050 ehae176-B1051 ehae176-B1052" data-open="ehae176-B1050 ehae176-B1051 ehae176-B1052" class="link link-ref link-reveal xref-bibr">1050–1052</a></sup>

- (5) Wearable patches (up to 14 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067"></span><a href="javascript:;" reveal-id="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" data-open="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" class="link link-ref link-reveal xref-bibr">1053–1067</a></sup>

- (6) Biotextiles (up to 30 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072"></span><a href="javascript:;" reveal-id="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" data-open="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" class="link link-ref link-reveal xref-bibr">1068–1072</a></sup>

- (7) Smart devices (30 s)<sup><span class="xrefLink" id="jumplink-ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091"></span><a href="javascript:;" reveal-id="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" data-open="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" class="link link-ref link-reveal xref-bibr">1073–1091</a></sup>

- (b) Implantable loop recorders (3–5 years)<sup><span class="xrefLink" id="jumplink-ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099"></span><a href="javascript:;" reveal-id="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" data-open="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" class="link link-ref link-reveal xref-bibr">1092–1099</a></sup>

- (iv) Non-ECG-based devices

- (a) Photoplethysmography and automatic algorithms: contact (fingertip, smart device, band) and contactless (video)<sup><span class="xrefLink" id="jumplink-ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106"></span><a href="javascript:;" reveal-id="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" data-open="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" class="link link-ref link-reveal xref-bibr">1100–1106</a></sup>

- (b) Oscillometry (blood pressure monitors that derive heart rhythm regularity algorithmically)<sup><span class="xrefLink" id="jumplink-ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110"></span><a href="javascript:;" reveal-id="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" data-open="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" class="link link-ref link-reveal xref-bibr">1107–1110</a></sup>

- (c) Mechanocardiography (accelerometers and gyroscopes to sense the mechanical activity of the heart)<sup><span class="xrefLink" id="jumplink-ehae176-B1111"></span><a href="javascript:;" reveal-id="ehae176-B1111" data-open="ehae176-B1111" class="link link-ref link-reveal xref-bibr">1111</a></sup>

- (d) Contactless video plethysmography (through video monitoring)<sup><span class="xrefLink" id="jumplink-ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115"></span><a href="javascript:;" reveal-id="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" data-open="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" class="link link-ref link-reveal xref-bibr">1112–1115</a></sup>

- (e) Smart speakers (through the identification of abnormal heart rate patterns)<sup><span class="xrefLink" id="jumplink-ehae176-B1116"></span><a href="javascript:;" reveal-id="ehae176-B1116" data-open="ehae176-B1116" class="link link-ref link-reveal xref-bibr">1116</a></sup>


 |

| Tools for AF screening .  |
| --- |
| 
- (i) Pulse palpation<sup><span class="xrefLink" id="jumplink-ehae176-B1045"></span><a href="javascript:;" reveal-id="ehae176-B1045" data-open="ehae176-B1045" class="link link-ref link-reveal xref-bibr">1045</a></sup>

- (ii) Use of artificial intelligence algorithms to identify patients at risk<sup><span class="xrefLink" id="jumplink-ehae176-B1046"></span><a href="javascript:;" reveal-id="ehae176-B1046" data-open="ehae176-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup>

- (iii) ECG-based devices

- (a) Conventional ECG devices

- (1) Classic 12-lead ECG <sup><span class="xrefLink" id="jumplink-ehae176-B1047"></span><a href="javascript:;" reveal-id="ehae176-B1047" data-open="ehae176-B1047" class="link link-ref link-reveal xref-bibr">1047</a></sup>

- (2) Holter monitoring (from 24 h to a week or more)<sup><span class="xrefLink" id="jumplink-ehae176-B1048"></span><a href="javascript:;" reveal-id="ehae176-B1048" data-open="ehae176-B1048" class="link link-ref link-reveal xref-bibr">1048</a></sup>

- (3) Mobile cardiac telemetry (during hospitalization)<sup><span class="xrefLink" id="jumplink-ehae176-B1049"></span><a href="javascript:;" reveal-id="ehae176-B1049" data-open="ehae176-B1049" class="link link-ref link-reveal xref-bibr">1049</a></sup>

- (4) Handheld devices<sup><span class="xrefLink" id="jumplink-ehae176-B1050 ehae176-B1051 ehae176-B1052"></span><a href="javascript:;" reveal-id="ehae176-B1050 ehae176-B1051 ehae176-B1052" data-open="ehae176-B1050 ehae176-B1051 ehae176-B1052" class="link link-ref link-reveal xref-bibr">1050–1052</a></sup>

- (5) Wearable patches (up to 14 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067"></span><a href="javascript:;" reveal-id="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" data-open="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" class="link link-ref link-reveal xref-bibr">1053–1067</a></sup>

- (6) Biotextiles (up to 30 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072"></span><a href="javascript:;" reveal-id="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" data-open="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" class="link link-ref link-reveal xref-bibr">1068–1072</a></sup>

- (7) Smart devices (30 s)<sup><span class="xrefLink" id="jumplink-ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091"></span><a href="javascript:;" reveal-id="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" data-open="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" class="link link-ref link-reveal xref-bibr">1073–1091</a></sup>

- (b) Implantable loop recorders (3–5 years)<sup><span class="xrefLink" id="jumplink-ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099"></span><a href="javascript:;" reveal-id="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" data-open="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" class="link link-ref link-reveal xref-bibr">1092–1099</a></sup>

- (iv) Non-ECG-based devices

- (a) Photoplethysmography and automatic algorithms: contact (fingertip, smart device, band) and contactless (video)<sup><span class="xrefLink" id="jumplink-ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106"></span><a href="javascript:;" reveal-id="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" data-open="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" class="link link-ref link-reveal xref-bibr">1100–1106</a></sup>

- (b) Oscillometry (blood pressure monitors that derive heart rhythm regularity algorithmically)<sup><span class="xrefLink" id="jumplink-ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110"></span><a href="javascript:;" reveal-id="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" data-open="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" class="link link-ref link-reveal xref-bibr">1107–1110</a></sup>

- (c) Mechanocardiography (accelerometers and gyroscopes to sense the mechanical activity of the heart)<sup><span class="xrefLink" id="jumplink-ehae176-B1111"></span><a href="javascript:;" reveal-id="ehae176-B1111" data-open="ehae176-B1111" class="link link-ref link-reveal xref-bibr">1111</a></sup>

- (d) Contactless video plethysmography (through video monitoring)<sup><span class="xrefLink" id="jumplink-ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115"></span><a href="javascript:;" reveal-id="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" data-open="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" class="link link-ref link-reveal xref-bibr">1112–1115</a></sup>

- (e) Smart speakers (through the identification of abnormal heart rate patterns)<sup><span class="xrefLink" id="jumplink-ehae176-B1116"></span><a href="javascript:;" reveal-id="ehae176-B1116" data-open="ehae176-B1116" class="link link-ref link-reveal xref-bibr">1116</a></sup>


 |

ECG, electrocardiogram.

© ESC 2024

Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884435)

Tools for AF screening

| Tools for AF screening .  |
| --- |
| 
- (i) Pulse palpation<sup><span class="xrefLink" id="jumplink-ehae176-B1045"></span><a href="javascript:;" reveal-id="ehae176-B1045" data-open="ehae176-B1045" class="link link-ref link-reveal xref-bibr">1045</a></sup>

- (ii) Use of artificial intelligence algorithms to identify patients at risk<sup><span class="xrefLink" id="jumplink-ehae176-B1046"></span><a href="javascript:;" reveal-id="ehae176-B1046" data-open="ehae176-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup>

- (iii) ECG-based devices

- (a) Conventional ECG devices

- (1) Classic 12-lead ECG <sup><span class="xrefLink" id="jumplink-ehae176-B1047"></span><a href="javascript:;" reveal-id="ehae176-B1047" data-open="ehae176-B1047" class="link link-ref link-reveal xref-bibr">1047</a></sup>

- (2) Holter monitoring (from 24 h to a week or more)<sup><span class="xrefLink" id="jumplink-ehae176-B1048"></span><a href="javascript:;" reveal-id="ehae176-B1048" data-open="ehae176-B1048" class="link link-ref link-reveal xref-bibr">1048</a></sup>

- (3) Mobile cardiac telemetry (during hospitalization)<sup><span class="xrefLink" id="jumplink-ehae176-B1049"></span><a href="javascript:;" reveal-id="ehae176-B1049" data-open="ehae176-B1049" class="link link-ref link-reveal xref-bibr">1049</a></sup>

- (4) Handheld devices<sup><span class="xrefLink" id="jumplink-ehae176-B1050 ehae176-B1051 ehae176-B1052"></span><a href="javascript:;" reveal-id="ehae176-B1050 ehae176-B1051 ehae176-B1052" data-open="ehae176-B1050 ehae176-B1051 ehae176-B1052" class="link link-ref link-reveal xref-bibr">1050–1052</a></sup>

- (5) Wearable patches (up to 14 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067"></span><a href="javascript:;" reveal-id="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" data-open="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" class="link link-ref link-reveal xref-bibr">1053–1067</a></sup>

- (6) Biotextiles (up to 30 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072"></span><a href="javascript:;" reveal-id="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" data-open="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" class="link link-ref link-reveal xref-bibr">1068–1072</a></sup>

- (7) Smart devices (30 s)<sup><span class="xrefLink" id="jumplink-ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091"></span><a href="javascript:;" reveal-id="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" data-open="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" class="link link-ref link-reveal xref-bibr">1073–1091</a></sup>

- (b) Implantable loop recorders (3–5 years)<sup><span class="xrefLink" id="jumplink-ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099"></span><a href="javascript:;" reveal-id="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" data-open="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" class="link link-ref link-reveal xref-bibr">1092–1099</a></sup>

- (iv) Non-ECG-based devices

- (a) Photoplethysmography and automatic algorithms: contact (fingertip, smart device, band) and contactless (video)<sup><span class="xrefLink" id="jumplink-ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106"></span><a href="javascript:;" reveal-id="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" data-open="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" class="link link-ref link-reveal xref-bibr">1100–1106</a></sup>

- (b) Oscillometry (blood pressure monitors that derive heart rhythm regularity algorithmically)<sup><span class="xrefLink" id="jumplink-ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110"></span><a href="javascript:;" reveal-id="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" data-open="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" class="link link-ref link-reveal xref-bibr">1107–1110</a></sup>

- (c) Mechanocardiography (accelerometers and gyroscopes to sense the mechanical activity of the heart)<sup><span class="xrefLink" id="jumplink-ehae176-B1111"></span><a href="javascript:;" reveal-id="ehae176-B1111" data-open="ehae176-B1111" class="link link-ref link-reveal xref-bibr">1111</a></sup>

- (d) Contactless video plethysmography (through video monitoring)<sup><span class="xrefLink" id="jumplink-ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115"></span><a href="javascript:;" reveal-id="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" data-open="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" class="link link-ref link-reveal xref-bibr">1112–1115</a></sup>

- (e) Smart speakers (through the identification of abnormal heart rate patterns)<sup><span class="xrefLink" id="jumplink-ehae176-B1116"></span><a href="javascript:;" reveal-id="ehae176-B1116" data-open="ehae176-B1116" class="link link-ref link-reveal xref-bibr">1116</a></sup>


 |

| Tools for AF screening .  |
| --- |
| 
- (i) Pulse palpation<sup><span class="xrefLink" id="jumplink-ehae176-B1045"></span><a href="javascript:;" reveal-id="ehae176-B1045" data-open="ehae176-B1045" class="link link-ref link-reveal xref-bibr">1045</a></sup>

- (ii) Use of artificial intelligence algorithms to identify patients at risk<sup><span class="xrefLink" id="jumplink-ehae176-B1046"></span><a href="javascript:;" reveal-id="ehae176-B1046" data-open="ehae176-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup>

- (iii) ECG-based devices

- (a) Conventional ECG devices

- (1) Classic 12-lead ECG <sup><span class="xrefLink" id="jumplink-ehae176-B1047"></span><a href="javascript:;" reveal-id="ehae176-B1047" data-open="ehae176-B1047" class="link link-ref link-reveal xref-bibr">1047</a></sup>

- (2) Holter monitoring (from 24 h to a week or more)<sup><span class="xrefLink" id="jumplink-ehae176-B1048"></span><a href="javascript:;" reveal-id="ehae176-B1048" data-open="ehae176-B1048" class="link link-ref link-reveal xref-bibr">1048</a></sup>

- (3) Mobile cardiac telemetry (during hospitalization)<sup><span class="xrefLink" id="jumplink-ehae176-B1049"></span><a href="javascript:;" reveal-id="ehae176-B1049" data-open="ehae176-B1049" class="link link-ref link-reveal xref-bibr">1049</a></sup>

- (4) Handheld devices<sup><span class="xrefLink" id="jumplink-ehae176-B1050 ehae176-B1051 ehae176-B1052"></span><a href="javascript:;" reveal-id="ehae176-B1050 ehae176-B1051 ehae176-B1052" data-open="ehae176-B1050 ehae176-B1051 ehae176-B1052" class="link link-ref link-reveal xref-bibr">1050–1052</a></sup>

- (5) Wearable patches (up to 14 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067"></span><a href="javascript:;" reveal-id="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" data-open="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" class="link link-ref link-reveal xref-bibr">1053–1067</a></sup>

- (6) Biotextiles (up to 30 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072"></span><a href="javascript:;" reveal-id="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" data-open="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" class="link link-ref link-reveal xref-bibr">1068–1072</a></sup>

- (7) Smart devices (30 s)<sup><span class="xrefLink" id="jumplink-ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091"></span><a href="javascript:;" reveal-id="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" data-open="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" class="link link-ref link-reveal xref-bibr">1073–1091</a></sup>

- (b) Implantable loop recorders (3–5 years)<sup><span class="xrefLink" id="jumplink-ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099"></span><a href="javascript:;" reveal-id="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" data-open="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" class="link link-ref link-reveal xref-bibr">1092–1099</a></sup>

- (iv) Non-ECG-based devices

- (a) Photoplethysmography and automatic algorithms: contact (fingertip, smart device, band) and contactless (video)<sup><span class="xrefLink" id="jumplink-ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106"></span><a href="javascript:;" reveal-id="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" data-open="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" class="link link-ref link-reveal xref-bibr">1100–1106</a></sup>

- (b) Oscillometry (blood pressure monitors that derive heart rhythm regularity algorithmically)<sup><span class="xrefLink" id="jumplink-ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110"></span><a href="javascript:;" reveal-id="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" data-open="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" class="link link-ref link-reveal xref-bibr">1107–1110</a></sup>

- (c) Mechanocardiography (accelerometers and gyroscopes to sense the mechanical activity of the heart)<sup><span class="xrefLink" id="jumplink-ehae176-B1111"></span><a href="javascript:;" reveal-id="ehae176-B1111" data-open="ehae176-B1111" class="link link-ref link-reveal xref-bibr">1111</a></sup>

- (d) Contactless video plethysmography (through video monitoring)<sup><span class="xrefLink" id="jumplink-ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115"></span><a href="javascript:;" reveal-id="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" data-open="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" class="link link-ref link-reveal xref-bibr">1112–1115</a></sup>

- (e) Smart speakers (through the identification of abnormal heart rate patterns)<sup><span class="xrefLink" id="jumplink-ehae176-B1116"></span><a href="javascript:;" reveal-id="ehae176-B1116" data-open="ehae176-B1116" class="link link-ref link-reveal xref-bibr">1116</a></sup>


 |

ECG, electrocardiogram.

© ESC 2024

Most consumer-based devices use photoplethysmography, and several large studies have been performed typically in low-risk individuals.<sup><span class="xrefLink" id="jumplink-ehae176-B633"></span><a href="javascript:;" reveal-id="ehae176-B633" data-open="ehae176-B633" class="link link-ref link-reveal xref-bibr">633</a>,<span class="xrefLink" id="jumplink-ehae176-B1076"></span><a href="javascript:;" reveal-id="ehae176-B1076" data-open="ehae176-B1076" class="link link-ref link-reveal xref-bibr">1076</a>,<span class="xrefLink" id="jumplink-ehae176-B1117"></span><a href="javascript:;" reveal-id="ehae176-B1117" data-open="ehae176-B1117" class="link link-ref link-reveal xref-bibr">1117</a>,<span class="xrefLink" id="jumplink-ehae176-B1118"></span><a href="javascript:;" reveal-id="ehae176-B1118" data-open="ehae176-B1118" class="link link-ref link-reveal xref-bibr">1118</a></sup> In an RCT of 5551 participants invited by their health insurer, smartphone-based photoplethysmography increased the odds of OAC-treated new AF by 2.12 (95% CI, 1.19–3.76; _P_ = .01) compared with usual care.<sup><span class="xrefLink" id="jumplink-ehae176-B605"></span><a href="javascript:;" reveal-id="ehae176-B605" data-open="ehae176-B605" class="link link-ref link-reveal xref-bibr">605</a></sup> RCTs powered for assessment of clinical outcomes are still lacking for consumer-based AF screening. Further head-to-head comparisons between novel digital devices and those commonly used in healthcare settings are needed to establish their comparative effectiveness in the clinical setting and account for different populations and settings.<sup><span class="xrefLink" id="jumplink-ehae176-B1119"></span><a href="javascript:;" reveal-id="ehae176-B1119" data-open="ehae176-B1119" class="link link-ref link-reveal xref-bibr">1119</a></sup> In a systematic review of smartphone-based photoplethysmography compared with a reference ECG, unrealistically high sensitivity and specificity were noted, likely due to small, low-quality studies with a high degree of patient selection bias.<sup><span class="xrefLink" id="jumplink-ehae176-B1120"></span><a href="javascript:;" reveal-id="ehae176-B1120" data-open="ehae176-B1120" class="link link-ref link-reveal xref-bibr">1120</a></sup> Hence, when AF is suggested by a photoplethysmography device or any other screening tool, a single-lead or continuous ECG tracing of >30 s or 12-lead ECG showing AF analysed by a physician with expertise in ECG rhythm interpretation is recommended to establish a definitive diagnosis of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1091"></span><a href="javascript:;" reveal-id="ehae176-B1091" data-open="ehae176-B1091" class="link link-ref link-reveal xref-bibr">1091</a>,<span class="xrefLink" id="jumplink-ehae176-B1121 ehae176-B1122 ehae176-B1123 ehae176-B1124 ehae176-B1125"></span><a href="javascript:;" reveal-id="ehae176-B1121 ehae176-B1122 ehae176-B1123 ehae176-B1124 ehae176-B1125" data-open="ehae176-B1121 ehae176-B1122 ehae176-B1123 ehae176-B1124 ehae176-B1125" class="link link-ref link-reveal xref-bibr">1121–1125</a></sup>

The combination of big data and artificial intelligence (AI) is having an increasing impact on the field of electrophysiology. Algorithms have been created to improve automated AF diagnosis and several algorithms to aid diagnostics are being investigated.<sup><span class="xrefLink" id="jumplink-ehae176-B1046"></span><a href="javascript:;" reveal-id="ehae176-B1046" data-open="ehae176-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup> However, the clinical performance and broad applicability of these solutions are not yet known. The use of AI may enable future treatment changes to be assessed with dynamic and continuous patient-directed monitoring using wearable devices.<sup><span class="xrefLink" id="jumplink-ehae176-B1126"></span><a href="javascript:;" reveal-id="ehae176-B1126" data-open="ehae176-B1126" class="link link-ref link-reveal xref-bibr">1126</a></sup> There are still challenges in the field that need clarification, such as data acquisition, model performance, external validity, clinical implementation, algorithm interpretation, and confidence, as well as the ethical aspects.<sup><span class="xrefLink" id="jumplink-ehae176-B1127"></span><a href="javascript:;" reveal-id="ehae176-B1127" data-open="ehae176-B1127" class="link link-ref link-reveal xref-bibr">1127</a></sup>

### 10.3. Screening strategies for AF

Screening can be performed systematically, with an invitation issued to a patient, or opportunistically, at the time of an _ad hoc_ meeting with a healthcare professional. Regardless of the mode of invitation, screening should be part of a structured programme<sup><span class="xrefLink" id="jumplink-ehae176-B1128"></span><a href="javascript:;" reveal-id="ehae176-B1128" data-open="ehae176-B1128" class="link link-ref link-reveal xref-bibr">1128</a></sup> and is not the same as identification of AF during a routine healthcare visit or secondary to arrhythmia symptoms.

Screening can be done at a single timepoint (snapshot of the heart rhythm), e.g. using pulse palpation or a 12-lead ECG. Screening can also be of an extended duration, i.e. prolonged, using either intermittent or continuous monitoring of heart rhythm. Most studies using an opportunistic strategy have screened for AF at a single timepoint with short duration (such as a single timepoint ECG), compared with systematic screening studies that have mainly used prolonged (repeated or continuous) rhythm assessment.<sup><span class="xrefLink" id="jumplink-ehae176-B1129"></span><a href="javascript:;" reveal-id="ehae176-B1129" data-open="ehae176-B1129" class="link link-ref link-reveal xref-bibr">1129</a></sup> The optimal screening method will vary depending on the population being studied (_[Figure 16](javascript:;)_) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S32](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). More sensitive methods will detect more AF but may lead to an increased risk of false positives and an increased detection of low burden AF, whereas more specific methods result in less false positives, at the risk of missing AF.

![Approaches to screening for AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f16.jpeg?Expires=1728478929&Signature=GnX9hvDuMJMjCN54e~pPiD6LPdW8r3m5EmK0wHqx9Lh12X7ug07Q6VpT3OQPXFYJYaZO2ckqTLZjkqOlQURtyPilLRNBjxax-8E~Yf7d6~8n5PEaO5bmnGfyqwHYStPEoovXjx1O-ioSwQEl~jBUeGu9yImJNS0Xv4h4ZrGXGmykzMlrXSpHr7uLOeuynqSaZ-f40kt6GSwAWggxn6onNQUPtpmPmFBTobTtV3yXNquAUiKlW58O3WQd4smRSRx-v9jIlf~2aNjBPvPng-K79LcLdANnlyTfPork52Nb9P40craWOBQSPmPjA6HOXyOgd-uM8JOgh7UrkkHfHRp4oA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 16

Approaches to screening for AF.

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; CHA<sub>2</sub>DS<sub>2</sub>\-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/TIA/arterial thromboembolism (2 points), vascular disease, age 65–74 years; ECG, electrocardiogram. See [Figure 15](javascript:;) for non-invasive ECG methods.

[Open in new tab](https://academic.oup.com/view-large/figure/479884441/ehae176f16.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f16.jpeg?Expires=1728478929&Signature=th7HndLdIrBczWLxqYHbpWAVwn6-amGHE~12EZVibrMz~Xqcu4IQPOU5ZSr14gyKjFWLp5tnIhcURRY~4oYdS58pDwDiGVtDyPyHwW-dvqeTGwXIM7KZDxyiSi1zwgIjS~Qt9MjQGc5RnYBposZbz4AuoWSkPCDpCh9~QmcTWpyYT9FCoPvY73AdwQblHDVNTH0Y55xOQAHJs7SliYQtx7RHSGayAmhDShIDzzP5myO5YECFwqE0OqDBSdi~t5JrxQJYcUI70fzgLUSUmTjl3KV5x6nxBycvGD8Oog9duhQaZXe0DbDmPhXLwG0MIwTxTtzj~KEAaRtW8t5KXTVZAA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884441&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Invasive monitoring of heart rhythm in high-risk populations extended for several years has been shown to result in device-detected AF prevalence of around 30%, albeit most of whom have a low burden of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B857"></span><a href="javascript:;" reveal-id="ehae176-B857" data-open="ehae176-B857" class="link link-ref link-reveal xref-bibr">857</a>,<span class="xrefLink" id="jumplink-ehae176-B1130"></span><a href="javascript:;" reveal-id="ehae176-B1130" data-open="ehae176-B1130" class="link link-ref link-reveal xref-bibr">1130</a>,<span class="xrefLink" id="jumplink-ehae176-B1131"></span><a href="javascript:;" reveal-id="ehae176-B1131" data-open="ehae176-B1131" class="link link-ref link-reveal xref-bibr">1131</a></sup> Pacemaker studies have shown that patients with a low burden of device-detected subclinical AF have a lower risk of ischaemic stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B24"></span><a href="javascript:;" reveal-id="ehae176-B24" data-open="ehae176-B24" class="link link-ref link-reveal xref-bibr">24</a>,<span class="xrefLink" id="jumplink-ehae176-B1131"></span><a href="javascript:;" reveal-id="ehae176-B1131" data-open="ehae176-B1131" class="link link-ref link-reveal xref-bibr">1131</a>,<span class="xrefLink" id="jumplink-ehae176-B1132"></span><a href="javascript:;" reveal-id="ehae176-B1132" data-open="ehae176-B1132" class="link link-ref link-reveal xref-bibr">1132</a></sup> This has been confirmed in RCTs assessing DOAC use in patients with device-detected subclinical AF (see _Section [6.1.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5.1.1)_).<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B281"></span><a href="javascript:;" reveal-id="ehae176-B281" data-open="ehae176-B281" class="link link-ref link-reveal xref-bibr">281</a>,<span class="xrefLink" id="jumplink-ehae176-B282"></span><a href="javascript:;" reveal-id="ehae176-B282" data-open="ehae176-B282" class="link link-ref link-reveal xref-bibr">282</a></sup> The burden needed for device-detected subclinical AF to translate into stroke risk is not known, and further studies are clearly needed.<sup><span class="xrefLink" id="jumplink-ehae176-B1133"></span><a href="javascript:;" reveal-id="ehae176-B1133" data-open="ehae176-B1133" class="link link-ref link-reveal xref-bibr">1133</a>,<span class="xrefLink" id="jumplink-ehae176-B1134"></span><a href="javascript:;" reveal-id="ehae176-B1134" data-open="ehae176-B1134" class="link link-ref link-reveal xref-bibr">1134</a></sup> Benefit and cost-effectiveness of screening are discussed in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA).

Recommendation Table 31

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884443)

Recommendations for screening for AF (see also Evidence Table 31)

![Recommendations for screening for AF (see also Evidence Table 31)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt31.jpeg?Expires=1728478929&Signature=bo6aXkxV26MTJXzmZ9BsqUH6AdkoznbpZmliYOTF-4thM4WHGIFf1e1Vp~~WZPAPnfKcfMQ0voCwhEbhm~NL406vXfOm-3yb6PAUFxwiUQeQyZmdEo1DmO7grjGAVbo~h2L1kJrc6u8r01UHwu5gzxhDJ4x~RMOjg6NZP6qCVYM7ro4bDeSiqd0TY8vN9DIw9qsPVPvRTd8SH-6psXdMH4rQsSpWH056XSTtpwML43DpEj0TGSjUEoDwHzTNBF0h7cEqfhVWXfbACtCtj7t74GnlBleydorhVKvjoHVVw4s4y9kSiNti~7f5nTO3SXHs3Yl5A8jjJLznKNt4JM8zng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 31

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884443)

Recommendations for screening for AF (see also Evidence Table 31)

![Recommendations for screening for AF (see also Evidence Table 31)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt31.jpeg?Expires=1728478929&Signature=bo6aXkxV26MTJXzmZ9BsqUH6AdkoznbpZmliYOTF-4thM4WHGIFf1e1Vp~~WZPAPnfKcfMQ0voCwhEbhm~NL406vXfOm-3yb6PAUFxwiUQeQyZmdEo1DmO7grjGAVbo~h2L1kJrc6u8r01UHwu5gzxhDJ4x~RMOjg6NZP6qCVYM7ro4bDeSiqd0TY8vN9DIw9qsPVPvRTd8SH-6psXdMH4rQsSpWH056XSTtpwML43DpEj0TGSjUEoDwHzTNBF0h7cEqfhVWXfbACtCtj7t74GnlBleydorhVKvjoHVVw4s4y9kSiNti~7f5nTO3SXHs3Yl5A8jjJLznKNt4JM8zng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 10.3.1. Single timepoint screening ‘snapshot’

Several cluster RCTs in primary care settings have explored whether screening performed as a snapshot of the heart rhythm at one timepoint can detect more AF compared with usual care in individuals aged ≥65 years.<sup><span class="xrefLink" id="jumplink-ehae176-B1138 ehae176-B1139 ehae176-B1140"></span><a href="javascript:;" reveal-id="ehae176-B1138 ehae176-B1139 ehae176-B1140" data-open="ehae176-B1138 ehae176-B1139 ehae176-B1140" class="link link-ref link-reveal xref-bibr">1138–1140</a></sup> No increased detection of AF was seen in groups randomized to single timepoint screening.<sup><span class="xrefLink" id="jumplink-ehae176-B1138 ehae176-B1139 ehae176-B1140"></span><a href="javascript:;" reveal-id="ehae176-B1138 ehae176-B1139 ehae176-B1140" data-open="ehae176-B1138 ehae176-B1139 ehae176-B1140" class="link link-ref link-reveal xref-bibr">1138–1140</a></sup> These findings were confirmed in a meta-analysis of RCTs showing that screening as a one-time event did not increase detection of AF compared with usual care.<sup><span class="xrefLink" id="jumplink-ehae176-B1135"></span><a href="javascript:;" reveal-id="ehae176-B1135" data-open="ehae176-B1135" class="link link-ref link-reveal xref-bibr">1135</a></sup> Notably, these studies were performed in healthcare settings where the detection of AF in the population might be high, hence the results might not be generalizable to healthcare settings with a lower spontaneous AF detection. There are no RCTs addressing clinical outcomes in patients with AF detected by single timepoint screening.<sup><span class="xrefLink" id="jumplink-ehae176-B1123"></span><a href="javascript:;" reveal-id="ehae176-B1123" data-open="ehae176-B1123" class="link link-ref link-reveal xref-bibr">1123</a>,<span class="xrefLink" id="jumplink-ehae176-B1135"></span><a href="javascript:;" reveal-id="ehae176-B1135" data-open="ehae176-B1135" class="link link-ref link-reveal xref-bibr">1135</a></sup>

#### 10.3.2. Prolonged screening

Studies using prolonged screening have shown an increased detection of AF leading to initiation of OAC.<sup><span class="xrefLink" id="jumplink-ehae176-B1129"></span><a href="javascript:;" reveal-id="ehae176-B1129" data-open="ehae176-B1129" class="link link-ref link-reveal xref-bibr">1129</a>,<span class="xrefLink" id="jumplink-ehae176-B1135"></span><a href="javascript:;" reveal-id="ehae176-B1135" data-open="ehae176-B1135" class="link link-ref link-reveal xref-bibr">1135</a>,<span class="xrefLink" id="jumplink-ehae176-B1141"></span><a href="javascript:;" reveal-id="ehae176-B1141" data-open="ehae176-B1141" class="link link-ref link-reveal xref-bibr">1141</a></sup> Two RCTs have investigated the effect on clinical outcomes in prolonged screening for AF.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> In the STROKESTOP trial (Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden), 75- and 76-year-olds were randomized to be invited to prolonged screening for AF using single-lead ECGs twice daily for 2 weeks, or to standard of care. After a median of 6.9 years there was a small reduction in the primary combined endpoint of all-cause mortality, stroke, systematic embolism, and severe bleeding in favour of prolonged screening (HR, 0.96; 95% CI, 0.92–1.00; _P_ = .045).<sup><span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> In the LOOP (Atrial Fibrillation Detected by Continuous ECG Monitoring) trial, individuals at increased risk of stroke were randomized to receive an implantable loop recorder that monitored heart rhythm for an average of 3.3 years, or to a control group receiving standard of care. Although there was a higher detection of AF (31.8%) and subsequent initiation of OAC in the loop recorder group compared with standard of care (12.2%), this was not accompanied by a difference in the primary outcome of stroke or systemic embolism.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a></sup> In a meta-analysis of recent RCTs on the outcome of stroke, a small but significant benefit was seen in favour of prolonged screening (RR, 0.91; 95% CI, 0.84–0.99).<sup><span class="xrefLink" id="jumplink-ehae176-B1136"></span><a href="javascript:;" reveal-id="ehae176-B1136" data-open="ehae176-B1136" class="link link-ref link-reveal xref-bibr">1136</a></sup> This was not repeated in a second meta-analysis including older RCTs, where no risk reduction was seen with regard to mortality or stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B1135"></span><a href="javascript:;" reveal-id="ehae176-B1135" data-open="ehae176-B1135" class="link link-ref link-reveal xref-bibr">1135</a></sup> Notably, both these meta-analyses are likely underpowered to assess clinical outcomes.

### 10.4. Factors associated with incident AF

The most common risk predictors for incident (new-onset) AF are shown in _[Table 16](javascript:;)_. While the factors listed are robustly associated with incident AF in observational studies, it is not known whether the relationships are causal. Studies using Mendelian randomization (genetic proxies for risk factors to estimate causal effects) robustly implicate systolic BP and higher BMI as causal risk factors for incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1142"></span><a href="javascript:;" reveal-id="ehae176-B1142" data-open="ehae176-B1142" class="link link-ref link-reveal xref-bibr">1142</a></sup>

Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884450)

Factors associated with incident AF

<table role="presentation" aria-labelledby="
label-20501" aria-describedby="
caption-20501"><tbody><tr><td rowspan="4">Demographic factors</td><td>Age<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Male sex<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" class="link link-ref link-reveal xref-bibr">1149–1152</a></sup></td></tr><tr><td>European ancestry<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Lower socioeconomic status<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td rowspan="6">Lifestyle behaviours</td><td>Smoking/tobacco use<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Alcohol intake<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Physical inactivity<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Vigorous exercise<sup><span class="xrefLink" id="jumplink-ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156"></span><a href="javascript:;" reveal-id="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" data-open="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" class="link link-ref link-reveal xref-bibr">1153–1156</a></sup></td></tr><tr><td>Competitive or athlete-level endurance sports<sup><span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1157"></span><a href="javascript:;" reveal-id="ehae176-B1157" data-open="ehae176-B1157" class="link link-ref link-reveal xref-bibr">1157</a></sup></td></tr><tr><td>Caffeine<sup><span class="xrefLink" id="jumplink-ehae176-B1158 ehae176-B1159 ehae176-B1160"></span><a href="javascript:;" reveal-id="ehae176-B1158 ehae176-B1159 ehae176-B1160" data-open="ehae176-B1158 ehae176-B1159 ehae176-B1160" class="link link-ref link-reveal xref-bibr">1158–1160</a></sup></td></tr><tr><td rowspan="18">Comorbidities and risk factors</td><td>Hypertension<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Heart failure<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a></sup></td></tr><tr><td>Valvular disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1162 ehae176-B1163 ehae176-B1164"></span><a href="javascript:;" reveal-id="ehae176-B1162 ehae176-B1163 ehae176-B1164" data-open="ehae176-B1162 ehae176-B1163 ehae176-B1164" class="link link-ref link-reveal xref-bibr">1162–1164</a></sup></td></tr><tr><td>Coronary artery disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a>,<span class="xrefLink" id="jumplink-ehae176-B1165"></span><a href="javascript:;" reveal-id="ehae176-B1165" data-open="ehae176-B1165" class="link link-ref link-reveal xref-bibr">1165</a></sup></td></tr><tr><td>Peripheral arterial disease<sup><span class="xrefLink" id="jumplink-ehae176-B785"></span><a href="javascript:;" reveal-id="ehae176-B785" data-open="ehae176-B785" class="link link-ref link-reveal xref-bibr">785</a></sup></td></tr><tr><td>Congenital heart disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1166"></span><a href="javascript:;" reveal-id="ehae176-B1166" data-open="ehae176-B1166" class="link link-ref link-reveal xref-bibr">1166</a></sup></td></tr><tr><td>Heart rate, heart rate variability<sup><span class="xrefLink" id="jumplink-ehae176-B1167"></span><a href="javascript:;" reveal-id="ehae176-B1167" data-open="ehae176-B1167" class="link link-ref link-reveal xref-bibr">1167</a>,<span class="xrefLink" id="jumplink-ehae176-B1168"></span><a href="javascript:;" reveal-id="ehae176-B1168" data-open="ehae176-B1168" class="link link-ref link-reveal xref-bibr">1168</a></sup></td></tr><tr><td>Total cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Low-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>High-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Triglycerides<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Impaired glucose tolerance,<sup><span class="xrefLink" id="jumplink-ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172"></span><a href="javascript:;" reveal-id="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" data-open="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" class="link link-ref link-reveal xref-bibr">1169–1172</a></sup>diabetes mellitus<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1169"></span><a href="javascript:;" reveal-id="ehae176-B1169" data-open="ehae176-B1169" class="link link-ref link-reveal xref-bibr">1169</a></sup></td></tr><tr><td>Renal dysfunction/CKD<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1173"></span><a href="javascript:;" reveal-id="ehae176-B1173" data-open="ehae176-B1173" class="link link-ref link-reveal xref-bibr">1173</a>,<span class="xrefLink" id="jumplink-ehae176-B1174"></span><a href="javascript:;" reveal-id="ehae176-B1174" data-open="ehae176-B1174" class="link link-ref link-reveal xref-bibr">1174</a></sup></td></tr><tr><td>Obesity<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1175"></span><a href="javascript:;" reveal-id="ehae176-B1175" data-open="ehae176-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<span class="xrefLink" id="jumplink-ehae176-B1176"></span><a href="javascript:;" reveal-id="ehae176-B1176" data-open="ehae176-B1176" class="link link-ref link-reveal xref-bibr">1176</a></sup></td></tr><tr><td>Body mass index, weight<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Height<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Sleep apnoea<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1177"></span><a href="javascript:;" reveal-id="ehae176-B1177" data-open="ehae176-B1177" class="link link-ref link-reveal xref-bibr">1177</a>,<span class="xrefLink" id="jumplink-ehae176-B1178"></span><a href="javascript:;" reveal-id="ehae176-B1178" data-open="ehae176-B1178" class="link link-ref link-reveal xref-bibr">1178</a></sup></td></tr><tr><td>Chronic obstructive pulmonary disease<sup><span class="xrefLink" id="jumplink-ehae176-B1179"></span><a href="javascript:;" reveal-id="ehae176-B1179" data-open="ehae176-B1179" class="link link-ref link-reveal xref-bibr">1179</a></sup></td></tr><tr><td rowspan="2">Subclinical atherosclerosis</td><td>Coronary artery calcification<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1180"></span><a href="javascript:;" reveal-id="ehae176-B1180" data-open="ehae176-B1180" class="link link-ref link-reveal xref-bibr">1180</a></sup></td></tr><tr><td>Carotid IMT and carotid plaque<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1181"></span><a href="javascript:;" reveal-id="ehae176-B1181" data-open="ehae176-B1181" class="link link-ref link-reveal xref-bibr">1181</a>,<span class="xrefLink" id="jumplink-ehae176-B1182"></span><a href="javascript:;" reveal-id="ehae176-B1182" data-open="ehae176-B1182" class="link link-ref link-reveal xref-bibr">1182</a></sup></td></tr><tr><td rowspan="3">ECG abnormalities</td><td>PR interval prolongation<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1183"></span><a href="javascript:;" reveal-id="ehae176-B1183" data-open="ehae176-B1183" class="link link-ref link-reveal xref-bibr">1183</a></sup></td></tr><tr><td>Sick sinus syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1184"></span><a href="javascript:;" reveal-id="ehae176-B1184" data-open="ehae176-B1184" class="link link-ref link-reveal xref-bibr">1184</a>,<span class="xrefLink" id="jumplink-ehae176-B1185"></span><a href="javascript:;" reveal-id="ehae176-B1185" data-open="ehae176-B1185" class="link link-ref link-reveal xref-bibr">1185</a></sup></td></tr><tr><td>Wolff–Parkinson–White<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1186"></span><a href="javascript:;" reveal-id="ehae176-B1186" data-open="ehae176-B1186" class="link link-ref link-reveal xref-bibr">1186</a></sup></td></tr><tr><td rowspan="4">Genetic factors</td><td>Family history of AF<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190"></span><a href="javascript:;" reveal-id="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" data-open="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" class="link link-ref link-reveal xref-bibr">1187–1190</a></sup></td></tr><tr><td>AF-susceptible loci identified by GWAS<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1191"></span><a href="javascript:;" reveal-id="ehae176-B1191" data-open="ehae176-B1191" class="link link-ref link-reveal xref-bibr">1191</a>,<span class="xrefLink" id="jumplink-ehae176-B1192"></span><a href="javascript:;" reveal-id="ehae176-B1192" data-open="ehae176-B1192" class="link link-ref link-reveal xref-bibr">1192</a></sup></td></tr><tr><td>Short QT syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a></sup></td></tr><tr><td>Genetic cardiomyopathies<sup><span class="xrefLink" id="jumplink-ehae176-B990"></span><a href="javascript:;" reveal-id="ehae176-B990" data-open="ehae176-B990" class="link link-ref link-reveal xref-bibr">990</a>,<span class="xrefLink" id="jumplink-ehae176-B1193"></span><a href="javascript:;" reveal-id="ehae176-B1193" data-open="ehae176-B1193" class="link link-ref link-reveal xref-bibr">1193</a></sup></td></tr><tr><td rowspan="6">Biomarkers</td><td>C-reactive protein<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td>Fibrinogen<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Growth differentiation factor-15<sup><span class="xrefLink" id="jumplink-ehae176-B1194"></span><a href="javascript:;" reveal-id="ehae176-B1194" data-open="ehae176-B1194" class="link link-ref link-reveal xref-bibr">1194</a></sup></td></tr><tr><td>Natriuretic peptides (atrial and B-type)<sup><span class="xrefLink" id="jumplink-ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200"></span><a href="javascript:;" reveal-id="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" data-open="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" class="link link-ref link-reveal xref-bibr">1195–1200</a></sup></td></tr><tr><td>Cardiac troponins<sup><span class="xrefLink" id="jumplink-ehae176-B1199"></span><a href="javascript:;" reveal-id="ehae176-B1199" data-open="ehae176-B1199" class="link link-ref link-reveal xref-bibr">1199</a></sup></td></tr><tr><td>Inflammatory biomarkers <sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td rowspan="5">Others</td><td>Thyroid dysfunction<sup><span class="xrefLink" id="jumplink-ehae176-B912"></span><a href="javascript:;" reveal-id="ehae176-B912" data-open="ehae176-B912" class="link link-ref link-reveal xref-bibr">912</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Autoimmune diseases<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Air pollution<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1201"></span><a href="javascript:;" reveal-id="ehae176-B1201" data-open="ehae176-B1201" class="link link-ref link-reveal xref-bibr">1201</a></sup></td></tr><tr><td>Sepsis<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1202"></span><a href="javascript:;" reveal-id="ehae176-B1202" data-open="ehae176-B1202" class="link link-ref link-reveal xref-bibr">1202</a></sup></td></tr><tr><td>Psychological factors <sup><span class="xrefLink" id="jumplink-ehae176-B1203"></span><a href="javascript:;" reveal-id="ehae176-B1203" data-open="ehae176-B1203" class="link link-ref link-reveal xref-bibr">1203</a>,<span class="xrefLink" id="jumplink-ehae176-B1204"></span><a href="javascript:;" reveal-id="ehae176-B1204" data-open="ehae176-B1204" class="link link-ref link-reveal xref-bibr">1204</a></sup></td></tr></tbody></table>

<table><tbody><tr><td rowspan="4">Demographic factors</td><td>Age<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Male sex<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" class="link link-ref link-reveal xref-bibr">1149–1152</a></sup></td></tr><tr><td>European ancestry<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Lower socioeconomic status<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td rowspan="6">Lifestyle behaviours</td><td>Smoking/tobacco use<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Alcohol intake<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Physical inactivity<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Vigorous exercise<sup><span class="xrefLink" id="jumplink-ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156"></span><a href="javascript:;" reveal-id="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" data-open="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" class="link link-ref link-reveal xref-bibr">1153–1156</a></sup></td></tr><tr><td>Competitive or athlete-level endurance sports<sup><span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1157"></span><a href="javascript:;" reveal-id="ehae176-B1157" data-open="ehae176-B1157" class="link link-ref link-reveal xref-bibr">1157</a></sup></td></tr><tr><td>Caffeine<sup><span class="xrefLink" id="jumplink-ehae176-B1158 ehae176-B1159 ehae176-B1160"></span><a href="javascript:;" reveal-id="ehae176-B1158 ehae176-B1159 ehae176-B1160" data-open="ehae176-B1158 ehae176-B1159 ehae176-B1160" class="link link-ref link-reveal xref-bibr">1158–1160</a></sup></td></tr><tr><td rowspan="18">Comorbidities and risk factors</td><td>Hypertension<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Heart failure<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a></sup></td></tr><tr><td>Valvular disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1162 ehae176-B1163 ehae176-B1164"></span><a href="javascript:;" reveal-id="ehae176-B1162 ehae176-B1163 ehae176-B1164" data-open="ehae176-B1162 ehae176-B1163 ehae176-B1164" class="link link-ref link-reveal xref-bibr">1162–1164</a></sup></td></tr><tr><td>Coronary artery disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a>,<span class="xrefLink" id="jumplink-ehae176-B1165"></span><a href="javascript:;" reveal-id="ehae176-B1165" data-open="ehae176-B1165" class="link link-ref link-reveal xref-bibr">1165</a></sup></td></tr><tr><td>Peripheral arterial disease<sup><span class="xrefLink" id="jumplink-ehae176-B785"></span><a href="javascript:;" reveal-id="ehae176-B785" data-open="ehae176-B785" class="link link-ref link-reveal xref-bibr">785</a></sup></td></tr><tr><td>Congenital heart disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1166"></span><a href="javascript:;" reveal-id="ehae176-B1166" data-open="ehae176-B1166" class="link link-ref link-reveal xref-bibr">1166</a></sup></td></tr><tr><td>Heart rate, heart rate variability<sup><span class="xrefLink" id="jumplink-ehae176-B1167"></span><a href="javascript:;" reveal-id="ehae176-B1167" data-open="ehae176-B1167" class="link link-ref link-reveal xref-bibr">1167</a>,<span class="xrefLink" id="jumplink-ehae176-B1168"></span><a href="javascript:;" reveal-id="ehae176-B1168" data-open="ehae176-B1168" class="link link-ref link-reveal xref-bibr">1168</a></sup></td></tr><tr><td>Total cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Low-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>High-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Triglycerides<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Impaired glucose tolerance,<sup><span class="xrefLink" id="jumplink-ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172"></span><a href="javascript:;" reveal-id="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" data-open="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" class="link link-ref link-reveal xref-bibr">1169–1172</a></sup>diabetes mellitus<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1169"></span><a href="javascript:;" reveal-id="ehae176-B1169" data-open="ehae176-B1169" class="link link-ref link-reveal xref-bibr">1169</a></sup></td></tr><tr><td>Renal dysfunction/CKD<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1173"></span><a href="javascript:;" reveal-id="ehae176-B1173" data-open="ehae176-B1173" class="link link-ref link-reveal xref-bibr">1173</a>,<span class="xrefLink" id="jumplink-ehae176-B1174"></span><a href="javascript:;" reveal-id="ehae176-B1174" data-open="ehae176-B1174" class="link link-ref link-reveal xref-bibr">1174</a></sup></td></tr><tr><td>Obesity<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1175"></span><a href="javascript:;" reveal-id="ehae176-B1175" data-open="ehae176-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<span class="xrefLink" id="jumplink-ehae176-B1176"></span><a href="javascript:;" reveal-id="ehae176-B1176" data-open="ehae176-B1176" class="link link-ref link-reveal xref-bibr">1176</a></sup></td></tr><tr><td>Body mass index, weight<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Height<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Sleep apnoea<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1177"></span><a href="javascript:;" reveal-id="ehae176-B1177" data-open="ehae176-B1177" class="link link-ref link-reveal xref-bibr">1177</a>,<span class="xrefLink" id="jumplink-ehae176-B1178"></span><a href="javascript:;" reveal-id="ehae176-B1178" data-open="ehae176-B1178" class="link link-ref link-reveal xref-bibr">1178</a></sup></td></tr><tr><td>Chronic obstructive pulmonary disease<sup><span class="xrefLink" id="jumplink-ehae176-B1179"></span><a href="javascript:;" reveal-id="ehae176-B1179" data-open="ehae176-B1179" class="link link-ref link-reveal xref-bibr">1179</a></sup></td></tr><tr><td rowspan="2">Subclinical atherosclerosis</td><td>Coronary artery calcification<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1180"></span><a href="javascript:;" reveal-id="ehae176-B1180" data-open="ehae176-B1180" class="link link-ref link-reveal xref-bibr">1180</a></sup></td></tr><tr><td>Carotid IMT and carotid plaque<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1181"></span><a href="javascript:;" reveal-id="ehae176-B1181" data-open="ehae176-B1181" class="link link-ref link-reveal xref-bibr">1181</a>,<span class="xrefLink" id="jumplink-ehae176-B1182"></span><a href="javascript:;" reveal-id="ehae176-B1182" data-open="ehae176-B1182" class="link link-ref link-reveal xref-bibr">1182</a></sup></td></tr><tr><td rowspan="3">ECG abnormalities</td><td>PR interval prolongation<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1183"></span><a href="javascript:;" reveal-id="ehae176-B1183" data-open="ehae176-B1183" class="link link-ref link-reveal xref-bibr">1183</a></sup></td></tr><tr><td>Sick sinus syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1184"></span><a href="javascript:;" reveal-id="ehae176-B1184" data-open="ehae176-B1184" class="link link-ref link-reveal xref-bibr">1184</a>,<span class="xrefLink" id="jumplink-ehae176-B1185"></span><a href="javascript:;" reveal-id="ehae176-B1185" data-open="ehae176-B1185" class="link link-ref link-reveal xref-bibr">1185</a></sup></td></tr><tr><td>Wolff–Parkinson–White<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1186"></span><a href="javascript:;" reveal-id="ehae176-B1186" data-open="ehae176-B1186" class="link link-ref link-reveal xref-bibr">1186</a></sup></td></tr><tr><td rowspan="4">Genetic factors</td><td>Family history of AF<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190"></span><a href="javascript:;" reveal-id="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" data-open="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" class="link link-ref link-reveal xref-bibr">1187–1190</a></sup></td></tr><tr><td>AF-susceptible loci identified by GWAS<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1191"></span><a href="javascript:;" reveal-id="ehae176-B1191" data-open="ehae176-B1191" class="link link-ref link-reveal xref-bibr">1191</a>,<span class="xrefLink" id="jumplink-ehae176-B1192"></span><a href="javascript:;" reveal-id="ehae176-B1192" data-open="ehae176-B1192" class="link link-ref link-reveal xref-bibr">1192</a></sup></td></tr><tr><td>Short QT syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a></sup></td></tr><tr><td>Genetic cardiomyopathies<sup><span class="xrefLink" id="jumplink-ehae176-B990"></span><a href="javascript:;" reveal-id="ehae176-B990" data-open="ehae176-B990" class="link link-ref link-reveal xref-bibr">990</a>,<span class="xrefLink" id="jumplink-ehae176-B1193"></span><a href="javascript:;" reveal-id="ehae176-B1193" data-open="ehae176-B1193" class="link link-ref link-reveal xref-bibr">1193</a></sup></td></tr><tr><td rowspan="6">Biomarkers</td><td>C-reactive protein<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td>Fibrinogen<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Growth differentiation factor-15<sup><span class="xrefLink" id="jumplink-ehae176-B1194"></span><a href="javascript:;" reveal-id="ehae176-B1194" data-open="ehae176-B1194" class="link link-ref link-reveal xref-bibr">1194</a></sup></td></tr><tr><td>Natriuretic peptides (atrial and B-type)<sup><span class="xrefLink" id="jumplink-ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200"></span><a href="javascript:;" reveal-id="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" data-open="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" class="link link-ref link-reveal xref-bibr">1195–1200</a></sup></td></tr><tr><td>Cardiac troponins<sup><span class="xrefLink" id="jumplink-ehae176-B1199"></span><a href="javascript:;" reveal-id="ehae176-B1199" data-open="ehae176-B1199" class="link link-ref link-reveal xref-bibr">1199</a></sup></td></tr><tr><td>Inflammatory biomarkers <sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td rowspan="5">Others</td><td>Thyroid dysfunction<sup><span class="xrefLink" id="jumplink-ehae176-B912"></span><a href="javascript:;" reveal-id="ehae176-B912" data-open="ehae176-B912" class="link link-ref link-reveal xref-bibr">912</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Autoimmune diseases<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Air pollution<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1201"></span><a href="javascript:;" reveal-id="ehae176-B1201" data-open="ehae176-B1201" class="link link-ref link-reveal xref-bibr">1201</a></sup></td></tr><tr><td>Sepsis<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1202"></span><a href="javascript:;" reveal-id="ehae176-B1202" data-open="ehae176-B1202" class="link link-ref link-reveal xref-bibr">1202</a></sup></td></tr><tr><td>Psychological factors <sup><span class="xrefLink" id="jumplink-ehae176-B1203"></span><a href="javascript:;" reveal-id="ehae176-B1203" data-open="ehae176-B1203" class="link link-ref link-reveal xref-bibr">1203</a>,<span class="xrefLink" id="jumplink-ehae176-B1204"></span><a href="javascript:;" reveal-id="ehae176-B1204" data-open="ehae176-B1204" class="link link-ref link-reveal xref-bibr">1204</a></sup></td></tr></tbody></table>

AF, atrial fibrillation; CKD, chronic kidney disease; GWAS, genome-wide association studies; HF, heart failure; IMT, intima-media thickness.

© ESC 2024

Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884450)

Factors associated with incident AF

<table role="presentation" aria-labelledby="
label-20501" aria-describedby="
caption-20501"><tbody><tr><td rowspan="4">Demographic factors</td><td>Age<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Male sex<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" class="link link-ref link-reveal xref-bibr">1149–1152</a></sup></td></tr><tr><td>European ancestry<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Lower socioeconomic status<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td rowspan="6">Lifestyle behaviours</td><td>Smoking/tobacco use<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Alcohol intake<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Physical inactivity<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Vigorous exercise<sup><span class="xrefLink" id="jumplink-ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156"></span><a href="javascript:;" reveal-id="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" data-open="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" class="link link-ref link-reveal xref-bibr">1153–1156</a></sup></td></tr><tr><td>Competitive or athlete-level endurance sports<sup><span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1157"></span><a href="javascript:;" reveal-id="ehae176-B1157" data-open="ehae176-B1157" class="link link-ref link-reveal xref-bibr">1157</a></sup></td></tr><tr><td>Caffeine<sup><span class="xrefLink" id="jumplink-ehae176-B1158 ehae176-B1159 ehae176-B1160"></span><a href="javascript:;" reveal-id="ehae176-B1158 ehae176-B1159 ehae176-B1160" data-open="ehae176-B1158 ehae176-B1159 ehae176-B1160" class="link link-ref link-reveal xref-bibr">1158–1160</a></sup></td></tr><tr><td rowspan="18">Comorbidities and risk factors</td><td>Hypertension<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Heart failure<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a></sup></td></tr><tr><td>Valvular disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1162 ehae176-B1163 ehae176-B1164"></span><a href="javascript:;" reveal-id="ehae176-B1162 ehae176-B1163 ehae176-B1164" data-open="ehae176-B1162 ehae176-B1163 ehae176-B1164" class="link link-ref link-reveal xref-bibr">1162–1164</a></sup></td></tr><tr><td>Coronary artery disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a>,<span class="xrefLink" id="jumplink-ehae176-B1165"></span><a href="javascript:;" reveal-id="ehae176-B1165" data-open="ehae176-B1165" class="link link-ref link-reveal xref-bibr">1165</a></sup></td></tr><tr><td>Peripheral arterial disease<sup><span class="xrefLink" id="jumplink-ehae176-B785"></span><a href="javascript:;" reveal-id="ehae176-B785" data-open="ehae176-B785" class="link link-ref link-reveal xref-bibr">785</a></sup></td></tr><tr><td>Congenital heart disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1166"></span><a href="javascript:;" reveal-id="ehae176-B1166" data-open="ehae176-B1166" class="link link-ref link-reveal xref-bibr">1166</a></sup></td></tr><tr><td>Heart rate, heart rate variability<sup><span class="xrefLink" id="jumplink-ehae176-B1167"></span><a href="javascript:;" reveal-id="ehae176-B1167" data-open="ehae176-B1167" class="link link-ref link-reveal xref-bibr">1167</a>,<span class="xrefLink" id="jumplink-ehae176-B1168"></span><a href="javascript:;" reveal-id="ehae176-B1168" data-open="ehae176-B1168" class="link link-ref link-reveal xref-bibr">1168</a></sup></td></tr><tr><td>Total cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Low-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>High-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Triglycerides<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Impaired glucose tolerance,<sup><span class="xrefLink" id="jumplink-ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172"></span><a href="javascript:;" reveal-id="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" data-open="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" class="link link-ref link-reveal xref-bibr">1169–1172</a></sup>diabetes mellitus<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1169"></span><a href="javascript:;" reveal-id="ehae176-B1169" data-open="ehae176-B1169" class="link link-ref link-reveal xref-bibr">1169</a></sup></td></tr><tr><td>Renal dysfunction/CKD<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1173"></span><a href="javascript:;" reveal-id="ehae176-B1173" data-open="ehae176-B1173" class="link link-ref link-reveal xref-bibr">1173</a>,<span class="xrefLink" id="jumplink-ehae176-B1174"></span><a href="javascript:;" reveal-id="ehae176-B1174" data-open="ehae176-B1174" class="link link-ref link-reveal xref-bibr">1174</a></sup></td></tr><tr><td>Obesity<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1175"></span><a href="javascript:;" reveal-id="ehae176-B1175" data-open="ehae176-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<span class="xrefLink" id="jumplink-ehae176-B1176"></span><a href="javascript:;" reveal-id="ehae176-B1176" data-open="ehae176-B1176" class="link link-ref link-reveal xref-bibr">1176</a></sup></td></tr><tr><td>Body mass index, weight<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Height<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Sleep apnoea<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1177"></span><a href="javascript:;" reveal-id="ehae176-B1177" data-open="ehae176-B1177" class="link link-ref link-reveal xref-bibr">1177</a>,<span class="xrefLink" id="jumplink-ehae176-B1178"></span><a href="javascript:;" reveal-id="ehae176-B1178" data-open="ehae176-B1178" class="link link-ref link-reveal xref-bibr">1178</a></sup></td></tr><tr><td>Chronic obstructive pulmonary disease<sup><span class="xrefLink" id="jumplink-ehae176-B1179"></span><a href="javascript:;" reveal-id="ehae176-B1179" data-open="ehae176-B1179" class="link link-ref link-reveal xref-bibr">1179</a></sup></td></tr><tr><td rowspan="2">Subclinical atherosclerosis</td><td>Coronary artery calcification<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1180"></span><a href="javascript:;" reveal-id="ehae176-B1180" data-open="ehae176-B1180" class="link link-ref link-reveal xref-bibr">1180</a></sup></td></tr><tr><td>Carotid IMT and carotid plaque<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1181"></span><a href="javascript:;" reveal-id="ehae176-B1181" data-open="ehae176-B1181" class="link link-ref link-reveal xref-bibr">1181</a>,<span class="xrefLink" id="jumplink-ehae176-B1182"></span><a href="javascript:;" reveal-id="ehae176-B1182" data-open="ehae176-B1182" class="link link-ref link-reveal xref-bibr">1182</a></sup></td></tr><tr><td rowspan="3">ECG abnormalities</td><td>PR interval prolongation<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1183"></span><a href="javascript:;" reveal-id="ehae176-B1183" data-open="ehae176-B1183" class="link link-ref link-reveal xref-bibr">1183</a></sup></td></tr><tr><td>Sick sinus syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1184"></span><a href="javascript:;" reveal-id="ehae176-B1184" data-open="ehae176-B1184" class="link link-ref link-reveal xref-bibr">1184</a>,<span class="xrefLink" id="jumplink-ehae176-B1185"></span><a href="javascript:;" reveal-id="ehae176-B1185" data-open="ehae176-B1185" class="link link-ref link-reveal xref-bibr">1185</a></sup></td></tr><tr><td>Wolff–Parkinson–White<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1186"></span><a href="javascript:;" reveal-id="ehae176-B1186" data-open="ehae176-B1186" class="link link-ref link-reveal xref-bibr">1186</a></sup></td></tr><tr><td rowspan="4">Genetic factors</td><td>Family history of AF<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190"></span><a href="javascript:;" reveal-id="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" data-open="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" class="link link-ref link-reveal xref-bibr">1187–1190</a></sup></td></tr><tr><td>AF-susceptible loci identified by GWAS<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1191"></span><a href="javascript:;" reveal-id="ehae176-B1191" data-open="ehae176-B1191" class="link link-ref link-reveal xref-bibr">1191</a>,<span class="xrefLink" id="jumplink-ehae176-B1192"></span><a href="javascript:;" reveal-id="ehae176-B1192" data-open="ehae176-B1192" class="link link-ref link-reveal xref-bibr">1192</a></sup></td></tr><tr><td>Short QT syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a></sup></td></tr><tr><td>Genetic cardiomyopathies<sup><span class="xrefLink" id="jumplink-ehae176-B990"></span><a href="javascript:;" reveal-id="ehae176-B990" data-open="ehae176-B990" class="link link-ref link-reveal xref-bibr">990</a>,<span class="xrefLink" id="jumplink-ehae176-B1193"></span><a href="javascript:;" reveal-id="ehae176-B1193" data-open="ehae176-B1193" class="link link-ref link-reveal xref-bibr">1193</a></sup></td></tr><tr><td rowspan="6">Biomarkers</td><td>C-reactive protein<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td>Fibrinogen<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Growth differentiation factor-15<sup><span class="xrefLink" id="jumplink-ehae176-B1194"></span><a href="javascript:;" reveal-id="ehae176-B1194" data-open="ehae176-B1194" class="link link-ref link-reveal xref-bibr">1194</a></sup></td></tr><tr><td>Natriuretic peptides (atrial and B-type)<sup><span class="xrefLink" id="jumplink-ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200"></span><a href="javascript:;" reveal-id="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" data-open="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" class="link link-ref link-reveal xref-bibr">1195–1200</a></sup></td></tr><tr><td>Cardiac troponins<sup><span class="xrefLink" id="jumplink-ehae176-B1199"></span><a href="javascript:;" reveal-id="ehae176-B1199" data-open="ehae176-B1199" class="link link-ref link-reveal xref-bibr">1199</a></sup></td></tr><tr><td>Inflammatory biomarkers <sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td rowspan="5">Others</td><td>Thyroid dysfunction<sup><span class="xrefLink" id="jumplink-ehae176-B912"></span><a href="javascript:;" reveal-id="ehae176-B912" data-open="ehae176-B912" class="link link-ref link-reveal xref-bibr">912</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Autoimmune diseases<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Air pollution<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1201"></span><a href="javascript:;" reveal-id="ehae176-B1201" data-open="ehae176-B1201" class="link link-ref link-reveal xref-bibr">1201</a></sup></td></tr><tr><td>Sepsis<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1202"></span><a href="javascript:;" reveal-id="ehae176-B1202" data-open="ehae176-B1202" class="link link-ref link-reveal xref-bibr">1202</a></sup></td></tr><tr><td>Psychological factors <sup><span class="xrefLink" id="jumplink-ehae176-B1203"></span><a href="javascript:;" reveal-id="ehae176-B1203" data-open="ehae176-B1203" class="link link-ref link-reveal xref-bibr">1203</a>,<span class="xrefLink" id="jumplink-ehae176-B1204"></span><a href="javascript:;" reveal-id="ehae176-B1204" data-open="ehae176-B1204" class="link link-ref link-reveal xref-bibr">1204</a></sup></td></tr></tbody></table>

<table><tbody><tr><td rowspan="4">Demographic factors</td><td>Age<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Male sex<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" class="link link-ref link-reveal xref-bibr">1149–1152</a></sup></td></tr><tr><td>European ancestry<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Lower socioeconomic status<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td rowspan="6">Lifestyle behaviours</td><td>Smoking/tobacco use<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Alcohol intake<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Physical inactivity<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Vigorous exercise<sup><span class="xrefLink" id="jumplink-ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156"></span><a href="javascript:;" reveal-id="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" data-open="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" class="link link-ref link-reveal xref-bibr">1153–1156</a></sup></td></tr><tr><td>Competitive or athlete-level endurance sports<sup><span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1157"></span><a href="javascript:;" reveal-id="ehae176-B1157" data-open="ehae176-B1157" class="link link-ref link-reveal xref-bibr">1157</a></sup></td></tr><tr><td>Caffeine<sup><span class="xrefLink" id="jumplink-ehae176-B1158 ehae176-B1159 ehae176-B1160"></span><a href="javascript:;" reveal-id="ehae176-B1158 ehae176-B1159 ehae176-B1160" data-open="ehae176-B1158 ehae176-B1159 ehae176-B1160" class="link link-ref link-reveal xref-bibr">1158–1160</a></sup></td></tr><tr><td rowspan="18">Comorbidities and risk factors</td><td>Hypertension<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Heart failure<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a></sup></td></tr><tr><td>Valvular disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1162 ehae176-B1163 ehae176-B1164"></span><a href="javascript:;" reveal-id="ehae176-B1162 ehae176-B1163 ehae176-B1164" data-open="ehae176-B1162 ehae176-B1163 ehae176-B1164" class="link link-ref link-reveal xref-bibr">1162–1164</a></sup></td></tr><tr><td>Coronary artery disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a>,<span class="xrefLink" id="jumplink-ehae176-B1165"></span><a href="javascript:;" reveal-id="ehae176-B1165" data-open="ehae176-B1165" class="link link-ref link-reveal xref-bibr">1165</a></sup></td></tr><tr><td>Peripheral arterial disease<sup><span class="xrefLink" id="jumplink-ehae176-B785"></span><a href="javascript:;" reveal-id="ehae176-B785" data-open="ehae176-B785" class="link link-ref link-reveal xref-bibr">785</a></sup></td></tr><tr><td>Congenital heart disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1166"></span><a href="javascript:;" reveal-id="ehae176-B1166" data-open="ehae176-B1166" class="link link-ref link-reveal xref-bibr">1166</a></sup></td></tr><tr><td>Heart rate, heart rate variability<sup><span class="xrefLink" id="jumplink-ehae176-B1167"></span><a href="javascript:;" reveal-id="ehae176-B1167" data-open="ehae176-B1167" class="link link-ref link-reveal xref-bibr">1167</a>,<span class="xrefLink" id="jumplink-ehae176-B1168"></span><a href="javascript:;" reveal-id="ehae176-B1168" data-open="ehae176-B1168" class="link link-ref link-reveal xref-bibr">1168</a></sup></td></tr><tr><td>Total cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Low-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>High-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Triglycerides<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Impaired glucose tolerance,<sup><span class="xrefLink" id="jumplink-ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172"></span><a href="javascript:;" reveal-id="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" data-open="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" class="link link-ref link-reveal xref-bibr">1169–1172</a></sup>diabetes mellitus<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1169"></span><a href="javascript:;" reveal-id="ehae176-B1169" data-open="ehae176-B1169" class="link link-ref link-reveal xref-bibr">1169</a></sup></td></tr><tr><td>Renal dysfunction/CKD<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1173"></span><a href="javascript:;" reveal-id="ehae176-B1173" data-open="ehae176-B1173" class="link link-ref link-reveal xref-bibr">1173</a>,<span class="xrefLink" id="jumplink-ehae176-B1174"></span><a href="javascript:;" reveal-id="ehae176-B1174" data-open="ehae176-B1174" class="link link-ref link-reveal xref-bibr">1174</a></sup></td></tr><tr><td>Obesity<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1175"></span><a href="javascript:;" reveal-id="ehae176-B1175" data-open="ehae176-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<span class="xrefLink" id="jumplink-ehae176-B1176"></span><a href="javascript:;" reveal-id="ehae176-B1176" data-open="ehae176-B1176" class="link link-ref link-reveal xref-bibr">1176</a></sup></td></tr><tr><td>Body mass index, weight<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Height<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Sleep apnoea<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1177"></span><a href="javascript:;" reveal-id="ehae176-B1177" data-open="ehae176-B1177" class="link link-ref link-reveal xref-bibr">1177</a>,<span class="xrefLink" id="jumplink-ehae176-B1178"></span><a href="javascript:;" reveal-id="ehae176-B1178" data-open="ehae176-B1178" class="link link-ref link-reveal xref-bibr">1178</a></sup></td></tr><tr><td>Chronic obstructive pulmonary disease<sup><span class="xrefLink" id="jumplink-ehae176-B1179"></span><a href="javascript:;" reveal-id="ehae176-B1179" data-open="ehae176-B1179" class="link link-ref link-reveal xref-bibr">1179</a></sup></td></tr><tr><td rowspan="2">Subclinical atherosclerosis</td><td>Coronary artery calcification<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1180"></span><a href="javascript:;" reveal-id="ehae176-B1180" data-open="ehae176-B1180" class="link link-ref link-reveal xref-bibr">1180</a></sup></td></tr><tr><td>Carotid IMT and carotid plaque<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1181"></span><a href="javascript:;" reveal-id="ehae176-B1181" data-open="ehae176-B1181" class="link link-ref link-reveal xref-bibr">1181</a>,<span class="xrefLink" id="jumplink-ehae176-B1182"></span><a href="javascript:;" reveal-id="ehae176-B1182" data-open="ehae176-B1182" class="link link-ref link-reveal xref-bibr">1182</a></sup></td></tr><tr><td rowspan="3">ECG abnormalities</td><td>PR interval prolongation<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1183"></span><a href="javascript:;" reveal-id="ehae176-B1183" data-open="ehae176-B1183" class="link link-ref link-reveal xref-bibr">1183</a></sup></td></tr><tr><td>Sick sinus syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1184"></span><a href="javascript:;" reveal-id="ehae176-B1184" data-open="ehae176-B1184" class="link link-ref link-reveal xref-bibr">1184</a>,<span class="xrefLink" id="jumplink-ehae176-B1185"></span><a href="javascript:;" reveal-id="ehae176-B1185" data-open="ehae176-B1185" class="link link-ref link-reveal xref-bibr">1185</a></sup></td></tr><tr><td>Wolff–Parkinson–White<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1186"></span><a href="javascript:;" reveal-id="ehae176-B1186" data-open="ehae176-B1186" class="link link-ref link-reveal xref-bibr">1186</a></sup></td></tr><tr><td rowspan="4">Genetic factors</td><td>Family history of AF<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190"></span><a href="javascript:;" reveal-id="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" data-open="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" class="link link-ref link-reveal xref-bibr">1187–1190</a></sup></td></tr><tr><td>AF-susceptible loci identified by GWAS<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1191"></span><a href="javascript:;" reveal-id="ehae176-B1191" data-open="ehae176-B1191" class="link link-ref link-reveal xref-bibr">1191</a>,<span class="xrefLink" id="jumplink-ehae176-B1192"></span><a href="javascript:;" reveal-id="ehae176-B1192" data-open="ehae176-B1192" class="link link-ref link-reveal xref-bibr">1192</a></sup></td></tr><tr><td>Short QT syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a></sup></td></tr><tr><td>Genetic cardiomyopathies<sup><span class="xrefLink" id="jumplink-ehae176-B990"></span><a href="javascript:;" reveal-id="ehae176-B990" data-open="ehae176-B990" class="link link-ref link-reveal xref-bibr">990</a>,<span class="xrefLink" id="jumplink-ehae176-B1193"></span><a href="javascript:;" reveal-id="ehae176-B1193" data-open="ehae176-B1193" class="link link-ref link-reveal xref-bibr">1193</a></sup></td></tr><tr><td rowspan="6">Biomarkers</td><td>C-reactive protein<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td>Fibrinogen<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Growth differentiation factor-15<sup><span class="xrefLink" id="jumplink-ehae176-B1194"></span><a href="javascript:;" reveal-id="ehae176-B1194" data-open="ehae176-B1194" class="link link-ref link-reveal xref-bibr">1194</a></sup></td></tr><tr><td>Natriuretic peptides (atrial and B-type)<sup><span class="xrefLink" id="jumplink-ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200"></span><a href="javascript:;" reveal-id="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" data-open="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" class="link link-ref link-reveal xref-bibr">1195–1200</a></sup></td></tr><tr><td>Cardiac troponins<sup><span class="xrefLink" id="jumplink-ehae176-B1199"></span><a href="javascript:;" reveal-id="ehae176-B1199" data-open="ehae176-B1199" class="link link-ref link-reveal xref-bibr">1199</a></sup></td></tr><tr><td>Inflammatory biomarkers <sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td rowspan="5">Others</td><td>Thyroid dysfunction<sup><span class="xrefLink" id="jumplink-ehae176-B912"></span><a href="javascript:;" reveal-id="ehae176-B912" data-open="ehae176-B912" class="link link-ref link-reveal xref-bibr">912</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Autoimmune diseases<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Air pollution<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1201"></span><a href="javascript:;" reveal-id="ehae176-B1201" data-open="ehae176-B1201" class="link link-ref link-reveal xref-bibr">1201</a></sup></td></tr><tr><td>Sepsis<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1202"></span><a href="javascript:;" reveal-id="ehae176-B1202" data-open="ehae176-B1202" class="link link-ref link-reveal xref-bibr">1202</a></sup></td></tr><tr><td>Psychological factors <sup><span class="xrefLink" id="jumplink-ehae176-B1203"></span><a href="javascript:;" reveal-id="ehae176-B1203" data-open="ehae176-B1203" class="link link-ref link-reveal xref-bibr">1203</a>,<span class="xrefLink" id="jumplink-ehae176-B1204"></span><a href="javascript:;" reveal-id="ehae176-B1204" data-open="ehae176-B1204" class="link link-ref link-reveal xref-bibr">1204</a></sup></td></tr></tbody></table>

AF, atrial fibrillation; CKD, chronic kidney disease; GWAS, genome-wide association studies; HF, heart failure; IMT, intima-media thickness.

© ESC 2024

A high degree of interaction occurs between all factors related to AF development (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S33](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B1038"></span><a href="javascript:;" reveal-id="ehae176-B1038" data-open="ehae176-B1038" class="link link-ref link-reveal xref-bibr">1038</a>,<span class="xrefLink" id="jumplink-ehae176-B1039"></span><a href="javascript:;" reveal-id="ehae176-B1039" data-open="ehae176-B1039" class="link link-ref link-reveal xref-bibr">1039</a>,<span class="xrefLink" id="jumplink-ehae176-B1143 ehae176-B1144 ehae176-B1145"></span><a href="javascript:;" reveal-id="ehae176-B1143 ehae176-B1144 ehae176-B1145" data-open="ehae176-B1143 ehae176-B1144 ehae176-B1145" class="link link-ref link-reveal xref-bibr">1143–1145</a></sup> For ease of clinical application, risk prediction tools have combined various factors, and have recently employed machine learning algorithms for prediction.<sup><span class="xrefLink" id="jumplink-ehae176-B1146"></span><a href="javascript:;" reveal-id="ehae176-B1146" data-open="ehae176-B1146" class="link link-ref link-reveal xref-bibr">1146</a>,<span class="xrefLink" id="jumplink-ehae176-B1147"></span><a href="javascript:;" reveal-id="ehae176-B1147" data-open="ehae176-B1147" class="link link-ref link-reveal xref-bibr">1147</a></sup> Classical risk scores are also available with variable predictive ability and model performance (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S7](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B1148"></span><a href="javascript:;" reveal-id="ehae176-B1148" data-open="ehae176-B1148" class="link link-ref link-reveal xref-bibr">1148</a></sup> Improved outcomes when using these risk scores have yet to be demonstrated. Although knowledge is rapidly increasing about the genetic basis for AF in some patients, the value of genetic screening is limited at the present time (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).

### 10.5. Primary prevention of AF

Preventing the onset of AF before clinical manifestation has clear potential to improve the lives of the general population and reduce the considerable health and social care costs associated with development of AF. Whereas the \[C\] in AF-CARE is focused on the effective management of risk factors and comorbidities to limit AF recurrence and progression, there is also evidence they can be targeted to prevent AF. Available data are presented below for hypertension, heart failure, type 2 diabetes mellitus, obesity, sleep apnoea syndrome, physical activity, and alcohol, although many other risk markers can also be targeted. Further information on each factor's attributable risk for AF is provided in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Evidence Table 32](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[Additional Evidence Tables S34–S39](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

Recommendation Table 32

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884454)

Recommendations for primary prevention of AF (see also Evidence Table 32)

![Recommendations for primary prevention of AF (see also Evidence Table 32)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt32.jpeg?Expires=1728478929&Signature=i4GYu1g7SI9nhGSq4-5JHgNuoEtP3Zca8AgqjF9~Jm0Os9aEV9ryCtgOBc9VEbaYfQNu7XMdUJc5djhzff9e5F6rhFNOMW-LjG17r3LDo7P7gVH0Vid~JocPuzQl9H9UdELMgJhV~ALXxZB-i88lcTnthps3dl2vQH1-Fo8mko0E6axTDdIEgAvFjW5fCDcYx7El8zRdixtpTSFkEq6tUIGCcpOUe3PHblWq7~30x1NL5wBBtwIcGFFucm5BB90C0sx2Nlydmd3jI-otMhkLOFYboKcTq~oVjH0kZySOsv2ZUyPiNIJWlm0IBYfkvwbuJ6Il4zsMJtUNSQEaJYDY5A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 32

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884454)

Recommendations for primary prevention of AF (see also Evidence Table 32)

![Recommendations for primary prevention of AF (see also Evidence Table 32)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt32.jpeg?Expires=1728478929&Signature=i4GYu1g7SI9nhGSq4-5JHgNuoEtP3Zca8AgqjF9~Jm0Os9aEV9ryCtgOBc9VEbaYfQNu7XMdUJc5djhzff9e5F6rhFNOMW-LjG17r3LDo7P7gVH0Vid~JocPuzQl9H9UdELMgJhV~ALXxZB-i88lcTnthps3dl2vQH1-Fo8mko0E6axTDdIEgAvFjW5fCDcYx7El8zRdixtpTSFkEq6tUIGCcpOUe3PHblWq7~30x1NL5wBBtwIcGFFucm5BB90C0sx2Nlydmd3jI-otMhkLOFYboKcTq~oVjH0kZySOsv2ZUyPiNIJWlm0IBYfkvwbuJ6Il4zsMJtUNSQEaJYDY5A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 10.5.1. Hypertension

Management of hypertension has been associated with a reduction in incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1205 ehae176-B1206 ehae176-B1207"></span><a href="javascript:;" reveal-id="ehae176-B1205 ehae176-B1206 ehae176-B1207" data-open="ehae176-B1205 ehae176-B1206 ehae176-B1207" class="link link-ref link-reveal xref-bibr">1205–1207</a>,<span class="xrefLink" id="jumplink-ehae176-B1232"></span><a href="javascript:;" reveal-id="ehae176-B1232" data-open="ehae176-B1232" class="link link-ref link-reveal xref-bibr">1232</a></sup> In the LIFE (Losartan Intervention for End point reduction in hypertension) trial, a 10 mmHg reduction in systolic BP was associated with a 17% reduction in incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1207"></span><a href="javascript:;" reveal-id="ehae176-B1207" data-open="ehae176-B1207" class="link link-ref link-reveal xref-bibr">1207</a></sup> Secondary analysis of RCTs and observational studies suggest that ACE inhibitors or ARBs may be superior to beta-blockers, calcium channel blockers, or diuretics for the prevention of incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1233 ehae176-B1234 ehae176-B1235 ehae176-B1236"></span><a href="javascript:;" reveal-id="ehae176-B1233 ehae176-B1234 ehae176-B1235 ehae176-B1236" data-open="ehae176-B1233 ehae176-B1234 ehae176-B1235 ehae176-B1236" class="link link-ref link-reveal xref-bibr">1233–1236</a></sup>

#### 10.5.2. Heart failure

Long-standing established pharmacological treatments for HFrEF have been associated with a reduction in incident AF. The use of ACE inhibitors or ARBs in patients with known HFrEF was associated with a 44% reduction in incidence of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1208"></span><a href="javascript:;" reveal-id="ehae176-B1208" data-open="ehae176-B1208" class="link link-ref link-reveal xref-bibr">1208</a></sup> Similarly, beta-blockers in HFrEF led to a 33% reduction in the odds of incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B133"></span><a href="javascript:;" reveal-id="ehae176-B133" data-open="ehae176-B133" class="link link-ref link-reveal xref-bibr">133</a></sup> Mineralocorticoid receptor antagonists have also been shown to reduce the risk of new-onset AF by 42% in patients with HFrEF.<sup><span class="xrefLink" id="jumplink-ehae176-B1209"></span><a href="javascript:;" reveal-id="ehae176-B1209" data-open="ehae176-B1209" class="link link-ref link-reveal xref-bibr">1209</a></sup> Although there have been variable effects of SGLT2 inhibitors on incident AF, several meta-analyses have demonstrated that there is an 18%–37% reduction in incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B136"></span><a href="javascript:;" reveal-id="ehae176-B136" data-open="ehae176-B136" class="link link-ref link-reveal xref-bibr">136</a>,<span class="xrefLink" id="jumplink-ehae176-B1210"></span><a href="javascript:;" reveal-id="ehae176-B1210" data-open="ehae176-B1210" class="link link-ref link-reveal xref-bibr">1210</a>,<span class="xrefLink" id="jumplink-ehae176-B1211"></span><a href="javascript:;" reveal-id="ehae176-B1211" data-open="ehae176-B1211" class="link link-ref link-reveal xref-bibr">1211</a>,<span class="xrefLink" id="jumplink-ehae176-B1237"></span><a href="javascript:;" reveal-id="ehae176-B1237" data-open="ehae176-B1237" class="link link-ref link-reveal xref-bibr">1237</a></sup> However, treatment of HFrEF with sacubitril/valsartan has not yet been shown to confer any adjunctive benefit in reducing new-onset AF when compared with ACE inhibitors/ARBs alone.<sup><span class="xrefLink" id="jumplink-ehae176-B1238"></span><a href="javascript:;" reveal-id="ehae176-B1238" data-open="ehae176-B1238" class="link link-ref link-reveal xref-bibr">1238</a></sup> There is some evidence to suggest that effective CRT in eligible patients with HFrEF reduces the risk of incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1239"></span><a href="javascript:;" reveal-id="ehae176-B1239" data-open="ehae176-B1239" class="link link-ref link-reveal xref-bibr">1239</a></sup> To date, no treatments in HFpEF have been shown to reduce incident AF.

#### 10.5.3. Type 2 diabetes mellitus

The integrated care of type 2 diabetes, based on lifestyle and pharmacological treatments for comorbidities such as obesity, hypertension, and dyslipidaemia, are useful steps in preventing atrial remodelling and subsequent AF. Intensive glucose-lowering therapy targeting an HbA1c level of <6.0% (<42 mmol/mol) failed to show a protective effect on incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1240"></span><a href="javascript:;" reveal-id="ehae176-B1240" data-open="ehae176-B1240" class="link link-ref link-reveal xref-bibr">1240</a></sup> More than glycaemic control _per se_, the class of glucose-lowering agent may influence the risk of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1240"></span><a href="javascript:;" reveal-id="ehae176-B1240" data-open="ehae176-B1240" class="link link-ref link-reveal xref-bibr">1240</a></sup> Insulin promotes adipogenesis and cardiac fibrosis, and sulfonylureas have been consistently associated with an increased risk of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B193"></span><a href="javascript:;" reveal-id="ehae176-B193" data-open="ehae176-B193" class="link link-ref link-reveal xref-bibr">193</a></sup> Observational studies have associated metformin with lower rates of incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1224"></span><a href="javascript:;" reveal-id="ehae176-B1224" data-open="ehae176-B1224" class="link link-ref link-reveal xref-bibr">1224</a>,<span class="xrefLink" id="jumplink-ehae176-B1225"></span><a href="javascript:;" reveal-id="ehae176-B1225" data-open="ehae176-B1225" class="link link-ref link-reveal xref-bibr">1225</a>,<span class="xrefLink" id="jumplink-ehae176-B1241 ehae176-B1242 ehae176-B1243"></span><a href="javascript:;" reveal-id="ehae176-B1241 ehae176-B1242 ehae176-B1243" data-open="ehae176-B1241 ehae176-B1242 ehae176-B1243" class="link link-ref link-reveal xref-bibr">1241–1243</a></sup> Various recent studies and meta-analyses point to the positive role of SGLT2 inhibitors to reduce the risk of incident AF in diabetic and non-diabetic patients.<sup><span class="xrefLink" id="jumplink-ehae176-B136"></span><a href="javascript:;" reveal-id="ehae176-B136" data-open="ehae176-B136" class="link link-ref link-reveal xref-bibr">136</a>,<span class="xrefLink" id="jumplink-ehae176-B1226"></span><a href="javascript:;" reveal-id="ehae176-B1226" data-open="ehae176-B1226" class="link link-ref link-reveal xref-bibr">1226</a>,<span class="xrefLink" id="jumplink-ehae176-B1244 ehae176-B1245 ehae176-B1246"></span><a href="javascript:;" reveal-id="ehae176-B1244 ehae176-B1245 ehae176-B1246" data-open="ehae176-B1244 ehae176-B1245 ehae176-B1246" class="link link-ref link-reveal xref-bibr">1244–1246</a></sup> Pooled data from 22 trials including 52 951 patients with type 2 diabetes and heart failure showed that SGLT2 inhibitors compared with placebo can significantly reduce the incidence of AF by 18% in studies on diabetes, and up to 37% in heart failure with or without type 2 diabetes.<sup><span class="xrefLink" id="jumplink-ehae176-B1210"></span><a href="javascript:;" reveal-id="ehae176-B1210" data-open="ehae176-B1210" class="link link-ref link-reveal xref-bibr">1210</a>,<span class="xrefLink" id="jumplink-ehae176-B1211"></span><a href="javascript:;" reveal-id="ehae176-B1211" data-open="ehae176-B1211" class="link link-ref link-reveal xref-bibr">1211</a></sup>

#### 10.5.4. Obesity

Management of weight is important in the prevention of AF. In a large population-based cohort study, normal weight was associated with a reduced risk of incident AF compared with those who were obese (4.7% increase in the risk of incident AF for each 1 kg/m<sup>2</sup> increase of BMI).<sup><span class="xrefLink" id="jumplink-ehae176-B208"></span><a href="javascript:;" reveal-id="ehae176-B208" data-open="ehae176-B208" class="link link-ref link-reveal xref-bibr">208</a></sup> In the Women's Health Study, participants who became obese had a 41% increased risk of incident AF compared with those who maintained their BMI <30 kg/m<sup>2</sup>.<sup><span class="xrefLink" id="jumplink-ehae176-B1212"></span><a href="javascript:;" reveal-id="ehae176-B1212" data-open="ehae176-B1212" class="link link-ref link-reveal xref-bibr">1212</a></sup> Similarly, observational studies in populations using bariatric surgery for weight loss in morbidly obese individuals (BMI ≥40 kg/m<sup>2</sup>) have observed a lower risk of incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1227 ehae176-B1228 ehae176-B1229 ehae176-B1230 ehae176-B1231"></span><a href="javascript:;" reveal-id="ehae176-B1227 ehae176-B1228 ehae176-B1229 ehae176-B1230 ehae176-B1231" data-open="ehae176-B1227 ehae176-B1228 ehae176-B1229 ehae176-B1230 ehae176-B1231" class="link link-ref link-reveal xref-bibr">1227–1231</a></sup>

#### 10.5.5. Sleep apnoea syndrome

Although it would seem rational to optimize sleep habits, to date there is no conclusive evidence to support this for the primary prevention of AF. The SAVE (Sleep Apnea cardioVascular Endpoints) trial failed to demonstrate a difference in clinical outcomes in those randomized to CPAP therapy or placebo.<sup><span class="xrefLink" id="jumplink-ehae176-B230"></span><a href="javascript:;" reveal-id="ehae176-B230" data-open="ehae176-B230" class="link link-ref link-reveal xref-bibr">230</a></sup> There was no difference in incident AF, albeit the analysis of AF was not based on systematic screening but rather on clinically documented AF.

#### 10.5.6. Physical activity

Several studies have demonstrated beneficial effects of moderate physical activity on cardiovascular health.<sup><span class="xrefLink" id="jumplink-ehae176-B1247"></span><a href="javascript:;" reveal-id="ehae176-B1247" data-open="ehae176-B1247" class="link link-ref link-reveal xref-bibr">1247</a></sup> Moderate aerobic exercise may also reduce the risk of new-onset AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1214 ehae176-B1215 ehae176-B1216 ehae176-B1217 ehae176-B1218 ehae176-B1219"></span><a href="javascript:;" reveal-id="ehae176-B1214 ehae176-B1215 ehae176-B1216 ehae176-B1217 ehae176-B1218 ehae176-B1219" data-open="ehae176-B1214 ehae176-B1215 ehae176-B1216 ehae176-B1217 ehae176-B1218 ehae176-B1219" class="link link-ref link-reveal xref-bibr">1214–1219</a></sup> It should be noted that the incidence of AF appears to be increased among athletes, with a meta-analysis of observational studies showing a 2.5-fold increased risk of AF compared with non-athlete controls.<sup><span class="xrefLink" id="jumplink-ehae176-B1248"></span><a href="javascript:;" reveal-id="ehae176-B1248" data-open="ehae176-B1248" class="link link-ref link-reveal xref-bibr">1248</a></sup>

#### 10.5.7. Alcohol intake

The premise that reducing alcohol intake can prevent AF is based on observational studies linking alcohol to an excess risk of incident AF in a dose-dependent manner (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><span class="xrefLink" id="jumplink-ehae176-B1220 ehae176-B1221 ehae176-B1222"></span><a href="javascript:;" reveal-id="ehae176-B1220 ehae176-B1221 ehae176-B1222" data-open="ehae176-B1220 ehae176-B1221 ehae176-B1222" class="link link-ref link-reveal xref-bibr">1220–1222</a></sup> In addition, a population cohort study of those with high alcohol consumption (>60 g/day for men and >40 g/day for women) found that abstinence from alcohol was associated with a lower incidence of AF compared with patients who continued heavy drinking.<sup><span class="xrefLink" id="jumplink-ehae176-B1223"></span><a href="javascript:;" reveal-id="ehae176-B1223" data-open="ehae176-B1223" class="link link-ref link-reveal xref-bibr">1223</a></sup>

## 11\. Key messages

1.General management: optimal treatment according to the AF-CARE pathway, which includes: \[C\] Comorbidity and risk factor management; \[A\] Avoid stroke and thromboembolism; \[R\] Reduce symptoms by rate and rhythm control; and \[E\] Evaluation and dynamic reassessment.

2.Shared care: patient-centred AF management with joint decision-making and a multidisciplinary team.

3.Equal care: avoid health inequalities based on gender, ethnicity, disability, and socioeconomic factors.

4.Education: for patients, family members, caregivers, and healthcare professionals to aid shared decision-making.

5.Diagnosis: clinical AF requires confirmation on an ECG device to initiate risk stratification and AF management.

6.Initial evaluation: medical history, assessment of symptoms and their impact, blood tests, echocardiography/other imaging, patient-reported outcome measures, and risk factors for thromboembolism and bleeding.

7.Comorbidities and risk factors: thorough evaluation and management critical to all aspects of care for patients with AF to avoid recurrence and progression of AF, improve success of AF treatments, and prevent AF-related adverse outcomes.

8.Focus on conditions associated with AF: including hypertension, heart failure, diabetes mellitus, obesity, obstructive sleep apnoea, physical inactivity, and high alcohol intake.

9.Assessing the risk of thromboembolism: use locally validated risk tools or the CHA<sub>2</sub>DS<sub>2</sub>\-VA score and assessment of other risk factors, with reassessment at periodic intervals to assist in decisions on anticoagulant prescription.

10.Oral anticoagulants: recommended for all eligible patients, except those at low risk of incident stroke or thromboembolism (CHA<sub>2</sub>DS<sub>2</sub>\-VA = 1 anticoagulation should be considered; CHA<sub>2</sub>DS<sub>2</sub>\-VA ≥2 anticoagulation recommended).

11.Choice of anticoagulant: DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are preferred over VKAs (warfarin and others), except in patients with mechanical heart valves and mitral stenosis.

12.Dose/range of anticoagulant: use full standard doses for DOACs unless the patient meets specific dose-reduction criteria; for VKAs, keep INR generally 2.0–3.0, and in range for >70% of the time.

13.Switching anticoagulants: switch from a VKA to DOAC if risk of intracranial haemorrhage or poor control of INR levels.

14.Bleeding risk: modifiable bleeding risk factors should be managed to improve safety; bleeding risk scores should not be used to decide on starting or withdrawing anticoagulants.

15.Antiplatelet therapy: avoid combining anticoagulants and antiplatelet agents, unless the patient has an acute vascular event or needs interim treatment for procedures.

16.Rate control therapy: use beta-blockers (any ejection fraction), digoxin (any ejection fraction), or diltiazem/verapamil (LVEF >40%) as initial therapy in the acute setting, an adjunct to rhythm control therapies, or as a sole treatment strategy to control heart rate and symptoms.

17.Rhythm control: consider in all suitable AF patients, explicitly discussing with patients all potential benefits and risks of cardioversion, antiarrhythmic drugs, and catheter or surgical ablation to reduce symptoms and morbidity.

18.Safety first: keep safety and anticoagulation in mind when considering rhythm control; e.g. delay cardioversion and provide at least 3 weeks of anticoagulation beforehand if AF duration >24 h, and consider toxicity and drug interactions for antiarrhythmic therapy.

19.Cardioversion: use electrical cardioversion in cases of haemodynamic instability; otherwise choose electrical or pharmacological cardioversion based on patient characteristics and preferences.

20.Indication for long-term rhythm control: the primary indication should be reduction in AF-related symptoms and improvement in quality of life; for selected patient groups, sinus rhythm maintenance can be pursued to reduce morbidity and mortality.

21.Success or failure of rhythm control: continue anticoagulation according to the patient's individual risk of thromboembolism, irrespective of whether they are in AF or sinus rhythm.

22.Catheter ablation: consider as second-line option if antiarrhythmic drugs fail to control AF, or first-line option in patients with paroxysmal AF.

23.Endoscopic or hybrid ablation: consider if catheter ablation fails, or an alternative to catheter ablation in persistent AF despite antiarrhythmic drugs.

24.Atrial fibrillation ablation during cardiac surgery: perform in centres with experienced teams, especially for patients undergoing mitral valve surgery.

25.Dynamic evaluation: periodically reassess therapy and give attention to new modifiable risk factors that could slow/reverse the progression of AF, increase quality of life, and prevent adverse outcomes.


## 12\. Gaps in evidence

The following bullet list gives the most important gaps in evidence where new clinical trials could substantially aid the patient pathway:

**Definition and clinical impact of AF**

- Paroxysmal AF is not one entity, and patterns of AF progression and regression are highly variable. It is uncertain what the relevance is for treatment strategies and management decisions.

- Thirty seconds as definition for clinical AF needs validation and evaluation whether it is related to AF-related outcomes.

- Definition, clinical features, diagnosis, and implementation for treatment choices of atrial cardiomyopathy in patients with AF is unsettled.

- Diversity in AF presentation, underlying pathophysiological mechanisms, and associated comorbidities is incompletely understood with regard to differences in sex, gender, race/ethnicity, socioeconomic state, education, and differences between low-, moderate-, and high-income countries.

- Personalized risk prediction for AF incidence, AF progression, and associated outcomes remains challenging.

- Insights into psychosocial and environmental factors and risk of AF and adverse outcomes in AF are understudied.


**Patient-centred, multidisciplinary AF management**

- The benefit of additional education directed to patients, to family members, and to healthcare professionals in order to optimize shared decision-making still needs to be proved.

- Access to patient-centred management according to the AF-CARE principles to ensure equality in healthcare provision and improve outcomes warrants evidence.

- The place of remote monitoring and telemedicine for identification and follow-up of patients with AF, or its subgroups is non-established, though widely applied.


**\[C\] Comorbidity and risk factor management**

- Methods to achieve consistent and reproducible weight loss in patients with AF requires substantial improvement. Despite some evidence demonstrating the benefits of weight loss, widespread adoption has been limited by the need for reproducible strategies.

- The importance of sleep apnoea syndrome and its treatment on AF-related outcomes remains to be elucidated.


**\[A\] Avoid stroke and thromboembolism**

- Data are lacking on how to treat patients with low risk of stroke (with a CHA<sub>2</sub>DS<sub>2</sub>\-VA score of 0 or 1), as these patients were excluded from large RCTs.

- Not enough evidence is available for OAC in elderly patients, frail polypharmacy patients, those with cognitive impairment/dementia, recent bleeding, previous ICH, severe end-stage renal failure, liver impairment, cancer, or severe obesity.

- In elderly patients, routinely switching VKAs to DOACs is associated with increased bleeding risk; however, the reasons why this happens are unclear.

- The selection of which patients with asymptomatic device-detected subclinical AF benefit from OAC therapy needs to be defined.

- There is a lack of evidence whether and when to (re)start anticoagulation after intracranial haemorrhage.

- There is lack of evidence about optimal anticoagulation in patients with ischaemic stroke or left atrial thrombus while being treated with OAC.

- There is uncertainty about the place of LAA closure and how to manage antithrombotic post-procedural management when LAAO is performed.

- Balance of thromboembolism and bleeding is unclear in patients with AF and incidental cerebral artery aneurysms identified on brain MRI.


**\[R\] Reduce symptoms by rate and rhythm control**

- In some patients, AF can be benign in terms of symptoms and outcomes. In which patients rhythm control is not needed warrants investigation.

- Application of antiarrhythmic drugs has been hampered by poor effectiveness and side effects; however, new antiarrhythmic drugs are needed to increase the therapeutic arsenal for AF patients.

- The amount of AF reduction obtained by rhythm control to improve outcomes is unknown.

- Large catheter ablation studies showed no improved outcome of patients with AF. Some small studies in specific subpopulations have observed an improved outcome. This warrants further investigation to provide each patient with AF with personalized treatment goals.

- Uncertainty exists on the time of duration of AF and risk of stroke when performing a cardioversion.

- The value of diagnostic cardioversion for persistent AF in steering management of AF is unknown.

- Decisions on continuation of OAC are completely based on stroke risk scores and irrespective of having (episodes) of AF; whether this holds for patients undergoing successful catheter ablation is uncertain.

- Large variability in ablation strategies and techniques exist for patients with persistent AF, or after first failed catheter ablation for paroxysmal AF. The optimal catheter ablation strategy and techniques, however, are unknown.

- Sham-controlled intervention studies are lacking to determine the effects on AF symptoms, quality of life, and PROMS, accounting for the placebo effect that is associated with interventions.


**The AF-CARE pathway in specific clinical settings**

- The optimal duration of triple therapy in patients with AF at high risk of recurrent coronary events after acute coronary syndrome is unclear.

- The role of the coronary vessel involved and whether this should impact on the duration of combined OAC and antiplatelet treatment needs further study.

- The role of antiplatelet therapy in patients with AF and peripheral artery disease on OAC is uncertain.

- The use of DOACs in patients with congenital heart disease, particularly in patients with complex corrected congenital defects, is poorly studied.

- Improved risk stratification for stroke in patients with AF and cancer, or with post-operative or trigger-induced AF is needed to inform on OAC treatment decisions.


**Screening and prevention of AF**

- There are a lack of adequately powered randomized controlled studies on ischaemic stroke rate in patients screened for AF, both in the primary prevention setting and in secondary prevention (post-stroke), and its cost-effectiveness.

- Population selection that might benefit the most from screening, the optimal duration of screening, and the burden of AF that might increase the risk for patients with screening-detected AF are uncertain.

- Evaluation of strategies to support longer-term use of technologies for AF detection are awaited.

- The role of photoplethysmography technology for AF screening in an effort to assess AF burden and reduce stroke is still unclear.

- How new consumer devices and wearable technology can be used for diagnostic and monitoring purposes in routine clinical practice needs to be clarified.


## 13\. ‘What to do’ and ‘What not to do’ messages from the guidelines

_[Table 17](javascript:;)_ lists all Class I and Class III recommendations from the text alongside their level of evidence.

Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884489)

‘What to do’ and ‘what not to do’

![‘What to do’ and ‘what not to do’](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t17.jpeg?Expires=1728478929&Signature=2Q-OXh7gcnSvLhb~elpZuvwPcWUoP19mETbvgOyDeM2i-qgNZsrDuCvzczGHJlFE~wD5eqqUIIWtNahwIf2EX-I5XE4Ftu97Tw4r6B8N87Ac8HwbvpOHttsxAmRpfO9LjIJGeT93v0htjJZnZ756kvAzkIfzOx8gqXd10vK6zyO-czEegDJwsD2Dal8Bms10U66MpRr8QhNS5~09xOaJHht6KUuxIqDg~Akxb5k5SkosOmo6euCxoz2ccJaSJ2wrZTMJqez4qBk~7yddBTiDWkSPwAhSkZSUtGhiMMpVN9ToiX5Nq9R2zEqiuVRTI-Mw-Qm8~79mbjyHt3qcPWzBwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884489)

‘What to do’ and ‘what not to do’

![‘What to do’ and ‘what not to do’](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t17.jpeg?Expires=1728478929&Signature=2Q-OXh7gcnSvLhb~elpZuvwPcWUoP19mETbvgOyDeM2i-qgNZsrDuCvzczGHJlFE~wD5eqqUIIWtNahwIf2EX-I5XE4Ftu97Tw4r6B8N87Ac8HwbvpOHttsxAmRpfO9LjIJGeT93v0htjJZnZ756kvAzkIfzOx8gqXd10vK6zyO-czEegDJwsD2Dal8Bms10U66MpRr8QhNS5~09xOaJHht6KUuxIqDg~Akxb5k5SkosOmo6euCxoz2ccJaSJ2wrZTMJqez4qBk~7yddBTiDWkSPwAhSkZSUtGhiMMpVN9ToiX5Nq9R2zEqiuVRTI-Mw-Qm8~79mbjyHt3qcPWzBwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 14\. Evidence tables

[Evidence tables](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) are available at _European Heart Journal_ online.

## 15\. Data availability statement

No new data were generated or analysed in support of this research.

## 16\. Author information

**Author/Task Force Member Affiliations: Michiel Rienstra**, Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands; **Karina V. Bunting**, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom, Cardiology Department, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; **Ruben Casado-Arroyo**, Department of Cardiology, H.U.B.-Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; **Valeria Caso**, Stroke Unit, Santa della Misericordia Hospital, Perugia, Italy; **Harry J.G.M. Crijns**, Cardiology Maastricht University Medical Centre, Maastricht, Netherlands, Cardiology Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands; **Tom J. R. De Potter**, Department of Cardiology, OLV Hospital, Aalst, Belgium; **Jeremy Dwight** (United Kingdom), ESC Patient Forum, Sophia Antipolis, France; **Luigina Guasti**, Department of Medicine and Surgery, University of Insubria, Varese, Italy, Division of Geriatrics and Clinical Gerontology, ASST-Settelaghi, Varese, Italy; **Thorsten Hanke**, Clinic For Cardiac Surgery, Asklepios Klinikum, Harburg, Hamburg, Germany; **Tiny Jaarsma**, Department of Cardiology, Linkoping University, Linkoping, Sweden, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands; **Maddalena Lettino**, Department for Cardiac, Thoracic and Vascular Diseases, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; **Maja-Lisa Løchen**, Deparment of Clincal Medicine UiT, The Arctic University of Norway, Tromsø, Norway, Department of Cardiology, University Hospital of North Norway, Tromsø, Norway; **R. Thomas Lumbers**, Institute of Health Informatics, University College London, London, United Kingdom, Saint Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom, University College Hospital, University College London Hospitals NHS Trust, London, United Kingdom; **Bart Maesen**, Department of Cardiothoracic Surgery, Maastricht University Medical Centre+, Maastricht, Netherlands, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands; **Inge Mølgaard** (Denmark), ESC Patient Forum, Sophia Antipolis, France; **Giuseppe M.C. Rosano**, Department of Human Sciences and Promotion of Quality of Life, Chair of Pharmacology, San Raffaele University of Rome, Rome, Italy, Cardiology, San Raffaele Cassino Hospital, Cassino, Italy, Cardiovascular Academic Group, St George's University Medical School, London, United Kingdom; **Prashanthan Sanders**, Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, Australia, Department of Cardiology, Royal Adelaide Hospital, Adelaide, Australia; **Renate B. Schnabel**, Cardiology University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, German Center for Cardiovascular Research (DZHK) Partner site Hamburg/Kiel/Lübeck, Germany; **Piotr Suwalski**, Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Centre of Postgraduate Medical Education, Warsaw, Poland; **Emma Svennberg**, Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden; **Juan Tamargo**, Pharmacology and Toxicology School of Medicine, Universidad Complutense, Madrid, Spain; **Otilia Tica**, Department of Cardiology, Emergency County Clinical Hospital of Bihor, Oradea, Romania, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; **Vassil Traykov**, Department of Invasive Electrophysiology, Acibadem City Clinic Tokuda University Hospital, Sofia, Bulgaria; and **Stylianos Tzeis**, Cardiology Department, Mitera Hospital, Athens, Greece.

### 17\. Appendix

**ESC Scientific Document Group**

Includes Document Reviewers and ESC National Cardiac Societies.

**Document Reviewers:** Nikolaos Dagres (CPG Review Co-ordinator) (Germany), Bianca Rocca (CPG Review Co-ordinator) (Italy), Syed Ahsan (United Kingdom), Pietro Ameri (Italy), Elena Arbelo (Spain), Axel Bauer (Austria), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Barbara Casadei (United Kingdom), Ovidiu Chioncel (Romania), Dobromir Dobrev (Germany), Laurent Fauchier (France), Bruna Gigante (Sweden), Michael Glikson (Israel), Ziad Hijazi (Sweden), Gerhard Hindricks (Germany), Daniela Husser (Germany), Borja Ibanez (Spain), Stefan James (Sweden), Stefan Kaab (Germany), Paulus Kirchhof (Germany), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Thomas Kumler (Denmark), Gregory Y.H. Lip (United Kingdom), John Mandrola (United States of America), Nikolaus Marx (Germany), John William Mcevoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Denisa Muraru (Italy), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Jonas Oldgren (Sweden), Maurizio Paciaroni (Italy), Agnes A. Pasquet (Belgium), Eva Prescott (Denmark), Filip Rega (Belgium), Francisco Javier Rossello (Spain), Marcin Rucinski (Poland), Sacha P. Salzberg (Switzerland), Sam Schulman (Canada), Philipp Sommer (Germany), Jesper Hastrup Svendsen (Denmark), Jurrien M. ten Berg (Netherlands), Hugo Ten Cate (Netherlands), Ilonca Vaartjes (Netherlands), Christiaan Jm. Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands).

**ESC National Cardiac Societies** actively involved in the review process of the 2024 ESC Guidelines for the management of atrial fibrillation:

**Albania**: Albanian Society of Cardiology, Leonard Simoni; **Algeria**: Algerian Society of Cardiology, Brahim Kichou; **Armenia**: Armenian Cardiologists Association, Hamayak S. Sisakian; **Austria**: Austrian Society of Cardiology, Daniel Scherr; **Belgium**: Belgian Society of Cardiology, Frank Cools; **Bosnia and Herzegovina**: Association of Cardiologists of Bosnia and Herzegovina, Elnur Smajić; **Bulgaria**: Bulgarian Society of Cardiology, Tchavdar Shalganov; **Croatia**: Croatian Cardiac Society, Sime Manola; **Cyprus**: Cyprus Society of Cardiology, Panayiotis Avraamides; **Czechia**: Czech Society of Cardiology, Milos Taborsky; **Denmark**: Danish Society of Cardiology, Axel Brandes; **Egypt**: Egyptian Society of Cardiology, Ahmed M. El-Damaty; **Estonia**: Estonian Society of Cardiology, Priit Kampus; **Finland**: Finnish Cardiac Society, Pekka Raatikainen; **France**: French Society of Cardiology, Rodrigue Garcia; **Georgia**: Georgian Society of Cardiology, Kakhaber Etsadashvili; **Germany**: German Cardiac Society, Lars Eckardt; **Greece**: Hellenic Society of Cardiology, Eleftherios Kallergis; **Hungary**: Hungarian Society of Cardiology, László Gellér; **Iceland**: Icelandic Society of Cardiology, Kristján Guðmundsson; **Ireland**: Irish Cardiac Society, Jonathan Lyne; **Israel**: Israel Heart Society, Ibrahim Marai; **Italy**: Italian Federation of Cardiology, Furio Colivicchi; **Kazakhstan**: Association of Cardiologists of Kazakhstan, Ayan Suleimenovich Abdrakhmanov; **Kosovo (Republic of)**: Kosovo Society of Cardiology, Ibadete Bytyci; **Kyrgyzstan**: Kyrgyz Society of Cardiology, Alina Kerimkulova; **Latvia**: Latvian Society of Cardiology, Kaspars Kupics; **Lebanon**: Lebanese Society of Cardiology, Marwan Refaat; **Libya**: Libyan Cardiac Society, Osama Abdulmajed Bheleel; **Lithuania**: Lithuanian Society of Cardiology, Jūratė Barysienė; **Luxembourg**: Luxembourg Society of Cardiology, Patrick Leitz; **Malta**: Maltese Cardiac Society, Mark A. Sammut; **Moldova (Republic of)**: Moldavian Society of Cardiology, Aurel Grosu; **Montenegro**: Montenegro Society of Cardiology, Nikola Pavlovic; **Morocco**: Moroccan Society of Cardiology, Abdelhamid Moustaghfir; **Netherlands**: Netherlands Society of Cardiology, Sing-Chien Yap; **North Macedonia**: National Society of Cardiology of North Macedonia, Jane Taleski; **Norway**: Norwegian Society of Cardiology, Trine Fink; **Poland**: Polish Cardiac Society, Jaroslaw Kazmierczak; **Portugal**: Portuguese Society of Cardiology, Victor M. Sanfins; **Romania**: Romanian Society of Cardiology, Dragos Cozma; **San Marino**: San Marino Society of Cardiology, Marco Zavatta; **Serbia**: Cardiology Society of Serbia, Dragan V. Kovačević; **Slovakia**: Slovak Society of Cardiology, Peter Hlivak; **Slovenia**: Slovenian Society of Cardiology, Igor Zupan; **Spain**: Spanish Society of Cardiology, David Calvo; **Sweden**: Swedish Society of Cardiology, Anna Björkenheim; **Switzerland:** Swiss Society of Cardiology, Michael Kühne; **Tunisia**: Tunisian Society of Cardiology and Cardiovascular Surgery, Sana Ouali; **Turkey**: Turkish Society of Cardiology, Sabri Demircan; **Ukraine**: Ukrainian Association of Cardiology, Oleg S. Sychov; **United Kingdom of Great Britain and Northern Ireland**: British Cardiovascular Society, Andre Ng; and **Uzbekistan**: Association of Cardiologists of Uzbekistan, Husniddin Kuchkarov.

**ESC Clinical Practice Guidelines (CPG) Committee:** Eva Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) (Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands). Andrea Sarkozy\* (Belgium) _\*Contributor either stepped down or was engaged in only a part of the review process._

## 18\. References

18. References
1	Alam   M, Bandeali   SJ, Shahzad   SA, Lakkis   N. Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry. Expert Rev Cardiovasc Ther  2012;10:283–91. https://doi.org/10.1586/erc.12.8
  
2	De With   RR, Erküner   Ö, Rienstra   M, Nguyen   BO, Körver   FWJ, Linz   D, et al.   Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. Europace  2020;22:1162–72. https://doi.org/10.1093/europace/euaa123
  
3	Packer   DL, Mark   DB, Robb   RA, Monahan   KH, Bahnson   TD, Poole   JE, et al.   Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA  2019;321:1261–74. https://doi.org/10.1001/jama.2019.0693
  
4	Marrouche   NF, Brachmann   J, Andresen   D, Siebels   J, Boersma   L, Jordaens   L, et al.   Catheter ablation for atrial fibrillation with heart failure. N Engl J Med  2018;378:417–27. https://doi.org/10.1056/NEJMoa1707855
  
5	Svendsen   JH, Diederichsen   SZ, Højberg   S, Krieger   DW, Graff   C, Kronborg   C, et al.   Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet  2021;398:1507–16. https://doi.org/10.1016/S0140-6736(21)01698-6
  
6	Svennberg   E, Friberg   L, Frykman   V, Al-Khalili   F, Engdahl   J, Rosenqvist   M. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet  2021;398:1498–506. https://doi.org/10.1016/S0140-6736(21)01637-8
  
7	Healey   JS, Connolly   SJ, Gold   MR, Israel   CW, Van Gelder   IC, Capucci   A, et al.   Subclinical atrial fibrillation and the risk of stroke. N Engl J Med  2012;366:120–9. https://doi.org/10.1056/NEJMoa1105575
  
8	McIntyre   WF, Healey   JS, Bhatnagar   AK, Wang   P, Gordon   JA, Baranchuk   A, et al.   Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis. Europace  2019;21:1159–66. https://doi.org/10.1093/europace/euz175
  
9	Bager   JE, Martín   A, Carbajosa Dalmau   J, Simon   A, Merino   JL, Ritz   B, et al.   Vernakalant for cardioversion of recent-onset atrial fibrillation in the emergency department: the SPECTRUM study. Cardiology  2022;147:566–77. https://doi.org/10.1159/000526831
  
10	Pluymaekers   N, Dudink   E, Luermans   J, Meeder   JG, Lenderink   T, Widdershoven   J, et al.   Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med  2019;380:1499–508. https://doi.org/10.1056/NEJMoa1900353
  
11	Lubitz   SA, Yin   X, Rienstra   M, Schnabel   RB, Walkey   AJ, Magnani   JW, et al.   Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. Circulation  2015;131:1648–55. https://doi.org/10.1161/CIRCULATIONAHA.114.014058
  
12	Wang   EY, Hulme   OL, Khurshid   S, Weng   LC, Choi   SH, Walkey   AJ, et al.   Initial precipitants and recurrence of atrial fibrillation. Circ Arrhythm Electrophysiol  2020;13:e007716. https://doi.org/10.1161/CIRCEP.119.007716
  
13	Corica   B, Romiti   GF, Basili   S, Proietti   M. Prevalence of new-onset atrial fibrillation and associated outcomes in patients with sepsis: a systematic review and meta-analysis. J Pers Med  2022;12:547. https://doi.org/10.3390/jpm12040547
  
14	Bedford   JP, Ferrando-Vivas   P, Redfern   O, Rajappan   K, Harrison   DA, Watkinson   PJ, et al.   New-onset atrial fibrillation in intensive care: epidemiology and outcomes. Eur Heart J Acute Cardiovasc Care  2022;11:620–8. https://doi.org/10.1093/ehjacc/zuac080
  
15	Wazni   OM, Marrouche   NF, Martin   DO, Verma   A, Bhargava   M, Saliba   W, et al.   Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA  2005;293:2634–40. https://doi.org/10.1001/jama.293.21.2634
  
16	Andrade   JG, Wells   GA, Deyell   MW, Bennett   M, Essebag   V, Champagne   J, et al.   Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med  2021;384:305–15. https://doi.org/10.1056/NEJMoa2029980
  
17	Kirchhof   P, Camm   AJ, Goette   A, Brandes   A, Eckardt   L, Elvan   A, et al.   Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med  2020;383:1305–16. https://doi.org/10.1056/NEJMoa2019422
  
18	Coats   AJS, Heymans   S, Farmakis   D, Anker   SD, Backs   J, Bauersachs   J, et al.   Atrial disease and heart failure: the common soil hypothesis proposed by the heart failure association of the European Society of Cardiology. Eur Heart J  2022:43:863–7. https://doi.org/10.1093/eurheartj/ehab834
  
19	Schnabel   RB, Marinelli   EA, Arbelo   E, Boriani   G, Boveda   S, Buckley   CM, et al.   Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. Europace  2023;25:6–27. https://doi.org/10.1093/europace/euac062
  
20	Goette   A, Kalman   JM, Aguinaga   L, Akar   J, Cabrera   JA, Chen   SA, et al.   EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace  2016;18:1455–90. https://doi.org/10.1093/europace/euw161
  
21	Sagris   D, Georgiopoulos   G, Pateras   K, Perlepe   K, Korompoki   E, Milionis   H, et al.   Atrial high-rate episode duration thresholds and thromboembolic risk: a systematic review and meta-analysis. J Am Heart Assoc  2021;10:e022487. https://doi.org/10.1161/JAHA.121.022487
  
22	Kaufman   ES, Israel   CW, Nair   GM, Armaganijan   L, Divakaramenon   S, Mairesse   GH, et al.   Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm  2012;9:1241–6. https://doi.org/10.1016/j.hrthm.2012.03.017
  
23	Miyazawa   K, Pastori   D, Martin   DT, Choucair   WK, Halperin   JL, Lip   GYH. Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices. Europace  2022;24:375–83. https://doi.org/10.1093/europace/euab186
  
24	Vitolo   M, Imberti   JF, Maisano   A, Albini   A, Bonini   N, Valenti   AC, et al.   Device-detected atrial high rate episodes and the risk of stroke/thromboembolism and atrial fibrillation incidence: a systematic review and meta-analysis. Eur J Intern Med  2021;92:100–6. https://doi.org/10.1016/j.ejim.2021.05.038
  
25	Connolly   SJ, Ezekowitz   MD, Yusuf   S, Eikelboom   J, Oldgren   J, Parekh   A, et al.   Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med  2009;361:1139–51. https://doi.org/10.1056/NEJMoa0905561
  
26	Giugliano   RP, Ruff   CT, Braunwald   E, Murphy   SA, Wiviott   SD, Halperin   JL, et al.   Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med  2013;369:2093–104. https://doi.org/10.1056/NEJMoa1310907
  
27	Granger   CB, Alexander   JH, McMurray   JJ, Lopes   RD, Hylek   EM, Hanna   M, et al.   Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med  2011;365:981–92. https://doi.org/10.1056/NEJMoa1107039
  
28	Patel   MR, Mahaffey   KW, Garg   J, Pan   G, Singer   DE, Hacke   W, et al.   Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med  2011;365:883–91. https://doi.org/10.1056/NEJMoa1009638
  
29	Stroke prevention in atrial fibrillation study. Final results. Circulation  1991;84:527–39. https://doi.org/10.1161/01.CIR.84.2.527
CrossrefPubMedWorldCat 
30	Mannina   C, Jin   Z, Matsumoto   K, Ito   K, Biviano   A, Elkind   MSV, et al.   Frequency of cardiac arrhythmias in older adults: findings from the subclinical atrial fibrillation and risk of ischemic stroke (SAFARIS) study. Int J Cardiol  2021;337:64–70. https://doi.org/10.1016/j.ijcard.2021.05.006
  
31	Schnabel   RB, Pecen   L, Ojeda   FM, Lucerna   M, Rzayeva   N, Blankenberg   S, et al.   Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart  2017;103:1024–30. https://doi.org/10.1136/heartjnl-2016-310406
  
32	Simantirakis   EN, Papakonstantinou   PE, Chlouverakis   GI, Kanoupakis   EM, Mavrakis   HE, Kallergis   EM, et al.   Asymptomatic versus symptomatic episodes in patients with paroxysmal atrial fibrillation via long-term monitoring with implantable loop recorders. Int J Cardiol  2017;231:125–30. https://doi.org/10.1016/j.ijcard.2016.12.025
  
33	Verma   A, Champagne   J, Sapp   J, Essebag   V, Novak   P, Skanes   A, et al.   Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med  2013;173:149–56. https://doi.org/10.1001/jamainternmed.2013.1561
  
34	Sgreccia   D, Manicardi   M, Malavasi   VL, Vitolo   M, Valenti   AC, Proietti   M, et al.   Comparing outcomes in asymptomatic and symptomatic atrial fibrillation: a systematic review and meta-analysis of 81,462 patients. J Clin Med  2021;10:3979. https://doi.org/10.3390/jcm10173979
  
35	Holmes   DN, Piccini   JP, Allen   LA, Fonarow   GC, Gersh   BJ, Kowey   PR, et al.   Defining clinically important difference in the atrial fibrillation effect on quality-of-life score. Circ Cardiovasc Qual Outcomes  2019;12:e005358. https://doi.org/10.1161/CIRCOUTCOMES.118.005358
  
36	Jones   J, Stanbury   M, Haynes   S, Bunting   KV, Lobban   T, Camm   AJ, et al.   Importance and assessment of quality of life in symptomatic permanent atrial fibrillation: patient focus groups from the RATE-AF trial. Cardiology  2020;145:666–75. https://doi.org/10.1159/000511048
  
37	Abu   HO, Wang   W, Otabil   EM, Saczynski   JS, Mehawej   J, Mishra   A, et al.   Perception of atrial fibrillation symptoms: impact on quality of life and treatment in older adults. J Am Geriatr Soc  2022;70:2805–17. https://doi.org/10.1111/jgs.17954
  
38	Rienstra   M, Vermond   RA, Crijns   HJ, Tijssen   JG, Van Gelder   IC; RACE Investigators. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. Heart Rhythm  2014;11:939–45. https://doi.org/10.1016/j.hrthm.2014.03.016
  
39	Rienstra   M, Hobbelt   AH, Alings   M, Tijssen   JGP, Smit   MD, Brugemann   J, et al.   Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J  2018;39:2987–96. https://doi.org/10.1093/eurheartj/ehx739
  
40	Mulder   BA, Van Veldhuisen   DJ, Crijns   HJ, Tijssen   JG, Hillege   HL, Alings   M, et al.   Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm  2014;11:1543–50. https://doi.org/10.1016/j.hrthm.2014.06.007
  
41	Kloosterman   M, Crijns   H, Mulder   BA, Groenveld   HF, Van Veldhuisen   DJ, Rienstra   M, et al.   Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study. Europace  2020;22:1619–27. https://doi.org/10.1093/europace/euz300
  
42	Park   YJ, Park   JW, Yu   HT, Kim   TH, Uhm   JS, Joung   B, et al.   Sex difference in atrial fibrillation recurrence after catheter ablation and antiarrhythmic drugs. Heart  2023;109:519–26. https://doi.org/10.1136/heartjnl-2021-320601
Google ScholarPubMedWorldCat 
43	Kupper   N, van den Broek   KC, Widdershoven   J, Denollet   J. Subjectively reported symptoms in patients with persistent atrial fibrillation and emotional distress. Front Psychol  2013;4:192. https://doi.org/10.3389/fpsyg.2013.00192
  
44	Schnabel   RB, Michal   M, Wilde   S, Wiltink   J, Wild   PS, Sinning   CR, et al.   Depression in atrial fibrillation in the general population. PLoS One  2013;8:e79109. https://doi.org/10.1371/journal.pone.0079109
  
45	Gleason   KT, Dennison Himmelfarb   CR, Ford   DE, Lehmann   H, Samuel   L, Han   HR, et al.   Association of sex, age and education level with patient reported outcomes in atrial fibrillation. BMC Cardiovasc Disord  2019;19:85. https://doi.org/10.1186/s12872-019-1059-6
  
46	Schnabel   RB, Pecen   L, Rzayeva   N, Lucerna   M, Purmah   Y, Ojeda   FM, et al.   Symptom burden of atrial fibrillation and its relation to interventions and outcome in Europe. J Am Heart Assoc  2018;7:e007559. https://doi.org/10.1161/JAHA.117.007559
  
47	Wynn   GJ, Todd   DM, Webber   M, Bonnett   L, McShane   J, Kirchhof   P, et al.   The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace  2014;16:965–72. https://doi.org/10.1093/europace/eut395
  
48	Kotecha   D, Bunting   KV, Gill   SK, Mehta   S, Stanbury   M, Jones   JC, et al.   Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA  2020;324:2497–508. https://doi.org/10.1001/jama.2020.23138
  
49	Kotecha   D, Ahmed   A, Calvert   M, Lencioni   M, Terwee   CB, Lane   DA. Patient-reported outcomes for quality of life assessment in atrial fibrillation: a systematic review of measurement properties. PLoS One  2016;11:e0165790. https://doi.org/10.1371/journal.pone.0165790
  
50	Mantovan   R, Macle   L, De Martino   G, Chen   J, Morillo   CA, Novak   P, et al.   Relationship of quality of life with procedural success of atrial fibrillation (AF) ablation and postablation AF burden: substudy of the STAR AF randomized trial. Can J Cardiol  2013;29:1211–7. https://doi.org/10.1016/j.cjca.2013.06.006
  
51	Samuel   M, Khairy   P, Champagne   J, Deyell   MW, Macle   L, Leong-Sit   P, et al.   Association of atrial fibrillation burden with health-related quality of life after atrial fibrillation ablation: substudy of the cryoballoon vs contact-force atrial fibrillation ablation (CIRCA-DOSE) randomized clinical trial. JAMA Cardiol  2021;6:1324–8. https://doi.org/10.1001/jamacardio.2021.3063
  
52	Sandhu   RK, Smigorowsky   M, Lockwood   E, Savu   A, Kaul   P, McAlister   FA. Impact of electrical cardioversion on quality of life for the treatment of atrial fibrillation. Can J Cardiol  2017;33:450–5. https://doi.org/10.1016/j.cjca.2016.11.013
  
53	Terricabras   M, Mantovan   R, Jiang   CY, Betts   TR, Chen   J, Deisenhofer   I, et al.   Association between quality of life and procedural outcome after catheter ablation for atrial fibrillation: a secondary analysis of a randomized clinical trial. JAMA Netw Open  2020;3:e2025473. https://doi.org/10.1001/jamanetworkopen.2020.25473
  
54	Zenger   B, Zhang   M, Lyons   A, Bunch   TJ, Fang   JC, Freedman   RA, et al.   Patient-reported outcomes and subsequent management in atrial fibrillation clinical practice: results from the Utah mEVAL AF program. J Cardiovasc Electrophysiol  2020;31:3187–95. https://doi.org/10.1111/jce.14795
  
55	Arbelo   E, Aktaa   S, Bollmann   A, D’Avila   A, Drossart   I, Dwight   J, et al.   Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace  2021;23:494–5. https://doi.org/10.1093/europace/euaa253
  
56	Kvist   LM, Vinter   N, Urbonaviciene   G, Lindholt   JS, Diederichsen   ACP, Frost   L. Diagnostic accuracies of screening for atrial fibrillation by cardiac nurses versus radiographers. Open Heart  2019;6:e000942. https://doi.org/10.1136/openhrt-2018-000942
  
57	Hijazi   Z, Oldgren   J, Siegbahn   A, Granger   CB, Wallentin   L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J  2013;34:1475–80. https://doi.org/10.1093/eurheartj/eht024
  
58	Berg   DD, Ruff   CT, Morrow   DA. Biomarkers for risk assessment in atrial fibrillation. Clin Chem  2021;67:87–95. https://doi.org/10.1093/clinchem/hvaa298
  
59	Tops   LF, Schalij   MJ, Bax   JJ. Imaging and atrial fibrillation: the role of multimodality imaging in patient evaluation and management of atrial fibrillation. Eur Heart J  2010;31:542–51. https://doi.org/10.1093/eurheartj/ehq005
  
60	Obeng-Gyimah   E, Nazarian   S. Advancements in imaging for atrial fibrillation ablation: is there a potential to improve procedural outcomes?  J Innov Card Rhythm Manag  2020;11:4172–8. https://doi.org/10.19102/icrm.2020.110701
  
61	Romero   J, Husain   SA, Kelesidis   I, Sanz   J, Medina   HM, Garcia   MJ. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Imaging  2013;6:185–94. https://doi.org/10.1161/CIRCIMAGING.112.000153
  
62	Bisbal   F, Benito   E, Teis   A, Alarcón   F, Sarrias   A, Caixal   G, et al.   Magnetic resonance imaging-guided fibrosis ablation for the treatment of atrial fibrillation: the ALICIA trial. Circ Arrhythm Electrophysiol  2020;13:e008707. https://doi.org/10.1161/CIRCEP.120.008707
  
63	Khurram   IM, Habibi   M, Gucuk Ipek   E, Chrispin   J, Yang   E, Fukumoto   K, et al.   Left atrial LGE and arrhythmia recurrence following pulmonary vein isolation for paroxysmal and persistent AF. JACC Cardiovasc Imaging  2016;9:142–8. https://doi.org/10.1016/j.jcmg.2015.10.015
  
64	Marrouche   NF, Wilber   D, Hindricks   G, Jais   P, Akoum   N, Marchlinski   F, et al.   Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA  2014;311:498–506. https://doi.org/10.1001/jama.2014.3
  
65	Roney   CH, Sillett   C, Whitaker   J, Lemus   JAS, Sim   I, Kotadia   I, et al.   Applications of multimodality imaging for left atrial catheter ablation. Eur Heart J Cardiovasc Imaging  2021;23:31–41. https://doi.org/10.1093/ehjci/jeab205
  
66	Potter   A, Augustine   DX, Ingram   TE. Referring for echocardiography: when not to test. Br J Gen Pract  2021;71:333–4. https://doi.org/10.3399/bjgp21X716441
  
67	Troughton   RW, Asher   CR, Klein   AL. The role of echocardiography in atrial fibrillation and cardioversion. Heart  2003;89:1447–54. https://doi.org/10.1136/heart.89.12.1447
  
68	Odutayo   A, Wong   CX, Hsiao   AJ, Hopewell   S, Altman   DG, Emdin   CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ  2016;354:i4482. https://doi.org/10.1136/bmj.i4482
Google ScholarPubMedWorldCat 
69	Ruddox   V, Sandven   I, Munkhaugen   J, Skattebu   J, Edvardsen   T, Otterstad   JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol  2017;24:1555–66. https://doi.org/10.1177/2047487317715769
  
70	Bassand   JP, Accetta   G, Al Mahmeed   W, Corbalan   R, Eikelboom   J, Fitzmaurice   DA, et al.   Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation. PLoS One  2018;13:e0191592. https://doi.org/10.1371/journal.pone.0191592
  
71	Bassand   JP, Accetta   G, Camm   AJ, Cools   F, Fitzmaurice   DA, Fox   KA, et al.   Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J  2016;37:2882–9. https://doi.org/10.1093/eurheartj/ehw233
  
72	Hornestam   B, Adiels   M, Wai Giang   K, Hansson   PO, Björck   L, Rosengren   A. Atrial fibrillation and risk of venous thromboembolism: a Swedish nationwide registry study. Europace  2021;23:1913–21. https://doi.org/10.1093/europace/euab180
  
73	Lutsey   PL, Norby   FL, Alonso   A, Cushman   M, Chen   LY, Michos   ED, et al.   Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the atherosclerosis risk in communities study. J Thromb Haemost  2018;16:670–9. https://doi.org/10.1111/jth.13974
  
74	Koh   YH, Lew   LZW, Franke   KB, Elliott   AD, Lau   DH, Thiyagarajah   A, et al.   Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals. Europace  2022;24:1229–39. https://doi.org/10.1093/europace/euac003
  
75	Papanastasiou   CA, Theochari   CA, Zareifopoulos   N, Arfaras-Melainis   A, Giannakoulas   G, Karamitsos   TD, et al.   Atrial fibrillation is associated with cognitive impairment, all-cause dementia, vascular dementia, and Alzheimer’s disease: a systematic review and meta-analysis. J Gen Intern Med  2021;36:3122–35. https://doi.org/10.1007/s11606-021-06954-8
  
76	Giannone   ME, Filippini   T, Whelton   PK, Chiari   A, Vitolo   M, Boriani   G, et al.   Atrial fibrillation and the risk of early-onset dementia: a systematic review and meta-analysis. J Am Heart Assoc  2022;11:e025653. https://doi.org/10.1161/JAHA.122.025653
  
77	Zuin   M, Roncon   L, Passaro   A, Bosi   C, Cervellati   C, Zuliani   G. Risk of dementia in patients with atrial fibrillation: short versus long follow-up. A systematic review and meta-analysis. Int J Geriatr Psychiatry  2021;36:1488–500. https://doi.org/10.1002/gps.5582
  
78	Mobley   AR, Subramanian   A, Champsi   A, Wang   X, Myles   P, McGreavy   P, et al.  Thromboembolic events and vascular dementia in patients with atrial fibrillation and low apparent stroke risk. Nat Med 2024. https://doi.org/10.1038/s41591-024-03049-9.
79	Wijtvliet   E, Tieleman   RG, van Gelder   IC, Pluymaekers   N, Rienstra   M, Folkeringa   RJ, et al.   Nurse-led vs. usual-care for atrial fibrillation. Eur Heart J  2020;41:634–41. https://doi.org/10.1093/eurheartj/ehz666
  
80	Wong   CX, Brooks   AG, Lau   DH, Leong   DP, Sun   MT, Sullivan   T, et al.   Factors associated with the epidemic of hospitalizations due to atrial fibrillation. Am J Cardiol  2012;110:1496–9. https://doi.org/10.1016/j.amjcard.2012.07.011
  
81	Dai   H, Zhang   Q, Much   AA, Maor   E, Segev   A, Beinart   R, et al.   Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes  2021;7:574–82. https://doi.org/10.1093/ehjqcco/qcaa061
  
82	Țica   O, Țica   O, Bunting   KV, deBono   J, Gkoutos   GV, Popescu   MI, et al.   Post-mortem examination of high mortality in patients with heart failure and atrial fibrillation. BMC Med  2022;20:331. https://doi.org/10.1186/s12916-022-02533-8
  
83	Bassand   JP, Virdone   S, Badoz   M, Verheugt   FWA, Camm   AJ, Cools   F, et al.   Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv  2021;5:1081–91. https://doi.org/10.1182/bloodadvances.2020003560
  
84	Pokorney   SD, Piccini   JP, Stevens   SR, Patel   MR, Pieper   KS, Halperin   JL, et al.   Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc  2016;5:e002197. https://doi.org/10.1161/JAHA.115.002197
  
85	Granada   J, Uribe   W, Chyou   PH, Maassen   K, Vierkant   R, Smith   PN, et al.   Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol  2000;36:2242–6. https://doi.org/10.1016/S0735-1097(00)00982-7
  
86	Vadmann   H, Nielsen   PB, Hjortshoj   SP, Riahi   S, Rasmussen   LH, Lip   GY, et al.   Atrial flutter and thromboembolic risk: a systematic review. Heart  2015;101:1446–55. https://doi.org/10.1136/heartjnl-2015-307550
  
87	Lelorier   P, Humphries   KH, Krahn   A, Connolly   SJ, Talajic   M, Green   M, et al.   Prognostic differences between atrial fibrillation and atrial flutter. Am J Cardiol  2004;93:647–9. https://doi.org/10.1016/j.amjcard.2003.11.042
  
88	Biblo   LA, Yuan   Z, Quan   KJ, Mackall   JA, Rimm   AA. Risk of stroke in patients with atrial flutter. Am J Cardiol  2001;87:346–9, A9. https://doi.org/10.1016/S0002-9149(00)01374-6
  
89	Corrado   G, Sgalambro   A, Mantero   A, Gentile   F, Gasparini   M, Bufalino   R, et al.   Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Società Italiana di Ecografia Cardiovascolare) multicentre study. Eur Heart J  2001;22:1042–51. https://doi.org/10.1053/euhj.2000.2427
  
90	Lin   YS, Chen   TH, Chi   CC, Lin   MS, Tung   TH, Liu   CH, et al.   Different implications of heart failure, ischemic stroke, and mortality between nonvalvular atrial fibrillation and atrial flutter–a view from a national cohort study. J Am Heart Assoc  2017;6:e006406. https://doi.org/10.1161/JAHA.117.006406
  
91	Giehm-Reese   M, Johansen   MN, Kronborg   MB, Jensen   HK, Gerdes   C, Kristensen   J, et al.   Discontinuation of oral anticoagulation and risk of stroke and death after ablation for typical atrial flutter: a nation-wide Danish cohort study. Int J Cardiol  2021;333:110–6. https://doi.org/10.1016/j.ijcard.2021.02.057
  
92	Gallagher   C, Rowett   D, Nyfort-Hansen   K, Simmons   S, Brooks   AG, Moss   JR, et al.   Patient-centered educational resources for atrial fibrillation. JACC Clin Electrophysiol  2019;5:1101–14. https://doi.org/10.1016/j.jacep.2019.08.007
  
93	Chung   MK, Fagerlin   A, Wang   PJ, Ajayi   TB, Allen   LA, Baykaner   T, et al.   Shared decision making in cardiac electrophysiology procedures and arrhythmia management. Circ Arrhythm Electrophysiol  2021;14:e007958. https://doi.org/10.1161/CIRCEP.121.007958
  
94	Wang   PJ, Lu   Y, Mahaffey   KW, Lin   A, Morin   DP, Sears   SF, et al.   A randomized clinical trial to evaluate an atrial fibrillation stroke prevention shared decision-making pathway. J Am Heart Assoc  2022;12:e028562. https://doi.org/10.1161/JAHA.122.028562
  
95	Seaburg   L, Hess   EP, Coylewright   M, Ting   HH, McLeod   CJ, Montori   VM. Shared decision making in atrial fibrillation: where we are and where we should be going. Circulation  2014;129:704–10. https://doi.org/10.1161/CIRCULATIONAHA.113.004498
  
96	Zhang   J, Lenarczyk   R, Marin   F, Malaczynska-Rajpold   K, Kosiuk   J, Doehner   W, et al.   The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) scientific initiatives committee, the EHRA young electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology council on stroke. Europace  2021;23:314–22. https://doi.org/10.1093/europace/euaa358
  
97	Omoush   A, Aloush   S, Albashtawy   M, Rayan   A, Alkhawaldeh   A, Eshah   N, et al.   Nurses’ knowledge of anticoagulation therapy for atrial fibrillation patients: effectiveness of an educational course. Nurs Forum  2022;57:825–32. https://doi.org/10.1111/nuf.12770
  
98	Heidbuchel   H, Dagres   N, Antz   M, Kuck   KH, Lazure   P, Murray   S, et al.   Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: a European Society of Cardiology international educational needs assessment. Europace  2018;20:1919–28. https://doi.org/10.1093/europace/euy039
  
99	Bunting   KV, Van Gelder   IC, Kotecha   D. STEEER-AF: a cluster-randomized education trial from the ESC. Eur Heart J  2020;41:1952–4. https://doi.org/10.1093/eurheartj/ehaa421
  
100	Tanner   FC, Brooks   N, Fox   KF, Gonçalves   L, Kearney   P, Michalis   L, et al.   ESC core curriculum for the cardiologist. Eur Heart J  2020;41:3605–92. https://doi.org/10.1093/eurheartj/ehaa641
  
101	Astin   F, Carroll   D, De Geest   S, Fernandez-Oliver   AL, Holt   J, Hinterbuchner   L, et al.   A core curriculum for the continuing professional development of nurses working in cardiovascular settings: developed by the education committee of the Council on Cardiovascular Nursing and Allied Professions (CCNAP) on behalf of the European Society of Cardiology. Eur J Cardiovasc Nurs  2015;14:S1–17. https://doi.org/10.1177/1474515115580905
  
102	Sterlinski   M, Bunting   KV, Boriani   G, Boveda   S, Guasch   E, Mont   L, et al.  STEEER-AF Trial Team. Design and deployment of the STEEER-AF trial to evaluate and improve guideline adherence: a cluster-randomised trial by the European Society of Cardiology and European Heart Rhythm Association. Europace 2024:euae178. https://doi.org/10.1093/europace/euae178
103	Vinereanu   D, Lopes   RD, Bahit   MC, Xavier   D, Jiang   J, Al-Khalidi   HR, et al.   A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet  2017;390:1737–46. https://doi.org/10.1016/S0140-6736(17)32165-7
  
104	Franchi   C, Antoniazzi   S, Ardoino   I, Proietti   M, Marcucci   M, Santalucia   P, et al.   Simulation-based education for physicians to increase oral anticoagulants in hospitalized elderly patients with atrial fibrillation. Am J Med  2019;132:e634–47. https://doi.org/10.1016/j.amjmed.2019.03.052
  
105	Baicus   C, Delcea   C, Dima   A, Oprisan   E, Jurcut   C, Dan   GA. Influence of decision aids on oral anticoagulant prescribing among physicians: a randomised trial. Eur J Clin Invest  2017;47:649–58. https://doi.org/10.1111/eci.12786
  
106	Ono   F, Akiyama   S, Suzuki   A, Ikeda   Y, Takahashi   A, Matsuoka   H, et al.   Impact of care coordination on oral anticoagulant therapy among patients with atrial fibrillation in routine clinical practice in Japan: a prospective, observational study. BMC Cardiovasc Disord  2019;19:235. https://doi.org/10.1186/s12872-019-1216-y
  
107	Ferguson   C, Hickman   LD, Phillips   J, Newton   PJ, Inglis   SC, Lam   L, et al.   An mHealth intervention to improve nurses’ atrial fibrillation and anticoagulation knowledge and practice: the EVICOAG study. Eur J Cardiovasc Nurs  2019;18:7–15. https://doi.org/10.1177/1474515118793051
  
108	Lip   GY, Laroche   C, Popescu   MI, Rasmussen   LH, Vitali-Serdoz   L, Dan   GA, et al.   Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF general pilot registry. Europace  2015;17:1777–86. https://doi.org/10.1093/europace/euv269
  
109	Linde   C, Bongiorni   MG, Birgersdotter-Green   U, Curtis   AB, Deisenhofer   I, Furokawa   T, et al.   Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace  2018;20:1565–1565ao. https://doi.org/10.1093/europace/euy067
  
110	Camm   AJ, Accetta   G, Al Mahmeed   W, Ambrosio   G, Goldhaber   SZ, Haas   S, et al.   Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open  2017;7:e014579. https://doi.org/10.1136/bmjopen-2016-014579
  
111	Emdin   CA, Wong   CX, Hsiao   AJ, Altman   DG, Peters   SA, Woodward   M, et al.   Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ  2016;532:h7013. https://doi.org/10.1136/bmj.h7013
Google ScholarPubMedWorldCat 
112	Tomasdottir   M, Friberg   L, Hijazi   Z, Lindback   J, Oldgren   J. Risk of ischemic stroke and utility of CHA2 DS2 -VASc score in women and men with atrial fibrillation. Clin Cardiol  2019;42:1003–9. https://doi.org/10.1002/clc.23257
  
113	Kloosterman   M, Chua   W, Fabritz   L, Al-Khalidi   HR, Schotten   U, Nielsen   JC, et al.   Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. Europace  2020;22:1026–35. https://doi.org/10.1093/europace/euaa015
  
114	Benjamin   EJ, Thomas   KL, Go   AS, Desvigne-Nickens   P, Albert   CM, Alonso   A, et al.   Transforming atrial fibrillation research to integrate social determinants of health: a national heart, lung, and blood institute workshop report. JAMA Cardiol  2023;8:182–91. https://doi.org/10.1001/jamacardio.2022.4091
  
115	Karlsson   LO, Nilsson   S, Bang   M, Nilsson   L, Charitakis   E, Janzon   M. A clinical decision support tool for improving adherence to guidelines on anticoagulant therapy in patients with atrial fibrillation at risk of stroke: a cluster-randomized trial in a Swedish primary care setting (the CDS-AF study). PLoS Med  2018;15:e1002528. https://doi.org/10.1371/journal.pmed.1002528
  
116	Biersteker   TE, Schalij   MJ, Treskes   RW. Impact of mobile health devices for the detection of atrial fibrillation: systematic review. JMIR Mhealth Uhealth  2021;9:e26161. https://doi.org/10.2196/26161
  
117	Romiti   GF, Pastori   D, Rivera-Caravaca   JM, Ding   WY, Gue   YX, Menichelli   D, et al.   Adherence to the ‘atrial fibrillation better care’ pathway in patients with atrial fibrillation: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 patients. Thromb Haemost  2022;122:406–14. https://doi.org/10.1055/a-1515-9630
Google ScholarPubMedWorldCat 
118	Gallagher   C, Elliott   AD, Wong   CX, Rangnekar   G, Middeldorp   ME, Mahajan   R, et al.   Integrated care in atrial fibrillation: a systematic review and meta-analysis. Heart  2017;103:1947–53. https://doi.org/10.1136/heartjnl-2016-310952
Google ScholarPubMedWorldCat 
119	Kirchhof   P, Benussi   S, Kotecha   D, Ahlsson   A, Atar   D, Casadei   B, et al.   2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J  2016;37:2893–962. https://doi.org/10.1093/eurheartj/ehw210
  
120	Hindricks   G, Potpara   T, Dagres   N, Arbelo   E, Bax   JJ, Blomström-Lundqvist   C, et al.   2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J  2021;42:373–498. https://doi.org/10.1093/eurheartj/ehaa612
  
121	Qvist   I, Hendriks   JM, Møller   DS, Albertsen   AE, Mogensen   HM, Oddershede   GD, et al.   Effectiveness of structured, hospital-based, nurse-led atrial fibrillation clinics: a comparison between a real-world population and a clinical trial population. Open Heart  2016;3:e000335. https://doi.org/10.1136/openhrt-2015-000335
  
122	Hendriks   JM, de Wit   R, Crijns   HJ, Vrijhoef   HJ, Prins   MH, Pisters   R, et al.   Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J  2012;33:2692–9. https://doi.org/10.1093/eurheartj/ehs071
  
123	Carter   L, Gardner   M, Magee   K, Fearon   A, Morgulis   I, Doucette   S, et al.   An integrated management approach to atrial fibrillation. J Am Heart Assoc  2016;5:e002950. https://doi.org/10.1161/JAHA.115.002950
  
124	van den Dries   CJ, van Doorn   S, Rutten   FH, Oudega   R, van de Leur   S, Elvan   A, et al.   Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial. Eur Heart J  2020;41:2836–44. https://doi.org/10.1093/eurheartj/ehaa055
  
125	Abed   HS, Wittert   GA, Leong   DP, Shirazi   MG, Bahrami   B, Middeldorp   ME, et al.   Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA  2013;310:2050–60. https://doi.org/10.1001/jama.2013.280521
  
126	Pathak   RK, Middeldorp   ME, Meredith   M, Mehta   AB, Mahajan   R, Wong   CX, et al.   Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol  2015;65:2159–69. https://doi.org/10.1016/j.jacc.2015.03.002
  
127	Middeldorp   ME, Pathak   RK, Meredith   M, Mehta   AB, Elliott   AD, Mahajan   R, et al.   PREVEntion and regReSsive effect of weight-loss and risk factor modification on atrial fibrillation: the REVERSE-AF study. Europace  2018;20:1929–35. https://doi.org/10.1093/europace/euy117
  
128	Pathak   RK, Middeldorp   ME, Lau   DH, Mehta   AB, Mahajan   R, Twomey   D, et al.   Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol  2014;64:2222–31. https://doi.org/10.1016/j.jacc.2014.09.028
  
129	Pinho-Gomes   AC, Azevedo   L, Copland   E, Canoy   D, Nazarzadeh   M, Ramakrishnan   R, et al.   Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis. PLoS Med  2021;18:e1003599. https://doi.org/10.1371/journal.pmed.1003599
  
130	Parkash   R, Wells   GA, Sapp   JL, Healey   JS, Tardif   J-C, Greiss   I, et al.   Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modification with Aggressive Blood Pressure Control]). Circulation  2017;135:1788–98. https://doi.org/10.1161/CIRCULATIONAHA.116.026230
  
131	McMurray   JJ, Adamopoulos   S, Anker   SD, Auricchio   A, Bohm   M, Dickstein   K, et al.   ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J  2012;33:1787–847. https://doi.org/10.1093/eurheartj/ehs104
Google ScholarPubMedWorldCat 
132	Olsson   LG, Swedberg   K, Ducharme   A, Granger   CB, Michelson   EL, McMurray   JJ, et al.   Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol  2006;47:1997–2004. https://doi.org/10.1016/j.jacc.2006.01.060
  
133	Kotecha   D, Holmes   J, Krum   H, Altman   DG, Manzano   L, Cleland   JG, et al.   Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet  2014;384:2235–43. https://doi.org/10.1016/S0140-6736(14)61373-8
  
134	Zannad   F, McMurray   JJ, Krum   H, van Veldhuisen   DJ, Swedberg   K, Shi   H, et al.   Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med  2011;364:11–21. https://doi.org/10.1056/NEJMoa1009492
  
135	McMurray   JJ, Packer   M, Desai   AS, Gong   J, Lefkowitz   MP, Rizkala   AR, et al.   Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med  2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077
  
136	Pandey   AK, Okaj   I, Kaur   H, Belley-Cote   EP, Wang   J, Oraii   A, et al.   Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc  2021;10:e022222. https://doi.org/10.1161/JAHA.121.022222
  
137	McDonagh   TA, Metra   M, Adamo   M, Gardner   RS, Baumbach   A, Bohm   M, et al.   2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J  2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368
  
138	Solomon   SD, McMurray   JJV, Claggett   B, de Boer   RA, DeMets   D, Hernandez   AF, et al.   Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med  2022;387:1089–98. https://doi.org/10.1056/NEJMoa2206286
  
139	Anker   SD, Butler   J, Filippatos   G, Ferreira   JP, Bocchi   E, Böhm   M, et al.   Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med  2021;385:1451–61. https://doi.org/10.1056/NEJMoa2107038
  
140	Bhatt   DL, Szarek   M, Steg   PG, Cannon   CP, Leiter   LA, McGuire   DK, et al.   Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med  2021;384:117–28. https://doi.org/10.1056/NEJMoa2030183
  
141	Pathak   RK, Elliott   A, Middeldorp   ME, Meredith   M, Mehta   AB, Mahajan   R, et al.   Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol  2015;66:985–96. https://doi.org/10.1016/j.jacc.2015.06.488
  
142	Hegbom   F, Stavem   K, Sire   S, Heldal   M, Orning   OM, Gjesdal   K. Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation. Int J Cardiol  2007;116:86–92. https://doi.org/10.1016/j.ijcard.2006.03.034
  
143	Osbak   PS, Mourier   M, Kjaer   A, Henriksen   JH, Kofoed   KF, Jensen   GB. A randomized study of the effects of exercise training on patients with atrial fibrillation. Am Heart J  2011;162:1080–7. https://doi.org/10.1016/j.ahj.2011.09.013
  
144	Malmo   V, Nes   BM, Amundsen   BH, Tjonna   AE, Stoylen   A, Rossvoll   O, et al.   Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. Circulation  2016;133:466–73. https://doi.org/10.1161/CIRCULATIONAHA.115.018220
  
145	Oesterle   A, Giancaterino   S, Van Noord   MG, Pellegrini   CN, Fan   D, Srivatsa   UN, et al.   Effects of supervised exercise training on atrial fibrillation: a meta-analysis of randomized controlled trials. J Cardiopulm Rehabil Prev  2022;42:258–65. https://doi.org/10.1097/HCR.0000000000000665
  
146	Elliott   AD, Verdicchio   CV, Mahajan   R, Middeldorp   ME, Gallagher   C, Mishima   RS, et al.   An exercise and physical activity program in patients with atrial fibrillation: the ACTIVE-AF randomized controlled trial. JACC Clin Electrophysiol  2023;9:455–65. https://doi.org/10.1016/j.jacep.2022.12.002
  
147	Voskoboinik   A, Kalman   JM, De Silva   A, Nicholls   T, Costello   B, Nanayakkara   S, et al.   Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med  2020;382:20–8. https://doi.org/10.1056/NEJMoa1817591
  
148	Holmqvist   F, Guan   N, Zhu   Z, Kowey   PR, Allen   LA, Fonarow   GC, et al.   Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J  2015;169:647–654.e2. https://doi.org/10.1016/j.ahj.2014.12.024
  
149	Fein   AS, Shvilkin   A, Shah   D, Haffajee   CI, Das   S, Kumar   K, et al.   Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol  2013;62:300–5. https://doi.org/10.1016/j.jacc.2013.03.052
  
150	Li   L, Wang   ZW, Li   J, Ge   X, Guo   LZ, Wang   Y, et al.   Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace  2014;16:1309–14. https://doi.org/10.1093/europace/euu066
  
151	Naruse   Y, Tada   H, Satoh   M, Yanagihara   M, Tsuneoka   H, Hirata   Y, et al.   Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm  2013;10:331–7. https://doi.org/10.1016/j.hrthm.2012.11.015
  
152	Qureshi   WT, Nasir   UB, Alqalyoobi   S, O’Neal   WT, Mawri   S, Sabbagh   S, et al.   Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation in obstructive sleep apnea. Am J Cardiol  2015;116:1767–73. https://doi.org/10.1016/j.amjcard.2015.08.046
  
153	Shukla   A, Aizer   A, Holmes   D, Fowler   S, Park   DS, Bernstein   S, et al.   Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis. JACC Clin Electrophysiol  2015;1:41–51. https://doi.org/10.1016/j.jacep.2015.02.014
  
154	Nalliah   CJ, Wong   GR, Lee   G, Voskoboinik   A, Kee   K, Goldin   J, et al.   Impact of CPAP on the atrial fibrillation substrate in obstructive sleep apnea: the SLEEP-AF study. JACC Clin Electrophysiol  2022;8:869–77. https://doi.org/10.1016/j.jacep.2022.04.015
  
155	Kadhim   K, Middeldorp   ME, Elliott   AD, Jones   D, Hendriks   JML, Gallagher   C, et al.   Self-reported daytime sleepiness and sleep-disordered breathing in patients with atrial fibrillation: SNOozE-AF. Can J Cardiol  2019;35:1457–64. https://doi.org/10.1016/j.cjca.2019.07.627
  
156	Traaen   GM, Overland   B, Aakeroy   L, Hunt   TE, Bendz   C, Sande   L, et al.   Prevalence, risk factors, and type of sleep apnea in patients with paroxysmal atrial fibrillation. Int J Cardiol Heart Vasc  2020;26:100447. https://doi.org/10.1016/j.ijcha.2019.100447
Google ScholarPubMedWorldCat 
157	Kadhim   K, Middeldorp   ME, Elliott   AD, Agbaedeng   T, Gallagher   C, Malik   V, et al.   Prevalence and assessment of sleep-disordered breathing in patients with atrial fibrillation: a systematic review and meta-analysis. Can J Cardiol  2021;37:1846–56. https://doi.org/10.1016/j.cjca.2021.09.026
  
158	Friberg   L, Rosenqvist   M, Lip   GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J  2012;33:1500–10. https://doi.org/10.1093/eurheartj/ehr488
  
159	Lopes   LC, Spencer   FA, Neumann   I, Ventresca   M, Ebrahim   S, Zhou   Q, et al.   Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants. PLoS One  2014;9:e88131. https://doi.org/10.1371/journal.pone.0088131
  
160	Potpara   TS, Polovina   MM, Licina   MM, Marinkovic   JM, Lip   GY. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade atrial fibrillation study. Eur J Heart Fail  2013;15:415–24. https://doi.org/10.1093/eurjhf/hft004
  
161	Noubiap   JJ, Feteh   VF, Middeldorp   ME, Fitzgerald   JL, Thomas   G, Kleinig   T, et al.   A meta-analysis of clinical risk factors for stroke in anticoagulant-naive patients with atrial fibrillation. Europace  2021;23:1528–38. https://doi.org/10.1093/europace/euab087
  
162	McEvoy JW, Touyz RM, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024. https://doi.org/10.1093/eurheartj/ehae178
163	Santoro   F, Di Biase   L, Trivedi   C, Burkhardt   JD, Paoletti Perini   A, Sanchez   J, et al.   Impact of uncontrolled hypertension on atrial fibrillation ablation outcome. JACC Clin Electrophysiol  2015;1:164–73. https://doi.org/10.1016/j.jacep.2015.04.002
  
164	Trines   SA, Stabile   G, Arbelo   E, Dagres   N, Brugada   J, Kautzner   J, et al.   Influence of risk factors in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. Pacing Clin Electrophysiol  2019;42:1365–73. https://doi.org/10.1111/pace.13763
  
165	Shah   AN, Mittal   S, Sichrovsky   TC, Cotiga   D, Arshad   A, Maleki   K, et al.   Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol  2008;19:661–7. https://doi.org/10.1111/j.1540-8167.2008.01101.x
  
166	Berruezo   A, Tamborero   D, Mont   L, Benito   B, Tolosana   JM, Sitges   M, et al.   Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J  2007;28:836–41. https://doi.org/10.1093/eurheartj/ehm027
  
167	Themistoclakis   S, Schweikert   RA, Saliba   WI, Bonso   A, Rossillo   A, Bader   G, et al.   Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm  2008;5:679–85. https://doi.org/10.1016/j.hrthm.2008.01.031
  
168	Letsas   KP, Weber   R, Burkle   G, Mihas   CC, Minners   J, Kalusche   D, et al.   Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace  2009;11:158–63. https://doi.org/10.1093/europace/eun309
  
169	Khaykin   Y, Oosthuizen   R, Zarnett   L, Essebag   V, Parkash   R, Seabrook   C, et al.   Clinical predictors of arrhythmia recurrences following pulmonary vein antrum isolation for atrial fibrillation: predicting arrhythmia recurrence post-PVAI. J Cardiovasc Electrophysiol  2011;22:1206–14. https://doi.org/10.1111/j.1540-8167.2011.02108.x
  
170	Kamioka   M, Hijioka   N, Matsumoto   Y, Nodera   M, Kaneshiro   T, Suzuki   H, et al.   Uncontrolled blood pressure affects atrial remodeling and adverse clinical outcome in paroxysmal atrial fibrillation. Pacing Clin Electrophysiol  2018;41:402–10. https://doi.org/10.1111/pace.13311
  
171	Zylla   MM, Hochadel   M, Andresen   D, Brachmann   J, Eckardt   L, Hoffmann   E, et al.   Ablation of atrial fibrillation in patients with hypertension—an analysis from the German ablation registry. J Clin Med  2020;9:1–14. https://doi.org/10.3390/jcm9082402
  
172	Galzerano   D, Di Michele   S, Paolisso   G, Tuccillo   B, Lama   D, Carbotta   S, et al.   A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. J Renin Angiotensin Aldosterone Syst  2012;13:496–503. https://doi.org/10.1177/1470320312443909
  
173	Du   H, Fan   J, Ling   Z, Woo   K, Su   L, Chen   S, et al.   Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients. Hypertension  2013;61:786–92. https://doi.org/10.1161/HYPERTENSIONAHA.111.202309
  
174	Giannopoulos   G, Kossyvakis   C, Efremidis   M, Katsivas   A, Panagopoulou   V, Doudoumis   K, et al.   Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study. Circulation  2014;130:1346–52. https://doi.org/10.1161/CIRCULATIONAHA.114.010999
  
175	Schneider   MP, Hua   TA, Bohm   M, Wachtell   K, Kjeldsen   SE, Schmieder   RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol  2010;55:2299–307. https://doi.org/10.1016/j.jacc.2010.01.043
  
176	Blum   S, Aeschbacher   S, Meyre   P, Zwimpfer   L, Reichlin   T, Beer   JH, et al.   Incidence and predictors of atrial fibrillation progression. J Am Heart Assoc  2019;8:e012554. https://doi.org/10.1161/JAHA.119.012554
  
177	Kotecha   D, Piccini   JP. Atrial fibrillation in heart failure: what should we do?  Eur Heart J  2015;36:3250–7. https://doi.org/10.1093/eurheartj/ehv513
Google ScholarPubMedWorldCat 
178	Santhanakrishnan   R, Wang   N, Larson   MG, Magnani   JW, McManus   DD, Lubitz   SA, et al.   Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation  2016;133:484–92. https://doi.org/10.1161/CIRCULATIONAHA.115.018614
  
179	Rossello   X, Gil   V, Escoda   R, Jacob   J, Aguirre   A, Martín-Sánchez   FJ, et al.   Editor’s choice – impact of identifying precipitating factors on 30-day mortality in acute heart failure patients. Eur Heart J Acute Cardiovasc Care  2019;8:667–80. https://doi.org/10.1177/2048872619869328
  
180	Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med  1998;158:1316–20. https://doi.org/10.1001/archinte.158.12.1316
CrossrefPubMedWorldCat 
181	Rohla   M, Weiss   TW, Pecen   L, Patti   G, Siller-Matula   JM, Schnabel   RB, et al.   Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open  2019;9:e022478. https://doi.org/10.1136/bmjopen-2018-022478
  
182	Kotecha   D, Chudasama   R, Lane   DA, Kirchhof   P, Lip   GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol  2016;203:660–6. https://doi.org/10.1016/j.ijcard.2015.10.220
  
183	McDonagh   TA, Metra   M, Adamo   M, Gardner   RS, Baumbach   A, Böhm   M, et al.   2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J  2023;44:3627–39. https://doi.org/10.1093/eurheartj/ehad195
  
184	ACTIVE I Investigators; Yusuf   S, Healey   JS, Pogue   J, Chrolavicius   S, Flather   M, et al.   Irbesartan in patients with atrial fibrillation. N Engl J Med  2011;364:928–38. https://doi.org/10.1056/NEJMoa1008816
Google ScholarPubMedWorldCat 
185	Ziff   OJ, Lane   DA, Samra   M, Griffith   M, Kirchhof   P, Lip   GY, et al.   Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ  2015;351:h4451. https://doi.org/10.1136/bmj.h4451
Google ScholarPubMedWorldCat 
186	Groenveld   HF, Crijns   HJ, Van den Berg   MP, Van Sonderen   E, Alings   AM, Tijssen   JG, et al.   The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol  2011;58:1795–803. https://doi.org/10.1016/j.jacc.2011.06.055
  
187	Glikson   M, Nielsen   JC, Kronborg   MB, Michowitz   Y, Auricchio   A, Barbash   IM, et al.   2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J  2021;42:3427–520. https://doi.org/10.1093/eurheartj/ehab364
  
188	Solomon   SD, Claggett   B, Lewis   EF, Desai   A, Anand   I, Sweitzer   NK, et al.   Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J  2016;37:455–62. https://doi.org/10.1093/eurheartj/ehv464
  
189	Lund   LH, Claggett   B, Liu   J, Lam   CS, Jhund   PS, Rosano   GM, et al.   Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail  2018;20:1230–9. https://doi.org/10.1002/ejhf.1149
  
190	Cleland   JGF, Bunting   KV, Flather   MD, Altman   DG, Holmes   J, Coats   AJS, et al.   Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J  2018;39:26–35. https://doi.org/10.1093/eurheartj/ehx564
  
191	Țica   O, Khamboo   W, Kotecha   D. Breaking the cycle of heart failure with preserved ejection fraction and atrial fibrillation. Card Fail Rev  2022;8:e32. https://doi.org/10.15420/cfr.2022.03
  
192	Nguyen   BO, Crijns   H, Tijssen   JGP, Geelhoed   B, Hobbelt   AH, Hemels   MEW, et al.   Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. Europace  2022;24:910–20. https://doi.org/10.1093/europace/euab270
  
193	Wang   A, Green   JB, Halperin   JL, Piccini   JP, Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol  2019;74:1107–15. https://doi.org/10.1016/j.jacc.2019.07.020
  
194	Alijla   F, Buttia   C, Reichlin   T, Razvi   S, Minder   B, Wilhelm   M, et al.   Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis. Cardiovasc Diabetol  2021;20:230. https://doi.org/10.1186/s12933-021-01423-2
  
195	Ding   WY, Kotalczyk   A, Boriani   G, Marin   F, Blomstrom-Lundqvist   C, Potpara   TS, et al.   Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF long-term general registry. Eur J Intern Med  2022;103:41–9. https://doi.org/10.1016/j.ejim.2022.04.026
  
196	Proietti   M, Romiti   GF, Basili   S. The case of diabetes mellitus and atrial fibrillation: underlining the importance of non-cardiovascular comorbidities. Eur J Intern Med  2022;103:38–40. https://doi.org/10.1016/j.ejim.2022.06.017
  
197	Karayiannides   S, Norhammar   A, Landstedt-Hallin   L, Friberg   L, Lundman   P. Prognostic impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study. Eur J Prev Cardiol  2022;29:1759–69. https://doi.org/10.1093/eurjpc/zwac093
  
198	Lip   GY, Nieuwlaat   R, Pisters   R, Lane   DA, Crijns   HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest  2010;137:263–72. https://doi.org/10.1378/chest.09-1584
  
199	Abdel-Qadir   H, Gunn   M, Lega   IC, Pang   A, Austin   PC, Singh   SM, et al.   Association of diabetes duration and glycemic control with stroke rate in patients with atrial fibrillation and diabetes: a population-based cohort study. J Am Heart Assoc  2022;11:e023643. https://doi.org/10.1161/JAHA.121.023643
  
200	Donnellan   E, Aagaard   P, Kanj   M, Jaber   W, Elshazly   M, Hoosien   M, et al.   Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation. JACC Clin Electrophysiol  2019;5:897–903. https://doi.org/10.1016/j.jacep.2019.05.018
  
201	D’Souza   S, Elshazly   MB, Dargham   SR, Donnellan   E, Asaad   N, Hayat   S, et al.   Atrial fibrillation catheter ablation complications in obese and diabetic patients: insights from the US nationwide inpatient sample 2005–2013. Clin Cardiol  2021;44:1151–60. https://doi.org/10.1002/clc.23667
  
202	Creta   A, Providencia   R, Adragao   P, de Asmundis   C, Chun   J, Chierchia   G, et al.   Impact of type-2 diabetes mellitus on the outcomes of catheter ablation of atrial fibrillation (European Observational Multicentre Study). Am J Cardiol  2020;125:901–6. https://doi.org/10.1016/j.amjcard.2019.12.037
  
203	Wang   Z, Wang   YJ, Liu   ZY, Li   Q, Kong   YW, Chen   YW, et al.   Effect of insulin resistance on recurrence after radiofrequency catheter ablation in patients with atrial fibrillation. Cardiovasc Drugs Ther  2023;37:705–13. https://doi.org/10.1007/s10557-022-07317-z
  
204	Papazoglou   AS, Kartas   A, Moysidis   DV, Tsagkaris   C, Papadakos   SP, Bekiaridou   A, et al.   Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation. Cardiovasc Diabetol  2022;21:39. https://doi.org/10.1186/s12933-022-01473-0
  
205	Zhang   Z, Zhang   X, Korantzopoulos   P, Letsas   KP, Tse   G, Gong   M, et al.   Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovasc Disord  2017;17:96. https://doi.org/10.1186/s12872-017-0531-4
  
206	Bell   DSH, Goncalves   E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab  2019;21:210–7. https://doi.org/10.1111/dom.13512
  
207	Marx   N, Federici   M, Schütt   K, Müller-Wieland   D, Ajjan   RA, Antunes   MJ, et al.   2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J  2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192
  
208	Di Benedetto   L, Michels   G, Luben   R, Khaw   KT, Pfister   R. Individual and combined impact of lifestyle factors on atrial fibrillation in apparently healthy men and women: the EPIC-Norfolk prospective population study. Eur J Prev Cardiol  2018;25:1374–83. https://doi.org/10.1177/2047487318782379
  
209	Grundvold   I, Bodegard   J, Nilsson   PM, Svennblad   B, Johansson   G, Ostgren   CJ, et al.   Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study. Cardiovasc Diabetol  2015;14:5. https://doi.org/10.1186/s12933-014-0170-3
  
210	Wong   CX, Sullivan   T, Sun   MT, Mahajan   R, Pathak   RK, Middeldorp   M, et al.   Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol  2015;1:139–52. https://doi.org/10.1016/j.jacep.2015.04.004
  
211	Providencia   R, Adragao   P, de Asmundis   C, Chun   J, Chierchia   G, Defaye   P, et al.   Impact of body mass index on the outcomes of catheter ablation of atrial fibrillation: a European observational multicenter study. J Am Heart Assoc  2019;8:e012253. https://doi.org/10.1161/JAHA.119.012253
  
212	Glover   BM, Hong   KL, Dagres   N, Arbelo   E, Laroche   C, Riahi   S, et al.   Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. Heart  2019;105:244–50. https://doi.org/10.1136/heartjnl-2018-313490
  
213	Gessler   N, Willems   S, Steven   D, Aberle   J, Akbulak   RO, Gosau   N, et al.   Supervised obesity reduction trial for AF ablation patients: results from the SORT-AF trial. Europace  2021;23:1548–58. https://doi.org/10.1093/europace/euab122
  
214	Mohanty   S, Mohanty   P, Natale   V, Trivedi   C, Gianni   C, Burkhardt   JD, et al.   Impact of weight loss on ablation outcome in obese patients with longstanding persistent atrial fibrillation. J Cardiovasc Electrophysiol  2018;29:246–53. https://doi.org/10.1111/jce.13394
  
215	Donnellan   E, Wazni   OM, Kanj   M, Elshazly   M, Hussein   AA, Patel   DR, et al.   Impact of risk-factor modification on arrhythmia recurrence among morbidly obese patients undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol  2020;31:1979–86. https://doi.org/10.1111/jce.14607
  
216	Donnellan   E, Wazni   OM, Kanj   M, Baranowski   B, Cremer   P, Harb   S, et al.   Association between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation. Europace  2019;21:1476–83. https://doi.org/10.1093/europace/euz183
  
217	Donnellan   E, Wazni   O, Kanj   M, Hussein   A, Baranowski   B, Lindsay   B, et al.   Outcomes of atrial fibrillation ablation in morbidly obese patients following bariatric surgery compared with a nonobese cohort. Circ Arrhythm Electrophysiol  2019;12:e007598. https://doi.org/10.1161/CIRCEP.119.007598
  
218	Moula   AI, Parrini   I, Tetta   C, Lucà   F, Parise   G, Rao   CM, et al.   Obstructive sleep apnea and atrial fibrillation. J Clin Med  2022;11:1242. https://doi.org/10.3390/jcm11051242
  
219	Kapur   VK, Auckley   DH, Chowdhuri   S, Kuhlmann   DC, Mehra   R, Ramar   K, et al.   Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med  2017;13:479–504. https://doi.org/10.5664/jcsm.6506
  
220	Linz   D, Brooks   AG, Elliott   AD, Nalliah   CJ, Hendriks   JML, Middeldorp   ME, et al.   Variability of sleep apnea severity and risk of atrial fibrillation: the VARIOSA-AF study. JACC Clin Electrophysiol  2019;5:692–701. https://doi.org/10.1016/j.jacep.2019.03.005
  
221	Linz   D, Linz   B, Dobrev   D, Baumert   M, Hendriks   JM, Pepin   JL, et al.   Personalized management of sleep apnea in patients with atrial fibrillation: an interdisciplinary and translational challenge. Int J Cardiol Heart Vasc  2021;35:100843. https://doi.org/10.1016/j.ijcha.2021.100843.
Google ScholarPubMedWorldCat 
222	Kanagala   R, Murali   NS, Friedman   PA, Ammash   NM, Gersh   BJ, Ballman   KV, et al.   Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation  2003;107:2589–94. https://doi.org/10.1161/01.CIR.0000068337.25994.21
  
223	Abumuamar   AM, Newman   D, Dorian   P, Shapiro   CM. Cardiac effects of CPAP treatment in patients with obstructive sleep apnea and atrial fibrillation. J Interv Card Electrophysiol  2019;54:289–97. https://doi.org/10.1007/s10840-018-0482-4
  
224	Mittal   S, Golombeck   D, Pimienta   J. Sleep apnoea and AF: where do we stand? Practical advice for clinicians. Arrhythm Electrophysiol Rev  2021;10:140–6. https://doi.org/10.15420/aer.2021.05
  
225	Hunt   TE, Traaen   GM, Aakeroy   L, Bendz   C, Overland   B, Akre   H, et al.   Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial. Heart Rhythm  2022;19:1433–41. https://doi.org/10.1016/j.hrthm.2022.06.016
  
226	Caples   SM, Mansukhani   MP, Friedman   PA, Somers   VK. The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: a randomized controlled trial. Int J Cardiol  2019;278:133–6. https://doi.org/10.1016/j.ijcard.2018.11.100
  
227	Labarca   G, Dreyse   J, Drake   L, Jorquera   J, Barbe   F. Efficacy of continuous positive airway pressure (CPAP) in the prevention of cardiovascular events in patients with obstructive sleep apnea: systematic review and meta-analysis. Sleep Med Rev  2020;52:101312. https://doi.org/10.1016/j.smrv.2020.101312
  
228	Abuzaid   AS, Al Ashry   HS, Elbadawi   A, Ld   H, Saad   M, Elgendy   IY, et al.   Meta-analysis of cardiovascular outcomes with continuous positive airway pressure therapy in patients with obstructive sleep apnea. Am J Cardiol  2017;120:693–9. https://doi.org/10.1016/j.amjcard.2017.05.042
  
229	Yu   J, Zhou   Z, McEvoy   RD, Anderson   CS, Rodgers   A, Perkovic   V, et al.   Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea: a systematic review and meta-analysis. JAMA  2017;318:156–66. https://doi.org/10.1001/jama.2017.7967
  
230	McEvoy   RD, Antic   NA, Heeley   E, Luo   Y, Ou   Q, Zhang   X, et al.   CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med  2016;375:919–31. https://doi.org/10.1056/NEJMoa1606599
  
231	Overvad   TF, Rasmussen   LH, Skjøth   F, Overvad   K, Albertsen   IE, Lane   DA, et al.   Alcohol intake and prognosis of atrial fibrillation. Heart  2013;99:1093–9. https://doi.org/10.1136/heartjnl-2013-304036
  
232	Lim   C, Kim   T-H, Yu   HT, Lee   S-R, Cha   M-J, Lee   J-M, et al.   Effect of alcohol consumption on the risk of adverse events in atrial fibrillation: from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) registry. EP Europace  2021;23:548–56. https://doi.org/10.1093/europace/euaa340
  
233	Lee   SR, Choi   EK, Jung   JH, Han   KD, Oh   S, Lip   GYH. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. Eur Heart J  2021;42:4759–68. https://doi.org/10.1093/eurheartj/ehab315
  
234	Pisters   R, Lane   DA, Nieuwlaat   R, de Vos   CB, Crijns   HJ, Lip   GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest  2010;138:1093–100. https://doi.org/10.1378/chest.10-0134
  
235	Takahashi   Y, Nitta   J, Kobori   A, Sakamoto   Y, Nagata   Y, Tanimoto   K, et al.   Alcohol consumption reduction and clinical outcomes of catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol  2021;14:e009770. https://doi.org/10.1161/CIRCEP.121.009770
  
236	Friberg   L, Hammar   N, Rosenqvist   M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm cohort of atrial fibrillation. Eur Heart J  2010;31:967–75. https://doi.org/10.1093/eurheartj/ehn599
  
237	Banerjee   A, Taillandier   S, Olesen   JB, Lane   DA, Lallemand   B, Lip   GY, et al.   Pattern of atrial fibrillation and risk of outcomes: the Loire valley atrial fibrillation project. Int J Cardiol  2013;167:2682–7. https://doi.org/10.1016/j.ijcard.2012.06.118
  
238	Wolf   PA, Abbott   RD, Kannel   WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke  1991;22:983–8. https://doi.org/10.1161/01.STR.22.8.983
  
239	Hart   RG, Pearce   LA, Aguilar   MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med  2007;146:857–67. https://doi.org/10.7326/0003-4819-146-12-200706190-00007
  
240	Ruff   CT, Giugliano   RP, Braunwald   E, Hoffman   EB, Deenadayalu   N, Ezekowitz   MD, et al.   Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet  2014;383:955–62. https://doi.org/10.1016/S0140-6736(13)62343-0
  
241	Sjalander   S, Sjalander   A, Svensson   PJ, Friberg   L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace  2014;16:631–8. https://doi.org/10.1093/europace/eut333
  
242	Connolly   SJ, Eikelboom   J, Joyner   C, Diener   HC, Hart   R, Golitsyn   S, et al.   Apixaban in patients with atrial fibrillation. N Engl J Med  2011;364:806–17. https://doi.org/10.1056/NEJMoa1007432
  
243	van Doorn   S, Rutten   FH, O’Flynn   CM, Oudega   R, Hoes   AW, Moons   KGM, et al.   Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial fibrillation: a cluster randomised trial in general practice. Int J Cardiol  2018;273:123–9. https://doi.org/10.1016/j.ijcard.2018.08.096
  
244	Borre   ED, Goode   A, Raitz   G, Shah   B, Lowenstern   A, Chatterjee   R, et al.   Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost  2018;118:2171–87. https://doi.org/10.1055/s-0038-1675400
Google ScholarPubMedWorldCat 
245	van der Endt   VHW, Milders   J, de Vries   BBLP, Trines   SA, Groenwold   RHH, Dekkers   OM, et al.   Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation. Europace  2022;24:1739–53. https://doi.org/10.1093/europace/euac096
  
246	Quinn   GR, Severdija   ON, Chang   Y, Singer   DE. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. Circulation  2017;135:208–19. https://doi.org/10.1161/CIRCULATIONAHA.116.024057
  
247	Pisters   R, Lane   DA, Marin   F, Camm   AJ, Lip   GY. Stroke and thromboembolism in atrial fibrillation. Circ J  2012;76:2289–304. https://doi.org/10.1253/circj.CJ-12-1036
  
248	Hohnloser   SH, Hijazi   Z, Thomas   L, Alexander   JH, Amerena   J, Hanna   M, et al.   Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J  2012;33:2821–30. https://doi.org/10.1093/eurheartj/ehs274
  
249	Fox   KA, Piccini   JP, Wojdyla   D, Becker   RC, Halperin   JL, Nessel   CC, et al.   Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J  2011;32:2387–94. https://doi.org/10.1093/eurheartj/ehr342
  
250	Yaghi   S, Henninger   N, Giles   JA, Leon Guerrero   C, Mistry   E, Liberman   AL, et al.   Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study. J Neurol Neurosurg Psychiatry  2021;92:1062–7. https://doi.org/10.1136/jnnp-2021-326166
  
251	Ocak   G, Khairoun   M, Khairoun   O, Bos   WJW, Fu   EL, Cramer   MJ, et al.   Chronic kidney disease and atrial fibrillation: a dangerous combination. PLoS One  2022;17:e0266046. https://doi.org/10.1371/journal.pone.0266046
  
252	Seiffge   DJ, De Marchis   GM, Koga   M, Paciaroni   M, Wilson   D, Cappellari   M, et al.   Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. Ann Neurol  2020;87:677–87. https://doi.org/10.1002/ana.25700
  
253	Paciaroni   M, Agnelli   G, Falocci   N, Caso   V, Becattini   C, Marcheselli   S, et al.   Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. J Neurol  2016;263:231–7. https://doi.org/10.1007/s00415-015-7957-3
  
254	Hijazi   Z, Oldgren   J, Siegbahn   A, Wallentin   L. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin Chem  2017;63:152–64. https://doi.org/10.1373/clinchem.2016.255182
  
255	Singleton   MJ, Yuan   Y, Dawood   FZ, Howard   G, Judd   SE, Zakai   NA, et al.   Multiple blood biomarkers and stroke risk in atrial fibrillation: the REGARDS study. J Am Heart Assoc  2021;10:e020157. https://doi.org/10.1161/JAHA.120.020157
  
256	Wu   VC, Wu   M, Aboyans   V, Chang   SH, Chen   SW, Chen   MC, et al.   Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart  2020;106:534–40. https://doi.org/10.1136/heartjnl-2019-315065
  
257	Mikkelsen   AP, Lindhardsen   J, Lip   GY, Gislason   GH, Torp-Pedersen   C, Olesen   JB. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost  2012;10:1745–51. https://doi.org/10.1111/j.1538-7836.2012.04853.x
  
258	Antonenko   K, Paciaroni   M, Agnelli   G, Falocci   N, Becattini   C, Marcheselli   S, et al.   Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: results from the RAF study (early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation). Eur Stroke J  2017;2:46–53. https://doi.org/10.1177/2396987316679577
  
259	Wang   X, Mobley   AR, Tica   O, Okoth   K, Ghosh   RE, Myles   P, et al.   Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomized trial. Eur Heart J - Dig Health  2022;3:426–36. https://doi.org/10.1093/ehjdh/ztac046
  
260	Rivard   L, Khairy   P, Talajic   M, Tardif   JC, Nattel   S, Bherer   L, et al.   Blinded randomized trial of anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation (BRAIN-AF): methods and design. Can J Cardiol  2019;35:1069–77. https://doi.org/10.1016/j.cjca.2019.04.022
  
261	Chung   S, Kim   TH, Uhm   JS, Cha   MJ, Lee   JM, Park   J, et al.   Stroke and systemic embolism and other adverse outcomes of heart failure with preserved and reduced ejection fraction in patients with atrial fibrillation (from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF]). Am J Cardiol  2020;125:68–75. https://doi.org/10.1016/j.amjcard.2019.09.035
  
262	Uhm   JS, Kim   J, Yu   HT, Kim   TH, Lee   SR, Cha   MJ, et al.   Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type. ESC Heart Fail  2021;8:1582–9. https://doi.org/10.1002/ehf2.13264
  
263	McMurray   JJ, Ezekowitz   JA, Lewis   BS, Gersh   BJ, van Diepen   S, Amerena   J, et al.   Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail  2013;6:451–60. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000143
  
264	Kim   D, Yang   PS, Kim   TH, Jang   E, Shin   H, Kim   HY, et al.   Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol  2018;72:1233–45. https://doi.org/10.1016/j.jacc.2018.05.076
  
265	Lip   GY, Clementy   N, Pericart   L, Banerjee   A, Fauchier   L. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire valley atrial fibrillation project. Stroke  2015;46:143–50. https://doi.org/10.1161/STROKEAHA.114.007199
  
266	American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care  2022;45:S17–38. https://doi.org/10.2337/dc22-S002
CrossrefPubMedWorldCat 
267	Steensig   K, Olesen   KKW, Thim   T, Nielsen   JC, Jensen   SE, Jensen   LO, et al.   Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the western Denmark heart registry. Thromb Haemost  2018;118:2162–70. https://doi.org/10.1055/s-0038-1675401
Google ScholarPubMedWorldCat 
268	Zabalgoitia   M, Halperin   JL, Pearce   LA, Blackshear   JL, Asinger   RW, Hart   RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation III investigators. J Am Coll Cardiol  1998;31:1622–6. https://doi.org/10.1016/S0735-1097(98)00146-6
  
269	Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiography in atrial fibrillation: standards for acquisition and interpretation and assessment of interobserver variability. Stroke prevention in atrial fibrillation investigators committee on echocardiography. J Am Soc Echocardiogr  1996;9:556–66. https://doi.org/10.1016/S0894-7317(96)90127-3
PubMedWorldCat 
270	Lozier   MR, Sanchez   AM, Lee   JJ, Donath   EM, Font   VE, Escolar   E. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: a systematic review. J Atr Fibrillation  2019;12:2207. https://doi.org/10.4022/jafib.2207
  
271	Guttmann   OP, Rahman   MS, O’Mahony   C, Anastasakis   A, Elliott   PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart  2014;100:465–72. https://doi.org/10.1136/heartjnl-2013-304276
  
272	Guttmann   OP, Pavlou   M, O’Mahony   C, Monserrat   L, Anastasakis   A, Rapezzi   C, et al.   Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy (HCM risk-CVA). Eur J Heart Fail  2015;17:837–45. https://doi.org/10.1002/ejhf.316
  
273	Vilches   S, Fontana   M, Gonzalez-Lopez   E, Mitrani   L, Saturi   G, Renju   M, et al.   Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail  2022;24:1387–96. https://doi.org/10.1002/ejhf.2566
  
274	Lee   SE, Park   JK, Uhm   JS, Kim   JY, Pak   HN, Lee   MH, et al.   Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart  2017;103:1496–501. https://doi.org/10.1136/heartjnl-2016-310720
  
275	Hirota   T, Kubo   T, Baba   Y, Ochi   Y, Takahashi   A, Yamasaki   N, et al.   Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort–results from Kochi RYOMA study. Circ J  2019;83:1747–54. https://doi.org/10.1253/circj.CJ-19-0186
  
276	Hsu   JC, Huang   YT, Lin   LY. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study. Aging (Albany NY)  2020;12:24219–27. https://doi.org/10.18632/aging.104133
  
277	Chao   TF, Lip   GYH, Liu   CJ, Lin   YJ, Chang   SL, Lo   LW, et al.   Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol  2018;71:122–32. https://doi.org/10.1016/j.jacc.2017.10.085
  
278	Weijs   B, Dudink   E, de Vos   CB, Limantoro   I, Tieleman   RG, Pisters   R, et al.   Idiopathic atrial fibrillation patients rapidly outgrow their low thromboembolic risk: a 10-year follow-up study. Neth Heart J  2019;27:487–97. https://doi.org/10.1007/s12471-019-1272-z
  
279	Bezabhe   WM, Bereznicki   LR, Radford   J, Wimmer   BC, Salahudeen   MS, Garrahy   E, et al.   Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten-year follow-up. Eur J Clin Invest  2021;51:e13489. https://doi.org/10.1111/eci.13489
  
280	Fauchier   L, Bodin   A, Bisson   A, Herbert   J, Spiesser   P, Clementy   N, et al.   Incident comorbidities, aging and the risk of stroke in 608,108 patients with atrial fibrillation: a nationwide analysis. J Clin Med  2020;9:1234. https://doi.org/10.3390/jcm9041234
  
281	Kirchhof   P, Toennis   T, Goette   A, Camm   AJ, Diener   HC, Becher   N, et al.   Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med  2023;389:1167–79. https://doi.org/10.1056/NEJMoa2303062
  
282	Healey   JS, Lopes   RD, Granger   CB, Alings   M, Rivard   L, McIntyre   WF, et al.   Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med  2024;390:107–17. https://doi.org/10.1056/NEJMoa2310234
  
283	van Walraven   C, Hart   RG, Singer   DE, Laupacis   A, Connolly   S, Petersen   P, et al.   Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA  2002;288:2441–8. https://doi.org/10.1001/jama.288.19.2441
  
284	Hart   RG, Pearce   LA, Rothbart   RM, McAnulty   JH, Asinger   RW, Halperin   JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol  2000;35:183–7. https://doi.org/10.1016/S0735-1097(99)00489-1
  
285	Nieuwlaat   R, Dinh   T, Olsson   SB, Camm   AJ, Capucci   A, Tieleman   RG, et al.   Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?  Eur Heart J  2008;29:915–22. https://doi.org/10.1093/eurheartj/ehn101
  
286	Ruff CT. AZALEA-TIMI 71 Steering Committee. Abelacimab, a novel factor XI/XIa inhibitor, vs rivaroxaban in patients with atrial fibrillation: primary results of the AZALEA-TIMI 71 randomized trial. Circulation 2024;148:e282–317. https://doi.org/10.1161/CIR.0000000000001200
287	Piccini   JP, Caso   V, Connolly   SJ, Fox   KAA, Oldgren   J, Jones   WS, et al.   Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet  2022;399:1383–90. https://doi.org/10.1016/S0140-6736(22)00456-1
  
288	Tan   CSS, Lee   SWH. Warfarin and food, herbal or dietary supplement interactions: a systematic review. Br J Clin Pharmacol  2021;87:352–74. https://doi.org/10.1111/bcp.14404
  
289	Holbrook   AM, Pereira   JA, Labiris   R, McDonald   H, Douketis   JD, Crowther   M, et al.   Systematic overview of warfarin and its drug and food interactions. Arch Intern Med  2005;165:1095–106. https://doi.org/10.1001/archinte.165.10.1095
  
290	Ferri   N, Colombo   E, Tenconi   M, Baldessin   L, Corsini   A. Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics  2022;14:1120. https://doi.org/10.3390/pharmaceutics14061120
  
291	Mar   PL, Gopinathannair   R, Gengler   BE, Chung   MK, Perez   A, Dukes   J, et al.   Drug interactions affecting oral anticoagulant use. Circ Arrhythm Electrophysiol  2022;15:e007956. https://doi.org/10.1161/CIRCEP.121.007956
Google ScholarPubMedWorldCat 
292	Carnicelli   AP, Hong   H, Connolly   SJ, Eikelboom   J, Giugliano   RP, Morrow   DA, et al.   Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation  2022;145:242–55. https://doi.org/10.1161/CIRCULATIONAHA.121.056355
  
293	Kotecha   D, Pollack   CV, Jr, De Caterina   R, Renda   G, Kirchhof   P. Direct oral anticoagulants halve thromboembolic events after cardioversion of AF compared with warfarin. J Am Coll Cardiol  2018;72:1984–6. https://doi.org/10.1016/j.jacc.2018.07.083
  
294	Connolly   SJ, Karthikeyan   G, Ntsekhe   M, Haileamlak   A, El Sayed   A, El Ghamrawy   A, et al.   Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med  2022;387:978–88. https://doi.org/10.1056/NEJMoa2209051
  
295	Halperin JL, Hart RG, Kronmal RA, McBride R. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet  1994;343:687–91. https://doi.org/10.1016/S0140-6736(94)91577-6
PubMedWorldCat 
296	Singer   DE, Hughes   RA, Gress   DR, Sheehan   MA, Oertel   LB, Maraventano   SW, et al.   The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med  1990;323:1505–11. https://doi.org/10.1056/NEJM199011293232201
Google ScholarPubMedWorldCat 
297	Gulløv   AL, Koefoed   BG, Petersen   P, Pedersen   TS, Andersen   ED, Godtfredsen   J, et al.   Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: second Copenhagen atrial fibrillation, aspirin, and anticoagulation study. Arch Intern Med  1998;158:1513–21. https://doi.org/10.1001/archinte.158.14.1513
  
298	Blackshear JL, Halperin JL, Hart RG, Laupacis A. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet  1996;348:633–8. https://doi.org/10.1016/S0140-6736(96)03487-3
CrossrefPubMedWorldCat 
299	Amin   A, Deitelzweig   S, Jing   Y, Makenbaeva   D, Wiederkehr   D, Lin   J, et al.   Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use–learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis  2014;38:150–9. https://doi.org/10.1007/s11239-013-1048-z
  
300	Själander   S, Sjögren   V, Renlund   H, Norrving   B, Själander   A. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Thromb Res  2018;167:113–8. https://doi.org/10.1016/j.thromres.2018.05.022
  
301	van Miert   JHA, Kooistra   HAM, Veeger   N, Westerterp   A, Piersma-Wichers   M, Meijer   K. Choosing between continuing vitamin K antagonists (VKA) or switching to a direct oral anticoagulant in currently well-controlled patients on VKA for atrial fibrillation: a randomised controlled trial (GAInN). Br J Haematol  2019;186:e21–3. https://doi.org/10.1111/bjh.15856
  
302	Krittayaphong   R, Chantrarat   T, Rojjarekampai   R, Jittham   P, Sairat   P, Lip   GYH. Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with non-valvular atrial fibrillation: a report from the nationwide COOL-AF registry. J Clin Med  2020;9:1698. https://doi.org/10.3390/jcm9061698
  
303	Szummer   K, Gasparini   A, Eliasson   S, Ärnlöv   J, Qureshi   AR, Bárány   P, et al.   Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc  2017;6:e004925. https://doi.org/10.1161/JAHA.116.004925
  
304	Cardoso   R, Ternes   CMP, Justino   GB, Fernandes   A, Rocha   AV, Knijnik   L, et al.   Non-vitamin K antagonists versus warfarin in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis. Am J Med  2022;135:228–234.e1. https://doi.org/10.1016/j.amjmed.2021.08.026
  
305	Wan   Y, Heneghan   C, Perera   R, Roberts   N, Hollowell   J, Glasziou   P, et al.   Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes  2008;1:84–91. https://doi.org/10.1161/CIRCOUTCOMES.108.796185
  
306	Vestergaard   AS, Skjøth   F, Larsen   TB, Ehlers   LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS One  2017;12:e0188482. https://doi.org/10.1371/journal.pone.0188482
  
307	Macaluso   GP, Pagani   FD, Slaughter   MS, Milano   CA, Feller   ED, Tatooles   AJ, et al.   Time in therapeutic range significantly impacts survival and adverse events in destination therapy patients. ASAIO J  2022;68:14–20. https://doi.org/10.1097/MAT.0000000000001572
  
308	Heneghan   C, Ward   A, Perera   R, Bankhead   C, Fuller   A, Stevens   R, et al.   Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet  2012;379:322–34. https://doi.org/10.1016/S0140-6736(11)61294-4
  
309	Joosten   LPT, van Doorn   S, van de Ven   PM, Köhlen   BTG, Nierman   MC, Koek   HL, et al.   Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation  2024;149:279–89. https://doi.org/10.1161/CIRCULATIONAHA.123.066485
Google ScholarPubMedWorldCat 
310	Yao   X, Shah   ND, Sangaralingham   LR, Gersh   BJ, Noseworthy   PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol  2017;69:2779–90. https://doi.org/10.1016/j.jacc.2017.03.600
  
311	Steinberg   BA, Shrader   P, Thomas   L, Ansell   J, Fonarow   GC, Gersh   BJ, et al.   Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol  2016;68:2597–604. https://doi.org/10.1016/j.jacc.2016.09.966
  
312	Alexander   JH, Andersson   U, Lopes   RD, Hijazi   Z, Hohnloser   SH, Ezekowitz   JA, et al.   Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. JAMA Cardiol  2016;1:673–81. https://doi.org/10.1001/jamacardio.2016.1829
  
313	Carmo   J, Moscoso Costa   F, Ferreira   J, Mendes   M. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost  2016;116:754–63. https://doi.org/10.1160/TH16-03-0203
Google ScholarPubMedWorldCat 
314	Huisman   MV, Rothman   KJ, Paquette   M, Teutsch   C, Diener   HC, Dubner   SJ, et al.   Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: global registry on long-term antithrombotic treatment in patients with atrial fibrillation (GLORIA-AF) registry. Am Heart J  2018;198:55–63. https://doi.org/10.1016/j.ahj.2017.08.018
  
315	Camm   AJ, Amarenco   P, Haas   S, Hess   S, Kirchhof   P, Kuhls   S, et al.   XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J  2016;37:1145–53. https://doi.org/10.1093/eurheartj/ehv466
  
316	Martinez   CAA, Lanas   F, Radaideh   G, Kharabsheh   SM, Lambelet   M, Viaud   MAL, et al.   XANTUS-EL: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. Egypt Heart J  2018;70:307–13. https://doi.org/10.1016/j.ehj.2018.09.002
  
317	Li   XS, Deitelzweig   S, Keshishian   A, Hamilton   M, Horblyuk   R, Gupta   K, et al.   Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost  2017;117:1072–82. https://doi.org/10.1160/TH17-01-0068
Google ScholarPubMedWorldCat 
318	Lee   SR, Choi   EK, Han   KD, Jung   JH, Oh   S, Lip   GYH. Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol  2018;72:838–53. https://doi.org/10.1016/j.jacc.2018.05.066
  
319	Cappato   R, Ezekowitz   MD, Klein   AL, Camm   AJ, Ma   CS, Le Heuzey   JY, et al.   Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J  2014;35:3346–55. https://doi.org/10.1093/eurheartj/ehu367
  
320	Goette   A, Merino   JL, Ezekowitz   MD, Zamoryakhin   D, Melino   M, Jin   J, et al.   Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet  2016;388:1995–2003. https://doi.org/10.1016/S0140-6736(16)31474-X
  
321	Ezekowitz   MD, Pollack   CV, Jr, Halperin   JL, England   RD, VanPelt Nguyen   S, Spahr   J, et al.   Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J  2018;39:2959–71. https://doi.org/10.1093/eurheartj/ehy148
  
322	Savarese   G, Giugliano   RP, Rosano   GM, McMurray   J, Magnani   G, Filippatos   G, et al.   Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC Heart Fail  2016;4:870–80. https://doi.org/10.1016/j.jchf.2016.07.012
  
323	von Lueder   TG, Atar   D, Agewall   S, Jensen   JK, Hopper   I, Kotecha   D, et al.   All-cause mortality and cardiovascular outcomes with non-vitamin K oral anticoagulants versus warfarin in patients with heart failure in the food and drug administration adverse event reporting system. Am J Ther  2019;26:e671–8. https://doi.org/10.1097/MJT.0000000000000883
  
324	Harrison   SL, Buckley   BJR, Ritchie   LA, Proietti   R, Underhill   P, Lane   DA, et al.   Oral anticoagulants and outcomes in adults >/=80 years with atrial fibrillation: a global federated health network analysis. J Am Geriatr Soc  2022;70:2386–92. https://doi.org/10.1111/jgs.17884
  
325	Malhotra   K, Ishfaq   MF, Goyal   N, Katsanos   AH, Parissis   J, Alexandrov   AW, et al.   Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis. Neurology  2019;92:e2421–31. https://doi.org/10.1212/WNL.0000000000007534
  
326	Steffel   J, Verhamme   P, Potpara   TS, Albaladejo   P, Antz   M, Desteghe   L, et al.   The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J  2018;39:1330–93. https://doi.org/10.1093/eurheartj/ehy136
  
327	Rhee   TM, Lee   SR, Choi   EK, Oh   S, Lip   GYH. Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis. Front Cardiovasc Med  2022;9:885548. https://doi.org/10.3389/fcvm.2022.885548
  
328	Reinecke   H, Engelbertz   C, Bauersachs   R, Breithardt   G, Echterhoff   HH, Gerß   J, et al.   A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation  2023;147:296–309. https://doi.org/10.1161/CIRCULATIONAHA.122.062779
  
329	Pokorney   SD, Chertow   GM, Al-Khalidi   HR, Gallup   D, Dignacco   P, Mussina   K, et al.   Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation  2022;146:1735–45. https://doi.org/10.1161/CIRCULATIONAHA.121.054990
  
330	De Vriese   AS, Caluwé   R, Van Der Meersch   H, De Boeck   K, De Bacquer   D. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol  2021;32:1474–83. https://doi.org/10.1681/ASN.2020111566
  
331	Eikelboom   JW, Connolly   SJ, Brueckmann   M, Granger   CB, Kappetein   AP, Mack   MJ, et al.   Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med  2013;369:1206–14. https://doi.org/10.1056/NEJMoa1300615
  
332	Wang   TY, Svensson   LG, Wen   J, Vekstein   A, Gerdisch   M, Rao   VU, et al.   Apixaban or warfarin in patients with an on-X mechanical aortic valve. NEJM Evid  2023;2:EVIDoa2300067. https://doi.org/10.1056/EVIDoa2300067
Google ScholarWorldCat 
333	Guimarães   HP, Lopes   RD, de Barros   ESPGM, Liporace   IL, Sampaio   RO, Tarasoutchi   F, et al.   Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med  2020;383:2117–26. https://doi.org/10.1056/NEJMoa2029603
  
334	Collet   JP, Van Belle   E, Thiele   H, Berti   S, Lhermusier   T, Manigold   T, et al.   Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J  2022;43:2783–97. https://doi.org/10.1093/eurheartj/ehac242
  
335	Steffel   J, Collins   R, Antz   M, Cornu   P, Desteghe   L, Haeusler   KG, et al.   2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace  2021;23:1612–76. https://doi.org/10.1093/europace/euab065
  
336	Grymonprez   M, Carnoy   L, Capiau   A, Boussery   K, Mehuys   E, De Backer   TL, et al.   Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother  2023;9:722–30. https://doi.org/10.1093/ehjcvp/pvad070
  
337	Testa   S, Legnani   C, Antonucci   E, Paoletti   O, Dellanoce   C, Cosmi   B, et al.   Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost  2019;17:1064–72. https://doi.org/10.1111/jth.14457
  
338	Suwa   M, Nohara   Y, Morii   I, Kino   M. Safety and efficacy re-evaluation of edoxaban and rivaroxaban dosing with plasma concentration monitoring in non-valvular atrial fibrillation: with observations of on-label and off-label dosing. Circ Rep  2023;5:80–9. https://doi.org/10.1253/circrep.CR-22-0076
  
339	Song   D, Zhou   J, Fan   T, Chang   J, Qiu   Y, Zhuang   Z, et al.   Decision aids for shared decision-making and appropriate anticoagulation therapy in patients with atrial fibrillation: a systematic review and meta-analysis. Eur J Cardiovasc Nurs  2022;21:97–106. https://doi.org/10.1093/eurjcn/zvab085
  
340	Vora   P, Morgan Stewart   H, Russell   B, Asiimwe   A, Brobert   G. Time trends and treatment pathways in prescribing individual oral anticoagulants in patients with nonvalvular atrial fibrillation: an observational study of more than three million patients from Europe and the United States. Int J Clin Pract  2022;2022:6707985. https://doi.org/10.1155/2022/6707985
Google ScholarPubMedWorldCat 
341	Grymonprez   M, Simoens   C, Steurbaut   S, De Backer   TL, Lahousse   L. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. Europace  2022;24:887–98. https://doi.org/10.1093/europace/euab303
  
342	De Caterina   R, Husted   S, Wallentin   L, Andreotti   F, Arnesen   H, Bachmann   F, et al.   Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC working group on thrombosis—task force on anticoagulants in heart disease. Thromb Haemost  2013;110:1087–107. https://doi.org/10.1160/TH13-06-0443
Google ScholarPubMedWorldCat 
343	Pandey   AK, Xu   K, Zhang   L, Gupta   S, Eikelboom   J, Cook   O, et al.   Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Thromb Haemost  2020;120:484–94. https://doi.org/10.1055/s-0039-3401823
Google ScholarPubMedWorldCat 
344	Sanders P, Svennberg E, Diederichsen SZ, Crijns HJGM, Lambiase PD, Boriani G, et al. Great debate: device-detected subclinical atrial fibrillation should be treated like clinical atrial fibrillation. Eur Heart J 2024:ehae365. https://doi.org/10.1093/eurheartj/ehae365
345	ACTIVE Investigators; Connolly   SJ, Pogue   J, Hart   RG, Hohnloser   SH, Pfeffer   Met al.   et al.   Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med  2009;360:2066–78. https://doi.org/10.1056/NEJMoa0901301
Google ScholarPubMedWorldCat 
346	Mant   J, Hobbs   FD, Fletcher   K, Roalfe   A, Fitzmaurice   D, Lip   GY, et al.   Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet  2007;370:493–503. https://doi.org/10.1016/S0140-6736(07)61233-1
  
347	Lip   GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol  2011;8:602–6. https://doi.org/10.1038/nrcardio.2011.112
  
348	ACTIVE Writing Group of the ACTIVE Investigators; Connolly   S, Pogue   J, Hart   R, Pfeffer   M, Hohnloser   S, et al.   Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet  2006;367:1903–12. https://doi.org/10.1016/S0140-6736(06)68845-4
Google ScholarPubMedWorldCat 
349	Fox   KAA, Velentgas   P, Camm   AJ, Bassand   JP, Fitzmaurice   DA, Gersh   BJ, et al.   Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation. JAMA Netw Open  2020;3:e200107. https://doi.org/10.1001/jamanetworkopen.2020.0107
  
350	Verheugt   FWA, Gao   H, Al Mahmeed   W, Ambrosio   G, Angchaisuksiri   P, Atar   D, et al.   Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur Heart J  2018;39:464–73. https://doi.org/10.1093/eurheartj/ehx730
  
351	Steffel   J, Eikelboom   JW, Anand   SS, Shestakovska   O, Yusuf   S, Fox   KAA. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation  2020;142:40–8. https://doi.org/10.1161/CIRCULATIONAHA.120.046048
  
352	Sharma   M, Hart   RG, Connolly   SJ, Bosch   J, Shestakovska   O, Ng   KKH, et al.   Stroke outcomes in the COMPASS trial. Circulation  2019;139:1134–45. https://doi.org/10.1161/CIRCULATIONAHA.118.035864
  
353	Yasuda   S, Kaikita   K, Akao   M, Ako   J, Matoba   T, Nakamura   M, et al.   Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med  2019;381:1103–13. https://doi.org/10.1056/NEJMoa1904143
  
354	Senoo   K, Lip   GY, Lane   DA, Büller   HR, Kotecha   D. Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation: AMADEUS trial. Stroke  2015;46:2523–8. https://doi.org/10.1161/STROKEAHA.115.009487
  
355	Meinel   TR, Branca   M, De Marchis   GM, Nedeltchev   K, Kahles   T, Bonati   L, et al.   Prior anticoagulation in patients with ischemic stroke and atrial fibrillation. Ann Neurol  2021;89:42–53. https://doi.org/10.1002/ana.25917
  
356	Polymeris   AA, Meinel   TR, Oehler   H, Hölscher   K, Zietz   A, Scheitz   JF, et al.   Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. J Neurol Neurosurg Psychiatry  2022;93:588–98. https://doi.org/10.1136/jnnp-2021-328391
  
357	Paciaroni   M, Agnelli   G, Caso   V, Silvestrelli   G, Seiffge   DJ, Engelter   S, et al.   Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention. Stroke  2019;50:2168–74. https://doi.org/10.1161/STROKEAHA.119.025350
  
358	Purrucker   JC, Hölscher   K, Kollmer   J, Ringleb   PA. Etiology of ischemic strokes of patients with atrial fibrillation and therapy with anticoagulants. J Clin Med  2020;9:2938. https://doi.org/10.3390/jcm9092938
  
359	Paciaroni   M, Caso   V, Agnelli   G, Mosconi   MG, Giustozzi   M, Seiffge   DJ, et al.   Recurrent ischemic stroke and bleeding in patients with atrial fibrillation who suffered an acute stroke while on treatment with nonvitamin K antagonist oral anticoagulants: the RENO-EXTEND study. Stroke  2022;53:2620–7. https://doi.org/10.1161/STROKEAHA.121.038239
  
360	Smits   E, Andreotti   F, Houben   E, Crijns   H, Haas   S, Spentzouris   G, et al.   Adherence and persistence with once-daily vs twice-daily direct oral anticoagulants among patients with atrial fibrillation: real-world analyses from The Netherlands, Italy and Germany. Drugs Real World Outcomes  2022;9:199–209. https://doi.org/10.1007/s40801-021-00289-w
  
361	Polymeris   AA, Zietz   A, Schaub   F, Meya   L, Traenka   C, Thilemann   S, et al.   Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation. Eur Stroke J  2022;7:221–9. https://doi.org/10.1177/23969873221099477
  
362	Glikson   M, Wolff   R, Hindricks   G, Mandrola   J, Camm   AJ, Lip   GYH, et al.   EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion—an update. Europace  2020;22:184. https://doi.org/10.1093/europace/euz258
  
363	Blackshear   JL, Odell   JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg  1996;61:755–9. https://doi.org/10.1016/0003-4975(95)00887-X
  
364	Reddy   VY, Doshi   SK, Kar   S, Gibson   DN, Price   MJ, Huber   K, et al.   5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol  2017;70:2964–75. https://doi.org/10.1016/j.jacc.2017.10.021
  
365	Lakkireddy   D, Thaler   D, Ellis   CR, Swarup   V, Sondergaard   L, Carroll   J, et al.   Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (amulet IDE): a randomized, controlled trial. Circulation  2021;144:1543–52. https://doi.org/10.1161/CIRCULATIONAHA.121.057063
  
366	Osmancik   P, Herman   D, Neuzil   P, Hala   P, Taborsky   M, Kala   P, et al.   Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol  2020;75:3122–35. https://doi.org/10.1016/j.jacc.2020.04.067
  
367	Osmancik   P, Herman   D, Neuzil   P, Hala   P, Taborsky   M, Kala   P, et al.   4-Year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J Am Coll Cardiol  2022;79:1–14. https://doi.org/10.1016/j.jacc.2021.10.023
  
368	Korsholm   K, Damgaard   D, Valentin   JB, Packer   EJS, Odenstedt   J, Sinisalo   J, et al.   Left atrial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial fibrillation: rationale and design of the multicenter randomized occlusion-AF trial. Am Heart J  2022;243:28–38. https://doi.org/10.1016/j.ahj.2021.08.020
  
369	Huijboom   M, Maarse   M, Aarnink   E, van Dijk   V, Swaans   M, van der Heijden   J, et al.   COMPARE LAAO: rationale and design of the randomized controlled trial “COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy”. Am Heart J  2022;250:45–56. https://doi.org/10.1016/j.ahj.2022.05.001
  
370	Freeman   JV, Higgins   AY, Wang   Y, Du   C, Friedman   DJ, Daimee   UA, et al.   Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation. J Am Coll Cardiol  2022;79:1785–98. https://doi.org/10.1016/j.jacc.2022.02.047
  
371	Patti   G, Sticchi   A, Verolino   G, Pasceri   V, Vizzi   V, Brscic   E, et al.   Safety and efficacy of single versus dual antiplatelet therapy after left atrial appendage occlusion. Am J Cardiol  2020;134:83–90. https://doi.org/10.1016/j.amjcard.2020.08.013
  
372	Boersma   LV, Schmidt   B, Betts   TR, Sievert   H, Tamburino   C, Teiger   E, et al.   Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J  2016;37:2465–74. https://doi.org/10.1093/eurheartj/ehv730
  
373	Garg   J, Shah   S, Shah   K, Turagam   MK, Tzou   W, Natale   A, et al.   Direct oral anticoagulant versus warfarin for watchman left atrial appendage occlusion—systematic review. JACC Clin Electrophysiol  2020;6:1735–7. https://doi.org/10.1016/j.jacep.2020.08.020
  
374	Osman   M, Busu   T, Osman   K, Khan   SU, Daniels   M, Holmes   DR, et al.   Short-term antiplatelet versus anticoagulant therapy after left atrial appendage occlusion: a systematic review and meta-analysis. JACC Clin Electrophysiol  2020;6:494–506. https://doi.org/10.1016/j.jacep.2019.11.009
  
375	Hildick-Smith   D, Landmesser   U, Camm   AJ, Diener   HC, Paul   V, Schmidt   B, et al.   Left atrial appendage occlusion with the Amplatzer Amulet device: full results of the prospective global observational study. Eur Heart J  2020;41:2894–901. https://doi.org/10.1093/eurheartj/ehaa169
  
376	Reddy   VY, Mobius-Winkler   S, Miller   MA, Neuzil   P, Schuler   G, Wiebe   J, et al.   Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol  2013;61:2551–6. https://doi.org/10.1016/j.jacc.2013.03.035
  
377	Sondergaard   L, Wong   YH, Reddy   VY, Boersma   LVA, Bergmann   MW, Doshi   S, et al.   Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with Watchman. JACC Cardiovasc Interv  2019;12:1055–63. https://doi.org/10.1016/j.jcin.2019.04.004
  
378	Flores-Umanzor   EJ, Cepas-Guillen   PL, Arzamendi   D, Cruz-Gonzalez   I, Regueiro   A, Freixa   X. Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study). J Interv Card Electrophysiol  2020;59:471–7. https://doi.org/10.1007/s10840-020-00884-x
  
379	Aminian   A, Schmidt   B, Mazzone   P, Berti   S, Fischer   S, Montorfano   M, et al.   Incidence, characterization, and clinical impact of device-related thrombus following left atrial appendage occlusion in the prospective global AMPLATZER amulet observational study. JACC Cardiovasc Interv  2019;12:1003–14. https://doi.org/10.1016/j.jcin.2019.02.003
  
380	Kany   S, Metzner   A, Lubos   E, Kirchhof   P. The atrial fibrillation heart team-guiding therapy in left atrial appendage occlusion with increasingly complex patients and little evidence. Eur Heart J  2022;43:1691–2. https://doi.org/10.1093/eurheartj/ehab744
  
381	Saw   J, Holmes   DR, Cavalcante   JL, Freeman   JV, Goldsweig   AM, Kavinsky   CJ, et al.   SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. Heart Rhythm  2023;20:e1–16. https://doi.org/10.1016/j.hrthm.2023.01.007
  
382	Cruz-González   I, González-Ferreiro   R, Freixa   X, Gafoor   S, Shakir   S, Omran   H, et al.   Left atrial appendage occlusion for stroke despite oral anticoagulation (resistant stroke). Results from the Amplatzer Cardiac Plug registry. Rev Esp Cardiol (Engl Ed)  2020;73:28–34. https://doi.org/10.1016/j.rec.2019.02.013
  
383	Willits   I, Keltie   K, Linker   N, de Belder   M, Henderson   R, Patrick   H, et al.   Left atrial appendage occlusion in the UK: prospective registry and data linkage to hospital episode statistics. Eur Heart J Qual Care Clin Outcomes  2021;7:468–75. https://doi.org/10.1093/ehjqcco/qcab042
  
384	Price   MJ, Valderrabano   M, Zimmerman   S, Friedman   DJ, Kar   S, Curtis   JP, et al.   Periprocedural pericardial effusion complicating transcatheter left atrial appendage occlusion: a report from the NCDR LAAO registry. Circ Cardiovasc Interv  2022;15:e011718. https://doi.org/10.1161/CIRCINTERVENTIONS.121.011718
  
385	Aminian   A, De Backer   O, Nielsen-Kudsk   JE, Mazzone   P, Berti   S, Fischer   S, et al.   Incidence and clinical impact of major bleeding following left atrial appendage occlusion: insights from the amplatzer amulet observational post-market study. EuroIntervention  2021;17:774–82. https://doi.org/10.4244/EIJ-D-20-01309
  
386	Boersma   LV, Ince   H, Kische   S, Pokushalov   E, Schmitz   T, Schmidt   B, et al.   Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2–year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage. Circ Arrhythm Electrophysiol  2019;12:e006841. https://doi.org/10.1161/CIRCEP.118.006841
  
387	Tzikas   A, Shakir   S, Gafoor   S, Omran   H, Berti   S, Santoro   G, et al.   Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. EuroIntervention  2016;11:1170–9. https://doi.org/10.4244/EIJY15M01_06
  
388	Nazir   S, Ahuja   KR, Kolte   D, Isogai   T, Michihata   N, Saad   AM, et al.   Association of hospital procedural volume with outcomes of percutaneous left atrial appendage occlusion. JACC Cardiovasc Interv  2021;14:554–61. https://doi.org/10.1016/j.jcin.2020.11.029
  
389	Freeman   JV, Varosy   P, Price   MJ, Slotwiner   D, Kusumoto   FM, Rammohan   C, et al.   The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol  2020;75:1503–18. https://doi.org/10.1016/j.jacc.2019.12.040
  
390	Cruz-Gonzalez   I, Korsholm   K, Trejo-Velasco   B, Thambo   JB, Mazzone   P, Rioufol   G, et al.   Procedural and short-term results with the new watchman FLX left atrial appendage occlusion device. JACC Cardiovasc Interv  2020;13:2732–41. https://doi.org/10.1016/j.jcin.2020.06.056
  
391	Simard   T, Jung   RG, Lehenbauer   K, Piayda   K, Pracon   R, Jackson   GG, et al.   Predictors of device-related thrombus following percutaneous left atrial appendage occlusion. J Am Coll Cardiol  2021;78:297–313. https://doi.org/10.1016/j.jacc.2021.04.098
  
392	Simard   TJ, Hibbert   B, Alkhouli   MA, Abraham   NS, Holmes   DR, Jr. Device-related thrombus following left atrial appendage occlusion. EuroIntervention  2022;18:224–32. https://doi.org/10.4244/EIJ-D-21-01010
  
393	Lempereur   M, Aminian   A, Freixa   X, Gafoor   S, Kefer   J, Tzikas   A, et al.   Device-associated thrombus formation after left atrial appendage occlusion: a systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheter Cardiovasc Interv  2017;90:E111–21. https://doi.org/10.1002/ccd.26903
  
394	Saw   J, Tzikas   A, Shakir   S, Gafoor   S, Omran   H, Nielsen-Kudsk   JE, et al.   Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the amplatzer cardiac plug. JACC Cardiovasc Interv  2017;10:391–9. https://doi.org/10.1016/j.jcin.2016.11.029
  
395	Fauchier   L, Cinaud   A, Brigadeau   F, Lepillier   A, Pierre   B, Abbey   S, et al.   Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol  2018;71:1528–36. https://doi.org/10.1016/j.jacc.2018.01.076
  
396	Dukkipati   SR, Kar   S, Holmes   DR, Doshi   SK, Swarup   V, Gibson   DN, et al.   Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation  2018;138:874–85. https://doi.org/10.1161/CIRCULATIONAHA.118.035090
  
397	Kar   S, Doshi   SK, Sadhu   A, Horton   R, Osorio   J, Ellis   C, et al.   Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation  2021;143:1754–62. https://doi.org/10.1161/CIRCULATIONAHA.120.050117
  
398	Alkhouli   M, Du   C, Killu   A, Simard   T, Noseworthy   PA, Friedman   PA, et al.   Clinical impact of residual leaks following left atrial appendage occlusion: insights from the NCDR LAAO registry. JACC Clin Electrophysiol  2022;8:766–78. https://doi.org/10.1016/j.jacep.2022.03.001
  
399	Tsai   YC, Phan   K, Munkholm-Larsen   S, Tian   DH, La Meir   M, Yan   TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. Eur J Cardiothorac Surg  2015;47:847–54. https://doi.org/10.1093/ejcts/ezu291
  
400	Whitlock   RP, Vincent   J, Blackall   MH, Hirsh   J, Fremes   S, Novick   R, et al.   Left atrial appendage occlusion study II (LAAOS II). Can J Cardiol  2013;29:1443–7. https://doi.org/10.1016/j.cjca.2013.06.015
  
401	Whitlock   RP, Belley-Cote   EP, Paparella   D, Healey   JS, Brady   K, Sharma   M, et al.   Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med  2021;384:2081–91. https://doi.org/10.1056/NEJMoa2101897
  
402	Zhang   S, Cui   Y, Li   J, Tian   H, Yun   Y, Zhou   X, et al.   Concomitant transcatheter occlusion versus thoracoscopic surgical clipping for left atrial appendage in patients undergoing ablation for atrial fibrillation: a meta-analysis. Front Cardiovasc Med  2022;9:970847. https://doi.org/10.3389/fcvm.2022.970847
  
403	van Laar   C, Verberkmoes   NJ, van Es   HW, Lewalter   T, Dunnington   G, Stark   S, et al.   Thoracoscopic left atrial appendage clipping: a multicenter cohort analysis. JACC Clin Electrophysiol  2018;4:893–901. https://doi.org/10.1016/j.jacep.2018.03.009
  
404	Kiviniemi   T, Bustamante-Munguira   J, Olsson   C, Jeppsson   A, Halfwerk   FR, Hartikainen   J, et al.   A randomized prospective multicenter trial for stroke prevention by prophylactic surgical closure of the left atrial appendage in patients undergoing bioprosthetic aortic valve surgery–LAA-CLOSURE trial protocol. Am Heart J  2021;237:127–34. https://doi.org/10.1016/j.ahj.2021.03.014
  
405	Cartledge   R, Suwalski   G, Witkowska   A, Gottlieb   G, Cioci   A, Chidiac   G, et al.   Standalone epicardial left atrial appendage exclusion for thromboembolism prevention in atrial fibrillation. Interact Cardiovasc Thorac Surg  2022;34:548–55. https://doi.org/10.1093/icvts/ivab334
  
406	Branzoli   S, Guarracini   F, Marini   M, D’Onghia   G, Penzo   D, Piffer   S, et al.   Heart team for left atrial appendage occlusion: a patient-tailored approach. J Clin Med  2022;11:176. https://doi.org/10.3390/jcm11010176
  
407	Toale   C, Fitzmaurice   GJ, Eaton   D, Lyne   J, Redmond   KC. Outcomes of left atrial appendage occlusion using the AtriClip device: a systematic review. Interact Cardiovasc Thorac Surg  2019;29:655–62. https://doi.org/10.1093/icvts/ivz156
  
408	Caliskan   E, Sahin   A, Yilmaz   M, Seifert   B, Hinzpeter   R, Alkadhi   H, et al.   Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. Europace  2018;20:e105–14. https://doi.org/10.1093/europace/eux211
  
409	Nso   N, Nassar   M, Zirkiyeva   M, Lakhdar   S, Shaukat   T, Guzman   L, et al.   Outcomes of cardiac surgery with left atrial appendage occlusion versus no occlusion, direct oral anticoagulants, and vitamin K antagonists: a systematic review with meta-analysis. Int J Cardiol Heart Vasc  2022;40:100998. https://doi.org/10.1016/j.ijcha.2022.100998
Google ScholarPubMedWorldCat 
410	Ibrahim   AM, Tandan   N, Koester   C, Al-Akchar   M, Bhandari   B, Botchway   A, et al.   Meta-analysis evaluating outcomes of surgical left atrial appendage occlusion during cardiac surgery. Am J Cardiol  2019;124:1218–25. https://doi.org/10.1016/j.amjcard.2019.07.032
  
411	Park-Hansen   J, Holme   SJV, Irmukhamedov   A, Carranza   CL, Greve   AM, Al-Farra   G, et al.   Adding left atrial appendage closure to open heart surgery provides protection from ischemic brain injury six years after surgery independently of atrial fibrillation history: the LAACS randomized study. J Cardiothorac Surg  2018;13:53. https://doi.org/10.1186/s13019-018-0740-7
  
412	Soltesz   EG, Dewan   KC, Anderson   LH, Ferguson   MA, Gillinov   AM. Improved outcomes in CABG patients with atrial fibrillation associated with surgical left atrial appendage exclusion. J Card Surg  2021;36:1201–8. https://doi.org/10.1111/jocs.15335
  
413	Fu   M, Qin   Z, Zheng   S, Li   Y, Yang   S, Zhao   Y, et al.   Thoracoscopic left atrial appendage occlusion for stroke prevention compared with long-term warfarin therapy in patients with nonvalvular atrial fibrillation. Am J Cardiol  2019;123:50–6. https://doi.org/10.1016/j.amjcard.2018.09.025
  
414	Peterson   D, Geison   E. Pharmacist interventions to reduce modifiable bleeding risk factors using HAS-BLED in patients taking warfarin. Fed Pract  2017;34:S16–20.
Google ScholarPubMedWorldCat 
415	Chao   TF, Lip   GYH, Lin   YJ, Chang   SL, Lo   LW, Hu   YF, et al.   Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and Delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost  2018;47:768–77. https://doi.org/10.1055/s-0038-1636534
  
416	Linkins   LA, Choi   PT, Douketis   JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med  2003;139:893–900. https://doi.org/10.7326/0003-4819-139-11-200312020-00007
  
417	Kirchhof   P, Haas   S, Amarenco   P, Hess   S, Lambelet   M, van Eickels   M, et al.   Impact of modifiable bleeding risk factors on major bleeding in patients with atrial fibrillation anticoagulated with rivaroxaban. J Am Heart Assoc  2020;9:e009530. https://doi.org/10.1161/JAHA.118.009530
  
418	Guo   Y, Lane   DA, Chen   Y, Lip   GYH; mAF-App II Trial investigators. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial. Am J Med  2020;133:1195–1202.e2. https://doi.org/10.1016/j.amjmed.2020.03.019
  
419	Lane   DA, Lip   GYH. Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. Eur Heart J Suppl  2020;22:O14–27. https://doi.org/10.1093/eurheartj/suaa178
  
420	Lip   GYH, Lane   DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost  2016;14:1711–4. https://doi.org/10.1111/jth.13386
  
421	Gorog   DA, Gue   YX, Chao   TF, Fauchier   L, Ferreiro   JL, Huber   K, et al.   Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: a position paper from the ESC working group on thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace  2022;24:1844–71. https://doi.org/10.1093/europace/euac020
  
422	Nelson   WW, Laliberté   F, Patel   AA, Germain   G, Pilon   D, McCormick   N, et al.   Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. Curr Med Res Opin  2017;33:631–8. https://doi.org/10.1080/03007995.2016.1275936
  
423	Hijazi   Z, Lindbäck   J, Oldgren   J, Benz   AP, Alexander   JH, Connolly   SJ, et al.   Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. Am Heart J  2023;261:55–63. https://doi.org/10.1016/j.ahj.2023.03.012
  
424	Hijazi   Z, Lindbäck   J, Alexander   JH, Hanna   M, Held   C, Hylek   EM, et al.   The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J  2016;37:1582–90. https://doi.org/10.1093/eurheartj/ehw054
  
425	Gao   X, Cai   X, Yang   Y, Zhou   Y, Zhu   W. Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med  2021;8:757087. https://doi.org/10.3389/fcvm.2021.757087
  
426	Zhu   W, He   W, Guo   L, Wang   X, Hong   K. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol  2015;38:555–61. https://doi.org/10.1002/clc.22435
  
427	Caldeira   D, Costa   J, Fernandes   RM, Pinto   FJ, Ferreira   JJ. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol  2014;40:277–84. https://doi.org/10.1007/s10840-014-9930-y
  
428	Zeng   J, Yu   P, Cui   W, Wang   X, Ma   J, Zeng   C. Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: a PRISMA-compliant article. Medicine (Baltimore)  2020;99:e20782. https://doi.org/10.1097/MD.0000000000020782
  
429	Wang   C, Yu   Y, Zhu   W, Yu   J, Lip   GYH, Hong   K. Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget  2017;8:109703–11. https://doi.org/10.18632/oncotarget.19858
  
430	Loewen   P, Dahri   K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol  2011;90:1191–200. https://doi.org/10.1007/s00277-011-1267-3
  
431	Hilkens   NA, Algra   A, Greving   JP. Predicting major bleeding in ischemic stroke patients with atrial fibrillation. Stroke  2017;48:3142–4. https://doi.org/10.1161/STROKEAHA.117.019183
  
432	Dalgaard   F, Pieper   K, Verheugt   F, Camm   AJ, Fox   KA, Kakkar   AK, et al.   GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. BMJ Open  2019;9:e033283. https://doi.org/10.1136/bmjopen-2019-033283
  
433	Mori   N, Sotomi   Y, Hirata   A, Hirayama   A, Sakata   Y, Higuchi   Y. External validation of the ORBIT bleeding score and the HAS-BLED score in nonvalvular atrial fibrillation patients using direct oral anticoagulants (Asian Data from the DIRECT Registry). Am J Cardiol  2019;124:1044–8. https://doi.org/10.1016/j.amjcard.2019.07.005
  
434	Yao   X, Gersh   BJ, Sangaralingham   LR, Kent   DM, Shah   ND, Abraham   NS, et al.   Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. Am J Cardiol  2017;120:1549–56. https://doi.org/10.1016/j.amjcard.2017.07.051
  
435	Giustozzi   M, Proietti   G, Becattini   C, Roila   F, Agnelli   G, Mandalà   M. ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv  2022;6:4873–83. https://doi.org/10.1182/bloodadvances.2022008086
  
436	Shoamanesh   A. Anticoagulation in patients with cerebral amyloid angiopathy. Lancet  2023;402:1418–9. https://doi.org/10.1016/S0140-6736(23)02025-1
  
437	Kurlander   JE, Barnes   GD, Fisher   A, Gonzalez   JJ, Helminski   D, Saini   SD, et al.   Association of antisecretory drugs with upper gastrointestinal bleeding in patients using oral anticoagulants: a systematic review and meta-analysis. Am J Med  2022;135:1231–1243.e8. https://doi.org/10.1016/j.amjmed.2022.05.031
  
438	Moayyedi   P, Eikelboom   JW, Bosch   J, Connolly   SJ, Dyal   L, Shestakovska   O, et al.   Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology  2019;157:403–412.e5. https://doi.org/10.1053/j.gastro.2019.04.041
  
439	DiMarco   JP, Flaker   G, Waldo   AL, Corley   SD, Greene   HL, Safford   RE, et al.   Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J  2005;149:650–6. https://doi.org/10.1016/j.ahj.2004.11.015
  
440	Harskamp   RE, Lucassen   WAM, Lopes   RD, Himmelreich   JCL, Parati   G, Weert   H. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiol  2022;77:191–5. https://doi.org/10.1080/00015385.2021.1882111
  
441	Schulman   S, Beyth   RJ, Kearon   C, Levine   MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest  2008;133:257s–98s. https://doi.org/10.1378/chest.08-0674
  
442	Gallego   P, Roldán   V, Torregrosa   JM, Gálvez   J, Valdés   M, Vicente   V, et al.   Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol  2012;5:312–8. https://doi.org/10.1161/CIRCEP.111.967000
  
443	Bouillon   K, Bertrand   M, Boudali   L, Ducimetière   P, Dray-Spira   R, Zureik   M. Short-term risk of bleeding during heparin bridging at initiation of vitamin K antagonist therapy in more than 90 000 patients with nonvalvular atrial fibrillation managed in outpatient care. J Am Heart Assoc  2016;5:e004065. https://doi.org/10.1161/JAHA.116.004065
  
444	White   HD, Gruber   M, Feyzi   J, Kaatz   S, Tse   HF, Husted   S, et al.   Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med  2007;167:239–45. https://doi.org/10.1001/archinte.167.3.239
  
445	January   CT, Wann   LS, Alpert   JS, Calkins   H, Cigarroa   JE, Cleveland   JC, Jr, et al.   2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation  2014;130:2071–104. https://doi.org/10.1161/CIR.0000000000000040
  
446	Olesen   JB, Lip   GY, Lindhardsen   J, Lane   DA, Ahlehoff   O, Hansen   ML, et al.   Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost  2011;106:739–49. https://doi.org/10.1160/TH11-05-0364
Google ScholarPubMedWorldCat 
447	Tomaselli   GF, Mahaffey   KW, Cuker   A, Dobesh   PP, Doherty   JU, Eikelboom   JW, et al.   2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol  2020;76:594–622. https://doi.org/10.1016/j.jacc.2020.04.053
  
448	Cuker   A. Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis  2016;41:241–7. https://doi.org/10.1007/s11239-015-1282-7
  
449	Douxfils   J, Ageno   W, Samama   CM, Lessire   S, Ten Cate   H, Verhamme   P, et al.   Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost  2018;16:209–19. https://doi.org/10.1111/jth.13912
  
450	Milling   TJ, Jr, Refaai   MA, Sarode   R, Lewis   B, Mangione   A, Durn   BL, et al.   Safety of a four-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal: an integrated analysis of two phase IIIb clinical trials. Acad Emerg Med  2016;23:466–75. https://doi.org/10.1111/acem.12911
  
451	Pollack   CV, Jr, Reilly   PA, van Ryn   J, Eikelboom   JW, Glund   S, Bernstein   RA, et al.   Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med  2017;377:431–41. https://doi.org/10.1056/NEJMoa1707278
  
452	Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, et al. ANNEXA–I investigators. Andexanet for factor Xa inhibitor–associated acute intracerebral hemorrhage. N Engl J Med 2024;390:1745–55. https://doi.org/10.1056/NEJMoa2313040
453	Milioglou   I, Farmakis   I, Neudeker   M, Hussain   Z, Guha   A, Giannakoulas   G, et al.   Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis. J Thromb Thrombolysis  2021;52:1137–50. https://doi.org/10.1007/s11239-021-02480-w
  
454	Meyre   PB, Blum   S, Hennings   E, Aeschbacher   S, Reichlin   T, Rodondi   N, et al.   Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing. Eur Heart J  2022;43:4899–908. https://doi.org/10.1093/eurheartj/ehac587
  
455	Connolly   SJ, Crowther   M, Eikelboom   JW, Gibson   CM, Curnutte   JT, Lawrence   JH, et al.   Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med  2019;380:1326–35. https://doi.org/10.1056/NEJMoa1814051
  
456	Fanikos   J, Murwin   D, Gruenenfelder   F, Tartakovsky   I, França   LR, Reilly   PA, et al.   Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program. Thromb Haemost  2020;120:27–35. https://doi.org/10.1055/s-0039-1695771
Google ScholarPubMedWorldCat 
457	Kotecha   D, Calvert   M, Deeks   JJ, Griffith   M, Kirchhof   P, Lip   GY, et al.   A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ Open  2017;7:e015099. https://doi.org/10.1136/bmjopen-2016-015099
  
458	Hess   PL, Sheng   S, Matsouaka   R, DeVore   AD, Heidenreich   PA, Yancy   CW, et al.   Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the get with the guidelines—heart failure program). Am J Cardiol  2020;125:894–900. https://doi.org/10.1016/j.amjcard.2019.12.025
  
459	Van Gelder   IC, Groenveld   HF, Crijns   HJ, Tuininga   YS, Tijssen   JG, Alings   AM, et al.   Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med  2010;362:1363–73. https://doi.org/10.1056/NEJMoa1001337
  
460	Olshansky   B, Rosenfeld   LE, Warner   AL, Solomon   AJ, O’Neill   G, Sharma   A, et al.   The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol  2004;43:1201–8. https://doi.org/10.1016/j.jacc.2003.11.032
  
461	Ulimoen   SR, Enger   S, Carlson   J, Platonov   PG, Pripp   AH, Abdelnoor   M, et al.   Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol  2013;111:225–30. https://doi.org/10.1016/j.amjcard.2012.09.020
  
462	Tisdale   JE, Padhi   ID, Goldberg   AD, Silverman   NA, Webb   CR, Higgins   RS, et al.   A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. Am Heart J  1998;135:739–47. https://doi.org/10.1016/S0002-8703(98)70031-6
  
463	Khand   AU, Rankin   AC, Martin   W, Taylor   J, Gemmell   I, Cleland   JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?  J Am Coll Cardiol  2003;42:1944–51. https://doi.org/10.1016/j.jacc.2003.07.020
  
464	Nikolaidou   T, Channer   KS. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J  2009;85:303–12. https://doi.org/10.1136/pgmj.2008.068908
  
465	Figulla   HR, Gietzen   F, Zeymer   U, Raiber   M, Hegselmann   J, Soballa   R, et al.   Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation  1996;94:346–52. https://doi.org/10.1161/01.CIR.94.3.346
  
466	Andrade   JG, Roy   D, Wyse   DG, Tardif   JC, Talajic   M, Leduc   H, et al.   Heart rate and adverse outcomes in patients with atrial fibrillation: a combined AFFIRM and AF-CHF substudy. Heart Rhythm  2016;13:54–61. https://doi.org/10.1016/j.hrthm.2015.08.028
  
467	Weerasooriya   R, Davis   M, Powell   A, Szili-Torok   T, Shah   C, Whalley   D, et al.   The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol  2003;41:1697–702. https://doi.org/10.1016/S0735-1097(03)00338-3
  
468	Lim   KT, Davis   MJ, Powell   A, Arnolda   L, Moulden   K, Bulsara   M, et al.   Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. Europace  2007;9:498–505. https://doi.org/10.1093/europace/eum091
  
469	Vijayaraman   P, Subzposh   FA, Naperkowski   A. Atrioventricular node ablation and His bundle pacing. Europace  2017;19:iv10–6. https://doi.org/10.1093/europace/eux263
  
470	Brignole   M, Pokushalov   E, Pentimalli   F, Palmisano   P, Chieffo   E, Occhetta   E, et al.   A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J  2018;39:3999–4008. https://doi.org/10.1093/eurheartj/ehy555
  
471	Brignole   M, Pentimalli   F, Palmisano   P, Landolina   M, Quartieri   F, Occhetta   E, et al.   AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J  2021;42:4731–9. https://doi.org/10.1093/eurheartj/ehab569
  
472	Delle Karth   G, Geppert   A, Neunteufl   T, Priglinger   U, Haumer   M, Gschwandtner   M, et al.   Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med  2001;29:1149–53. https://doi.org/10.1097/00003246-200106000-00011
  
473	Hou   ZY, Chang   MS, Chen   CY, Tu   MS, Lin   SL, Chiang   HT, et al.   Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J  1995;16:521–8. https://doi.org/10.1093/oxfordjournals.eurheartj.a060945
  
474	Van Gelder   IC, Wyse   DG, Chandler   ML, Cooper   HA, Olshansky   B, Hagens   VE, et al.   Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace  2006;8:935–42. https://doi.org/10.1093/europace/eul106
  
475	Scheuermeyer   FX, Grafstein   E, Stenstrom   R, Christenson   J, Heslop   C, Heilbron   B, et al.   Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med  2013;20:222–30. https://doi.org/10.1111/acem.12091
  
476	Siu   CW, Lau   CP, Lee   WL, Lam   KF, Tse   HF. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med  2009;37:2174–9, quiz 2180. https://doi.org/10.1097/CCM.0b013e3181a02f56
  
477	Perrett   M, Gohil   N, Tica   O, Bunting   KV, Kotecha   D. Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trials. Clin Res Cardiol  2023;113:831–41. https://doi.org/10.1007/s00392-023-02295-0
Google ScholarWorldCat 
478	Darby   AE, Dimarco   JP. Management of atrial fibrillation in patients with structural heart disease. Circulation  2012;125:945–57. https://doi.org/10.1161/CIRCULATIONAHA.111.019935
  
479	Imamura   T, Kinugawa   K. Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation. ESC Heart Fail  2020;7:2208–13. https://doi.org/10.1002/ehf2.12879
  
480	Ulimoen   SR, Enger   S, Pripp   AH, Abdelnoor   M, Arnesen   H, Gjesdal   K, et al.   Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J  2014;35:517–24. https://doi.org/10.1093/eurheartj/eht429
  
481	Connolly   SJ, Camm   AJ, Halperin   JL, Joyner   C, Alings   M, Amerena   J, et al.   Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med  2011;365:2268–76. https://doi.org/10.1056/NEJMoa1109867
  
482	Karwath A, Bunting KV, Gill SK, Tica O, Pendleton S, Aziz F, et al. Redefining betablocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. Lancet 2021;398:1427–35. https://doi.org/10.1016/S0140-6736(21)01638-X
483	Koldenhof   T, Wijtvliet   P, Pluymaekers   N, Rienstra   M, Folkeringa   RJ, Bronzwaer   P, et al.   Rate control drugs differ in the prevention of progression of atrial fibrillation. Europace  2022;24:384–9. https://doi.org/10.1093/europace/euab191
  
484	Champsi   A, Mitchell   C, Tica   O, Ziff   OJ, Bunting   KV, Mobley   AR, et al.  Digoxin in patients with heart failure and/or atrial fibrillation: a systematic review and meta-analysis of 5.9 million patient years of follow-up. SSRN preprint. 2023. https://doi.org/10.2139/ssrn.4544769.
485	Andrews   P, Anseeuw   K, Kotecha   D, Lapostolle   F, Thanacoody   R. Diagnosis and practical management of digoxin toxicity: a narrative review and consensus. Eur J Emerg Med  2023;30:395–401. https://doi.org/10.1097/MEJ.0000000000001065
Google ScholarPubMedWorldCat 
486	Bavendiek   U, Berliner   D, Dávila   LA, Schwab   J, Maier   L, Philipp   SA, et al.   Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. Eur J Heart Fail  2019;21:676–84. https://doi.org/10.1002/ejhf.1452
  
487	Clemo   HF, Wood   MA, Gilligan   DM, Ellenbogen   KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol  1998;81:594–8. https://doi.org/10.1016/S0002-9149(97)00962-4
  
488	Queiroga   A, Marshall   HJ, Clune   M, Gammage   MD. Ablate and pace revisited: long term survival and predictors of permanent atrial fibrillation. Heart  2003;89:1035–8. https://doi.org/10.1136/heart.89.9.1035
  
489	Geelen   P, Brugada   J, Andries   E, Brugada   P. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol  1997;20:343–8. https://doi.org/10.1111/j.1540-8159.1997.tb06179.x
  
490	Wang   RX, Lee   HC, Hodge   DO, Cha   YM, Friedman   PA, Rea   RF, et al.   Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation. Heart Rhythm  2013;10:696–701. https://doi.org/10.1016/j.hrthm.2013.01.021
  
491	Chatterjee   NA, Upadhyay   GA, Ellenbogen   KA, McAlister   FA, Choudhry   NK, Singh   JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol  2012;5:68–76. https://doi.org/10.1161/CIRCEP.111.967810
  
492	Bradley   DJ, Shen   WK. Overview of management of atrial fibrillation in symptomatic elderly patients: pharmacologic therapy versus AV node ablation. Clin Pharmacol Ther  2007;81:284–7. https://doi.org/10.1038/sj.clpt.6100062
  
493	Ozcan   C, Jahangir   A, Friedman   PA, Patel   PJ, Munger   TM, Rea   RF, et al.   Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med  2001;344:1043–51. https://doi.org/10.1056/NEJM200104053441403
  
494	Chatterjee   NA, Upadhyay   GA, Ellenbogen   KA, Hayes   DL, Singh   JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode. Eur J Heart Fail  2012;14:661–7. https://doi.org/10.1093/eurjhf/hfs036
  
495	Huang   W, Su   L, Wu   S. Pacing treatment of atrial fibrillation patients with heart failure: His bundle pacing combined with atrioventricular node ablation. Card Electrophysiol Clin  2018;10:519–35. https://doi.org/10.1016/j.ccep.2018.05.016
  
496	Huang   W, Su   L, Wu   S, Xu   L, Xiao   F, Zhou   X, et al.   Benefits of permanent His bundle pacing combined with atrioventricular node ablation in atrial fibrillation patients with heart failure with both preserved and reduced left ventricular ejection fraction. J Am Heart Assoc  2017;6:e005309. https://doi.org/10.1161/JAHA.116.005309
  
497	Van Gelder   IC, Hagens   VE, Bosker   HA, Kingma   JH, Kamp   O, Kingma   T, et al.   A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med  2002;347:1834–40. https://doi.org/10.1056/NEJMoa021375
  
498	Wyse   DG, Waldo   AL, DiMarco   JP, Domanski   MJ, Rosenberg   Y, Schron   EB, et al.   A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med  2002;347:1825–33. https://doi.org/10.1056/NEJMoa021328
Google ScholarPubMedWorldCat 
499	Hohnloser   SH, Kuck   KH, Lilienthal   J. Rhythm or rate control in atrial fibrillation—pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet  2000;356:1789–94. https://doi.org/10.1016/S0140-6736(00)03230-X
  
500	Roy   D, Talajic   M, Nattel   S, Wyse   DG, Dorian   P, Lee   KL, et al.   Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med  2008;358:2667–77. https://doi.org/10.1056/NEJMoa0708789
  
501	Blomström-Lundqvist   C, Gizurarson   S, Schwieler   J, Jensen   SM, Bergfeldt   L, Kennebäck   G, et al.   Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA  2019;321:1059–68. https://doi.org/10.1001/jama.2019.0335
  
502	Mark   DB, Anstrom   KJ, Sheng   S, Piccini   JP, Baloch   KN, Monahan   KH, et al.   Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA  2019;321:1275–85. https://doi.org/10.1001/jama.2019.0692
  
503	Wilber   DJ, Pappone   C, Neuzil   P, De Paola   A, Marchlinski   F, Natale   A, et al.   Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA  2010;303:333–40. https://doi.org/10.1001/jama.2009.2029
  
504	Calkins   H, Reynolds   MR, Spector   P, Sondhi   M, Xu   Y, Martin   A, et al.   Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol  2009;2:349–61. https://doi.org/10.1161/CIRCEP.108.824789
  
505	Jais   P, Cauchemez   B, Macle   L, Daoud   E, Khairy   P, Subbiah   R, et al.   Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation  2008;118:2498–505. https://doi.org/10.1161/CIRCULATIONAHA.108.772582
  
506	Packer   DL, Kowal   RC, Wheelan   KR, Irwin   JM, Champagne   J, Guerra   PG, et al.   Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol  2013;61:1713–23. https://doi.org/10.1016/j.jacc.2012.11.064
  
507	Poole   JE, Bahnson   TD, Monahan   KH, Johnson   G, Rostami   H, Silverstein   AP, et al.   Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA trial. J Am Coll Cardiol  2020;75:3105–18. https://doi.org/10.1016/j.jacc.2020.04.065
  
508	Mont   L, Bisbal   F, Hernandez-Madrid   A, Perez-Castellano   N, Vinolas   X, Arenal   A, et al.   Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J  2014;35:501–7. https://doi.org/10.1093/eurheartj/eht457
  
509	Scherr   D, Khairy   P, Miyazaki   S, Aurillac-Lavignolle   V, Pascale   P, Wilton   SB, et al.   Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol  2015;8:18–24. https://doi.org/10.1161/CIRCEP.114.001943
  
510	Lau   DH, Nattel   S, Kalman   JM, Sanders   P. Modifiable risk factors and atrial fibrillation. Circulation  2017;136:583–96. https://doi.org/10.1161/CIRCULATIONAHA.116.023163
  
511	Sanders   P, Elliott   AD, Linz   D. Upstream targets to treat atrial fibrillation. J Am Coll Cardiol  2017;70:2906–8. https://doi.org/10.1016/j.jacc.2017.10.043
  
512	Hohnloser   SH, Crijns   HJ, van Eickels   M, Gaudin   C, Page   RL, Torp-Pedersen   C, et al.   Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med  2009;360:668–78. https://doi.org/10.1056/NEJMoa0803778
  
513	Sohns   C, Fox   H, Marrouche   NF, Crijns   H, Costard-Jaeckle   A, Bergau   L, et al.   Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med  2023;389:1380–9. https://doi.org/10.1056/NEJMoa2306037
  
514	Di Biase   L, Mohanty   P, Mohanty   S, Santangeli   P, Trivedi   C, Lakkireddy   D, et al.   Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation  2016;133:1637–44. https://doi.org/10.1161/CIRCULATIONAHA.115.019406
  
515	Nuotio   I, Hartikainen   JE, Gronberg   T, Biancari   F, Airaksinen   KE. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA  2014;312:647–9. https://doi.org/10.1001/jama.2014.3824
  
516	Garg   A, Khunger   M, Seicean   S, Chung   MK, Tchou   PJ. Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset. JACC Clin Electrophysiol  2016;2:487–94. https://doi.org/10.1016/j.jacep.2016.01.018
  
517	Tampieri   A, Cipriano   V, Mucci   F, Rusconi   AM, Lenzi   T, Cenni   P. Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk. Intern Emerg Med  2018;13:87–93. https://doi.org/10.1007/s11739-016-1589-1
  
518	Airaksinen   KE, Gronberg   T, Nuotio   I, Nikkinen   M, Ylitalo   A, Biancari   F, et al.   Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol  2013;62:1187–92. https://doi.org/10.1016/j.jacc.2013.04.089
  
519	Hansen   ML, Jepsen   RM, Olesen   JB, Ruwald   MH, Karasoy   D, Gislason   GH, et al.   Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace  2015;17:18–23. https://doi.org/10.1093/europace/euu189
  
520	Bonfanti   L, Annovi   A, Sanchis-Gomar   F, Saccenti   C, Meschi   T, Ticinesi   A, et al.   Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experience. Clin Exp Emerg Med  2019;6:64–9. https://doi.org/10.15441/ceem.17.286
  
521	Telles-Garcia   N, Dahal   K, Kocherla   C, Lip   GYH, Reddy   P, Dominic   P. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol  2018;268:143–8. https://doi.org/10.1016/j.ijcard.2018.04.034
  
522	Klein   AL, Grimm   RA, Murray   RD, Apperson-Hansen   C, Asinger   RW, Black   IW, et al.   Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med  2001;344:1411–20. https://doi.org/10.1056/NEJM200105103441901
  
523	Brunetti   ND, Tarantino   N, De Gennaro   L, Correale   M, Santoro   F, Di Biase   M. Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis. J Thromb Thrombolysis  2018;45:550–6. https://doi.org/10.1007/s11239-018-1622-5
  
524	Steinberg   JS, Sadaniantz   A, Kron   J, Krahn   A, Denny   DM, Daubert   J, et al.   Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation  2004;109:1973–80. https://doi.org/10.1161/01.CIR.0000118472.77237.FA
  
525	Crijns   HJ, Weijs   B, Fairley   AM, Lewalter   T, Maggioni   AP, Martín   A, et al.   Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study. Int J Cardiol  2014;172:588–94. https://doi.org/10.1016/j.ijcard.2014.01.099
  
526	Kirchhof   P, Andresen   D, Bosch   R, Borggrefe   M, Meinertz   T, Parade   U, et al.   Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet  2012;380:238–46. https://doi.org/10.1016/S0140-6736(12)60570-4
  
527	Zhu   W, Wu   Z, Dong   Y, Lip   GYH, Liu   C. Effectiveness of early rhythm control in improving clinical outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. BMC Med  2022;20:340. https://doi.org/10.1186/s12916-022-02545-4
  
528	Stellbrink   C, Nixdorff   U, Hofmann   T, Lehmacher   W, Daniel   WG, Hanrath   P, et al.   Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation  2004;109:997–1003. https://doi.org/10.1161/01.CIR.0000120509.64740.DC
  
529	Lip   GY, Hammerstingl   C, Marin   F, Cappato   R, Meng   IL, Kirsch   B, et al.   Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J  2016;178:126–34. https://doi.org/10.1016/j.ahj.2016.05.007
  
530	Stiell   IG, Eagles   D, Nemnom   MJ, Brown   E, Taljaard   M, Archambault   PM, et al.   Adverse events associated with electrical cardioversion in patients with acute atrial fibrillation and atrial flutter. Can J Cardiol  2021;37:1775–82. https://doi.org/10.1016/j.cjca.2021.08.018
  
531	Stiell   IG, Archambault   PM, Morris   J, Mercier   E, Eagles   D, Perry   JJ, et al.   RAFF-3 Trial: a stepped-wedge cluster randomised trial to improve care of acute atrial fibrillation and flutter in the emergency department. Can J Cardiol  2021;37:1569–77. https://doi.org/10.1016/j.cjca.2021.06.016
  
532	Gurevitz   OT, Ammash   NM, Malouf   JF, Chandrasekaran   K, Rosales   AG, Ballman   KV, et al.   Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter. Am Heart J  2005;149:316–21. https://doi.org/10.1016/j.ahj.2004.07.007
  
533	Mortensen   K, Risius   T, Schwemer   TF, Aydin   MA, Köster   R, Klemm   HU, et al.   Biphasic versus monophasic shock for external cardioversion of atrial flutter: a prospective, randomized trial. Cardiology  2008;111:57–62. https://doi.org/10.1159/000113429
  
534	Inácio   JF, da Rosa Mdos   S, Shah   J, Rosário   J, Vissoci   JR, Manica   AL, et al.   Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: systematic review and network meta-analysis. Resuscitation  2016;100:66–75. https://doi.org/10.1016/j.resuscitation.2015.12.009
  
535	Eid   M, Abu Jazar   D, Medhekar   A, Khalife   W, Javaid   A, Ahsan   C, et al.   Anterior-posterior versus anterior-lateral electrodes position for electrical cardioversion of atrial fibrillation: a meta-analysis of randomized controlled trials. Int J Cardiol Heart Vasc  2022;43:101129. https://doi.org/10.1016/j.ijcha.2022.101129
Google ScholarPubMedWorldCat 
536	Squara   F, Elbaum   C, Garret   G, Liprandi   L, Scarlatti   D, Bun   SS, et al.   Active compression versus standard anterior-posterior defibrillation for external cardioversion of atrial fibrillation: a prospective randomized study. Heart Rhythm  2021;18:360–5. https://doi.org/10.1016/j.hrthm.2020.11.005
  
537	Schmidt   AS, Lauridsen   KG, Torp   P, Bach   LF, Rickers   H, Løfgren   B. Maximum-fixed energy shocks for cardioverting atrial fibrillation. Eur Heart J  2020;41:626–31. https://doi.org/10.1093/eurheartj/ehz585
  
538	Müssigbrodt   A, John   S, Kosiuk   J, Richter   S, Hindricks   G, Bollmann   A. Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion. Europace  2016;18:51–6. https://doi.org/10.1093/europace/euv194
  
539	Climent   VE, Marin   F, Mainar   L, Gomez-Aldaravi   R, Martinez   JG, Chorro   FJ, et al.   Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol  2004;27:368–72. https://doi.org/10.1111/j.1540-8159.2004.00444.x
  
540	Tieleman   RG, Van Gelder   IC, Bosker   HA, Kingma   T, Wilde   AA, Kirchhof   CJ, et al.   Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation?  Heart Rhythm  2005;2:223–30. https://doi.org/10.1016/j.hrthm.2004.11.014
  
541	Oral   H, Souza   JJ, Michaud   GF, Knight   BP, Goyal   R, Strickberger   SA, et al.   Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med  1999;340:1849–54. https://doi.org/10.1056/NEJM199906173402401
  
542	Nair   M, George   LK, Koshy   SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation. J Am Board Fam Med  2011;24:86–92. https://doi.org/10.3122/jabfm.2011.01.080096
  
543	Bianconi   L, Mennuni   M, Lukic   V, Castro   A, Chieffi   M, Santini   M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol  1996;28:700–6. https://doi.org/10.1016/S0735-1097(96)00230-6
  
544	Channer   KS, Birchall   A, Steeds   RP, Walters   SJ, Yeo   WW, West   JN, et al.   A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J  2004;25:144–50. https://doi.org/10.1016/j.ehj.2003.10.020
  
545	Capucci   A, Villani   GQ, Aschieri   D, Rosi   A, Piepoli   MF. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J  2000;21:66–73. https://doi.org/10.1053/euhj.1999.1734
  
546	Um   KJ, McIntyre   WF, Healey   JS, Mendoza   PA, Koziarz   A, Amit   G, et al.   Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. Europace  2019;21:856–63. https://doi.org/10.1093/europace/euy310
  
547	Toso   E, Iannaccone   M, Caponi   D, Rotondi   F, Santoro   A, Gallo   C, et al.   Does antiarrhythmic drugs premedication improve electrical cardioversion success in persistent atrial fibrillation?  J Electrocardiol  2017;50:294–300. https://doi.org/10.1016/j.jelectrocard.2016.12.004
  
548	Ganapathy   AV, Monjazeb   S, Ganapathy   KS, Shanoon   F, Razavi   M. “Asymptomatic” persistent or permanent atrial fibrillation: a misnomer in selected patients. Int J Cardiol  2015;185:112–3. https://doi.org/10.1016/j.ijcard.2015.03.122
  
549	Voskoboinik   A, Kalman   E, Plunkett   G, Knott   J, Moskovitch   J, Sanders   P, et al.   A comparison of early versus delayed elective electrical cardioversion for recurrent episodes of persistent atrial fibrillation: a multi-center study. Int J Cardiol  2019;284:33–7. https://doi.org/10.1016/j.ijcard.2018.10.068
  
550	Airaksinen   KEJ. Early versus delayed cardioversion: why should we wait?  Expert Rev Cardiovasc Ther  2020;18:149–54. https://doi.org/10.1080/14779072.2020.1736563
  
551	Boriani   G, Diemberger   I, Biffi   M, Martignani   C, Branzi   A. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs  2004;64:2741–62. https://doi.org/10.2165/00003495-200464240-00003
  
552	Dan   GA, Martinez-Rubio   A, Agewall   S, Boriani   G, Borggrefe   M, Gaita   F, et al.   Antiarrhythmic drugs–clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace  2018;20:731–732an. https://doi.org/10.1093/europace/eux373
  
553	Gitt   AK, Smolka   W, Michailov   G, Bernhardt   A, Pittrow   D, Lewalter   T. Types and outcomes of cardioversion in patients admitted to hospital for atrial fibrillation: results of the German RHYTHM-AF study. Clin Res Cardiol  2013;102:713–23. https://doi.org/10.1007/s00392-013-0586-x
  
554	Calkins   H, Hindricks   G, Cappato   R, Kim   YH, Saad   EB, Aguinaga   L, et al.   2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace  2018;20:157–208. https://doi.org/10.1093/europace/eux275
  
555	Danias   PG, Caulfield   TA, Weigner   MJ, Silverman   DI, Manning   WJ. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol  1998;31:588–92. https://doi.org/10.1016/S0735-1097(97)00534-2
  
556	Tsiachris   D, Doundoulakis   I, Pagkalidou   E, Kordalis   A, Deftereos   S, Gatzoulis   KA, et al.   Pharmacologic cardioversion in patients with paroxysmal atrial fibrillation: a network meta-analysis. Cardiovasc Drugs Ther  2021;35:293–308. https://doi.org/10.1007/s10557-020-07127-1
  
557	Grönberg   T, Nuotio   I, Nikkinen   M, Ylitalo   A, Vasankari   T, Hartikainen   JE, et al.   Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study. Europace  2013;15:1432–5. https://doi.org/10.1093/europace/eut106
  
558	Brandes   A, Crijns   H, Rienstra   M, Kirchhof   P, Grove   EL, Pedersen   KB, et al.   Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. Europace  2020;22:1149–61. https://doi.org/10.1093/europace/euaa057
  
559	Stiell   IG, Sivilotti   MLA, Taljaard   M, Birnie   D, Vadeboncoeur   A, Hohl   CM, et al.   Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. Lancet  2020;395:339–49. https://doi.org/10.1016/S0140-6736(19)32994-0
  
560	Alboni   P, Botto   GL, Baldi   N, Luzi   M, Russo   V, Gianfranchi   L, et al.   Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med  2004;351:2384–91. https://doi.org/10.1056/NEJMoa041233
  
561	Brembilla-Perrot   B, Houriez   P, Beurrier   D, Claudon   O, Terrier de la Chaise   A, Louis   P. Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias. Int J Cardiol  2001;80:7–15. https://doi.org/10.1016/S0167-5273(01)00459-4
  
562	Conde   D, Costabel   JP, Caro   M, Ferro   A, Lambardi   F, Corrales Barboza   A, et al.   Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J Cardiol  2013;168:2423–5. https://doi.org/10.1016/j.ijcard.2013.02.006
  
563	Markey   GC, Salter   N, Ryan   J. Intravenous flecainide for emergency department management of acute atrial fibrillation. J Emerg Med  2018;54:320–7. https://doi.org/10.1016/j.jemermed.2017.11.016
  
564	Martinez-Marcos   FJ, Garcia-Garmendia   JL, Ortega-Carpio   A, Fernandez-Gomez   JM, Santos   JM, Camacho   C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol  2000;86:950–3. https://doi.org/10.1016/S0002-9149(00)01128-0
  
565	Reisinger   J, Gatterer   E, Lang   W, Vanicek   T, Eisserer   G, Bachleitner   T, et al.   Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J  2004;25:1318–24. https://doi.org/10.1016/j.ehj.2004.04.030
  
566	Zhang   N, Guo   JH, Zhang   H, Li   XB, Zhang   P, Xn   Y. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract  2005;59:1395–400. https://doi.org/10.1111/j.1368-5031.2005.00705.x
  
567	Camm   AJ, Capucci   A, Hohnloser   SH, Torp-Pedersen   C, Van Gelder   IC, Mangal   B, et al.   A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol  2011;57:313–21. https://doi.org/10.1016/j.jacc.2010.07.046
  
568	Roy   D, Pratt   CM, Torp-Pedersen   C, Wyse   DG, Toft   E, Juul-Moller   S, et al.   Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation  2008;117:1518–25. https://doi.org/10.1161/CIRCULATIONAHA.107.723866
  
569	Deedwania   PC, Singh   BN, Ellenbogen   K, Fisher   S, Fletcher   R, Singh   SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation  1998;98:2574–9. https://doi.org/10.1161/01.cir.98.23.2574
  
570	Hofmann   R, Steinwender   C, Kammler   J, Kypta   A, Wimmer   G, Leisch   F. Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with advanced congestive heart failure or cardiogenic shock. Wien Klin Wochenschr  2004;116:744–9. https://doi.org/10.1007/s00508-004-0264-0
  
571	Alboni   P, Botto   GL, Boriani   G, Russo   G, Pacchioni   F, Iori   M, et al.   Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during ‘pill-in-the-pocket’ treatment. Heart  2010;96:546–9. https://doi.org/10.1136/hrt.2009.187963
  
572	Khan   IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol  2001;37:542–7. https://doi.org/10.1016/S0735-1097(00)01116-5
  
573	Khan   IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol  2003;87:121–8. https://doi.org/10.1016/S0167-5273(02)00467-9
  
574	Al-Khatib   SM, Allen LaPointe   NM, Chatterjee   R, Crowley   MJ, Dupre   ME, Kong   DF, et al.   Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med  2014;160:760–73. https://doi.org/10.7326/M13-1467
  
575	Andrade   JG, Aguilar   M, Atzema   C, Bell   A, Cairns   JA, Cheung   CC, et al.   The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol  2020;36:1847–948. https://doi.org/10.1016/j.cjca.2020.09.001
  
576	Lafuente-Lafuente   C, Valembois   L, Bergmann   JF, Belmin   J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev  2015;3:CD005049. https://doi.org/10.1002/14651858.CD005049.pub4
Google ScholarWorldCat 
577	Valembois   L, Audureau   E, Takeda   A, Jarzebowski   W, Belmin   J, Lafuente-Lafuente   C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev  2019;2019:Cd005049. https://doi.org/10.1002/14651858.CD005049.pub5
Google ScholarWorldCat 
578	Crijns   HJ, Van Gelder   IC, Van Gilst   WH, Hillege   H, Gosselink   AM, Lie   KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol  1991;68:335–41. https://doi.org/10.1016/0002-9149(91)90828-9
  
579	Chatterjee   S, Sardar   P, Lichstein   E, Mukherjee   D, Aikat   S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol  2013;36:122–33. https://doi.org/10.1111/j.1540-8159.2012.03513.x
  
580	Kotecha   D, Kirchhof   P. Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. Evid Based Med  2014;19:222–3. https://doi.org/10.1136/ebmed-2014-110062
  
581	Piccini   JP, Hasselblad   V, Peterson   ED, Washam   JB, Califf   RM, Kong   DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol  2009;54:1089–95. https://doi.org/10.1016/j.jacc.2009.04.085
  
582	Eckardt   L, Sehner   S, Suling   A, Borof   K, Breithardt   G, Crijns   H, et al.   Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J  2022;43:4127–44. https://doi.org/10.1093/eurheartj/ehac471
  
583	Freemantle   N, Lafuente-Lafuente   C, Mitchell   S, Eckert   L, Reynolds   M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace  2011;13:329–45. https://doi.org/10.1093/europace/euq450
  
584	Frommeyer   G, Eckardt   L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol  2016;13:36–47. https://doi.org/10.1038/nrcardio.2015.110
  
585	Kochiadakis   GE, Marketou   ME, Igoumenidis   NE, Chrysostomakis   SI, Mavrakis   HE, Kaleboubas   MD, et al.   Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?  Pacing Clin Electrophysiol  2000;23:1883–7. https://doi.org/10.1111/j.1540-8159.2000.tb07044.x
  
586	Roy   D, Talajic   M, Dorian   P, Connolly   S, Eisenberg   MJ, Green   M, et al.   Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med  2000;342:913–20. https://doi.org/10.1056/NEJM200003303421302
  
587	Singh   BN, Singh   SN, Reda   DJ, Tang   XC, Lopez   B, Harris   CL, et al.   Amiodarone versus sotalol for atrial fibrillation. N Engl J Med  2005;352:1861–72. https://doi.org/10.1056/NEJMoa041705
  
588	Ehrlich   JR, Look   C, Kostev   K, Israel   CW, Goette   A. Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in Germany. Int J Cardiol  2019;278:126–32. https://doi.org/10.1016/j.ijcard.2018.11.133
  
589	Singh   BN, Connolly   SJ, Crijns   HJ, Roy   D, Kowey   PR, Capucci   A, et al.   Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med  2007;357:987–99. https://doi.org/10.1056/NEJMoa054686
  
590	Stroobandt   R, Stiels   B, Hoebrechts   R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol  1997;79:418–23. https://doi.org/10.1016/S0002-9149(96)00779-5
  
591	Wazni   OM, Dandamudi   G, Sood   N, Hoyt   R, Tyler   J, Durrani   S, et al.   Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med  2021;384:316–24. https://doi.org/10.1056/NEJMoa2029554
  
592	Cosedis Nielsen   J, Johannessen   A, Raatikainen   P, Hindricks   G, Walfridsson   H, Kongstad   O, et al.   Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med  2012;367:1587–95. https://doi.org/10.1056/NEJMoa1113566
  
593	Morillo   CA, Verma   A, Connolly   SJ, Kuck   KH, Nair   GM, Champagne   J, et al.   Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA  2014;311:692–700. https://doi.org/10.1001/jama.2014.467
  
594	Kuniss   M, Pavlovic   N, Velagic   V, Hermida   JS, Healey   S, Arena   G, et al.   Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace  2021;23:1033–41. https://doi.org/10.1093/europace/euab029
  
595	Hocini   M, Sanders   P, Deisenhofer   I, Jais   P, Hsu   LF, Scavee   C, et al.   Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation  2003;108:1172–5. https://doi.org/10.1161/01.CIR.0000090685.13169.07
  
596	Inada   K, Yamane   T, Tokutake   K, Yokoyama   K, Mishima   T, Hioki   M, et al.   The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses: outcome during a 5-year follow-up. Europace  2014;16:208–13. https://doi.org/10.1093/europace/eut159
  
597	Chen   YW, Bai   R, Lin   T, Salim   M, Sang   CH, Long   DY, et al.   Pacing or ablation: which is better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome?  Pacing Clin Electrophysiol  2014;37:403–11. https://doi.org/10.1111/pace.12340
  
598	Zhang   R, Wang   Y, Yang   M, Yang   Y, Wang   Z, Yin   X, et al.   Risk stratification for atrial fibrillation and outcomes in tachycardia-bradycardia syndrome: ablation vs. pacing. Front Cardiovasc Med  2021;8:674471. https://doi.org/10.3389/fcvm.2021.674471
  
599	Oral   H, Pappone   C, Chugh   A, Good   E, Bogun   F, Pelosi   F, Jr, et al.   Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med  2006;354:934–41. https://doi.org/10.1056/NEJMoa050955
  
600	Yan Huo   TG, Schönbauer   R, Wójcik   M, Fiedler   L, Roithinger   FX, Martinek   M, et al.   Low-voltage myocardium-guided ablation trial of persistent atrial fibrillation. NEJM Evid  2022;1:EVIDoa2200141. https://doi.org/10.1056/EVIDoa2200141.
Google ScholarWorldCat 
601	Reddy   VY, Gerstenfeld   EP, Natale   A, Whang   W, Cuoco   FA, Patel   C, et al.   Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med  2023;389:1660–71. https://doi.org/10.1056/NEJMoa2307291
  
602	Kalman   JM, Al-Kaisey   AM, Parameswaran   R, Hawson   J, Anderson   RD, Lim   M, et al.   Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia recurrences. Eur Heart J  2023;44:2447–54. https://doi.org/10.1093/eurheartj/ehad247
  
603	Kalman   JM, Sanders   P, Rosso   R, Calkins   H. Should we perform catheter ablation for asymptomatic atrial fibrillation?  Circulation  2017;136:490–9. https://doi.org/10.1161/CIRCULATIONAHA.116.024926
  
604	Hunter   RJ, Berriman   TJ, Diab   I, Kamdar   R, Richmond   L, Baker   V, et al.   A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol  2014;7:31–8. https://doi.org/10.1161/CIRCEP.113.000806
  
605	Jones   DG, Haldar   SK, Hussain   W, Sharma   R, Francis   DP, Rahman-Haley   SL, et al.   A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol  2013;61:1894–903. https://doi.org/10.1016/j.jacc.2013.01.069
  
606	Kuck   KH, Merkely   B, Zahn   R, Arentz   T, Seidl   K, Schluter   M, et al.   Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. Circ Arrhythm Electrophysiol  2019;12:e007731. https://doi.org/10.1161/CIRCEP.119.007731
  
607	MacDonald   MR, Connelly   DT, Hawkins   NM, Steedman   T, Payne   J, Shaw   M, et al.   Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart  2011;97:740–7. https://doi.org/10.1136/hrt.2010.207340
  
608	Parkash   R, Wells   GA, Rouleau   J, Talajic   M, Essebag   V, Skanes   A, et al.   Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial. Circulation  2022;145:1693–704. https://doi.org/10.1161/CIRCULATIONAHA.121.057095
  
609	Romero   J, Gabr   M, Alviz   I, Briceno   D, Diaz   JC, Rodriguez   D, et al.   Improved survival in patients with atrial fibrillation and heart failure undergoing catheter ablation compared to medical treatment: a systematic review and meta-analysis of randomized controlled trials. J Cardiovasc Electrophysiol  2022;33:2356–66. https://doi.org/10.1111/jce.15622
  
610	Chen   S, Purerfellner   H, Meyer   C, Acou   WJ, Schratter   A, Ling   Z, et al.   Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J  2020;41:2863–73. https://doi.org/10.1093/eurheartj/ehz443
  
611	Prabhu   S, Taylor   AJ, Costello   BT, Kaye   DM, McLellan   AJA, Voskoboinik   A, et al.   Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol  2017;70:1949–61. https://doi.org/10.1016/j.jacc.2017.08.041
  
612	Packer   DL, Piccini   JP, Monahan   KH, Al-Khalidi   HR, Silverstein   AP, Noseworthy   PA, et al.   Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation  2021;143:1377–90. https://doi.org/10.1161/CIRCULATIONAHA.120.050991
  
613	Smit   MD, Moes   ML, Maass   AH, Achekar   ID, Van Geel   PP, Hillege   HL, et al.   The importance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail  2012;14:1030–40. https://doi.org/10.1093/eurjhf/hfs097
  
614	Sohns   C, Zintl   K, Zhao   Y, Dagher   L, Andresen   D, Siebels   J, et al.   Impact of left ventricular function and heart failure symptoms on outcomes post ablation of atrial fibrillation in heart failure: CASTLE-AF trial. Circ Arrhythm Electrophysiol  2020;13:e008461. https://doi.org/10.1161/CIRCEP.120.008461
  
615	Sugumar   H, Prabhu   S, Costello   B, Chieng   D, Azzopardi   S, Voskoboinik   A, et al.   Catheter ablation versus medication in atrial fibrillation and systolic dysfunction: late outcomes of CAMERA-MRI study. JACC Clin Electrophysiol  2020;6:1721–31. https://doi.org/10.1016/j.jacep.2020.08.019
  
616	Kirstein   B, Neudeck   S, Gaspar   T, Piorkowski   J, Wechselberger   S, Kronborg   MB, et al.   Left atrial fibrosis predicts left ventricular ejection fraction response after atrial fibrillation ablation in heart failure patients: the fibrosis-HF study. Europace  2020;22:1812–21. https://doi.org/10.1093/europace/euaa179
  
617	Ishiguchi   H, Yoshiga   Y, Shimizu   A, Ueyama   T, Fukuda   M, Kato   T, et al.   Long-term events following catheter-ablation for atrial fibrillation in heart failure with preserved ejection fraction. ESC Heart Fail  2022;9:3505–18. https://doi.org/10.1002/ehf2.14079
  
618	Gu   G, Wu   J, Gao   X, Liu   M, Jin   C, Xu   Y. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction: a meta-analysis. Clin Cardiol  2022;45:786–93. https://doi.org/10.1002/clc.23841
  
619	Yamauchi   R, Morishima   I, Okumura   K, Kanzaki   Y, Morita   Y, Takagi   K, et al.   Catheter ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with preserved ejection fraction: feasibility and benefits in functions and B-type natriuretic peptide. Europace  2021;23:1252–61. https://doi.org/10.1093/europace/euaa420
  
620	Rordorf   R, Scazzuso   F, Chun   KRJ, Khelae   SK, Kueffer   FJ, Braegelmann   KM, et al.   Cryoballoon ablation for the treatment of atrial fibrillation in patients with concomitant heart failure and either reduced or preserved left ventricular ejection fraction: results from the Cryo AF global registry. J Am Heart Assoc  2021;10:e021323. https://doi.org/10.1161/JAHA.121.021323
  
621	Cha   YM, Wokhlu   A, Asirvatham   SJ, Shen   WK, Friedman   PA, Munger   TM, et al.   Success of ablation for atrial fibrillation in isolated left ventricular diastolic dysfunction: a comparison to systolic dysfunction and normal ventricular function. Circ Arrhythm Electrophysiol  2011;4:724–32. https://doi.org/10.1161/CIRCEP.110.960690
  
622	Machino-Ohtsuka   T, Seo   Y, Ishizu   T, Sugano   A, Atsumi   A, Yamamoto   M, et al.   Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol  2013;62:1857–65. https://doi.org/10.1016/j.jacc.2013.07.020
  
623	Aldaas   OM, Lupercio   F, Darden   D, Mylavarapu   PS, Malladi   CL, Han   FT, et al.   Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. Am J Cardiol  2021;142:66–73. https://doi.org/10.1016/j.amjcard.2020.11.039
  
624	Black-Maier   E, Ren   X, Steinberg   BA, Green   CL, Barnett   AS, Rosa   NS, et al.   Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Heart Rhythm  2018;15:651–7. https://doi.org/10.1016/j.hrthm.2017.12.001
  
625	von Olshausen   G, Benson   L, Dahlström   U, Lund   LH, Savarese   G, Braunschweig   F. Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure Registry. Eur J Heart Fail  2022;24:1636–46. https://doi.org/10.1002/ejhf.2604
  
626	Shiraishi   Y, Kohsaka   S, Ikemura   N, Kimura   T, Katsumata   Y, Tanimoto   K, et al.   Catheter ablation for patients with atrial fibrillation and heart failure with reduced and preserved ejection fraction: insights from the KiCS-AF multicentre cohort study. Europace  2023;25:83–91. https://doi.org/10.1093/europace/euac108
  
627	Wu   L, Narasimhan   B, Ho   KS, Zheng   Y, Shah   AN, Kantharia   BK. Safety and complications of catheter ablation for atrial fibrillation: predictors of complications from an updated analysis the national inpatient database. J Cardiovasc Electrophysiol  2021;32:1024–34. https://doi.org/10.1111/jce.14979
  
628	Tripathi   B, Arora   S, Kumar   V, Abdelrahman   M, Lahewala   S, Dave   M, et al.   Temporal trends of in-hospital complications associated with catheter ablation of atrial fibrillation in the United States: an update from nationwide inpatient sample database (2011–2014). J Cardiovasc Electrophysiol  2018;29:715–24. https://doi.org/10.1111/jce.13471
  
629	Steinbeck   G, Sinner   MF, Lutz   M, Muller-Nurasyid   M, Kaab   S, Reinecke   H. Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014. Eur Heart J  2018;39:4020–9. https://doi.org/10.1093/eurheartj/ehy452
  
630	Deshmukh   A, Patel   NJ, Pant   S, Shah   N, Chothani   A, Mehta   K, et al.   In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation  2013;128:2104–12. https://doi.org/10.1161/CIRCULATIONAHA.113.003862
  
631	Cheng   EP, Liu   CF, Yeo   I, Markowitz   SM, Thomas   G, Ip   JE, et al.   Risk of mortality following catheter ablation of atrial fibrillation. J Am Coll Cardiol  2019;74:2254–64. https://doi.org/10.1016/j.jacc.2019.08.1036
  
632	Gawalko   M, Duncker   D, Manninger   M, van der Velden   RMJ, Hermans   ANL, Verhaert   DVM, et al.   The European TeleCheck-AF project on remote app-based management of atrial fibrillation during the COVID-19 pandemic: centre and patient experiences. Europace  2021;23:1003–15. https://doi.org/10.1093/europace/euab050
  
633	Rizas   KD, Freyer   L, Sappler   N, von Stülpnagel   L, Spielbichler   P, Krasniqi   A, et al.   Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial. Nat Med  2022;28:1823–30. https://doi.org/10.1038/s41591-022-01979-w
  
634	Andrade   JG, Champagne   J, Dubuc   M, Deyell   MW, Verma   A, Macle   L, et al.   Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation  2019;140:1779–88. https://doi.org/10.1161/CIRCULATIONAHA.119.042622
  
635	Duytschaever   M, Demolder   A, Phlips   T, Sarkozy   A, El Haddad   M, Taghji   P, et al.   PulmOnary vein isolation with vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J  2018;39:1429–37. https://doi.org/10.1093/eurheartj/ehx666
  
636	Darkner   S, Chen   X, Hansen   J, Pehrson   S, Johannessen   A, Nielsen   JB, et al.   Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J  2014;35:3356–64. https://doi.org/10.1093/eurheartj/ehu354
  
637	Leong-Sit   P, Roux   JF, Zado   E, Callans   DJ, Garcia   F, Lin   D, et al.   Antiarrhythmics after ablation of atrial fibrillation (5A study): six-month follow-up study. Circ Arrhythm Electrophysiol  2011;4:11–4. https://doi.org/10.1161/CIRCEP.110.955393
  
638	Kaitani   K, Inoue   K, Kobori   A, Nakazawa   Y, Ozawa   T, Kurotobi   T, et al.   Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. Eur Heart J  2016;37:610–8. https://doi.org/10.1093/eurheartj/ehv501
  
639	Noseworthy   PA, Van Houten   HK, Sangaralingham   LR, Deshmukh   AJ, Kapa   S, Mulpuru   SK, et al.   Effect of antiarrhythmic drug initiation on readmission after catheter ablation for atrial fibrillation. JACC Clin Electrophysiol  2015;1:238–44. https://doi.org/10.1016/j.jacep.2015.04.016
  
640	Xu   X, Alida   CT, Yu   B. Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis. Cardiovasc Ther  2015;33:242–6. https://doi.org/10.1111/1755-5922.12133
  
641	Chen   W, Liu   H, Ling   Z, Xu   Y, Fan   J, Du   H, et al.   Efficacy of short-term antiarrhythmic drugs use after catheter ablation of atrial fibrillation—a systematic review with meta-analyses and trial sequential analyses of randomized controlled trials. PLoS One  2016;11:e0156121. https://doi.org/10.1371/journal.pone.0156121
  
642	Schleberger   R, Metzner   A, Kuck   KH, Andresen   D, Willems   S, Hoffmann   E, et al.   Antiarrhythmic drug therapy after catheter ablation for atrial fibrillation–insights from the German Ablation Registry. Pharmacol Res Perspect  2021;9:e00880. https://doi.org/10.1002/prp2.880
  
643	Zhang   XD, Gu   J, Jiang   WF, Zhao   L, Zhou   L, Wang   YL, et al.   Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial. Eur Heart J  2014;35:1327–34. https://doi.org/10.1093/eurheartj/ehu017
  
644	Zhou   L, He   L, Wang   W, Li   C, Li   S, Tang   R, et al.   Effect of repeat catheter ablation vs. antiarrhythmic drug therapy among patients with recurrent atrial tachycardia/atrial fibrillation after atrial fibrillation catheter ablation: data from CHINA-AF registry. Europace  2023;25:382–9. https://doi.org/10.1093/europace/euac169
  
645	Fink   T, Metzner   A, Willems   S, Eckardt   L, Ince   H, Brachmann   J, et al.   Procedural success, safety and patients satisfaction after second ablation of atrial fibrillation in the elderly: results from the German ablation registry. Clin Res Cardiol  2019;108:1354–63. https://doi.org/10.1007/s00392-019-01471-5
  
646	Winkle   RA, Mead   RH, Engel   G, Kong   MH, Fleming   W, Salcedo   J, et al.   Impact of obesity on atrial fibrillation ablation: patient characteristics, long-term outcomes, and complications. Heart Rhythm  2017;14:819–27. https://doi.org/10.1016/j.hrthm.2017.02.023
  
647	Sticherling   C, Marin   F, Birnie   D, Boriani   G, Calkins   H, Dan   G-A, et al.   Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). EP Europace  2015;17:1197–214. https://doi.org/10.1093/europace/euv190
  
648	Calkins   H, Kuck   KH, Cappato   R, Brugada   J, Camm   AJ, Chen   SA, et al.   2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol  2012;33:171–257. https://doi.org/10.1007/s10840-012-9672-7
  
649	Noubiap   JJ, Agbaedeng   TA, Ndoadoumgue   AL, Nyaga   UF, Kengne   AP. Atrial thrombus detection on transoesophageal echocardiography in patients with atrial fibrillation undergoing cardioversion or catheter ablation: a pooled analysis of rates and predictors. J Cardiovasc Electrophysiol  2021;32:2179–88. https://doi.org/10.1111/jce.15082
  
650	Lurie   A, Wang   J, Hinnegan   KJ, McIntyre   WF, Belley-Côté   EP, Amit   G, et al.   Prevalence of left atrial thrombus in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol  2021;77:2875–86. https://doi.org/10.1016/j.jacc.2021.04.036
  
651	Efremidis   M, Bazoukis   G, Vlachos   K, Prappa   E, Megarisiotou   A, Dragasis   S, et al.   Safety of catheter ablation of atrial fibrillation without pre- or peri-procedural imaging for the detection of left atrial thrombus in the era of uninterrupted anticoagulation. J Arrhythm  2021;37:28–32. https://doi.org/10.1002/joa3.12466
  
652	Diab   M, Wazni   OM, Saliba   WI, Tarakji   KG, Ballout   JA, Hutt   E, et al.   Ablation of atrial fibrillation without left atrial appendage imaging in patients treated with direct oral anticoagulants. Circ Arrhythm Electrophysiol  2020;13:e008301. https://doi.org/10.1161/CIRCEP.119.008301
  
653	Patel   K, Natale   A, Yang   R, Trivedi   C, Romero   J, Briceno   D, et al.   Is transesophageal echocardiography necessary in patients undergoing ablation of atrial fibrillation on an uninterrupted direct oral anticoagulant regimen? Results from a prospective multicenter registry. Heart Rhythm  2020;17:2093–9. https://doi.org/10.1016/j.hrthm.2020.07.017
  
654	Mao   YJ, Wang   H, Huang   PF. Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation. J Interv Card Electrophysiol  2021;60:407–17. https://doi.org/10.1007/s10840-020-00754-6
  
655	van Vugt   SPG, Westra   SW, Volleberg   R, Hannink   G, Nakamura   R, de Asmundis   C, et al.   Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation. Europace  2021;23:1961–9. https://doi.org/10.1093/europace/euab175
  
656	Ge   Z, Faggioni   M, Baber   U, Sartori   S, Sorrentino   S, Farhan   S, et al.   Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Cardiovasc Ther  2018;36:e12457. https://doi.org/10.1111/1755-5922.12457
  
657	Asad   ZUA, Akhtar   KH, Jafry   AH, Khan   MH, Khan   MS, Munir   MB, et al.   Uninterrupted versus interrupted direct oral anticoagulation for catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Cardiovasc Electrophysiol  2021;32:1995–2004. https://doi.org/10.1111/jce.15043
  
658	Mao   YJ, Wang   H, Huang   PF. Peri-procedural novel oral anticoagulants dosing strategy during atrial fibrillation ablation: a meta-analysis. Pacing Clin Electrophysiol  2020;43:1104–14. https://doi.org/10.1111/pace.14040
  
659	Basu-Ray   I, Khanra   D, Kupó   P, Bunch   J, Theus   SA, Mukherjee   A, et al.   Outcomes of uninterrupted vs interrupted periprocedural direct oral anticoagulants in atrial fibrillation ablation: a meta-analysis. J Arrhythm  2021;37:384–93. https://doi.org/10.1002/joa3.12507
  
660	Romero   J, Cerrud-Rodriguez   RC, Diaz   JC, Rodriguez   D, Arshad   S, Alviz   I, et al.   Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: a systematic review and meta-analysis. J Cardiovasc Electrophysiol  2019;30:1250–7. https://doi.org/10.1111/jce.14052
  
661	Liu   XH, Xu   Q, Luo   T, Zhang   L, Liu   HJ. Discontinuation of oral anticoagulation therapy after successful atrial fibrillation ablation: a systematic review and meta-analysis of prospective studies. PLoS One  2021;16:e0253709. https://doi.org/10.1371/journal.pone.0253709
  
662	Proietti   R, AlTurki   A, Di Biase   L, China   P, Forleo   G, Corrado   A, et al.   Anticoagulation after catheter ablation of atrial fibrillation: an unnecessary evil? A systematic review and meta-analysis. J Cardiovasc Electrophysiol  2019;30:468–78. https://doi.org/10.1111/jce.13822
  
663	Maduray   K, Moneruzzaman   M, Changwe   GJ, Zhong   J. Benefits and risks associated with long-term oral anticoagulation after successful atrial fibrillation catheter ablation: systematic review and meta-analysis. Clin Appl Thromb Hemost  2022;28:10760296221118480. https://doi.org/10.1177/10760296221118480
Google ScholarWorldCat 
664	Brockmeyer   M, Lin   Y, Parco   C, Karathanos   A, Krieger   T, Schulze   V, et al.   Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials. Acta Cardiol  2021;76:288–95. https://doi.org/10.1080/00015385.2020.1724689
  
665	Di Monaco   A, Guida   P, Vitulano   N, Quadrini   F, Troisi   F, Langialonga   T, et al.   Catheter ablation of atrial fibrillation with uninterrupted anticoagulation: a meta-analysis of six randomized controlled trials. J Cardiovasc Med (Hagerstown)  2020;21:483–90. https://doi.org/10.2459/JCM.0000000000000939
  
666	Maesen   B, Luermans   J, Bidar   E, Chaldoupi   SM, Gelsomino   S, Maessen   JG, et al.   A hybrid approach to complex arrhythmias. Europace  2021;23:ii28–33. https://doi.org/10.1093/europace/euab027
  
667	van der Heijden   CAJ, Vroomen   M, Luermans   JG, Vos   R, Crijns   H, Gelsomino   S, et al.   Hybrid versus catheter ablation in patients with persistent and longstanding persistent atrial fibrillation: a systematic review and meta-analysis. Eur J Cardiothorac Surg  2019;56:433–43. https://doi.org/10.1093/ejcts/ezy475
  
668	Boersma   LV, Castella   M, van Boven   W, Berruezo   A, Yilmaz   A, Nadal   M, et al.   Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation  2012;125:23–30. https://doi.org/10.1161/CIRCULATIONAHA.111.074047
  
669	Castella   M, Kotecha   D, van Laar   C, Wintgens   L, Castillo   Y, Kelder   J, et al.   Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial. Europace  2019;21:746–53. https://doi.org/10.1093/europace/euy325
  
670	van der Heijden   CAJ, Weberndörfer   V, Vroomen   M, Luermans   JG, Chaldoupi   SM, Bidar   E, et al.   Hybrid ablation versus repeated catheter ablation in persistent atrial fibrillation: a randomized controlled trial. JACC Clin Electrophysiol  2023;9:1013–23. https://doi.org/10.1016/j.jacep.2022.12.011
  
671	DeLurgio   DB, Crossen   KJ, Gill   J, Blauth   C, Oza   SR, Magnano   AR, et al.   Hybrid convergent procedure for the treatment of persistent and long-standing persistent atrial fibrillation: results of CONVERGE clinical trial. Circ Arrhythm Electrophysiol  2020;13:e009288. https://doi.org/10.1161/CIRCEP.120.009288
  
672	Pokushalov   E, Romanov   A, Elesin   D, Bogachev-Prokophiev   A, Losik   D, Bairamova   S, et al.   Catheter versus surgical ablation of atrial fibrillation after a failed initial pulmonary vein isolation procedure: a randomized controlled trial. J Cardiovasc Electrophysiol  2013;24:1338–43. https://doi.org/10.1111/jce.12245
  
673	Haldar   S, Khan   HR, Boyalla   V, Kralj-Hans   I, Jones   S, Lord   J, et al.   Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial. Eur Heart J  2020;41:4471–80. https://doi.org/10.1093/eurheartj/ehaa658
  
674	Doll   N, Weimar   T, Kosior   DA, Bulava   A, Mokracek   A, Mönnig   G, et al.   Efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation: a randomised, controlled trial. EClinicalMedicine  2023;61:102052. https://doi.org/10.1016/j.eclinm.2023.102052
  
675	Malaisrie   SC, McCarthy   PM, Kruse   J, Matsouaka   R, Andrei   AC, Grau-Sepulveda   MV, et al.   Burden of preoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg  2018;155:2358–2367 e1. https://doi.org/10.1016/j.jtcvs.2018.01.069
  
676	Saxena   A, Dinh   DT, Reid   CM, Smith   JA, Shardey   GC, Newcomb   AE. Does preoperative atrial fibrillation portend a poorer prognosis in patients undergoing isolated aortic valve replacement? A multicentre Australian study. Can J Cardiol  2013;29:697–703. https://doi.org/10.1016/j.cjca.2012.08.016
  
677	Quader   MA, McCarthy   PM, Gillinov   AM, Alster   JM, Cosgrove   DM, 3rd, Lytle   BW, et al.   Does preoperative atrial fibrillation reduce survival after coronary artery bypass grafting?  Ann Thorac Surg  2004;77:1514–22; discussion 1522–4. https://doi.org/10.1016/j.athoracsur.2003.09.069
  
678	Damiano   RJ, Jr, Schwartz   FH, Bailey   MS, Maniar   HS, Munfakh   NA, Moon   MR, et al.   The Cox Maze IV procedure: predictors of late recurrence. J Thorac Cardiovasc Surg  2011;141:113–21. https://doi.org/10.1016/j.jtcvs.2010.08.067
  
679	Cox   JL, Schuessler   RB, Boineau   JP. The development of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg  2000;12:2–14. https://doi.org/10.1016/S1043-0679(00)70010-4
  
680	Melby   SJ, Zierer   A, Bailey   MS, Cox   JL, Lawton   JS, Munfakh   N, et al.   A new era in the surgical treatment of atrial fibrillation: the impact of ablation technology and lesion set on procedural efficacy. Ann Surg  2006;244:583–92. https://doi.org/10.1097/01.sla.0000237654.00841.26
Google ScholarPubMedWorldCat 
681	Badhwar   V, Rankin   JS, Damiano   RJ, Jr, Gillinov   AM, Bakaeen   FG, Edgerton   JR, et al.   The Society of Thoracic Surgeons 2017 clinical practice guidelines for the surgical treatment of atrial fibrillation. Ann Thorac Surg  2017;103:329–41. https://doi.org/10.1016/j.athoracsur.2016.10.076
  
682	Ad   N, Henry   L, Hunt   S, Holmes   SD. Impact of clinical presentation and surgeon experience on the decision to perform surgical ablation. Ann Thorac Surg  2013;96:763–8; discussion 768–9. https://doi.org/10.1016/j.athoracsur.2013.03.066
  
683	Cheng   DC, Ad   N, Martin   J, Berglin   EE, Chang   BC, Doukas   G, et al.   Surgical ablation for atrial fibrillation in cardiac surgery: a meta-analysis and systematic review. Innovations (Phila)  2010;5:84–96. https://doi.org/10.1177/155698451000500204
  
684	McClure   GR, Belley-Cote   EP, Jaffer   IH, Dvirnik   N, An   KR, Fortin   G, et al.   Surgical ablation of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Europace  2018;20:1442–50. https://doi.org/10.1093/europace/eux336
  
685	Phan   K, Xie   A, La Meir   M, Black   D, Yan   TD. Surgical ablation for treatment of atrial fibrillation in cardiac surgery: a cumulative meta-analysis of randomised controlled trials. Heart  2014;100:722–30. https://doi.org/10.1136/heartjnl-2013-305351
  
686	Barnett   SD, Ad   N. Surgical ablation as treatment for the elimination of atrial fibrillation: a meta-analysis. J Thorac Cardiovasc Surg  2006;131:1029–35. https://doi.org/10.1016/j.jtcvs.2005.10.020
  
687	Gillinov   AM, Gelijns   AC, Parides   MK, DeRose   JJ, Jr, Moskowitz   AJ, Voisine   P, et al.   Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med  2015;372:1399–409. https://doi.org/10.1056/NEJMoa1500528
  
688	MacGregor   RM, Bakir   NH, Pedamallu   H, Sinn   LA, Maniar   HS, Melby   SJ, et al.   Late results after stand-alone surgical ablation for atrial fibrillation. J Thorac Cardiovasc Surg  2022;164:1515–1528.e8. https://doi.org/10.1016/j.jtcvs.2021.03.109
  
689	Musharbash   FN, Schill   MR, Sinn   LA, Schuessler   RB, Maniar   HS, Moon   MR, et al.   Performance of the Cox-Maze IV procedure is associated with improved long-term survival in patients with atrial fibrillation undergoing cardiac surgery. J Thorac Cardiovasc Surg  2018;155:159–70. https://doi.org/10.1016/j.jtcvs.2017.09.095
  
690	Rankin   JS, Lerner   DJ, Braid-Forbes   MJ, McCrea   MM, Badhwar   V. Surgical ablation of atrial fibrillation concomitant to coronary-artery bypass grafting provides cost-effective mortality reduction. J Thorac Cardiovasc Surg  2020;160:675–686 e13. https://doi.org/10.1016/j.jtcvs.2019.07.131
  
691	Suwalski   P, Kowalewski   M, Jasinski   M, Staromlynski   J, Zembala   M, Widenka   K, et al.   Survival after surgical ablation for atrial fibrillation in mitral valve surgery: analysis from the Polish National Registry of Cardiac Surgery Procedures (KROK). J Thorac Cardiovasc Surg  2019;157:1007–1018 e4. https://doi.org/10.1016/j.jtcvs.2018.07.099
  
692	Suwalski   P, Kowalewski   M, Jasinski   M, Staromlynski   J, Zembala   M, Widenka   K, et al.   Surgical ablation for atrial fibrillation during isolated coronary artery bypass surgery. Eur J Cardiothorac Surg  2020;57:691–700. https://doi.org/10.1093/ejcts/ezz298
Google ScholarPubMedWorldCat 
693	Wehbe   M, Albert   M, Lewalter   T, Ouarrak   T, Senges   J, Hanke   T, et al.   The German cardiosurgery atrial fibrillation registry: 1-year follow-up outcomes. Thorac Cardiovasc Surg  2023;71:255–63. https://doi.org/10.1055/s-0042-1750311
Google ScholarPubMedWorldCat 
694	Kim   HJ, Kim   YJ, Kim   M, Yoo   JS, Kim   DH, Park   DW, et al.   Surgical ablation for atrial fibrillation during aortic and mitral valve surgery: a nationwide population-based cohort study. J Thorac Cardiovasc Surg  2024;167:981–93. https://doi.org/10.1016/j.jtcvs.2022.08.038
  
695	Ad   N, Henry   L, Hunt   S, Holmes   SD. Do we increase the operative risk by adding the Cox Maze III procedure to aortic valve replacement and coronary artery bypass surgery?  J Thorac Cardiovasc Surg  2012;143:936–44. https://doi.org/10.1016/j.jtcvs.2011.12.018
  
696	Maesen   B, van der Heijden   CAJ, Bidar   E, Vos   R, Athanasiou   T, Maessen   JG. Patient-reported quality of life after stand-alone and concomitant arrhythmia surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg  2022;34:339–48. https://doi.org/10.1093/icvts/ivab282
  
697	Osmancik   P, Budera   P, Talavera   D, Hlavicka   J, Herman   D, Holy   J, et al.   Five-year outcomes in cardiac surgery patients with atrial fibrillation undergoing concomitant surgical ablation versus no ablation. The long-term follow-up of the PRAGUE-12 study. Heart Rhythm  2019;16:1334–40. https://doi.org/10.1016/j.hrthm.2019.05.001
  
698	Lee   R, Jivan   A, Kruse   J, McGee   EC, Jr, Malaisrie   SC, Bernstein   R, et al.   Late neurologic events after surgery for atrial fibrillation: rare but relevant. Ann Thorac Surg  2013;95:126–31; discussion 131–2. https://doi.org/10.1016/j.athoracsur.2012.08.048
  
699	Kowalewski   M, Pasierski   M, Kołodziejczak   M, Litwinowicz   R, Kowalówka   A, Wańha   W, et al.   Atrial fibrillation ablation improves late survival after concomitant cardiac surgery. J Thorac Cardiovasc Surg  2023;166:1656–1668.e8. https://doi.org/10.1016/j.jtcvs.2022.04.035
  
700	Cox   JL, Ad   N, Palazzo   T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg  1999;118:833–40. https://doi.org/10.1016/S0022-5223(99)70052-8
  
701	Huffman   MD, Karmali   KN, Berendsen   MA, Andrei   AC, Kruse   J, McCarthy   PM, et al.   Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. Cochrane Database Syst Rev  2016;8:CD011814. https://doi.org/10.1002/14651858.CD011814.pub2
Google ScholarWorldCat 
702	Kowalewski   M, Pasierski   M, Finke   J, Kolodziejczak   M, Staromlynski   J, Litwinowicz   R, et al.   Permanent pacemaker implantation after valve and arrhythmia surgery in patients with preoperative atrial fibrillation. Heart Rhythm  2022;19:1442–9. https://doi.org/10.1016/j.hrthm.2022.04.007
  
703	Pokushalov   E, Romanov   A, Corbucci   G, Cherniavsky   A, Karaskov   A. Benefit of ablation of first diagnosed paroxysmal atrial fibrillation during coronary artery bypass grafting: a pilot study. Eur J Cardiothorac Surg  2012;41:556–60. https://doi.org/10.1093/ejcts/ezr101
  
704	Yoo   JS, Kim   JB, Ro   SK, Jung   Y, Jung   SH, Choo   SJ, et al.   Impact of concomitant surgical atrial fibrillation ablation in patients undergoing aortic valve replacement. Circ J  2014;78:1364–71. https://doi.org/10.1253/circj.CJ-13-1533
  
705	Malaisrie   SC, Lee   R, Kruse   J, Lapin   B, Wang   EC, Bonow   RO, et al.   Atrial fibrillation ablation in patients undergoing aortic valve replacement. J Heart Valve Dis  2012;21:350–7.
Google ScholarPubMedWorldCat 
706	Rankin   JS, Lerner   DJ, Braid-Forbes   MJ, Ferguson   MA, Badhwar   V. One-year mortality and costs associated with surgical ablation for atrial fibrillation concomitant to coronary artery bypass grafting. Eur J Cardiothorac Surg  2017;52:471–7. https://doi.org/10.1093/ejcts/ezx126
  
707	Schill   MR, Musharbash   FN, Hansalia   V, Greenberg   JW, Melby   SJ, Maniar   HS, et al.   Late results of the Cox-Maze IV procedure in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg  2017;153:1087–94. https://doi.org/10.1016/j.jtcvs.2016.12.034
  
708	Gupta   D, Ding   WY, Calvert   P, Williams   E, Das   M, Tovmassian   L, et al.   Cryoballoon pulmonary vein isolation as first-line treatment for typical atrial flutter. Heart  2023;109:364–71. https://doi.org/10.1136/heartjnl-2022-321729
Google ScholarPubMedWorldCat 
709	Steinberg   C, Champagne   J, Deyell   MW, Dubuc   M, Leong-Sit   P, Calkins   H, et al.   Prevalence and outcome of early recurrence of atrial tachyarrhythmias in the cryoballoon vs irrigated radiofrequency catheter ablation (CIRCA-DOSE) study. Heart Rhythm  2021;18:1463–70. https://doi.org/10.1016/j.hrthm.2021.06.1172
  
710	Heijman   J, Linz   D, Schotten   U. Dynamics of atrial fibrillation mechanisms and comorbidities. Annu Rev Physiol  2021;83:83–106. https://doi.org/10.1146/annurev-physiol-031720-085307
  
711	Fabritz   L, Crijns   H, Guasch   E, Goette   A, Hausler   KG, Kotecha   D, et al.   Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA consensus conference. Europace  2021;23:329–44. https://doi.org/10.1093/europace/euaa279
  
712	Brandes   A, Smit   MD, Nguyen   BO, Rienstra   M, Van Gelder   IC. Risk factor management in atrial fibrillation. Arrhythm Electrophysiol Rev  2018;7:118–27. https://doi.org/10.15420/aer.2018.18.2
  
713	Pokorney   SD, Cocoros   N, Al-Khalidi   HR, Haynes   K, Li   S, Al-Khatib   SM, et al.   Effect of mailing educational material to patients with atrial fibrillation and their clinicians on use of oral anticoagulants: a randomized clinical trial. JAMA Netw Open  2022;5:e2214321. https://doi.org/10.1001/jamanetworkopen.2022.14321
  
714	Ritchie   LA, Penson   PE, Akpan   A, Lip   GYH, Lane   DA. Integrated care for atrial fibrillation management: the role of the pharmacist. Am J Med  2022;135:1410–26. https://doi.org/10.1016/j.amjmed.2022.07.014
  
715	Guo   Y, Guo   J, Shi   X, Yao   Y, Sun   Y, Xia   Y, et al.   Mobile health technology-supported atrial fibrillation screening and integrated care: a report from the mAFA-II trial long-term extension cohort. Eur J Intern Med  2020;82:105–11. https://doi.org/10.1016/j.ejim.2020.09.024
  
716	Yan   H, Du   YX, Wu   FQ, Lu   XY, Chen   RM, Zhang   Y. Effects of nurse-led multidisciplinary team management on cardiovascular hospitalization and quality of life in patients with atrial fibrillation: randomized controlled trial. Int J Nurs Stud  2022;127:104159. https://doi.org/10.1016/j.ijnurstu.2021.104159
  
717	Stewart   S, Ball   J, Horowitz   JD, Marwick   TH, Mahadevan   G, Wong   C, et al.   Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet  2015;385:775–84. https://doi.org/10.1016/S0140-6736(14)61992-9
  
718	Cox   JL, Parkash   R, Foster   GA, Xie   F, MacKillop   JH, Ciaccia   A, et al.   Integrated management program advancing community treatment of atrial fibrillation (IMPACT-AF): a cluster randomized trial of a computerized clinical decision support tool. Am Heart J  2020;224:35–46. https://doi.org/10.1016/j.ahj.2020.02.019
  
719	Sposato   LA, Stirling   D, Saposnik   G. Therapeutic decisions in atrial fibrillation for stroke prevention: the role of aversion to ambiguity and physicians’ risk preferences. J Stroke Cerebrovasc Dis  2018;27:2088–95. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.03.005
  
720	Noseworthy   PA, Brito   JP, Kunneman   M, Hargraves   IG, Zeballos-Palacios   C, Montori   VM, et al.   Shared decision-making in atrial fibrillation: navigating complex issues in partnership with the patient. J Interv Card Electrophysiol  2019;56:159–63. https://doi.org/10.1007/s10840-018-0465-5
  
721	Poorcheraghi   H, Negarandeh   R, Pashaeypoor   S, Jorian   J. Effect of using a mobile drug management application on medication adherence and hospital readmission among elderly patients with polypharmacy: a randomized controlled trial. BMC Health Serv Res  2023;23:1192. https://doi.org/10.1186/s12913-023-10177-4
  
722	Kotecha   D, Chua   WWL, Fabritz   L, Hendriks   J, Casadei   B, Schotten   U, et al.   European Society of Cardiology (ESC) Atrial Fibrillation Guidelines Taskforce, the CATCH ME consortium, and the European Heart Rhythm Association (EHRA). European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. Europace  2018;20:225–33. https://doi.org/10.1093/europace/eux299
  
723	Bunting   KV, Gill   SK, Sitch   A, Mehta   S, O’Connor   K, Lip   GY, et al.   Improving the diagnosis of heart failure in patients with atrial fibrillation. Heart  2021;107:902–8. https://doi.org/10.1136/heartjnl-2020-318557
  
724	Donal   E, Lip   GY, Galderisi   M, Goette   A, Shah   D, Marwan   M, et al.   EACVI/EHRA expert consensus document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging  2016;17:355–83. https://doi.org/10.1093/ehjci/jev354
  
725	Bunting   KV, O’Connor   K, Steeds   RP, Kotecha   D. Cardiac imaging to assess left ventricular systolic function in atrial fibrillation. Am J Cardiol  2021;139:40–9. https://doi.org/10.1016/j.amjcard.2020.10.012
  
726	Timperley   J, Mitchell   AR, Becher   H. Contrast echocardiography for left ventricular opacification. Heart  2003;89:1394–7. https://doi.org/10.1136/heart.89.12.1394
  
727	Kotecha   D, Mohamed   M, Shantsila   E, Popescu   BA, Steeds   RP. Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review. Europace  2017;19:1427–38. https://doi.org/10.1093/europace/eux027
  
728	Quintana   RA, Dong   T, Vajapey   R, Reyaldeen   R, Kwon   DH, Harb   S, et al.   Preprocedural multimodality imaging in atrial fibrillation. Circ Cardiovasc Imaging  2022;15:e014386. https://doi.org/10.1161/CIRCIMAGING.122.014386
Google ScholarPubMedWorldCat 
729	Laubrock   K, von Loesch   T, Steinmetz   M, Lotz   J, Frahm   J, Uecker   M, et al.   Imaging of arrhythmia: real-time cardiac magnetic resonance imaging in atrial fibrillation. Eur J Radiol Open  2022;9:100404. https://doi.org/10.1016/j.ejro.2022.100404
  
730	Sciagrà   R, Sotgia   B, Boni   N, Pupi   A. Assessment of the influence of atrial fibrillation on gated SPECT perfusion data by comparison with simultaneously acquired nongated SPECT data. J Nucl Med  2008;49:1283–7. https://doi.org/10.2967/jnumed.108.051797
  
731	Clayton   B, Roobottom   C, Morgan-Hughes   G. CT coronary angiography in atrial fibrillation: a comparison of radiation dose and diagnostic confidence with retrospective gating vs prospective gating with systolic acquisition. Br J Radiol  2015;88:20150533. https://doi.org/10.1259/bjr.20150533
  
732	Thrall   G, Lane   D, Carroll   D, Lip   GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med  2006;119:448.e1–19. https://doi.org/10.1016/j.amjmed.2005.10.057
  
733	Steinberg   BA, Dorian   P, Anstrom   KJ, Hess   R, Mark   DB, Noseworthy   PA, et al.   Patient-reported outcomes in atrial fibrillation research: results of a Clinicaltrials.gov analysis. JACC Clin Electrophysiol  2019;5:599–605. https://doi.org/10.1016/j.jacep.2019.03.008
  
734	Potpara   TS, Mihajlovic   M, Zec   N, Marinkovic   M, Kovacevic   V, Simic   J, et al.   Self-reported treatment burden in patients with atrial fibrillation: quantification, major determinants, and implications for integrated holistic management of the arrhythmia. Europace  2020;22:1788–97. https://doi.org/10.1093/europace/euaa210
  
735	Moons   P, Norekvål   TM, Arbelo   E, Borregaard   B, Casadei   B, Cosyns   B, et al.   Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management. Eur Heart J  2023;44:3405–22. https://doi.org/10.1093/eurheartj/ehad514
  
736	Allan   KS, Aves   T, Henry   S, Banfield   L, Victor   JC, Dorian   P, et al.   Health-related quality of life in patients with atrial fibrillation treated with catheter ablation or antiarrhythmic drug therapy: a systematic review and meta-analysis. CJC Open  2020;2:286–95. https://doi.org/10.1016/j.cjco.2020.03.013
  
737	Vanderhout   S, Fergusson   DA, Cook   JA, Taljaard   M. Patient-reported outcomes and target effect sizes in pragmatic randomized trials in ClinicalTrials.gov: a cross-sectional analysis. PLoS Med  2022;19:e1003896. https://doi.org/10.1371/journal.pmed.1003896
  
738	Steinberg   BA, Piccini   JP, Sr. Tackling patient-reported outcomes in atrial fibrillation and heart failure: identifying disease-specific symptoms?  Cardiol Clin  2019;37:139–46. https://doi.org/10.1016/j.ccl.2019.01.013
  
739	Härdén   M, Nyström   B, Bengtson   A, Medin   J, Frison   L, Edvardsson   N. Responsiveness of AF6, a new, short, validated, atrial fibrillation-specific questionnaire—symptomatic benefit of direct current cardioversion. J Interv Card Electrophysiol  2010;28:185–91. https://doi.org/10.1007/s10840-010-9487-3
  
740	Tailachidis   P, Tsimtsiou   Z, Galanis   P, Theodorou   M, Kouvelas   D, Athanasakis   K. The atrial fibrillation effect on QualiTy-of-Life (AFEQT) questionnaire: cultural adaptation and validation of the Greek version. Hippokratia  2016;20:264–7.
Google ScholarPubMedWorldCat 
741	Moreira   RS, Bassolli   L, Coutinho   E, Ferrer   P, Bragança   ÉO, Carvalho   AC, et al.   Reproducibility and reliability of the quality of life questionnaire in patients with atrial fibrillation. Arq Bras Cardiol  2016;106:171–81. https://doi.org/10.5935/abc.20160026
Google ScholarPubMedWorldCat 
742	Arribas   F, Ormaetxe   JM, Peinado   R, Perulero   N, Ramírez   P, Badia   X. Validation of the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. Europace  2010;12:364–70. https://doi.org/10.1093/europace/eup421
  
743	Braganca   EO, Filho   BL, Maria   VH, Levy   D, de Paola   AA. Validating a new quality of life questionnaire for atrial fibrillation patients. Int J Cardiol  2010;143:391–8. https://doi.org/10.1016/j.ijcard.2009.03.087
  
744	International Consortium for Health Outcomes Measurement. Atrial fibrillation data collection reference guide Version 5.0.1. https://connect.ichom.org/wp-content/uploads/2023/02/03-Atrial-Fibrillation-Reference-Guide-2023.5.0.1.pdf.
745	Dan   GA, Dan   AR, Ivanescu   A, Buzea   AC. Acute rate control in atrial fibrillation: an urgent need for the clinician. Eur Heart J Suppl  2022;24:D3–D10. https://doi.org/10.1093/eurheartjsupp/suac022
  
746	Shima   N, Miyamoto   K, Kato   S, Yoshida   T, Uchino   S; AFTER-ICU study group. Primary success of electrical cardioversion for new-onset atrial fibrillation and its association with clinical course in non-cardiac critically ill patients: sub-analysis of a multicenter observational study. J Intensive Care  2021;9:46. https://doi.org/10.1186/s40560-021-00562-8
  
747	Betthauser   KD, Gibson   GA, Piche   SL, Pope   HE. Evaluation of amiodarone use for new-onset atrial fibrillation in critically ill patients with septic shock. Hosp Pharm  2021;56:116–23. https://doi.org/10.1177/0018578719868405
  
748	Drikite   L, Bedford   JP, O’Bryan   L, Petrinic   T, Rajappan   K, Doidge   J, et al.   Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review. Crit Care  2021;25:257. https://doi.org/10.1186/s13054-021-03684-5
  
749	Bedford   JP, Johnson   A, Redfern   O, Gerry   S, Doidge   J, Harrison   D, et al.   Comparative effectiveness of common treatments for new-onset atrial fibrillation within the ICU: accounting for physiological status. J Crit Care  2022;67:149–56. https://doi.org/10.1016/j.jcrc.2021.11.005
  
750	Iwahashi   N, Takahashi   H, Abe   T, Okada   K, Akiyama   E, Matsuzawa   Y, et al.   Urgent control of rapid atrial fibrillation by landiolol in patients with acute decompensated heart failure with severely reduced ejection fraction. Circ Rep  2019;1:422–30. https://doi.org/10.1253/circrep.CR-19-0076
  
751	Unger   M, Morelli   A, Singer   M, Radermacher   P, Rehberg   S, Trimmel   H, et al.   Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial. Trials  2018;19:637. https://doi.org/10.1186/s13063-018-3024-6
  
752	Gonzalez-Pacheco   H, Marquez   MF, Arias-Mendoza   A, Alvarez-Sangabriel   A, Eid-Lidt   G, Gonzalez-Hermosillo   A, et al.   Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation. J Cardiol  2015;66:148–54. https://doi.org/10.1016/j.jjcc.2014.11.001
  
753	Krijthe   BP, Leening   MJ, Heeringa   J, Kors   JA, Hofman   A, Franco   OH, et al.   Unrecognized myocardial infarction and risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol  2013;168:1453–7. https://doi.org/10.1016/j.ijcard.2012.12.057
  
754	Soliman   EZ, Safford   MM, Muntner   P, Khodneva   Y, Dawood   FZ, Zakai   NA, et al.   Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med  2014;174:107–14. https://doi.org/10.1001/jamainternmed.2013.11912
  
755	Kralev   S, Schneider   K, Lang   S, Suselbeck   T, Borggrefe   M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One  2011;6:e24964. https://doi.org/10.1371/journal.pone.0024964
  
756	Coscia   T, Nestelberger   T, Boeddinghaus   J, Lopez-Ayala   P, Koechlin   L, Miró   Ò, et al.   Characteristics and outcomes of type 2 myocardial infarction. JAMA Cardiol  2022;7:427–34. https://doi.org/10.1001/jamacardio.2022.0043
  
757	Guimaraes   PO, Zakroysky   P, Goyal   A, Lopes   RD, Kaltenbach   LA, Wang   TY. Usefulness of antithrombotic therapy in patients with atrial fibrillation and acute myocardial infarction. Am J Cardiol  2019;123:12–8. https://doi.org/10.1016/j.amjcard.2018.09.031
  
758	Erez   A, Goldenberg   I, Sabbag   A, Nof   E, Zahger   D, Atar   S, et al.   Temporal trends and outcomes associated with atrial fibrillation observed during acute coronary syndrome: real-world data from the Acute Coronary Syndrome Israeli Survey (ACSIS), 2000–2013. Clin Cardiol  2017;40:275–80. https://doi.org/10.1002/clc.22654
  
759	Vrints C, Andreotti F, Koskinas K, Rossell X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024. https://doi.org/10.1093/eurheartj/ehae177
760	Byrne   RA, Rossello   X, Coughlan   JJ, Barbato   E, Berry   C, Chieffo   A, et al.   2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J  2023;44:3720–826. https://doi.org/10.1093/eurheartj/ehad191
  
761	Park   DY, Wang   P, An   S, Grimshaw   AA, Frampton   J, Ohman   EM, et al.   Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis. Am Heart J  2022;251:101–14. https://doi.org/10.1016/j.ahj.2022.05.019
  
762	Gargiulo   G, Goette   A, Tijssen   J, Eckardt   L, Lewalter   T, Vranckx   P, et al.   Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J  2019;40:3757–67. https://doi.org/10.1093/eurheartj/ehz732
  
763	Dewilde   WJ, Oirbans   T, Verheugt   FW, Kelder   JC, De Smet   BJ, Herrman   JP, et al.   Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet  2013;381:1107–15. https://doi.org/10.1016/S0140-6736(12)62177-1
  
764	Lopes   RD, Heizer   G, Aronson   R, Vora   AN, Massaro   T, Mehran   R, et al.   Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med  2019;380:1509–24. https://doi.org/10.1056/NEJMoa1817083
  
765	Gibson   CM, Mehran   R, Bode   C, Halperin   J, Verheugt   FW, Wildgoose   P, et al.   Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med  2016;375:2423–34. https://doi.org/10.1056/NEJMoa1611594
  
766	Cannon   CP, Bhatt   DL, Oldgren   J, Lip   GYH, Ellis   SG, Kimura   T, et al.   Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med  2017;377:1513–24. https://doi.org/10.1056/NEJMoa1708454
  
767	Vranckx   P, Valgimigli   M, Eckardt   L, Tijssen   J, Lewalter   T, Gargiulo   G, et al.   Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet  2019;394:1335–43. https://doi.org/10.1016/S0140-6736(19)31872-0
  
768	Lopes   RD, Hong   H, Harskamp   RE, Bhatt   DL, Mehran   R, Cannon   CP, et al.   Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol  2019;4:747–55. https://doi.org/10.1001/jamacardio.2019.1880
  
769	Oldgren   J, Steg   PG, Hohnloser   SH, Lip   GYH, Kimura   T, Nordaby   M, et al.   Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J  2019;40:1553–62. https://doi.org/10.1093/eurheartj/ehz059
  
770	Potpara   TS, Mujovic   N, Proietti   M, Dagres   N, Hindricks   G, Collet   JP, et al.   Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace  2020;22:33–46. https://doi.org/10.1093/europace/euz259
  
771	Haller   PM, Sulzgruber   P, Kaufmann   C, Geelhoed   B, Tamargo   J, Wassmann   S, et al.   Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother  2019;5:226–36. https://doi.org/10.1093/ehjcvp/pvz021
  
772	Lopes   RD, Hong   H, Harskamp   RE, Bhatt   DL, Mehran   R, Cannon   CP, et al.   Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis. JAMA Cardiol  2020;5:582–9. https://doi.org/10.1001/jamacardio.2019.6175
  
773	Lopes   RD, Vora   AN, Liaw   D, Granger   CB, Darius   H, Goodman   SG, et al.   An open-label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial. Am Heart J  2018;200:17–23. https://doi.org/10.1016/j.ahj.2018.03.001
  
774	Windecker   S, Lopes   RD, Massaro   T, Jones-Burton   C, Granger   CB, Aronson   R, et al.   Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS trial. Circulation  2019;140:1921–32. https://doi.org/10.1161/CIRCULATIONAHA.119.043308
  
775	Harskamp   RE, Fanaroff   AC, Lopes   RD, Wojdyla   DM, Goodman   SG, Thomas   LE, et al.   Antithrombotic therapy in patients with atrial fibrillation after acute coronary syndromes or percutaneous intervention. J Am Coll Cardiol  2022;79:417–27. https://doi.org/10.1016/j.jacc.2021.11.035
  
776	Alexander   JH, Wojdyla   D, Vora   AN, Thomas   L, Granger   CB, Goodman   SG, et al.   Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. Circulation  2020;141:1618–27. https://doi.org/10.1161/CIRCULATIONAHA.120.046534
  
777	Moayyedi   P, Eikelboom   JW, Bosch   J, Connolly   SJ, Dyal   L, Shestakovska   O, et al.   Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology  2019;157:682–691.e2. https://doi.org/10.1053/j.gastro.2019.05.056
  
778	Jeridi   D, Pellat   A, Ginestet   C, Assaf   A, Hallit   R, Corre   F, et al.   The safety of long-term proton pump inhibitor use on cardiovascular health: a meta-analysis. J Clin Med  2022;11:4096. https://doi.org/10.3390/jcm11144096
  
779	Scally   B, Emberson   JR, Spata   E, Reith   C, Davies   K, Halls   H, et al.   Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol  2018;3:231–41. https://doi.org/10.1016/S2468-1253(18)30037-2
  
780	Fiedler   KA, Maeng   M, Mehilli   J, Schulz-Schupke   S, Byrne   RA, Sibbing   D, et al.   Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol  2015;65:1619–29. https://doi.org/10.1016/j.jacc.2015.02.050
  
781	Matsumura-Nakano   Y, Shizuta   S, Komasa   A, Morimoto   T, Masuda   H, Shiomi   H, et al.   Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation  2019;139:604–16. https://doi.org/10.1161/CIRCULATIONAHA.118.036768
  
782	Jensen   T, Thrane   PG, Olesen   KKW, Würtz   M, Mortensen   MB, Gyldenkerne   C, et al.   Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother  2023;9:208–19. https://doi.org/10.1093/ehjcvp/pvac058
  
783	Vitalis   A, Shantsila   A, Proietti   M, Vohra   RK, Kay   M, Olshansky   B, et al.   Peripheral arterial disease in patients with atrial fibrillation: the AFFIRM study. Am J Med  2021;134:514–8. https://doi.org/10.1016/j.amjmed.2020.08.026
  
784	Wasmer   K, Unrath   M, Köbe   J, Malyar   NM, Freisinger   E, Meyborg   M, et al.   Atrial fibrillation is a risk marker for worse in-hospital and long-term outcome in patients with peripheral artery disease. Int J Cardiol  2015;199:223–8. https://doi.org/10.1016/j.ijcard.2015.06.094
  
785	Griffin   WF, Salahuddin   T, O’Neal   WT, Soliman   EZ. Peripheral arterial disease is associated with an increased risk of atrial fibrillation in the elderly. Europace  2016;18:794–8. https://doi.org/10.1093/europace/euv369
  
786	Lin   LY, Lee   CH, Yu   CC, Tsai   CT, Lai   LP, Hwang   JJ, et al.   Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation—a nation wide database analysis. Atherosclerosis  2011;217:292–5. https://doi.org/10.1016/j.atherosclerosis.2011.03.033
  
787	Su   MI, Cheng   YC, Huang   YC, Liu   CW. The impact of atrial fibrillation on one-year mortality in patients with severe lower extremity arterial disease. J Clin Med  2022;11:1936. https://doi.org/10.3390/jcm11071936
  
788	Winkel   TA, Hoeks   SE, Schouten   O, Zeymer   U, Limbourg   T, Baumgartner   I, et al.   Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. Eur J Vasc Endovasc Surg  2010;40:9–16. https://doi.org/10.1016/j.ejvs.2010.03.003
  
789	Nejim   B, Mathlouthi   A, Weaver   L, Faateh   M, Arhuidese   I, Malas   MB. Safety of carotid artery revascularization procedures in patients with atrial fibrillation. J Vasc Surg  2020;72:2069–2078.e4. https://doi.org/10.1016/j.jvs.2020.01.074
  
790	Jones   WS, Hellkamp   AS, Halperin   J, Piccini   JP, Breithardt   G, Singer   DE, et al.   Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J  2014;35:242–9. https://doi.org/10.1093/eurheartj/eht492
  
791	Aboyans   V, Ricco   JB, Bartelink   MEL, Björck   M, Brodmann   M, Cohnert   T, et al.   2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J  2018;39:763–816. https://doi.org/10.1093/eurheartj/ehx095
  
792	Schirmer   CM, Bulsara   KR, Al-Mufti   F, Haranhalli   N, Thibault   L, Hetts   SW. Antiplatelets and antithrombotics in neurointerventional procedures: guideline update. J Neurointerv Surg  2023;15:1155–62. https://doi.org/10.1136/jnis-2022-019844
  
793	Berge   E, Whiteley   W, Audebert   H, De Marchis   GM, Fonseca   AC, Padiglioni   C, et al.   European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J  2021;6:I–LXII. https://doi.org/10.1177/2396987321989865
  
794	Caso   V, Masuhr   F. A narrative review of nonvitamin K antagonist oral anticoagulant use in secondary stroke prevention. J Stroke Cerebrovasc Dis  2019;28:2363–75. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.05.017
  
795	Fischer   U, Koga   M, Strbian   D, Branca   M, Abend   S, Trelle   S, et al.   Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med  2023;388:2411–21. https://doi.org/10.1056/NEJMoa2303048
  
796	Oldgren   J, Åsberg   S, Hijazi   Z, Wester   P, Bertilsson   M, Norrving   B. Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): a registry-based randomized controlled noninferiority study. Circulation  2022;146:1056–66. https://doi.org/10.1161/CIRCULATIONAHA.122.060666
  
797	Schreuder   F, van Nieuwenhuizen   KM, Hofmeijer   J, Vermeer   SE, Kerkhoff   H, Zock   E, et al.   Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in The Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol  2021;20:907–16. https://doi.org/10.1016/S1474-4422(21)00298-2
  
798	SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol  2021;20:842–53. https://doi.org/10.1016/S1474-4422(21)00264-7
CrossrefPubMedWorldCat 
799	Klein Klouwenberg   PM, Frencken   JF, Kuipers   S, Ong   DS, Peelen   LM, van Vught   LA, et al.   Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis. A cohort study. Am J Respir Crit Care Med  2017;195:205–11. https://doi.org/10.1164/rccm.201603-0618OC
  
800	Gundlund   A, Olesen   JB, Butt   JH, Christensen   MA, Gislason   GH, Torp-Pedersen   C, et al.   One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study. Eur Heart J  2020;41:1112–9. https://doi.org/10.1093/eurheartj/ehz873
  
801	Induruwa   I, Hennebry   E, Hennebry   J, Thakur   M, Warburton   EA, Khadjooi   K. Sepsis-driven atrial fibrillation and ischaemic stroke. Is there enough evidence to recommend anticoagulation?  Eur J Intern Med  2022;98:32–6. https://doi.org/10.1016/j.ejim.2021.10.022
  
802	Ko   D, Saleeba   C, Sadiq   H, Crawford   S, Paul   T, Shi   Q, et al.   Secondary precipitants of atrial fibrillation and anticoagulation therapy. J Am Heart Assoc  2021;10:e021746. https://doi.org/10.1161/JAHA.121.021746
  
803	Li   YG, Borgi   M, Lip   GY. Atrial fibrillation occurring initially during acute medical illness: the heterogeneous nature of disease, outcomes and management strategies. Eur Heart J Acute Cardiovasc Care  2018;10:2048872618801763. https://doi.org/10.1177/2048872618801763
Google ScholarWorldCat 
804	Lowres   N, Hillis   GS, Gladman   MA, Kol   M, Rogers   J, Chow   V, et al.   Self-monitoring for recurrence of secondary atrial fibrillation following non-cardiac surgery or acute illness: a pilot study. Int J Cardiol Heart Vasc  2020;29:100566. https://doi.org/10.1016/j.ijcha.2020.100566
Google ScholarPubMedWorldCat 
805	Søgaard   M, Skjøth   F, Nielsen   PB, Smit   J, Dalager-Pedersen   M, Larsen   TB, et al.   Thromboembolic risk in patients with pneumonia and new-onset atrial fibrillation not receiving anticoagulation therapy. JAMA Netw Open  2022;5:e2213945. https://doi.org/10.1001/jamanetworkopen.2022.13945
  
806	Walkey   AJ, Hammill   BG, Curtis   LH, Benjamin   EJ. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest  2014;146:1187–95. https://doi.org/10.1378/chest.14-0003
  
807	McIntyre   WF, Um   KJ, Cheung   CC, Belley-Côté   EP, Dingwall   O, Devereaux   PJ, et al.   Atrial fibrillation detected initially during acute medical illness: a systematic review. Eur Heart J Acute Cardiovasc Care  2019;8:130–41. https://doi.org/10.1177/2048872618799748
  
808	Marcus   GM, Vittinghoff   E, Whitman   IR, Joyce   S, Yang   V, Nah   G, et al.   Acute consumption of alcohol and discrete atrial fibrillation events. Ann Intern Med  2021;174:1503–9. https://doi.org/10.7326/M21-0228
  
809	Marcus   GM, Modrow   MF, Schmid   CH, Sigona   K, Nah   G, Yang   J, et al.   Individualized studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial. JAMA Cardiol  2022;7:167–74. https://doi.org/10.1001/jamacardio.2021.5010
  
810	Lin   AL, Nah   G, Tang   JJ, Vittinghoff   E, Dewland   TA, Marcus   GM. Cannabis, cocaine, methamphetamine, and opiates increase the risk of incident atrial fibrillation. Eur Heart J  2022;43:4933–42. https://doi.org/10.1093/eurheartj/ehac558
  
811	Butt   JH, Olesen   JB, Havers-Borgersen   E, Gundlund   A, Andersson   C, Gislason   GH, et al.   Risk of thromboembolism associated with atrial fibrillation following noncardiac surgery. J Am Coll Cardiol  2018;72:2027–36. https://doi.org/10.1016/j.jacc.2018.07.088
  
812	Gundlund   A, Kümler   T, Bonde   AN, Butt   JH, Gislason   GH, Torp-Pedersen   C, et al.   Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant–Danish nationwide cohort study. BMJ Open  2019;9:e028468. https://doi.org/10.1136/bmjopen-2018-028468
  
813	Walkey   AJ, Quinn   EK, Winter   MR, McManus   DD, Benjamin   EJ. Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis. JAMA Cardiol  2016;1:682–90. https://doi.org/10.1001/jamacardio.2016.2181
  
814	Darwish   OS, Strube   S, Nguyen   HM, Tanios   MA. Challenges of anticoagulation for atrial fibrillation in patients with severe sepsis. Ann Pharmacother  2013;47:1266–71. https://doi.org/10.1177/1060028013500938
  
815	Quon   MJ, Behlouli   H, Pilote   L. Anticoagulant use and risk of ischemic stroke and bleeding in patients with secondary atrial fibrillation associated with acute coronary syndromes, acute pulmonary disease, or sepsis. JACC Clin Electrophysiol  2018;4:386–93. https://doi.org/10.1016/j.jacep.2017.08.003
  
816	Echahidi   N, Pibarot   P, O’Hara   G, Mathieu   P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol  2008;51:793–801. https://doi.org/10.1016/j.jacc.2007.10.043
  
817	Gillinov   AM, Bagiella   E, Moskowitz   AJ, Raiten   JM, Groh   MA, Bowdish   ME, et al.   Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med  2016;374:1911–21. https://doi.org/10.1056/NEJMoa1602002
  
818	Gaudino   M, Di Franco   A, Rong   LQ, Piccini   J, Mack   M. Postoperative atrial fibrillation: from mechanisms to treatment. Eur Heart J  2023;44:1020–39. https://doi.org/10.1093/eurheartj/ehad019
  
819	Kotecha   D, Castella   M. Is it time to treat post-operative atrial fibrillation just like regular atrial fibrillation?  Eur Heart J  2020;41:652–654a. https://doi.org/10.1093/eurheartj/ehz412
  
820	Konstantino   Y, Zelnik Yovel   D, Friger   MD, Sahar   G, Knyazer   B, Amit   G. Postoperative atrial fibrillation following coronary artery bypass graft surgery predicts long-term atrial fibrillation and stroke. Isr Med Assoc J  2016;18:744–8.
Google ScholarPubMedWorldCat 
821	Lee   SH, Kang   DR, Uhm   JS, Shim   J, Sung   JH, Kim   JY, et al.   New-onset atrial fibrillation predicts long-term newly developed atrial fibrillation after coronary artery bypass graft. Am Heart J  2014;167:593–600.e1. https://doi.org/10.1016/j.ahj.2013.12.010
  
822	Lin   MH, Kamel   H, Singer   DE, Wu   YL, Lee   M, Ovbiagele   B. Perioperative/postoperative atrial fibrillation and risk of subsequent stroke and/or mortality. Stroke  2019;50:1364–71. https://doi.org/10.1161/STROKEAHA.118.023921
  
823	AlTurki   A, Marafi   M, Proietti   R, Cardinale   D, Blackwell   R, Dorian   P, et al.   Major adverse cardiovascular events associated with postoperative atrial fibrillation after noncardiac surgery: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol  2020;13:e007437. https://doi.org/10.1161/CIRCEP.119.007437
  
824	Goyal   P, Kim   M, Krishnan   U, McCullough   SA, Cheung   JW, Kim   LK, et al.   Post-operative atrial fibrillation and risk of heart failure hospitalization. Eur Heart J  2022;43:2971–80. https://doi.org/10.1093/eurheartj/ehac285
  
825	Eikelboom   R, Sanjanwala   R, Le   ML, Yamashita   MH, Arora   RC. Postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis. Ann Thorac Surg  2021;111:544–54. https://doi.org/10.1016/j.athoracsur.2020.05.104
  
826	Benedetto   U, Gaudino   MF, Dimagli   A, Gerry   S, Gray   A, Lees   B, et al.   Postoperative atrial fibrillation and long-term risk of stroke after isolated coronary artery bypass graft surgery. Circulation  2020;142:1320–9. https://doi.org/10.1161/CIRCULATIONAHA.120.046940
  
827	Taha   A, Nielsen   SJ, Bergfeldt   L, Ahlsson   A, Friberg   L, Björck   S, et al.   New-onset atrial fibrillation after coronary artery bypass grafting and long-term outcome: a population-based nationwide study from the SWEDEHEART registry. J Am Heart Assoc  2021;10:e017966. https://doi.org/10.1161/JAHA.120.017966
  
828	Dobrev   D, Aguilar   M, Heijman   J, Guichard   JB, Nattel   S. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol  2019;16:417–36. https://doi.org/10.1038/s41569-019-0166-5
  
829	Mathew   JP, Fontes   ML, Tudor   IC, Ramsay   J, Duke   P, Mazer   CD, et al.   A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA  2004;291:1720–9. https://doi.org/10.1001/jama.291.14.1720
  
830	Villareal   RP, Hariharan   R, Liu   BC, Kar   B, Lee   VV, Elayda   M, et al.   Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol  2004;43:742–8. https://doi.org/10.1016/j.jacc.2003.11.023
  
831	Cardinale   D, Sandri   MT, Colombo   A, Salvatici   M, Tedeschi   I, Bacchiani   G, et al.   Prevention of atrial fibrillation in high-risk patients undergoing lung cancer surgery: the PRESAGE trial. Ann Surg  2016;264:244–51. https://doi.org/10.1097/SLA.0000000000001626
  
832	Ojima   T, Nakamori   M, Nakamura   M, Katsuda   M, Hayata   K, Kato   T, et al.   Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. Br J Surg  2017;104:1003–9. https://doi.org/10.1002/bjs.10548
  
833	Arsenault   KA, Yusuf   AM, Crystal   E, Healey   JS, Morillo   CA, Nair   GM, et al.   Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev  2013;1:CD003611. https://doi.org/10.1002/14651858.CD003611.pub3
Google ScholarWorldCat 
834	Ozaydin   M, Icli   A, Yucel   H, Akcay   S, Peker   O, Erdogan   D, et al.   Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. Eur Heart J  2013;34:597–604. https://doi.org/10.1093/eurheartj/ehs423
  
835	O’Neal   JB, Billings   F, Liu   X, Shotwell   MS, Liang   Y, Shah   AS, et al.   Effect of preoperative beta-blocker use on outcomes following cardiac surgery. Am J Cardiol  2017;120:1293–7. https://doi.org/10.1016/j.amjcard.2017.07.012
  
836	Ziff   OJ, Samra   M, Howard   JP, Bromage   DI, Ruschitzka   F, Francis   DP, et al.   Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med  2020;18:103. https://doi.org/10.1186/s12916-020-01564-3
  
837	Tisdale   JE, Wroblewski   HA, Wall   DS, Rieger   KM, Hammoud   ZT, Young   JV, et al.   A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection. Ann Thorac Surg  2009;88:886–93; discussion 894–5. https://doi.org/10.1016/j.athoracsur.2009.04.074
  
838	Auer   J, Weber   T, Berent   R, Puschmann   R, Hartl   P, Ng   CK, et al.   A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot Study of Prevention of Postoperative Atrial Fibrillation (SPPAF), a randomized, placebo-controlled trial. Am Heart J  2004;147:636–43. https://doi.org/10.1016/j.ahj.2003.10.041
  
839	Buckley   MS, Nolan   PE, Jr, Slack   MK, Tisdale   JE, Hilleman   DE, Copeland   JG. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. Pharmacotherapy  2007;27:360–8. https://doi.org/10.1592/phco.27.3.360
  
840	Riber   LP, Christensen   TD, Jensen   HK, Hoejsgaard   A, Pilegaard   HK. Amiodarone significantly decreases atrial fibrillation in patients undergoing surgery for lung cancer. Ann Thorac Surg  2012;94:339–44; discussion 345–6. https://doi.org/10.1016/j.athoracsur.2011.12.096
  
841	Couffignal   C, Amour   J, Ait-Hamou   N, Cholley   B, Fellahi   JL, Duval   X, et al.   Timing of β-blocker reintroduction and the occurrence of postoperative atrial fibrillation after cardiac surgery: a prospective cohort study. Anesthesiology  2020;132:267–79. https://doi.org/10.1097/ALN.0000000000003064
  
842	Piccini   JP, Ahlsson   A, Dorian   P, Gillinov   MA, Kowey   PR, Mack   MJ, et al.   Design and rationale of a phase 2 study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of post-operative atrial fibrillation—the NOVA study. Am Heart J  2022;245:51–9. https://doi.org/10.1016/j.ahj.2021.10.114
  
843	O’Brien   B, Burrage   PS, Ngai   JY, Prutkin   JM, Huang   CC, Xu   X, et al.   Society of Cardiovascular Anesthesiologists/European Association of Cardiothoracic Anaesthetists Practice Advisory for the management of perioperative atrial fibrillation in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth  2019;33:12–26. https://doi.org/10.1053/j.jvca.2018.09.039
  
844	Gaudino   M, Sanna   T, Ballman   KV, Robinson   NB, Hameed   I, Audisio   K, et al.   Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial. Lancet  2021;398:2075–83. https://doi.org/10.1016/S0140-6736(21)02490-9
  
845	Abdelaziz   A, Hafez   AH, Elaraby   A, Roshdy   MR, Abdelaziz   M, Eltobgy   MA, et al.   Posterior pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: a systematic review and meta-analysis of 25 randomised controlled trials. EuroIntervention  2023;19:e305–17. https://doi.org/10.4244/EIJ-D-22-00948
  
846	Soletti   GJ, Perezgrovas-Olaria   R, Harik   L, Rahouma   M, Dimagli   A, Alzghari   T, et al.   Effect of posterior pericardiotomy in cardiac surgery: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med  2022;9:1090102. https://doi.org/10.3389/fcvm.2022.1090102
  
847	Conen   D, Ke Wang   M, Popova   E, Chan   MTV, Landoni   G, Cata   JP, et al.   Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. Lancet  2023;402:1627–35. https://doi.org/10.1016/S0140-6736(23)01689-6
  
848	Fragão-Marques   M, Teixeira   F, Mancio   J, Seixas   N, Rocha-Neves   J, Falcão-Pires   I, et al.   Impact of oral anticoagulation therapy on postoperative atrial fibrillation outcomes: a systematic review and meta-analysis. Thromb J  2021;19:89. https://doi.org/10.1186/s12959-021-00342-2
  
849	Neves   IA, Magalhães   A, Lima da Silva   G, Almeida   AG, Borges   M, Costa   J, et al.   Anticoagulation therapy in patients with post-operative atrial fibrillation: systematic review with meta-analysis. Vascul Pharmacol  2022;142:106929. https://doi.org/10.1016/j.vph.2021.106929
  
850	Daoud   EG, Strickberger   SA, Man   KC, Goyal   R, Deeb   GM, Bolling   SF, et al.   Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med  1997;337:1785–91. https://doi.org/10.1056/NEJM199712183372501
  
851	Yagdi   T, Nalbantgil   S, Ayik   F, Apaydin   A, Islamoglu   F, Posacioglu   H, et al.   Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting. J Thorac Cardiovasc Surg  2003;125:1420–5. https://doi.org/10.1016/S0022-5223(02)73292-3
  
852	Butt   JH, Xian   Y, Peterson   ED, Olsen   PS, Rorth   R, Gundlund   A, et al.   Long-term thromboembolic risk in patients with postoperative atrial fibrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial fibrillation. JAMA Cardiol  2018;3:417–24. https://doi.org/10.1001/jamacardio.2018.0405
  
853	Gialdini   G, Nearing   K, Bhave   PD, Bonuccelli   U, Iadecola   C, Healey   JS, et al.   Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA  2014;312:616–22. https://doi.org/10.1001/jama.2014.9143
  
854	Horwich   P, Buth   KJ, Legare   JF. New onset postoperative atrial fibrillation is associated with a long-term risk for stroke and death following cardiac surgery. J Card Surg  2013;28:8–13. https://doi.org/10.1111/jocs.12033
  
855	Devereaux   PJ, Yang   H, Yusuf   S, Guyatt   G, Leslie   K, et al.   Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet  2008;371:1839–47. https://doi.org/10.1016/S0140-6736(08)60601-7
Google ScholarPubMedWorldCat 
856	Hart   RG, Diener   HC, Coutts   SB, Easton   JD, Granger   CB, O’Donnell   MJ, et al.   Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol  2014;13:429–38. https://doi.org/10.1016/S1474-4422(13)70310-7
  
857	Sanna   T, Diener   HC, Passman   RS, Di Lazzaro   V, Bernstein   RA, Morillo   CA, et al.   Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med  2014;370:2478–86. https://doi.org/10.1056/NEJMoa1313600
  
858	Rubiera   M, Aires   A, Antonenko   K, Lémeret   S, Nolte   CH, Putaala   J, et al.   European Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin. Eur Stroke J  2022;7:VI. https://doi.org/10.1177/23969873221099478
  
859	von Falkenhausen   AS, Feil   K, Sinner   MF, Schönecker   S, Müller   J, Wischmann   J, et al.   Atrial fibrillation risk assessment after embolic stroke of undetermined source. Ann Neurol  2023;93:479–88. https://doi.org/10.1002/ana.26545
  
860	Gladstone   DJ, Spring   M, Dorian   P, Panzov   V, Thorpe   KE, Hall   J, et al.   Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med  2014;370:2467–77. https://doi.org/10.1056/NEJMoa1311376
  
861	Wachter   R, Gröschel   K, Gelbrich   G, Hamann   GF, Kermer   P, Liman   J, et al.   Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF(RANDOMISED)): an open-label randomised controlled trial. Lancet Neurol  2017;16:282–90. https://doi.org/10.1016/S1474-4422(17)30002-9
  
862	Buck   BH, Hill   MD, Quinn   FR, Butcher   KS, Menon   BK, Gulamhusein   S, et al.   Effect of implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke: the PER DIEM randomized clinical trial. JAMA  2021;325:2160–8. https://doi.org/10.1001/jama.2021.6128
  
863	Bernstein   RA, Kamel   H, Granger   CB, Piccini   JP, Sethi   PP, Katz   JM, et al.   Effect of long-term continuous cardiac monitoring vs usual care on detection of atrial fibrillation in patients with stroke attributed to large- or small-vessel disease: the STROKE-AF randomized clinical trial. JAMA  2021;325:2169–77. https://doi.org/10.1001/jama.2021.6470
  
864	Tsivgoulis   G, Katsanos   AH, Köhrmann   M, Caso   V, Perren   F, Palaiodimou   L, et al.   Duration of implantable cardiac monitoring and detection of atrial fibrillation in ischemic stroke patients: a systematic review and meta-analysis. J Stroke  2019;21:302–11. https://doi.org/10.5853/jos.2019.01067
  
865	Sagris   D, Harrison   SL, Buckley   BJR, Ntaios   G, Lip   GYH. Long-term cardiac monitoring after embolic stroke of undetermined source: search longer, look harder. Am J Med  2022;135:e311–7. https://doi.org/10.1016/j.amjmed.2022.04.030
  
866	Liantinioti   C, Palaiodimou   L, Tympas   K, Parissis   J, Theodorou   A, Ikonomidis   I, et al.   Potential utility of neurosonology in paroxysmal atrial fibrillation detection in patients with cryptogenic stroke. J Clin Med  2019;8:2002. https://doi.org/10.3390/jcm8112002
  
867	Tsivgoulis   G, Katsanos   AH, Grory   BM, Köhrmann   M, Ricci   BA, Tsioufis   K, et al.   Prolonged cardiac rhythm monitoring and secondary stroke prevention in patients with cryptogenic cerebral ischemia. Stroke  2019;50:2175–80. https://doi.org/10.1161/STROKEAHA.119.025169
  
868	Favilla   CG, Ingala   E, Jara   J, Fessler   E, Cucchiara   B, Messé   SR, et al.   Predictors of finding occult atrial fibrillation after cryptogenic stroke. Stroke  2015;46:1210–5. https://doi.org/10.1161/STROKEAHA.114.007763
  
869	Lip   GY, Nielsen   PB. Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc score 1 in men, 2 in women) be anticoagulated? Yes: even 1 stroke risk factor confers a real risk of stroke. Circulation  2016;133:1498–503; discussion 1503. https://doi.org/10.1161/CIRCULATIONAHA.115.016713
  
870	Ricci   B, Chang   AD, Hemendinger   M, Dakay   K, Cutting   S, Burton   T, et al.   A simple score that predicts paroxysmal atrial fibrillation on outpatient cardiac monitoring after embolic stroke of unknown source. J Stroke Cerebrovasc Dis  2018;27:1692–6. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.028
  
871	Kwong   C, Ling   AY, Crawford   MH, Zhao   SX, Shah   NH. A clinical score for predicting atrial fibrillation in patients with cryptogenic stroke or transient ischemic attack. Cardiology  2017;138:133–40. https://doi.org/10.1159/000476030
  
872	Li   YG, Bisson   A, Bodin   A, Herbert   J, Grammatico-Guillon   L, Joung   B, et al.   C(2) HEST score and prediction of incident atrial fibrillation in poststroke patients: a French nationwide study. J Am Heart Assoc  2019;8:e012546. https://doi.org/10.1161/JAHA.119.012546
  
873	Haeusler   KG, Gröschel   K, Köhrmann   M, Anker   SD, Brachmann   J, Böhm   M, et al.   Expert opinion paper on atrial fibrillation detection after ischemic stroke. Clin Res Cardiol  2018;107:871–80. https://doi.org/10.1007/s00392-018-1256-9
  
874	Dilaveris   PE, Antoniou   CK, Caiani   EG, Casado-Arroyo   R, Climent   A, Cluitmans   M, et al.   ESC working group on e-cardiology position paper: accuracy and reliability of electrocardiogram monitoring in the detection of atrial fibrillation in cryptogenic stroke patients: in collaboration with the Council on Stroke, the European Heart Rhythm Association, and the Digital Health Committee. Eur Heart J Digit Health  2022;3:341–58. https://doi.org/10.1093/ehjdh/ztac026
  
875	Diener   HC, Sacco   RL, Easton   JD, Granger   CB, Bernstein   RA, Uchiyama   S, et al.   Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med  2019;380:1906–17. https://doi.org/10.1056/NEJMoa1813959
  
876	Hart   RG, Sharma   M, Mundl   H, Kasner   SE, Bangdiwala   SI, Berkowitz   SD, et al.   Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med  2018;378:2191–201. https://doi.org/10.1056/NEJMoa1802686
  
877	Poli   S, Meissner   C, Baezner   HJ, Kraft   A, Hillenbrand   F, Hobohm   C, et al.   Apixaban for treatment of embolic stroke of undetermined source (ATTICUS) randomized trial—update of patient characteristics and study timeline after interim analysis. Eur Heart J  2021;42:ehab724.2070. https://doi.org/10.1093/eurheartj/ehab724.2070
  
878	Vaidya   VR, Arora   S, Patel   N, Badheka   AO, Patel   N, Agnihotri   K, et al.   Burden of arrhythmia in pregnancy. Circulation  2017;135:619–21. https://doi.org/10.1161/CIRCULATIONAHA.116.026681
  
879	Lee   MS, Chen   W, Zhang   Z, Duan   L, Ng   A, Spencer   HT, et al.   Atrial fibrillation and atrial flutter in pregnant women—a population-based study. J Am Heart Assoc  2016;5:e003182. https://doi.org/10.1161/JAHA.115.003182
  
880	Tamirisa   KP, Elkayam   U, Briller   JE, Mason   PK, Pillarisetti   J, Merchant   FM, et al.   Arrhythmias in pregnancy. JACC Clin Electrophysiol  2022;8:120–35. https://doi.org/10.1016/j.jacep.2021.10.004
  
881	Salam   AM, Ertekin   E, van Hagen   IM, Al Suwaidi   J, Ruys   TPE, Johnson   MR, et al.   Atrial fibrillation or flutter during pregnancy in patients with structural heart disease: data from the ROPAC (Registry on Pregnancy and Cardiac Disease). JACC Clin Electrophysiol  2015;1:284–92. https://doi.org/10.1016/j.jacep.2015.04.013
  
882	Chokesuwattanaskul   R, Thongprayoon   C, Bathini   T, O’Corragain   OA, Sharma   K, Prechawat   S, et al.   Incidence of atrial fibrillation in pregnancy and clinical significance: a meta-analysis. Adv Med Sci  2019;64:415–22. https://doi.org/10.1016/j.advms.2019.07.003
  
883	Tamirisa   KP, Dye   C, Bond   RM, Hollier   LM, Marinescu   K, Vaseghi   M, et al.   Arrhythmias and heart failure in pregnancy: a dialogue on multidisciplinary collaboration. J Cardiovasc Dev Dis  2022;9:199. https://doi.org/10.3390/jcdd9070199
Google ScholarPubMedWorldCat 
884	Al Bahhawi   T, Aqeeli   A, Harrison   SL, Lane   DA, Skjøth   F, Buchan   I, et al.   Pregnancy-related complications and incidence of atrial fibrillation: a systematic review. J Clin Med  2023;12:1316. https://doi.org/10.3390/jcm12041316
  
885	Regitz-Zagrosek   V, Roos-Hesselink   JW, Bauersachs   J, Blomstrom-Lundqvist   C, Cifkova   R, De Bonis   M, et al.   2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J  2018;39:3165–241. https://doi.org/10.1093/eurheartj/ehy340
  
886	Areia   AL, Mota-Pinto   A. Experience with direct oral anticoagulants in pregnancy—a systematic review. J Perinat Med  2022;50:457–61. https://doi.org/10.1515/jpm-2021-0457
  
887	Ueberham   L, Hindricks   G. Anticoagulation in special patient populations with atrial fibrillation. Herz  2021;46:323–8. https://doi.org/10.1007/s00059-021-05042-1
  
888	Bateman   BT, Heide-Jørgensen   U, Einarsdóttir   K, Engeland   A, Furu   K, Gissler   M, et al.   β-Blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med  2018;169:665–73. https://doi.org/10.7326/M18-0338
  
889	Butters   L, Kennedy   S, Rubin   PC. Atenolol in essential hypertension during pregnancy. BMJ  1990;301:587–9. https://doi.org/10.1136/bmj.301.6752.587
  
890	Ramlakhan   KP, Kauling   RM, Schenkelaars   N, Segers   D, Yap   SC, Post   MC, et al.   Supraventricular arrhythmia in pregnancy. Heart  2022;108:1674–81. https://doi.org/10.1136/heartjnl-2021-320451
  
891	Katritsis   DG, Boriani   G, Cosio   FG, Hindricks   G, Jais   P, Josephson   ME, et al.   European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Eur Heart J  2017;19:465–511. https://doi.org/10.1093/europace/euw301
Google ScholarWorldCat 
892	Moore   JS, Teefey   P, Rao   K, Berlowitz   MS, Chae   SH, Yankowitz   J. Maternal arrhythmia: a case report and review of the literature. Obstet Gynecol Surv  2012;67:298–312. https://doi.org/10.1097/OGX.0b013e318253a76e
  
893	Wang   YC, Chen   CH, Su   HY, Yu   MH. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol  2006;126:268–9. https://doi.org/10.1016/j.ejogrb.2005.11.021
  
894	European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm   AJ, Kirchhof   P, Lip   GY, Schotten   U, et al.   Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J  2010;31:2369–429. https://doi.org/10.1093/eurheartj/ehq278
Google ScholarPubMedWorldCat 
895	Kockova   R, Kocka   V, Kiernan   T, Fahy   GJ. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol  2007;18:545–7. https://doi.org/10.1111/j.1540-8167.2006.00752.x
  
896	Georgiopoulos   G, Tsiachris   D, Kordalis   A, Kontogiannis   C, Spartalis   M, Pietri   P, et al.   Pharmacotherapeutic strategies for atrial fibrillation in pregnancy. Expert Opin Pharmacother  2019;20:1625–36. https://doi.org/10.1080/14656566.2019.1621290
  
897	Jensen   AS, Idorn   L, Nørager   B, Vejlstrup   N, Sondergaard   L. Anticoagulation in adults with congenital heart disease: the who, the when and the how?  Heart  2015;101:424–9. https://doi.org/10.1136/heartjnl-2014-305576
  
898	Pujol   C, Niesert   AC, Engelhardt   A, Schoen   P, Kusmenkov   E, Pittrow   D, et al.   Usefulness of direct oral anticoagulants in adult congenital heart disease. Am J Cardiol  2016;117:450–5. https://doi.org/10.1016/j.amjcard.2015.10.062
  
899	Yang   H, Bouma   BJ, Dimopoulos   K, Khairy   P, Ladouceur   M, Niwa   K, et al.   Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. Int J Cardiol  2020;299:123–30. https://doi.org/10.1016/j.ijcard.2019.06.014
  
900	Renda   G, Ricci   F, Giugliano   RP, De Caterina   R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol  2017;69:1363–71. https://doi.org/10.1016/j.jacc.2016.12.038
  
901	Caldeira   D, David   C, Costa   J, Ferreira   JJ, Pinto   FJ. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother  2018;4:111–8. https://doi.org/10.1093/ehjcvp/pvx028
  
902	Ammash   NM, Phillips   SD, Hodge   DO, Connolly   HM, Grogan   MA, Friedman   PA, et al.   Outcome of direct current cardioversion for atrial arrhythmias in adults with congenital heart disease. Int J Cardiol  2012;154:270–4. https://doi.org/10.1016/j.ijcard.2010.09.028
  
903	Feltes   TF, Friedman   RA. Transesophageal echocardiographic detection of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol  1994;24:1365–70. https://doi.org/10.1016/0735-1097(94)90121-X
  
904	Roos-Hesselink   JW, Meijboom   FJ, Spitaels   SE, van Domburg   R, van Rijen   EH, Utens   EM, et al.   Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. A prospective follow-up study of 21–33 years. Eur Heart J  2003;24:190–7. https://doi.org/10.1016/S0195-668X(02)00383-4
  
905	Mas   JL, Derumeaux   G, Guillon   B, Massardier   E, Hosseini   H, Mechtouff   L, et al.   Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med  2017;377:1011–21. https://doi.org/10.1056/NEJMoa1705915
  
906	Gutierrez   SD, Earing   MG, Singh   AK, Tweddell   JS, Bartz   PJ. Atrial tachyarrhythmias and the Cox-Maze procedure in congenital heart disease. Congenit Heart Dis  2013;8:434–9. https://doi.org/10.1111/chd.12031
Google ScholarPubMedWorldCat 
907	Kobayashi   J, Yamamoto   F, Nakano   K, Sasako   Y, Kitamura   S, Kosakai   Y. Maze procedure for atrial fibrillation associated with atrial septal defect. Circulation  1998;98:II399–402.
  
908	Shim   H, Yang   JH, Park   PW, Jeong   DS, Jun   TG. Efficacy of the Maze procedure for atrial fibrillation associated with atrial septal defect. Korean J Thorac Cardiovasc Surg  2013;46:98–103. https://doi.org/10.5090/kjtcs.2013.46.2.98
  
909	Sherwin   ED, Triedman   JK, Walsh   EP. Update on interventional electrophysiology in congenital heart disease: evolving solutions for complex hearts. Circ Arrhythm Electrophysiol  2013;6:1032–40. https://doi.org/10.1161/CIRCEP.113.000313
  
910	Chiha   M, Samarasinghe   S, Kabaker   AS. Thyroid storm: an updated review. J Intensive Care Med  2015;30:131–40. https://doi.org/10.1177/0885066613498053
  
911	Y-Hassan   S, Falhammar   H. Cardiovascular manifestations and complications of pheochromocytomas and paragangliomas. J Clin Med  2020;9:2435. https://doi.org/10.3390/jcm9082435
  
912	Baumgartner   C, da Costa   BR, Collet   TH, Feller   M, Floriani   C, Bauer   DC, et al.   Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation  2017;136:2100–16. https://doi.org/10.1161/CIRCULATIONAHA.117.028753
  
913	Huang   M, Yang   S, Ge   G, Zhi   H, Wang   L. Effects of thyroid dysfunction and the thyroid-stimulating hormone levels on the risk of atrial fibrillation: a systematic review and dose-response meta-analysis from cohort studies. Endocr Pract  2022;28:822–31. https://doi.org/10.1016/j.eprac.2022.05.008
  
914	Shin   DG, Kang   MK, Han   D, Choi   S, Cho   JR, Lee   N. Enlarged left atrium and decreased left atrial strain are associated with atrial fibrillation in patients with hyperthyroidism irrespective of conventional risk factors. Int J Cardiovasc Imaging  2022;38:613–20. https://doi.org/10.1007/s10554-021-02450-6
  
915	Sawin   CT, Geller   A, Wolf   PA, Belanger   AJ, Baker   E, Bacharach   P, et al.   Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med  1994;331:1249–52. https://doi.org/10.1056/NEJM199411103311901
  
916	Lyon   AR, López-Fernández   T, Couch   LS, Asteggiano   R, Aznar   MC, Bergler-Klein   J, et al.   2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J  2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244
  
917	El Sabbagh   R, Azar   NS, Eid   AA, Azar   ST. Thyroid dysfunctions due to immune checkpoint inhibitors: a review. Int J Gen Med  2020;13:1003–9. https://doi.org/10.2147/IJGM.S261433
  
918	Gammage   MD, Parle   JV, Holder   RL, Roberts   LM, Hobbs   FD, Wilson   S, et al.   Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med  2007;167:928–34. https://doi.org/10.1001/archinte.167.9.928
  
919	Selmer   C, Olesen   JB, Hansen   ML, Lindhardsen   J, Olsen   AM, Madsen   JC, et al.   The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ  2012;345:e7895. https://doi.org/10.1136/bmj.e7895
  
920	Kim   K, Yang   PS, Jang   E, Yu   HT, Kim   TH, Uhm   JS, et al.   Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: a nationwide cohort study. Am Heart J  2021;242:123–31. https://doi.org/10.1016/j.ahj.2021.08.018
  
921	Zhang   J, Bisson   A, Fauchier   G, Bodin   A, Herbert   J, Ducluzeau   PH, et al.   Yearly incidence of stroke and bleeding in atrial fibrillation with concomitant hyperthyroidism: a national discharge database study. J Clin Med  2022;11:1342. https://doi.org/10.3390/jcm11051342
  
922	Bartalena   L, Bogazzi   F, Chiovato   L, Hubalewska-Dydejczyk   A, Links   TP, Vanderpump   M. 2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. Eur Thyroid J  2018;7:55–66. https://doi.org/10.1159/000486957
  
923	Cappellani   D, Papini   P, Di Certo   AM, Morganti   R, Urbani   C, Manetti   L, et al.   Duration of exposure to thyrotoxicosis increases mortality of compromised AIT patients: the role of early thyroidectomy. J Clin Endocrinol Metab  2020;105:dgaa464. https://doi.org/10.1210/clinem/dgaa464
  
924	Trevisan   C, Piovesan   F, Lucato   P, Zanforlini   BM, De Rui   M, Maggi   S, et al.   Parathormone, vitamin D and the risk of atrial fibrillation in older adults: a prospective study. Nutr Metab Cardiovasc Dis  2019;29:939–45. https://doi.org/10.1016/j.numecd.2019.05.064
  
925	Pepe   J, Cipriani   C, Curione   M, Biamonte   F, Colangelo   L, Danese   V, et al.   Reduction of arrhythmias in primary hyperparathyroidism, by parathyroidectomy, evaluated with 24-h ECG monitoring. Eur J Endocrinol  2018;179:117–24. https://doi.org/10.1530/EJE-17-0948
  
926	Pepe   J, Cipriani   C, Sonato   C, Raimo   O, Biamonte   F, Minisola   S. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol  2017;177:R297–308. https://doi.org/10.1530/EJE-17-0485
  
927	Monticone   S, D’Ascenzo   F, Moretti   C, Williams   TA, Veglio   F, Gaita   F, et al.   Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol  2018;6:41–50. https://doi.org/10.1016/S2213-8587(17)30319-4
  
928	Bollati   M, Lopez   C, Bioletto   F, Ponzetto   F, Ghigo   E, Maccario   M, et al.   Atrial fibrillation and aortic ectasia as complications of primary aldosteronism: focus on pathophysiological aspects. Int J Mol Sci  2022;23:2111. https://doi.org/10.3390/ijms23042111
  
929	Kim   KJ, Hong   N, Yu   MH, Lee   H, Lee   S, Lim   JS, et al.   Time-dependent risk of atrial fibrillation in patients with primary aldosteronism after medical or surgical treatment initiation. Hypertension  2021;77:1964–73. https://doi.org/10.1161/HYPERTENSIONAHA.120.16909
  
930	Larsson   SC, Lee   WH, Burgess   S, Allara   E. Plasma cortisol and risk of atrial fibrillation: a Mendelian randomization study. J Clin Endocrinol Metab  2021;106:e2521–6. https://doi.org/10.1210/clinem/dgab219
  
931	Di Dalmazi   G, Vicennati   V, Pizzi   C, Mosconi   C, Tucci   L, Balacchi   C, et al.   Prevalence and incidence of atrial fibrillation in a large cohort of adrenal incidentalomas: a long-term study. J Clin Endocrinol Metab  2020;105:dgaa270. https://doi.org/10.1210/clinem/dgaa270
Google ScholarWorldCat 
932	Hong   S, Kim   KS, Han   K, Park   CY. Acromegaly and cardiovascular outcomes: a cohort study. Eur Heart J  2022;43:1491–9. https://doi.org/10.1093/eurheartj/ehab822
  
933	Polina   I, Jansen   HJ, Li   T, Moghtadaei   M, Bohne   LJ, Liu   Y, et al.   Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes. Proc Natl Acad Sci USA  2020;117:7990–8000. https://doi.org/10.1073/pnas.1914853117
  
934	Lee   YB, Han   K, Kim   B, Lee   SE, Jun   JE, Ahn   J, et al.   Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study. Cardiovasc Diabetol  2019;18:157. https://doi.org/10.1186/s12933-019-0953-7
  
935	Bisson   A, Bodin   A, Fauchier   G, Herbert   J, Angoulvant   D, Ducluzeau   PH, et al.   Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. Cardiovasc Diabetol  2021;20:24. https://doi.org/10.1186/s12933-021-01216-7
  
936	Dahlqvist   S, Rosengren   A, Gudbjörnsdottir   S, Pivodic   A, Wedel   H, Kosiborod   M, et al.   Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabetes Endocrinol  2017;5:799–807. https://doi.org/10.1016/S2213-8587(17)30262-0
  
937	Cai   X, Li   J, Cai   W, Chen   C, Ma   J, Xie   Z, et al.   Meta-analysis of type 1 diabetes mellitus and risk of cardiovascular disease. J Diabetes Complications  2021;35:107833. https://doi.org/10.1016/j.jdiacomp.2020.107833
  
938	Zellerhoff   S, Pistulli   R, Monnig   G, Hinterseer   M, Beckmann   BM, Kobe   J, et al.   Atrial arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. J Cardiovasc Electrophysiol  2009;20:401–7. https://doi.org/10.1111/j.1540-8167.2008.01339.x
  
939	Johnson   JN, Tester   DJ, Perry   J, Salisbury   BA, Reed   CR, Ackerman   MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm  2008;5:704–9. https://doi.org/10.1016/j.hrthm.2008.02.007
  
940	Gaita   F, Giustetto   C, Bianchi   F, Wolpert   C, Schimpf   R, Riccardi   R, et al.   Short QT syndrome: a familial cause of sudden death. Circulation  2003;108:965–70. https://doi.org/10.1161/01.CIR.0000085071.28695.C4
  
941	Borggrefe   M, Wolpert   C, Antzelevitch   C, Veltmann   C, Giustetto   C, Gaita   F, et al.   Short QT syndrome genotype-phenotype correlations. J Electrocardiol  2005;38:75–80. https://doi.org/10.1016/j.jelectrocard.2005.06.009
  
942	Giustetto   C, Di Monte   F, Wolpert   C, Borggrefe   M, Schimpf   R, Sbragia   P, et al.   Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J  2006;27:2440–7. https://doi.org/10.1093/eurheartj/ehl185
  
943	Bordachar   P, Reuter   S, Garrigue   S, Cai   X, Hocini   M, Jais   P, et al.   Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J  2004;25:879–84. https://doi.org/10.1016/j.ehj.2004.01.004
  
944	Francis   J, Antzelevitch   C. Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol  2008;51:1149–53. https://doi.org/10.1016/j.jacc.2007.10.062
  
945	Giustetto   C, Schimpf   R, Mazzanti   A, Scrocco   C, Maury   P, Anttonen   O, et al.   Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol  2011;58:587–95. https://doi.org/10.1016/j.jacc.2011.03.038
  
946	Gollob   MH, Redpath   CJ, Roberts   JD. The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol  2011;57:802–12. https://doi.org/10.1016/j.jacc.2010.09.048
  
947	Kusano   KF, Taniyama   M, Nakamura   K, Miura   D, Banba   K, Nagase   S, et al.   Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol  2008;51:1169–75. https://doi.org/10.1016/j.jacc.2007.10.060
  
948	Rodriguez-Manero   M, Namdar   M, Sarkozy   A, Casado-Arroyo   R, Ricciardi   D, de Asmundis   C, et al.   Prevalence, clinical characteristics and management of atrial fibrillation in patients with Brugada syndrome. Am J Cardiol  2013;111:362–7. https://doi.org/10.1016/j.amjcard.2012.10.012
  
949	Choi   YJ, Choi   EK, Han   KD, Jung   JH, Park   J, Lee   E, et al.   Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: a nationwide population-based study. Int J Cardiol  2018;273:130–5. https://doi.org/10.1016/j.ijcard.2018.08.038
  
950	Hernandez-Ojeda   J, Arbelo   E, Borras   R, Berne   P, Tolosana   JM, Gomez-Juanatey   A, et al.   Patients with Brugada syndrome and implanted cardioverter-defibrillators: long-term follow-up. J Am Coll Cardiol  2017;70:1991–2002. https://doi.org/10.1016/j.jacc.2017.08.029
  
951	Klopotowski   M, Kwapiszewska   A, Kukula   K, Jamiolkowski   J, Dabrowski   M, Derejko   P, et al.   Clinical and echocardiographic parameters as risk factors for atrial fibrillation in patients with hypertrophic cardiomyopathy. Clin Cardiol  2018;41:1336–40. https://doi.org/10.1002/clc.23050
  
952	Rowin   EJ, Orfanos   A, Estes   NAM, Wang   W, Link   MS, Maron   MS, et al.   Occurrence and natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomyopathy. Am J Cardiol  2017;119:1862–5. https://doi.org/10.1016/j.amjcard.2017.02.040
  
953	Sacher   F, Probst   V, Maury   P, Babuty   D, Mansourati   J, Komatsu   Y, et al.   Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2. Circulation  2013;128:1739–47. https://doi.org/10.1161/CIRCULATIONAHA.113.001941
  
954	Siontis   KC, Geske   JB, Ong   K, Nishimura   RA, Ommen   SR, Gersh   BJ. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc  2014;3:e001002. https://doi.org/10.1161/JAHA.114.001002
  
955	Sumitomo   N, Sakurada   H, Taniguchi   K, Matsumura   M, Abe   O, Miyashita   M, et al.   Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia. Circ J  2007;71:1606–9. https://doi.org/10.1253/circj.71.1606
  
956	Sy   RW, Gollob   MH, Klein   GJ, Yee   R, Skanes   AC, Gula   LJ, et al.   Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm  2011;8:864–71. https://doi.org/10.1016/j.hrthm.2011.01.048
  
957	van Velzen   HG, Theuns   DA, Yap   SC, Michels   M, Schinkel   AF. Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy. Am J Cardiol  2017;119:100–5. https://doi.org/10.1016/j.amjcard.2016.08.092
  
958	Bourfiss   M, Te Riele   AS, Mast   TP, Cramer   MJ, Van Der Heijden   J, Van Veen   TAB, et al.   Influence of genotype on structural atrial abnormalities and atrial fibrillation or flutter in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol  2016;27:1420–8. https://doi.org/10.1111/jce.13094
  
959	Camm   CF, James   CA, Tichnell   C, Murray   B, Bhonsale   A, te Riele   AS, et al.   Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm  2013;10:1661–8. https://doi.org/10.1016/j.hrthm.2013.08.032
  
960	Chu   AF, Zado   E, Marchlinski   FE. Atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and ventricular tachycardia. Am J Cardiol  2010;106:720–2. https://doi.org/10.1016/j.amjcard.2010.04.031
  
961	Hasselberg   NE, Haland   TF, Saberniak   J, Brekke   PH, Berge   KE, Leren   TP, et al.   Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J  2018;39:853–60. https://doi.org/10.1093/eurheartj/ehx596
  
962	Kumar   S, Baldinger   SH, Gandjbakhch   E, Maury   P, Sellal   JM, Androulakis   AF, et al.   Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol  2016;68:2299–307. https://doi.org/10.1016/j.jacc.2016.08.058
  
963	Mussigbrodt   A, Knopp   H, Efimova   E, Weber   A, Bertagnolli   L, Hilbert   S, et al.   Supraventricular arrhythmias in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy associate with long-term outcome after catheter ablation of ventricular tachycardias. Europace  2018;20:1182–7. https://doi.org/10.1093/europace/eux179
  
964	Pasotti   M, Klersy   C, Pilotto   A, Marziliano   N, Rapezzi   C, Serio   A, et al.   Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol  2008;52:1250–60. https://doi.org/10.1016/j.jacc.2008.06.044
  
965	Saguner   AM, Ganahl   S, Kraus   A, Baldinger   SH, Medeiros-Domingo   A, Saguner   AR, et al.   Clinical role of atrial arrhythmias in patients with arrhythmogenic right ventricular dysplasia. Circ J  2014;78:2854–61. https://doi.org/10.1253/circj.CJ-14-0474
  
966	Tonet   JL, Castro-Miranda   R, Iwa   T, Poulain   F, Frank   R, Fontaine   GH. Frequency of supraventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia. Am J Cardiol  1991;67:1153. https://doi.org/10.1016/0002-9149(91)90886-P
  
967	van Rijsingen   IA, Nannenberg   EA, Arbustini   E, Elliott   PM, Mogensen   J, Hermans-van Ast   JF, et al.   Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers. Eur J Heart Fail  2013;15:376–84. https://doi.org/10.1093/eurjhf/hfs191
  
968	Aras   D, Tufekcioglu   O, Ergun   K, Ozeke   O, Yildiz   A, Topaloglu   S, et al.   Clinical features of isolated ventricular noncompaction in adults long-term clinical course, echocardiographic properties, and predictors of left ventricular failure. J Card Fail  2006;12:726–33. https://doi.org/10.1016/j.cardfail.2006.08.002
  
969	Li   S, Zhang   C, Liu   N, Bai   H, Hou   C, Wang   J, et al.   Genotype-positive status is associated with poor prognoses in patients with left ventricular noncompaction cardiomyopathy. J Am Heart Assoc  2018;7:e009910. https://doi.org/10.1161/JAHA.118.009910
  
970	Stollberger   C, Blazek   G, Winkler-Dworak   M, Finsterer   J. Atrial fibrillation in left ventricular noncompaction with and without neuromuscular disorders is associated with a poor prognosis. Int J Cardiol  2009;133:41–5. https://doi.org/10.1016/j.ijcard.2007.11.099
  
971	Fatkin   D, MacRae   C, Sasaki   T, Wolff   MR, Porcu   M, Frenneaux   M, et al.   Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med  1999;341:1715–24. https://doi.org/10.1056/NEJM199912023412302
  
972	Hong   K, Bjerregaard   P, Gussak   I, Brugada   R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol  2005;16:394–6. https://doi.org/10.1046/j.1540-8167.2005.40621.x
  
973	Olesen   MS, Yuan   L, Liang   B, Holst   AG, Nielsen   N, Nielsen   JB, et al.   High prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial fibrillation. Circ Cardiovasc Genet  2012;5:450–9. https://doi.org/10.1161/CIRCGENETICS.111.962597
  
974	Pappone   C, Radinovic   A, Manguso   F, Vicedomini   G, Sala   S, Sacco   FM, et al.   New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significance. Eur Heart J  2009;30:2985–92. https://doi.org/10.1093/eurheartj/ehp326
  
975	Peters   S. Atrial arrhythmias in arrhythmogenic cardiomyopathy: at the beginning or at the end of the disease story?  Circ J  2015;79:446. https://doi.org/10.1253/circj.CJ-14-1193
  
976	Rowin   EJ, Hausvater   A, Link   MS, Abt   P, Gionfriddo   W, Wang   W, et al.   Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation  2017;136:2420–36. https://doi.org/10.1161/CIRCULATIONAHA.117.029267
  
977	Mazzanti   A, Ng   K, Faragli   A, Maragna   R, Chiodaroli   E, Orphanou   N, et al.   Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. J Am Coll Cardiol  2016;68:2540–50. https://doi.org/10.1016/j.jacc.2016.09.951
  
978	Giustetto   C, Cerrato   N, Gribaudo   E, Scrocco   C, Castagno   D, Richiardi   E, et al.   Atrial fibrillation in a large population with Brugada electrocardiographic pattern: prevalence, management, and correlation with prognosis. Heart Rhythm  2014;11:259–65. https://doi.org/10.1016/j.hrthm.2013.10.043
  
979	Beckmann   BM, Holinski-Feder   E, Walter   MC, Haserück   N, Reithmann   C, Hinterseer   M, et al.   Laminopathy presenting as familial atrial fibrillation. Int J Cardiol  2010;145:394–6. https://doi.org/10.1016/j.ijcard.2010.04.024
  
980	Pizzale   S, Gollob   MH, Gow   R, Birnie   DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol  2008;19:1319–21. https://doi.org/10.1111/j.1540-8167.2008.01211.x
  
981	Sugiyasu   A, Oginosawa   Y, Nogami   A, Hata   Y. A case with catecholaminergic polymorphic ventricular tachycardia unmasked after successful ablation of atrial tachycardias from pulmonary veins. Pacing Clin Electrophysiol  2009;32:e21–4. https://doi.org/10.1111/j.1540-8159.2009.02519.x
  
982	Veltmann   C, Kuschyk   J, Schimpf   R, Streitner   F, Schoene   N, Borggrefe   M, et al.   Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clin Res Cardiol  2010;99:37–44. https://doi.org/10.1007/s00392-009-0075-4
  
983	Brugada   J, Katritsis   DG, Arbelo   E, Arribas   F, Bax   JJ, Blomstrom-Lundqvist   C, et al.   2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J  2020;41:655–720. https://doi.org/10.1093/eurheartj/ehz467
  
984	Klein   GJ, Bashore   TM, Sellers   TD, Pritchett   EL, Smith   WM, Gallagher   JJ. Ventricular fibrillation in the Wolff–Parkinson–White syndrome. N Engl J Med  1979;301:1080–5. https://doi.org/10.1056/NEJM197911153012003
  
985	Morady   F, DiCarlo   LA, Jr, Baerman   JM, De Buitleir   M. Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff–Parkinson–White syndrome. Pacing Clin Electrophysiol  1987;10:492–6. https://doi.org/10.1111/j.1540-8159.1987.tb04511.x
  
986	Sellers   TD, Jr, Bashore   TM, Gallagher   JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation  1977;56:260–7. https://doi.org/10.1161/01.CIR.56.2.260
  
987	Glatter   KA, Dorostkar   PC, Yang   Y, Lee   RJ, Van Hare   GF, Keung   E, et al.   Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation  2001;104:1933–9. https://doi.org/10.1161/hc4101.097538
  
988	Ludmer   PL, McGowan   NE, Antman   EM, Friedman   PL. Efficacy of propafenone in Wolff–Parkinson–White syndrome: electrophysiologic findings and long-term follow-up. J Am Coll Cardiol  1987;9:1357–63. https://doi.org/10.1016/S0735-1097(87)80478-3
  
989	Simonian   SM, Lotfipour   S, Wall   C, Langdorf   MI. Challenging the superiority of amiodarone for rate control in Wolff–Parkinson–White and atrial fibrillation. Intern Emerg Med  2010;5:421–6. https://doi.org/10.1007/s11739-010-0385-6
  
990	Arbelo   E, Protonotarios   A, Gimeno   JR, Arbustini   E, Barriales-Villa   R, Basso   C, et al.   2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J  2023;44:3503–626. https://doi.org/10.1093/eurheartj/ehad194
  
991	Hu   YF, Liu   CJ, Chang   PM, Tsao   HM, Lin   YJ, Chang   SL, et al.   Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol  2013;165:355–7. https://doi.org/10.1016/j.ijcard.2012.08.036
  
992	Mosarla   RC, Vaduganathan   M, Qamar   A, Moslehi   J, Piazza   G, Giugliano   RP. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J Am Coll Cardiol  2019;73:1336–49. https://doi.org/10.1016/j.jacc.2019.01.017
  
993	Malavasi   VL, Fantecchi   E, Gianolio   L, Pesce   F, Longo   G, Marietta   M, et al.   Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality. Eur J Intern Med  2019;59:27–33. https://doi.org/10.1016/j.ejim.2018.10.012
  
994	Farmakis   D, Parissis   J, Filippatos   G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol  2014;63:945–53. https://doi.org/10.1016/j.jacc.2013.11.026
  
995	Yun   JP, Choi   EK, Han   KD, Park   SH, Jung   JH, Ahn   HJ, et al.   Risk of atrial fibrillation according to cancer type: a nationwide population-based study. JACC CardioOncol  2021;3:221–32. https://doi.org/10.1016/j.jaccao.2021.03.006
  
996	Alexandre   J, Salem   JE, Moslehi   J, Sassier   M, Ropert   C, Cautela   J, et al.   Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother  2021;7:312–20. https://doi.org/10.1093/ehjcvp/pvaa037
  
997	Guha   A, Fradley   MG, Dent   SF, Weintraub   NL, Lustberg   MB, Alonso   A, et al.   Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-medicare analysis. Eur Heart J  2022;43:300–12. https://doi.org/10.1093/eurheartj/ehab745
  
998	Pastori   D, Marang   A, Bisson   A, Menichelli   D, Herbert   J, Lip   GYH, et al.   Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study. Cancer  2021;127:2122–9. https://doi.org/10.1002/cncr.33470
  
999	Aspberg   S, Yu   L, Gigante   B, Smedby   KE, Singer   DE. Risk of ischemic stroke and major bleeding in patients with atrial fibrillation and cancer. J Stroke Cerebrovasc Dis  2020;29:104560. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104560
  
1000	D’Souza   M, Carlson   N, Fosbøl   E, Lamberts   M, Smedegaard   L, Nielsen   D, et al.   CHA(2)DS(2)-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol  2018;25:651–8. https://doi.org/10.1177/2047487318759858
  
1001	Chen   ST, Hellkamp   AS, Becker   RC, Berkowitz   SD, Breithardt   G, Fox   KAA, et al.   Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes  2019;5:145–52. https://doi.org/10.1093/ehjqcco/qcy040
  
1002	Melloni   C, Dunning   A, Granger   CB, Thomas   L, Khouri   MG, Garcia   DA, et al.   Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med  2017;130:1440–8.e1. https://doi.org/10.1016/j.amjmed.2017.06.026
  
1003	Fanola   CL, Ruff   CT, Murphy   SA, Jin   J, Duggal   A, Babilonia   NA, et al.   Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc  2018;7:e008987. https://doi.org/10.1161/JAHA.118.008987
  
1004	Sawant   AC, Kumar   A, McCray   W, Tetewsky   S, Parone   L, Sridhara   S, et al.   Superior safety of direct oral anticoagulants compared to warfarin in patients with atrial fibrillation and underlying cancer: a national veterans affairs database study. J Geriatr Cardiol  2019;16:706–9. https://doi.org/10.11909/j.issn.1671-5411.2019.09.006
Google ScholarPubMedWorldCat 
1005	Shah   S, Norby   FL, Datta   YH, Lutsey   PL, MacLehose   RF, Chen   LY, et al.   Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv  2018;2:200–9. https://doi.org/10.1182/bloodadvances.2017010694
  
1006	Mariani   MV, Magnocavallo   M, Straito   M, Piro   A, Severino   P, Iannucci   G, et al.   Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. J Thromb Thrombolysis  2021;51:419–29. https://doi.org/10.1007/s11239-020-02304-3
  
1007	Deitelzweig   S, Keshishian   AV, Zhang   Y, Kang   A, Dhamane   AD, Luo   X, et al.   Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer. JACC CardioOncol  2021;3:411–24. https://doi.org/10.1016/j.jaccao.2021.06.004
  
1008	Lin   YS, Kuan   FC, Chao   TF, Wu   M, Chen   SW, Chen   MC, et al.   Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: dabigatran versus rivaroxaban. Cancer Med  2021;10:7079–88. https://doi.org/10.1002/cam4.4241
  
1009	Atterman   A, Asplund   K, Friberg   L, Engdahl   J. Use of oral anticoagulants after ischaemic stroke in patients with atrial fibrillation and cancer. J Intern Med  2020;288:457–68. https://doi.org/10.1111/joim.13092
  
1010	Atterman   A, Friberg   L, Asplund   K, Engdahl   J. Net benefit of oral anticoagulants in patients with atrial fibrillation and active cancer: a nationwide cohort study. Europace  2020;22:58–65. https://doi.org/10.1093/europace/euz306
Google ScholarPubMedWorldCat 
1011	Falanga   A, Leader   A, Ambaglio   C, Bagoly   Z, Castaman   G, Elalamy   I, et al.   EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. Hemasphere  2022;6:e750. https://doi.org/10.1097/HS9.0000000000000750
  
1012	Lancellotti   P, Suter   TM, López-Fernández   T, Galderisi   M, Lyon   AR, Van der Meer   P, et al.   Cardio-oncology services: rationale, organization, and implementation. Eur Heart J  2019;40:1756–63. https://doi.org/10.1093/eurheartj/ehy453
  
1013	Richter   D, Guasti   L, Walker   D, Lambrinou   E, Lionis   C, Abreu   A, et al.   Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) aorta and peripheral vascular diseases, WG e-cardiology, WG thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol  2022;29:216–27. https://doi.org/10.1093/eurjpc/zwaa167
  
1014	Proietti   M, Vitolo   M, Harrison   SL, Lane   DA, Fauchier   L, Marin   F, et al.   Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) general long-term registry. BMC Med  2021;19:256. https://doi.org/10.1186/s12916-021-02120-3
  
1015	Proietti   M, Romiti   GF, Vitolo   M, Harrison   SL, Lane   DA, Fauchier   L, et al.   Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing  2022;51:afac192. https://doi.org/10.1093/ageing/afac192
  
1016	Savelieva   I, Fumagalli   S, Kenny   RA, Anker   S, Benetos   A, Boriani   G, et al.   EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace  2023;25:1249–76. https://doi.org/10.1093/europace/euac123
  
1017	Clegg   A, Young   J, Iliffe   S, Rikkert   MO, Rockwood   K. Frailty in elderly people. Lancet  2013;381:752–62. https://doi.org/10.1016/S0140-6736(12)62167-9
  
1018	Villani   ER, Tummolo   AM, Palmer   K, Gravina   EM, Vetrano   DL, Bernabei   R, et al.   Frailty and atrial fibrillation: a systematic review. Eur J Intern Med  2018;56:33–8. https://doi.org/10.1016/j.ejim.2018.04.018
  
1019	Hang   F, Chen   J, Wang   Z, Yan   J, Wu   Y. Association between the frailty and new-onset atrial fibrillation/flutter among elderly hypertensive patients. Front Cardiovasc Med  2022;9:881946. https://doi.org/10.3389/fcvm.2022.881946
  
1020	Steinberg   BA, Holmes   DN, Ezekowitz   MD, Fonarow   GC, Kowey   PR, Mahaffey   KW, et al.   Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J  2013;165:622–9. https://doi.org/10.1016/j.ahj.2012.12.019
  
1021	Ko   D, Lin   KJ, Bessette   LG, Lee   SB, Walkey   AJ, Cheng   S, et al.   Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010–2020. JAMA Netw Open  2022;5:e2242964. https://doi.org/10.1001/jamanetworkopen.2022.42964
  
1022	Bul   M, Shaikh   F, McDonagh   J, Ferguson   C. Frailty and oral anticoagulant prescription in adults with atrial fibrillation: a systematic review. Aging Med (Milton)  2023;6:195–206. https://doi.org/10.1002/agm2.12214
  
1023	Hu   J, Zhou   Y, Cai   Z. Outcome of novel oral anticoagulant versus warfarin in frail elderly patients with atrial fibrillation: a systematic review and meta-analysis of retrospective studies. Acta Clin Belg  2023;78:367–77. https://doi.org/10.1080/17843286.2023.2179908
  
1024	Zeng   S, Zheng   Y, Jiang   J, Ma   J, Zhu   W, Cai   X. Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis. Front Cardiovasc Med  2022;9:907197. https://doi.org/10.3389/fcvm.2022.907197
  
1025	Grymonprez   M, Petrovic   M, De Backer   TL, Steurbaut   S, Lahousse   L. Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J Qual Care Clin Outcomes  2024;10:55–65. https://doi.org/10.1093/ehjqcco/qcad019
  
1026	Kim   D, Yang   PS, Sung   JH, Jang   E, Yu   HT, Kim   TH, et al.   Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation. Stroke  2022;53:1873–82. https://doi.org/10.1161/STROKEAHA.121.036757
  
1027	Chao   TF, Liu   CJ, Lin   YJ, Chang   SL, Lo   LW, Hu   YF, et al.   Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation  2018;138:37–47. https://doi.org/10.1161/CIRCULATIONAHA.117.031658
  
1028	Da Costa   A, Thévenin   J, Roche   F, Romeyer-Bouchard   C, Abdellaoui   L, Messier   M, et al.   Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation  2006;114:1676–81. https://doi.org/10.1161/CIRCULATIONAHA.106.638395
  
1029	Natale   A, Newby   KH, Pisano   E, Leonelli   F, Fanelli   R, Potenza   D, et al.   Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol  2000;35:1898–904. https://doi.org/10.1016/S0735-1097(00)00635-5
  
1030	Chinitz   JS, Gerstenfeld   EP, Marchlinski   FE, Callans   DJ. Atrial fibrillation is common after ablation of isolated atrial flutter during long-term follow-up. Heart Rhythm  2007;4:1029–33. https://doi.org/10.1016/j.hrthm.2007.04.002
  
1031	De Bortoli   A, Shi   LB, Ohm   OJ, Hoff   PI, Schuster   P, Solheim   E, et al.   Incidence and clinical predictors of subsequent atrial fibrillation requiring additional ablation after cavotricuspid isthmus ablation for typical atrial flutter. Scand Cardiovasc J  2017;51:123–8. https://doi.org/10.1080/14017431.2017.1304570
  
1032	Rahman   F, Wang   N, Yin   X, Ellinor   PT, Lubitz   SA, LeLorier   PA, et al.   Atrial flutter: clinical risk factors and adverse outcomes in the Framingham Heart Study. Heart Rhythm  2016;13:233–40. https://doi.org/10.1016/j.hrthm.2015.07.031
  
1033	Roth   GA, Mensah   GA, Johnson   CO, Addolorato   G, Ammirati   E, Baddour   LM, et al.   Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol  2020;76:2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010
  
1034	Lippi   G, Sanchis-Gomar   F, Cervellin   G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke  2021;16:217–21. https://doi.org/10.1177/1747493019897870
  
1035	Alonso   A, Alam   AB, Kamel   H, Subbian   V, Qian   J, Boerwinkle   E, et al.   Epidemiology of atrial fibrillation in the all of US research program. PLoS One  2022;17:e0265498. https://doi.org/10.1371/journal.pone.0265498
  
1036	Ghelani   KP, Chen   LY, Norby   FL, Soliman   EZ, Koton   S, Alonso   A. Thirty-year trends in the incidence of atrial fibrillation: the ARIC study. J Am Heart Assoc  2022;11:e023583. https://doi.org/10.1161/JAHA.121.023583
  
1037	Williams   BA, Chamberlain   AM, Blankenship   JC, Hylek   EM, Voyce   S. Trends in atrial fibrillation incidence rates within an integrated health care delivery system, 2006 to 2018. JAMA Netw Open  2020;3:e2014874. https://doi.org/10.1001/jamanetworkopen.2020.14874
  
1038	Magnussen   C, Niiranen   TJ, Ojeda   FM, Gianfagna   F, Blankenberg   S, Njølstad   I, et al.   Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation  2017;136:1588–97. https://doi.org/10.1161/CIRCULATIONAHA.117.028981
  
1039	Rodriguez   CJ, Soliman   EZ, Alonso   A, Swett   K, Okin   PM, Goff   DC, Jr, et al.   Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the multi-ethnic study of atherosclerosis. Ann Epidemiol  2015;25:71–6, 76.e1. https://doi.org/10.1016/j.annepidem.2014.11.024
  
1040	Ugowe   FE, Jackson   LR, 2nd, Thomas   KL. Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: a systematic review. Heart Rhythm  2018;15:1337–45. https://doi.org/10.1016/j.hrthm.2018.05.019
  
1041	Volgman   AS, Bairey Merz   CN, Benjamin   EJ, Curtis   AB, Fang   MC, Lindley   KJ, et al.   Sex and race/ethnicity differences in atrial fibrillation. J Am Coll Cardiol  2019;74:2812–5. https://doi.org/10.1016/j.jacc.2019.09.045
  
1042	Chung   SC, Sofat   R, Acosta-Mena   D, Taylor   JA, Lambiase   PD, Casas   JP, et al.   Atrial fibrillation epidemiology, disparity and healthcare contacts: a population-wide study of 5.6 million individuals. Lancet Reg Health Eur  2021;7:100157. https://doi.org/10.1016/j.lanepe.2021.100157
  
1043	Svennberg   E, Tjong   F, Goette   A, Akoum   N, Di Biase   L, Bordachar   P, et al.   How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace  2022;24:979–1005. https://doi.org/10.1093/europace/euac038
  
1044	Spatz   ES, Ginsburg   GS, Rumsfeld   JS, Turakhia   MP. Wearable digital health technologies for monitoring in cardiovascular medicine. N Engl J Med  2024;390:346–56. https://doi.org/10.1056/NEJMra2301903
  
1045	Cooke   G, Doust   J, Sanders   S. Is pulse palpation helpful in detecting atrial fibrillation? A systematic review. J Fam Pract  2006;55:130–4.
Google ScholarWorldCat 
1046	Attia   ZI, Noseworthy   PA, Lopez-Jimenez   F, Asirvatham   SJ, Deshmukh   AJ, Gersh   BJ, et al.   An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet  2019;394:861–7. https://doi.org/10.1016/S0140-6736(19)31721-0
  
1047	Hobbs   FD, Fitzmaurice   DA, Mant   J, Murray   E, Jowett   S, Bryan   S, et al.   A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess  2005;9:iii–iv, ix-x, 1–74. https://doi.org/10.3310/hta9400
  
1048	Grond   M, Jauss   M, Hamann   G, Stark   E, Veltkamp   R, Nabavi   D, et al.   Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke  2013;44:3357–64. https://doi.org/10.1161/STROKEAHA.113.001884
  
1049	Rizos   T, Guntner   J, Jenetzky   E, Marquardt   L, Reichardt   C, Becker   R, et al.   Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke  2012;43:2689–94. https://doi.org/10.1161/STROKEAHA.112.654954
  
1050	Doliwa   PS, Frykman   V, Rosenqvist   M. Short-term ECG for out of hospital detection of silent atrial fibrillation episodes. Scand Cardiovasc J  2009;43:163–8. https://doi.org/10.1080/14017430802593435
  
1051	Tieleman   RG, Plantinga   Y, Rinkes   D, Bartels   GL, Posma   JL, Cator   R, et al.   Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace  2014;16:1291–5. https://doi.org/10.1093/europace/euu057
  
1052	Kearley   K, Selwood   M, Van den Bruel   A, Thompson   M, Mant   D, Hobbs   FR, et al.   Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors. BMJ Open  2014;4:e004565. https://doi.org/10.1136/bmjopen-2013-004565
  
1053	Barrett   PM, Komatireddy   R, Haaser   S, Topol   S, Sheard   J, Encinas   J, et al.   Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med  2014;127:95.e11–7. https://doi.org/10.1016/j.amjmed.2013.10.003
  
1054	Turakhia   MP, Hoang   DD, Zimetbaum   P, Miller   JD, Froelicher   VF, Kumar   UN, et al.   Diagnostic utility of a novel leadless arrhythmia monitoring device. Am J Cardiol  2013;112:520–4. https://doi.org/10.1016/j.amjcard.2013.04.017
  
1055	Rosenberg   MA, Samuel   M, Thosani   A, Zimetbaum   PJ. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. Pacing Clin Electrophysiol  2013;36:328–33. https://doi.org/10.1111/pace.12053
  
1056	Turakhia   MP, Ullal   AJ, Hoang   DD, Than   CT, Miller   JD, Friday   KJ, et al.   Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). Clin Cardiol  2015;38:285–92. https://doi.org/10.1002/clc.22387
  
1057	Rooney   MR, Soliman   EZ, Lutsey   PL, Norby   FL, Loehr   LR, Mosley   TH, et al.   Prevalence and characteristics of subclinical atrial fibrillation in a community-dwelling elderly population: the ARIC study. Circ Arrhythm Electrophysiol  2019;12:e007390. https://doi.org/10.1161/CIRCEP.119.007390
  
1058	Stehlik   J, Schmalfuss   C, Bozkurt   B, Nativi-Nicolau   J, Wohlfahrt   P, Wegerich   S, et al.   Continuous wearable monitoring analytics predict heart failure hospitalization: the LINK-HF multicenter study. Circ Heart Fail  2020;13:e006513. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006513
  
1059	Ganne   C, Talkad   SN, Srinivas   D, Somanna   S. Ruptured blebs and racing hearts: autonomic cardiac changes in neurosurgeons during microsurgical clipping of aneurysms. Br J Neurosurg  2016;30:450–2. https://doi.org/10.3109/02688697.2016.1159656
  
1060	Smith   WM, Riddell   F, Madon   M, Gleva   MJ. Comparison of diagnostic value using a small, single channel, P-wave centric sternal ECG monitoring patch with a standard 3-lead Holter system over 24 hours. Am Heart J  2017;185:67–73. https://doi.org/10.1016/j.ahj.2016.11.006
  
1061	Olson   JA, Fouts   AM, Padanilam   BJ, Prystowsky   EN. Utility of mobile cardiac outpatient telemetry for the diagnosis of palpitations, presyncope, syncope, and the assessment of therapy efficacy. J Cardiovasc Electrophysiol  2007;18:473–7. https://doi.org/10.1111/j.1540-8167.2007.00779.x
  
1062	Derkac   WM, Finkelmeier   JR, Horgan   DJ, Hutchinson   MD. Diagnostic yield of asymptomatic arrhythmias detected by mobile cardiac outpatient telemetry and autotrigger looping event cardiac monitors. J Cardiovasc Electrophysiol  2017;28:1475–8. https://doi.org/10.1111/jce.13342
  
1063	Teplitzky   BA, McRoberts   M, Ghanbari   H. Deep learning for comprehensive ECG annotation. Heart Rhythm  2020;17:881–8. https://doi.org/10.1016/j.hrthm.2020.02.015
  
1064	Jeon   E, Oh   K, Kwon   S, Son   H, Yun   Y, Jung   ES, et al.   A lightweight deep learning model for fast electrocardiographic beats classification with a wearable cardiac monitor: development and validation study. JMIR Med Inform  2020;8:e17037. https://doi.org/10.2196/17037
  
1065	Breteler   MJMM, Huizinga   E, van Loon   K, Leenen   LPH, Dohmen   DAJ, Kalkman   CJ, et al.   Reliability of wireless monitoring using a wearable patch sensor in high-risk surgical patients at a step-down unit in The Netherlands: a clinical validation study. BMJ Open  2018;8:e020162. https://doi.org/10.1136/bmjopen-2017-020162
  
1066	Hopkins   L, Stacey   B, Robinson   DBT, James   OP, Brown   C, Egan   RJ, et al.   Consumer-grade biosensor validation for examining stress in healthcare professionals. Physiol Rep  2020;8:e14454. https://doi.org/10.14814/phy2.14454
  
1067	Steinhubl   SR, Waalen   J, Edwards   AM, Ariniello   LM, Mehta   RR, Ebner   GS, et al.   Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA  2018;320:146–55. https://doi.org/10.1001/jama.2018.8102
  
1068	Elliot   CA, Hamlin   MJ, Lizamore   CA. Validity and reliability of the hexoskin wearable biometric vest during maximal aerobic power testing in elite cyclists. J Strength Cond Res  2019;33:1437–44. https://doi.org/10.1519/JSC.0000000000002005
  
1069	Eysenck   W, Freemantle   N, Sulke   N. A randomized trial evaluating the accuracy of AF detection by four external ambulatory ECG monitors compared to permanent pacemaker AF detection. J Interv Card Electrophysiol  2020;57:361–9. https://doi.org/10.1007/s10840-019-00515-0
  
1070	Fabregat-Andres   O, Munoz-Macho   A, Adell-Beltran   G, Ibanez-Catala   X, Macia   A, Facila   L. Evaluation of a new shirt-based electrocardiogram device for cardiac screening in soccer players: comparative study with treadmill ergospirometry. Cardiol Res  2014;5:101–7. https://doi.org/10.14740/cr333w
Google ScholarWorldCat 
1071	Feito   Y, Moriarty   TA, Mangine   G, Monahan   J. The use of a smart-textile garment during high-intensity functional training: a pilot study. J Sports Med Phys Fitness  2019;59:947–54. https://doi.org/10.23736/S0022-4707.18.08689-9
  
1072	Pagola   J, Juega   J, Francisco-Pascual   J, Moya   A, Sanchis   M, Bustamante   A, et al.   Yield of atrial fibrillation detection with textile wearable Holter from the acute phase of stroke: pilot study of crypto-AF registry. Int J Cardiol  2018;251:45–50. https://doi.org/10.1016/j.ijcard.2017.10.063
  
1073	Lau   JK, Lowres   N, Neubeck   L, Brieger   DB, Sy   RW, Galloway   CD, et al.   iphone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. Int J Cardiol  2013;165:193–4. https://doi.org/10.1016/j.ijcard.2013.01.220
  
1074	Bumgarner   JM, Lambert   CT, Hussein   AA, Cantillon   DJ, Baranowski   B, Wolski   K, et al.   Smartwatch algorithm for automated detection of atrial fibrillation. J Am Coll Cardiol  2018;71:2381–8. https://doi.org/10.1016/j.jacc.2018.03.003
  
1075	Lubitz   SA, Faranesh   AZ, Atlas   SJ, McManus   DD, Singer   DE, Pagoto   S, et al.   Rationale and design of a large population study to validate software for the assessment of atrial fibrillation from data acquired by a consumer tracker or smartwatch: the Fitbit heart study. Am Heart J  2021;238:16–26. https://doi.org/10.1016/j.ahj.2021.04.003
  
1076	Perez   MV, Mahaffey   KW, Hedlin   H, Rumsfeld   JS, Garcia   A, Ferris   T, et al.   Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med  2019;381:1909–17. https://doi.org/10.1056/NEJMoa1901183
  
1077	Saghir   N, Aggarwal   A, Soneji   N, Valencia   V, Rodgers   G, Kurian   T. A comparison of manual electrocardiographic interval and waveform analysis in lead 1 of 12-lead ECG and apple watch ECG: a validation study. Cardiovasc Digit Health J  2020;1:30–6. https://doi.org/10.1016/j.cvdhj.2020.07.002
  
1078	Seshadri   DR, Bittel   B, Browsky   D, Houghtaling   P, Drummond   CK, Desai   MY, et al.   Accuracy of apple watch for detection of atrial fibrillation. Circulation  2020;141:702–3. https://doi.org/10.1161/CIRCULATIONAHA.119.044126
  
1079	Zhang   H, Zhang   J, Li   HB, Chen   YX, Yang   B, Guo   YT, et al.   Validation of single centre pre-mobile atrial fibrillation apps for continuous monitoring of atrial fibrillation in a real-world setting: pilot cohort study. J Med Internet Res  2019;21:e14909. https://doi.org/10.2196/14909
  
1080	Fan   YY, Li   YG, Li   J, Cheng   WK, Shan   ZL, Wang   YT, et al.   Diagnostic performance of a smart device with photoplethysmography technology for atrial fibrillation detection: pilot study (Pre-mAFA II registry). JMIR Mhealth Uhealth  2019;7:e11437. https://doi.org/10.2196/11437
  
1081	Brito   R, Mondouagne   LP, Stettler   C, Combescure   C, Burri   H. Automatic atrial fibrillation and flutter detection by a handheld ECG recorder, and utility of sequential finger and precordial recordings. J Electrocardiol  2018;51:1135–40. https://doi.org/10.1016/j.jelectrocard.2018.10.093
  
1082	Desteghe   L, Raymaekers   Z, Lutin   M, Vijgen   J, Dilling-Boer   D, Koopman   P, et al.   Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. Europace  2017;19:29–39. https://doi.org/10.1093/europace/euw025
  
1083	Nigolian   A, Dayal   N, Nigolian   H, Stettler   C, Burri   H. Diagnostic accuracy of multi-lead ECGs obtained using a pocket-sized bipolar handheld event recorder. J Electrocardiol  2018;51:278–81. https://doi.org/10.1016/j.jelectrocard.2017.11.004
  
1084	Magnusson   P, Lyren   A, Mattsson   G. Diagnostic yield of chest and thumb ECG after cryptogenic stroke, Transient ECG Assessment in Stroke Evaluation (TEASE): an observational trial. BMJ Open  2020;10:e037573. https://doi.org/10.1136/bmjopen-2020-037573
  
1085	Carnlöf   C, Schenck-Gustafsson   K, Jensen-Urstad   M, Insulander   P. Instant electrocardiogram feedback with a new digital technique reduces symptoms caused by palpitations and increases health-related quality of life (the RedHeart study). Eur J Cardiovasc Nurs  2021;20:402–10. https://doi.org/10.1093/eurjcn/zvaa031
  
1086	Haverkamp   HT, Fosse   SO, Schuster   P. Accuracy and usability of single-lead ECG from smartphones—a clinical study. Indian Pacing Electrophysiol J  2019;19:145–9. https://doi.org/10.1016/j.ipej.2019.02.006
  
1087	Attia   ZI, Kapa   S, Lopez-Jimenez   F, McKie   PM, Ladewig   DJ, Satam   G, et al.   Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med  2019;25:70–4. https://doi.org/10.1038/s41591-018-0240-2
  
1088	Bekker   CL, Noordergraaf   F, Teerenstra   S, Pop   G, van den Bemt   BJF. Diagnostic accuracy of a single-lead portable ECG device for measuring QTc prolongation. Ann Noninvasive Electrocardiol  2020;25:e12683. https://doi.org/10.1111/anec.12683
  
1089	Kaleschke   G, Hoffmann   B, Drewitz   I, Steinbeck   G, Naebauer   M, Goette   A, et al.   Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. Europace  2009;11:1362–8. https://doi.org/10.1093/europace/eup262
  
1090	Guan   J, Wang   A, Song   W, Obore   N, He   P, Fan   S, et al.   Screening for arrhythmia with the new portable single-lead electrocardiographic device (SnapECG): an application study in community-based elderly population in Nanjing, China. Aging Clin Exp Res  2021;33:133–40. https://doi.org/10.1007/s40520-020-01512-4
  
1091	Svennberg   E, Stridh   M, Engdahl   J, Al-Khalili   F, Friberg   L, Frykman   V, et al.   Safe automatic one-lead electrocardiogram analysis in screening for atrial fibrillation. Europace  2017;19:1449–53. https://doi.org/10.1093/europace/euw286
Google ScholarWorldCat 
1092	Musat   DL, Milstein   N, Mittal   S. Implantable loop recorders for cryptogenic stroke (plus real-world atrial fibrillation detection rate with implantable loop recorders). Card Electrophysiol Clin  2018;10:111–8. https://doi.org/10.1016/j.ccep.2017.11.011
  
1093	Sakhi   R, Theuns   D, Szili-Torok   T, Yap   SC. Insertable cardiac monitors: current indications and devices. Expert Rev Med Devices  2019;16:45–55. https://doi.org/10.1080/17434440.2018.1557046
  
1094	Tomson   TT, Passman   R. The reveal LINQ insertable cardiac monitor. Expert Rev Med Devices  2015;12:7–18. https://doi.org/10.1586/17434440.2014.953059
  
1095	Ciconte   G, Saviano   M, Giannelli   L, Calovic   Z, Baldi   M, Ciaccio   C, et al.   Atrial fibrillation detection using a novel three-vector cardiac implantable monitor: the atrial fibrillation detect study. Europace  2017;19:1101–8. https://doi.org/10.1093/europace/euw181
  
1096	Hindricks   G, Pokushalov   E, Urban   L, Taborsky   M, Kuck   KH, Lebedev   D, et al.   Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial. Circ Arrhythm Electrophysiol  2010;3:141–7. https://doi.org/10.1161/CIRCEP.109.877852
  
1097	Mittal   S, Rogers   J, Sarkar   S, Koehler   J, Warman   EN, Tomson   TT, et al.   Real-world performance of an enhanced atrial fibrillation detection algorithm in an insertable cardiac monitor. Heart Rhythm  2016;13:1624–30. https://doi.org/10.1016/j.hrthm.2016.05.010
  
1098	Nölker   G, Mayer   J, Boldt   LH, Seidl K   VVAND, Massa   T, Kollum   M, et al.   Performance of an implantable cardiac monitor to detect atrial fibrillation: results of the DETECT AF study. J Cardiovasc Electrophysiol  2016;27:1403–10. https://doi.org/10.1111/jce.13089
  
1099	Sanders   P, Pürerfellner   H, Pokushalov   E, Sarkar   S, Di Bacco   M, Maus   B, et al.   Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: results from the reveal LINQ usability study. Heart Rhythm  2016;13:1425–30. https://doi.org/10.1016/j.hrthm.2016.03.005
  
1100	Chan   PH, Wong   CK, Poh   YC, Pun   L, Leung   WW, Wong   YF, et al.   Diagnostic performance of a smartphone-based photoplethysmographic application for atrial fibrillation screening in a primary care setting. J Am Heart Assoc  2016;5:e003428. https://doi.org/10.1161/JAHA.116.003428
  
1101	Mc   MD, Chong   JW, Soni   A, Saczynski   JS, Esa   N, Napolitano   C, et al.   PULSE-SMART: pulse-based arrhythmia discrimination using a novel smartphone application. J Cardiovasc Electrophysiol  2016;27:51–7. https://doi.org/10.1111/jce.12842
Google ScholarWorldCat 
1102	Proesmans   T, Mortelmans   C, Van Haelst   R, Verbrugge   F, Vandervoort   P, Vaes   B. Mobile phone-based use of the photoplethysmography technique to detect atrial fibrillation in primary care: diagnostic accuracy study of the FibriCheck app. JMIR Mhealth Uhealth  2019;7:e12284. https://doi.org/10.2196/12284
  
1103	Rozen   G, Vaid   J, Hosseini   SM, Kaadan   MI, Rafael   A, Roka   A, et al.   Diagnostic accuracy of a novel mobile phone application for the detection and monitoring of atrial fibrillation. Am J Cardiol  2018;121:1187–91. https://doi.org/10.1016/j.amjcard.2018.01.035
  
1104	O’Sullivan   JW, Grigg   S, Crawford   W, Turakhia   MP, Perez   M, Ingelsson   E, et al.   Accuracy of smartphone camera applications for detecting atrial fibrillation: a systematic review and meta-analysis. JAMA Netw Open  2020;3:e202064. https://doi.org/10.1001/jamanetworkopen.2020.2064
  
1105	Koenig   N, Seeck   A, Eckstein   J, Mainka   A, Huebner   T, Voss   A, et al.   Validation of a new heart rate measurement algorithm for fingertip recording of video signals with smartphones. Telemed J E Health  2016;22:631–6. https://doi.org/10.1089/tmj.2015.0212
  
1106	Krivoshei   L, Weber   S, Burkard   T, Maseli   A, Brasier   N, Kühne   M, et al.   Smart detection of atrial fibrillation†. Europace  2017;19:753–7. https://doi.org/10.1093/europace/euw125
Google ScholarWorldCat 
1107	Wiesel   J, Fitzig   L, Herschman   Y, Messineo   FC. Detection of atrial fibrillation using a modified microlife blood pressure monitor. Am J Hypertens  2009;22:848–52. https://doi.org/10.1038/ajh.2009.98
  
1108	Chen   Y, Lei   L, Wang   JG. Atrial fibrillation screening during automated blood pressure measurement—comment on “diagnostic accuracy of new algorithm to detect atrial fibrillation in a home blood pressure monitor”. J Clin Hypertens (Greenwich)  2017;19:1148–51. https://doi.org/10.1111/jch.13081
  
1109	Kane   SA, Blake   JR, McArdle   FJ, Langley   P, Sims   AJ. Opportunistic detection of atrial fibrillation using blood pressure monitors: a systematic review. Open Heart  2016;3:e000362. https://doi.org/10.1136/openhrt-2015-000362
  
1110	Kario   K. Evidence and perspectives on the 24-hour management of hypertension: hemodynamic biomarker-initiated ‘anticipation medicine’ for zero cardiovascular event. Prog Cardiovasc Dis  2016;59:262–81. https://doi.org/10.1016/j.pcad.2016.04.001
  
1111	Jaakkola   J, Jaakkola   S, Lahdenoja   O, Hurnanen   T, Koivisto   T, Pänkäälä   M, et al.   Mobile phone detection of atrial fibrillation with mechanocardiography: the MODE-AF study (mobile phone detection of atrial fibrillation). Circulation  2018;137:1524–7. https://doi.org/10.1161/CIRCULATIONAHA.117.032804
  
1112	Couderc   JP, Kyal   S, Mestha   LK, Xu   B, Peterson   DR, Xia   X, et al.   Detection of atrial fibrillation using contactless facial video monitoring. Heart Rhythm  2015;12:195–201. https://doi.org/10.1016/j.hrthm.2014.08.035
  
1113	Yan   BP, Lai   WHS, Chan   CKY, Au   ACK, Freedman   B, Poh   YC, et al.   High-throughput, contact-free detection of atrial fibrillation from video with deep learning. JAMA Cardiol  2020;5:105–7. https://doi.org/10.1001/jamacardio.2019.4004
  
1114	Yan   BP, Lai   WHS, Chan   CKY, Chan   SC, Chan   LH, Lam   KM, et al.   Contact-free screening of atrial fibrillation by a smartphone using facial pulsatile photoplethysmographic signals. J Am Heart Assoc  2018;7:e008585. https://doi.org/10.1161/JAHA.118.008585
  
1115	Tsouri   GR, Li   Z. On the benefits of alternative color spaces for noncontact heart rate measurements using standard red-green-blue cameras. J Biomed Opt  2015;20:048002. https://doi.org/10.1117/1.JBO.20.4.048002
  
1116	Chan   J, Rea   T, Gollakota   S, Sunshine   JE. Contactless cardiac arrest detection using smart devices. NPJ Digit Med  2019;2:52. https://doi.org/10.1038/s41746-019-0128-7
  
1117	Guo   Y, Wang   H, Zhang   H, Liu   T, Liang   Z, Xia   Y, et al.   Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol  2019;74:2365–75. https://doi.org/10.1016/j.jacc.2019.08.019
  
1118	Lubitz   SA, Faranesh   AZ, Selvaggi   C, Atlas   SJ, McManus   DD, Singer   DE, et al.   Detection of atrial fibrillation in a large population using wearable devices: the Fitbit heart study. Circulation  2022;146:1415–24. https://doi.org/10.1161/CIRCULATIONAHA.122.060291
  
1119	Lopez Perales   CR, Van Spall   HGC, Maeda   S, Jimenez   A, Laţcu   DG, Milman   A, et al.   Mobile health applications for the detection of atrial fibrillation: a systematic review. Europace  2021;23:11–28. https://doi.org/10.1093/europace/euaa139
  
1120	Gill   S, Bunting   KV, Sartini   C, Cardoso   VR, Ghoreishi   N, Uh   HW, et al.   Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis. Heart  2022;108:1600–7. https://doi.org/10.1136/heartjnl-2021-320417
  
1121	Mant   J, Fitzmaurice   DA, Hobbs   FD, Jowett   S, Murray   ET, Holder   R, et al.   Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ  2007;335:380. https://doi.org/10.1136/bmj.39227.551713.AE
  
1122	Halcox   JPJ, Wareham   K, Cardew   A, Gilmore   M, Barry   JP, Phillips   C, et al.   Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. Circulation  2017;136:1784–94. https://doi.org/10.1161/CIRCULATIONAHA.117.030583
  
1123	Duarte   R, Stainthorpe   A, Greenhalgh   J, Richardson   M, Nevitt   S, Mahon   J, et al.   Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation. Health Technol Assess  2020;24:1–164. https://doi.org/10.3310/hta24030
  
1124	Mannhart   D, Lischer   M, Knecht   S, du Fay de Lavallaz   J, Strebel   I, Serban   T, et al.   Clinical validation of 5 direct-to-consumer wearable smart devices to detect atrial fibrillation: BASEL wearable study. JACC Clin Electrophysiol  2023;9:232–42. https://doi.org/10.1016/j.jacep.2022.09.011
  
1125	Paul Nordin   A, Carnlöf   C, Insulander   P, Mohammad Ali   A, Jensen-Urstad   M, Saluveer   O, et al.   Validation of diagnostic accuracy of a handheld, smartphone-based rhythm recording device. Expert Rev Med Devices  2023;20:55–61. https://doi.org/10.1080/17434440.2023.2171290
  
1126	Gill   SK, Barsky   A, Guan   X, Bunting   KV, Karwath   A, Tica   O, et al.   Consumer wearable devices to evaluate dynamic heart rate with digoxin versus beta-blockers: the RATE-AF randomised trial. Nat Med  2024;30:2030–2036. https://doi.org/10.1038/s41591-024-03094-4.
  
1127	Kahwati   LC, Asher   GN, Kadro   ZO, Keen   S, Ali   R, Coker-Schwimmer   E, et al.   Screening for atrial fibrillation: updated evidence report and systematic review for the US preventive services task force. JAMA  2022;327:368–83. https://doi.org/10.1001/jama.2021.21811
  
1128	Strong   K, Wald   N, Miller   A, Alwan   A. Current concepts in screening for noncommunicable disease: World Health Organization Consultation Group Report on methodology of noncommunicable disease screening. J Med Screen  2005;12:12–9. https://doi.org/10.1258/0969141053279086
  
1129	Whitfield   R, Ascenção   R, da Silva   GL, Almeida   AG, Pinto   FJ, Caldeira   D. Screening strategies for atrial fibrillation in the elderly population: a systematic review and network meta-analysis. Clin Res Cardiol  2023;112:705–15. https://doi.org/10.1007/s00392-022-02117-9
  
1130	Proietti   M, Romiti   GF, Vitolo   M, Borgi   M, Rocco   AD, Farcomeni   A, et al.   Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: a systematic review and meta-regression. Eur J Intern Med  2022;103:84–94. https://doi.org/10.1016/j.ejim.2022.06.023
  
1131	Healey   JS, Alings   M, Ha   A, Leong-Sit   P, Birnie   DH, de Graaf   JJ, et al.   Subclinical atrial fibrillation in older patients. Circulation  2017;136:1276–83. https://doi.org/10.1161/CIRCULATIONAHA.117.028845
  
1132	Van Gelder   IC, Healey   JS, Crijns   H, Wang   J, Hohnloser   SH, Gold   MR, et al.   Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J  2017;38:1339–44. https://doi.org/10.1093/eurheartj/ehx042
  
1133	Kemp Gudmundsdottir   K, Fredriksson   T, Svennberg   E, Al-Khalili   F, Friberg   L, Frykman   V, et al.   Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace  2020;22:24–32. https://doi.org/10.1093/europace/euz255
  
1134	Williams   K, Modi   RN, Dymond   A, Hoare   S, Powell   A, Burt   J, et al.   Cluster randomised controlled trial of screening for atrial fibrillation in people aged 70 years and over to reduce stroke: protocol for the pilot study for the SAFER trial. BMJ Open  2022;12:e065066. https://doi.org/10.1136/bmjopen-2022-065066
  
1135	Elbadawi   A, Sedhom   R, Gad   M, Hamed   M, Elwagdy   A, Barakat   AF, et al.   Screening for atrial fibrillation in the elderly: a network meta-analysis of randomized trials. Eur J Intern Med  2022;105:38–45. https://doi.org/10.1016/j.ejim.2022.07.015
  
1136	McIntyre   WF, Diederichsen   SZ, Freedman   B, Schnabel   RB, Svennberg   E, Healey   JS. Screening for atrial fibrillation to prevent stroke: a meta-analysis. Eur Heart J Open  2022;2:oeac044. https://doi.org/10.1093/ehjopen/oeac044
  
1137	Lyth   J, Svennberg   E, Bernfort   L, Aronsson   M, Frykman   V, Al-Khalili   F, et al.   Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study. Eur Heart J  2023;44:196–204. https://doi.org/10.1093/eurheartj/ehac547
  
1138	Lubitz   SA, Atlas   SJ, Ashburner   JM, Lipsanopoulos   ATT, Borowsky   LH, Guan   W, et al.   Screening for atrial fibrillation in older adults at primary care visits: VITAL-AF randomized controlled trial. Circulation  2022;145:946–54. https://doi.org/10.1161/CIRCULATIONAHA.121.057014
  
1139	Uittenbogaart   SB, Verbiest-van Gurp   N, Lucassen   WAM, Winkens   B, Nielen   M, Erkens   PMG, et al.   Opportunistic screening versus usual care for detection of atrial fibrillation in primary care: cluster randomised controlled trial. BMJ  2020;370:m3208. https://doi.org/10.1136/bmj.m3208
Google ScholarWorldCat 
1140	Kaasenbrood   F, Hollander   M, de Bruijn   SH, Dolmans   CP, Tieleman   RG, Hoes   AW, et al.   Opportunistic screening versus usual care for diagnosing atrial fibrillation in general practice: a cluster randomised controlled trial. Br J Gen Pract  2020;70:e427–33. https://doi.org/10.3399/bjgp20X708161
  
1141	Petryszyn   P, Niewinski   P, Staniak   A, Piotrowski   P, Well   A, Well   M, et al.   Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis. PLoS One  2019;14:e0213198. https://doi.org/10.1371/journal.pone.0213198
  
1142	Wang   Q, Richardson   TG, Sanderson   E, Tudball   MJ, Ala-Korpela   M, Davey Smith   G, et al.   A phenome-wide bidirectional Mendelian randomization analysis of atrial fibrillation. Int J Epidemiol  2022;51:1153–66. https://doi.org/10.1093/ije/dyac041
  
1143	Siddiqi   HK, Vinayagamoorthy   M, Gencer   B, Ng   C, Pester   J, Cook   NR, et al.   Sex differences in atrial fibrillation risk: the VITAL rhythm study. JAMA Cardiol  2022;7:1027–35. https://doi.org/10.1001/jamacardio.2022.2825
  
1144	Lu   Z, Aribas   E, Geurts   S, Roeters van Lennep   JE, Ikram   MA, Bos   MM, et al.   Association between sex-specific risk factors and risk of new-onset atrial fibrillation among women. JAMA Netw Open  2022;5:e2229716. https://doi.org/10.1001/jamanetworkopen.2022.29716
  
1145	Wong   GR, Nalliah   CJ, Lee   G, Voskoboinik   A, Chieng   D, Prabhu   S, et al.   Sex-related differences in atrial remodeling in patients with atrial fibrillation: relationship to ablation outcomes. Circ Arrhythm Electrophysiol  2022;15:e009925. https://doi.org/10.1161/CIRCEP.121.009925
  
1146	Mokgokong   R, Schnabel   R, Witt   H, Miller   R, Lee   TC. Performance of an electronic health record-based predictive model to identify patients with atrial fibrillation across countries. PLoS One  2022;17:e0269867. https://doi.org/10.1371/journal.pone.0269867
  
1147	Schnabel   RB, Witt   H, Walker   J, Ludwig   M, Geelhoed   B, Kossack   N, et al.   Machine learning-based identification of risk-factor signatures for undiagnosed atrial fibrillation in primary prevention and post-stroke in clinical practice. Eur Heart J Qual Care Clin Outcomes  2022;9:16–23. https://doi.org/10.1093/ehjqcco/qcac013
  
1148	Himmelreich   JCL, Veelers   L, Lucassen   WAM, Schnabel   RB, Rienstra   M, van Weert   H, et al.   Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis. Europace  2020;22:684–94. https://doi.org/10.1093/europace/euaa005
  
1149	Benjamin   EJ, Muntner   P, Alonso   A, Bittencourt   MS, Callaway   CW, Carson   AP, et al.   Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation  2019;139:e56–528. https://doi.org/10.1161/CIR.0000000000000659
  
1150	Allan   V, Honarbakhsh   S, Casas   JP, Wallace   J, Hunter   R, Schilling   R, et al.   Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost  2017;117:837–50. https://doi.org/10.1160/TH16-11-0825
  
1151	Kirchhof   P, Lip   GY, Van Gelder   IC, Bax   J, Hylek   E, Kaab   S, et al.   Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace  2012;14:8–27. https://doi.org/10.1093/europace/eur241
  
1152	Lu   Z, Tilly   MJ, Geurts   S, Aribas   E, Roeters van Lennep   J, de Groot   NMS, et al.   Sex-specific anthropometric and blood pressure trajectories and risk of incident atrial fibrillation: the Rotterdam study. Eur J Prev Cardiol  2022;29:1744–55. https://doi.org/10.1093/eurjpc/zwac083
  
1153	Giacomantonio   NB, Bredin   SS, Foulds   HJ, Warburton   DE. A systematic review of the health benefits of exercise rehabilitation in persons living with atrial fibrillation. Can J Cardiol  2013;29:483–91. https://doi.org/10.1016/j.cjca.2012.07.003
  
1154	Andersen   K, Farahmand   B, Ahlbom   A, Held   C, Ljunghall   S, Michaelsson   K, et al.   Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J  2013;34:3624–31. https://doi.org/10.1093/eurheartj/eht188
  
1155	Qureshi   WT, Alirhayim   Z, Blaha   MJ, Juraschek   SP, Keteyian   SJ, Brawner   CA, et al.   Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the Henry Ford exercise testing (FIT) project. Circulation  2015;131:1827–34. https://doi.org/10.1161/CIRCULATIONAHA.114.014833
  
1156	Kwok   CS, Anderson   SG, Myint   PK, Mamas   MA, Loke   YK. Physical activity and incidence of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol  2014;177:467–76. https://doi.org/10.1016/j.ijcard.2014.09.104
  
1157	Abdulla   J, Nielsen   JR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. Europace  2009;11:1156–9. https://doi.org/10.1093/europace/eup197
  
1158	Cheng   M, Hu   Z, Lu   X, Huang   J, Gu   D. Caffeine intake and atrial fibrillation incidence: dose response meta-analysis of prospective cohort studies. Can J Cardiol  2014;30:448–54. https://doi.org/10.1016/j.cjca.2013.12.026
  
1159	Conen   D, Chiuve   SE, Everett   BM, Zhang   SM, Buring   JE, Albert   CM. Caffeine consumption and incident atrial fibrillation in women. Am J Clin Nutr  2010;92:509–14. https://doi.org/10.3945/ajcn.2010.29627
  
1160	Shen   J, Johnson   VM, Sullivan   LM, Jacques   PF, Magnani   JW, Lubitz   SA, et al.   Dietary factors and incident atrial fibrillation: the Framingham heart study. Am J Clin Nutr  2011;93:261–6. https://doi.org/10.3945/ajcn.110.001305
  
1161	Schnabel   RB, Yin   X, Gona   P, Larson   MG, Beiser   AS, McManus   DD, et al.   50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham heart study: a cohort study. Lancet  2015;386:154–62. https://doi.org/10.1016/S0140-6736(14)61774-8
  
1162	Furberg   CD, Psaty   BM, Manolio   TA, Gardin   JM, Smith   VE, Rautaharju   PM. Prevalence of atrial fibrillation in elderly subjects (the cardiovascular health study). Am J Cardiol  1994;74:236–41. https://doi.org/10.1016/0002-9149(94)90363-8
  
1163	Lip   GYH, Collet   JP, de Caterina   R, Fauchier   L, Lane   DA, Larsen   TB, et al.   Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: executive summary of a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Thromb Haemost  2017;117:2215–36. https://doi.org/10.1160/TH-17-10-0709
  
1164	Benjamin   EJ, Levy   D, Vaziri   SM, D’Agostino   RB, Belanger   AJ, Wolf   PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA  1994;271:840–4. https://doi.org/10.1001/jama.1994.03510350050036
  
1165	Michniewicz   E, Mlodawska   E, Lopatowska   P, Tomaszuk-Kazberuk   A, Malyszko   J. Patients with atrial fibrillation and coronary artery disease—double trouble. Adv Med Sci  2018;63:30–5. https://doi.org/10.1016/j.advms.2017.06.005
  
1166	Loomba   RS, Buelow   MW, Aggarwal   S, Arora   RR, Kovach   J, Ginde   S. Arrhythmias in adults with congenital heart disease: what are risk factors for specific arrhythmias?  Pacing Clin Electrophysiol  2017;40:353–61. https://doi.org/10.1111/pace.12983
  
1167	Siland   JE, Geelhoed   B, Roselli   C, Wang   B, Lin   HJ, Weiss   S, et al.   Resting heart rate and incident atrial fibrillation: a stratified Mendelian randomization in the AFGen consortium. PLoS One  2022;17:e0268768. https://doi.org/10.1371/journal.pone.0268768
  
1168	Geurts   S, Tilly   MJ, Arshi   B, Stricker   BHC, Kors   JA, Deckers   JW, et al.   Heart rate variability and atrial fibrillation in the general population: a longitudinal and Mendelian randomization study. Clin Res Cardiol  2023;112:747–58. https://doi.org/10.1007/s00392-022-02072-5
  
1169	Aune   D, Feng   T, Schlesinger   S, Janszky   I, Norat   T, Riboli   E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabetes Complications  2018;32:501–11. https://doi.org/10.1016/j.jdiacomp.2018.02.004
  
1170	Nakanishi   K, Daimon   M, Fujiu   K, Iwama   K, Yoshida   Y, Hirose   K, et al.   Prevalence of glucose metabolism disorders and its association with left atrial remodelling before and after catheter ablation in patients with atrial fibrillation. Europace  2023;25:euad119. https://doi.org/10.1093/europace/euad119
  
1171	Kim   J, Kim   D, Jang   E, Kim   D, You   SC, Yu   HT, et al.   Associations of high-normal blood pressure and impaired fasting glucose with atrial fibrillation. Heart  2023;109:929–35. https://doi.org/10.1136/heartjnl-2022-322094
  
1172	Lee   SS, Ae Kong   K, Kim   D, Lim   YM, Yang   PS, Yi   JE, et al.   Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. Eur Heart J  2017;38:2599–607. https://doi.org/10.1093/eurheartj/ehx316
  
1173	Alonso   A, Lopez   FL, Matsushita   K, Loehr   LR, Agarwal   SK, Chen   LY, et al.   Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation  2011;123:2946–53. https://doi.org/10.1161/CIRCULATIONAHA.111.020982
  
1174	Bansal   N, Zelnick   LR, Alonso   A, Benjamin   EJ, de Boer   IH, Deo   R, et al.   eGFR and albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson heart study, the multi-ethnic study of atherosclerosis, and the cardiovascular health study. Clin J Am Soc Nephrol  2017;12:1386–98. https://doi.org/10.2215/CJN.01860217
  
1175	Asad   Z, Abbas   M, Javed   I, Korantzopoulos   P, Stavrakis   S. Obesity is associated with incident atrial fibrillation independent of gender: a meta-analysis. J Cardiovasc Electrophysiol  2018;29:725–32. https://doi.org/10.1111/jce.13458
  
1176	Aune   D, Sen   A, Schlesinger   S, Norat   T, Janszky   I, Romundstad   P, et al.   Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol  2017;32:181–92. https://doi.org/10.1007/s10654-017-0232-4
  
1177	May   AM, Blackwell   T, Stone   PH, Stone   KL, Cawthon   PM, Sauer   WH, et al.   Central sleep-disordered breathing predicts incident atrial fibrillation in older men. Am J Respir Crit Care Med  2016;193:783–91. https://doi.org/10.1164/rccm.201508-1523OC
  
1178	Tung   P, Levitzky   YS, Wang   R, Weng   J, Quan   SF, Gottlieb   DJ, et al.   Obstructive and central sleep apnea and the risk of incident atrial fibrillation in a community cohort of men and women. J Am Heart Assoc  2017;6:e004500. https://doi.org/10.1161/JAHA.116.004500
  
1179	Desai   R, Patel   U, Singh   S, Bhuva   R, Fong   HK, Nunna   P, et al.   The burden and impact of arrhythmia in chronic obstructive pulmonary disease: insights from the national inpatient sample. Int J Cardiol  2019;281:49–55. https://doi.org/10.1016/j.ijcard.2019.01.074
  
1180	O’Neal   WT, Efird   JT, Qureshi   WT, Yeboah   J, Alonso   A, Heckbert   SR, et al.   Coronary artery calcium progression and atrial fibrillation: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging  2015;8:e003786. https://doi.org/10.1161/CIRCIMAGING.115.003786
  
1181	Chen   LY, Leening   MJ, Norby   FL, Roetker   NS, Hofman   A, Franco   OH, et al.   Carotid intima-media thickness and arterial stiffness and the risk of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study, Multi-Ethnic Study of Atherosclerosis (MESA), and the Rotterdam study. J Am Heart Assoc  2016;5:e002907. https://doi.org/10.1161/JAHA.115.002907
  
1182	Geurts   S, Brunborg   C, Papageorgiou   G, Ikram   MA, Kavousi   M. Subclinical measures of peripheral atherosclerosis and the risk of new-onset atrial fibrillation in the general population: the Rotterdam study. J Am Heart Assoc  2022;11:e023967. https://doi.org/10.1161/JAHA.121.023967
  
1183	Cheng   S, Keyes   MJ, Larson   MG, McCabe   EL, Newton-Cheh   C, Levy   D, et al.   Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA  2009;301:2571–7. https://doi.org/10.1001/jama.2009.888
  
1184	Alonso   A, Jensen   PN, Lopez   FL, Chen   LY, Psaty   BM, Folsom   AR, et al.   Association of sick sinus syndrome with incident cardiovascular disease and mortality: the atherosclerosis risk in communities study and cardiovascular health study. PLoS One  2014;9:e109662. https://doi.org/10.1371/journal.pone.0109662
  
1185	Bodin   A, Bisson   A, Gaborit   C, Herbert   J, Clementy   N, Babuty   D, et al.   Ischemic stroke in patients with sinus node disease, atrial fibrillation, and other cardiac conditions. Stroke  2020;51:1674–81. https://doi.org/10.1161/STROKEAHA.120.029048
  
1186	Bunch   TJ, May   HT, Bair   TL, Anderson   JL, Crandall   BG, Cutler   MJ, et al.   Long-term natural history of adult Wolff–Parkinson–White syndrome patients treated with and without catheter ablation. Circ Arrhythm Electrophysiol  2015;8:1465–71. https://doi.org/10.1161/CIRCEP.115.003013
  
1187	Chang   SH, Kuo   CF, Chou   IJ, See   LC, Yu   KH, Luo   SF, et al.   Association of a family history of atrial fibrillation with incidence and outcomes of atrial fibrillation: a population-based family cohort study. JAMA Cardiol  2017;2:863–70. https://doi.org/10.1001/jamacardio.2017.1855
  
1188	Fox   CS, Parise   H, D’Agostino   RB, Sr, Lloyd-Jones   DM, Vasan   RS, Wang   TJ, et al.   Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA  2004;291:2851–5. https://doi.org/10.1001/jama.291.23.2851
  
1189	Lubitz   SA, Yin   X, Fontes   JD, Magnani   JW, Rienstra   M, Pai   M, et al.   Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA  2010;304:2263–9. https://doi.org/10.1001/jama.2010.1690
  
1190	Zoller   B, Ohlsson   H, Sundquist   J, Sundquist   K. High familial risk of atrial fibrillation/atrial flutter in multiplex families: a nationwide family study in Sweden. J Am Heart Assoc  2013;2:e003384. https://doi.org/10.1161/JAHA.112.003384
  
1191	Ko   D, Benson   MD, Ngo   D, Yang   Q, Larson   MG, Wang   TJ, et al.   Proteomics profiling and risk of new-onset atrial fibrillation: Framingham heart study. J Am Heart Assoc  2019;8:e010976. https://doi.org/10.1161/JAHA.118.010976
  
1192	Khera   AV, Chaffin   M, Aragam   KG, Haas   ME, Roselli   C, Choi   SH, et al.   Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet  2018;50:1219–24. https://doi.org/10.1038/s41588-018-0183-z
  
1193	Buckley   BJR, Harrison   SL, Gupta   D, Fazio-Eynullayeva   E, Underhill   P, Lip   GYH. Atrial fibrillation in patients with cardiomyopathy: prevalence and clinical outcomes from real-world data. J Am Heart Assoc  2021;10:e021970. https://doi.org/10.1161/JAHA.121.021970
  
1194	Chen   M, Ding   N, Mok   Y, Mathews   L, Hoogeveen   RC, Ballantyne   CM, et al.   Growth differentiation factor 15 and the subsequent risk of atrial fibrillation: the atherosclerosis risk in communities study. Clin Chem  2022;68:1084–93. https://doi.org/10.1093/clinchem/hvac096
  
1195	Chua   W, Purmah   Y, Cardoso   VR, Gkoutos   GV, Tull   SP, Neculau   G, et al.   Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. Eur Heart J  2019;40:1268–76. https://doi.org/10.1093/eurheartj/ehy815
  
1196	Brady   PF, Chua   W, Nehaj   F, Connolly   DL, Khashaba   A, Purmah   YJV, et al.   Interactions between atrial fibrillation and natriuretic peptide in predicting heart failure hospitalization or cardiovascular death. J Am Heart Assoc  2022;11:e022833. https://doi.org/10.1161/JAHA.121.022833
  
1197	Werhahn   SM, Becker   C, Mende   M, Haarmann   H, Nolte   K, Laufs   U, et al.   NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. ESC Heart Fail  2022;9:100–9. https://doi.org/10.1002/ehf2.13703
  
1198	Geelhoed   B, Börschel   CS, Niiranen   T, Palosaari   T, Havulinna   AS, Fouodo   CJK, et al.   Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: a Mendelian randomization study in the FINRISK cohort. Europace  2020;22:1463–9. https://doi.org/10.1093/europace/euaa158
  
1199	Toprak   B, Brandt   S, Brederecke   J, Gianfagna   F, Vishram-Nielsen   JKK, Ojeda   FM, et al.   Exploring the incremental utility of circulating biomarkers for robust risk prediction of incident atrial fibrillation in European cohorts using regressions and modern machine learning methods. Europace  2023;25:812–9. https://doi.org/10.1093/europace/euac260
  
1200	Benz   AP, Hijazi   Z, Lindbäck   J, Connolly   SJ, Eikelboom   JW, Oldgren   J, et al.   Biomarker-based risk prediction with the ABC-AF scores in patients with atrial fibrillation not receiving oral anticoagulation. Circulation  2021;143:1863–73. https://doi.org/10.1161/CIRCULATIONAHA.120.053100
  
1201	Monrad   M, Sajadieh   A, Christensen   JS, Ketzel   M, Raaschou-Nielsen   O, Tjonneland   A, et al.   Long-term exposure to traffic-related air pollution and risk of incident atrial fibrillation: a cohort study. Environ Health Perspect  2017;125:422–7. https://doi.org/10.1289/EHP392
  
1202	Walkey   AJ, Greiner   MA, Heckbert   SR, Jensen   PN, Piccini   JP, Sinner   MF, et al.   Atrial fibrillation among medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am Heart J  2013;165:949–955.e3. https://doi.org/10.1016/j.ahj.2013.03.020
  
1203	Svensson   T, Kitlinski   M, Engstrom   G, Melander   O. Psychological stress and risk of incident atrial fibrillation in men and women with known atrial fibrillation genetic risk scores. Sci Rep  2017;7:42613. https://doi.org/10.1038/srep42613
  
1204	Eaker   ED, Sullivan   LM, Kelly-Hayes   M, D’Agostino   RB, Sr, Benjamin   EJ. Anger and hostility predict the development of atrial fibrillation in men in the Framingham offspring study. Circulation  2004;109:1267–71. https://doi.org/10.1161/01.CIR.0000118535.15205.8F
  
1205	Chen   LY, Bigger   JT, Hickey   KT, Chen   H, Lopez-Jimenez   C, Banerji   MA, et al.   Effect of intensive blood pressure lowering on incident atrial fibrillation and P-wave indices in the ACCORD blood pressure trial. Am J Hypertens  2016;29:1276–82. https://doi.org/10.1093/ajh/hpv172
  
1206	Soliman   EZ, Rahman   AF, Zhang   ZM, Rodriguez   CJ, Chang   TI, Bates   JT, et al.   Effect of intensive blood pressure lowering on the risk of atrial fibrillation. Hypertension  2020;75:1491–6. https://doi.org/10.1161/HYPERTENSIONAHA.120.14766
  
1207	Larstorp   ACK, Stokke   IM, Kjeldsen   SE, Hecht Olsen   M, Okin   PM, Devereux   RB, et al.   Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. Blood Press  2019;28:317–26. https://doi.org/10.1080/08037051.2019.1633905
  
1208	Healey   JS, Baranchuk   A, Crystal   E, Morillo   CA, Garfinkle   M, Yusuf   S, et al.   Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol  2005;45:1832–9. https://doi.org/10.1016/j.jacc.2004.11.070
  
1209	Swedberg   K, Zannad   F, McMurray   JJ, Krum   H, van Veldhuisen   DJ, Shi   H, et al.   Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (eplerenone in mild patients hospitalization and SurvIval study in heart failure) study. J Am Coll Cardiol  2012;59:1598–603. https://doi.org/10.1016/j.jacc.2011.11.063
  
1210	Wang   M, Zhang   Y, Wang   Z, Liu   D, Mao   S, Liang   B. The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis. J Thorac Dis  2022;14:1620–37. https://doi.org/10.21037/jtd-22-550
  
1211	Yin   Z, Zheng   H, Guo   Z. Effect of sodium-glucose co-transporter protein 2 inhibitors on arrhythmia in heart failure patients with or without type 2 diabetes: a meta-analysis of randomized controlled trials. Front Cardiovasc Med  2022;9:902923. https://doi.org/10.3389/fcvm.2022.902923
  
1212	Tedrow   UB, Conen   D, Ridker   PM, Cook   NR, Koplan   BA, Manson   JE, et al.   The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (Women’s Health Study). J Am Coll Cardiol  2010;55:2319–27. https://doi.org/10.1016/j.jacc.2010.02.029
  
1213	Chan   YH, Chen   SW, Chao   TF, Kao   YW, Huang   CY, Chu   PH. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor. Cardiovasc Diabetol  2021;20:93. https://doi.org/10.1186/s12933-021-01285-8
  
1214	Mishima   RS, Verdicchio   CV, Noubiap   JJ, Ariyaratnam   JP, Gallagher   C, Jones   D, et al.   Self-reported physical activity and atrial fibrillation risk: a systematic review and meta-analysis. Heart Rhythm  2021;18:520–8. https://doi.org/10.1016/j.hrthm.2020.12.017
  
1215	Elliott   AD, Linz   D, Mishima   R, Kadhim   K, Gallagher   C, Middeldorp   ME, et al.   Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort. Eur Heart J  2020;41:1479–86. https://doi.org/10.1093/eurheartj/ehz897
  
1216	Jin   MN, Yang   PS, Song   C, Yu   HT, Kim   TH, Uhm   JS, et al.   Physical activity and risk of atrial fibrillation: a nationwide cohort study in general population. Sci Rep  2019;9:13270. https://doi.org/10.1038/s41598-019-49686-w
  
1217	Khurshid   S, Weng   LC, Al-Alusi   MA, Halford   JL, Haimovich   JS, Benjamin   EJ, et al.   Accelerometer-derived physical activity and risk of atrial fibrillation. Eur Heart J  2021;42:2472–83. https://doi.org/10.1093/eurheartj/ehab250
  
1218	Tikkanen   E, Gustafsson   S, Ingelsson   E. Associations of fitness, physical activity, strength, and genetic risk with cardiovascular disease: longitudinal analyses in the UK biobank study. Circulation  2018;137:2583–91. https://doi.org/10.1161/CIRCULATIONAHA.117.032432
  
1219	Morseth   B, Graff-Iversen   S, Jacobsen   BK, Jørgensen   L, Nyrnes   A, Thelle   DS, et al.   Physical activity, resting heart rate, and atrial fibrillation: the Tromsø study. Eur Heart J  2016;37:2307–13. https://doi.org/10.1093/eurheartj/ehw059
  
1220	Csengeri   D, Sprünker   NA, Di Castelnuovo   A, Niiranen   T, Vishram-Nielsen   JK, Costanzo   S, et al.   Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes. Eur Heart J  2021;42:1170–7. https://doi.org/10.1093/eurheartj/ehaa953
  
1221	Gallagher   C, Hendriks   JML, Elliott   AD, Wong   CX, Rangnekar   G, Middeldorp   ME, et al.   Alcohol and incident atrial fibrillation – a systematic review and meta-analysis. Int J Cardiol  2017;246:46–52. https://doi.org/10.1016/j.ijcard.2017.05.133
  
1222	Tu   SJ, Gallagher   C, Elliott   AD, Linz   D, Pitman   BM, Hendriks   JML, et al.   Risk thresholds for total and beverage-specific alcohol consumption and incident atrial fibrillation. JACC Clin Electrophysiol  2021;7:1561–9. https://doi.org/10.1016/j.jacep.2021.05.013
  
1223	Lee   JW, Roh   SY, Yoon   WS, Kim   J, Jo   E, Bae   DH, et al.   Changes in alcohol consumption habits and risk of atrial fibrillation: a nationwide population-based study. Eur J Prev Cardiol  2024;31:49–58. https://doi.org/10.1093/eurjpc/zwad270
  
1224	Chang   SH, Wu   LS, Chiou   MJ, Liu   JR, Yu   KH, Kuo   CF, et al.   Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol  2014;13:123. https://doi.org/10.1186/s12933-014-0123-x
  
1225	Tseng   CH. Metformin use is associated with a lower incidence of hospitalization for atrial fibrillation in patients with type 2 diabetes mellitus. Front Med (Lausanne)  2021;7:592901. https://doi.org/10.3389/fmed.2020.592901
  
1226	Li   WJ, Chen   XQ, Xu   LL, Li   YQ, Luo   BH. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol  2020;19:130. https://doi.org/10.1186/s12933-020-01105-5
  
1227	Srivatsa   UN, Malhotra   P, Zhang   XJ, Beri   N, Xing   G, Brunson   A, et al.   Bariatric surgery to aLleviate OCcurrence of atrial fibrillation hospitalization—BLOC-AF. Heart Rhythm O2  2020;1:96–102. https://doi.org/10.1016/j.hroo.2020.04.004
  
1228	Hoskuldsdottir   G, Sattar   N, Miftaraj   M, Naslund   I, Ottosson   J, Franzen   S, et al.   Potential effects of bariatric surgery on the incidence of heart failure and atrial fibrillation in patients with type 2 diabetes mellitus and obesity and on mortality in patients with preexisting heart failure: a nationwide, matched, observational cohort study. J Am Heart Assoc  2021;10:e019323. https://doi.org/10.1161/JAHA.120.019323
  
1229	Chokesuwattanaskul   R, Thongprayoon   C, Bathini   T, Sharma   K, Watthanasuntorn   K, Lertjitbanjong   P, et al.   Incident atrial fibrillation in patients undergoing bariatric surgery: a systematic review and meta-analysis. Intern Med J  2020;50:810–7. https://doi.org/10.1111/imj.14436
  
1230	Lynch   KT, Mehaffey   JH, Hawkins   RB, Hassinger   TE, Hallowell   PT, Kirby   JL. Bariatric surgery reduces incidence of atrial fibrillation: a propensity score-matched analysis. Surg Obes Relat Dis  2019;15:279–85. https://doi.org/10.1016/j.soard.2018.11.021
  
1231	Jamaly   S, Carlsson   L, Peltonen   M, Jacobson   P, Sjostrom   L, Karason   K. Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol  2016;68:2497–504. https://doi.org/10.1016/j.jacc.2016.09.940
  
1232	Okin   PM, Hille   DA, Larstorp   AC, Wachtell   K, Kjeldsen   SE, Dahlöf   B, et al.   Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension  2015;66:368–73. https://doi.org/10.1161/HYPERTENSIONAHA.115.05728
  
1233	Wachtell   K, Lehto   M, Gerdts   E, Olsen   MH, Hornestam   B, Dahlof   B, et al.   Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End point reduction in hypertension (LIFE) study. J Am Coll Cardiol  2005;45:712–9. https://doi.org/10.1016/j.jacc.2004.10.068
  
1234	Schmieder   RE, Kjeldsen   SE, Julius   S, McInnes   GT, Zanchetti   A, Hua   TA, et al.   Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens  2008;26:403–11. https://doi.org/10.1097/HJH.0b013e3282f35c67
  
1235	Schaer   BA, Schneider   C, Jick   SS, Conen   D, Osswald   S, Meier   CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med  2010;152:78–84. https://doi.org/10.7326/0003-4819-152-2-201001190-00005
  
1236	Dewland   TA, Soliman   EZ, Yamal   JM, Davis   BR, Alonso   A, Albert   CM, et al.   Pharmacologic prevention of incident atrial fibrillation: long-term results from the ALLHAT (antihypertensive and lipid-lowering treatment to prevent heart attack trial). Circ Arrhythm Electrophysiol  2017;10:e005463. https://doi.org/10.1161/CIRCEP.117.005463
  
1237	Butt   JH, Docherty   KF, Jhund   PS, de Boer   RA, Böhm   M, Desai   AS, et al.   Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail  2022;24:513–25. https://doi.org/10.1002/ejhf.2381
  
1238	Liu   X, Liu   H, Wang   L, Zhang   L, Xu   Q. Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. PLOS ONE  2022;17:e0263131. https://doi.org/10.1371/journal.pone.0263131
  
1239	Hess   PL, Jackson   KP, Hasselblad   V, Al-Khatib   SM. Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis. Curr Cardiol Rep  2013;15:330. https://doi.org/10.1007/s11886-012-0330-6
  
1240	Fatemi   O, Yuriditsky   E, Tsioufis   C, Tsachris   D, Morgan   T, Basile   J, et al.   Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study). Am J Cardiol  2014;114:1217–22. https://doi.org/10.1016/j.amjcard.2014.07.045
  
1241	Nantsupawat   T, Wongcharoen   W, Chattipakorn   SC, Chattipakorn   N. Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. Cardiovasc Diabetol  2020;19:198. https://doi.org/10.1186/s12933-020-01176-4
  
1242	Chang   CY, Yeh   YH, Chan   YH, Liu   JR, Chang   SH, Lee   HF, et al.   Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovasc Diabetol  2017;16:159. https://doi.org/10.1186/s12933-017-0640-5
  
1243	Ostropolets   A, Elias   PA, Reyes   MV, Wan   EY, Pajvani   UB, Hripcsak   G, et al.   Metformin is associated with a lower risk of atrial fibrillation and ventricular arrhythmias compared with sulfonylureas: an observational study. Circ Arrhythm Electrophysiol  2021;14:e009115. https://doi.org/10.1161/CIRCEP.120.009115
  
1244	Proietti   R, Lip   GYH. Sodium-glucose cotransporter 2 inhibitors: an additional management option for patients with atrial fibrillation?  Diabetes Obes Metab  2022;24:1897–900. https://doi.org/10.1111/dom.14818
  
1245	Karamichalakis   N, Kolovos   V, Paraskevaidis   I, Tsougos   E. A new hope: sodium-glucose cotransporter-2 inhibition to prevent atrial fibrillation. J Cardiovasc Dev Dis  2022;9:236. https://doi.org/10.3390/jcdd9080236
Google ScholarWorldCat 
1246	Lee   S, Zhou   J, Leung   KSK, Wai   AKC, Jeevaratnam   K, King   E, et al.   Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther  2023;37:561–9. https://doi.org/10.1007/s10557-022-07319-x
  
1247	Elliott   AD, Maatman   B, Emery   MS, Sanders   P. The role of exercise in atrial fibrillation prevention and promotion: finding optimal ranges for health. Heart Rhythm  2017;14:1713–20. https://doi.org/10.1016/j.hrthm.2017.07.001
  
1248	Newman   W, Parry-Williams   G, Wiles   J, Edwards   J, Hulbert   S, Kipourou   K, et al.   Risk of atrial fibrillation in athletes: a systematic review and meta-analysis. Br J Sports Med  2021;55:1233–8. https://doi.org/10.1136/bjsports-2021-103994
  

## Author notes

Isabelle C Van Gelder and Dipak Kotecha Chairpersons contributed equally to the document and are joint corresponding authors.

Michiel Rienstra and Karina V Bunting Task Force Co-ordinators contributed equally to the document.

**Author/Task Force Member affiliations are listed in author information.**

Representing European Stroke Organisation (ESO).

Representing European Association for Cardio-Thoracic Surgery (EACTS).

**ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.**

**ESC subspecialty communities having participated in the development of this document:**

**Associations:** Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).

**Councils:** Council for Cardiology Practice, Council of Cardio-Oncology, Council on Cardiovascular Genomics, Council on Stroke.

**Working Groups:** Cardiac Cellular Electrophysiology, Cardiovascular Pharmacotherapy, E-Cardiology, Thrombosis.

**Patient Forum**

  ![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176il3.jpeg?Expires=1728478928&Signature=b8EXSSoYiZSs2eV1M4JryJE~7183OIpBkS5PJCvFlDevadWt~6Lmxl1yWaKA2qr0PLinxPFFd3eGNSx5gwdV35a8VOF7kA-lkiBW-eYEEtyUOyNldz~J-rMWD52FuvkGmW8Yh1MDBkwKtnoeOq2NeHzxgbL8usJLibzceXgSv4HbzUjn2NraEI8mvHerlaSKar6oJxrJkb024JxxVJmjCaD46CXtWDfXP51bzWBLdi9k0gStSwHmtU75BiAQ10XBUWFyDR165QNn380cws3wt4Z1ge5lsIvyyorFl5Ldc3rECMR0V4XGEcJJ0v7ZtCEfi-CGaHZMfTzuB4Ss-qkwKw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  **All experts involved in the development of these guidelines have submitted declarations of interest which are reported in a supplementary document to the guidelines. See the _European Heart Journal_ online or [www.escardio.org/guidelines](https://www.escardio.org/Guidelines) for supplementary documents as well as evidence tables.**

**Disclaimer.** The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.

**Permissions.** The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the _European Heart Journal_ and the party authorized to handle such permissions on behalf of the ESC ([journals.permissions@oup.com](mailto:journals.permissions@oup.com)).

© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ([https://academic.oup.com/pages/standard-publication-reuse-rights](https://academic.oup.com/pages/standard-publication-reuse-rights))

[Download all slides](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=&PPTtype=SlideSet&ar=7738779&xsltPath=~/UI/app/XSLT&siteId=5375)

## Supplementary data

[ehae176\_Supplementary\_Data](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478930&Signature=ghcq3T3R~y6OPFOt-UD-LShlzfsAGhfuHZSZR1iskTZp0kP9wFQHo9MM1QQpDT4DO2cFrvlH7UNpu0bf8zfwx1mgS2IDOJ35Uczula2cgRPnYA-WELhJkeefITYNM0pYArtKASszKBFSkZWz2hrILtLqnsgFwcgJwzkTf3WCN64k1ORC5zHr0emEDNcekP71YyFICwqimiGRbm2a2dDD8~yjRzYsvyS928cR04ZnN4-kqIa4AuGNTlG4TAixpL1ieydrE5nPherSLSwhgT2h2V8R4Pr1RIy5R6gbqVR~Lci8vCdKyOX76uXnauntnoFBanKF8-ATIVmSqiYBbAwYow__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

[2024\_AFIB\_GIs\_Evidence\_tables\_Final](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478930&Signature=2xU1cCFUkxr7sZEA3tsnMZFkibl1YCqDeTJFKZkoDdYK7cqQIq5H7gZ7aHxuIr8TVuGNIpqtHMkRNhO~Z1-lsSYCC92h6SQMJss2LUnUv~mLwLTxqX4vu-izXqwxMCnbRnoaYx6vWmB6ySqUicmx1i4jPZLqJTa7x7IIjRaU0RDlr7joMhd5rw2pFuOipIC6LdSUJurmjRRg-oZwZ3jqRr1F89js5f6stN-IKScNxEUF6DtJ2nklV~nZ8WAqXTpLI3IpvjKo8W5cMGPcpXfhur2NpYT4ggIPpj4c5oYy~cX-y90-UCNKBH5ZHWPv9qDY~JPkycYOO8cEOdUpGatD8Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

[DOI\_summary\_2024\_ESC\_Guidelines\_AFIB\_EHAE176](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/doi_summary_2024_esc_guidelines_afib_ehae176.pdf?Expires=1728478930&Signature=FSDZdGNR9z9VL2sjnN7vy5XuyaCwcDyrwtbrEgdPQ5tyXdO9SrDlLoFjz~PimnFUG0jJMY~jd83YQ7H5wvh7-UVmjeIShb204SUhjMXWZXeob88S~rp6I76B2233Yz3VrnjI4JpUHaQeUPyeiMO4OiCRPoHSJbVxwN4xSD8ujaTeORRBgmavOe9axyMPbmz5kHWA8vzS6K74sSKRLScgcNUoQ~2AnfcHci3uMmdXLn2b5uPBjHVAs64i2gjojdblniXeZqy~fISw-KdpeEnlLxoNKzVN9iNbf~RCtZYJzRrcl19RUY9-H3qe9ZSVO7vjTDHEs11aAdGSfpf6P~Sfug__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file
